0001178913-24-000730.txt : 20240227 0001178913-24-000730.hdr.sgml : 20240227 20240227091546 ACCESSION NUMBER: 0001178913-24-000730 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 107 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240227 DATE AS OF CHANGE: 20240227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ReWalk Robotics Ltd. CENTRAL INDEX KEY: 0001607962 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36612 FILM NUMBER: 24682564 BUSINESS ADDRESS: STREET 1: 3 HATNUFA ST. STREET 2: FLOOR 6 CITY: YOKNEAM ILIT STATE: L3 ZIP: 2069203 BUSINESS PHONE: 97249590123 MAIL ADDRESS: STREET 1: 3 HATNUFA ST. STREET 2: FLOOR 6 CITY: YOKNEAM ILIT STATE: L3 ZIP: 2069203 FORMER COMPANY: FORMER CONFORMED NAME: Argo Medical Technologies Ltd. DATE OF NAME CHANGE: 20140513 10-K 1 zk2431037.htm 10-K ReWalk Robotics Ltd. - 1607962 - 2024
0001607962FYfalse00-0000000Less than 10% Represents an amount lower than $1. See Note 9a. See Note 9f. Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.  Represents warrants for ordinary shares issuable upon an exercise price of $7.500 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2022. Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms. Represents common warrants that were issued as part of the Company’s follow-on public offering in November 2018. Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on public offering in November 2018. Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on public offering in February 2019. Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering. Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants. Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants. Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of December 31, 2022, 3,740,100 warrants were exercised for total consideration of $4,675,125. During the twelve months that ended December 31, 2022, no warrants were exercised. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of December 31, 2022, 230,160 warrants were exercised for total consideration of $359,625. During the twelve months that ended December 31, 2022, no warrants were exercised. Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. As of December 31, 2022, 2,020,441 warrants were exercised for total consideration of $3,555,976. During the twelve months that ended December 31, 2022, no warrants were exercised. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering. Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. As of December 31, 2022, 3,598,072 warrants were exercised for total consideration of $4,821,416. During the twelve months that ended December 31, 2022, no warrants were exercised. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of December 31, 2022, 225,981 warrants were exercised for total consideration of $405,003. During the twelve months that ended December 31, 2022, no warrants were exercised. Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering. P5YBalance presented net of unrecognized revenue that was not yet collected. $401 thousands of the December 31, 2022 deferred revenue balance was recognized as revenue during the year ended December 31, 2023. 0001607962 2023-01-01 2023-12-31 0001607962lfwd:AltergIncMember 2023-08-08 0001607962lfwd:AltergIncMember 2023-08-01 2023-08-08 0001607962 2023-12-31 0001607962us-gaap:TrademarksMember 2023-01-01 2023-12-31 0001607962us-gaap:TrademarksMember 2023-12-31 0001607962us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0001607962us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-12-31 0001607962lfwd:CustomerRelationshipWarrantyMember 2023-12-31 0001607962lfwd:CustomerRelationshipWarrantyMember 2023-01-01 2023-12-31 0001607962lfwd:CustomerRelationshipRentalMember 2023-12-31 0001607962lfwd:CustomerRelationshipRentalMember 2023-01-01 2023-12-31 0001607962lfwd:CustomerRelationshipDistributionMember 2023-12-31 0001607962lfwd:CustomerRelationshipDistributionMember 2023-01-01 2023-12-31 0001607962us-gaap:OrderOrProductionBacklogMember 2023-12-31 0001607962us-gaap:OrderOrProductionBacklogMember 2023-01-01 2023-12-31 0001607962 2022-01-01 2022-12-31 0001607962 2023-08-01 2023-08-08 0001607962lfwd:AltergIncMember 2023-01-01 2023-12-31 0001607962 2021-01-01 2021-12-31 0001607962 2022-12-31 0001607962lfwd:IsraelInnovationAuthorityMember 2023-01-01 2023-12-31 0001607962lfwd:IsraelInnovationAuthorityMemberus-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-12-31 0001607962lfwd:IsraelInnovationAuthorityMemberus-gaap:ConvertiblePreferredStockMember 2023-12-31 0001607962us-gaap:IPOMember 2023-01-01 2023-12-31 0001607962lfwd:IsraelInnovationAuthorityMember 2023-12-31 0001607962country:US 2023-01-01 2023-12-31 0001607962country:US 2022-01-01 2022-12-31 0001607962country:US 2021-01-01 2021-12-31 0001607962srt:EuropeMember 2023-01-01 2023-12-31 0001607962srt:EuropeMember 2022-01-01 2022-12-31 0001607962srt:EuropeMember 2021-01-01 2021-12-31 0001607962srt:AsiaPacificMember 2023-01-01 2023-12-31 0001607962srt:AsiaPacificMember 2022-01-01 2022-12-31 0001607962srt:AsiaPacificMember 2021-01-01 2021-12-31 0001607962country:IL 2023-12-31 0001607962country:IL 2022-12-31 0001607962country:US 2023-12-31 0001607962country:US 2022-12-31 0001607962country:DE 2023-12-31 0001607962country:DE 2022-12-31 0001607962lfwd:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001607962lfwd:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001607962lfwd:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001607962lfwd:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001607962lfwd:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001607962lfwd:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001607962lfwd:RestOfWorldMember 2023-01-01 2023-12-31 0001607962lfwd:RestOfWorldMember 2022-01-01 2022-12-31 0001607962lfwd:RestOfWorldMember 2021-01-01 2021-12-31 0001607962us-gaap:CustomerRelationshipsMember 2023-12-31 0001607962us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0001607962lfwd:BacklogMember 2023-12-31 0001607962lfwd:BacklogMember 2023-01-01 2023-12-31 0001607962lfwd:AltergIncMember 2023-01-01 2023-09-30 0001607962us-gaap:PrivatePlacementMember 2023-01-01 2023-12-31 0001607962lfwd:RegisteredDirectMember 2023-01-01 2023-12-31 0001607962 2021-12-31 0001607962 2020-12-31 0001607962lfwd:LicenseAgreementAndCollaborationAgreementMember 2023-01-01 2023-12-31 0001607962lfwd:LicenseAgreementAndCollaborationAgreementMember 2022-01-01 2022-12-31 0001607962lfwd:LicenseAgreementAndCollaborationAgreementMember 2021-01-01 2021-12-31 0001607962 2023-06-30 0001607962 2024-02-27 0001607962lfwd:PurchaseAgreementWithCertainInstitutionalAccerditedInvestorsMember 2021-02-02 2021-02-19 0001607962lfwd:PurchaseAgreementWithCertainInstitutionalAccerditedInvestorsMember 2021-02-19 0001607962lfwd:AdditionallyWarrantsIssuedMemberlfwd:PurchaseAgreementWithCertainInstitutionalAccerditedInvestorsMember 2021-02-19 0001607962lfwd:PurchaseAgreementWithCertainInstitutionalInvestorsMember 2021-09-01 2021-09-27 0001607962lfwd:PurchaseAgreementWithCertainInstitutionalInvestorsMember 2021-09-27 0001607962lfwd:AdditionallyWarrantsIssuedMemberlfwd:PurchaseAgreementWithCertainInstitutionalInvestorsMember 2021-09-01 2021-09-27 0001607962lfwd:AdditionallyWarrantsIssuedMemberlfwd:PurchaseAgreementWithCertainInstitutionalInvestorsMember 2021-09-27 0001607962lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember 2022-12-31 0001607962lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember 2023-01-01 2023-12-31 0001607962lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember 2023-12-31 0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeMember 2023-12-31 0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeOneMember 2023-01-01 2023-12-31 0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeOneMember 2023-12-31 0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeTwoMember 2023-01-01 2023-12-31 0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeTwoMember 2023-12-31 0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeThreeMember 2023-01-01 2023-12-31 0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeFourMember 2023-01-01 2023-12-31 0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeFourMember 2023-12-31 0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeFiveMember 2023-12-31 0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeFiveMember 2023-01-01 2023-12-31 0001607962us-gaap:EmployeeStockOptionMember 2023-12-31 0001607962us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001607962us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001607962us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001607962us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001607962us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001607962us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001607962us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001607962us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-12-31 0001607962us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0001607962us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001607962us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001607962us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001607962us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberTwoThousandFifteenMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberTwoThousandSixteenMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnNovemberTwentyTwoThousandEighteenMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnNovemberTwentyTwoThousandEighteenMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnNovemberTwentyTwoThousandEighteenOneMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnNovemberTwentyTwoThousandEighteenOneMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentyFiveTwoThousandNineteenMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentyFiveTwoThousandNineteenMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenOneMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenOneMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneFiveAndSixTwoThousandNineteenMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneFiveAndSixTwoThousandNineteenMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneFiveTwoThousandNineteenMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneFiveTwoThousandNineteenMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTweleveTwoThousandNineteenMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTweleveTwoThousandNineteenMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTenTwoThousandNineteenMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTenTwoThousandNineteenMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyOneMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyOneMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyOneMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyOneMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyOneMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyOneMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneMember 2023-01-01 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneOneMember 2023-12-31 0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneOneMember 2023-01-01 2023-12-31 0001607962lfwd:KreosCapitalVMember 2015-01-01 2015-12-31 0001607962lfwd:KreosCapitalMember 2016-12-28 0001607962srt:MinimumMember 2023-12-31 0001607962srt:MaximumMember 2023-12-31 0001607962us-gaap:EmployeeStockOptionMember 2022-12-31 0001607962us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001607962us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001607962us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001607962us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001607962us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001607962lfwd:KreosCapitalMember 2015-12-31 0001607962lfwd:ShareRepurchaseProgramMember 2022-06-02 0001607962lfwd:ShareRepurchaseProgramMember 2023-12-31 0001607962lfwd:ShareRepurchaseProgramMember 2023-01-01 2023-12-31 0001607962lfwd:PurchaseAgreementWithCertainInstitutionalAccerditedInvestorsMember 2021-02-01 2021-02-19 0001607962lfwd:AdditionallyWarrantsIssuedMemberlfwd:PurchaseAgreementWithCertainInstitutionalAccerditedInvestorsMember 2021-02-01 2021-02-19 0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:OfferingOfOrdinarySharesInDecember2020Member 2022-12-31 0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:OfferingOfOrdinarySharesInDecember2020Member 2022-01-01 2022-12-31 0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:OfferingOfOrdinarySharesInJuly2020Member 2022-12-31 0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:OfferingOfOrdinarySharesInJuly2020Member 2022-01-01 2022-12-31 0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:OfferingOfOrdinarySharesInFebruary2020TwoMember 2022-12-31 0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:OfferingOfOrdinarySharesInFebruary2020TwoMember 2022-01-01 2022-12-31 0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:OfferingOfOrdinarySharesInFebruary2020Member 2022-12-31 0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:OfferingOfOrdinarySharesInFebruary2020Member 2022-01-01 2022-12-31 0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:December2020PrivatePlacementMember 2022-12-31 0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:December2020PrivatePlacementMember 2022-01-01 2022-12-31 0001607962lfwd:ShareRepurchaseProgramMember 2022-07-21 0001607962lfwd:ShareRepurchaseProgramMember 2022-12-22 0001607962us-gaap:CommonStockMember 2020-12-31 0001607962us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001607962us-gaap:RetainedEarningsMember 2020-12-31 0001607962us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001607962us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001607962lfwd:BestOfferingMember 2021-01-01 2021-12-31 0001607962lfwd:RegisteredDirectOfferingMember 2021-01-01 2021-12-31 0001607962us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001607962us-gaap:CommonStockMember 2021-12-31 0001607962us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001607962us-gaap:RetainedEarningsMember 2021-12-31 0001607962us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001607962us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001607962us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001607962us-gaap:CommonStockMember 2022-12-31 0001607962us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001607962us-gaap:RetainedEarningsMember 2022-12-31 0001607962us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001607962us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001607962us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001607962us-gaap:RetainedEarningsMember 2023-12-31 0001607962us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001607962us-gaap:CommonStockMember 2023-12-31 0001607962us-gaap:TreasuryStockPreferredMember 2023-01-01 2023-12-31 0001607962us-gaap:TreasuryStockPreferredMember 2023-12-31 0001607962us-gaap:TreasuryStockPreferredMember 2020-12-31 0001607962us-gaap:TreasuryStockPreferredMember 2021-01-01 2021-12-31 0001607962us-gaap:TreasuryStockPreferredMember 2021-12-31 0001607962us-gaap:TreasuryStockPreferredMember 2022-01-01 2022-12-31 0001607962us-gaap:TreasuryStockPreferredMember 2022-12-31 0001607962lfwd:TwoZeroTwoThreeReorganizationPlanMember 2023-12-01 2023-12-12 0001607962lfwd:TwoZeroTwoThreeReorganizationPlanMember 2023-01-01 2023-12-31 0001607962srt:MinimumMemberus-gaap:ComputerEquipmentMember 2023-12-31 0001607962srt:MaximumMemberus-gaap:ComputerEquipmentMember 2023-12-31 0001607962srt:MaximumMemberus-gaap:FurnitureAndFixturesMember 2023-12-31 0001607962lfwd:MachineryAndLaboratoryEquipmentMember 2023-12-31 0001607962srt:MaximumMemberlfwd:FieldServiceUnitsMember 2023-12-31 0001607962lfwd:CustomerAMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001607962lfwd:CustomerBMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001607962lfwd:CustomerCMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001607962lfwd:CustomerDMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001607962lfwd:ReStoreProductMember 2023-12-31 0001607962lfwd:CustomerAMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2022-01-01 2022-12-31 0001607962lfwd:CustomerBMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2022-01-01 2022-12-31 0001607962lfwd:CustomerCMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2022-01-01 2022-12-31 0001607962lfwd:CustomerDMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember 2022-01-01 2022-12-31 0001607962lfwd:SCIProductsMember 2023-12-31 0001607962srt:MinimumMemberus-gaap:FurnitureAndFixturesMember 2023-12-31 0001607962us-gaap:ProductMember 2021-01-01 2021-12-31 0001607962us-gaap:ProductMember 2022-01-01 2022-12-31 0001607962us-gaap:ProductMember 2023-01-01 2023-12-31 0001607962lfwd:RentalMember 2021-01-01 2021-12-31 0001607962lfwd:RentalMember 2022-01-01 2022-12-31 0001607962lfwd:RentalMember 2023-01-01 2023-12-31 0001607962lfwd:ServiceAndWarrantyMember 2021-01-01 2021-12-31 0001607962lfwd:ServiceAndWarrantyMember 2022-01-01 2022-12-31 0001607962lfwd:ServiceAndWarrantyMember 2023-01-01 2023-12-31 0001607962 2023-01-01 2023-09-30 0001607962us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001607962us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001607962us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001607962us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001607962us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001607962us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001607962us-gaap:FairValueInputsLevel3Memberlfwd:EarnoutMemberus-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001607962us-gaap:FairValueInputsLevel3Memberlfwd:EarnoutMemberus-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001607962lfwd:EarnoutMemberus-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001607962lfwd:EarnoutMemberus-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001607962lfwd:EarnoutMember 2023-08-11 0001607962lfwd:EarnoutMember 2023-08-12 2023-09-30 0001607962lfwd:EarnoutMember 2023-09-30 0001607962srt:MinimumMemberlfwd:FieldServiceUnitsMember 2023-12-31 0001607962srt:MinimumMember 2023-01-01 2023-12-31 0001607962srt:MaximumMember 2023-01-01 2023-12-31 0001607962us-gaap:ComputerEquipmentMember 2023-12-31 0001607962us-gaap:ComputerEquipmentMember 2022-12-31 0001607962us-gaap:FurnitureAndFixturesMember 2023-12-31 0001607962us-gaap:FurnitureAndFixturesMember 2022-12-31 0001607962lfwd:MachineryAndLaboratoryEquipmentMember 2022-12-31 0001607962lfwd:FieldServiceUnitsMember 2023-12-31 0001607962lfwd:FieldServiceUnitsMember 2022-12-31 0001607962us-gaap:LeaseholdImprovementsMember 2023-12-31 0001607962us-gaap:LeaseholdImprovementsMember 2022-12-31 0001607962us-gaap:IsraelTaxAuthorityMember 2020-01-01 2020-12-31 0001607962us-gaap:IsraelTaxAuthorityMember 2021-01-01 2021-12-31 0001607962us-gaap:IsraelTaxAuthorityMember 2022-01-01 2022-12-31 0001607962lfwd:ReWalkRoboticsIncMember 2023-01-01 2023-12-31 0001607962lfwd:ReWalkRoboticsIncMember 2022-01-01 2022-12-31 0001607962lfwd:ReWalkRoboticsIncMember 2021-01-01 2021-12-31 0001607962lfwd:RewalkRoboticsGmbhMember 2023-01-01 2023-12-31 0001607962lfwd:RewalkRoboticsGmbhMember 2022-01-01 2022-12-31 0001607962lfwd:RewalkRoboticsGmbhMember 2021-01-01 2021-12-31 0001607962lfwd:ReWalkRoboticsIncMember 2023-12-31 0001607962lfwd:AltergIncMember 2023-12-31 0001607962lfwd:AltergIncMemberus-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001607962lfwd:AltergIncMember 2023-01-01 2023-12-31 0001607962lfwd:AltergIncMemberus-gaap:ForeignCountryMember 2018-01-01 0001607962lfwd:AltergIncMember 2018-01-01 iso4217:ILSxbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure lfwd:segment xbrli:shares

 
UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
 
FORM 10-K
 
 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended December 31, 2023
 
or
 
 TRANSITION REPORT PURSUANT OR SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from ______ to ______
 
Commission File Number: 001-36612

 

image00001.jpg
ReWalk Robotics Ltd.
(Exact name of registrant as specified in charter)
 
Israel
 
Not applicable
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. employer
identification no.)
 
 
 
3 Hatnufa Street, Floor 6, Yokneam Illit, Israel
 
2069203
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: +972.4.959.0123
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
 
Trading Symbol(s)
 
Name of Each Exchange on Which Registered

Ordinary Shares, par value NIS 0.25 per share

 
LFWD
 
Nasdaq Capital Market
 
Securities Registered Pursuant to Section 12(g) of the Act: None
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
 
Yes No 
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
 
Yes No 

 
Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 
Yes No 
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
 
Yes  No 
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
       
Large accelerated filer
 
Accelerated filer 
 
Non-accelerated filer
 
Smaller reporting company
 
 
 
Emerging growth company
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 USC. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
 
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
 
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
 
Yes  No 
 
The aggregate market value of the Ordinary Shares held by non-affiliates of the Registrant based upon the closing price of the Ordinary Shares as reported by The Nasdaq Capital Market on June 30, 2023 (the last business day of the Registrant’s most recently completed second fiscal quarter) was $35,050,478.
 
As of February 27, 2024, the Registrant had outstanding 59,480,132 Ordinary Shares, par value NIS 0.25 per share.
 
DOCUMENTS INCORPORATED BY REFERENCE
 
Portions of our proxy statement for our 2024 Annual Meeting of Shareholders, which is to be filed within 120 days after the end of our 2023 fiscal year, are incorporated by reference into Part III of this annual report on Form 10-K.
 

 
 
REWALK ROBOTICS LTD.
FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2023
TABLE OF CONTENTS

 
Page
No
PART I
     
1
24
55
 55
56
     
56
56
 
 
 
PART II
 
57
58
58
71
71
71
71
72
72
 
 
 
PART III
 
73
 74
74
74
74
 
 
 
PART IV
 
75
77
78
79
F -1

i

 
Definitions and Introduction
 
Our legal name is ReWalk Robotics Ltd. As of January 29, 2024, we began doing business as “Lifeward”. We are a company limited by shares organized under the laws of the State of Israel and were founded in 2001. In September 2014, we listed our shares on The Nasdaq Global Market, and in May 2017, we transferred our listing to The Nasdaq Capital Market. We have irrevocably appointed Lifeward, Inc. (formerly ReWalk Robotics, Inc.) as our agent to receive service of process in any action against us in any United States federal or state court. The address of Lifeward, Inc. is 200 Donald Lynch Blvd., Marlborough, Massachusetts 01752. As used herein, and unless the context clearly indicates otherwise, the terms “ReWalk”, “Lifeward”, the “Company”, “we”, “us”, “our” or “ours” refer to ReWalk Robotics Ltd. DBA Lifeward and its subsidiaries.
 
Special Note Regarding Forward-Looking Statements and Risk Factors Summary
 
This annual report on Form 10-K (“annual report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities, potential market opportunities and the effects of competition. Forward-looking statements may include projections regarding our future performance and, in some cases, can be identified by words such as “anticipate,” “assume,” “believe,” “could,” “seek,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “should,” “will,” “would” or similar expressions that convey uncertainty of future events or outcomes and the negatives of those terms. These statements may be found in the sections of this annual report titled “Part I. Item 1. Business,” “Part I. Item 1A. Risk Factors,” “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this annual report. The statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the statements.
 
These factors include those listed in “Part I. Item 1A. Risk Factors,” including those factors summarized below.
 
our expectations regarding future growth, including our ability to increase sales in our existing geographic markets and expand to new markets;
our ability to maintain and grow our reputation and the market acceptance of our products;
our ability to achieve reimbursement from third-party payors or advance Centers for Medicare & Medicaid Services (“CMS”) coverage for our products;
our ability to regain and maintain compliance with the continued requirements of The Nasdaq Capital Market and the risk that our ordinary shares will be delisted if we fail to regain and maintain compliance with such requirements;
our ability to successfully integrate the operations of AlterG, Inc. into our organization, and realize the anticipated benefits therefrom;
our ability to have sufficient funds to meet certain future capital requirements, which could impair our efforts to develop and commercialize existing and new products;
our ability to leverage our sales, marketing and training infrastructure;
our ability to grow our business through acquisitions of businesses, products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business;
our expectations as to our clinical research program and clinical results;
our ability to obtain certain components of our products from third-party suppliers and our continued access to our product manufacturers;
our ability to improve our products and develop new products;
our compliance with medical device reporting regulations to report adverse events involving our products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on our ability to market and sell our products;
our ability to gain and maintain regulatory approvals and to comply with any post-marketing requests;
the risk of a cybersecurity attack or incident relating to our information technology systems significantly disrupting our business operations;
our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;

ii

the impact of substantial sales of our shares by certain shareholders on the market price of our ordinary shares;
our ability to use effectively the proceeds of our offerings of securities;
the impact of the market price of our ordinary shares on the determination of whether we are a passive foreign investment company;
market and other conditions, including the extent to which inflation or global instability may disrupt our business operations or our financial condition or the financial condition of our customers and suppliers, including the outbreak of war between Israel and Hamas and the ongoing tension between China and Taiwan; and
other factors discussed in “Part I. Item 1A. Risk Factors.”
 
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur.
 
You should not put undue reliance on any forward-looking statements. Any forward-looking statement in this annual report speaks only as of the date hereof. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this annual report, to conform these statements to actual results or to changes in our expectations.
 
Where You Can Find Other Information
 
Our principal executive offices are located at 3 Hatnufa Street, Floor 6, Yokneam Illit 2069203, Israel, and our telephone number is +972 (4) 959-0123. Our website is golifeward.comInformation contained, or that can be accessed through, our website does not constitute a part of this annual report and is not incorporated by reference herein. We have included our website address in this annual report solely for informational purposes. Information that we furnish or file with the Securities and Exchange Commission (the “SEC”), including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to, or exhibits included in, these reports are available for download, free of charge, on our website as soon as reasonably practicable after such materials are filed or furnished with the SEC. The SEC also maintains a website at www.SEC.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our SEC filings, including exhibits filed or furnished therewith, are also available on this website.

iii


PART I
 
ITEM 1. BUSINESS
 
Overview
 
We are a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community.  Our initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury (“SCI Products”).  These devices are robotic exoskeletons that are designed for individuals with paraplegia that use our patented tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement.  These SCI Products allow individuals with spinal cord injury (“SCI”) the ability to stand and walk again during everyday activities at home or in the community. In March 2023, we received clearance of our premarket notification (“510(k)”) from the U.S. Food and Drug Administration (“FDA”) for the ReWalk Personal Exoskeleton with stair and curb functionality, which adds usage on stairs and curbs to the indication for use for the device in the United States (U.S.). The clearance permits U.S. customers to participate in more walking activities in real-world environments in their daily lives where stairs or curbs may have previously limited them when using the exoskeleton for its intended, FDA-indicated uses. This feature has been available in Europe since initial CE Clearance, and real-world data from a cohort of 47 European users throughout a period of over seven years consisting of over 18,000 stair steps was collected to demonstrate the safety and efficacy of this feature and support the FDA submission.
 
We have sought to expand our product offerings beyond the SCI Products through internal development and distribution agreements and acquisitions.  We have developed our ReStore Exo-Suit device, which we began commercializing in June 2019. The ReStore is a powered, lightweight soft exo-suit intended for use during the rehabilitation of individuals with lower limb disabilities due to stroke. During the second quarter of 2020, we finalized and moved to implement two separate agreements to distribute additional product lines in the United States. We are the exclusive distributor of the MYOLYN MyoCycle FES Pro cycles to U.S. rehabilitation clinics and for the MyoCycle Home cycles available to US veterans through the Veterans Health Administration (“VHA”) hospitals. In the second quarter of 2020, we also became the exclusive distributor of the MediTouch Tutor movement biofeedback systems in the United States; however, due to unsatisfactory sales performance of the MediTouch product lines, we terminated this agreement as of January 31, 2023. We refer to the MediTouch and MyoCycle devices as our “Distributed Products.”
 
On August 11, 2023, we made our first acquisition to supplement our internal growth when we acquired AlterG, Inc. (“AlterG”), a leading provider of Anti-Gravity systems for use in physical and neurological rehabilitation. Our AlterG Anti-Gravity systems use patented, National Aeronautics and Space Administration (“NASA”) derived differential air pressure (“DAP”) technology to reduce the effects of gravity and allow patients to rehabilitate with finely calibrated support and reduced pain. AlterG Anti-Gravity systems are utilized in over 4,000 facilities globally in more than 40 countries. We will continue to evaluate other products for distribution or acquisition that can broaden our product offerings further to help individuals with neurological injury and disability.
 
We are in the research stage of ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke, and we are currently evaluating the reimbursement landscape and the potential clinical impact of this device. This product would be a complementary product to ReStore as it provides active assistance to the ankle during plantar flexion and dorsiflexion for gait and mobility improvement in the home environment, and it received Breakthrough Device Designation from the FDA in November 2021.  Further investment in the development path of the ReBoot was paused in 2023 pending determination regarding the clinical and commercial opportunity of this device.
 
Our principal markets are primarily in the United States and Europe with some lesser sales in Asia, the Middle East and South America. We sell our products primarily directly in the United States, through a combination of direct sales and distributors (depending on the product line) in Germany, Canada, and Australia, and primarily through distributors in other markets. In markets where we sell direct to consumers, we have established relationships with clinics and rehabilitation centers, professional and college sports teams, and individuals and organizations in the SCI community, and in markets where we do not sell direct to consumers, our distributors maintain these relationships. We have primary offices in Marlborough, Massachusetts, Fremont, California, Berlin, Germany and Yokneam, Israel, from where we operate our business.
 
We have in the past generated and expect to generate in the future revenue from a combination of clinics and rehabilitation centers, commercial distributors, third-party payors (including private and government payors), professional and college sports teams, and self-pay individuals. While a broad uniform policy of coverage and reimbursement by third-party commercial payors currently does not exist in the United States for exoskeleton technologies such as the ReWalk Personal Exoskeleton, we are pursuing various paths of reimbursement and support fundraising efforts by institutions and clinics, such as the VHA policy that was issued in December 2015 for the evaluation, training, and procurement of ReWalk Personal Exoskeleton systems for all qualifying veterans living with SCI across the United States.
 
We have also pursued updates with the CMS to clarify the Medicare coverage category (i.e., benefit category) applicable for personal exoskeletons. In 2022, the National Spinal Cord Injury Statistical Center (“NSCISC”) reported that CMS is the primary payor for approximately 57% of the SCI population which are at least five years post their injury date, with Medicare representing a majority of this percentage. In July 2020, following a successful submission and hearing process, a code was issued for ReWalk Personal Exoskeleton, which may be used for purposes of claim submission to Medicare, Medicaid, and other payors. 

1

 
On November 1, 2023, CMS released the Calendar Year 2024 Home Health Prospective Payment System Final Rule, CMS-1780-F (“Final Rule”), which was adopted through the notice and comment rulemaking process. The Final Rule includes a policy confirming that personal exoskeletons are included in the Medicare brace benefit category, as of January 1, 2024. Medicare personal exoskeleton claims with dates of service on or after January 1, 2024 that are billed using HCPCS code K1007 are assigned to the brace benefit category. CMS reimburses items classified under the brace benefit category using a lump sum payment methodology.
 
On November 29, 2023, CMS included the “ReWalk Personal Prosthetic Exoskeleton System” in the HCPCS public meeting where it solicited feedback on a preliminary payment determination of $94,617 for HCPCS code K1007. The preliminary payment determination was made by CMS by applying a “gap filling” process, which was used in light of CMS determining that the code describing the technology has no fee schedule pricing history and that lower extremity exoskeletons incorporate “revolutionary features” that cannot be described by or considered comparable to any other existing code or combination of codes. As part of gap-filling, CMS utilizes verifiable supplier or commercial pricing information and adjusts this pricing information according to a deflation and update factor methodology. In applying this formula to the K1007 code describing the ReWalk Personal Exoskeleton, CMS says that it relied on information about average prices from 2020 market transactions for which CMS had data.
 
CMS solicited information on updated verifiable market transactions from ReWalk, as well as any other makers of similar bilateral, lower limb exoskeletons, to “ensure that the Medicare payment amount for this code accurately reflects the full market of devices that would be classified in this code.” We participated in the HCPCS meeting process on November 29, 2023 to provide additional information to help ensure that the final payment determination accurately reflects current pricing information related to the market of lower-limb exoskeleton devices, including the current ReWalk Personal Exoskeleton. A final Medicare payment determination is expected from CMS in first quarter of 2024 with an April 1, 2024, effective date.
 
In Germany, we continue to make progress toward achieving coverage from the various government, private and worker’s compensation payors for our SCI products. In September 2017, each of German insurer BARMER GEK (“BARMER”) and national social accident insurance provider Deutsche Gesetzliche Unfallversicherung (“DGUV”), indicated that they will provide coverage to users who meet certain inclusion and exclusion criteria. In February 2018, the head office of German Statutory Health Insurance (“SHI”) Spitzenverband (“GKV”) confirmed their decision to list the ReWalk Personal Exoskeleton system in the German Medical Device Directory. This decision means that ReWalk is listed among all medical devices for compensation, which SHI providers can procure for any approved beneficiary on a case-by-case basis. During the year 2020 and 2021, we announced several new agreements with German SHIs, including TK and DAK Gesundheit, as well as the first German Private Health Insurer (“PHI”), which outline the process of obtaining our devices for eligible insured patients. We are also currently working with several additional SHIs on securing a formal operating contract that will establish the process of obtaining a ReWalk Personal Exoskeleton for their beneficiaries within their system. Additionally, to date, several private insurers in the United States and Europe are providing reimbursement for ReWalk in certain cases.
 
ReWalk Personal Exoskeleton and ReWalk Rehabilitation Exoskeleton
 
Development of our SCI Products took over a decade and was spurred by the experiences of our founder, Dr. Amit Goffer, who became a quadriplegic due to an accident. Current ReWalk designs are intended for people with paraplegia, an SCI resulting in complete or incomplete paralysis of the legs, who have the use of their upper bodies and arms. We currently offer two products in this category: the ReWalk Personal Exoskeleton and the ReWalk Rehabilitation Exoskeleton. The ReWalk Rehabilitation Exoskeleton is substantially similar to the ReWalk Personal Exoskeleton system except that it is sold with multiple sizes of our adjustable parts to allow different users the ability to train within a clinic.
 
The ReWalk Personal Exoskeleton is a novel product that seeks to fundamentally change the health and life experiences of users. Designed for daily use, the device is battery-powered and consists of a wearable exoskeleton with integrated motors at the joints, an array of sensors and a computer-based control system to power knee and hip movement. The user controls the device movement using a combination of user inputs on the wrist-worn controller, as well as through subtle weight shifts of the upper body. Because the exoskeleton supports its own weight and facilitates the user’s gait, users do not expend unnecessary energy while walking. The ReWalk Personal Exoskeleton also allows users to sit, stand and climb and descend stairs and curbs. In March 2023, the FDA cleared the ReWalk Personal Exoskeleton for use on stairs and curbs, allowing users to participate in walking activities in more real-world environments in their daily lives and experience more opportunities to enjoy the health benefits of walking.

2

 
●    ReWalk Personal Exoskeleton: intended for everyday use at home, at work or in the community with a trained companion. We began marketing ReWalk Personal Exoskeleton in Europe with CE mark clearance at the end of 2012. We received FDA clearance to market the ReWalk Personal Exoskeleton in the United States in June 2014. ReWalk Personal Exoskeleton units are all manufactured according to the same mechanical specifications. Each unit is then permanently sized to fit the individual user and the software is configured for the user’s specifications by the rehabilitation center, clinic, or distributor. We are currently offering our 6th generation device (6.0) with current research and development for our 7th generation device (7.0).

●    ReWalk Rehabilitation Exoskeleton: the current offering for clinics who wish to implement exoskeleton training is composed of our Rewalk Personal Exoskeleton unit along with multiple sizing of different parts, enabling multiple patient use. The ReWalk Rehabilitation Exoskeleton provides a valuable means of exercise, training, and therapy. Use of the ReWalk Rehabilitation Exoskeleton in the clinic also enables individuals to evaluate their capacity for using the ReWalk Personal Exoskeleton in the future.
          
ReWalk Personal Exoskeleton
 
 
Additionally, we have received regulatory approval to sell the ReWalk Personal Exoskeleton device in other countries. In the future we intend to seek approval from the applicable regulatory agencies in other jurisdictions where we may seek to market ReWalk Personal Exoskeleton. For more information about the safety of using our SCI products see “Part I, Item 1A. Risk Factors—Risks Related to our Business and our Industry— Defects in our products or the software that drives them could adversely affect the results of our operations.”
 
Overview of Spinal Cord Injury
 
Spinal Cord Injury
 
The spine is the central core of the human skeleton and provides structural support, alignment, and flexibility to the body. The spinal cord, housed inside the bones of the spinal column, is a complex bundle of nerves serving as the main pathway for information connecting the brain, and nervous system. Spinal cord injury is a serious medical condition that occurs as a result of physical damage to the nerves of the spinal cord, resulting in a loss of function, such as mobility or feeling. In most people who have spinal cord injury, the spinal cord is intact. Spinal cord injury is not the same as back injury, which may result from pinched nerves or ruptured disks. Even when a person sustains a break in a vertebra or vertebrae, there may not be any spinal cord injury if the spinal cord itself is not affected. There are two types of spinal cord injury – complete and incomplete. In a complete injury, a person loses all ability to feel and voluntarily move below the level of the injury. In an incomplete injury, there is some functioning below the level of the injury.
 
Upon medical examination, a patient is assigned a level of injury depending on the location of the spinal cord injury. Cervical level injuries cause paralysis or weakness in both arms and legs and is referred to as quadriplegia. Sometimes this type of injury is accompanied by loss of physical sensation, respiratory issues, bowel, bladder, and sexual dysfunction. Thoracic level injuries can cause paralysis or weakness of the legs (paraplegia) along with loss of physical sensation, bowel, bladder, and sexual dysfunction. In most cases, arms and hands are not affected. Lumbar level injuries result in paralysis or weakness of the legs (paraplegia). Loss of physical sensation, bowel, bladder, and sexual dysfunction can occur. The shoulder, arm, and hand functions are usually unaffected. Sacral level injuries primarily cause loss of bowel and bladder function as well as sexual dysfunction.

3

 
Clinical Evidence
 
Published clinical studies indicate the ReWalk Personal Exoskeleton’s ability to deliver a functional walking speed. In addition, certain potential secondary health benefits have been reported by healthcare practitioners and ReWalk users, including study participants. Although these benefits have not been established as conclusive clinical data in randomized controlled trials, these reported secondary health benefits include:
 

reduced pain;
 

improved bowel and urinary tract function;
 

reduced spasticity;
 

increases in joint range of motion for the hip and ankle joints;
 

improved sleep and reduced fatigue;
 

increase in oxygen uptake and heart rate as a result of walking as opposed to sitting and standing;
 

ability to ambulate at a speed greater than 0.4 meters per second, which is considered to be conducive to outdoor related community ambulation; and
 

reduced hospitalizations.
 
We believe that using our SCI Products may have the ability to reduce the lifetime healthcare costs of individuals with spinal cord injuries, which we believe will make our SCI Products economically attractive for individuals and third-party payors. While we believe that using our SCI Products could potentially offer significant advantages over competing technologies and therapies, disadvantages include the time it takes for a user to put on the device, the slower pace of the device compared to a wheelchair, the training required by the user and companion to use the device, the weight of the device when carried, which makes it more burdensome for a companion to transport than a wheelchair, and the requirement that users be accompanied by a trained companion.
 
Market Opportunity
 
Current and near-term market opportunities include providing a solution for persons with SCI that can be used in the clinic and/or home settings. For persons with SCI, reduced physical activity and the predominance of seated activities can lead to severe physical and psychological deterioration, resulting in bad health, poor quality of life, low self-esteem, and high medical expenses. In addition, the secondary medical consequences of paralysis can include difficulty with bowel and urinary tract function, osteoporosis, loss of lean mass, gain in fat mass, insulin resistance, diabetes, and heart disease. The cost of treating these conditions is substantial. The NSCISC estimates that complications related to paraplegia cost approximately $500,000 in the first-year post-injury, excluding indirect costs such as loss in wages, fringe benefits, and productivity, and significant additional amounts over the course of an individual’s lifetime. Further, secondary complications related to spinal cord injury can reduce life expectancies for SCI patients. The young average age at time of injury and significant remaining life expectancy, the likelihood of living at home, and the lifetime cost of treatment highlight the need for an out-of-hospital solution with demonstrated health and social benefits.
 
The NSCISC estimates according to its 2023 SCI Data Sheet that there are 302,000 people in the United States living with SCI, with an annual incidence of approximately 18,000 new cases per year.  According to the VHA data there are approximately 42,000 of such patients who are veterans and are eligible for medical care and other benefits from the VHA, out of which the VHA states that 27,000 veterans are receiving SCI treatment annually. With 25 VHA spinal cord injury centers designated SCI/D Hub locations, the VHA has the largest single network of spinal cord injury care in the United States.
 
The University of Alabama-Birmingham Department of Physical Medicine and Rehabilitation operates the NSCISC, which maintains the world’s largest database on spinal cord injury research. Since 2015, motor vehicle crashes have been the leading cause of reported spinal cord injury cases (38%), followed by falls (32%), acts of violence (15%) and sports injuries (8%). Approximately 79% of spinal cord injuries occur among the male population. According to NSCISC data, upon hospital discharge, 87% of persons with spinal cord injuries are sent to private, non-institutional residence (in most cases, their homes prior to injury).
 
Based on information from the 2022 annual report published by the NSCISC, 40% of the total U.S. population of SCI patients suffered injuries between levels T4 and L5. Four published ReWalk trials for SCI patients had an aggregate screening acceptance rate of 50% considering all current FDA limitations, resulting in an estimated 20% of the total population of SCI patients can be considered as candidates for current ReWalk Personal Exoskeleton or ReWalk Rehabilitation Exoskeleton according to the device instructions for use. For important qualifying information about this determination, see “Part I, Item 1A. Risk Factors—Risks Related to our Business and our Industry—The market for medical exoskeletons, including soft exo-suit devices, remains relatively new and unproven, and important assumptions about the potential market for our current and future products may be inaccurate.”

4

 
Third-Party Reimbursements
 
United States
 
In the U.S., individuals typically obtain a ReWalk Personal Exoskeleton for home use through third-party medical coverage. For an individual who suffered an SCI through a work-related incident, workers’ compensation insurance can be a source of funding to purchase the device.  Similarly, for U.S. veterans, an individual may be covered by the VHA for the purchase of the device regardless of whether the SCI occurred during active military service.
 
 In December 2014, the VHA issued a national policy or standard operating procedure (“SOP”) for the evaluation, training, and procurement of ReWalk Personal Exoskeleton systems for all qualifying veterans across the United States and U.S. Territories.  The VHA SOP is the first national coverage policy in the United States for qualifying individuals who are living with spinal cord injury. In June 2018, the VHA updated the SOP, in part, to expand training options for individuals who could not complete the mandatory training due to excessive distance/drive times from a VHA-designated site. As of December 31, 2023, we had placed 42 units as part of the VHA policy. The VHA accounted for 12% of our total revenue for the year ended December 31, 2023.
 
We continue to work with the VHA to both accelerate the pace of implementation of the current VHA policy nationally, and to again expand opportunities for veterans to gain access to assessments, training, and devices in facilities outside VHA’s traditional spinal cord injury “hub and spoke” infrastructure.  Community-based, non-VHA clinics are also being leveraged to allow veterans to be trained closer to their homes, while still being reimbursed by the VHA as part of the VHA’s Community Care Network program.
 
Successful commercialization depends in significant part on adequate coverage and reimbursement from third party payors, which may include government payors (such as Medicare and Medicaid programs in the United States), managed care organizations, and private health insurers.  In general, each third-party payor decides which devices will be covered and reimbursed, establishes reimbursement and co-pay levels and sets conditions for coverage and reimbursement.
 
While no broad uniform policy of coverage and reimbursement for electronic exoskeleton medical technology exists among commercial insurance payors in the United States, reimbursement may be evaluated by the payor on a case-by-case basis. To date, payments for the ReWalk Personal Exoskeleton have been made primarily through case-by-case determinations by third-party payors, including commercial insurers in the United States, by self-payors and donations and, to a lesser extent, through the use of funds from insurance and/or accident settlements.
 
As of December 31, 2023, we had 21 cases pending in the United States for private insurance and CMS coverage decisions.
 
According to the NSCISC 2022 annual report, approximately 57% of the spinal cord injury population received primary coverage from Medicare and Medicaid within five years after their injury date, with Medicare representing the larger primary payor.
 
In order to be covered and reimbursed by Medicare, the ReWalk Personal Exoskeleton must, among other things, be classified into an applicable Medicare benefit category.  In addition, appropriate codes describing the technology must also be established to facilitate billing and claims processing.
 
In December 2019, we submitted the first application for a unique code to describe the ReWalk Personal Exoseleton and, in July 2020, a unique code was issued for ReWalk Personal Exoskeleton.  On November 1, 2023, CMS released the Final Rule, which was adopted through the notice and comment rulemaking process. The Final Rule includes a policy confirming that personal exoskeletons are included in the Medicare brace benefit category Medicare personal exoskeleton claims with dates of service on or after January 1, 2024 that are billed using HCPCS code K1007 will be assigned to the brace benefit category. CMS reimburses items classified under the brace benefit category using a lump sum payment methodology.
 
On November 29, 2023, CMS included the “ReWalk Personal Prosthetic Exoskeleton System” in the HCPCS public meeting, where the agency had proposed a preliminary payment determination of $94,617 for HCPCS code K1007. The preliminary payment determination was made by CMS by applying a “gap filling” process, which was used in light of CMS determining that the code describing the technology has no fee schedule pricing history and that lower extremity exoskeletons incorporate “revolutionary features” that cannot be described by or considered comparable to any other existing code or combination of codes. As part of gap-filling, CMS stated that it relied on information about average prices from 2020 market transactions for which CMS had data. In the agenda describing the preliminary payment determination, CMS noted that it would welcome information on updated verifiable market transactions. We participated in the HCPCS meeting process to provide additional information to help ensure that the final payment determination accurately reflects current pricing information related to the market of lower-limb exoskeleton devices, including the current ReWalk Personal Exoskeleton. A final Medicare payment determination is expected from CMS in first quarter of 2024 with an April 1, 2024, effective date.

5

 
For more information about coverage and reimbursement risk factors, see “Part I, Item 1A. Risk Factors—Risks Related to our Business and our Industry.”
 
As part of our plan for growth, we intend to continue working with both national and regional commercial insurance companies, health care practitioners, physicians, researchers, and the SCI community to support efforts to demonstrate the benefits of our SCI Products. In addition, we plan to pursue potential coverage policies with third party payors based on supportive data and appeal rulings that have deemed exoskeleton devices a “medically necessary” under the standard of care for individuals with SCI. Our efforts in the future will be focused on continued education of third-party payors through data application, supporting clinical trials to demonstrate the clinical benefits of using the SCI Products, working with advocacy groups, ongoing communication as well continuing to seek greater clarity regarding Medicare coverage and reimbursement standards applicable to the ReWalk Personal Exoskeleton.
 
Europe
 
Reimbursement for ReWalk in Europe varies by country and historically certain third-party payors have provided reimbursement for our products in certain cases in Germany and Italy.
 
We initially focused our European efforts in Germany where we continue to make progress toward achieving ReWalk coverage from the various government, private, and workers’ compensation payors. Specifically:
 

In September 2017, the German insurer BARMER confirmed it will provide ReWalk systems to all qualifying beneficiaries. BARMER provides coverage for nearly nine million people in Germany, as a member of the SHI network and one of the most significant national insurers in the country. Exoskeletons are provided to users that meet certain inclusion criteria and assessment by the German Health Insurance Medical Service (Medizinischer Dienst der Krankenversicherungen) before and after training. We remain in discussion with BARMER regarding a contract based on their 2017 decision.
 

In September 2017 Germany’s national social accident insurance provider, DGUV, indicated that the DGUV’s member payors, including the health insurance association Berufsgenossenschaft (also known as BG) and state insurers, will approve the supply of exoskeleton systems for qualifying beneficiaries on a case-by-case basis. DGUV is comprised of 36 different insurers, which provide coverage for more than 80 million individuals in Germany. Per the agreement, eligible individuals go to BG clinics for evaluation as a part of the procurement.  In May 2020 the DGUV agreed to a binding offer to the evaluation, training, and supply of the ReWalk Personal Exoskeleton to qualified individuals.
 

In February 2018, the GKV-Spitzenverband (Central Federal Association of (the) Statutory Health Insurance Funds) confirmed its decision to list the ReWalk Personal Exoskeleton system in the German MDD, a comprehensive list of all medical devices which are principally and regularly reimbursed by German SHI and PHI providers. The ReWalk Personal was added to the official German list of medical aids, code number 23.29.01.2001, in June 2018. This decision means that ReWalk Personal Exoskeleton is listed among all medical devices for compensation, which SHI providers can procure for any approved beneficiary on a case-by-case basis.
 

During the year 2020 we announced several new agreements with SHIs such as TK and DAK-Gesundheit and others as well as the first PHI that chose to enter into an agreement with us that outline the process to obtaining a device for eligible insured patients.
 

In March 2021 we entered into a contract with BKK Mobile Oil health insurance to supply ReWalk’s Personal Exoskeleton to eligible persons in Germany.
 

In June 2020, BARMER appealed the decision of the State Social Court, which ordered the supply of the SHI’s insured SCI person with ReWalk. The State Social Court ruled and deemed ReWalk as the medical aid which will directly compensate the plaintiff’s disability. BARMER initially appealed this ruling with the Federal Social Court (Bundessozialgericht), but later, in November 2022, withdrew its pending case and accepted the prior ruling from the state court that exoskeletons are considered as a direct disability compensation.  This outcome means that an eligible insured person with spinal cord injury (SCI) in Germany has a legal basis for the supply of an exoskeleton as an orthopedic aid for direct disability compensation. Patients in Germany who are covered under these contracts and policies must be medically evaluated for their eligibility to use the ReWalk Personal Exoskeleton device. If medically qualified, the patient, along with his or her physician, must apply for coverage of the device. If a patient is found eligible and medically fit to use our ReWalk Personal Exoskeleton device, we first enter into a rental agreement which allows the patient the necessary period to train on how to use the device which usually takes between 3 to 6 months and then after approval from the insurer the patient receives a personal device to use at home or in the community. We are currently working with several additional SHIs and PHIs on securing a formal operating contract that will establish the process of obtaining a ReWalk Personal Exoskeleton for their beneficiaries within their system.
 
6


As of December 31, 2023, there were 49 insurance cases pending in Germany. We believe that our recent coverage decisions and the existing claims will eventually lead other German insurers to provide coverage on a broader scale, but this is not guaranteed.   For more information, see “Part I, Item 1A. Risk Factors—Risks Related to our Business and our Industry— We may fail to secure or maintain adequate insurance coverage or reimbursement for our products by third-party payors which risk may be heightened if insurers find the products to be investigational or experimental or if new government regulations change existing reimbursement policies. Additionally, such coverage or reimbursement, even if maintained, may not produce revenue that is high enough to allow us to sell our products profitably.”
 
We continue to support clinical research and academic publications, which we believe will further support the case for coverage.
 
We have distribution agreements in several European countries where we also had success with reimbursement by private insurers and worker’s compensation. One of the examples was achieved in March 2018, when the Italian Ministry of Labor and Social Policy’s statutory insurance corporation put in place a coverage policy that will provide exoskeleton systems for all qualifying beneficiaries. This policy, the first of its kind in Italy, provides individuals with spinal cord injury access to obtain their own ReWalk Personal Exoskeleton device so that they can stand and walk again. Since the initiation of coverage, we have supplied 10 units through our Italian distributor to individuals covered by this policy.
 
Other Funding Sources
 
In addition to being funded by third-party payors, including private insurance plans, government programs such as the VHA, and workers’ compensation plans, ReWalk Personal Exoskeleton is also funded by self-payors. This includes individuals who purchase ReWalk with funds from legal settlements with insurance companies or third parties.
 
AlterG Anti-Gravity System
 
The DAP technology that underpins our AlterG Anti-Gravity systems was originally developed by researchers at the NASA Moffet Field Research Center to help astronauts maintain their muscle strength and bone density during extended periods in space outside of the effects of earth’s gravity.  The DAP technology was used to create a pressurized bubble that could exert pressure on an astronaut while exercising to simulate the impact of gravity.  While the technology ultimately was never implemented by NASA, it also had promise for use on earth.
 
The DAP technology was modified by the founders of AlterG, Inc. for the opposite purpose of using the buoyancy of a pressurized air chamber to uniformly reduce gravitational load and body weight.  With subsequent product development, the initial AlterG Anti-Gravity system design was supplemented with other complementary features.  Our current models utilize a precise air calibration system which modulates the air pressure supporting the user 100 times a second to ensure precise and consistent weight displacement that allows for modification of the pressurized support in one-percent increments of each user’s weight.  Additionally, the AlterG systems can be fitted with cameras for live video monitoring and pressure sensors that track the user’s gait pattern.
 
Our proprietary Stride Smart software can provide real-time data and analytics so that the user can watch and self-correct gate abnormalities.  Clinicians also can simultaneously read and respond to five gait assessment key performance indicators (“KPIs”).  The five KPIs include:
 
weight-bearing symmetry;
 
step length symmetry;
 
stance time symmetry;
 
cadence (stepping frequency); and
 
pain level.
 
  The Stride Smart software provides clinicians with clear, objective data with which to assess, adjust, and modify a patient’s rehabilitation progress. Since Stride Smart collects and presents patient gait data automatically, clinicians can focus their efforts rehabbing the patient and selecting the data most useful to their gait analysis and correction recommendations.
 
Based on usage patterns and feedback of clinicians, we believe that the AlterG Anti-Gravity system provides a versatile tool for the rehabilitation of lower extremity injuries and conditions.  By treating a broad range of conditions and facilitating faster recovery times, the AlterG Anti-Gravity system enables rehabilitation clinics the opportunity to gain more referrals, increase the throughput of the facility, and improve the productivity of the staff.

7

 
We offer a range of AlterG Anti-Gravity systems depending on the needs and budget of each customer as follows:
 

FIT – This is the entry-level and most affordable model of anti-gravity system.  In addition to the standard DAP technology, the FIT also includes live video monitoring.  The treadmill is equipped to run at up to 12 miles per hour (“mph”) in forward and 3 mph in reverse with a maximum incline of 15 degrees;
 

VIA – The mid-range model has the features of the FIT, plus the inclusion of the Stride Smart analytics and the AlterG Assistant; and
 

PRO – The PRO is our top-of-the-line model for sports medicine applications with utilization by professional and collegiate athletes.  The PRO includes all the features of the VIA, plus several additional features that add durability and accommodate elite user performance.  The treadmill is a high-performance slat belt design equipped to run at up to 18 m.p.h in forward and 10 m.p.h in reverse.
 
In addition to sales of the AlterG Anti-Gravity systems, we also provide consumables and services that support the utilization of the installed base.   For example, the AlterG systems require the users to wear proprietary shorts that zip the user into the air chamber to create the seal to retain the air that pressurizes the chamber.  With frequent use, these shorts need to be periodically replaced.  Additionally, we maintain a network of approximately 40 contract service engineers who perform the installation, maintenance, and repair work.  As the 12-month assurance warranties expire, we market extended service contracts which can provide a recurring revenue base that can grow with the size of the installed base.
 
The potential market for AlterG Anti-Gravity systems is large and fragmented with several types of facilities that treat patients with conditions who could benefit from rehabilitation using partial weight displacement.  According to the MedPAC 2021 Report, there are approximately 1,150 inpatient rehabilitation facilities in the U.S.  These facilities treat patients with a range of conditions including stroke, lower extremity fractures, joint replacements, neurological conditions and brain injury, cardiac conditions, and other types of orthopaedic conditions.  Depending on the specific details of each case, many of these patients are candidates for therapy using partial weight displacement.  Globally, we estimate that there are approximately 3,500 inpatient rehabilitation facilities that are comparable in budget and quality of care to those in the U.S.
 
The largest potential market for the AlterG Anti-Gravity are outpatient clinics, some of which are in national and regional affiliations and most of which are independent facilities.  According to the IBIS World website (which tracks the number of physical therapy rehabilitation centers), there are approximately 44,000 outpatient clinics in the U.S.  These facilities treat patients with less severe conditions than inpatient facilities with a greater mix of patients skewed towards lower extremity fractures, joint replacements, and other types of orthopedic conditions.  Globally, we estimate that there are over 100,000 outpatient clinics based on scaling of population and standard of living that there are over 100,000 outpatient clinics. One other major segment of the market for AlterG systems consists of professional and elite level sports teams, including major university and college sports programs.  These teams use the AlterG Anti-Gravity system to assist their players in maintaining higher levels of fitness and accelerating the recovery time from sports-related injuries.  Based on our internal estimates of the market, we believe that there are approximately 1,400 sports programs in the U.S. who are potential AlterG customers.  Globally, we estimate this figure to be greater than 4,000 teams.

8

 

 
ReStore Exo-Suit
 
In June 2017 we unveiled our lightweight exo-suit ReStore system designed initially for rehabilitation of stroke patients. The patented soft exo-suit technology was originally developed at Harvard University’s Wyss Institute for Biologically Inspired Engineering (“Harvard”), where it also underwent initial clinical testing that demonstrated potential to improve walking for stroke survivors. ReWalk and Harvard entered into a multi-year research collaboration agreement in 2016 which provides ReWalk license to intellectual property relating to lightweight exo-suit system technologies for lower limb disabilities and provides access to future innovations that emerge from this collaboration and may be relevant to additional stroke products or other therapies. The development and regulatory clearance process for ReStore took us approximately three years.  We received FDA clearance for ReStore in June 2019 and CE clearance in May 2019. Following the regulatory clearances, we began to commercialize the ReStore product. For more information on the collaboration with Harvard, see “Research and Development-Research and Development Collaborations.”
 
 
 
ReStore Exo-Suit
 
The ReStore product consists of a soft, fabric-based design that connects to a lightweight waist pack and mechanical cables that help lift the patient’s affected leg in synchronized timing with their natural walking pattern. The lightweight structure wraps around the waist and supports an actuator with a motor, computer, and cable, along with sensors attached to a stable point on the user’s calf and footplate in the user’s shoe. This design provides targeted mechanical assistance to the patient’s ankle during forward propulsion (plantarflexion) and ground clearance (dorsiflexion), two key phases of the gait cycle. The ReStore system is designed to provide advantages to stroke rehabilitation clinics and therapists as compared to other traditional therapies and devices by enabling the therapist to specifically target and train for improved propulsion symmetry, which is a key contributor to improved walking speed and efficiency for patients recovering from stroke.
 
Published clinical trials using the soft exo-suit design on stroke patients have shown varying levels of improvements, with the main ones being improved walking speed, improved propulsion symmetry, reductions in compensatory behaviors including paretic hip hiking and circumduction as well as reduction in metabolic burden associated with post stroke walking. There are additional studies on-going with the ReStore device that examine the improvement in walking speed following training with the soft exo-suit as well as comparing the results of traditional training with soft exo-suit training.
 
9


The main market for ReStore is rehabilitation clinics with a stroke therapy program or clinics that would like to broaden their stroke presence. This product is marketed and sold directly to rehabilitation clinics for use during the treatment of their patients which is generally reimbursed by commercial and government payors. During the second half of 2019 we expanded our sales and marketing presence in the United States to accelerate product penetration after receiving FDA and CE clearance. These efforts were adversely impacted by the COVID-19 pandemic, as clinics and hospitals shifted resources and attention during the pandemic. During 2023, new research has been published on the clinical efficacy using ReStore in stroke rehabilitation and we see this technology as a building block for future portfolio development. Geographically, the ReStore system is commercially available through our direct sales teams in the United States and Germany.
 
Stroke incidence rate in the United States is approximately 800,000 incidences per year and the survival rate is approximately 80%. Of this stroke population, 80% are left with some type of lower limb disability. This patient population seeks treatment in one of the approximately 1,600 primary and comprehensive inpatient, outpatient, and rehabilitation clinics providing therapy to stroke patients. With the clinical evidence we have to date on ReStore, its unique design and its cost-effectiveness compared to other products, we believe the ReStore soft exosuit has an opportunity to be adopted by clinics for use in therapy of their stroke patients.  However, we also recognize that the process to achieve that might be long and will likely only occur once national or regional healthcare providers include the device within their stroke therapy programs. We also believe that to accelerate adoption, further clinical evidence is required as well as continued education on the new ReStore design and its unique advantages compared to current therapies and products.
 
As of December 31, 2023, and December 31, 2022, we had placed 42 and 33 ReStore units, respectively.
 
ReBoot Product
 
We are also in the research stage of ReBoot, a soft exoskeleton for stroke home and community use, and are currently evaluating the reimbursement landscape and the potential clinical impact of this device. This product would be a complementary product to ReStore, and it received Breakthrough Device Designation from the FDA in November 2021.  The ReBoot is a lightweight, battery-powered exo-suit intended to assist ambulatory functions in individuals with reduced ankle function related to neurological injuries, such as stroke.  The ReBoot is a customizable personalized device intended for home and community use with an estimated market of approximately 400,000 annual stroke patients who require walking assistance after being discharged home.  Further investment in the development path of the ReBoot was paused in 2023 pending further determination about the clinical and commercial opportunity of this device.
 
Sales and Marketing Activities
 
With added resources from the AlterG acquisition, we have created a U.S. commercial team that we believe has the capacity and capabilities to support a broad range of physical and neurological rehabilitation products for use in facilities, the home and the community.  As part of this integration, we have rebranded our company under the name Lifeward, to emphasize our commitment to pioneering a portfolio of innovative technologies to empower the pursuit of life’s ambitions in the face of physical limitation or disability. For the sake of clarity, we will continue to use the ReWalk name to designate our line of Exoskeleton products and the AlterG name to describe our line of anti-gravity systems.
 
In the U.S., our commercial efforts are direct sales focused generally on rehabilitation centers, hospitals, rehabilitation clinics, and similar facilities that treat patients who could benefit from offerings within our portfolio of products.  We market our facility-based products, such as the AlterG and the MyoCycle Pro to these institutions for their use in providing care to their patients.  We also market our home-based products, such as the ReWalk Personal Exoskeleton or MyoCycle Home, to physicians and physical therapists for referrals to individuals who could benefit from these devices as part of a home-based activity regimen that elevates the health and wellness of these individuals.  Additionally, some sales of the ReWalk Personal Exoskeleton or MyoCycle Home are also generated from referrals through the spinal cord injury community and direct inquiries from potential users through our different marketing efforts. Beyond healthcare facilities, we also market our AlterG systems to professional and college sports teams who use the systems to help their athletes recover from lower extremity sports injuries.
 
Outside the U.S., our distribution varies depending on the product and the geographic market.  We market our ReWalk Personal Exoskeleton product directly in Germany and primarily through third-party distributors, who maintain the customer relationships, in our other markets. We market our AlterG systems directly in Canada and Australia, and in other territories utilize a network of over 40 third-party distributors who generally have exclusivity in their respective geographic territories.
 
As of December 31, 2023, we had placed 131 ReWalk Rehabilitation Exoskeleton units in use at rehabilitation centers and 598 ReWalk Personal Exoskeleton units in a home or community use, compared to 128 ReWalk Rehabilitation Exoskeleton units and 572 ReWalk Personal Exoskeleton units as of December 31, 2022.  We estimate the installed base of AlterG systems is over 6,000 installed units worldwide as of December 31, 2023.  With the anticipated finalization of the Medicare payment rates for exoskeletons which will be effective April 1, 2024, we intend to aggressively target the eligible Medicare customer base for growth while also continuing to focus on expanding commercial and other reimbursement coverage. Additionally, with our increased direct sales resources and distributor network, we also expect to greater penetrate the base of facilities which could utilize AlterG systems for rehabilitation of their patients.

10

 
Competition
 
The market in which we operate is characterized by active competition and rapid technological change, and we expect competition to increase. Competition arises from providers of other mobility systems and prosthetic devices used in the clinic and/or home settings.
 
We are aware of several other companies developing competing technology and devices, and some of these competitors may have greater resources, greater name recognition, broader product lines, or larger customer bases than we do.
 
Our principal competitors in the medical exoskeleton market consist of Ekso Bionics (NASDAQ: EKSO), Rex Bionics Pty, Cyberdyne (Tokyo Stock Exchange: 7779), FREE Bionics, DIH (formerly known as Hocoma), Wandercraft, and Bioness (acquired by Bioventus (NASDAQ: BVS). The competitors’ products may also compete with the ReStore soft exo-suit, as well as manual forms of gait training which do not involve robotic assistive devices.
 
We believe that our ReWalk Personal Exoskeleton possesses key competitive advantages over these companies’ products, such as our tilt-sensor technology that provides a self-initiated walking experience, six degrees of freedom which enable a more natural gait, faster functional walking speed, the ability to support its own weight, and broad user specifications. In addition, ReWalk Personal Exoskeleton is the only medical exoskeleton with FDA and CE clearance for use on stairs and curbs, which greatly improves the ability to use the device in everyday real-world environments.
 
We believe that our ReStore soft exo-suit device has several competitive advantages over the products of our competitors, including a design that facilitates a natural, functional walking pattern through flexible materials, sensors, and powered plantarflexion as well as dorsiflexion, making it the only solution of its type of which we are aware of that supports such movements, achieving that with a lower cost and weight than rigid exoskeletal devices.
 
In addition, we compete with alternative devices and alternative therapies, including treadmill-based gait therapies, such as those offered by Hocoma, Tyromotion, Boost, Aretech, BTL, and Reha Technology. Other medical device or robotics companies, academic and research institutions, or others may develop new technologies or therapies that provide a superior walking experience, are more effective in treating the secondary medical conditions that we target or are less expensive than our current or future products. Our technologies and products could be rendered obsolete by such developments.
 
We may also compete with other treatments and technologies that address the secondary medical conditions that ReWalk seeks to mitigate.
 
Community Engagement and Education
 
We devote significant resources to engagement with and education of the spinal cord injury community with respect to the benefits of our SCI Products, as well as for our ReStore device. We actively seek opportunities to partner with hospitals, rehabilitation centers and key opinion leaders to engage in research and development and clinical activities. We also seek to educate and gain support from organizations such as patient advocacy groups and clinician societies with the goal of promoting adoption of exoskeleton technology from patient, clinician, and payor communities. We believe that our success has been and will continue to be driven in part by our reputation and acceptance within the spinal cord injury community.
 
To date, multiple advocacy groups have issued public endorsements of the ReWalk Personal Exoskeleton, including leading United States-based national organizations such as the United Spinal Association and the Dana and Christopher Reeves Foundation, as well as others. In addition, the National Institute for Health and Care excellence in the United Kingdom (also known as “NICE”), has issued a public announcement regarding the ReStore device.

11

 
Services and Customer Support
 
Our centers of operations in Marlborough, Massachusetts, Fremont, California, and Berlin, Germany coordinate all customer support and product service functions for North America and Europe, respectively, through dedicated technical service personnel who provide product services and customer support through training to healthcare providers and support to product users.
 
Research and Development
 
We are committed to investing in a robust research and development program to support our current product line and to potentially develop our pipeline of new and complementary products, and we believe that ongoing research and development efforts are essential to our success. Our research and development team consists of both in-house and external staff, including engineers, machinists, researchers and marketing, quality, manufacturing, regulatory and clinical personnel, which we employ as efficiently as possible meet our current and future needs, and who work closely together to design, enhance, and validate our technologies. This research and development team conceptualizes technologies and then builds and tests prototypes before refining and/or redesigning, as necessary. Our regulatory and clinical personnel work in parallel with engineers and researchers, allowing us to anticipate and resolve potential issues at early stages in the development cycle. Our level of research and development investment depends on our available resources, business plans, and future needs. For more information, see “Part I, Item 1A. Risk Factors — Risks Related to Our Business and Our Industry — Our future growth and operating results will depend on our ability to develop, receive regulatory clearance for, and commercialize new products and penetrate new product and geographic markets.”
 
We are working on product design improvements and expanded labeling for the ReWalk Personal Exoskeleton product which we plan to launch following obtaining regulatory clearance and approvals. In the longer term we are conducting research for our next generation exoskeleton with design improvements and advanced robotic technologies as part of the Human Robot Interaction Consortium research program. New medical indications impacting the ability to walk that we may pursue include multiple sclerosis, cerebral palsy, Parkinson’s disease, and elderly assistance.
 
We are also developing new generations of anti-gravity systems utilizing our DAP technology.  We plan to introduce a new model of the AlterG system in mid-2024 that reduces the cost of manufacturing which in turn will allow us to make it more affordable for independent rehabilitation clinics, thereby expanding the potential market opportunity.  Additionally, we are evaluating other applications for DAP technology to create entirely new rehabilitation systems for our facility-based customers.
 
We conduct our research and development efforts mainly at our facility in Yokneam, Israel. We believe that the close interaction among our research and development and manufacturing groups allows for timely and effective realization of our new product concepts.
 
Our research and development efforts have been financed, in part, through funding from the Israel Innovation Authority (formerly known as Office of the Chief Scientist in the Israel Ministry of Economy) (the “IIA”). From our inception through December 31, 2023, we received funding totaling $2.6 million from the IIA. For more information regarding our research and development financing arrangements, see “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” and “—Grants and Other Funding.”
 
Research and Development Collaborations
 
On April 1, 2022, we entered a research and development cooperation agreement with several companies and universities in the Human Robot Interaction (“HRI”) Consortium, part of the IIA’s MAGNET incentive program. This incentive program provides grants for R&D collaboration as part of a consortium comprised of private businesses and leading academic centers. The goals of the HRI consortium are to “develop advanced technologies aimed at providing robots with social capabilities, enabling them to carry out various tasks and effective interactions with different users in diverse operational environments.”  The total program has a budget of NIS 57 million, which includes funding for research and development grants to help drive technological innovation. The Consortium is a 3-year program which has allocated NIS 1.745 million to fund ReWalk-specific projects over the first 18-month period of the program. As of December 31, 2023, the Company spent total funds in the amount of NIS 1.571 million which has allocated for the first 18-month period. In November 2023, we entered the second 18-month period of the program, the Consortium has allocated NIS 1.336 million to fund ReWalk-specific projects over the second 18-month period. As a member of the HRI Consortium, we collaborate with several universities to develop advanced technologies aimed at improving the human-exoskeleton interaction.  This research collaboration with top researchers in the fields of robotics, behavioral sciences and human-computer interaction will seek to make the use of exoskeletons easier and more natural to promote wider adoption of the technology.

12

 
On May 16, 2016, we entered into the Research Collaboration Agreement (“Collaboration Agreement”) and the Exclusive License Agreement (“Harvard License Agreement”) with Harvard. Under the Collaboration Agreement, we and Harvard agreed to collaborate on research regarding the development of lightweight soft suit exoskeleton system technologies for lower limb disabilities, which are intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications. Under the Collaboration Agreement, we paid Harvard quarterly installment payments to help fund the research. Subject to the terms of the Collaboration Agreement, we and Harvard were required to report our respective research results and findings to each other on a regular basis. The Collaboration Agreement governed ownership of the research results and inventions generated in performance of the research collaboration and provided us the option to negotiate with Harvard for a license to certain new inventions of Harvard conceived in performance of the collaboration. The Collaboration Agreement concluded on March 31, 2022.
 
Under the Harvard License Agreement, we have been granted an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license to certain inventions conceived under our joint research collaboration. Harvard retains the right to practice the patents for research, educational and scholarly purposes. We are required to use commercially reasonable efforts to develop products under the Harvard License Agreement in accordance with an agreed-upon development plan and to introduce and market such products commercially. In addition to an upfront fee and royalties on net sales, we are obligated to pay Harvard certain milestone payments upon the achievement of certain product development and commercialization milestones. We have also agreed to reimburse Harvard for expenses incurred in connection with the filing, prosecution, and maintenance of the licensed patents.
 
The Harvard License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents, or it is terminated in accordance with its terms. We may terminate the License Agreement for any reason upon 60 days’ prior written notice, while Harvard may terminate the License Agreement if we do not maintain requisite insurance or become insolvent. The Harvard License Agreement may also be terminated by Harvard or us due to the other party’s material uncured breach. 
 
The Harvard License Agreement contains, as applicable, customary representations and warranties and customary enforcement, indemnification, and insurance provisions. For further discussion of the Collaboration Agreement and Harvard License Agreement, see Note 10 to our consolidated financial statements for the fiscal year ended December 31, 2023 included elsewhere in this annual report.
 
Intellectual Property
 
Protection of our intellectual property is important to our business. We seek to protect our intellectual property through a combination of patents, trademarks, confidentiality, and assignment agreements with our employees and certain of our contractors and confidentiality agreements with certain of our consultants, scientific advisors and other vendors and contractors. In addition, we rely on trade secrets law to protect our proprietary software and product candidates/products in development.
 
In addition to our portfolio of issued patents and pending patent applications, we license certain patented and patented pending technology from a third party as described above under the “Research and Development” section.
 
As of December 31, 2023, we have 11 issued patents in the United States and 19 issued patents outside of the United States, as well as 13 pending patent applications for our technology in the United States, China, and Europe.  For our patents associated with DAP and other AlterG technology, we have 25 issued patents in the United States and 21 patents issued outside the United States, as well as 10 pending patent applications for anti-gravity associated technology in the United States.
 
In the United States and Europe, we have apparatus patent claims covering aspects of both our exoskeleton and our anti-gravity products and similar devices or systems, which focus on protecting our products in terms of structural characteristics and functionality.  Moreover, we also have method patent claims covering certain methods of operation and control of our exoskeleton and anti-gravity products, which provide additional protection for our technology. We do not currently license any of the technology contained in our currently commercialized ReWalk and AlterG products, other than with respect to technology that is generally publicly available, but we may do so in the future.
 
Patents filed both in the United States and Europe (as well as other countries) generally have a term of 20 years from their earliest effective filing date, although they can be slightly longer depending upon a local jurisdiction’s rules and laws. For example, the oldest of our issued patents relating to our tilt-sensor technology was filed in May 2001 in the United States and would typically expire in May 2021. However, this patent actually expired in April of 2023 due to patent term adjustment (PTA) of 689 days for delays in examination by the United States Patent and Trademark Office.

13

 
We currently hold a registered trademark in the United States, Europe, Israel, and the United Kingdom, for the mark “ReWalk.” We currently hold a registered trademark in United States, Europe and the United Kingdom for the mark “ReStore”.  We currently hold a registered trademark in the United States, Europe, Israel, and the United Kingdom for the mark “Alter G.”  We have also recently sought trademark registration of “Lifeward” in the United States, Europe, and Israel.
 
 We cannot be sure that our intellectual property will provide us with a competitive advantage especially as some of our older patents begin to expire, or that we will not infringe on the intellectual property rights of others. In addition, we cannot be sure that any patents will be granted in a timely manner or at all with respect to any of our patent pending applications. For a more comprehensive discussion of the risks related to our intellectual property, see “Part I, Item 1A. Risk Factors—Risks Related to Our Intellectual Property.”
 
Government Regulation
 
U.S. Regulation  
 
Our medical products and manufacturing operations are regulated by the FDA and other federal and state agencies. Our products are regulated as medical devices in the United States under the Federal Food, Drug, and Cosmetic Act, or the FFDCA, as implemented and enforced by the FDA. The FDA regulates the development, testing, manufacturing, labeling, storage, installation, servicing, advertising, promotion, marketing, distribution, import, export, and market surveillance of our medical devices.
 
Premarket Regulatory Requirements
 
Unless an exemption applies, each medical device commercially distributed in the United States requires either FDA clearance of a 510(k) premarket notification, approval of a premarket approval application (PMA), or issuance of a de novo classification order. Under the FFDCA, medical devices are classified into one of three classes—Class I, Class II or Class III—depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurance of safety and effectiveness. Classification of a device is important because the class to which a device is assigned determines, among other things, the necessity and type of FDA review required prior to marketing the device. Class I devices are those for which reasonable assurance of safety and effectiveness can be assured by adherence to general controls that include compliance with the applicable portions of the FDA’s Quality System Regulation, or QSR, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. Class I also includes devices for which there is insufficient information to determine that general controls are sufficient to provide reasonable assurance of the safety and effectiveness of the device or to establish special controls to provide such assurance, but that are not life-supporting or life-sustaining or for a use which is of substantial importance in preventing impairment of human health, and that do not present a potential unreasonable risk of illness of injury.
 
Class II devices are those for which general controls alone are insufficient to provide reasonable assurance of safety and effectiveness and there is sufficient information to establish “special controls.” These special controls can include performance standards, post-market surveillance, and patient registries. While most Class I devices are exempt from the 510(k) premarket notification requirement, most Class II devices require a 510(k) premarket notification to be marketed in the U.S. As a result, manufacturers of most Class II devices are required to submit to the FDA premarket notifications under Section 510(k) of the FFDCA in order to market or commercially distribute those devices. To obtain 510(k) clearance, manufacturers must demonstrate that the proposed device is “substantially equivalent” to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to premarket approval, or PMA, meaning, (i) a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, (ii) a device that has been reclassified from Class III to Class II or I, or (iii) a device that was found substantially equivalent through the 510(k) process. If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If the device is not “substantially equivalent” to a previously cleared device, the device is automatically a Class III device. The device sponsor must then fulfill more rigorous premarket approval requirements or can request a risk-based classification determination for the device in accordance with the “de novo” classification process, which is a route to market for medical devices that are low to moderate risk but are not substantially equivalent to a predicate device.

14

 
Devices that are intended to be life sustaining or life supporting, devices that are implantable, devices that present a potential unreasonable risk of harm or are of substantial importance in preventing impairment of health, and devices that are not substantially equivalent to a predicate device are placed in Class III and generally require approval of a PMA, unless the device is a pre-amendment device not yet subject to a regulation requiring premarket approval. The PMA process is more demanding than the 510(k) premarket notification process. In a PMA, the manufacturer must demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, including data from preclinical studies and clinical trials. The PMA must also contain a full description of the device and its components, a full description of the methods, facilities and controls used for manufacturing, and proposed labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180 days under the FFDCA to complete its review of a PMA, although in practice, the FDA’s review often takes significantly longer, and can take one year or even longer.
 
Clinical trials are almost always required to support PMAs and are sometimes required to support 510(k) submissions. All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA’s investigational device exemption, or IDE, regulations that govern investigational device labeling, prohibit promotion of the investigational device, and specify recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a “significant risk,” as defined by the FDA, the agency requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. The IDE will automatically become effective 30 days after receipt by the FDA, unless the FDA denies the application or notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE that require modification of the study, the FDA may permit a clinical trial to proceed under a conditional approval. In addition, the study must be approved by, and conducted under the oversight of, an Institutional Review Board, or IRB, for each clinical site. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still comply with abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements.
 
In June 2014, the FDA granted our request for “de novo” classification, and classified ReWalk as a Class II powered exoskeleton device subject to special controls. The ReWalk is intended to enable individuals with spinal cord injuries to perform ambulatory functions under supervision of a specially trained companion, and inside rehabilitation institutions. The special controls established in the de novo classification order for all powered exoskeleton devices include the following: clinical testing to demonstrate safe and effective use considering the level of supervision necessary and the use environment; non-clinical safety and performance testing, including durability testing to demonstrate that the device performs as intended under anticipated conditions of use; a training program; and labeling related to device use and user training. The special controls of this de novo order also apply to competing powered exoskeleton products seeking FDA clearance.
 
In June 2019, the FDA issued a 510(k) clearance for ReStore, which means that the device can be marketed in the U.S. ReStore is intended to be used to assist ambulatory functions in rehabilitation institutions under the supervision of a trained therapist for people with hemiplegia or hemiparesis due to stroke. ReStore complies with special controls for powered exoskeletons as described above. In order for us to market ReStore and ReWalk, we must comply with both these special controls as well as general controls, including controls related to quality, facility registration, reporting of adverse events and labeling. Failure to comply with the general and special controls could lead to removal of ReStore or ReWalk from the market, which would have a material adverse effect on our business.
 
In June 2022, we submitted a 510(k) premarket notification for ReWalk Personal Exoskeleton seeking to enable the stairs functionality and add uses on stairs and curbs to the indication for use for the device in the US. In March 2023, the FDA issued the 510(k) clearance.
 
For more information, see “Part I, Item 1A. Risk Factors-Risks Related to Government Regulation-We are subject to extensive governmental regulations relating to the manufacturing, labeling and marketing of our products, and a failure to comply with such regulations could lead to withdrawal or recall of our products from the market.”
 
Expedited Development and Review Programs
 
FDA’s Breakthrough Devices Program is a voluntary program offered to manufacturers of certain medical devices and device-led combination products that may provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The goal of the program is to provide patients and health care providers with more timely access to qualifying devices by expediting their development, assessment and review, while preserving the statutory standards for marketing authorization.

15

 
The program is available to medical devices that meet certain eligibility criteria, including that the device provides more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, and that the device meets one of the following criteria: (i) the device represents a breakthrough technology, (ii) no approved or cleared alternatives exist, (iii) the device offers significant advantages over existing approved or cleared alternatives, or (iv) the availability of the device is in the best interest of patients. Breakthrough Device designation provides certain benefits to device developers, including more interactive and timely communications with FDA staff, use of post market data collection, when scientifically appropriate, to facilitate expedited and efficient development and review of the device, opportunities for efficient and flexible clinical study design, and prioritized review of premarket submissions.
 
Post-Market Regulatory Requirements
 
After a device is cleared for marketing, numerous regulatory requirements apply. These include:
 

establishment registration and device listing;
 

development of a quality assurance system, including establishing and implementing procedures to design and manufacture devices;
 

labeling regulations that prohibit the promotion of products for unapproved or “off-label” uses and impose other restrictions on labeling;
 

FDA’s Unique Device Identification requirements that call for a unique device identifier (UDI) on device labels and packages and submission of data to the FDA’s Global Unique Device Identification Database (GUDID);
 

medical device reporting regulations that require manufacturers to report to the FDA if a device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; and corrections and removal reporting regulations that require manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FFDCA that may present a risk to health; and
 

post-market surveillance.
 
Our manufacturing processes are required to comply with the applicable portions of the FDA’s Quality System Regulation (“QSR”) that covers the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation, and servicing of finished devices intended for human use. In February 2024, the FDA issued the Quality Management System Regulation (“QMSR”) Final Rule to amend the QSR, incorporating by reference the international standard for medical device quality management systems set by the International Organization for Standardization (ISO), ISO 13485:2016. The rule will become effective on February 2, 2026. Until then, manufacturers are required to comply with the QSR. We actively maintain compliance with the FDA’s QSR, and the European Union’s Quality Management Systems requirements, ISO 13485:2016. 
 
As a manufacturer, we are subject to periodic scheduled or unscheduled inspections by the FDA. If the FDA believes we or any of our contract manufacturers are not in compliance with the quality system requirements, or other post-market requirements, it has significant enforcement authority. Specifically, if the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:
 

untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
 

customer notifications or repair, replacement, or refunds;
 

recalls, withdrawals, or administrative detention or seizure of our products;
 

operating restrictions or partial suspension or total shutdown of production;
 

refusing or delaying requests for approval of pre-market approval applications relating to new products or modified products;
 

withdrawing PMA approval or reclassifying our devices;
 

refusal to grant export approvals for our products; or
 

pursuing criminal prosecution.
 
Any such action by the FDA would have a material adverse effect on our business. In addition, these regulatory controls, as well as any changes in FDA policies, can affect the time and cost associated with the development, introduction, and continued availability of new products. Where possible, we anticipate these factors in our product development processes.

16

 
Regulation Outside of the U.S.
 
In addition to the United States regulations, we are subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products. In the E.U., medical devices are regulated by the European Union Medical Devices Regulation (EU) 2017/745 or MDR, which became applicable on 26 May 2021 and replaced the EU Medical Devices Directive 93/42/EEC, or MDD. The MDR and its associated guidance documents and harmonized standards, govern, among other things, device design and development, preclinical and clinical or performance testing, premarket conformity assessment, registration and listing, manufacturing, labeling, storage, claims, sales and distribution, export and import and post-market surveillance, vigilance, and market surveillance.
 
Before a device can be placed on the market in the E.U., compliance with the MDR requirements must be demonstrated in order to affix the CE Mark to the product. The method of assessing conformity varies depending on the class of the product, but normally involves a combination of self-assessment by the manufacturer and a third-party assessment by a “Notified Body.” This third-party assessment may consist of an audit of the manufacturer’s quality system or specific testing of the manufacturer’s product. The Notified Body issues a CE Certificate of Conformity to confirm successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the essential requirements provided in the MDR. Under transitional provisions provided in the MDR, medical devices that had valid CE Certificates of Conformity issued under the MDD prior to May 26, 2021 and that remained valid (and not withdrawn) on March 20, 2023, can continue to be placed on the EEA market until the end of December 2027 or 2028 (depending on the class of device), provided the device’s manufacturer complies with  certain requirements, including that there are no significant changes in the design and intended purpose of the applicable device. After the expiry of any applicable transitional period, only devices that have been CE marked on the basis of the MDR may be placed on the market in the EEA. We comply with the E.U. requirements and have received ta Notified Body Certificate of Conformity under the MDD for all of our ReWalk systems including the ReStore device which are distributed in the E.U. This allows us to continue to apply the CE mark to our products and place them on the market throughout the E.U. during the transition period or until we have completed an appropriate conformity assessment procedure under the MDR.
 
Following the U.K.’s exit from the E.U. (known as “Brexit”), the MDR does not apply in the United Kingdom (except for Northern Ireland, which under the Northern Ireland Protocol is bound by certain E.U. laws).  The medical device legislative framework in the United Kingdom is set out in the Medical Devices Regulations 2002, as amended.  These regulations are based on the previous medical device directives of the E.U. but have been amended so that they function properly now the United Kingdom is no longer part of the E.U.  The Medical Devices Regulations 2002 have introduced several changes including (but not limited to) replacing the CE mark with a UKCA marking (although E.U. CE marks will be recognized potentially up until June 2030), requiring manufacturers outside of the United Kingdom to appoint a “UK Responsible Person” if they place devices on the Great Britain market and more wide-ranging device registration requirements.
 
Sales in other jurisdictions are subject to the foreign government regulations of the relevant jurisdiction, and in most cases, we must obtain approval by the appropriate regulatory authorities before we can commence clinical trials or marketing activities in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required to obtain a marketing authorization in the United States or the CE mark in the E.U. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.
 
The policies of the FDA and foreign regulatory authorities may change, and additional government regulations may be enacted that could prevent or delay regulatory approval of our products and could also increase the cost of regulatory compliance. We cannot predict the likelihood, nature, or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the United States or abroad.
 
U.S. Anti-Kickback, False Claims and Other Healthcare Fraud and Abuse Laws
 
In the United States, there are federal and state anti-kickback laws that prohibit the payment or receipt of kickbacks, bribes or other remuneration intended to induce the purchase or recommendation of healthcare products and services. Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal healthcare programs. These laws apply to manufacturers of products, such as us, with respect to our financial relationship with hospitals, physicians and other potential purchasers or acquirers of our products. The U.S. government has published regulations that identify “safe harbors” or exemptions for certain practices from enforcement actions under the federal anti-kickback statute, and we will seek to comply with the safe harbors where possible. To qualify for a safe harbor, the activity must fit squarely within the safe harbor. Arrangements that do not meet a safe harbor are not necessarily illegal but must be evaluated on a case-by-case basis. A person or entity may be found to violate the anti-kickback statute even absent actual knowledge of this statute or specific intent to violate it. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (“FCA”).

17

 
The civil FCA prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or avoiding, decreasing, or concealing an obligation to pay money to the federal government. A claim includes “any request or demand” for money or property presented to the U.S. government. The civil FCA has been used to assert liability on the basis of kickbacks and other improper referrals, improper use of Medicare provider or supplier numbers when detailing a provider of services, improper promotion of off-label uses not covered by a device’s clearance or approval, and allegations as to misrepresentations with respect to products, contract requirements, and services rendered. In addition, private payors have been filing follow-on lawsuits alleging fraudulent misrepresentation, although establishing liability and damages in these cases is more difficult than under the FCA. Intent to deceive is not required to establish liability under the civil FCA. Civil FCA actions may be brought by the government or may be brought by private individuals on behalf of the government, called “qui tam” actions. If the government decides to intervene in a qui tam action and prevails in the lawsuit, the individual will share in the proceeds from any fines or settlement funds. If the government declines to intervene, the individual may pursue the case alone. The civil FCA provides for treble damages and a civil penalty for each false claim, such as an invoice or pharmacy claim for reimbursement, which can aggregate into millions of dollars. For these reasons, FCA lawsuits against biopharmaceutical and device companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements, as much as $3.0 billion, regarding certain sales practices and promoting off label uses. Civil FCA liability may further be imposed for known Medicare or Medicaid overpayments that are not refunded within 60 days of discovering the overpayment, even if the overpayment was not caused by a false or fraudulent act. In addition, conviction or civil judgment for violating the FCA may result in exclusion from federal health care programs, and suspension and debarment from government contracts, and refusal of orders under existing government contracts.
 
The government may further prosecute conduct constituting a false claim under the criminal FCA. The criminal FCA prohibits the making or presenting of a claim to the government knowing such claim to be false, fictitious, or fraudulent and, unlike the civil FCA, requires proof of intent to submit a false claim.
 
The civil monetary penalties statute is another statute under which medical device companies may potentially be subject to enforcement. Among other things, the civil monetary penalties statue imposes fines against any person who offers to provide remuneration to any individual eligible for benefits under Medicare or Medicaid that the offerer knows or should know is likely to influence the individual to order or receive from a particular provider or supplier of any item or service reimbursable under those programs.
 
The federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) also created federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, a healthcare benefit program, regardless of whether the payor is public or private, in connection with the delivery or payment for health care benefits, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Additionally, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the “ACA”, amended the intent requirement of certain of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation.
 
The Physician Payments Sunshine Act (“Sunshine Act”) requires annual reporting, by applicable device and drug manufacturers, of covered products, payments, and other transfers of value to certain health care providers, and ownership and investment interests held by physicians and their immediate family members.

18

 
Further, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”) and its respective implementing regulations imposes certain requirements on covered entities relating to the privacy, security, and transmission of certain individually identifiable health information, known as protected health information. Among other things, HITECH, through its implementing regulations, makes HIPAA’s security standards and certain privacy standards directly applicable to business associates, defined as a person or organization, other than a member of a covered entity’s workforce, that creates, receives, maintains, or transmits protected health information on behalf of a covered entity for a function or activity regulated by HIPAA. HITECH also strengthened the civil and criminal penalties that may be imposed against covered entities, business associates, and individuals, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions. In addition, other federal and state laws may govern the privacy and security of health and other information in certain circumstances, many of which differ from each other in significant ways and may not be pre-empted by HIPAA, thus complicating compliance efforts.
 
Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party payor, including commercial insurers.  Certain states also require implementation of commercial compliance programs and compliance with the medical device industry’s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments or the provision of other items of value that may be made to healthcare providers and other potential referral sources; impose restrictions on marketing practices; or require companies to track and report information related to payments, and other items of value to physicians and other healthcare providers.
 
If our operations are found to be in violation of any of the laws or regulations described above or any other applicable laws, we may be subject to penalties or other enforcement actions, including criminal and significant civil monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Enforcement actions can be brought by federal or state governments, or as “qui tam” actions brought by individual whistleblowers in the name of the government under the civil FCA if the violations are alleged to have caused the government to pay a false or fraudulent claim.
 
To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.
 
Coverage and Reimbursement
 
The commercial success of our product candidates and our ability to commercialize any approved product candidates successfully will depend in part on the extent to which governmental payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers, and other third-party payors provide coverage for and establish adequate reimbursement levels for our products. Government authorities, private health insurers, and other organizations generally decide which products and services they will pay for and establish reimbursement levels for healthcare. Medicare is a federally funded program managed by CMS through local fiscal intermediaries and carriers that administer coverage and reimbursement for certain healthcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and assets fall below state defined levels and who are otherwise uninsured that is both federally and state funded and managed by each state. In the United States, private health insurers and other third-party payors often provide reimbursement for products and services based on the level at which the government provides reimbursement through the Medicare or Medicaid programs for such products and services.
 
In the United States, the European Union, and other potentially significant markets for our products, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which often has resulted in average selling prices lower than they would otherwise be. In the United States, it is also common for certain government and private health plans to use coverage determinations to leverage rebates from labelers to reduce the plans’ net costs. These restrictions and limitations influence the purchase of healthcare services and products and lower the realization on manufacturers’ sales of products.  Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs. Third-party payors may limit coverage to specific therapeutic products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication or might impose high co-payment amounts to influence patient choice. Third-party payors also control costs by requiring prior authorization or imposing other restrictions. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy.

19

 
Federal programs also impose price controls through mandatory ceiling prices on purchases by federal agencies and federally funded hospitals and clinics. These restrictions and limitations influence the purchase of healthcare services and products. Legislative proposals to reform healthcare or reduce costs under government programs may result in lower reimbursement for our products or exclusion of our products.
 
Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Therefore, achieving favorable CMS coverage and reimbursement is usually a significant gating issue for successful introduction of a new product.
 
Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing, reimbursement, and utilization, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, competition from other products, judicial decisions and governmental laws and regulations related to Medicare, Medicaid, and healthcare reform, and pricing in general. Patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Sales of our product candidates will therefore depend substantially, both domestically and abroad, on the extent to which the costs of our products will be paid by health maintenance, managed care, and similar healthcare management organizations, or reimbursed by government health administration authorities, such as Medicare and Medicaid, private health insurers, and other third-party payors.
 
Moreover, a payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved or that significant price concessions will not be required to avoid restrictive conditions. High health plan co-payment requirements may result in patients seeking alternative therapies. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment. Legislative proposals to reform healthcare or reduce costs under government insurance programs may result in lower reimbursement for our products or exclusion of our products from coverage. The cost containment measures that healthcare payors and providers are instituting and any healthcare reform could significantly reduce our revenue from the sale of any approved product candidates.
 
Healthcare Reform Measures
 
The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The United States government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs.
 
The ACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The ACA is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms.
 
The ACA has been subject to challenges in the courts.  On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress.  On December 18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional, but did not invalidate the entire law, and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire ACA.  An appeal was taken to the U.S. Supreme Court, which ruled on June 17, 2021, that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct.  As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.
 
Other legislative changes have been proposed and adopted since passage of the ACA. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation’s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year.  The Bipartisan Budget Act of 2018 retained the federal budget “sequestration” Medicare payment reductions of 2% and extended it through 2027 unless congressional action is taken.  On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

20

 
Further legislative and regulatory changes under the ACA remain possible, although President Biden indicated that he intends to use executive orders to undo changes to the ACA made by the Trump administration and would advocate for legislation to build on the ACA.  It is unknown what form any such changes or any law would take, and how or whether it may affect our business in the future. We expect that changes or additions to the ACA or the Medicare and Medicaid programs, and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.
 
At the state level, legislatures may also increasingly pass legislation and implement regulations designed to control product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures.
 
We expect that additional federal, state, and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, or additional pricing pressures.
 
Environmental Matters 
 
We are subject to various environmental, health and safety laws and regulations, including those governing air emissions, water and wastewater discharges, noise emissions, the use, transport, management and disposal of chemicals and hazardous materials, the import, export and registration of chemicals, and the cleanup of contaminated sites. Based on information currently available to us, we do not expect environmental costs and contingencies to have a material adverse effect on us. The operation of our business and facilities, however, entails risks in these areas. Significant expenditures could be required in the future to comply with environmental or health and safety laws, regulations, or requirements.
 
In Israel, where our contract manufacturer produces all of our ReWalk and ReStore products, businesses storing or using certain hazardous materials (including materials necessary for our manufacturing process) are required, pursuant to the Israeli Dangerous Substances Law, 5753-1993, to obtain a toxin permit from the Ministry of Environmental Protection.  In the U.S., where we manufacture our AlterG products in our Fremont, California facility, we do not utilize chemicals which require a toxic materials license.  We have a hazardous waste disposal license with the County of Alameda and dispose of our expired and empty containers through a process in accordance with the license.
 
In the European marketplace, electrical and electronic equipment is required to comply with the Directive on Waste Electrical and Electronic Equipment, which aims to prevent waste by encouraging reuse and recycling, and the Directive on Restriction of Use of Certain Hazardous Substances, which restricts the use of ten hazardous substances in electrical and electronic products. Our products and certain components of such products “put on the market” in the E.U. (whether or not manufactured in the E.U.) are subject to these directives. Additionally, we are required to comply with certain laws, regulations, and directives, including the Toxic Substances Control Act in the United States and REACH in the E.U., governing chemicals. These and similar laws and regulations require the testing, reporting and registration of certain chemicals we use and ship. We believe we comply in all material respects with applicable environmental laws and regulations.
 
Manufacturing
 
Our ReWalk exoskeletons, ReStore exo-suits, and AlterG Anti-Gravity systems include off-the-shelf and custom-made components produced to our specifications by various third parties, for technical and cost-effectiveness. We have contracted with Sanmina Corporation (“Sanmina”), a well-established contract manufacturer with expertise in the medical device industry, for the manufacture of our SCI Products and ReStore at its facility in Ma’alot, Israel. We manufacture the AlterG product ourselves at our facility in Fremont, California. Each product line is manufactured pursuant to the same applicable set of specifications. We place our manufacturing orders with Sanmina and other suppliers pursuant to purchase orders or by providing forecasts for future requirements. We may terminate our relationship with Sanmina or our other suppliers at any time upon written notice. Either we or Sanmina may terminate the relationship in the event of a material breach, subject to a 30-day cure period. Our agreement with Sanmina contains a limitation on liability that applies equally to us and Sanmina.
 
We believe that this contract manufacturing relationship with Sanmina allows us to operate our business efficiently by focusing our internal efforts on the development and commercialization of our technology and our products and provides us with substantial scale-up capacity. We regularly test quality on-site at Sanmina’s facility and we obtain full quality inspection reports. We maintain a non-disclosure agreement with Sanmina.

21

 
We develop certain of the software components internally and license other software components that are generally available for commercial use as open-source software.
 
We manufacture products based upon internal sales forecasts. We deliver products to customers and distributors based upon purchase orders received, and our goal is to fulfill each customer’s order for products in regular production within two weeks of receipt of the order.
 
Suppliers
 
We have contracted with Sanmina for the sourcing of all components and raw materials necessary for the manufacture of our ReWalk and ReStore products, although there are instances that we purchase raw materials ourselves. In addition, we directly source all components and raw materials necessary for the manufacture of our AlterG products.  Components of our products and raw materials come from suppliers in the United States, Europe, China, Taiwan, and Israel, and we depend on certain of these components and raw materials, including certain electronic parts, for the manufacture of our products. To date, we have not experienced significant volatility in the prices of these components and raw materials. However, during the COVID-19 pandemic several specific parts, mainly electronic parts, experienced temporary price increases which have returned to more normal levels. Such prices are subject to a number of factors, including purchase volumes, general economic conditions, currency exchange rates, industry cycles, production levels, and scarcity of supply.
 
We believe that our in-house manufacturing, Sanmina’s facilities, our contracted manufacturing arrangement, and our supply arrangements are sufficient to support our potential capacity needs for the foreseeable future.
 
Human Capital
 
Employees
 
As of December 31, 2023, we had 108 employees (including full-time and hourly employees), of whom 74 were located in the United States, 20 were located in Israel and 14 were located in Europe. The majority of our employees are, and have been, engaged in sales and marketing activities. We do not employ a significant number of temporary or part time employees.
 
We are subject to labor laws and regulations within our locations mainly in the U.S., Germany, and Israel. These laws and regulations principally concern matters such as pensions, paid annual vacation, paid sick days, length of the workday and work week, minimum wages, overtime pay, insurance for work-related accidents, severance pay and other conditions of employment. Our employees are not represented by a labor union. We consider our relationship with our employees to be good. To date, we have not experienced any work stoppages.
 
Compensation and Benefits
 
We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, and a robust employment package that promotes well-being across all aspects of our employees’ lives, including health care, retirement planning, and paid time off. We also invest in the ongoing development of our employees through our internal training programs.
 
Diversity and Inclusion
 
We value the diversity of our employees and take pride in our commitment to diversity and inclusion across all levels of our organizational structure. We encourage a diversity of views and strive to create an equal opportunity workplace, including working with managers to develop strategies for building diverse teams and promoting the advancement of employees from diverse backgrounds.
 
Financial Information about Geographic Areas and Significant Customer Information
 
The following table sets forth the geographical breakdown of our revenue for each of the years ended December 31, 2023, and 2022 (in thousands):

 
 
Year Ended December 31,
 
 
 
2023
   
2022
 
Revenue based on customer’s location:
           
United States
   
7,636
     
2,303
 
Europe
   
5,044
     
3,057
 
Asia-Pacific
   
387
     
115
 
Rest of the world
   
787
     
36
 
Total revenue
 
$
13,854
   
$
5,511
 
 
22

 
Additional discussion of financial information by reportable segment and geographic area and sales in excess of 10% of total revenue to certain of our customers is contained in Note 13 to our consolidated financial statements set forth in “Part II. Item 8. Financial Statements and Supplementary Data” of this annual report.
 
2023 Recent Developments 
 

In March 2023, the ReWalk Personal Exoskeleton technology received clearance from the FDA for use on stairs and curbs in the United States, making it the only personal exoskeleton to receive FDA clearance for this indication. The clearance follows the FDA’s designation of the device as a "Breakthrough Device" in recognition of its unprecedented ability to provide ambulatory access to environments containing stairs and curbs for paralyzed individuals with SCI.
 

In August 2023, we completed the acquisition of AlterG, which adds significant scale to our revenue base, extensive sales and service capabilities to our commercial team, and innovative systems that utilize DAP technology to our portfolio of rehabilitation solutions that facilitate mobility and wellness in rehabilitation and daily life.


In November 2023, CMS released the Final Rule, which explicitly includes exoskeletons within a Medicare brace benefit category. The rule went into effect on January 1, 2024.


In November 2023, CMS included the ReWalk Personal Exoskeleton system in the agenda for the November 29, 2023 HCPCS public meeting.  The agency also proposed a preliminary payment determination of $94,617 for HCPCS code K1007 based on a “gap filling” process applied to 2020 market data. At the meeting, CMS solicited additional information for updated market transactions for use in developing a final payment determination. We participated in the HCPCS meeting process to provide additional information to help ensure that the final payment determination accurately reflects current pricing information related to the market of lower-limb exoskeleton devices, including the current ReWalk Personal Exoskeleton. A final Medicare payment determination is expected from CMS in first quarter of 2024 with an April 1, 2024, effective date.
 

In December 2023, our first claim with Medicare for reimbursement for a ReWalk Personal Exoskeleton was paid;
 

Record annual revenue for 2023 was $13.9 million, compared to $5.5 million in 2022, an increase of 151%.
 

Our cash position remained strong with $28.1 million as of December 31, 2023, with no debt.

 
23

 
ITEM 1A. RISK FACTORS
 
Our business faces significant risks. You should carefully consider all of the information set forth in this annual report and in our other filings with the SEC, including the following risk factors which we face and which are faced by our industry. Our business, financial condition and results of operations could be materially and adversely affected by any of these risks. In that event, the trading price of our ordinary shares would likely decline and you might lose all or part of your investment. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described below and elsewhere in this report and our other SEC filings. See also “Special Note Regarding Forward-Looking Statements and Risk Factors Summary” on page (ii).
 
Risks Related to Our Business and Our Industry
 
We may fail to realize the benefits expected from our acquisition of AlterG, which could adversely affect the price of our ordinary shares.

As discussed above in “Part I. Item 1. Business - Overview”, on August 11, 2023, we completed the acquisition of AlterG which became an indirect and wholly-owned subsidiary of the Company. 
 
The anticipated benefits from our acquisition of AlterG are based on projections and assumptions about the combined businesses of ReWalk and AlterG, which may not materialize as expected or which may prove to be inaccurate. The value of our ordinary shares could be adversely affected if we are unable to realize the anticipated benefits from the acquisition on a timely basis or at all. Achieving the benefits of the acquisition will depend, in part, on our ability to integrate the business, operations and products of AlterG successfully and efficiently with our business. The process of integrating the operations of ReWalk and AlterG could encounter unexpected costs and delays, which include: the loss of key personnel; the loss of key customers; the loss of key suppliers; inability to properly identify, acquire or obtained required regulatory approvals; and unanticipated issues in integrating sales, marketing and administrative functions. In addition, the acquired AlterG business, products and technologies may not achieve anticipated revenues and income growth.
 
Further, the integration of AlterG may involve a number of additional risks, including diversion of management’s attention away from the rest of the business, which could adversely affect our results of operations. In addition, our failure to identify or accurately assess the magnitude of certain liabilities we assumed in the acquisition could result in unexpected litigation or regulatory exposure, unfavorable accounting charges, unexpected increases in taxes due, a loss of anticipated tax benefits or other adverse effects on our business, operating results or financial condition. If we do not realize the expected benefits or synergies of the acquisition, such as revenue gains or cost reductions, there could be a material adverse effect on our business, results of operations, and financial condition.
 
Global, regional, and local economic weakness and uncertainty could adversely affect our demand for our products and services and our business and financial performance.
 
Our business and financial performance depends on worldwide economic conditions and the demand for our products and services in the markets in which we compete. Ongoing economic weakness, including an economic slowdown or recession, uncertainty in markets throughout the world and other adverse economic conditions, including inflation, changes in monetary policy and increased interest rates, have resulted, and may result in the future, in decreased demand for our products and services and increased expenses and difficulty in managing inventory levels and accurately forecasting revenue, gross margin, cash flows and expenses. Ongoing U.S. federal government spending limits may continue to reduce demand for our products and services from organizations that receive funding from the U.S. government and could negatively affect macroeconomic conditions in the United States, which could further reduce demand for our products and services.
 
Prolonged or more severe economic weakness and uncertainty could also cause our expenses to vary materially from our expectations. Any financial turmoil affecting the banking system and financial markets or any significant financial services institution failures could negatively impact our treasury operations, as the financial condition of such parties may deteriorate rapidly and without notice. Poor financial performance of asset markets and the adverse effects of fluctuating currency exchange rates could lead to higher pension and post-retirement benefit expenses. Interest and other expenses could vary materially from expectations depending on changes in interest rates, borrowing costs, currency exchange rates, costs of hedging activities and the fair value of derivative instruments. Economic downturns also may lead to future restructuring actions and associated expenses. 

24

 
We may not have sufficient funds to meet certain future operating needs or capital requirements, which could impair our efforts to develop and commercialize existing and new products, and as a result, we may in the future consider one or more capital-raising transactions, including future equity or debt financings, strategic transactions, or borrowings which may also further dilute our shareholders or place us under restrictive covenants limiting our ability to operate freely.
 
We intend to finance our business by close management of our operating expenses until we reach profitable operation using existing cash on hand, issuances of equity and/or debt securities, and other future public or private issuances of securities, cash exercised of outstanding warrants, or through a combination of the foregoing, though we may also consider additional capital raising alternatives, such as entering into a credit facility, if the foregoing alternatives are not available to us or unavailable on reasonable terms. Although we had a cash and cash equivalents of $28.1 million as of December 31, 2023, which we believe will be sufficient to fund our planned operations through at least the next twelve months from the date of this annual report, if we are incorrect in our assumptions, we may need to raise additional capital sooner than expected or on less favorable terms than what might otherwise be available. Raising additional capital through one or more of these alternatives may further dilute our shareholders or place us under restrictive covenants limiting our ability to operate freely.
 
Raising additional capital in the public markets could also entail certain downsides. Although we are currently eligible to use our Form S-3, we are limited to selling no more than one-third of our unaffiliated market capitalization, or public float, on Form S-3 in a 12-month period unless our public float rises above $75 million. For more information on our inability to use Form S-3, see “Part II. Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Equity Raises” below. Additionally, due to these limitations on our use of Form S-3, we may be required to seek other methods for access to capital, such as a registration statement on Form S-1.  The preparation of a registration statement on Form S-1 is, and has in the past, been more time-consuming and costly than using Form S-3. We may also conduct fundraising transactions in the form of private placements, potentially with registration rights or priced at a discount to the market value of our ordinary shares, which could require shareholder approval under the rules of The Nasdaq Stock Market LLC (“Nasdaq”), or other equity raise transactions such as equity lines of credit. In addition to entailing increased capital costs, any such transactions have historically resulted in and could result in substantial dilution of our shareholders’ interests and may also transfer control to a new investor or diminish the value of an investment in our ordinary shares.
 
We may also need to pursue strategic transactions, such as joint ventures, in-licensing transactions, or the sale of our business, or all, or substantially all, of our assets if our financial stability is uncertain, and we are unable to raise additional capital effectively. These strategic transactions have in the past and could in the future require significant management attention, disrupt our business, adversely affect our financial results, be unsuccessful or fail to achieve the desired results.
 
Overall, if we cannot raise the required funds, or cannot raise them on terms acceptable to us or investors, we may be forced to curtail substantially our current operations or cease operations altogether.
 
We face economic and political risks associated with doing business in Taiwan, particularly due to the geopolitical tension between Taiwan and China, and in Russia that could negatively affect our business and hence the value of your investment.
 
 Currently, we rely on third party suppliers in Taiwan for a portion of the components we use in our AlterG products. Accordingly, our business, financial condition and results of operations and the market price of our securities may be affected by changes in governmental policies, taxation, growth rate, inflation rate or interest rates and by social instability and diplomatic and social developments in or affecting Taiwan. In particular, the unique political status of Taiwan and its internal political movement cause sustained tension between China and Taiwan. Past developments related to the interactions between China and Taiwan, especially in relation to trade activities such as bans on exports of goods from time to time, have on occasions depressed the transactions and business operations of certain Taiwanese companies and overall economic environment. We cannot predict whether there will be escalation of the tensions between China and Taiwan, which would lead to new bans or tariffs on exports or even conflict. Any conflict which threatens the military, political or economic stability in Taiwan could have a material adverse effect on our current or future business and financial conditions and results of operations.
 
In addition, we also sell our AlterG products in Russia. The current invasion of Ukraine by Russia has escalated tensions among the United States, the North Atlantic Treaty Organization (“NATO”) and Russia. The United States and other NATO member states, as well as non-member states, have announced new sanctions against Russia and certain Russian banks, enterprises and individuals. AlterG prior to the acquisition and Lifeward subsequent to the acquisition has remained in compliance with these sanctions by obtaining export licenses for each shipment to our distributor that serves Russia. These and any future additional sanctions and any resulting conflict between Russia, the United States and NATO countries could have an adverse impact on our current operations.
 
25

 
Further, such invasion, ongoing military conflict, resulting sanctions and related countermeasures by NATO states, the United States and other countries are likely to lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions for equipment, which could have an adverse impact on our operations and financial performance.
 
We do not satisfy all requirements for continued listing on The Nasdaq Capital Market. We can provide no assurance that we will be able to comply with the continued listing requirements over time or that our ordinary shares will continue to be listed on The Nasdaq Capital Market.
 
As previously disclosed, on October 10, 2022, we received a notification letter (the “Bid Price Letter”) from Nasdaq that we failed to evidence a minimum closing bid price of $1.00 per share for the prior 30-consecutive business day period in contravention of Nasdaq Listing Rule 5550(a) (“Rule 5550(a)”).  We were provided an initial period of 180 days to regain compliance with Rule 5550(a).  On April 11, 2023, we received a second notification letter from Nasdaq indicating that we had been provided with an additional period of 180 calendar days, or until October 9, 2023, to regain compliance with Rule 5550(a). The bid price of our ordinary shares did not close at $1.00 per share or more for a minimum of 10 consecutive business days by October 5, 2023, and on October 6, 2023 we were notified by Nasdaq that, based upon our non-compliance with Rule 5550(a), as of October 5, 2023, our securities were subject to delisting unless we timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). We participated in an expedited review with the Panel, which first granted us an extension until January 31, 2024, to regain compliance with Rule 5550(a), including by implementing a reverse share split should such action be necessary to regain compliance.
 
We thereafter requested a further extension, through March 30, 2024, to allow for additional time for the finalization and implementation of the home health rule administrative proposal by CMS that explicitly includes exoskeletons within a Medicare benefit category. Our updated compliance plan continues to include the possible implementation of a reverse share split should such action be deemed necessary to maintain our listing on Nasdaq. On December 8, 2023, we were notified that the Panel had granted us the requested extension through March 30, 2024, to regain compliance with Rule 5550(a)(2). To do so, we must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days by March 30, 2024.
 
If we are not successful in regaining compliance with Rule 5550(a)(2) during the extension period, our ordinary shares will be removed from trading on The Nasdaq Capital Market. Any delisting determination could seriously decrease or eliminate the value of an investment in our ordinary shares and other securities linked to our ordinary shares. While an alternative listing on an over-the-counter exchange could maintain some degree of a market in our ordinary shares, we could face substantial material adverse consequences, including, but not limited to, the following: limited availability for market quotations for our ordinary shares; reduced liquidity with respect to our ordinary shares; a determination that our ordinary shares are “penny stock” under SEC rules, subjecting brokers trading our ordinary shares to more stringent rules on disclosure and the class of investors to which the broker may sell the ordinary shares; limited news and analyst coverage, in part due to the “penny stock” rules; decreased ability to issue additional securities or obtain additional financing in the future; and potential breaches under or terminations of our agreements with current or prospective large shareholders, strategic investors and banks. The perception among investors that we are at heightened risk of delisting could also negatively affect the market price of our securities and trading volume of our ordinary shares. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with the listing requirements would allow our ordinary shares to become listed again, stabilize the market price or improve the liquidity of our ordinary shares, prevent our ordinary shares from dropping below the Nasdaq minimum bid price requirement, or prevent future non-compliance with Nasdaq’s listing requirements.
 
Our future growth and operating results will depend on our ability to develop, receive regulatory clearance for and commercialize new products and penetrate new product and geographic markets.
 
We are currently engaged in research and development efforts to address the needs of patients with mobility impairments besides paraplegia, such as stroke, and, in the future, we may engage in efforts to address these needs in patients with other conditions such as multiple sclerosis, cerebral palsy, Parkinson’s disease and elderly assistance. In 2019, we commercialized our first product for stroke patients, the ReStore Exo-Suit. For more information, see “Part, Item 1. Business—ReStore Products” above. While our Collaboration Agreement with Harvard for the design, research and develop lightweight exoskeleton system technologies for lower limb disabilities intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications successfully concluded on March 31, 2022, Harvard has licensed to us certain of its intellectual property relating to lightweight exoskeleton system technologies for lower limb disabilities. We are obligated to use commercially reasonable efforts to develop products under the license in accordance with an agreed-upon development plan and to introduce and market such products commercially.

26

 
We expect that a portion of our revenue will be derived, in the next few years, from the ReStore soft exo-suit product, other new products utilizing DAP, and, in later years, if we choose to advance the current designs, from other potential new products, such as ReBoot, a home use device for stroke patients, or new products aimed at addressing other medical indications which affect the ability to walk, including multiple sclerosis, cerebral palsy, Parkinson’s disease and elderly assistance. As such, our future results will depend on our ability to successfully develop and commercialize such new products and to penetrate our targeted markets with our existing ReStore product in larger scale than we have done to date. We cannot ensure that we will be able to introduce new products, products currently under development or products contemplated for future development for additional indications in a timely manner, or at all, as it depends on our available resources to fund such projects, as well as our ability to conduct clinical trials and testing. While we received governmental clearance to market our ReStore product on the anticipated timetable in 2019, obtaining clearance for any other products we may develop could be an extensive, costly, and time-consuming process, which could delay any planned commercialization timelines. For more information on the clearance processes for our products, see “Part I, Item 1. Business—Government Regulation” above.
 
Harvard may terminate its License Agreement with us if we fail to maintain the requisite insurance or become insolvent. Any such termination of this aspect of the collaboration with Harvard could impair our research and development efforts into lightweight soft suit exoskeleton system technologies for lower limb disabilities such as the ReBoot device which is intended to be used at home by people who suffered a stroke. In addition, we may not be able to clinically demonstrate the medical benefits of our products for new indications. We have limited clinical data demonstrating the benefits of our products and we might not be able to support the economic benefits our products have for our potential customers. We may also be unable to gain necessary regulatory clearances or approvals to enable us to market new products for additional indications or the regulatory process may be more costly and time-consuming than expected, which could adversely impact us given our cash position and ongoing capital requirements.
 
Even if we are successful in the design and development of new products, our growth and results of operations will depend on our ability to penetrate new markets and gain acceptance and reimbursement coverage in non-SCI markets such as the stroke rehabilitation market, and, in the longer term, the home use device market for stroke-caused lower limb disability, multiple sclerosis, elderly assistance and cerebral palsy patients. We may not be able to gain such market acceptance and coverage for these indications in a timely manner, or at all.
 
While our new products currently under development will share some aspects of the core technology platform of our current products, their design features and components may differ from our current products. Accordingly, these products will also be subject to the risks described in the risk factor immediately below entitled “We rely on sales of our ReWalk Personal Exoskeletons, ReStore Exo-Suits, and AlterG Anti-Gravity systems and related service contracts and extended warranties for our revenue. We may not be able to achieve or maintain market acceptance of our ReWalk, ReStore, or AlterG Anti-Gravity products, or to generate sufficient revenue from these current and future products to sustain our operations.” To the extent we are unable to successfully develop and commercialize products beyond our existing commercial product portfolio, we will not meet our operating and financial objectives.
 
We rely on sales of our ReWalk Personal Exoskeletons, ReStore Exo-Suits, and AlterG Anti-Gravity systems and related service contracts and extended warranties for our revenue. We may not be able to achieve or maintain market acceptance of our ReWalk, ReStore, or AlterG Anti-Gravity products or to generate sufficient revenue from these current and future products to sustain our operations.
 
We currently rely, and expect in the future to rely, on sales of our ReWalk Personal Exoskeleton, ReStore Exo-Suit, and AlterG Anti-Gravity systems, and related service contracts and extended warranties for our revenue. We began marketing the ReStore lightweight soft exo-suit in 2019 in the United States and the E.U. (following the receipt of FDA and CE mark clearance) to support mobility for individuals suffering from other lower limb disabilities. Several factors could negatively affect our ability to achieve and maintain market acceptance of our ReWalk, AlterG, or ReStore systems, which could in turn materially impair our business, financial condition, and operating results, as follows:
 

ReWalk. We have sold a limited number of ReWalk systems, and market acceptance and adoption depend on educating people with limited upright mobility and health care providers as to the distinct features, ease-of-use, positive lifestyle impact, and other benefits of ReWalk compared to alternative technologies. ReWalk may not be perceived to have sufficient potential benefits compared with these alternatives. Users may also choose other alternatives due to disadvantages of ReWalk, including the time it takes for a user to put on the device, the slower pace of ReWalk compared to a wheelchair, the weight of ReWalk when carried, which makes it more burdensome for a companion to transport than a wheelchair, the required training, and the requirement that users be accompanied by a trained companion. Also, we believe that healthcare providers tend to be slow to change their medical treatment practices because of perceived liability risks arising from the use of new products and the uncertainty of third-party reimbursement. Accordingly, healthcare providers may not recommend ReWalk until there is sufficient support for the device to convince them to alter the treatment methods they typically recommend, such as expanded reimbursement coverage by payors, and/or recommendations by prominent healthcare providers or other key opinion leaders in the spinal cord injury community that ReWalk is effective in providing identifiable immediate and long-term health benefits.
 
27


In the United States, many private third-party payors use coverage decisions and payment amounts determined by CMS as guidelines in setting their coverage and reimbursement policies. In July 2020, CMS issued a Healthcare Common Procedure Coding System Level II Code for ReWalk Personal Exoskeleton. These codes are used to identify medical products and supplies and to facilitate insurance claim submissions and processing for these items. On November 1, 2023, CMS issued Calendar Year 2024 Home Health Prospective Payment System Rule CMS-1780, which explicitly included exoskeletons within a Medicare brace benefit category. The rule went into effect on January 1, 2024. However, even with a positive coverage and reimbursement response from CMS regarding a product of ours, future action by CMS or other government agencies may diminish possible payments to clinicians, outpatient centers and/or hospitals that provide training to the patients so that they can operate the ReWalk Personal Exoskeletons satisfactorily before they take them home, which would discourage access to training sites to prospective users of ReWalk Personal Exoskeletons.  Additionally, any decision by CMS regarding reimbursement could influence other payors, including private insurers. If CMS declines to provide for reimbursements of our products, or if its reimbursement price is lower than that of other payors, our products may not be reimbursed at a cost-effective level or at all. Those private third-party payors that do not follow the Medicare guidelines may adopt different coverage and reimbursement policies for purchase of our products or their use in a hospital or rehabilitative setting. In addition, we expect that the purchase of ReWalk Rehabilitation Exoskeleton systems and the ReStore system, as it is currently being sold for use in rehabilitative settings, will require the approval of senior management at hospitals or rehabilitation facilities, inclusion in the hospitals’ or rehabilitation facilities’ budget process for capital expenditures, and in the case of ReWalk Personal Exoskeleton, fundraising, and financial planning or assistance.
 

ReStore. The ReStore system is designed to provide advantages to stroke rehabilitation clinics and therapists as compared to other traditional therapies and devices by minimizing setup time, improving patients’ clinical results during therapy, supplying real-time analytics to optimize session productivity, and generating ongoing data reports to assist with tracking patient progress Since the ReStore device is currently only indicated for use in the rehabilitative clinical setting, its market reception will depend heavily on our ability to demonstrate to clinics and therapists the systemic and economic benefits of using the ReStore device, its clinical advantage when compared to other devices or manual therapy, the functionality of the device for a significant portion of the patients that they treat and the overall advantages that the device provides to their patients compared to other technologies. Because the ReStore system is only indicated for use in a clinical setting and we received FDA approval and CE clearance in 2019, close in time to the start of the COVID-19 pandemic, the overall sales of the system have been lower than originally anticipated, as many healthcare providers and rehabilitation centers have shifted focus from the clinical setting to at-home therapies and are generally less open for introduction of new technologies such as the ReStore
 

.
AlterG. The AlterG Anti-Gravity system has broad clinical utility for treating a wide variety of lower extremity conditions where partial displacement of a patient’s weight can enable exercise which facilitates healing and recovery of improved function.  The potential of the AlterG Anti-Gravity systems to achieve greater penetration of the addressable market of rehabilitation hospitals, clinics, and sports medicine practices will depend upon the continued expansion of conditions for which clinicians utilize the AlterG and the ability for greater numbers of these facilities to afford the initial capital outlay for these devices. We are developing and hope to introduce in 2024 a new, lower-cost AlterG system, which we believe will make it more affordable for smaller, independent rehabilitation clinics. However, there can be no assurance that the introduction of this product can expand the size of the addressable market or will not reduce the sales of the existing, higher-priced models.
 
As a general matter, achieving and maintaining market acceptance of our current or future products could be negatively impacted by many other factors, including, but not limited to the following: contribution to death or serious injury or malfunction, results of clinical studies relating to our or similar products; claims that our products, or any of their components, infringe on patent or other intellectual property rights of third parties; our ability to support financially and leverage our sales, marketing and training infrastructure, as well as our level of research and development efforts; our ability to enhance and broaden our research and development efforts and product offerings in response to the evolving demands of people with paraplegia and lower limb disability and healthcare providers; our estimates regarding our current or future addressable market; perceived risks associated with the use of our products or similar products or technologies; the introduction of new competitive products or greater acceptance of competitive products; adverse regulatory or legal actions relating to our products or similar products or technologies; and problems arising from the outsourcing of our manufacturing capabilities, or our existing manufacturing and supply relationships. Any or all of these factors could materially and negatively impact our business, financial condition and operating results.

28

 
The market for medical exoskeletons, including soft suit devices, remains relatively new and unproven, and important assumptions about the potential market for our current and future products may be inaccurate.
 
The market for medical exoskeletons, including lightweight exo-suit devices, remains relatively new and unproven. Accordingly, it is difficult to predict the future size and rate of growth of the market. We cannot be certain whether the market will continue to develop or if medical exoskeletons will achieve and sustain a level of market acceptance and demand sufficient for us to continue to generate revenue and achieve profitability.
 
We obtained FDA clearance for our ReWalk Personal Exoskeleton device in June 2014. This clearance permits us to market the device for use by individuals with spinal cord injury at levels T7 to L5 and for use by individuals in rehabilitation institutions with spinal cord injury at levels T4 to T6. We obtained FDA clearance for our ReStore system in June 2019. This clearance permits us to market the device to be used to assist ambulatory functions in rehabilitation institutions under supervision of a trained therapist for people with hemiplegia or hemiparesis due to stroke who can ambulate at least 1.5 meters (5 feet) with no more than minimal to moderate levels of assistance.
 
Future products for those with paraplegia or other mobility impairments or spinal cord injuries may have the same or other restrictions.
 
Our business strategy is based, in part, on our estimates of the number of individuals with physical limitations and disability and considers the occurrence of spinal cord injuries, strokes, lower-extremity orthopedic injury or surgery, neurological disease, and obesity in our target markets, and the percentage of those groups that would be able to use our current and future products. Limited sources exist to obtain reliable market data with respect to the number of mobility-impaired individuals and the incurrence of spinal cord injuries and strokes in our target markets. In addition, there are no third-party reports or studies regarding what percentage of those with limited mobility and/or spinal cord injuries would be able to use exoskeletons, in general, or our current or planned future products, in particular. Our assumptions may be inaccurate and may change.
 
The NSCISC estimates according to its 2023 SCI Data Sheet that there are 302,000 people in the United States living with SCI, with an annual incidence of approximately 18,000 new cases per year. Based on information from the 2022 annual report published by the NSCISC, 40% of the total U.S. population of SCI patients suffered injuries between levels T4 and L5.  Four published ReWalk trials with respect to such eligible SCI patients had an aggregate screening acceptance rate of 50% considering all current FDA limitations, resulting in an estimated 20% of the total population of SCI patients being qualified candidates for current ReWalk products under its medical labeling criteria. There may be other permanent or short-term factors that affect the market size such as the ability to participate in the training program, the ability to use the device in the user’s current home environment as well as available companion support. With regards to our ReStore product for stroke rehabilitation, as the indication of use is currently in rehabilitation clinics our target market is based on the number of current and future clinics who treat stroke patients. Although there are thousands of inpatient, outpatient and rehabilitation clinics providing therapy in the U.S. for example, we currently see that only a limited portion of the clinics have decided to include ReStore in their stroke rehab program. For more information on our expectations regarding these plans, see “—Our future growth and operating results will depend on our ability to develop, receive regulatory clearance for and commercialize new products and penetrate new product and geographic markets” below. For more information regarding the potential market for future products, including our lightweight soft suit exoskeleton, see “Part I, Item 1. Business—ReWalk Personal and ReWalk Rehabilitation Products—Market Opportunity” above.
 
We cannot assure you that our estimate regarding our current products is accurate or that our estimate regarding future products will remain the same. FDA or CE mark clearance for such products, if received at all, may contain different limitations from the ones the FDA or EU has placed on the devices we currently market for paraplegia. If our estimates of our current or future addressable market are incorrect, our business may not develop as we expect, and the price of our securities may suffer.

29

 
We may fail to secure or maintain adequate insurance coverage or reimbursement for our products by third-party payors, which risk may be heightened if insurers find the products to be investigational or experimental or if new government regulations change existing reimbursement policies. Additionally, such coverage or reimbursement, even if maintained, may not produce revenue that are high enough to allow us to sell our products profitably.
 
We expect that in the future a significant source of payment for ReWalk systems will be private insurance plans and managed care programs, government programs such as the VHA, CMS, workers’ compensation plans, and other third-party payors.
 
In December 2015, the VHA issued a national reimbursement policy for the ReWalk system, which entails the evaluation, training and procurement of ReWalk Personal Exoskeleton systems for all qualifying veterans across the United States. Additionally, in September 2017, German insurer Barmer signed a confirmation and letter of agreement regarding the provision of ReWalk systems for all qualifying beneficiaries and the German national social accident insurance provider DGUV indicated that its member payors will approve the supply of exoskeleton systems for qualifying beneficiaries on a case-by-case basis. However, no broad uniform policy of coverage and reimbursement for electronic exoskeleton medical technology exists among third-party payors in the United States, although reimbursement may be achieved on a case-by-case basis. To date, payments for our products, which are largely for our ReWalk systems, have been made primarily through case-by-case determinations by third-party payors (including several private insurers in the United States), by self-payors and, to a lesser extent, through the use of funds from insurance and/or accident settlements.
 
Generally, private insurance companies in the United States do not cover or provide reimbursement for any medical exoskeleton products for personal use, including ReWalk Personal Exoskeleton, and may ultimately provide no coverage at all. Additionally, there is limited clinical data related to the ReWalk and ReStore systems, and third-party payors may consider use of them to be experimental and therefore refuse to cover any or all of them. Additionally, the majority of independent medical review decisions to date made following the denial of ReWalk coverage have determined that ReWalk is experimental and/or investigational, citing a lack of clinical data.
 
As described above, in the United States, many private third-party payors use coverage decisions and payment amounts determined by CMS as guidelines in setting their coverage and reimbursement policies. On November 1, 2023, CMS issued Calendar Year 2024 Home Health Prospective Payment System Rule CMS-1780, which explicitly included exoskeletons within a Medicare brace benefit category, effective January 1, 2024. CMS also solicited comment on a preliminary payment determination for the ReWalk Personal Exoskeleton as part of the November 29, 2023 HCPCS meeting process, and we participated to provide updated pricing information to inform CMS’s final payment determination. A final Medicare payment determination is expected from CMS in first quarter of 2024 with an April 1, 2024, effective date.
 
However, even with a positive coverage and reimbursement response from CMS regarding a product of ours, future action by CMS or other government agencies may diminish possible payments to physicians, outpatient centers and/or hospitals that purchase our products for use by their patients and possible payments to individuals who purchase the ReWalk Personal Exoskeleton for their own use. Additionally, a decision by CMS to provide reimbursement could influence other payors, including private insurers. If CMS declines to provide for reimbursements of our products or if its reimbursement price is lower than that of other payors, our products may not be reimbursed at a cost-effective level or at all. Those private third-party payors that do not follow the Medicare guidelines may adopt different coverage and reimbursement policies for purchase of our products or their use in a hospital or rehabilitative setting. In addition, we expect that the purchase of ReWalk Rehabilitation Exoskeleton systems and the ReStore system, as it is currently being sold for use in rehabilitative settings, will require the approval of senior management at hospitals or rehabilitation facilities, inclusion in the hospitals’ or rehabilitation facilities’ budget process for capital expenditures, and in the case of ReWalk Personal Exoskeleton, fundraising, and financial planning or assistance.
 
Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs. These cost control methods include prospective payment systems, capitated rates, benefit redesigns and an exploration of other cost-effective methods of delivering healthcare. These cost control methods potentially limit the amount that healthcare providers may be willing to pay for electronic exoskeleton medical technology if they provide coverage at all. We may be unable to sell our products on a profitable basis if third-party payors deny coverage or provide insufficient levels of reimbursement.
 
Future legislation could result in modifications to the existing public and private health care insurance systems that would have a material adverse effect on the reimbursement policies discussed above. If enacted and implemented, any measures to restrict health care spending could result in decreased revenue from our products and decrease potential returns from our research and development initiatives.

30

 
Defects in our products or the software that drives them could adversely affect the results of our operations.
 
The design, manufacture and marketing of our products involve certain inherent risks. Manufacturing or design defects, unanticipated use of ReWalk, ReStore, or AlterG, or inadequate disclosure of risks relating to the use of our products can lead to injury or other adverse events. In addition, because the manufacturing of some of our products is outsourced to Sanmina, the original equipment manufacturer of such products, we may not be aware of manufacturing defects that could occur. Such adverse events could lead to recalls or safety alerts relating to those products (either voluntary or required by the FDA or similar governmental authorities in other countries), and could result, in certain cases, in the removal of our products from the market. A recall could result in significant costs. To the extent any manufacturing defect occurs, our agreement with Sanmina contains a limitation on Sanmina’s liability, and therefore we could be required to incur the majority of related costs. Product defects or recalls could also result in our inability to profitably grow our business due to parts shortages, increased field service demand, and inventory shortages, and the resulting negative publicity, customer dissatisfaction, damage to our reputation or, in some circumstances, delays in new product clearances or approvals.
 
When an exoskeleton is used by a paralyzed individual to walk, the individual relies completely on the exoskeleton to hold him or her upright. Between 2013 and 2021, we submitted medical device reports (“MDRs”) to the FDA (and equivalent authorities outside of the United States) relating to reports of falls and fractures of individuals using the ReWalk Personal Exoskeleton system.  We conducted a voluntary correction related to certain use instructions in the device’s labeling, which the FDA classified as a Class II recall.  The recall was closed in November 2019, and the FDA cleared our 510(k) containing revised instructions for use in May 2020.  Since that time, we have submitted no further MDRs.
 
In addition, our products incorporate sophisticated computer software and hardware. Complex software frequently contains errors, especially when first introduced. Our software may experience errors or performance problems in the future. If any part of our product’s hardware or software were to fail, the user could experience death or serious injury. For example, in 2021 ReWalk submitted medical device reports to the FDA and medical device vigilance reports to the European regulatory authorities and initiated a correction in response to two complaints regarding battery thermal runaway events. The correction that includes clarification of previous instructions and additional information on battery operation and storage is closed in Europe and in the United States. ReWalk has separately initiated a design project to improve power management and battery operation during charge and discharge, and this project remains in process. Additionally, users may not use or maintain our products in accordance with safety, storage, and training protocols, which could enhance the risk of death or injury. Any such occurrence could cause delay in market acceptance of our products, damage to our reputation, the need for additional regulatory filings, product recalls, increased service and warranty costs, product liability claims, and loss of revenue relating to hardware or software defects.
 
The medical device industry has historically been subject to extensive litigation over product liability claims. We have been and anticipate that as part of our ordinary course of business we may be subject to product liability claims alleging defects in the design, manufacture, or labeling of any of our products which has resulted in an injury or death. A product liability claim, regardless of its merit or eventual outcome, could result in significant legal defense costs and high punitive damage payments. Although we maintain product liability insurance, the coverage is subject to deductibles and limitations, and may not be adequate to cover future claims. Additionally, we may be unable to maintain our existing product liability insurance in the future at satisfactory rates or adequate amounts. Any alleged defect that has resulted in an adverse event involving our products could result in future voluntary corrective actions, such as recalls or customer letters, or in an FDA enforcement action, such as a mandatory recall, notification to healthcare professionals and users, warning letter, seizure, injunction or import alert. In addition, failure to report such adverse events to appropriate government authorities on a timely basis, or at all, could result in enforcement action against us. Any action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require financial resources and distract management, and may harm our reputation and financial results.
 
If we are unable to leverage our sales, marketing, and training infrastructure we may fail to increase our sales.
 
A key element of our long-term business strategy is the continued leveraging of our sales, marketing, training, and reimbursement infrastructure, through the training, retention, and motivation of skilled sales and marketing representatives and reimbursement personnel with industry experience and knowledge. Our ability to derive revenue from sales of our products depends largely on our ability to market the products and obtain reimbursements for them. In order to continue growing our business efficiently, we must therefore coordinate the development of our sales, marketing, training and reimbursement infrastructure with the timing of regulatory approvals, decisions regarding reimbursements, limited resources consideration and other factors in various geographies. Managing and maintaining our sales and marketing infrastructure is expensive and time consuming, and an inability to leverage such an organization effectively, or in coordination with regulatory or other developments, could inhibit potential sales and the penetration and adoption of our products into both existing and new markets. However, certain decisions we make regarding staffing in these areas in our efforts to maintain an adequate spending level could have unintended negative effects on our revenue, such as by weakening our sales infrastructure, impairing our reimbursement efforts and/or harming the quality of our customer service.

31

 
Additionally, we expect to face significant challenges as we manage and continue to improve our sales and marketing infrastructure and work to retain the individuals who make up those networks. Newly hired sales representatives require training and take time to achieve full productivity. If we fail to train new hires adequately, or if we experience high turnover in our sales force in the future, we cannot be certain that new hires will become as productive as may be necessary to maintain or increase our sales. Likewise, following our acquisition of AlterG in August 2023 and in connection with integrating AlterG with ReWalk, each set of sales representatives had to learn how to sell new products and services. In addition, if we are not able to retain existing and recruit new trainers to our clinical staff, we may not be able to successfully train customers on the use of ReWalk, ReStore, or AlterG systems which could inhibit new sales and harm our reputation. If we are unable to expand our sales, marketing, and training capabilities, we may not be able to effectively commercialize our products, or enhance the strength of our brand, which could have a material adverse effect on our operating results.
 
The potential health benefits of our ReWalk products have not been substantiated by long-term clinical data, which could limit sales of such products.
 
Although published research and users of our ReWalk products have reported the potential secondary health benefits of our ReWalk products such as a reduction in pain and spasticity, improved bowel and urinary tract functions and emotional and psychosocial benefits, among others, currently there is no large scale, randomized clinical trial establishing the secondary health benefits of ReWalk products due to the relatively small size of the applicable user population. There is also a lack of randomized clinical data for such health benefits of the ReStore-specifically its long-term benefits following the usage of the product within the clinic as the trials conducted to date using this product are limited.
 
As a result, potential customers and healthcare providers may be slower to adopt or recommend ReWalk products or ReStore and third-party payors may not be willing to provide coverage or reimbursement for our products. In addition, future studies or clinical experience may indicate that treatment with our current or future products is not superior to treatment with alternative products or therapies. Such results could slow the adoption of our products and significantly reduce our sales.
 
We depend on a single third-party supplier to manufacture some of our products, and we rely on a limited number of third-party suppliers for certain components of our products.
 
We have contracted with Sanmina, a well-established contract manufacturer with expertise in the medical device industry, for the manufacture of all our ReWalk and ReStore systems and the sourcing of all of our components and raw materials for those products. We may terminate our relationship with Sanmina at any time upon written notice. In addition, either we or Sanmina may terminate the relationship in the event of a material breach, subject to a 30-day cure period. For our business strategy to be successful, Sanmina must be able to manufacture our products in sufficient quantities, in compliance with regulatory requirements and quality control standards, in accordance with agreed upon specifications, at acceptable costs and quality levels, and on a timely basis. Increases in our product sales, whether forecasted or unanticipated, could strain the ability of Sanmina to manufacture an increasingly large supply of our current or future products in a manner that meets these various requirements. In addition, although we are not restricted from engaging an alternative manufacturer, and potentially have the capabilities to manufacture our products in-house, the process of moving our manufacturing activities would be time consuming and costly, and may limit our ability to meet our sales commitments, which could harm our reputation and could have a material adverse effect on our business. Moreover, the failure of Sanmina to comply with applicable regulatory requirements could expose us to regulatory action including warning letters, product recalls, termination of distribution, product seizures or civil penalties.
 
We also rely on third-party suppliers, many of which contract directly with Sanmina, to supply certain components of our products, and in some cases, we purchase these components ourselves. In our factory in Fremont, California, where we manufacture our AlterG products, we also rely on third-party suppliers for key components of our products.  Neither Lifeward nor Sanmina has long-term supply agreements with most of the suppliers and, in many cases, make purchases on a purchase order basis and our ability to secure adequate quantities of such products may be limited. Suppliers may encounter problems that limit their ability to manufacture components for our products, including financial difficulties or damage to their manufacturing equipment or facilities. If Lifeward or Sanmina fails to obtain sufficient quantities of high-quality components to meet demand on a timely basis, we could lose customer orders, our reputation may be harmed, and our business could suffer.
 
Our results of operations and liquidity could be adversely impacted by supply chain disruptions and operational challenges faced by our manufacturer or suppliers. Sanmina generally uses a small number of suppliers for ReWalk and ReStore. Our manufacturing operations for AlterG also utilize a limited number of suppliers, some of which are the sole suppliers to us of such supplies.  Depending on a limited number of suppliers exposes us to risks, including limited control over pricing, availability, quality, and delivery schedules. Such risks were heightened in light of the interruptions in supply chains and distribution networks related to the COVID-19 pandemic. For example, as a result of the COVID-19 pandemic, several components, mainly electronic parts, experienced price increases. If any one or more of our suppliers ceases to provide sufficient quantities of components in a timely manner or on acceptable terms, we or Sanmina would have to seek alternative sources of supply or accept price increase as we saw during the pandemic. It may be difficult to engage additional or replacement suppliers in a timely manner. Failure of these suppliers to deliver products at the level our business requires would limit our ability to meet our sales commitments, which could harm our reputation and could have a material adverse effect on our business. We or Sanmina also may have difficulty obtaining similar components from other acceptable suppliers, which could require Sanmina or us to cease using the components, seek alternative components or technologies and we could be forced to modify our products to incorporate alternative components or technologies, which could result in a requirement to seek additional regulatory clearances or approvals. Any disruption of this nature or increased expenses could harm our commercialization efforts and adversely affect our operating results.

32

 
Sanmina’s manufacturing and assembly of our ReWalk and Restore products pursuant to our specifications is conducted at a single facility in Ma’alot, Israel. Accordingly, we are highly dependent on the uninterrupted and efficient operation of this facility. If operations at this facility were to be disrupted as a result of acts of war or terrorism, equipment failures, earthquakes and other natural disasters, fires, accidents, work stoppages, power outages, or other reasons such as a local shutdown as we experienced during the COVID-19 pandemic, our business, financial condition and results of operations could be materially adversely affected. In particular, this facility is located in the north of Israel within range of rockets that have from time to time been fired into the country during armed conflicts with Hezbollah and other armed groups in Lebanon, Syria or other countries in the region. For more information, see the risk factor below entitled “Risks Related to Our Incorporation and Location in Israel - Conditions in Israel, including Israel’s war against Hamas and other terrorist organizations in the Gaza Strip and a potential escalation of the conflict on Israel’s northern border, may materially and adversely affect our business and results of operations.” Although our manufacturing and assembly operations could be transferred elsewhere, either in-house or to an alternative Sanmina facility, the process of relocating these operations would cause delays in production. Lost sales or increased costs that we may experience during the disruption, or a forced relocation, of operations may not be recoverable under our insurance policies, and longer-term business disruptions could result in a loss of customers. If this were to occur, our business, financial condition and operations could be materially negatively impacted. Additionally, our reliance on Sanmina as a contract manufacturer or any other contract manufacturer makes us vulnerable to possible capacity constraints and reduced control over component availability, delivery schedules, manufacturing yields and costs.
 
We operate in a competitive industry that is subject to rapid technological change, and we expect competition to increase.
 
There are several other companies developing technology and devices that compete with our products. Our principal competitors in the medical exoskeleton market consist of Ekso Bionics, Rex Bionics, Cyberdyne, FREE Bionics, Wandercraft, and others. These companies have products currently available for institutional use and in some cases personal use. We expect some of such products to become available for personal use in the next few years, especially as we continue to expand coverage by different payors and geographies. In addition, we compete with alternative devices and alternative therapies, including treadmill-based gait therapies, such as those offered by DIH (formerly known as Hocoma), Boost, Aretech, BTL, Reha Technology, and Bioness, which is a unit of Bioventus. Our competitor base may change or expand as we continue to develop and commercialize our soft suit exoskeleton product in the future. These or other medical device or robotics companies, academic and research institutions, or others, may develop new technologies or therapies that provide a superior walking and usage experience, are more effective in treating the secondary medical conditions that we target or are less expensive than ReWalk, ReStore, AlterG, or future products. Our technologies and products could be rendered obsolete by such developments. We may also compete with other treatments and technologies that address the secondary medical conditions that our products seek to mitigate.
 
Our competitors may respond more quickly to new or emerging technologies, undertake more extensive marketing campaigns, have greater financial, marketing, and other resources than we do or may be more successful in attracting potential customers, employees, and strategic partners. In addition, potential customers, such as hospitals and rehabilitation centers, could have long-standing or contractual relationships with competitors or other medical device companies. Potential customers may be reluctant to adopt ReWalk, ReStore, or AlterG, particularly if it competes with or has the potential to compete with or diminish the need/utilization of products or treatments supported through these existing relationships. If we are not able to compete effectively, our business and results of operations will be negatively impacted.

33

 
In addition, because we operate in a new market, the actions of our competitors could adversely affect our business. Adverse events such as product defects or legal claims with respect to competing or similar products could cause reputational harm to the exoskeleton market on the whole. Further, adverse regulatory findings or reimbursement-related decisions with respect to other exoskeleton products could negatively impact the entire market and, accordingly, our business.
 
We utilize independent distributors for the ReWalk and ReStore products who are free to market other products that compete with ours.
 
While we expect that the percentage of our sales generated from independent distributors will decrease over time as we continue to focus our resources on achieving reimbursement within our direct markets in the United States and Europe, we believe that independent distributors of the ReWalk or ReStore products will continue to be an important distribution channel for us in the future. None of our independent distributors has been required to sell our products exclusively. Our agreements with these distributors generally have one-year initial terms and automatic renewals for an additional year. If any of our key independent distributors of the ReWalk or ReStore products were to cease to distribute our products, our sales could be adversely affected. In such a situation, we may need to seek alternative independent distributors or increase our reliance on our other independent distributors or our direct sales representatives, which may not prevent our sales from being adversely affected. Additionally, to the extent that we enter into additional arrangements with independent distributors to perform sales, marketing, or distribution services, the terms of the arrangements could cause our product margins to be lower than if we directly marketed and sold our products.
 
We may receive a significant number of warranty claims or our ReWalk, ReStore, or AlterG systems may require significant amounts of service after sale.
 
Sales of ReWalk generally include a five-year warranty for parts and services, other than for normal wear and tear. Some of our active devices were delivered prior to 2019 with a two-year warranty so we provide these customers with the option to purchase an extended warranty for up to an additional three years. Our ReStore product offering includes a two-year warranty for parts and services. The AlterG Anti-Gravity systems are sold with a one-year factory warranty covering parts and services.  If product returns or warranty claims are significant or exceed our expectations, we could incur unanticipated expenditures for parts and services, which could have a material adverse effect on our operating results.
 
We may not be able to enhance our exoskeleton product offerings through our research and development efforts.
 
In order to increase our sales and our market share in the exoskeleton market, we are working to enhance and broaden our research and development efforts and product offerings in response to the evolving demands of people with paraplegia, paralysis, other medical conditions and healthcare providers, as well as competitive technologies. We are also currently involved in ongoing research and development efforts directed to the needs of patients with other mobility impairments, such as stroke, and began commercializing our ReStore product for stroke patients in 2019. Depending on our future resources and business focus, we plan to address these needs in patients with other conditions or devices for stroke patients to be used at home, improving our current products, or developing products to address additional medical conditions such as multiple sclerosis, Parkinson’s disease or cerebral palsy and support elderly assistance. We may decide to invest our business development resources in partnerships, licensing agreements, business acquisition and other ways that will provide us new product offerings without significant research and development activities. We may not be successful in developing, obtaining regulatory approval for, or marketing our currently proposed products, or our approved products for additional indications, products proposed to be created in the future or products that will be available for us through business acquisitions. In addition, notwithstanding our market research efforts, our future products may not be accepted by consumers, their caregivers, healthcare providers or third-party payors who reimburse consumers for our products. The success of any proposed product offerings will depend on numerous factors, including our ability to:
 

identify the product features that people with paraplegia or paralysis, their caregivers, and healthcare providers are seeking in a medical device that restores upright mobility and successfully incorporate those features into our products;
 

identify the product features that people with stroke, multiple sclerosis or other similar indications require while the products are used at home as well as what items are valuable to the clinics that provide them rehabilitation;
 

develop and introduce proposed products in sufficient quantities and in a timely manner;
 

adequately protect our intellectual property and avoid infringing upon the intellectual property rights of third-parties;
 
34



demonstrate the safety, efficacy, and health benefits of proposed products; and
 

obtain the necessary regulatory clearances and approvals for proposed products.
 
If we fail to generate demand by developing products that incorporate features desired by consumers, their caregivers or healthcare providers, or if we do not obtain regulatory clearance or approval for proposed products in time to meet market demand, we may fail to generate sales sufficient to achieve or maintain profitability. We have in the past experienced, and we may in the future experience, delays in various phases of product development, including during research and development, manufacturing, limited release testing, marketing, and customer education efforts. Such delays could cause customers to delay or forgo purchases of our products, or to purchase our competitors’ products. Even if we are able to successfully develop proposed products when anticipated, these products may not produce sales in excess of the costs of development, and they may be quickly rendered obsolete by changing consumer preferences or the introduction by our competitors of products embodying new technologies or features.
 
We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, business acquisitions or partnerships with third parties that may not result in the development of commercially viable products or the generation of significant future revenue.
 
In the ordinary course of our business, we may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, business acquisitions, partnerships or other arrangements to develop our products and to pursue new geographic or product markets. Proposing, negotiating, and implementing collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations may not result in the development of products that achieve commercial success or result in significant revenue and could be terminated prior to developing any products. For example, we have entered into agreements with MediTouch and MYOLYN for the distribution of their products in the U.S. After several years of commercial collaboration, we determined that the agreement with MediTouch would not yield commercially acceptable results for us and we terminated the agreement as of January 31, 2023. Similarly, the distribution arrangement with MYOLYN or other new future arrangements may not be as productive or successful as we hope.
 
On May 16, 2016, we entered into the Collaboration Agreement and License Agreement with Harvard. Pursuant to the Collaboration Agreement, we have agreed to collaborate with Harvard for the research, design, development, and commercialization of lightweight exoskeleton system technologies for lower limb disabilities, aimed to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications. The Collaboration Agreement concluded on March 31, 2022.  The License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents. For more information on the collaboration with Harvard, see “Part I. Item 1. Business - Research and Development - Research and Development Collaborations”.
 
Additionally, as we pursue these arrangements and choose to pursue other collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships in the future, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement. This could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators. Our collaborators or any future collaborators may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. Disputes between us and our collaborators or any future collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements. Our collaborators or any future collaborators may allege that we have breached our agreement with them, and accordingly seek to terminate such agreement, which could adversely affect our competitive business position and harm our business prospects.

35

 
We may seek to grow our business through acquisitions of businesses, products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business, could have a material adverse effect on our business, financial condition, and operating results.
 
From time to time, we may consider opportunities to acquire or license other products or technologies that may enhance our product platform or technology, expand the breadth of our markets or customer base, or advance our business strategies. For example, as discussed above in “Part I. Item 1. Business - Overview”, on August 11, 2023, we completed the acquisition of AlterG, and AlterG became an indirect and wholly-owned subsidiary of the Company. Potential acquisitions involve numerous risks, including:
 

problems assimilating the acquired products or technologies;
 

issues maintaining uniform standards, procedures, controls and policies;
 

problems integrating employees from an acquired organization into our company and integrating each company’s accounting, management information, human resources and other administrative systems;
 

unanticipated costs associated with acquisitions;
 

diversion of management’s attention from our existing business operations;
 

potential incurrence of debt, contingent liabilities or amortization expenses, or write-offs of goodwill;
 

risks associated with entering new markets in which we have limited or no experience; and
 

increased legal and accounting costs relating to the acquisitions or compliance with regulatory matters.
 
We have no current commitments with respect to any acquisition or licensing. We do not know if we will be able to identify such acquisitions or licensing we deem suitable, whether we will be able to successfully complete any such transactions on favorable terms, or at all, or whether we will be able to successfully integrate any acquired products or technologies. Our potential inability to integrate any acquired products or technologies effectively may adversely affect our business, operating results, and financial condition. For more information, see the risk factor above entitled “Risks Related to Our Business and Our Industry – We may fail to realize the benefits expected from our acquisition of AlterG, which could adversely affect the price of our ordinary shares.”
 
Risks Related to Government Regulation
 
Although the FDA granted Breakthrough Device Designation status to our ReBoot device, this designation does not guarantee regulatory clearance, or a speedier clearance timeline.
 
In November 2021, the FDA granted Breakthrough Device Designation status to ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.  In May 2021, the FDA granted Breakthrough Device Designation status to the ReWalk with stair functionality.  For more information regarding the Breakthrough Device, see “Part I, Item 1. Business-Government Regulation” above.
 
However, achieving Breakthrough Device Designation status does not guarantee regulatory clearance or approval or a speedier clearance or approval timeline.  We have not yet submitted a premarket submission to the FDA or any foreign regulatory agency for clearance or other marketing authorization of ReBoot.
 
U.S. healthcare reform measures and other potential legislative initiatives could adversely affect our business.
 
Recent political changes in the United States could result in significant changes in, and uncertainty with respect to, legislation, regulation, global trade, and government policy that could substantially impact our business and the medical device industry generally. Certain proposals, if enacted into law, could impose limitations on the prices we will be able to charge for our ReWalk system or any products we may develop and offer in the future, or the amounts of reimbursement available for such products from governmental agencies or third-party payors. Additionally, any reduction in reimbursement from Medicare or other government-funded federal programs, including the VHA, or state healthcare programs could lead to a similar reduction in payments from private commercial payors. The FDA’s policies may also change, and additional government regulations may be issued that could prevent, limit, or delay regulatory approval of our future products, or impose more stringent product labeling and post-marketing testing and other requirements.
 
We expect that changes or additions to the ACA or the Medicare and Medicaid programs, changes allowing the federal government to directly negotiate drug prices and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.

36

 
Other legislative changes have been proposed and adopted since passage of the ACA. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation’s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2% per fiscal year. This 2% reduction was temporarily suspended during the pandemic, but has since been reinstated and, unless Congress and/or the Administration take additional action, will begin to increase gradually starting in April 2030, reaching 4% in April 2031, until sequestration ends in October 2031. On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The 2022 Inflation Reduction Act, among other things, directs CMS to engage in price-capped negotiation for certain drugs and biologics that CMS reimburses under Medicare Part B and Part D, penalizes drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation, and redesigns the Part D drug benefit, effective in 2025.
 
The implementation of cost containment measures or other healthcare reforms may thus prevent us from being able to generate revenue, attain profitability or further commercialize our existing or future products. We are currently unable to predict what additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval of such proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to enter into collaboration agreements for the further development and commercialization of our programs and products.
 
Our devices are subject to the FDA’s regulations pertaining to marketing and promotional communications, among others. Failure to comply with such regulations may give rise to a number of potential FDA enforcement actions, any of which could have a material adverse effect on our business.
 
Our sales and marketing efforts, as well as promotions, are subject to various laws and regulations. Medical device promotions must be consistent with and not contrary to labeling and the indication for use, be truthful and not false or misleading, and be adequately substantiated. In addition to the requirements applicable to 510(k)-cleared products, we may also be subject to enforcement action in connection with any promotion of an investigational new device. A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, may not represent in a promotional context that an investigational new device is safe or effective for the purposes for which it is under investigation or otherwise promote the device.
 
Our marketing and promotional materials are subject to FDA scrutiny to ensure that the device is being marketed in compliance with these requirements. If the FDA investigates our marketing and promotional materials and finds that any of our current or future commercial products were being marketed for unapproved or uncleared uses or in a false or misleading manner, we could be subject to FDA enforcement and/or false advertising consumer lawsuits, each of which could have a material adverse effect on our business.
 
We are subject to extensive governmental regulations relating to the manufacturing, labeling, and marketing of our products, and a failure to comply with such regulations could lead to withdrawal or recall of our products from the market.
 
Our medical products and manufacturing operations are subject to regulation by the FDA, the European Union, and other governmental authorities both inside and outside of the United States. These agencies enforce laws and regulations that govern the development, testing, manufacturing, labeling, storage, installation, servicing, advertising, promoting, marketing, distribution, import, export and market surveillance of our products.
 
Our products are regulated as medical devices in the United States under the FFDCA as implemented and enforced by the FDA. Under the FFDCA, medical devices are classified into one of three classes (Class I, Class II or Class III) depending on the degree of risk associated with the medical device, what is known about the type of device, and the extent of control needed to provide reasonable assurance of safety and effectiveness. Classification of a device is important because the class to which a device is assigned determines, among other things, the necessity and type of FDA review required prior to marketing the device. For more information, see “Part I, Item 1. Business-Government Regulation” above.

37

 
In June 2014, the FDA granted our request for “de novo” classification, which provides a route to market for medical devices that are low to moderate risk, but are not substantially equivalent to a predicate device, and classified ReWalk as Class II powered exoskeleton device subject to certain special controls. In March 2023 the FDA granted 510(k) clearance for the ReWalk Personal Exoskeleton with stair and curb functionality, which adds usage on stairs and curbs to the indication for use for the device in the U.S. The ReWalk is intended to enable individuals with spinal cord injuries to perform ambulatory functions under supervision of a specially trained companion, and inside rehabilitation institutions. The special controls established in the de novo order for all powered exoskeletons include the following: clinical testing to demonstrate safe and effective use considering the level of supervision necessary and the use environment; non-clinical safety and performance testing, including durability testing to demonstrate that the device performs as intended under anticipated conditions of use; a training program; and labeling related to device use and user training. In order for us to market ReWalk, we must comply with both general controls, including controls related to quality, facility registration, reporting of adverse events and labeling, and the special controls established for the device. Failure to comply with these requirements could lead to an FDA enforcement action, which would have a material adverse effect on our business.
 
In June 2019, the FDA issued a 510(k) clearance for our ReStore device. ReStore is intended to be used to assist ambulatory functions in rehabilitation institutions under the supervision of a trained therapist for people with hemiplegia or hemiparesis due to stroke who have a specified amount of ambulatory function. In order for us to market ReStore and ReWalk, we must comply with both general controls, including controls related to quality, facility registration, reporting of adverse events and labeling, and the special controls established for powered exoskeleton devices as described above. Failure to comply with these requirements could lead to an FDA enforcement action, which would have a material adverse effect on our business.
 
In the E.U. we are subject to regulations and standards regulating the design, manufacture, clinical trials, labeling and adverse event (i.e., vigilance) reporting for medical devices. The Medical Devices Regulation (EU) 2017/745 (MDR) became fully applicable on May 26, 2021, repealing and replacing the pre-existing E.U. Medical Devices Directive 93/42/EEC. Devices that comply with the requirements of the MDR, subject to certain transitional provisions that allow continued compliance of certain products to the Directive, are entitled to bear the CE mark, indicating that the device conforms to the essential requirements of the MDR and, accordingly, can be commercially distributed throughout the European Economic Area (i.e., the E.U. Member States plus Norway, Iceland, and Lichtenstein). We comply with the E.U. requirements and have received the CE mark for all of our ReWalk systems including the ReStore device which are distributed in the E.U. As compared with the Directive, the MDR includes additional premarket and post-market requirements, as well as potential product reclassifications and more stringent commercialization requirements that could adversely affect our CE mark. Failure to comply with these new requirements could lead to substantial penalties, including fines, revocation or suspension of CE mark and criminal sanctions.
 
Following the introduction of a product, the governmental agencies will periodically inspect our manufacturing processes and quality controls, and we are under a continuing obligation to ensure that all applicable regulatory requirements continue to be met. The process of complying with the applicable good manufacturing practices, adverse event reporting and other requirements can be costly and time consuming, and could delay or prevent the production, manufacturing, or sale of our devices. In addition, if we fail to comply with applicable regulatory requirements, it could result in fines, closure of manufacturing sites, seizures or recalls of products and damage to our reputation, as well as enforcement actions against us. For example, the FDA could request that we recall our ReWalk Personal Exoskeleton or ReStore device in case of product defects or require us to conduct post-market surveillance studies. If we fail to recall the device and/or conduct requested post-market surveillance studies to FDA’s satisfaction, we could be subject to FDA enforcement action.
 
In addition, governmental agencies may impose new requirements regarding registration or labeling that may require us to modify or re-register our products or otherwise impact our ability to market our products in those countries, such as the May 2021 Medical Device Regulation changes in the European Union. The process of complying with these governmental regulations can be costly and time consuming, and could delay or prevent the production, manufacturing, or sale of our products.

38

 
If we or our third-party manufacturers fail to comply with the FDA’s Quality System Regulation, or QSR, our manufacturing operations could be interrupted.
 
We and our manufacturer Sanmina are required to comply with the FDA’s QSR which covers the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage, and shipping of our products. We, Sanmina, and our suppliers are also subject to the regulations of foreign jurisdictions regarding the manufacturing process if we or our distributors market our products abroad. We continue to monitor our quality management to maintain our overall level of compliance. Our facilities are subject to periodic and unannounced inspection by U.S. and foreign regulatory agencies to audit compliance with the QSR and comparable foreign regulations. If our facilities or those of Sanmina or our suppliers are found to be in violation of applicable laws and regulations, or if we, Sanmina, or our suppliers fail to take satisfactory corrective action in response to an adverse inspection, the regulatory authority could take enforcement action, including any of the following sanctions: 
 

untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
 

customer notifications or repair, replacement, or refunds;
 

operating restrictions or partial suspension or total shutdown of production;
 

recalls, withdrawals, or administrative detention or seizure of our products;
 

denials or delays of approvals for pre-market approval applications relating to new products or modified products;
 

withdrawals of a PMA approvals;
 

refusal to provide Certificates for Foreign Government;
 

refusal to grant export approval for our products; or
 

pursuit of criminal prosecution. 
 
Any of these sanctions could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers’ demands and could have a material adverse effect on our reputation, business, results of operations, and financial condition. We may also be required to bear other costs or take other actions that may have a negative impact on our future sales and our ability to generate profits.
 
We are subject to various laws and regulations, including “fraud and abuse” laws and anti-bribery laws, which, if violated, could subject us to substantial penalties.
 
Medical device companies such as ours have faced lawsuits and investigations pertaining to alleged violations of numerous statutes and regulations, including anti-corruption laws and health care “fraud and abuse” laws, such as the federal False Claims Act, the federal Anti-Kickback Statute, and the U.S. Foreign Corrupt Practices Act, or the FCPA.
 
U.S. federal and state laws, including the federal Sunshine Act, and the implementation of Open Payments regulations under the Sunshine Act, require medical device companies to disclose certain payments or other transfers of value made to certain healthcare providers or funds spent on marketing and promotion of medical device products. Further, some state laws require medical device companies to report information related to payments to physicians and other health care providers or marketing expenditures. They also impose additional administrative and compliance burdens on us. In particular, these laws influence, among other things, how we structure our sales offerings and other interactions with health care providers, including discount practices, customer support, education and training programs and physician consulting and other service arrangements, including those with marketers and sales agents. We may face significant costs in attempting to comply with these laws and regulations. If we are found to be in violation of any of these requirements or any actions or investigations are instituted against us, those actions could be costly to defend and could have a significant impact on our business, including the imposition of significant criminal and civil fines and penalties, exclusion from federal healthcare programs or other sanctions, and damage to our reputation or business.   
 
The FCPA applies to companies, including ours, with a class of securities registered under the Exchange Act. The FCPA and other anti-bribery laws to which various aspects of our operations may be subject generally prohibit companies and their employees, agents, and other intermediaries from authorizing, promising, offering, providing, or making, directly or indirectly, improper payments or anything else of value to government officials for the purpose of obtaining or retaining business. The FCPA also requires covered companies such as ours to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls.  In various jurisdictions, our operations require that we and third parties acting on our behalf routinely interact with government officials, including medical personnel who may be considered government officials for purposes of these laws because they are employees of state-owned or controlled facilities. Other anti-bribery laws to which various aspects of our operations may be subject, including the United Kingdom Bribery Act, also prohibit improper payments to private parties and prohibit receipt of improper payments. Our policies prohibit our employees from making or receiving corrupt payments, including, among other things, to require compliance by third parties engaged to act on our behalf. Our policies mandate compliance with these anti-bribery laws; however, recent years have seen an increase in the global enforcement of anti-corruption laws and our international operations could increase the risk of such violations. As a result, the existence and implementation of a robust anti-corruption program cannot eliminate all risk that unauthorized improper acts have been or will be committed by our employees or agents. Violations of these anti-corruption laws, or allegations of such violations, could result in civil or criminal sanctions or other adverse consequences, including disruption of our business and harming our financial condition, results of operations, cash flows and reputation.  

39

 
If we are found to have violated laws protecting the confidentiality of patient health information, we could be subject to civil or criminal penalties, which could increase our liabilities and harm our reputation or our business.
 
There are a number of federal, state and foreign laws protecting the confidentiality of certain patient health information, including patient records, and restricting the use and disclosure of that protected information. In particular, the U.S. Department of Health and Human Services, or HHS, promulgated patient privacy rules under HIPAA. These privacy rules protect medical records and other personal health information by limiting their use and disclosure, giving individuals the right to access, amend and seek accounting of their own health information and limiting most use and disclosures of health information to the minimum amount reasonably necessary to accomplish the intended purpose. Additionally, the E.U. General Data Protection Regulation (the “GDPR”), imposes more stringent data protection requirements and provides for penalties for noncompliance. Thus, with respect to our operations in Europe, the GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. This may be onerous and adversely affect our business, financial condition, results of operations and prospects. Additionally, if we or any of our service providers are found to be in violation of the promulgated patient privacy rules under HIPAA or the GDPR, we could be subject to civil or criminal penalties, which could be substantial and could increase our liabilities, harm our reputation and have a material adverse effect on our business, financial condition and operating results.
 
In addition, a number of U.S. states have enacted data privacy and security laws and regulations that govern the collection, use, disclosure, transfer, storage, disposal, and protection of sensitive personal information, such as social security numbers, financial information and other personal information. For example, several U.S. territories and all 50 states now have data breach laws that require timely notification to individual victims, and at times regulators, if a company has experienced the unauthorized access or acquisition of sensitive personal data. Other state laws include the California Consumer Privacy Act (“CCPA”) which, among other things, contains new obligations for businesses that collect personal information about California residents and affords those individuals new rights relating to their personal information that may affect our ability to use personal information or share it with our business partners. Meanwhile, other states have enacted or are considering enacting privacy laws like the CCPA.  Furthermore, it is anticipated that the California Privacy Rights Act of 2020, effective January 1, 2023, expands the CCPA’s requirements, including applying to personal information of business representatives and employees and establishing a new regulatory agency to implement and enforce the law.  We will continue to monitor and assess the impact of state law developments, which may impose substantial penalties for violations, impose significant costs for investigations and compliance, allow private class-action litigation and carry significant potential liability for our business.
 
The interpretation and enforcement of the laws and regulations described above are uncertain and subject to change and may require substantial costs to monitor and implement compliance with any additional requirements. Failure to comply with U.S. or international data protection laws and regulations could result in government enforcement actions (which could include substantial civil and/or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.   
 
Compliance with various regulations, including those related to our status as a U.S. public company and the manufacturing, labeling, and marketing of our products, may result in heightened general and administrative expenses and costs, divert management’s attention from revenue-generating activities and pose challenges for our management team, which has limited time, personnel and finances to devote to regulatory compliance. 
 
As a U.S. public company, we are subject to various regulatory and reporting requirements, including those imposed by the SEC, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or the Dodd-Frank Act, the listing requirements of The Nasdaq Capital Market and other applicable securities rules and regulations. Additionally, our medical products and manufacturing operations are regulated by the FDA, the European Union and other governmental authorities both inside and outside of the United States. Compliance with the rules and regulations applicable to us as a publicly traded company in the United States and medical device manufacturer has greatly increased, and may continue to increase, our legal, general and administrative and financial compliance costs and has made, and may continue to make, some activities more difficult, time-consuming or costly. Additionally, these regulatory requirements have diverted, and may continue to divert, management’s attention from revenue-generating activities and may increase demands on management’s already-limited resources. 

40

 
Our management team consists of few employees, as the majority of our employees are engaged in sales and marketing and research and development activities. For more information, see “Part I, Item 1. Business—Employees” above. In light of such constraints on its time, personnel and finances, our management may not be able to implement programs and policies in an effective and timely manner to respond adequately to the heightened legal, regulatory and reporting requirements applicable to us. In the past, for example, we have not always been able to respond on a timely basis to requests from regulators, although we have not to date experienced any long-term material adverse consequences as a result. Similar deficiencies, weaknesses, or lack of compliance with public company, medical device and other regulations could harm our reputation in the capital markets or for quality and safety, negatively affect our ability to maintain our public company status and to develop, commercialize or continue selling our products on a timely and effective basis, and cause us to incur sanctions, including fines, injunctions, and penalties.
 
In addition, complying with public disclosure rules makes our business more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business and operating results could be harmed, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm our business and operating results.
 
We are also subject to the requirement of Section 1502 of the Dodd-Frank Act and SEC rules related thereto to conduct due diligence and disclose and report on whether certain minerals and metals, known as “conflict minerals,” are contained in our products and whether they originate from the Democratic Republic of Congo and certain adjoining countries.  Each year our management team devotes significant time to conduct the required due diligence, and we may face reputational challenges if we determine that certain of our products contain minerals not determined to be conflict free or if we are unable to sufficiently verify the origins of all conflict minerals used in our products through the procedures we implement.
 
Risks Related to Our Intellectual Property and Information Technology
 
We depend on computer and telecommunications systems we do not own or control and failures in our systems or a cybersecurity attack or incident relating to our IT systems or technology could significantly disrupt our business operations or result in sensitive customer information being compromised which would negatively materially affect our reputation and/or results of operations.
 
We have entered into agreements with third parties for hardware, software, telecommunications, and other information technology services in connection with the operation of our business. It is possible we or a third party that we rely on could incur interruptions from a loss of communications, hardware or software failures, a cybersecurity attack or an incident relating to our IT systems or technology, ransomware, phishing attacks, computer viruses or malware. We believe that we have positive relations with our vendors and maintain adequate anti-virus and malware software and controls; however, any interruptions to our arrangements with third parties, to our computing and communications infrastructure, or to our information systems or any of those operated by a third party that we rely on could significantly disrupt our business operations.
 
In the current environment, there are numerous and evolving risks to cybersecurity and privacy, including criminal hackers, hacktivists, state-sponsored intrusions, industrial espionage, employee malfeasance and human or technological error. High-profile cybersecurity incidents at other companies and in government agencies have increased in recent years, and security industry experts and government officials have warned about the risks of hackers and cyberattacks targeting businesses such as ours. Computer hackers and others routinely attempt to breach the security of technology products, services, and systems, and to fraudulently induce employees, customers, or others to disclosure information or unwittingly provide access to systems or data. A cyberattack of our systems or networks that impairs our information technology systems could disrupt our business operations and result in loss of service to customers, including technical support for our ReWalk devices. While we have certain cybersecurity safeguards in place designed to protect and preserve the integrity of our information technology systems, we have experienced and expect to continue to experience actual or attempted cyberattacks of our IT systems or networks. However, none of these actual or attempted cyberattacks has had a material effect on our operations, business strategy, or financial condition.

41

 
Additionally, we have access to sensitive customer information in the ordinary course of business. If a significant cybersecurity incident occurred, our reputation may be adversely affected, customer confidence may be diminished, or we may be subject to legal claims, any of which may contribute to the loss of customers and have a material adverse effect on us. For more information, see “—Risks Related to Government Regulation” above.  If we are found to have violated laws protecting the confidentiality of patient health information, we could be subject to civil or criminal penalties, which could increase our liabilities and harm our reputation or our business.” above.
 
Our success depends in part on our ability to obtain and maintain protection for the intellectual property relating to or incorporated into our products.
 
Our success depends in part on our ability to obtain and maintain protection for the intellectual property relating to or incorporated into our products. We seek to protect our intellectual property through a combination of patents, trademarks, confidentiality, and assignment agreements with our employees and certain of our contractors, and confidentiality agreements with certain of our consultants, scientific advisors, and other vendors and contractors. In addition, we rely on trade secret law to protect our proprietary software and product candidates/products in development. For more information, see “Part I, Item 1. Business—Intellectual Property” above.
 
Our patent position with respect to our exoskeleton and anti-gravity systems can be highly uncertain and involves many new and evolving complex legal, factual, and technical issues. Patent laws and interpretations of those laws are subject to change and any such changes may diminish the value of our patents or narrow the scope of our right to exclude others. In addition, we may fail to apply for or be unable to obtain patents necessary to protect our technology or products from competition or fail to enforce our patents due to lack of information about the exact use of technology or processes by third parties. Also, we cannot be sure that any patents will be granted in a timely manner or at all with respect to any of our patent pending applications or that any patents that are granted will be adequate to exclude others for any significant period of time or at all. Given the foregoing and in order to continue reducing operational expenses in the future, we may invest fewer resources in filing and prosecuting new patents and on maintaining and enforcing various patents, especially in regions where we currently do not focus our market growth strategy.
 
Litigation to establish or challenge the validity of patents, or to defend against or assert against others infringement, unauthorized use, enforceability, or invalidity, can be lengthy and expensive and may result in our patents being invalidated or interpreted narrowly and restricting our ability to be granted new patents related to our pending patent applications. Even if we prevail, litigation may be time consuming, force us to incur significant costs, and could divert management’s attention from managing our business while any damages or other remedies awarded to us may not be valuable. In addition, U.S. patents and patent applications may be subject to interference proceedings, and U.S. patents may be subject to re-examination and review proceedings in the U.S. Patent and Trademark Office. Foreign patents may also be subject to opposition or comparable proceedings in the corresponding foreign patent offices. Any of these proceedings may be expensive and could result in the loss of a patent or denial of a patent application, or the loss or reduction in the scope of one or more of the claims of a patent or patent application.   
 
In addition, we seek to protect our trade secrets, know-how, and confidential information that is not patentable by entering into confidentiality and assignment agreements with our employees and certain of our contractors and confidentiality agreements with certain of our consultants, scientific advisors, and other vendors and contractors. However, we may fail to enter into the necessary agreements, and even if entered into, these agreements may be breached or otherwise fail to prevent disclosure, third-party infringement, or misappropriation of our proprietary information, may be limited as to their term and may not provide an adequate remedy in the event of unauthorized disclosure or use of proprietary information. Enforcing a claim that a third party illegally obtained or is using our trade secrets without authorization may be expensive and time consuming, and the outcome is unpredictable. Some of our employees or consultants may own certain technology which they license to us for a set term. If these technologies are material to our business after the term of the license, our inability to use them could adversely affect our business and profitability. 
 
We also have taken precautions to initiate reasonable safeguards to protect our information technology systems. However, these measures may not be adequate to safeguard our proprietary information, which could lead to the loss or impairment thereof or to expensive litigation to defend our rights against competitors who may be better funded and have superior resources. In addition, unauthorized parties may attempt to copy or reverse engineer certain aspects of our products that we consider proprietary, or our proprietary information may otherwise become known or may be independently developed by our competitors or other third parties. If other parties are able to use our proprietary technology or information, our ability to compete in the market could be harmed. Further, unauthorized use of our intellectual property may have occurred, or may occur in the future, without our knowledge.
 
If we are unable to obtain or maintain adequate protection for intellectual property, or if any protection is reduced or eliminated, competitors may be able to use our technologies, resulting in harm to our competitive position.

42

 
Our patents and proprietary technology and processes may not provide us with a competitive advantage.
 
Robotics, exoskeletons, and anti-gravity system technologies have been developing rapidly in recent years. We are aware of several other companies developing competing exoskeleton devices for individuals with limited mobility and we expect the level of competition and the pace of development in our industry to increase.  Likewise, we are aware of several companies with commercial anti-gravity or treadmill-based gait therapy systems. For more information, see “Part I, Item 1. Business—Competition” above. While we believe our tilt-sensor technology provides a more natural and superior method of exoskeleton activation, which creates a better user experience, as well as that our licensed technology used in our ReStore device is unique and provides better results when compared to other products, a variety of other activation and control methods exist for exoskeletons, several of which are being developed by our competitors, or may be developed in the future. Additionally, while our DAP technology provides what we believe is a superior method for partial weight displacement with strong market acceptance, there may be competitors developing innovative alternative gait therapies that could be introduced in the future. As a result, our patent portfolio and proprietary technology and processes may not provide us with a significant advantage over our competitors, and competitors may be able to design and sell alternative products that are equal to or superior to our products without infringing on our patents. In addition, as our current patents begin to expire, we may lose a competitive advantage over our competitors as we will no longer be able to keep our competitors from practicing the technology covered by the claim of the expired patents. We may also be unable to adequately develop new technologies and obtain future patent protection to preserve a competitive advantage. If we are unable to maintain a competitive advantage, our business and results of operations may be materially adversely affected.
 
Even in instances where others are found to infringe on our patents, many countries have laws under which a patent owner may be compelled to grant licenses for the use of the patented technology to other parties. In addition, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, a patent owner may have limited remedies, which could diminish the value of a patent in those countries. Further, the laws of some countries do not protect intellectual property rights to the same extent as the laws of the United States, particularly in the field of medical products, and effective enforcement in those countries may not be available. The ability of others to market comparable products could adversely affect our business.
 
We are not able to protect our intellectual property rights in all countries.
 
Filing, prosecuting, maintaining, and defending patents on each of our products in all countries throughout the world would be prohibitively expensive, and thus our intellectual property rights outside the United States and Europe are limited. In addition, the laws of some foreign countries, especially developing countries, such as China, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Also, it may not be possible to effectively enforce intellectual property rights in some countries at all or to the same extent as in the United States and other countries. Consequently, we are unable to prevent third parties from using our inventions in all countries, or from selling or importing products made using our inventions in the jurisdictions in which we do not have (or are unable to effectively enforce) patent protection. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop, market or otherwise commercialize their own products, and we may be unable to prevent those competitors from importing those infringing products into territories where we have patent protection, but enforcement may not be as strong as in the United States. These products may compete with our products and our patents and other intellectual property rights may not be effective or sufficient to prevent them from competing in those jurisdictions. Moreover, strategic partners, competitors, or others in the chain of commerce may raise legal challenges against our intellectual property rights or may infringe upon our intellectual property rights, including through means that may be difficult to prevent or detect.  
 
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. Proceedings to enforce our patent rights in the United States or foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert patent infringement or other claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights in the United States and around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license from third parties. 
 
43


We may be subject to patent infringement claims, which could result in substantial costs and liability and prevent us from commercializing our current and future products.
 
The medical device industry is characterized by competing intellectual property and a substantial amount of litigation over patent rights. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in competing technologies, have been issued patents and filed patent applications with respect to their products and processes and may apply for other patents in the future. The large number of patents, the rapid rate of new patent issuances, and the complexities of the technology involved increase the risk of patent litigation.
 
Determining whether a product infringes a patent involves complex legal and factual issues and the outcome of patent litigation is often uncertain. Even though we have conducted research of issued patents, no assurance can be given that patents containing claims covering our products, technology or methods do not exist, have not been filed or could not be filed or issued. In addition, because patent applications can take years to issue and because publication schedules for pending applications vary by jurisdiction, there may be applications now pending of which we are unaware, and which may result in issued patents that our current or future products infringe. Also, because the claims of published patent applications can change between publication and patent grant, published applications that initially do not appear to be problematic may issue with claims that potentially cover our products, technology, or methods.  
 
Infringement actions and other intellectual property claims brought against us, whether with or without merit, may cause us to incur substantial costs and could place a significant strain on our financial resources, divert the attention of management, and harm our reputation. We cannot be certain that we will successfully defend against any allegations of infringement. If we are found to infringe another party’s patents, we could be required to pay damages. We could also be prevented from selling our infringing products, unless we can obtain a license to use the technology covered by such patents or can redesign our products so that they do not infringe. A license may be available on commercially reasonable terms or none at all, and we may not be able to redesign our products to avoid infringement. Further, any modification to our products could require us to conduct clinical trials and revise our filings with the FDA and other regulatory bodies, which would be time consuming and expensive. In these circumstances, we may not be able to sell our products at competitive prices or at all, and our business and operating results could be harmed. 
 
We rely on trademark protection to distinguish our products from the products of our competitors.
 
We rely on trademark protection to distinguish our products from the products of our competitors. We have registered the trademark “ReWalk” in Israel and in the United States. The trademark “ReStore” is registered in Europe, the United States and the United Kingdom. The trademark “Alter G” is registered in the United States, Europe, Israel, and the United Kingdom.  We have also recently sought trademark registration of “Lifeward” in the United States, Europe, and Israel.  In jurisdictions where we have not registered our trademark and are using it, and as permitted by applicable local law, we rely on common law trademark protection. Third parties may oppose our trademark applications, or otherwise challenge our use of the trademarks, and may be able to use our trademarks in jurisdictions where they are not registered or otherwise protected by law. If our trademarks are successfully challenged or if a third party is using confusingly similar or identical trademarks in particular jurisdictions before we do, we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote additional resources to marketing new brands. If others are able to use our trademarks, our ability to distinguish our products may be impaired, which could adversely affect our business. Further, we cannot assure you that competitors will not infringe upon our trademarks, or that we will have adequate resources to enforce our trademarks.
 
We may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of their former employers.
 
Many of our employees were previously employed at other medical device companies, including our competitors or potential competitors, and we may hire employees in the future that are so employed. We could in the future be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. If we fail in defending against such claims, a court could order us to pay substantial damages and prohibit us from using technologies or features that are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. If any of these technologies or features that are important to our products, this could prevent us from selling those products and could have a material adverse effect on our business. Even if we are successful in defending against these claims, such litigation could result in substantial costs and divert the attention of management. 

44

 
Risks Related to Ownership of Our Ordinary Shares
 
Sales of a substantial number of ordinary shares by us or our large shareholders, certain of whom may have registration rights, or dilutive exercises of a substantial number of warrants by our warrant-holders could adversely affect the value of our ordinary shares.
 
Sales by us or our shareholders of a substantial number of ordinary shares in the public market, or the perception that these sales might occur, could cause the value of our ordinary shares to decline or could impair our ability to raise capital through a future sale of our equity securities. Additionally, dilutive exercises of a substantial number of warrants by our warrant-holders, or the perception that such exercises may occur, could put downward price on the market price of our ordinary shares.
 
As of February 27, 2024, 19,135,096 ordinary shares were issuable pursuant to the exercise of warrants, with exercise prices ranging from $1.25 to $9.375 per warrant, issued in private and registered offerings of ordinary shares and warrants in April 2019, June 2019, February 2020, July 2020, December 2020, February 2021 and September 2021. We have registered with the SEC all of these warrants and/or the resale of the shares issuable upon their exercise. There were also 6,679 ordinary shares issuable pursuant to the exercise of warrants granted to Kreos Capital V (Expert Fund) Limited (“Kreos”), in connection with the loan agreement we signed with Kreos on December 30, 2015 (the “Loan Agreement”) in January and December 2016, with an exercise price that is  set to $7.50 per warrant. For more information, “Part I, Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Equity Raises”, below.
 
All shares sold pursuant to an offering covered by a registration statement would be freely transferable. With respect to the outstanding warrants, there may be certain restrictions on the holders to sell the underlying ordinary shares to the extent they are restricted securities, held by “affiliates” or would exceed certain ownership thresholds. Certain of our largest shareholders, may also have limitations under Rule 144 under the Securities Act on the resale of certain ordinary shares they hold unless they are registered for resale under the Securities Act. Despite these limitations and the liquidity that we may gain from cash exercises of outstanding warrants, if we, our existing shareholders, or their affiliates sell a substantial number of the above-mentioned ordinary shares in the public market, the market price of our ordinary shares could decrease significantly. Shareholders may also incur substantial dilution if holders of our warrants exercise their warrants to purchase ordinary shares, which could lower the market price of our ordinary shares. Any such decrease could impair the value of your investment in us.
 
Future grants of ordinary shares under our equity incentive plans to our employees, non-employee directors and consultants, or sales by these individuals in the public market, could result in substantial dilution, thus decreasing the value of your investment in our ordinary shares, and certain grants may also require shareholder approval. In addition, stockholders will experience dilution upon the exercise of outstanding warrants.
 
We have historically used, and continue to use, our ordinary shares as a means of both rewarding our employees, non-employee directors, and consultants and aligning their interests with those of our shareholders. As of December 31, 2023, 4,824,530 ordinary shares remained available for issuance to our and our affiliates’ respective employees, non-employee directors, and consultants under our equity incentive plans, including 3,805,585 ordinary shares subject to outstanding awards (consisting of outstanding options to purchase 33,171 ordinary shares and 3,772,414 ordinary shares underlying unvested RSUs, and we may seek to increase the number of shares available under our equity incentive plans in the future. For more information, see Note 9b to our consolidated financial statements for the year ended December 31, 2023, below.
 
Additionally, to the extent registered on a Form S-8, ordinary shares granted or issued under our equity incentive plans will, subject to vesting provisions, lock-up restrictions, and Rule 144 volume limitations applicable to our “affiliates,” be available for sale in the open market immediately upon registration. Further, as of December 31, 2023, there were 19,187,375 ordinary shares underlying issued and outstanding warrants, which if exercised for ordinary shares, could decrease the net tangible book value of our ordinary shares and cause dilution to our existing shareholders. Sales of a substantial number of the above-mentioned ordinary shares in the public market could result in a significant decrease in the market price of our ordinary shares and have a material adverse effect on an investment in our ordinary shares.
 
If we do not meet the expectations of equity research analysts, if any, if the sole remaining equity analyst following our business does not continue to publish research or reports about our business, or if the analyst issues unfavorable commentary or downgrade our ordinary shares, the price of our ordinary shares could decline. Additionally, we may fail to meet publicly announced financial guidance or other expectations about our business, which would cause our ordinary shares to decline in value.
 
There is currently one equity analyst publishing research reports about our business, and we are currently seeking to attract additional coverage. If our results of operations are below the estimates or expectations of our sole analyst or consensus assuming we have some analysts and investors, our share price could decline. Moreover, the price of our ordinary shares could decline if one or more securities analysts downgrade our ordinary shares or if analysts issue other unfavourable commentary or stop publishing research or reports about us or our business (as has occurred over time, with a decrease in the number of analysts following us from five in 2014 to one in 2022). Given that there is only one analyst that currently covers our business, we face an increased risk that such analyst’s evaluation of our business, if less than positive, will cause a larger decline in our stock price than would otherwise be the case if we had multiple analysts covering our business.

45

 
From time to time, we have also faced difficulty accurately projecting our earnings and have missed certain of our publicly announced guidance. If our financial results for a particular period do not meet our guidance or if we reduce our guidance for future periods, the market price of our ordinary shares may decline.
 
We are a “smaller reporting company” and the reduced reporting requirements applicable to such companies may make our ordinary shares less attractive to investors.
 
We are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K, which allows us to take advantage of certain scaled disclosure requirements available specifically to smaller reporting companies. For example, we may continue to use reduced compensation disclosure obligations, and, provided we are also a “non-accelerated filer,” we will not be obligated to follow the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. We will remain a smaller reporting company until the last day of the fiscal year in which we have at least $100 million in revenue and at least $700 million in aggregate market value of ordinary shares held by non-affiliated persons and entities (known as “public float”), or, alternatively, if our revenue exceed $100 million, until the last day of the fiscal year in which our public float was at least $250.0 million (in each case, with respect to public float, as measured as of the last business day of the second quarter of such fiscal year).  For the year ended December 31, 2023, we recorded revenue of approximately $13.9 million.
 
We cannot predict or otherwise determine if investors will find our securities less attractive as a result of our reliance on exemptions as a smaller reporting company and/or “non-accelerated filer.” If some investors find our securities less attractive as a result, there may be a less active trading market for our ordinary shares and the price of our ordinary shares may be more volatile.
 
We are subject to ongoing costs and risks associated with determining whether our existing internal controls over financial reporting systems are compliant with Section 404 of the Sarbanes-Oxley Act, and if we fail to achieve and maintain adequate internal controls it could have a material adverse effect on our stated results of operations and harm our reputation.
 
We are required to comply with the internal control, evaluation, and certification requirements of Section 404 of the Sarbanes-Oxley Act and the Public Company Accounting Oversight Board, which requires us to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. Once we no longer qualify as a “smaller reporting company” and “non-accelerated filer,” our independent registered public accounting firm will need to attest to the effectiveness of our internal control over financial reporting under Section 404. When our independent registered public accounting firm is required to undertake an assessment of our internal control over financial reporting, the cost of our compliance with Section 404 will correspondingly increase. Our compliance with applicable provisions of Section 404 will require that we incur substantial accounting expense and expend significant management time on compliance-related issues as we implement additional corporate governance practices and comply with reporting requirements. Moreover, if we are not able to comply with the requirements of Section 404 applicable to us in a timely manner, or if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.
 
The process of determining whether our existing internal controls over financial reporting systems are compliant with Section 404 and whether there are any material weaknesses or significant deficiencies in our existing internal controls requires the investment of substantial time and resources, including by our Chief Financial Officer and other members of our senior management. This determination and any remedial actions required could divert internal resources and take a significant amount of time and effort to complete and could result in us incurring additional costs that we did not anticipate, including the hiring of outside consultants. We could experience higher than anticipated operating expenses and higher independent auditor fees during and after the implementation of these changes.
 
Irrespective of compliance with Section 404, any failure of our internal controls could have a material adverse effect on our stated results of operations and harm our reputation. If we are unable to implement any of the required changes to our internal control over financial reporting effectively or efficiently or are required to do so earlier than anticipated, it could adversely affect our operations, financial reporting and/or results of operations and could result in an adverse opinion on internal controls from our management and our independent auditors. Further, if our internal control over financial reporting is not effective, the reliability of our financial statements may be questioned, and our share price may suffer.

46

 
U.S. holders of our ordinary shares may suffer adverse U.S. tax consequences if we are characterized as a passive foreign investment company, or a PFIC, under Section 1297(a) of the Code.
 
Generally, if for any taxable year 75% or more of our gross income is passive income, or at least 50% of the average quarterly value of our assets (which may be determined in part by the market value of our ordinary shares, which is subject to change) are held for the production of, or produce passive income, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. Passive income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents, and gains from commodities and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary investment of funds, including those raised in an offering. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.
 
The determination of whether we are a PFIC will depend on the nature and composition of our income and the nature, composition, and value of our assets from time to time. The 50% passive asset test described above is generally based on the fair market value of each asset, with the value of goodwill and going concern value determined in large part by reference to the market value of our ordinary shares, which may be volatile. If we are characterized as a “controlled foreign corporation,” or a “CFC”, under Section 957(a) of the Code and not considered publicly traded throughout the relevant taxable year, however, the passive asset test may be applied based on the adjusted tax bases of our assets instead of the fair market value of each asset (as described above). However, if we are treated as publicly traded for at least 20 trading days during the relevant taxable year, our assets would generally be required to be measured at their fair market value, even if we are a CFC.
 
Based on our gross income and assets, the market price of our ordinary shares, and the nature of our business, we believe that we were not a PFIC for the taxable year ended December 31, 2023. However, this determination is subject to uncertainty. In addition, there is a significant risk that we may be a PFIC for future taxable years, unless the market price of our ordinary shares increases, or we reduce the amount of cash and other passive assets we hold relative to the amount of non-passive assets we hold. Accordingly, no assurances can be made regarding our PFIC status in one or more subsequent years, and our U.S. counsel expresses no opinion with respect to our PFIC status in the taxable year ended December 31, 2023, or the current year 2024, and also expresses no opinion with respect to our predictions or past determinations regarding our PFIC status in the past or in the future.
 
If we are characterized as a PFIC, U.S. holders of our ordinary shares may suffer adverse tax consequences, including having gains realized on the sale of our ordinary shares treated as ordinary income, rather than capital gain, the loss of the preferential tax rate applicable to dividends received on our ordinary shares by individuals who are U.S. holders and having interest charges apply to distributions by us and to the proceeds of sales of our ordinary shares. In addition, special information reporting may be required. Certain elections exist that may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment (such as mark-to-market treatment or being able to make a qualified electing fund election). However, we do not intend to provide the information necessary for U.S. Holders to make qualified electing fund elections if we are classified as a PFIC.
 
Additionally, if we are characterized as a PFIC, for any taxable year during which a U.S. holder holds ordinary shares, we generally will continue to be treated as a PFIC with respect to such U.S. holder for all succeeding years during which such U.S. holder holds ordinary shares unless we cease to be a PFIC and such U.S. holder makes a “deemed sale” election with respect to such ordinary shares. If such election is made, such U.S. holder will be deemed to have sold such ordinary shares held by such U.S. holder at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain from such deemed sale would be treated as described above.
 
Each U.S. holder of our ordinary shares is strongly urged to consult his, her or its tax advisor regarding the application of these rules and the availability of any potential elections.

47

 
The price of our ordinary shares may be volatile, and you may lose all or part of your investment.
 
Our ordinary shares were first publicly offered in our initial public offering in September 2014, at a price of $300.00 The market price of our ordinary shares has been in the past, and could continue to be, highly volatile and may fluctuate substantially as a result of many factors. Moreover, while there is no established public trading market for the warrants offered in our follow-on public offerings, and we do not expect one to develop, our ordinary shares will be issuable pursuant to exercise of these warrants. Because the warrants are exercisable into our ordinary shares, volatility, or a reduction in the market price of our ordinary shares could have an adverse effect on the trading price of the warrants. Factors which may cause fluctuations in the price of our ordinary shares include, but are not limited to:
 

actual or anticipated fluctuations in our growth rate or results of operations or those of our competitors;
 

customer acceptance of our products;
 

announcements by us or our competitors of new products or services, commercial relationships, acquisitions, or expansion plans;
 

announcements by us or our competitors of other material developments;
 

our involvement in litigation;
 

changes in government regulation applicable to us and our products;
 

sales, or the anticipation of sales, of our ordinary shares, warrants and debt securities by us, or sales of our ordinary shares by our insiders or other shareholders, including upon expiration of contractual lock-up agreements;
 

developments with respect to intellectual property rights;
 

competition from existing or new technologies and products;
 

changes in key personnel;
 

the trading volume of our ordinary shares;
 

changes in the estimation of the future size and growth rate of our markets;
 

changes in our quarterly or annual forecasts with respect to operating results and financial conditions;
 

general economic and market conditions and;
 

announcements regarding business acquisitions.
 
In addition, the stock markets have experienced extreme price and volume fluctuations. Broad market and industry factors may materially harm the market price of our ordinary shares, regardless of our operating performance. Technical factors in the public trading market for our ordinary shares may produce price movements that may or may not comport with macro, industry or Company-specific fundamentals, including, without limitation, the sentiment of retail investors (including as may be expressed on financial trading and other social media sites), the amount and status of short interest in our securities, access to margin debt, trading in options and other derivatives on our ordinary shares and any related hedging or other technical trading factors. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted against that company, as was the case for ReWalk in a securities class action dismissed in full in November 2020. If we become involved in any similar litigation, we could incur substantial costs and our management’s attention and resources could be diverted.
 
Risks Related to Our Incorporation and Location in Israel
 
Conditions in Israel, including Israel’s war against Hamas and other terrorist organizations in the Gaza Strip and a potential escalation of the conflict on Israel’s northern border, may materially and adversely affect our business and results of operations.
 
             In early October 2023, Hamas terrorists based in the Gaza Strip attacked cities and villages inside Israel, murdering approximately 1,400 Israelis, wounding thousands, and abducting more than 200. The attack was accompanied by numerous rocket attacks on central and southern Israel. These rocket attacks continue through the date of this annual report. Israel called up substantial numbers of reservists and responded with extensive aerial attacks and a broad ground attack on terrorist targets in Gaza.
 
              Following the attack by Hamas on Israel’s southern border, Hezbollah in Lebanon has also launched missile, rocket, and shooting attacks against Israeli military sites, troops, and civilian areas in northern Israel. In response to these attacks, the Israeli army has carried out a number of targeted strikes on Hezbollah in southern Lebanon and targets in Syria. It is possible that other terrorist organizations, including those located in the West Bank, as well as other countries hostile to Israel, such as Iran, will join the hostilities. Terrorist groups have also attacked U.S. military targets in the Middle East. These clashes have recently intensified and may escalate into a greater regional conflict.

48

 
             Although we continue to monitor the situation closely, to date our operations in Israel – consisting primarily of the operations, quality, and R&D functions of the legacy ReWalk business and some finance functions – have continued without material interruption. In 2023, sales to customers in Israel accounted for less than 2% of our total revenues, and as of the date of this filing, approximately 80% of our employees are located outside of Israel. With the acquisition of AlterG in August 2023 and the anticipated shift in our sources of revenue in connection therewith, our Israel operations have become a less significant portion of our consolidated ReWalk operations. Our Israeli facilities are based in northern Israel, in an area that to date has seen minor disruptions from rocket attacks. Although to date none of our Israeli employees have been mobilized for emergency military service, we cannot predict whether there will be further mobilization of reservists and any further mobilization could further impact our employees, including employees who serve in critical roles in our company, which could adversely affect our ability to operate and our results of operations.
 
              Sanmina, a well-established contract manufacturer with expertise in the medical device industry, manufactures all of our legacy ReWalk products at its facility in northern Israel. There has been no disruption to date to Sanmina’s business. If this facility were to be damaged or destroyed, or if Sanmina were otherwise unable to operate this facility, this could affect the supply of our legacy ReWalk products, and our business and our operating results would be negatively affected.
 
             This is a rapidly changing situation, and we cannot predict how events will develop over the coming weeks and months. There can be no assurance that a significant expansion or worsening of the war will not have a material adverse effect on our ongoing development efforts, our business and our operating results.
 
Our technology development and quality headquarters and the manufacturing facility for our products are located in Israel and, therefore, our results may be adversely affected by economic restrictions imposed on, and political and military instability in, Israel.
 
Our technology development and quality headquarters, which houses substantially all of our research and development and our core research and development team, including engineers, machinists, and quality and regulatory personnel, as well as the facility of our contract manufacturer, Sanmina, are located in Israel. Many of our employees, directors and officers are residents of Israel. Accordingly, political, economic, and military conditions in Israel and the surrounding region may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its Arab neighbors, Hamas, Hezbollah (an Islamist militia and political group in Lebanon) and other armed groups. Any hostilities involving Israel or the interruption or curtailment of trade within Israel or between Israel and its trading partners could materially and adversely affect our business, financial condition and results of operations and could make it more difficult for us to raise capital. In particular, an interruption of operations at the Tel Aviv airport related to the conflict in the Gaza Strip or otherwise could prevent or delay shipments of our components or products. Although we maintain inventory in the United States and Germany, an extended interruption could materially and adversely affect our business, financial condition, and results of operations.
 
Recent political uprisings, social unrest, and violence in various countries in the Middle East and North Africa, including Israel’s neighbors Lebanon, Egypt, and Syria, are affecting the political stability of those countries. This instability may lead to deterioration of the political relationships that exist between Israel and these countries and has raised concerns regarding security in the region and the potential for armed conflict. Our commercial insurance covers some, but not all, losses that may occur as a result of an event associated with the security situation in the Middle East. Any losses or damages incurred by us could have a material adverse effect on our business. In addition, Iran has threatened to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among parties hostile to Israel in areas that neighbor Israel, such as the Syrian government, Hamas in Gaza and Hezbollah in Lebanon. Any armed conflicts, terrorist activities or political instability in the region could materially and adversely affect our business, financial condition, and results of operations.
 
Our operations and the operations of our contract manufacturer, Sanmina, may be disrupted as a result of the obligation of Israeli citizens to perform military service.
 
Many Israeli citizens are obligated to perform one month, and in some cases more, of annual military reserve duty until they reach the age of 45 (or older, for reservists with certain occupations) and, in the event of a military conflict, may be called to active duty. In response to terrorist activity, there have been periods of significant call-ups of military reservists. Some of our executive officers and employees, as well as those of Sanmina, the manufacturer of all of our products, are required to perform annual military reserve duty in Israel and may be called to active duty at any time under emergency circumstances. As described in the risk factor above entitled “Conditions in Israel, including Israel’s war against Hamas and other terrorist organizations in the Gaza Strip and a potential escalation of the conflict on Israel’s northern border, may materially and adversely affect our business and results of operations,” in response to the attack by Hamas on Israel in October 2023 Israel has called up substantial numbers of reservists. Although to date these call-ups have not had a material impact on our operations or on Sanmina’s ability to manufacture our products, we cannot predict whether there will be further mobilization of reservists and our operations and the operations of Sanmina could be disrupted by such call-ups.

49

 
Our sales may be adversely affected by boycotts of Israel.
 
Several countries, principally in the Middle East, restrict doing business with Israel and Israeli companies, and additional countries may impose restrictions on doing business with Israel and Israeli companies whether as a result of hostilities in the region or otherwise. In addition, there have been increased efforts by activists to cause companies and consumers to boycott Israeli goods based on Israeli government policies. Such actions, particularly if they become more widespread, may adversely impact our ability to sell our products.
 
The tax benefits that are available to us require us to continue to meet various conditions and may be terminated or reduced in the future, which could increase our costs and taxes.
 
Some of our operations in Israel, referred to as “Beneficiary Enterprises,” carry certain tax benefits under the Israeli Law for the Encouragement of Capital Investments, 5719-1959, or the Investment Law. Substantially all of our future income before taxes can be attributed to these programs. If we do not meet the requirements for maintaining these benefits or if our assumptions regarding the key elements affecting our tax rates are rejected by the tax authorities, they may be reduced or cancelled, and the relevant operations would be subject to Israeli corporate tax at the standard rate. In addition to being subject to the standard corporate tax rate, we could be required to refund any tax benefits that we may receive in the future, plus interest and penalties thereon. Even if we continue to meet the relevant requirements, the tax benefits that our current “Beneficiary Enterprises” receive may not be continued in the future at their current levels or at all. If these tax benefits were reduced or eliminated, the amount of taxes that we pay would likely increase, as all of our Israeli operations would consequently be subject to corporate tax at the standard rate, which could adversely affect our results of operations. Additionally, if we increase our activities outside of Israel, for example, by way of acquisitions, our increased activities may not be eligible for inclusion in Israeli tax benefit programs. For a discussion of our current tax obligations, see “Part II. Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
 
We have received Israeli government grants for certain of our research and development activities and we may receive additional grants in the future. The terms of those grants restrict our ability to manufacture products or transfer technologies outside of Israel, and we may be required to pay penalties in such cases or upon the sale of our company.
 
From our inception through December 31, 2023, we received a total of $2.6 million from the IIA. We may in the future apply to receive additional grants from the IIA to support our research and development activities. With respect to some grants that were royalty-bearing grants, we are committed to paying royalties at a rate of 3.0% on sales proceeds up to the total amount of grants received, linked to the dollar, and bearing interest at an annual rate of LIBOR applicable to dollar deposits. Even after payment in full of these amounts, we will still be required to comply with the requirements of the Israeli Encouragement of Industrial Research, Development and Technological Innovation Law, 1984, or the R&D Law, and related regulations, with respect to those past grants. When a company develops know-how, technology or products using IIA grants, the terms of these grants and the R&D Law restrict the transfer outside of Israel of such know-how, and of the manufacturing or manufacturing rights of such products, technologies, or know-how, without the prior approval of the IIA. Therefore, if aspects of our technologies are deemed to have been developed with IIA funding, the discretionary approval of an IIA committee would be required for any transfer to third parties outside of Israel of know-how or manufacturing or manufacturing rights related to those aspects of such technologies. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits us to transfer technology or development out of Israel or may not grant such approvals at all.
 
Furthermore, the consideration available to our shareholders in a future transaction involving the transfer outside of Israel of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are required to pay to the IIA.
 
In addition to the above, any non-Israeli citizen, resident or entity that, among other things, (i) becomes a holder of 5% or more of our share capital or voting rights, (ii) is entitled to appoint one or more of our directors or our chief executive officer or (iii) serves as one of our directors or as our chief executive officer (including holders of 25% or more of the voting power, equity or the right to nominate directors in such direct holder, if applicable) is required to notify the IIA and undertake to comply with the rules and regulations applicable to the grant programs of the IIA, including the restrictions on transfer described above. Such notification will be required in connection with the investment being made by an investor which may discourage or limit investments from foreign investors in our company.

50

 
We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business.
 
A significant portion of our intellectual property has been developed by our employees in the course of their employment for us. Under the Israeli Patent Law, 5727-1967 (the “Patent Law”) and recent decisions by the Israeli Supreme Court and the Israeli Compensation and Royalties Committee, a body constituted under the Patent Law, employees may be entitled to remuneration for intellectual property that they develop for us unless they explicitly waive any such rights. Although we enter into agreements with our employees pursuant to which they agree that any inventions created in the scope of their employment or engagement are owned exclusively by us, we may face claims demanding remuneration. As a consequence of such claims, we could be required to pay additional remuneration or royalties to our current and former employees, or be forced to litigate such claims, which could negatively affect our business.
 
Provisions of Israeli law and our Articles of Association may delay, prevent, or otherwise impede a merger with, or an acquisition of, us, even when the terms of such a transaction are favorable to us and our shareholders.
 
Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example, a tender offer for all of a company’s issued and outstanding shares can only be completed if the acquirer receives positive responses from the holders of at least 95% of the issued share capital. Completion of the tender offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless at least 98% of the company’s outstanding shares are tendered. Furthermore, the shareholders, including those who indicated their acceptance of the tender offer (unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek appraisal rights), may, at any time within six months following the completion of the tender offer, petition an Israeli court to alter the consideration for the acquisition. Israeli law also requires a “special tender offer” in certain cases where a shareholder crosses the 25% or 45% holding threshold, and it imposes procedural and special voting requirements for the approval of a merger in certain cases.
 
Our Articles of Association provide that our directors (other than external directors, a requirement of Israeli corporate law from which we have opted out in accordance with an exemption for which we are currently eligible) are elected on a staggered basis, such that a potential acquirer cannot readily replace our entire board of directors at a single annual general shareholder meeting. This could prevent a potential acquirer from receiving board approval for an acquisition proposal that our board of directors opposes.
 
Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers involving an exchange of shares, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has occurred. These and other similar provisions could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.
 
It may be difficult to enforce a judgment of a U.S. court against us, our officers, and directors, to assert U.S. securities laws claims in Israel or to serve process on our officers and directors.
 
We are incorporated in Israel. Although the majority of our directors and executive officers reside within the United States and most of the assets of these persons are also likely located within the United States, some of our directors and executive officers reside and may have the majority of their assets outside the United States. Additionally, most of our assets are located outside of the United States. Therefore, a judgment obtained against us, or those of our directors and executive officers residing outside of the United States, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. It also may be difficult for you to effect service of process in the United States on those directors and executive officers residing outside of the United States or to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may be able to collect only limited, or may be unable to collect any, damages awarded by either a U.S. or foreign court.

51

 
In April 2021, we amended our articles of association such that, unless we consent in writing to the selection of an alternative forum, (i) the federal courts of the United States will be the exclusive forum for the resolution of any claim arising under the Securities Act, and (ii) the Tel-Aviv District Court will be the exclusive forum for (a) a derivative action or derivative proceeding that is filed in the name of the Company; (b) any action grounded in a breach of fiduciary duty of a director, officeholder or other employee towards us or our shareholders; or (c) any action the cause of which results from any provision of the Companies Law or the Israel Securities Law, 5728-1968. We have retained the ability to consent to an alternative forum in circumstances if we determine shareholder interests are best served by permitting a particular dispute to proceed in a forum other than the federal district courts or State of Israel, as applicable. However, there is uncertainty as to whether a court would enforce these provisions.
 
Your rights and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies.
 
The rights and responsibilities of the holders of our ordinary shares are governed by our Articles of Association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S.-based corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in the company, including, among other things, in voting at a general meeting of shareholders on matters such as amendments to a company’s articles of association, increases in a company’s authorized share capital, mergers and acquisitions and related party transactions requiring shareholder approval. In addition, a shareholder who is aware that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company. There is limited case law available to assist us in understanding the nature of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. corporations.
 
Our business could be negatively affected as a result of actions of activist shareholders, and such activism could impact the trading value of our securities.
 
In recent years, certain Israeli issuers listed on United States exchanges have been faced with governance-related demands from activist shareholders, unsolicited tender offers and proxy contests. Given our relatively low market cap and cash balance we might be an attractive target for such activists, in connection with our 2022 Annual General Meeting of Shareholders, Creative Value Capital Limited Partnership (“CVC”), which claimed to hold approximately three percent of our outstanding shares, nominated two candidates for election to our board of directors and submitted two additional proposals (including amendments to our Articles of Association) for approval at our 2022 Annual General Meeting of Shareholders held on July 27, 2022. Although none of CVC’s proposals were approved at the meeting, addressing and responding to such proposals was significantly costly and time-consuming, and diverted the attention of our management and employees.
 
Responding to these types of actions by activist shareholders could be costly and time-consuming, disrupting our operations and diverting the attention of management and our employees. Such activities could interfere with our ability to execute our strategic plan. In addition, a proxy contest for the election of directors at our annual meeting would require us to incur significant legal fees and proxy solicitation expenses and require significant time and attention by management and our board of directors. The perceived uncertainties as to our future direction also could affect the market price and volatility of our securities.
 
General Risks
 
Exchange rate fluctuations between the U.S. dollar, the euro and the NIS may negatively affect our earnings.
 
The U.S. dollar is our functional and reporting currency. However, we pay a significant portion of our expenses in NIS and in euro, and we expect this to continue. As a result, we are exposed to exchange rate risks that may materially and adversely affect our financial results. Accordingly, any appreciation of the NIS or euro relative to the U.S. dollar would adversely impact our net loss or net income, if any. For example, if the NIS appreciates against the U.S. dollar or if the value of the NIS declines against the U.S. dollar at a time when the rate of inflation in the cost of Israeli goods and services exceeds the rate of decline in the relative value of the NIS, then the U.S. dollar cost of our operations in Israel would increase and our results of operations could be materially and adversely affected.
 
52

 
Our operations also could be adversely affected if we are unable to effectively hedge against currency fluctuations in the future.
 
We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the NIS against the U.S. dollar. For example, while the NIS devalued against the U.S. dollar at a rate of approximately 3.1% and 4% during the fiscal year 2023 and 2022, respectively, during the fiscal year 2021 the NIS appreciated against the U.S. dollar at a rate of approximately 3%, respectively. The Israeli annual rate of inflation amounted to 2.96%, 5.3%, and 1.5% for the years ended December 31, 2023, 2022 and 2021, respectively.
 
We have in the past engaged in limited hedging activities, and we may enter into other hedging arrangements with financial institutions from time to time. Any hedging strategies that we may implement in the future to mitigate currency risks, such as forward contracts, options and foreign exchange swaps related to transaction exposures may not eliminate our exposure to foreign exchange fluctuations.
 
We are subject to certain regulatory regimes that may affect the way that we conduct business internationally, and our failure to comply with applicable laws and regulations could materially adversely affect our reputation and result in penalties and increased costs.
 
We are subject to a complex system of laws and regulations related to international trade, including economic sanctions and export control laws and regulations. We also depend on our distributors and agents for compliance and adherence to local laws and regulations in the markets in which they operate. Significant political or regulatory developments in the jurisdictions in which we sell our products, such as those stemming from the presidential administration in the United States or the U.K.’s exit from the E.U., are difficult to predict and may have a material adverse effect on us. For example, in the United States, the Trump administration-imposed tariffs on imports from China, Mexico, Canada, and other countries, and expressed support for greater restrictions on free trade and increase tariffs on goods imported into the United States. Changes in U.S. political, regulatory, and economic conditions or in its policies governing international trade and foreign manufacturing and investment in the United States could adversely affect our sales in the United States.
 
We are also subject to the FCPA and may be subject to similar worldwide anti-bribery laws that generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business.  Despite our compliance and training programs, we cannot be certain that our procedures will be sufficient to ensure consistent compliance with all applicable international trade and anti-corruption laws, or that our employees or channel partners will strictly follow all policies and requirements to which we subject them. Any alleged or actual violations of these laws may subject us to government scrutiny, investigation, debarment, and civil and criminal penalties, which may have an adverse effect on our results of operations, financial condition and reputation.
 
Our business may be materially affected by changes to fiscal and tax policies. Potentially negative or unexpected tax consequences of these policies, or the uncertainty surrounding their potential effects, could adversely affect our results of operations and share price.
 
The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service (the “IRS”) and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our ordinary shares. In recent years, many such changes have been made, and changes are likely to continue to occur in the future. It cannot be predicted whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our shareholders’ tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law.
 
In addition, foreign governments may enact tax laws in response to the changes in the rules dealing with U.S. federal, state and local income taxation or otherwise that could result in further changes to global taxation and materially affect our financial position and results of operations. The uncertainty surrounding the effect of the reforms on our financial results and business could also weaken confidence among investors.
 
Certain U.S. holders of our ordinary shares may suffer adverse U.S. tax consequences if we are characterized as a controlled foreign corporation, or a CFC, under Section 957 of the Code.
 
Each “Ten Percent Shareholder” (as defined below) in a non-U.S. corporation that is classified as a “controlled foreign corporation,” or a CFC, for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder’s pro rata share of the CFC’s “Subpart F income,” global intangible low-taxed income, and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. Subpart F income generally includes dividends, interest, rents and royalties, gains from the sale of securities and income from certain transactions with related parties.  In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A “Ten Percent Shareholder” is a United States person (as defined by the Code), who owns or is considered to own 10% or more of (1) the total combined voting power of all classes of stock entitled to vote or (2) the value of all classes of stock of such corporation. The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain.
 
53

 
During our 2023 taxable year, we believe that we had one shareholder that was a Ten Percent Shareholder for U.S. federal income tax purposes. However, our CFC status for the taxable year ending on December 31, 2023, and our current taxable year is unknown, and we may be a CFC for the taxable year ending on December 31, 2023, our current taxable year or a following year. In addition, recent changes to the attribution rules relation to the determination of CFC status may make it difficult to determine our CFC status for any taxable year or the CFC status of any of our subsidiaries. U.S. holders should consult their own tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC. If we are classified as both a CFC and a passive foreign investment company, or PFIC, we generally will not be treated as a PFIC with respect to those U.S. holders that meet the definition of a Ten Percent Shareholder during the period in which we are a CFC.
 
If there are significant disruptions in our information technology systems, our business, financial condition, and operating results could be adversely affected.
 
The efficient operation of our business depends on our information technology systems. We rely on our information technology systems to effectively manage sales and marketing data, accounting and financial functions, inventory management, product development tasks, research and development data, customer service and technical support functions. Our information technology systems are vulnerable to damage or interruption from earthquakes, fires, floods and other natural disasters, terrorist attacks, attacks by computer viruses or hackers, power losses, and computer system or data network failures. In addition, our data management application is hosted by a third-party service provider whose security and information technology systems are subject to similar risks, and our products’ systems contain software which could be subject to computer virus or hacker attacks or other failures.
 
The failure of our or our service providers’ information technology systems or our products’ software to perform as we anticipate or our failure to effectively implement new information technology systems could disrupt our entire operation or adversely affect our software products and could result in decreased sales, increased overhead costs, and product shortages, all of which could have a material adverse effect on our reputation, business, financial condition, and operating results.
 
If we fail to properly manage our anticipated growth, our business could suffer.
 
Our growth and product expansion has placed, and we expect that it will continue to place, a significant strain on our management team and on our financial resources. Failure to manage our growth effectively could cause us to misallocate management or financial resources, and result in losses or weaknesses in our infrastructure, which could materially adversely affect our business. Additionally, our anticipated growth will increase the demands placed on our suppliers, resulting in an increased need for us to manage our suppliers and monitor for quality assurance. Any failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our business objectives.
 
We are highly dependent on the knowledge and skills of our senior management, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
 
Our ability to compete in the highly competitive medical devices industry depends upon our ability to attract and retain highly qualified managerial, scientific, sales and medical personnel. We are highly dependent on our senior management team and have benefited substantially from the leadership and performance of our senior management. For example, we depend on our Chief Executive Officer’s experience successfully scaling an early-stage medical device company, as well as the experience of other members of management. The loss of the services of any of our executive officers and other key employees, and our inability to find suitable replacements could result in delays in product development and harm our business. Competition for senior management in our industry is intense and we cannot guarantee that we will be able to retain our personnel. Additionally, we do not carry key man insurance on any of our current executive officers. The loss of the services of certain members of our senior management could prevent or delay the implementation and completion of our strategic objectives or divert management’s attention to seeking qualified replacements.

54

 
 
Shutdowns of the U.S. federal government could materially impair our business and financial condition.
 
Development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control. For example, in 2018 and 2019 the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical FDA, SEC, and other government employees and stop critical activities. If a prolonged government shutdown or budget sequestration occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets, such as through the declaration of effectiveness of registration statements and obtain necessary capital in order to properly capitalize and continue our operations.
 
ITEM 1B. UNRESOLVED STAFF COMMENTS
 
None.
 
ITEM 1C. CYBERSECURITY
 
Cybersecurity Risk Management and Strategy
 
The Company relies on information systems and the data stored on them to conduct its operations. We have adopted and maintain a cybersecurity risk management program in accordance with our risk profile and business that is informed by and incorporates elements of industry standards.
 
Our cybersecurity risk management program incorporates multiple components, including, but not limited to, ongoing monitoring of critical risks from cybersecurity threats using automated tools. Additionally, we have implemented an employee education and training program, which we provide on an annual basis, that is designed to raise awareness of cybersecurity threats. To support our cybersecurity risk management program, we leverage managed service providers and other third-party information technology and cybersecurity providers and consultants, including to perform regular system scans and threat intelligence analysis. Additionally, we require certain third-party providers and consultants to adhere to contractual requirements relating to privacy and cybersecurity standards.
 
We have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. However, like other companies in our industry, we and our third-party vendors have from time to time experienced threats and security incidents that could affect our information or systems. For more information, please see the section entitled “Risk Factors” in this Annual Report on Form 10-K.
 
Governance
 
Our audit committee, which reports directly to the board of directors, is responsible for overseeing our cybersecurity risk management program. The audit committee receives periodic updates on cybersecurity risks, mitigation strategies, and, in the event of a cybersecurity incident, incident response strategies from our Chief Financial Officer (“CFO”). The audit committee updates the full board of directors on matters relating to cybersecurity risk management and critical cybersecurity risks as appropriate.
 
Our Chief Technology Officer (“CTO”), who reports directly to our Vice President of Finance and, ultimately, our Chief Financial Officer, is responsible for the day-to-day management of our cybersecurity risk management program. The individual currently serving in this position is a third-party consultant who maintains 20 years of experience advising similarly situated companies on information technology and cybersecurity risk management.  Our CTO provides regular cybersecurity updates to our Vice President of Finance and Chief Financial Officer on matters relating to our cybersecurity program and cybersecurity risk management.
 
55


ITEM 2. PROPERTIES
 
Our corporate headquarters are located in Yokneam, Israel, our U.S. headquarters are located in Marlborough, Massachusetts, with additional offices in Fremont, California, and Queens, New York, and our European headquarters are located in Berlin, Germany.
 
All of our facilities are leased, and we do not own any real property. The table below sets forth details of the square footage of our current leased properties, all of which are utilized. We have no material tangible fixed assets apart from the properties described below.

   
Square
feet (approximate)
 
Fremont, California
   
40,320
 
Marlborough, Massachusetts
   
11,850
 
Yokneam, Israel
   
11,500
 
Queens, New York
   
1,105
 
Berlin, Germany
   
950
 
Total
   
65,725
 
 
We believe our facilities are adequate and suitable for our current needs.
 
ITEM 3. LEGAL PROCEEDINGS
 
Occasionally we are involved in various claims, lawsuits, regulatory examinations, investigations and other legal matters arising, for the most part, in the ordinary course of business. The outcome of litigation and other legal matters is inherently uncertain. In making a determination regarding accruals, using available information, we evaluate the likelihood of an unfavorable outcome in legal or regulatory proceedings to which we are a party and records a loss contingency when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated.
 
Where we determine an unfavorable outcome is not probable or reasonably estimable, we do not accrue for any potential litigation loss. These subjective determinations are based on the status of such legal or regulatory proceedings, the merits of our defenses and consultation with legal counsel. Actual outcomes of these legal and regulatory proceedings may materially differ from our current estimates. It is possible that resolution of one or more of the legal matters currently pending or threatened could result in losses material to our consolidated results of operations, liquidity, or financial condition.
 
For information regarding legal proceedings, see Note 7 “Commitments and Contingent Liabilities” in the notes to our audited consolidated financial statements included in this annual report, which discussion we incorporate by reference into this Item.
 
ITEM 4. MINE SAFETY DISCLOSURES.
 
Not applicable.
 
56

PART II
 
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
 
Market Information
 
Our ordinary shares began trading publicly on The Nasdaq Global Market on September 12, 2014 under the symbol “RWLK” and were transferred for listing on The Nasdaq Capital Market effective May 25, 2017. In January 2024, the symbol for our ordinary shares was changed to “LFWD”. As of February 23, 2024, we had approximately 278,478 shareholders of record.
 
Dividend Policy
 
We have never declared or paid any cash dividends on our ordinary shares. We do not anticipate paying any cash dividends in the foreseeable future. We currently intend to retain future earnings, if any, to finance operations and expand our business. Any future determination relating to our dividend policy will be made at the discretion of our board of directors and will depend on a number of factors, including future earnings, capital requirements, financial condition and future prospects and other factors our board of directors may deem relevant. The distribution of dividends may also be limited by Israeli law, which permits the distribution of dividends only out of retained earnings or otherwise upon the permission of an Israeli court.
 
Israeli Taxes Applicable to U.S. Holders
 
A non-Israeli resident who derives capital gains from the sale of shares in an Israeli resident company that were purchased after the company was listed for trading on a stock exchange outside of Israel will be exempt from Israeli tax so long as (amongst other things) the shares were not held through a permanent establishment that the non-resident maintains in Israel. A partial exemption may be available for non-Israeli resident shareholders who acquired their shares prior to the issuer’s initial public offering.
 
However, non-Israeli corporations will not be entitled to the foregoing exemption if Israeli residents (i) have a controlling interest of more than 25% in such non-Israeli corporation or (ii) are the beneficiaries of, or are entitled to, 25% or more of the revenue or profits of such non-Israeli corporation, whether directly or indirectly. Such exemption is not applicable to a person whose gains from selling or otherwise disposing of the shares are deemed to be a business income. Additionally, under the United States-Israel Tax Treaty, or the treaty, the sale, exchange or other disposition of shares by a shareholder who (i) is a U.S. resident (for purposes of the treaty), (ii) holds the shares as a capital asset, and (iii) is entitled to claim the benefits afforded to such person by the treaty, is generally exempt from Israeli capital gains tax. Such exemption will not apply if: (i) the capital gain arising from the sale, exchange or other disposition can be attributed to a permanent establishment in Israel; (ii) the shareholder holds, directly or indirectly, shares representing 10% or more of the voting capital during any part of the 12-month period preceding the disposition, subject to certain conditions; or (iii) such U.S. resident is an individual and was present in Israel for 183 days or more during the relevant taxable year. In such case, the sale, exchange, or disposition of our ordinary shares should be subject to Israeli tax, to the extent applicable; however, under the treaty, the taxpayer would be permitted to claim a credit for such taxes against the U.S. federal income tax imposed with respect to such sale, exchange, or disposition, subject to the limitations under U.S. law applicable to foreign tax credits.  The treaty does not relate to U.S. state or local taxes.
 
In some instances where our shareholders may be liable for Israeli tax on the sale of their ordinary shares, the payment of the consideration may be subject to the withholding of Israeli tax at source. If the above exemptions from capital gains tax are not available, individuals will be subject to a 25% tax rate on real capital gains derived from the sale of shares as long as the individual is not a substantial shareholder of the corporation issuing the shares (in which case the individual will be subject to a 30% tax rate), and corporations will be subject to a 23% corporate tax rate. A substantial shareholder is generally a person who alone or together with such person’s relative or another person who collaborates with such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the means of control of the corporation, including the right to vote, receive profits, nominate a director or an executive officer, receive assets upon liquidation, or order someone who holds any of the aforesaid rights how to act, regardless of the source of such right. The determination of whether the individual is a substantial shareholder will be made on the date on which the securities are sold. In addition, the individual will be deemed to be a substantial shareholder if at any time during the 12 months preceding the date of the sale he or she was a substantial shareholder.

57

 
Dividends paid on publicly traded shares, like our ordinary shares, to non-Israeli residents are generally subject to Israeli income tax at the rate of 25%, or 30% if the recipient of the dividend was a substantial shareholder at the time of distribution or at any time during the prior 12-month period. Such dividends are generally subject to Israeli withholding tax at a rate of 25% if the shares are registered with a nominee company (whether the recipient is a substantial shareholder or not), unless a different rate is provided under an applicable tax treaty, provided that a certificate from the Israeli Tax Authority allowing for a reduced withholding tax rate is obtained in advance. Under the United States-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ordinary shares who is a U.S. resident (for purposes of the treaty) is 25%. The treaty provides for reduced tax rates on dividends if (a) the shareholder is a U.S. corporation holding at least 10% of our issued voting power during the part of the tax year that precedes the date of payment of the dividend and held such minimal percentage during the whole of its prior tax year, and (b) not more than 25% of the Israeli company’s gross income consists of interest or dividends, other than dividends or interest received from subsidiary corporations or corporations 50% or more of the outstanding voting shares of which is owned by the Israeli company. The reduced treaty rate, if applicable, is 15% in the case of dividends paid from income derived from a Beneficiary or Preferred Enterprise (which is entitled to corporate tax benefits) or 12.5% otherwise. We cannot assure you that in the event we declare a dividend we will designate the income out of which the dividend is paid in a manner that will reduce shareholders’ tax liability. If the dividend is attributable partly to income derived from a Beneficiary or Preferred Enterprise and partly to other sources of income, the withholding rate will be a blended rate reflecting the relative portions of the two types of income. U.S. residents who are subject to Israeli withholding tax on a dividend may be entitled to a credit or deduction for U.S. federal income tax purposes in the amount of the taxes withheld.
 
Individuals who are subject to tax in Israel are also subject to an additional tax at the rate of 3% on annual income exceeding a certain threshold (NIS 721,560 for 2024, linked to the annual change in the Israeli Consumer Price Index), including, but not limited to, income derived from dividends, interest, and capital gains.
 
Recent Sales of Unregistered Equity Securities
 
None.
 
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
 
None.
 
ITEM 6.   [RESERVED]
 
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
The following discussion and analysis should be read in conjunction with our audited consolidated financial statements and the related notes included elsewhere in this annual report. This discussion contains forward-looking statements that are based on our management’s current expectations, estimates and projections for our business, which are subject to a number of risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those set forth under “Special Note Regarding Forward-Looking Statements and “Part I. Item 1A. Risk Factors.”
 
Overview
 
We are a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community.  Our initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury (“SCI Products”).  These devices are robotic exoskeletons that are designed for individuals with paraplegia that use our patented tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement.  These SCI Products allow individuals with spinal cord injury (“SCI”) the ability to stand and walk again during everyday activities at home or in the community. In March 2023, we received clearance of our premarket notification (“510(k)”) from the U.S. Food and Drug Administration (“FDA”) for the ReWalk Personal Exoskeleton with stair and curb functionality, which adds usage on stairs and curbs to the indication for use for the device in the United States (U.S.). The clearance permits U.S. customers to participate in more walking activities in real-world environments in their daily lives where stairs or curbs may have previously limited them when using the exoskeleton for its intended, FDA-indicated uses. This feature has been available in Europe since initial CE Clearance, and real-world data from a cohort of 47 European users throughout a period of over seven years consisting of over 18,000 stair steps was collected to demonstrate the safety and efficacy of this feature and support the FDA submission.

58

 
We have sought to expand our product offerings beyond the SCI Products through internal development and distribution agreements and acquisitions.  We have developed our ReStore Exo-Suit device, which we began commercializing in June 2019. The ReStore is a powered, lightweight soft exo-suit intended for use during the rehabilitation of individuals with lower limb disabilities due to stroke. During the second quarter of 2020, we finalized and moved to implement two separate agreements to distribute additional product lines in the United States. We are the exclusive distributor of the MYOLYN MyoCycle FES Pro cycles to U.S. rehabilitation clinics and for the MyoCycle Home cycles available to US veterans through the Veterans Health Administration (“VHA”) hospitals. In the second quarter of 2020, we also became the exclusive distributor of the MediTouch Tutor movement biofeedback systems in the United States; however, due to unsatisfactory sales performance of the MediTouch product lines, we terminated this agreement as of January 31, 2023. We refer to the MediTouch and MyoCycle devices as our “Distributed Products.”

On August 11, 2023, we made our first acquisition to supplement our internal growth when we acquired AlterG, Inc. (“AlterG”), a leading provider of Anti-Gravity systems for use in physical and neurological rehabilitation. Our AlterG Anti-Gravity systems use patented, National Aeronautics and Space Administration (“NASA”) derived differential air pressure (“DAP”) technology to reduce the effects of gravity and allow patients to rehabilitate with finely calibrated support and reduced pain. AlterG Anti-Gravity systems are utilized in over 4,000 facilities globally in more than 40 countries. We will continue to evaluate other products for distribution or acquisition that can broaden our product offerings further to help individuals with neurological injury and disability.
 
We are in the research stage of ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke, and we are currently evaluating the reimbursement landscape and the potential clinical impact of this device. This product would be a complementary product to ReStore as it provides active assistance to the ankle during plantar flexion and dorsiflexion for gait and mobility improvement in the home environment, and it received Breakthrough Device Designation from the FDA in November 2021.  Further investment in the development path of the ReBoot was paused in 2023 pending determination regarding the clinical and commercial opportunity of this device.
 
Our principal markets are primarily in the United States and Europe with some lesser sales in Asia, the Middle East and South America. We sell our products primarily directly in the United States, through a combination of direct sales and distributors (depending on the product line) in Germany, Canada, and Australia, and primarily through distributors in other markets. In markets where we sell direct to consumers, we have established relationships with clinics and rehabilitation centers, professional and college sports teams, and individuals and organizations in the SCI community, and in markets where we do not sell direct to consumers, our distributors maintain these relationships. We have primary offices in Marlborough, Massachusetts, Fremont, California, Berlin, Germany and Yokneam, Israel, from where we operate our business.
 
We have in the past generated and expect to generate in the future revenue from a combination of clinics and rehabilitation centers, commercial distributors, third-party payors (including private and government payors), professional and college sports teams, and self-pay individuals. While a broad uniform policy of coverage and reimbursement by third-party commercial payors currently does not exist in the United States for exoskeleton technologies such as the ReWalk Personal Exoskeleton, we are pursuing various paths of reimbursement and support fundraising efforts by institutions and clinics, such as the VHA policy that was issued in December 2015 for the evaluation, training, and procurement of ReWalk Personal Exoskeleton systems for all qualifying veterans living with SCI across the United States.
 
We have also pursued updates with the Centers for Medicare & Medicaid Services (“CMS”) to clarify the Medicare coverage category (i.e., benefit category) applicable for personal exoskeletons. In 2022, the National Spinal Cord Injury Statistical Center (“NSCISC”) reported that CMS is the primary payor for approximately 57% of the SCI population which are at least five years post their injury date, with Medicare representing a majority of this percentage. In July 2020, following a successful submission and hearing process, a code was issued for ReWalk Personal Exoskeleton, which may be used for purposes of claim submission to Medicare, Medicaid, and other payors. 
 
On November 1, 2023, CMS released the Calendar Year 2024 Home Health Prospective Payment System Final Rule, CMS-1780-F (“Final Rule”), which was adopted through the notice and comment rulemaking process. The Final Rule includes a policy confirming that personal exoskeletons are included in the Medicare brace benefit category, as of January 1, 2024. Medicare personal exoskeleton claims with dates of service on or after January 1, 2024 that are billed using HCPCS code K1007 are assigned to the brace benefit category. CMS reimburses items classified under the brace benefit category using a lump sum payment methodology.
 
On November 29, 2023, CMS included the “ReWalk Personal Prosthetic Exoskeleton System” in the HCPCS public meeting where it solicited feedback on a preliminary payment determination of $94,617 for HCPCS code K1007. The preliminary payment determination was made by CMS by applying a “gap filling” process, which was used in light of CMS determining that the code describing the technology has no fee schedule pricing history and that lower extremity exoskeletons incorporate “revolutionary features” that cannot be described by or considered comparable to any other existing code or combination of codes. As part of gap-filling, CMS utilizes verifiable supplier or commercial pricing information and adjusts this pricing information according to a deflation and update factor methodology. In applying this formula to the K1007 code describing the ReWalk Personal Exoskeleton, CMS says that it relied on information about average prices from 2020 market transactions for which CMS had data.

59

 
CMS solicited information on updated verifiable market transactions from ReWalk, as well as any other makers of similar bilateral, lower limb exoskeletons, to “ensure that the Medicare payment amount for this code accurately reflects the full market of devices that would be classified in this code.” We participated in the HCPCS meeting process on November 29, 2023 to provide additional information to help ensure that the final payment determination accurately reflects current pricing information related to the market of lower-limb exoskeleton devices, including the current ReWalk Personal Exoskeleton. A final Medicare payment determination is expected from CMS in first quarter of 2024 with an April 1, 2024, effective date.
 
In Germany, we continue to make progress toward achieving coverage from the various government, private and worker’s compensation payors for our SCI products. In September 2017, each of German insurer BARMER GEK (“BARMER”) and national social accident insurance provider Deutsche Gesetzliche Unfallversicherung (“DGUV”), indicated that they will provide coverage to users who meet certain inclusion and exclusion criteria. In February 2018, the head office of German Statutory Health Insurance (“SHI”) Spitzenverband (“GKV”) confirmed their decision to list the ReWalk Personal Exoskeleton system in the German Medical Device Directory. This decision means that ReWalk is listed among all medical devices for compensation, which SHI providers can procure for any approved beneficiary on a case-by-case basis. During the year 2020 and 2021, we announced several new agreements with German SHIs, including TK and DAK Gesundheit, as well as the first German Private Health Insurer (“PHI”), which outline the process of obtaining our devices for eligible insured patients. We are also currently working with several additional SHIs on securing a formal operating contract that will establish the process of obtaining a ReWalk Personal Exoskeleton for their beneficiaries within their system. Additionally, to date, several private insurers in the United States and Europe are providing reimbursement for ReWalk in certain cases.
 
Components of Our Statements of Operations
 
Revenue
 
We currently rely, and in the future will rely, on sales and rentals of our ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices, sales and rentals of our AlterG Anti-Gravity systems and related consumables and services, and sales of our ReStore exo-suit device, additional Distributed Products such as the MyoCycle, and related extended service contracts for the SCI Products. Our revenue is generated from a combination of third-party payors, including private and government employers, institutions, and self-payors. Payments for our products by third party payors have been made primarily through case-by-case determinations. Third-party payors include, without limitation, private insurance plans, workers’ compensation programs, managed care organizations, and government programs including the VHA and Medicare. We expect that third-party payors will be an increasingly important source of revenue in the future as we increase the volume of sales of ReWalk Personal systems to Medicare-eligible beneficiaries following establishment of a benefit category and anticipated pricing.  In December 2015, the VHA issued a national policy for the evaluation, training, and procurement of ReWalk Personal Exoskeleton systems for all qualifying veterans across the United States. The VHA policy is the first national coverage policy in the United States for qualifying individuals who have suffered spinal cord injury.
 
 ReWalk Personal and ReWalk Rehabilitation Exoskeleton systems are generally covered by a five-year warranty from the date of purchase, which is included in the purchase price. The warranty covers all elements of the systems, including the batteries, other than normal wear and tear. Our ReStore device is sold with a two-year warranty. The AlterG Anti-Gravity systems are sold with a one-year factory warranty covering parts and services in the U.S. and a two-year factory warranty covering parts only in the rest of the world. Warranties for our Distributed Products range between three years to ten years depending on the specific product and part and are the responsibility of the manufacturers.
 
Cost of Revenue and Gross Profit
 
For ReWalk and ReStore, cost of revenue consists primarily of complete systems purchased from our outsourced manufacturer, Sanmina.  For these products, cost of revenue also includes internal costs such as salaries and related personnel costs including non-cash share-based compensation, functions that support manufacturing and inventory management, training and inspection, service activities, freight costs, and reserves for warranty and inventory condition. The cost of revenue also includes royalties and expenses related to royalty-bearing research and development grants.

60

 
For our AlterG systems, which we manufacture ourselves at our facility in Fremont, California, cost of revenue consists primarily of raw materials, direct labor, indirect labor, and other factory overhead costs such as rent and utilities.  In addition, cost of revenue also includes field service costs, shipping expenses and reserves for warranty and inventory condition.
 
For Distributed Products such as the MyoCycle cost of revenue consists primarily of complete systems purchased from MYOLYN. In addition, the cost of revenue also includes field service costs and shipping expenses.
 
Our gross profit and gross margin (defined as gross profit as a percentage of revenue) are influenced by a number of factors, including the volume and price of our products sold, fluctuations in the mix of products sold, and variability in our cost of revenue. We expect gross profit and gross margin will expand in the future as we increase our revenue volumes and realize operating efficiencies associated with greater scale which will reduce the cost of revenue as a percentage of revenue.
 
Operating Expenses
 
Research and Development Expenses, Net
 
Research and development expenses, net consist primarily of salaries and related personnel costs including share-based compensation, supplies, materials, and consulting expenses associated with to product design and development, clinical studies, regulatory submissions, patent costs, sponsored research and other related activities. We expense all research and development expenses as they are incurred.
 
Research and development expenses are presented net of the amount of any grants we receive for research and development in the period in which we receive the grant. We previously received grants and other funding from the IIA. Certain of those grants require us to pay royalties on sales of certain systems, which are recorded as cost of revenue. We may receive additional funding from these entities or others in the future. See “Grants and Other Funding” below.
 
Sales and Marketing Expenses
 
Our sales and marketing expenses consist primarily of salaries and related personnel costs including share-based compensation for sales, sales support, marketing, and reimbursement related activities, travel, marketing, advertisement, tradeshows and conferences, lobbying, and public relations activities.
 
General and Administrative Expenses
 
Our general and administrative expenses consist primarily of salaries and related personnel costs including share-based compensation for our administrative, finance, and general management personnel, professional services, and insurance.
 
Financial Expenses (Income), Net
 
Financial income and expenses consist of bank commissions, foreign exchange gains and losses, interest earned on investments in short term deposits and royalty income.
 
Interest income consists of interest earned on our cash and cash equivalent balances. Interest expense consists of interest accrued on, and certain other costs with respect to any indebtedness. Foreign currency exchange changes reflect gains or losses related to transactions denominated in currencies other than the U.S. dollar.
 
Taxes on Income
 
As of December 31, 2023, we had not yet generated taxable income in Israel. As of that date, our net operating loss carryforwards for Israeli tax purposes amounted to approximately $242.6 million. After we utilize our net operating loss carryforwards, we are eligible for certain tax benefits in Israel under the Law for the Encouragement of Capital Investments, 1959. Our benefit period currently ends ten years after the year in which we first have taxable income in Israel provided that the benefit period will not extend beyond 2024. AlterG had federal net operating loss carry forwards totalling $31.4 million and state net operating loss carry forwards of $47.2 million, set to expire in 2025 and 2028, respectively.
 
Our taxable income generated outside of Israel will be subject to the regular corporate tax rate in the applicable jurisdictions. As a result, our effective tax rate will be a function of the relative proportion of our taxable income that is generated in those locations compared to our overall net income.

61

 
Grants and Other Funding
 
Israel Innovation Authority (formerly known as the Office of the Chief Scientist)
 
From our inception through December 31, 2023, we have received a total of $2.6 million in funding from the IIA, $1.6 million of which are royalty-bearing grants, $400 thousand were received in consideration for an investment in our preferred shares while $570 thousand was received without future obligation. Of the royalty-bearing grants received, we have paid royalties to the IIA in the total amount of $110 thousand. The agreements with IIA require us to pay royalties at a rate of 3% on sales of certain systems and related services up to the total amount of funding received for the development of these systems, linked to the dollar, and bearing interest at an annual rate of LIBOR applicable to dollar deposits. If we transfer IIA-supported technology or know-how outside of Israel, we will be liable for additional payments to IIA depending upon the value of the transferred technology or know-how, the amount of IIA support, the time of completion of the IIA-supported research project and other factors. As of December 31, 2023, the aggregate contingent liability to the IIA was $1.6 million. For more information, see “Part I, Item 1A. Risk Factors-We have received Israeli government grants for certain of our research and development activities and we may receive additional grants in the future. The terms of those grants restrict our ability to manufacture products or transfer technologies outside of Israel and we may be required to pay penalties in such cases or upon the sale of our company.”
 
Results of Operations
 
Year Ended December 31, 2023 Compared to Year Ended December 31, 2022
 
Revenue
 
Our revenue for 2023 and 2022 were as follows (dollars in thousands, except unit amounts):

   
Years Ended December 31,
 
   
2023
   
2022
 
Revenue
 
$
13,854
   
$
5,511
 
 
Revenues consist of SCI Products, AlterG Anti-Gravity systems, ReStore and Distributed Products.

62

 
Revenue was $13.9 million, an increase of $8.3 million, or 51%, during 2023 as compared to 2022. Of this increase, $7.7 million was attributable to the AlterG business, which was acquired on August 11, 2023.  The remaining increase of $0.7 million was a result of a higher revenues from ReWalk Personal Exoskeletons and MyoCycles.
 
In the future, we expect our growth to be driven by sales of our ReWalk Personal device through expansion of coverage and reimbursement by commercial and government third-party payors, and our AlterG Anti-Gravity systems, as well as sales of Distributed Products, and the ReStore device to rehabilitation clinics and personal users.
 
Gross Profit
 
Our gross profit for 2023 and 2022 were as follows (in thousands): 

   
Years Ended December 31,
 
   
2023
   
2022
 
Gross profit
 
$
4,453
   
$
1,905
 
 
Gross profit was $4.5 million, or 32% of revenue, for 2023, as compared to a gross profit of $1.9 million, or 35% of revenue for 2022. The AlterG business contributed $2.1 million of gross profit for 2023. Gross profit for 2023 also included the impact of $1.5 million for the amortization of intangible assets and purchase accounting inventory adjustments from the acquisition of AlterG.  Excluding the impact of these factors resulting from the acquisition of AlterG, gross profit was $2.4 million, or 38% of revenue for 2023, as compared to $1.9 million, or 35% of revenue for 2022. This increase was a result of a higher average selling price in 2023 due to new features in our ReWalk Personal Exoskeleton and MyoCycles.
 
We expect gross profit and gross margin will increase in the future as we increase our revenue volumes and realize operating efficiencies associated with greater scale which will reduce the cost of revenue as a percentage of revenue. Improvements may be partially offset by the lower margins we currently expect from ReStore as well as due to an increase in material costs.
 
Research and Development Expense, Net
 
Our research and development expense, net for 2023 and 2022 was as follows (in thousands): 

   
Years Ended December 31,
 
   
2023
   
2022
 
Research and development expense, net
 
$
4,148
   
$
4,031
 
 
Research and development expense was $4.1 million in 2023, an increase of $0.1 million, or 3%, during 2023 as compared to 2022. The AlterG business contributed $0.8 million of research and development spending for 2023.  Excluding the impact of the acquisition of AlterG, research and development declined by $0.7 million, or 17% for the year ended December 31, 2023. The decrease is attributable to the conclusion of the stairs capability project and the gradual reduction of spend on the ReWalk 7 development project as it approached conclusion.
 
We intend to focus the rest of our research and development expenses mainly on our current product support, as well as to advance the FDA submission for clearance of the ReWalk 7 next-generation exoskeleton model. We have ongoing product development activity with our AlterG Anti-Gravity systems, including a program to develop a new entry level model of AlterG Anti-Gravity system aimed to improve the affordability to price-conscious customers.

63

 
Sales and Marketing Expense
 
Our sales and marketing expense for 2023 and 2022 was as follows (in thousands): 

   
Years Ended December 31,
 
   
2023
   
2022
 
Sales and marketing expense
 
$
13,922
   
$
9,842
 
 
Sales and marketing expense was $13.9 million in 2023, an increase of $4.1 million, or 41%, during 2023 as compared to 2022. The AlterG business contributed $2.0 million of sales and marketing expenses for 2023. Sales and marketing expenses for 2023 also included $0.6 million of amortization of intangible assets from the acquisition of AlterG. Excluding the impact of these factors resulting from the acquisition of AlterG, sales and marketing expenses increased $1.5 million, or 15%, for 2023. The remaining increase was primarily driven by higher consulting expenses related to the CMS reimbursement process and market access initiatives.
 
In the near term our sales and marketing expense are expected to be driven by our efforts to expand the reimbursement coverage of our ReWalk Personal Exoskeleton device, to integrate and unify the combined sales and marketing resources of the ReWalk and AlterG organizations, and to support our current commercial product activities.
 
General and Administrative Expense
 
Our general and administrative expense for 2023 and 2022 was as follows (in thousands): 

   
Years Ended December 31,
 
   
2023
   
2021
 
General and administrative
 
$
9,995
   
$
7,134
 
 
General and administrative expense was $10.0 million, an increase of $2.9 million, or 40%, during 2023 as compared to 2022. The AlterG business contributed $1.1 million of general and administrative expenses for 2023. General and administrative expenses also included $2.5 million of M&A-related expenses, and $0.1 million of amortization of intangible assets from the acquisition of AlterG offset partially by $0.3 remeasurement of earn out liability. Excluding the impact of these factors resulting from the acquisition of AlterG, general and administrative expenses decreased $0.6 million, or 7%, for 2023.  The decrease was mainly driven by lower professional services expenses.
 
Financial income, net
 
Our financial income, net for 2023 and 2022 was as follows (in thousands): 

   
Years Ended December 31,
 
   
2023
   
2022
 
Financial income, net
 
$
1,467
   
$
*)
 
 
Financial income, net, reflects an increase in financial income of $1.5 million during 2023 as compared to 2022. The increase in financial income was primarily due to a change in cash management practices to move cash balances to accounts that pay a higher interest rate and yield greater interest income, as well as exchange rate fluctuations.
 
*) Represents an amount lower than $1.
 
Income Tax
 
Our income tax for 2023 and 2022 was as follows (in thousands): 

   
Years Ended December 31,
 
   
2023
   
2022
 
Taxes on income (benefit)
 
$
(12
)
 
$
467
 
 
Income tax decreased by $0.5 million during 2023 as compared to 2022, mainly due to the utilization of net operation losses forward arising from the acquisition of AlterG.

64

 
Year Ended December 31, 2022 Compared to Year Ended December 31, 2021
 
A discussion of changes in our results of operations in 2022 compared to 2021 has been omitted from this annual report on Form 10-K but may be found in “Part I. Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations” of our Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 23, 2023, which is available free of charge on the SEC's website at www.sec.gov and at golifeward.com, and is incorporated by reference herein.
 
Critical Accounting Policies
 
Our consolidated financial statements are prepared in accordance with United States generally accepted accounting principles. The preparation of our financial statements requires us to make estimates, judgments and assumptions that can affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates, judgments and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. Besides the estimates identified above that are considered critical, we make many other accounting estimates in preparing our financial statements and related disclosures. See Note 2 to our consolidated financial statements presented elsewhere in this annual report for a description of the significant accounting policies that we used to prepare our consolidated financial statements. The critical accounting policies that were impacted by the estimates, judgments and assumptions used in the preparation of our consolidated financial statements are discussed below.
 
Revenue Recognition
 
Our revenue is recognized in accordance with ASC Topic 606 when obligations under the terms of a contract with our customer are satisfied; generally, this occurs with the transfer of control of our products or services. Revenue is measured as the amount of consideration to which we expect to be entitled in exchange for transferring products or providing services. To achieve this core principle, we apply the following five steps:
 
1. identify the contract with a customer;
 
2. identify the performance obligations in the contract;
 
3. determine the transaction price;
 
4. allocate the transaction price to performance obligations in the contract; and
 
5. recognize revenue when or as we satisfy a performance obligation.
 
Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred. The timing for revenue recognition among the various products and customers is dependent upon satisfaction of such criteria and generally varies from either shipment or delivery to the customer depending on the specific shipping terms of a given transaction, as stipulated in the agreement with each customer. Other than pricing terms which may differ due to the different volumes of purchases between distributors and end-users, there are no material differences in the terms and arrangements involving direct and indirect customers. Our products sold through agreements with distributors are non-exchangeable, non-refundable, non-returnable and without any rights of price protection or stock rotation. Accordingly, we consider all the distributors as end-users. We generally do not grant a right of return for our products except in rare circumstances, and in those cases we record reductions to revenue for expected future product returns based on our historical experience and estimates.

65

 
For the majority of sales of ReWalk Rehabilitation Exoskeleton systems, we include insignificant training and consider the elements in the arrangement to be a single performance obligation. Therefore, the Company recognizes revenue for the system only when control is transferred after delivery and when the training has been completed, in accordance with the agreement terms with the customer, once all other revenue recognition criteria have been met. For sales of ReWalk Personal Exoskeleton systems to end users, and for sales of ReWalk Personal Exoskeleton or ReWalk Rehabilitation Exoskeleton systems to third party distributors, we do not provide training to the end user as this training is completed by the rehabilitation centers or by the distributor that have previously completed the ReWalk Training program.
 
Warranties are classified as either assurance type or service type warranty. A warranty is considered an assurance type warranty if it provides the consumer with assurance that the product will function as intended for a limited period of time.
 
SCI Products include a five-year warranty. The first two years are considered as an assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. A service type warranty is either sold with a unit or separately for a unit for which the warranty has expired. A service type warranty is accounted as a separate performance obligation and revenue is recognized ratably over the life of the warranty.
 
The ReStore device is sold with a two-year warranty which is considered as assurance type warranty.
 
The Distributed Products are sold with an assurance type warranty ranging from between three years to ten years, depending on the specific part.
 
The AlterG Anti-Gravity systems are sold with a one-year assurance type warranty for parts and labor in the US and with a two-year assurance type warranty for parts for distributors.  We also sell extended warranties for AlterG Anti-Gravity systems for the periods after the expiration of the original warranty.  These are accounted for as separate performance obligations from the AlterG Anti-Gravity system.
 
We rent our AlterG Anti-Gravity systems to customers for a fixed monthly fee over the rental term, which typically ranges from 2 to 3 years. Rental revenues accounted for under ASC Topic 842 and are recorded as earned on a monthly basis. We also offer for the SCI Products a rent-to-purchase model in which we recognize revenue ratably according to the agreed rental monthly fee for a limited period prior to selling its products. For units placed, we transfer control and recognize a sale when title has passed to our customer and rental revenue ratably according to the agreed rental monthly fee. Each unit placed is considered an independent, unbundled performance obligation.
 
Income Taxes
 
As part of the process of preparing our consolidated financial statements, we are required to estimate our taxes in each of the jurisdictions in which we operate. We account for income taxes in accordance with ASC Topic 740, “Income Taxes,” or ASC Topic 740. ASC Topic 740 prescribes the use of an asset and liability method whereby deferred tax asset and liability account balances are determined based on the difference between book value and the tax bases of assets and liabilities and carryforward tax losses. Deferred taxes are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. We exercise judgment and provide a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that some portion or all of the deferred tax asset will not be realized. We have established a full valuation allowance with respect to our deferred tax assets.
 
ASU 2015-17, “Balance Sheet Classification of Deferred Taxes” provides presentation requirements to classify deferred tax assets and liabilities, along with any related valuation allowance, are classified as non-current on the balance sheet. We account for uncertain tax positions in accordance with ASC 740 and recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Accordingly, we report a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. We recognize interest and penalties, if any, related to unrecognized tax benefits in tax expense.
 
66

 
Recently Issued and Adopted Accounting Pronouncements
 
A discussion of recent accounting pronouncements is included in Note 2w, New Accounting Pronouncements, to our consolidated financial statements included elsewhere in this annual report.
 
Liquidity and Capital Resources
 
Sources of Liquidity and Outlook
 
Since inception, we have funded our operations primarily through the sale of our equity securities and convertible notes to investors in private placements, the sale of our equity securities in public offerings, cash exercises of outstanding warrants and the incurrence of bank debt.
 
For the full year ended December 31, 2023, we incurred a consolidated net loss of $22.1 million and had an accumulated deficit in the total amount of $235.9 million. Our cash and cash equivalents on December 31, 2023, totalled $28.1 million. Our negative operating cash flow for the full year ended December 31, 2023, was $20.7 million. We have sufficient funds to support our operation for more than 12 months following the approval of our consolidated financial statements for the fiscal year ended December 31, 2023.
 
We expect to incur future net losses and our transition to profitability is dependent upon, among other things, the successful development and commercialization of our products and product candidates, the establishment of contracts for the distribution of new product lines, or the acquisition of additional product lines, any of which, or in combination, would contribute to the achievement of a level of revenue adequate to support our cost structure.  Until we achieve profitability or generate positive cash flows, we will continue to need to raise additional cash from time to time.
 
We intend to fund future operations through cash on hand, additional private and/or public offerings of debt or equity securities, cash exercises of outstanding warrants or a combination of the foregoing. In addition, we may seek additional capital through arrangements with strategic partners or from other sources and we will continue to address our cost structure. Notwithstanding, there can be no assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.
 
Our anticipated primary uses of cash are funding (i) sales, marketing, and promotion activities related to market development for our ReWalk Personal Exoskeleton device and AlterG Anti-Gravity system, broadening third-party payor and CMS coverage for our ReWalk Personal Exoskeleton device and commercializing our new product lines added through distribution agreements; (ii) development of future generation designs for our ReWalk device, new AlterG products utilizing DAP technology, and our lightweight exo-suit technology for potential home personal health utilization for multiple indications; (iii) routine product updates; (iv) potential acquisitions of businesses, such as our recent acquisition of AlterG, and (v) general corporate purposes, including working capital needs.  Our future cash requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities, the timing and extent of our spending on research and development efforts, the attractiveness of potential acquisition candidates and international expansion. If our current estimates of revenue, expenses or capital or liquidity requirements change or are inaccurate, we may seek to sell additional equity or debt securities, arrange for additional bank debt financing, or refinance our indebtedness. There can be no assurance that we will be able to raise such funds on acceptable terms.
 
Equity Raises
 
Use of Form S-3
 
Beginning with the filing of our Form 10-K on February 17, 2017, we were subject to limitations under the applicable rules of Form S-3, which constrained our ability to secure capital with respect to public offerings pursuant to our effective Form S-3. These rules limit the size of primary securities offerings conducted by issuers with a public float of less than $75 million to no more than one-third of their public float in any 12-month period. At the time of filing this annual report, we were subject to these limitations because our public float did not reach at least $75 million in the 60 days preceding the filing of this annual report. We will continue to be subject to these limitations for the remainder of the 2024 fiscal year and until the earlier of such time as our public float reaches at least $75 million or when we file our next annual report for the year ended December 31, 2024, at which time we will be required to re-test our status under these rules. If our public float is below $75 million as of the filing of our next annual report on Form 10-K, or at the time we file a new Form S-3, we will continue to be subject to these limitations, until the date that our public float again reaches $75 million. These limitations do not apply to secondary offerings for the resale of our ordinary shares or other securities by selling shareholders or to the issuance of ordinary shares upon conversion by holders of convertible securities, such as warrants. We have registered up to $100 million of ordinary shares warrants and/or debt securities and certain other outstanding securities with registration rights on our registration statement on Form S-3, which was declared effective by the SEC in May 2022.
 
67

 
Equity Offerings and Warrant Exercises
 
On February 19, 2021, the Company entered into a purchase agreement with certain institutional and other accredited investors for the issuance and sale of 10,921,502 ordinary shares, par value NIS 0.25 per share at $3.6625 per ordinary share and warrants to purchase up to an aggregate of 5,460,751 ordinary shares with an exercise price of $3.60 per share, exercisable from February 19, 2021, until August 26, 2026. Additionally, the Company issued warrants to purchase up to 655,290 ordinary shares, with an exercise price of $4.578125 per share, exercisable from February 19, 2021, until August 26, 2026, to certain representatives of H.C. Wainwright as compensation for its role as the placement agent in our February 2021 private placement offering.
 
On September 27, 2021, we signed a purchase agreement with certain institutional investors for the issuance and sale of 15,403,014 ordinary shares, pre-funded warrants to purchase up to an aggregate of 610,504 ordinary shares and ordinary warrants to purchase up to an aggregate of 8,006,759 ordinary shares at an exercise price of $2.00 per share. The pre-funded warrants have an exercise price of $0.001 per ordinary share and are immediately exercisable and can be exercised at any time after their original issuance until such pre-funded warrants are exercised in full. Each ordinary share was sold at an offering price of $2.035 and each pre-funded warrant was sold at an offering price of $2.034 (equal to the purchase price per ordinary share minus the exercise price of the pre-funded warrant). The offering of the ordinary shares, the pre-funded warrants and the ordinary shares that are issuable from time to time upon exercise of the pre-funded warrants was made pursuant to our shelf registration statement on Form S-3 initially filed with the SEC on May 9, 2019, and declared effective by the SEC on May 23, 2019, and the ordinary warrants were issued in a concurrent private placement. The ordinary warrants are exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending five and one-half years from the date of issuance. All of the pre-funded warrants were exercised in full on September 27, 2021, and the offering closed on September 29, 2021. Additionally, we issued warrants to purchase up to 960,811 ordinary shares, with an exercise price of $2.5438 per share, exercisable from September 27, 2021, until September 27, 2026, to certain representatives of H.C. Wainwright as compensation for its role as the placement agent in our September 2021 private placement offering.
 
As of December 31, 2023, warrants to purchase a total of 9,814,754 ordinary shares with exercise prices ranging from $1.25 to $1.79 were exercised, for total gross proceeds of approximately $13.8 million. During the twelve months that ended December 31, 2023, no warrants were exercised.
 
Share Repurchase Program
 
On June 2, 2022, our board of directors approved a share repurchase program to repurchase up to $8.0 million of our ordinary shares . On July 21, 2022, we received approval from an Israeli court for the share repurchase program. The program was scheduled to expire on the earlier of January 20, 2023, or reaching $8.0 million of repurchases. On December 22, 2022, our board of directors approved an extension of the repurchase program, with such extension to be in the aggregate amount of up to $5.8 million. The extension was approved by an Israeli court on February 9, 2023, and it expired on August 9, 2023.
 
As of December 31, 2023, pursuant to the share repurchase program, we had repurchased a total of 4,022,607 of our outstanding ordinary shares at a total cost of $3.5 million.
 
Cash Flows

   
Years Ended December 31,
 
   
2023
   
2022
   
2021
 
Net cash used in operating activities
 
$
(20,667
)
 
$
(17,891
)
 
$
(11,469
)
Net cash used in investing activities          
   
(18,149
)
   
(25
)
   
(47
)
Net cash (used in) provided by financing activities          
   
(992
)
   
(2,500
)
   
79,512
 
Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash
   
45
     
(79
)
   
 
Net cash flow
 
$
(39,763
)
 
$
(20,495
)
 
$
67,996
 
 
68

 
Year Ended December 31, 2023 to Year Ended December 31, 2022
 
Net Cash Used in Operating Activities
 
Net cash used in operating activities was $20.7 million in 2023, an increase of $2.8 million as compared to 2022 mainly due to higher consulting and professional services fees primarily associated with the acquisition of AlterG and the CMS reimbursement process, as well as increased inventory purchases.
 
Net Cash Used in Investing Activities
 
Net cash used in investing activities increased to $18.1 million in 2023 as compared to $0.03 million in 2022, primarily due to the acquisition of AlterG.
 
Net Cash Used in Financing Activities
 
Net cash used in financing activities was $0.9 million in 2023, a decrease of $1.5 million, as compared to 2022. The decrease was due to the repurchase of our ordinary shares under our share repurchase program, which expired on August 9, 2023.
 
Year Ended December 31, 2022 Compared to Year Ended December 31, 2021
 
A discussion of changes in our cash flows in 2022 compared to 2021 has been omitted from this annual report on Form 10-K but may be found in “Part I. Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations” of our Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 23, 2023, which is available free of charge on the SECs website at www.sec.gov and at golifeward.com, and is incorporated by reference herein.

69

 
Obligations and Commercial Commitments
 
Set forth below is a summary of our contractual obligations as of December 31, 2023:

   
Payments due by period (in dollars, in thousands)
 
Contractual obligations
 
Total
   
Less than
1 year
   
1-3 years
 
                   
Purchase obligations (1)
 
$
8,551
   
$
8,551
   
$
 
Collaboration Agreement and License Agreement obligations (2)
   
34
     
34
     
 
Operating lease obligations (3)
   
2,050
     
1,364
     
686
 
Earnout liability (4)
   
3,292
     
576
     
2,716
 
Total
 
$
13,927
   
$
10,525
   
$
3,402
 
 
(1)
We depend on one contract manufacturer, Sanmina Corporation, for both the SCI products and the ReStore Products. We place our manufacturing orders with Sanmina pursuant to purchase orders or by providing forecasts for future requirements. The AlterG Anti-Gravity systems are produced in Fremont, California by us. Purchase orders are executed with suppliers based on our sales forecast.
 
(2)
Under the Collaboration Agreement, we were required to pay in quarterly installments the funding of our joint research collaboration with Harvard, subject to a minimum funding commitment under applicable circumstances. Our License Agreement with Harvard consists of patent reimbursement expenses payments and a license upfront fee payment. There are also several milestone payments contingent upon the achievement of certain product development and commercialization milestones and royalty payments on net sales from certain patents licensed to Harvard. All product development milestones contemplated by the License Agreement have been met as of December 31, 2023; however, there are still outstanding commercialization milestones under the License Agreement that depend on us reaching certain sales amounts, some or all of which may not occur. Our Collaboration Agreement with Harvard was concluded on March 31, 2022.
 
(3)
Our operating leases consist of leases for our facilities in the United States, Israel and Germany and motor vehicles in Israel.
 
(4)
Earnout payments based on AlterG’s revenue growth during the two consecutive trailing twelve-month periods following closing of the acquisition.
 
We calculated the payments due under our operating lease obligation for our Israeli office that are to be paid in NIS at a rate of exchange of NIS 3.627:$1.00, of which were the applicable exchange rate as of December 31, 2023.
 
Off-Balance Sheet Arrangements
 
We had no off-balance sheet arrangements or guarantees of third-party obligations during the periods presented.
 
Trend Information
 
For information on significant known trends, please see “Part I-Item 1. “Business – Overview” in this annual report.
70



ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
Currency Exchange Risk
 
Our results of operations and cash flows are affected by fluctuations in foreign currency exchange rates. Since 2015, most of our expenses were denominated in U.S. dollars and the remaining expenses were denominated in NIS and euro, until 2018 most of our revenue was denominated in U.S. dollars and the remainder of our revenue was denominated in euro and British pound whereas in the last four years our euro revenue is higher than our U.S dollar revenue. Accordingly, changes in the value of the NIS and Euro relative to the U.S. dollar in each of the years 2023, 2022, and 2021 impacted amounts recorded on our consolidated statements of operations for these periods. We expect that the denominations of our revenue and expenses in 2024 will be consistent with what we experienced in 2023.
 
The following table presents information about the devaluation in the exchange rates of the NIS and euro against the U.S. dollar in 2023, 2022 and 2021:

   
Change in Average Exchange Rate
 
Period
 
NIS against the
U.S. Dollar (%)
   
Euro against the
U.S. Dollar (%)
 
2023
   
(9.00
)
   
2.67
 
2022
   
3.70
     
10.84
 
2021
   
(6.38
)
   
3.46
 
 
The figures above represent the change in the average exchange rate in the given period compared to the average exchange rate in the immediately preceding period. Negative figures represent the devaluation of the U.S. dollar compared to the NIS or the euro. A 10% increase or decrease in the value of the NIS against the U.S. dollar would have decreased or increased our net loss by approximately $513 thousand in 2023. A 10% increase or decrease in the value of the euro against the U.S. dollar would have decreased or increased our net loss by approximately $14 thousand in 2023.
 
Other Market Risks
 
We do not believe that we have material exposure to interest rate risks or to inflationary risks.
 
ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
 
The information required hereunder is set forth under Report of Independent Registered Public Accounting Firm, Consolidated Balance Sheets, Consolidated Statements of Operations, Statements of Changes in Shareholders’ Equity, Consolidated Statements of Cash Flows and Notes to Consolidated Financial Statements included in the Consolidated Financial Statements that are a part of this annual report. Other financial information is included in the Consolidated Financial Statements that are a part of this annual report.
 
ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
 
None.
 
ITEM 9A. CONTROLS AND PROCEDURES
 
Disclosure Controls and Procedures
 
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure.
 
As of the end of the period covered by this annual report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon, and as of the date of, this evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures were effective such that the information required to be disclosed by us in our SEC reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

71

 
Management’s Report on Internal Control over Financial Reporting
 
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.
 
Our internal control over financial reporting includes those policies and procedures that:
 

pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
 

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
 

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on our financial statements.
 
Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making its assessment, management used the criteria described in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
 
We have excluded from the scope of our assessment of internal control over financial reporting the operations and related assets of AlterG, which we acquired on August 11, 2023. Based on management’s assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2023 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external reporting purposes in accordance with U.S. GAAP.
 
This annual report does not include an attestation report of our independent registered public accounting firm regarding internal controls over financial reporting because we are exempt from this requirement as a smaller reporting company and non-accelerated filer.
 
Changes in Internal Control over Financial Reporting
 
During the fourth quarter of the fiscal year ended December 31, 2023, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.
 
ITEM 9B.   OTHER INFORMATION
 
Not applicable
 
ITEM 9C.   DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
 
Not applicable

72

 
PART III
 
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
 
Information About Our Executive Officers
 
The following table sets forth the name, age and position of each of our executive officers as of February 27, 2024:
         
Name
 
Age
 
Position
Larry Jasinski
 
66
 
Chief Executive Officer and Director
Michael Lawless
 
56
 
Chief Financial Officer
Charles Remsberg
 
62
 
Chief Sales Officer
Jeannine Lynch
 
59
 
Vice President of Market Access
Almog Adar
 
40
 
Vice President of Finance
 
Larry Jasinski has served as our Chief Executive Officer and as a member of our board since February 2012. From 2005 until 2012, Mr. Jasinski served as the President and Chief Executive Officer of Soteira, Inc., a company engaged in development and commercialization of products used to treat individuals with vertebral compression fractures, which was acquired by Globus Medical in 2012. From 2001 to 2005, Mr. Jasinski was President and Chief Executive Officer of Cortek, Inc., a company that developed next-generation treatments for degenerative disc disease, which was acquired by Alphatec in 2005. From 1985 until 2001, Mr. Jasinski served in multiple sales, research and development, and general management roles at Boston Scientific Corporation. Mr. Jasinski has served on the board of directors of Massachusetts Bay Lines since 2015 and of LeMaitre Vascular, Inc. since 2003. Mr. Jasinski holds a B.Sc. in marketing from Providence College and an MBA from the University of Bridgeport.
 
Michael Lawless has served as our Chief Financial Officer since September 2022. Prior to Lifeward, Mr. Lawless served as a CFO consultant for Danforth Advisors, LLC, a provider of financial consulting services to the life sciences industry. From 2015 to 2020, Mr. Lawless held several financial leadership positions including Division CFO at Azenta, Inc. (formerly Brooks Automation, Inc.), a worldwide provider of management solutions for biological samples. Previously, Mr. Lawless also held financial leadership roles for AECOM Technology, Inc., PerkinElmer, Inc., Momenta Pharmaceuticals, Inc. and CTI Molecular Imaging, Inc.  Mr. Lawless has a Bachelor of Arts degree in Economics from Swarthmore College, a Master of Business Administration degree from the Tuck School of Business at Dartmouth College and is a Certified Public Accountant.
 
Charles Remsberg has served as our Chief Sales Officer since August 2023.  Prior to Lifeward, Mr. Remsberg served as CEO of AlterG from March 2017 until the acquisition of AlterG in August 2023.  An industry veteran of over 30 years, Charles has been responsible for bringing innovative rehabilitation technology to physical therapy, neuro-rehabilitation, sports medicine, and wellness customers.  Prior to serving at AlterG, Mr. Remsberg served in both executive and commercial leadership roles for Tibion (for which he served as the CEO from December 2009 to April 2013, when it was acquired by AlterG), Hocoma (for which he served as the U.S. CEO and Global Head of Sales from September 2003 to November 2009), and Biodex Medical Systems (for which he served as the Head of Worldwide Sales from January 1997 to October 2002).  He holds an AS in Business Administration from Suffolk County Community College.
 
Jeannine Lynch has served as our Vice President of Market Access and Strategy since August 2021. Prior to Lifeward, Ms. Lynch served as Senior Director of Patient Access Services at BioMarin Pharmaceuticals from April 2009 to September 2021. In addition to her work with BioMarin, Ms. Lynch has worked for industry leaders such as Genentech and Pfizer/Agouron. She has held leadership roles in commercial management, product launches and built customized patient services to address several different rare and ultrarare medical conditions. Ms. Lynch also sits on the Board of Directors for MVP, a non-profit organization to help young people of color prepare, perform, progress, and prosper in their education, leadership and early professional careers. Ms. Lynch is a graduate of the University of California Berkeley and holds a Master of Public Health from the University of Michigan.
 
Almog Adar has served as our Vice President of Finance since December 2022. From 2020 to 2022, Mr. Adar served as our Director of Finance and Corporate Financial Controller. Prior to Lifeward, Mr. Adar served as Controller of Infinya Recycling Ltd. (previously Amnir Recycling) from January 2018 until December 2019. From January 2016 until December 2017, Mr. Adar served as Assistant Controller of Delta Galil Industries. Mr. Adar has a Bachelor of Arts degree in Accounting and Economics from the Open University of Israel and is a Certified Public Accountant licensed by the Israeli Ministry of Justice.
 
73

 
The remaining information required by this Item will be included in, and is incorporated herein by reference from, our definitive proxy statement for our 2024 Annual Meeting of Shareholders to be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our fiscal year ended December 31, 2023 (the “Proxy Statement”).
 
ITEM 11. EXECUTIVE COMPENSATION
 
The information required by this Item 11 will be included in, and is incorporated herein by reference from, our Proxy Statement.
 
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 
The information required by this Item 12 will be included in and is incorporated herein by reference from, our Proxy Statement.
 
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
 
The information required by this Item 13 will be included in and is incorporated herein by reference, from our Proxy Statement.
 
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
 
The information required by this Item 14 will be included in and is incorporated herein by reference, from our Proxy Statement. 
 
74

 
PART IV
 
 
ITEM 15.   EXHIBITS, FINANCIAL STATEMENT SCHEDULES
 
(a)(1) Financial Statements.
 
The Consolidated Financial Statements filed as part of this annual report are identified in the Index to Consolidated Financial Statements on page F-1 hereto.
 
(a)(2) Financial Statement Schedules.
 
 Financial Statement Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.
 
(a)(3) Exhibits.
 
See accompanying Exhibit Index included after the signature page of this report for a list of the exhibits filed or furnished with or incorporated by reference in this report.
 
EXHIBIT INDEX

75



4.18
4.19

76

10.14
10.17
101.INS
XBRL Instance Document.
101.SCH
XBRL Taxonomy Extension Schema Document.
101.PRE
XBRL Taxonomy Presentation Linkbase Document.
101.CAL
XBRL Taxonomy Calculation Linkbase Document.
101.LAB
XBRL Taxonomy Label Linkbase Document.
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document.
 
+
Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K.
*
Certain identified information in the exhibit has been omitted because it is the type of information that (i) the Company customarily and actually treats as private and confidential, and (ii) is not material.
**
Management contract or compensatory plan, contract or arrangement.
***
Furnished herewith.
 
ITEM 16. FORM 10-K SUMMARY
 
Not applicable.
 
77

 
SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
 
ReWalk Robotics Ltd.
     
 
By:
/s/ Larry Jasinski
   
Name: Larry Jasinski
   
Title: Chief Executive Officer
 
Date: February 27, 2024

78

 
POWER OF ATTORNEY
 
KNOW ALL PERSONS BY THESE PRESENT: That the undersigned officers and directors of ReWalk Robotics Ltd. do hereby constitute and appoint Larry Jasinski and Mike Lawless the lawful attorney and agent with power and authority to do any and all acts and things and to execute any and all instruments which said attorney and agent determines may be necessary or advisable or required to enable ReWalk Robotics Ltd. to comply with the Securities and Exchange Act of 1934, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this report. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this report or amendments or supplements thereto, and each of the undersigned hereby ratifies and confirms all that said attorneys and agents, or either of them, shall do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature
 
Title
 
Date
         
/s/ Larry Jasinski
 
Director and Chief Executive Officer
 
February 27, 2024
Larry Jasinski
 
(Principal Executive Officer)
   
         
/s/ Mike Lawless
 
Chief Financial Officer
 
February 27, 2024
Mike Lawless
 
(Principal Financial Officer)
   
         
/s/ Almog Adar
 
Vice President of Finance
 
February 27, 2024
Almog Adar
 
(Principal Accounting Officer)
   
         
/s/ Jeff Dykan
 
Chairman of the Board
 
February 27, 2024
Jeff Dykan
       
         
/s/ Dr. John William Poduska
 
Director
 
February 27, 2024
Dr. John William Poduska
       
         
/s/ Randel Richner
 
Director
 
February 27, 2024
Randel Richner
       
         
/s/ Joseph Turk
 
Director
 
February 27, 2024
Joseph Turk
       
         
/s/ Hadar Levy
 
Director
 
February 27, 2024
Hadar Levy
       

79



PART IV
 
REWALK ROBOTICS LTD
 
CONSOLIDATED FINANCIAL STATEMENTS
 
U.S. DOLLARS IN THOUSANDS
 
INDEX
 
 

 
image0.jpg
Kost Forer Gabbay & Kasierer
Menachem Begin 144,
Tel-Aviv 6492102, Israel
Tel: +972-3-6232525
Fax: +972-2-5622555
ey.com
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
To the Shareholders and the Board of Directors of
 
REWALK ROBOTICS LTD.
 
Opinion on the Financial Statements
 
We have audited the accompanying consolidated balance sheets of Rewalk Robotics Ltd. and subsidiaries (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, changes is shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.
 
Basis for Opinion
 
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
 
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
 
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
 
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
 

F - 2


 

 
Revenue recognition
 
 
Description of the Matter
As described in Note 2 to the consolidated financial statements, the Company generates revenues from sales of its medical devices. Revenue is recognized when obligations under the terms of a contract with the Company's customers are satisfied. Revenue is measured as the amount of consideration to which the Company expects to be entitled in exchange for transferring products or providing services. In addition, the Company provides a service type warranty which is accounted for as a separate performance obligation. Revenue is recognized ratably over the life of the warranty. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis. The Company does not sell the service type warranty of its SCI products on a standalone basis.
 
Auditing the Company’s evaluation of the allocation of the transaction price to the distinct performance obligations was challenging due to the effort and assumptions required to evaluate the standalone selling price of the SCI products service type warranty. The assumptions used in determining the standalone selling price of the service type warranty included costs allocation, inflation rates and expected margins.
 
 
How We Addressed the
Matter in Our Audit
To test the management’s determination of standalone selling prices of the SCI products service type warranty, our audit procedures included, among others, evaluating the methodology applied and testing the calculations as well as the completeness and accuracy of the underlying data including the costs allocation, inflation rates and expected margins used by the Company in its estimates. We also evaluated the Company’s disclosures included in notes to the consolidated financial statements.
 
Business Combinations – Valuation
 
Description of the Matter
 
 
 
 
As discussed in Notes 2 and 5 to the consolidated financial statements, the Company completed an acquisition of AlterG Inc. during 2023 for consideration of $22.1 million. The Company accounted for this acquisition as a business combination. The acquisition resulted in the recognition of intangible assets amounting to $14.1 million, which consisted of technology, customer relationship, trademark assets and backlog of $6.1 million, $6.9 million, $0.8 million and $0.3 million respectively.
 
Auditing the Company’s estimation of the fair value of the acquired intangible assets was complex due to the estimation and uncertainty in the Company’s determination of the fair value of acquired identifiable intangible assets. The estimation uncertainty for the acquired intangible assets was primarily due to the underlying assumptions about the future performance of the acquired business, which were utilized in determining the fair value of the acquired intangible assets. The significant assumptions used by management included discount rates and certain assumptions that form the basis of the forecasted results, including revenue growth rates. These significant assumptions were forward-looking and could be affected by future economic and market conditions.
 
 
How We Addressed the
Matter in Our Audit
To test the estimated fair value of the acquired intangible assets, our audit procedures included, among others, assessing the fair value methodology used by the Company and testing the significant assumptions and the underlying data used by the Company in its analyses. We also performed sensitivity analyses over the significant assumptions used to evaluate the change in the fair value resulting from changes in the assumptions. Additionally, we tested the completeness and accuracy of the underlying data used in the valuation. We involved our valuation specialists to assist us in our evaluation of the Company’s valuation model, related assumptions and output of the valuation model.
 
KOST FORER GABBAY & KASIERER
A Member of EY Global
 
We have served as the Company’s auditor since 2014.
 
Tel-Aviv, Israel
February 27, 2024

 

F - 3


 

REWALK ROBOTICS LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
 
 
 
December 31,
 
 
 
2023
   
2022
 
ASSETS
           
CURRENT ASSETS:
           
Cash and cash equivalents
 
$
28,083
   
$
67,896
 
Trade receivable, net of credit losses of $328 and $26, respectively
   
3,120
     
1,036
 
Prepaid expenses and other current assets
   
2,366
     
649
 
Inventories
   
5,653
     
2,929
 
Total current assets
   
39,222
     
72,510
 
 
               
LONG-TERM ASSETS
               
 
               
Restricted cash and other long-term assets
   
784
     
694
 
Operating lease right-of-use assets
   
1,861
     
836
 
Property and equipment, net
   
1,262
     
196
 
Intangible assets
   
12,525
     
-
 
Goodwill
   
7,538
     
-
 
Total long-term assets
   
23,970
     
1,726
 
 
               
Total assets
 
$
63,192
   
$
74,236
 
 
The accompanying notes are an integral part of these consolidated financial statements.
 

F - 4


 

REWALK ROBOTICS LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except share and per share data)
 
 
 
December 31,
 
 
 
2023
   
2022
 
LIABILITIES AND SHAREHOLDERS’ EQUITY
           
CURRENT LIABILITIES:
           
Trade payables
 
$
5,069
   
$
1,950
 
Employees and payroll accruals
   
2,034
     
1,282
 
Deferred revenue
   
1,504
     
301
 
Current maturities of operating leases liability
   
1,296
     
564
 
Earnout liability
   
576
     
-
 
Other current liabilities
   
1,316
     
685
 
Total current liabilities
   
11,795
     
4,782
 
 
               
LONG-TERM LIABILITIES
               
 
               
Earnout liability
   
2,716
     
-
 
Deferred revenues
   
1,506
     
890
 
Non-current operating leases liability
   
607
     
333
 
Other long-term liabilities
   
58
     
66
 
Total long-term liabilities
   
4,887
     
1,289
 
 
               
Total liabilities
   
16,682
     
6,071
 
 
               
COMMITMENTS AND CONTINGENT LIABILITIES
           
Shareholders’ equity:
               
 
               
Share capital
               
Ordinary share of NIS 0.25 par value-Authorized: 120,000,000 shares at December 31, 2023 and December 31, 2022; Issued: 64,132,706 and 63,023,506 shares at December 31, 2023 and December 31, 2022, respectively; Outstanding: 60,110,099 and 60,090,298 shares as of December 31, 2023 and December 31, 2022 respectively
   
4,487
     
4,489
 
Additional paid-in capital
   
281,109
     
279,857
 
Treasury Shares at cost, 4,022,607 and 2,933,208 ordinary shares at December 31, 2023 and December 31, 2022, respectively
   
(3,203
)
   
(2,431
)
Accumulated deficit
   
(235,883
)
   
(213,750
)
 
               
Total shareholders’ equity
   
46,510
     
68,165
 
 
               
Total liabilities and shareholders’ equity
 
$
63,192
   
$
74,236
 
 
The accompanying notes are an integral part of these consolidated financial statements.

 

F - 5


 

REWALK ROBOTICS LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share and per share data)
 
 
 
Year ended December 31,
 
 
 
2023
   
2022
   
2021
 
Revenue
 
$
13,854
   
$
5,511
   
$
5,966
 
Cost of revenue
   
9,401
     
3,606
     
3,063
 
 
                       
Gross profit
   
4,453
     
1,905
     
2,903
 
 
                       
Operating expenses:
                       
Research and development, net
   
4,148
     
4,031
     
2,939
 
Sales and marketing
   
13,922
     
9,842
     
6,993
 
General and administrative
   
9,995
     
7,134
     
5,626
 
 
                       
Total operating expenses
   
28,065
     
21,007
     
15,558
 
 
                       
Operating loss
   
(23,612
)
   
(19,102
)
   
(12,655
)
 
                       
Financial income, net
   
1,467
     
*
)
   
13
 
 
                       
Loss before income taxes
   
(22,145
)
   
(19,102
)
   
(12,642
)
Taxes on income (benefit)
   
(12
)
   
467
     
94
 
 
                       
Net loss
 
$
(22,133
)
 
$
(19,569
)
 
$
(12,736
)
 
                       
Net loss per ordinary share, basic and diluted
 
$
(0.37
)
 
$
(0.31
)
 
$
(0.27
)
 
                       
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted
   
59,719,064
     
62,378,797
     
47,935,652
 
 
The accompanying notes are an integral part of these consolidated financial statements.
 
*)          Represents an amount lower than $1.

 

F - 6


 

REWALK ROBOTICS LTD. AND SUBSIDIARIES
STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
U.S. dollars in thousands (except share data)
 
 
 
Ordinary Share
   
Additional
paid-in
   
Treasury
   
Accumulated
   
Total
shareholders’
 
 
 
Number
   
Amount
   
capital
   
Shares
   
deficit
   
equity
 
Balance as of December 31, 2020
   
25,332,225
     
1,827
     
201,392
     
-
     
(181,445
)
   
21,774
 
Share-based compensation to employees and non-employees
   
-
     
-
     
833
     
-
     
-
     
833
 
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees
   
398,164
     
31
     
(31
)
   
-
     
-
     
-
 
Issuance of ordinary shares in a “Best Efforts” offering, net of issuance expenses in the amount of $3,679 (1)
   
10,921,502
     
832
     
35,489
     
-
     
-
     
36,321
 
Exercise of pre-funded warrants and warrants (1)(2)
   
10,425,258
     
772
     
14,288
     
-
     
-
     
15,060
 
Issuance of ordinary shares in a “registered direct” offering, net of issuance expenses in the amount of $3,215 (1)
   
15,403,014
     
1,199
     
26,932
     
-
     
-
     
28,131
 
Net loss
   
-
     
-
     
-
     
-
     
(12,736
)
   
(12,736
)
Balance as of December 31, 2021
   
62,480,163
     
4,661
     
278,903
             
(194,181
)
   
89,383
 
Share-based compensation to employees and non-employees
   
-
     
-
     
993
     
-
     
-
     
993
 
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees
   
543,343
     
39
     
(39
)
   
-
     
-
     
-
 
Treasury shares at cost
   
(2,933,208
)
   
(211
)
   
-
     
(2,431
)
   
-
     
(2,642
)
Net loss
   
-
     
-
     
-
     
-
     
(19,569
)
   
(19,569
)
Balance as of December 31, 2022
   
60,090,298
   
$
4,489
   
$
279,857
   
$
(2,431
)
 
$
(213,750
)
 
$
68,165
 
Share-based compensation to employees and non-employees
   
-
     
-
     
1,328
     
-
     
-
     
1,328
 
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees
   
1,109,200
     
76
     
(76
)
   
-
     
-
     
-
 
Treasury shares at cost
   
(1,089,399
)
   
(78
)
   
-
     
(772
)
   
-
     
(850
)
Net loss
   
-
     
-
     
-
     
-
     
(22,133
)
   
(22,133
)
Balance as of December 31, 2023
   
60,110,099
     
4,487
     
281,109
     
(3,203
)
   
(235,883
)
   
46,510
 
 
(1)  See Note 9a.
 
(2)  See Note 9f.
 
The accompanying notes are an integral part of these consolidated financial statements.

 

F - 7


 

REWALK ROBOTICS LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
 
 
 
Year ended December 31,
 
 
 
2023
   
2022
   
2021
 
Cash flows used in operating activities:
                 
Net loss
 
$
(22,133
)
 
$
(19,569
)  
$
(12,736
)
Adjustments to reconcile net loss to net cash used in operating activities:
                       
 
                       
Depreciation
   
239
     
202
     
266
 

Amortization of intangible assets

   

1,608

      -       -  
Share-based compensation
   
1,328
     
993
     
833
 
Deferred taxes
   
-
     
316
     
(29
)
Remeasurement of earnout liability
   
(315
)    
-
     
-
 
Interest income
   
(11
)    
-
     
-
 
Exchange rate fluctuations
   
(45
)    
79
     
-
 
 
                       
Changes in assets and liabilities:
                       
                         
Trade receivables, net
   
(311
)    
(408
)    
99
 
Prepaid expenses, operating lease right-of-use assets and other assets
   
(531
)    
94
     
592
 
Inventories
   
(277
)    
(117
)    
432
 
Trade payables
   
1,037
     
566
     
(884
)
Employees and payroll accruals
   
(14
)    
140
     
275
 
Deferred revenues
   
(269
)    
(34
)    
74
 
Operating lease liabilities and other liabilities
   
(973
)    
(153
)    
(391
)
Net cash used in operating activities
   
(20,667
)    
(17,891
)    
(11,469
)
 
                       
Cash flows used in investing activities:
                       
Acquisition of a business, net of cash acquired
   
(18,068
)    
-
     
-
 
Purchase of property and equipment
   
(81
)    
(25
)    
(47
)
Net cash used in investing activities
   
(18,149
)    
(25
)    
(47
)
 
                       
Cash flows from financing activities:
                       
Issuance of ordinary shares in a private placement, net of issuance expenses paid in the amount of $3,679 (1)
   
-
     
-
     
36,321
 
Issuance of ordinary shares in a “registered direct” offering, net of issuance expenses in the amount of $3,215 (1)
   
-
     
-
     
28,131
 
Exercise of pre-funded warrants and warrants (1)(2)
   
-
     
-
     
15,060
 
Purchase of treasury shares
   
(992
)    
(2,500
)    
-
 
Net cash (used in) provided by financing activities
   
(992
)    
(2,500
)    
79,512
 
 
                       
Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash
   
45
     
(79
)    
-
 
Increase (decrease) in cash, cash equivalents, and restricted cash
   
(39,763
)    
(20,495
)    
67,996
 
Cash, cash equivalents, and restricted cash at beginning of period
   
68,555
     
89,050
     
21,054
 
Cash, cash equivalents, and restricted cash at end of period
 
$
28,792
   
$
68,555
   
$
89,050
 
 

(1)          See Note 9a.

(2)          See Note 9f.

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F - 8


 

REWALK ROBOTICS LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
 
 
 
Year ended December 31,
 
 
 
2023
   
2022
   
2021
 
 
                 
Supplemental disclosures of non-cash flow information
                 
Classification of other current assets to property and equipment, net
 
$
-
   
$
22
   
$
34
 
Classification of inventory to property and equipment
 
$
481
   
$
67
   
$
32
 
Amounts related to shares re-purchase not yet paid
 
$
-
   
$
142
   
$
-
 
ROU assets obtained from new lease liabilities
 
$
513
   
$
-
   
$
-
 
 
                       
Supplemental disclosures of cash flow information:
                       
Cash paid for income taxes
 
$
126
   
$
113
   
$
40
 
Cash received from interest
 
$
1,341
     
-
     
-
 
 
                       
Reconciliation of cash, cash equivalents and restricted cash as shown in the consolidated statements of cash flows
                       
Cash and cash equivalents
 
$
28,083
   
$
67,896
   
$
88,337
 
Restricted cash included in other long-term assets
 
$
709
   
$
659
   
$
713
 
Total Cash, cash equivalents, and restricted cash
 
$
28,792
   
$
68,555
   
$
89,050
 
 

(1)          See Note 9a.

(2)          See Note 9f.

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F - 9


 

REWALK ROBOTICS LTD. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
U.S. dollars in thousands

 

NOTE 1:-
GENERAL
 
  a.
ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date.
 
  b.
RRL has three wholly-owned (directly and indirectly) subsidiaries: (i) ReWalk Robotics, Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012, (ii) ReWalk Robotics GMBH (“RRG”) incorporated under the laws of Germany on January 14, 2013, and (iii) AlterG, Inc. (“AlterG”) incorporated in Delaware on October 21, 2004 under the name of Gravus, Inc. On June 30, 2005, the Company re-incorporated in Delaware and changed its name to AlterG, Inc. in September 2005.
 
  c.
The Company is a medical device company that is designing, developing, and commercializing innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions. The Company’s initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury (collectively, the “SCI Products”). These devices are robotic exoskeletons that are designed for individuals with paraplegia that use the Company’s patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. These SCI Products allow individuals with spinal cord injury the ability to stand and walk again during everyday activities at home or in the community.
 
The Company has sought to expand the product offerings beyond the SCI Products through internal development and distribution agreements. The Company has developed its ReStore Exo-Suit device, which it began commercializing in June 2019. The ReStore is a powered, lightweight soft exo-suit intended for use during the rehabilitation of individuals with lower limb disability due to stroke. During the second quarter of 2020, the Company signed two separate agreements to distribute additional product lines in the United States. The Company is the exclusive distributor of the MYOLYN MyoCycle FES Pro cycles to United States (“U.S.”) rehabilitation clinics and for the MyoCycle Home cycles available to US veterans through VA hospitals. In the second quarter of 2020, the Company also became the exclusive distributor of the MediTouch Tutor movement biofeedback systems in the United States; however, due to unsatisfactory sales performance of the MediTouch product lines, the Company terminated this agreement as of January 31, 2023. We refer to the MediTouch and MyoCycle devices as the Company’s “Distributed Products.”
 
On August 11, 2023, pursuant to an Agreement and Plan of Merger among RRI, AlterG, Atlas Merger Sub, Inc., a wholly owned subsidiary of RRI (“Merger Sub”), and Shareholder Representative Services LLC, dated August 11, 2023, RRI acquired AlterG and AlterG became a wholly owned subsidiary of the Company.
 
For accounting purposes, RRI was considered the acquirer and AlterG was considered the acquiree. The acquisition was accounted for using the acquisition method of accounting. See Note 5 for additional information.
 
The Company made its first acquisition to supplement its internal growth when it acquired AlterG, a leading provider of AlterG Anti-Gravity systems for use in physical and neurological rehabilitation.  The Company paid a cash purchase price of $19.0 million at closing and additional cash earnouts may be paid based upon a percentage of AlterG’s year-over-year revenue growth over the two years following the closing. The AlterG Anti-Gravity systems use patented, NASA-derived Differential Air Pressure (“DAP”) technology to reduce the effects of gravity and allow people to rehabilitate with finely calibrated support and reduced pain.  The Company will continue to evaluate other products for distribution or acquisition that can broaden its product offerings further to help individuals with physical and neurological injury and disability.
 
The Company markets and sells its products directly to institutions and individuals and through third-party distributors. The Company sells its products directly primarily in the United States, through a combination of direct sales and distributors (depending on the product line) in Germany, Canada, and Australia, and primarily through distributors in other markets. In its direct markets, the Company has established relationships with clinics and rehabilitation centers, professional and college sports teams, and individuals and organizations in the spinal cord injury community, and in its indirect markets, the Company’s distributors maintain these relationships. RRI and AlterG market and sell products mainly in the United States. RRG markets and sells the Company’s products mainly in Germany and Europe.
 

F - 10


 

  d.
The Company depends on one contract manufacturer to manufacture the ReWalk and the ReStore products in its portfolio, Sanmina. Reliance on this vendor makes the Company vulnerable to possible capacity constraints and reduces control over component availability, delivery schedules, manufacturing yields and costs.
 
  e.
For the full year ended December 31, 2023 the Company incurred a consolidated net loss of $22.1 million and has an accumulated deficit in the total amount of $235.9 million. The Company’s negative operating cash flow for the full year ended December 31, 2023 was $20.7 million. Our cash and cash equivalent on December 31, 2023 totalled $28.1 million. The Company has sufficient funds to support its operation for more than 12 months following the approval of its consolidated financial statements for the fiscal year ended December 31, 2023.
 
The Company expects to incur future net losses and the transition to profitability is dependent upon, among other things, the successful development and commercialization of the Company’s products and product candidates, the establishment of contracts for the distribution of new product lines, or the acquisition of additional product lines, any of which, or in combination, would contribute to the achievement of a level of revenue adequate to support the cost structure. Until the Company achieves profitability or generates positive cash flows, it will continue to need to raise additional cash. The Company intends to fund future operations through existing cash on hand, additional private and/or public offerings of debt or equity securities, cash exercises of outstanding warrants or a combination of the foregoing. In addition, the Company may seek additional capital through arrangements with strategic partners or from other sources and will continue to address its cost structure. Notwithstanding, there can be no assurance that the Company will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.
 
NOTE 2:-
SIGNIFICANT ACCOUNTING POLICIES
 
The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), applied on a consistent basis, as follows:
 
  a.
Use of Estimates
 
The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to inventories, fair values of share-based awards, contingent liabilities, provision for warranty, allowance for credit losses and sales return reserve. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
 
  b.
Financial Statements in U.S. Dollars:
 
The functional currency is the currency that best reflects the economic environment in which the Company and its subsidiaries operate and conduct their transactions. Most of the Company’s revenues and costs are incurred in U.S. dollar. In addition, the Company’s financing activities are incurred in U.S. dollars. The Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and each of its subsidiaries operate. Thus, the dollar is the Company’s and its subsidiary's functional and reporting currency.
 
Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are remeasured into U.S. dollars in accordance with ASC 830 “Foreign Currency Matters.” All transaction gains and losses of the remeasured monetary balance sheet items are reflected in the consolidated statements of operations as financing income or expenses as appropriate.

 

F - 11


 

  c.
Principles of Consolidation:
 
The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances have been eliminated upon consolidation.
 
  d.
Cash Equivalents:
 
Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less, at the date acquired.
 
  e.
Inventories:
 
Inventories are stated at the lower of cost or net realizable value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence.
 
The Company periodically evaluates the quantities on hand relative to historical, current, and projected sales volume. Based on this evaluation, an impairment charge is recorded when required to write-down inventory to its net realized value.
 
Cost is determined as follows:
 
Finished products - based on raw materials and manufacturing costs on an average basis.
 
Raw materials - The weighted average cost method.
 
The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors, including historical usage rates and forecasted sales according to outstanding backlogs. Purchasing requirements and alternative usage are explored within these processes to mitigate inventory exposure. When recorded, the reserves are intended to reduce the carrying value of inventory to its net realizable value. If actual demand for the Company’s products deteriorates, or market conditions are less favourable than those projected, additional inventory reserves may be required.
 
  f.
Property and Equipment:
 
Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:
 
 
%
Computer equipment
20-33 (mainly 33)
Office furniture and equipment
6 - 10 (mainly 10)
Machinery and laboratory equipment
15
Field service units
20-50
Leasehold improvements
Over the shorter of the lease term
or estimated useful life
 
  g.
Business Combinations
 
The Company accounts for business combinations in accordance with ASC 805, “Business Combinations” (“ASC 805”). For business combinations accounted for under the acquisition method, ASC 805 requires recognition of assets acquired, liabilities assumed, and any non-controlling interest at the acquisition date, measured at their fair values as of that date. The Company determines the recognition of intangible assets based on the following criteria: (i) the intangible asset arises from contractual or other rights; or (ii) the intangible asset is separable or divisible from the acquired entity and capable of being sold, transferred, licensed, returned or exchanged.
 
The excess of the fair value of the purchase price over the fair values of the identifiable assets and liabilities is recorded as goodwill. Determining the fair value of the identifiable assets and liabilities requires management to use significant judgment and estimates including the forecasted revenue and revenues growth rates, discount rates, customer contract renewal rates and customer attrition rates. The process of estimating the fair values requires significant estimates, especially with respect to intangible assets. Management’s determination of fair value of assets acquired and liabilities assumed at the acquisition date is based on the best information available in the circumstances and incorporates management’s own assumptions and involves a significant degree of judgment.
 
Acquisition related costs include legal fees, consulting and success fees, and other non-recurring integration related costs. Acquisition-related costs are expensed as incurred.

 

F - 12


 

  h.
Goodwill and Other Intangibles
 
For business combinations, the purchase prices are allocated to the tangible assets and intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition dates, with the remaining unallocated purchase prices recorded as goodwill.
 
The Company has no indefinite-lived intangible assets other than goodwill. Acquired identifiable finite-lived intangible assets include identifiable acquired technology, customer relationships, trademarks and backlog and are amortized on a straight-line basis over the estimated useful lives of the assets. The Company routinely reviews the remaining estimated useful lives of finite-lived intangible assets.
 
Goodwill is not amortized and is tested for impairment at least annually.
The Company operates as one reporting unit and the fair value of the reporting unit is estimated using quoted market prices of the Company’s stock in active markets. The Company tests goodwill for impairment annually in the fourth quarter and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable.
 
When testing goodwill for impairment, the Company may first perform a qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. The Company may elect to bypass the qualitative assessment and proceed directly to performing a quantitative analysis. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company recognizes an impairment of goodwill for the amount of this excess.
 
As of December 31, 2023, no impairments of goodwill have been recognized.
 
  i.
Impairment of Long-Lived Assets
 
The Company’s long-lived assets, including right-of-use (“ROU”) assets and identifiable intangible assets that are subject to amortization, are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2023, 2022 and 2021, no impairment losses have been recorded.
 
  j.
Restricted cash and Other long-term assets:
 
Other long-term assets include long-term prepaid expenses and restricted cash deposits for offices and cars leasing based upon the term of the remaining restrictions.
 
  k.
Treasury shares
 
The Company repurchased its ordinary shares and holds them as treasury shares. The Company presents the cost to repurchase treasury shares as a reduction of shareholders' equity.

 

F - 13


 

  l.
Revenue Recognition:
 
The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to clinics and rehabilitation centres, professional and college sports teams, private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), and distributors.
 
The Company recognizes revenue in accordance with ASC 606, “Revenue Recognition” when, or as, control of the promised good or service is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company applies the following five steps:
 
  1.
Identify the contract with a customer
 
The Company generally considers a purchase order or a signed quote to be a contract with a customer. In evaluating the contract with a customer, the Company analyzes the customer’s intent and ability to pay the amount of promised consideration (credit risk) and considers the probability of collecting substantially all of the consideration.
 
  2.
Identify the performance obligations in the contract
 
At a contract’s inception, the Company assesses the goods or services promised in a contract with a customer and identifies the performance obligations.
 
  3.
Determine the transaction price
 
The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring products or services to the customer.
 
The Company does not offer extended payment terms beyond one year to customers.
 
  4.
Allocate the transaction price to performance obligations in the contract
 
If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.
 
  5.
Recognize revenue when or as the Company satisfies a performance obligation
 
Revenue is recognized when or as performance obligations are satisfied by transferring control of a promised good or service to a customer. Control either transfers over time or at a point in time, which affects when revenue is recorded.
 
The Company has elected to apply the practical expedient for financing component for transactions in which the difference between the payment date and the revenue recognition timing is up to 12 months.
 
Disaggregation of Revenue (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Product
 
$
10,681
   
$
4,175
   
$
4,916
 
Rental
   
1,033
     
859
     
533
 
Service and warranty
   
2,140
     
477
     
517
 
Total Revenues
 
$
13,854
   
$
5,511
   
$
5,966
 
 
Product revenue
 
Revenue from Products is comprised of sale of Anti-Gravity products, sale of systems products to rehabilitation facilities and sale of ReWalk Personal Exoskeleton systems to end users. Revenues generated from the sale of Products are recognized at a point in time, once the customer has obtained the legal title to the items purchased.
 
For systems sold to rehabilitation facilities, the Company includes insignificant training and considers the elements in the arrangement to be a single performance obligation. Therefore, the Company recognizes revenue for the system only when control is transferred after delivery and when the training has been completed, in accordance with the agreements terms with the customer.

 

F - 14


 

For sales of ReWalk Personal Exoskeleton systems to end users, and for sales of ReWalk Personal or ReWalk Rehabilitation Exoskeleton systems to third party distributors, the Company does not provide training to the end user as this training is completed by the rehabilitation center or by the distributor that have previously completed the ReWalk Training program. Therefore, the Company recognizes revenue in such sales upon delivery.
 
The Company generally does not grant a right of return for its products. In rare circumstances when the Company provides a right of return for its products. the Company records reductions to revenue for expected future product returns based on the Company’s historical experience and estimates.
 
During 2023, the Company offered six products: (1) ReWalk Personal Exoskeletons, (2) ReWalk Rehabilitation Exoskeleton, (3) ReStore, (4) AlterG Anti-Gravity systems, (5) MyoCycle and (6) MediTouch. Due to unsatisfactory sales performance of the MediTouch product lines, the Company terminated this agreement as of January 31, 2023.
 
Rental revenue
 
Rental revenue for the AlterG Anti-Gravity systems is accounted for under ASC Topic 842, Leases. The Company rents its products to customers for a fixed monthly fee over the rental term, which typically ranges from 2 to 3 years. Rental revenues are recorded as earned on a monthly basis. See Note 2x for additional information.
 
For the SCI Products, the Company also offers a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee for a limited period prior to selling its products.
 
Service and warranties
 
The Company services its products after expiration of the initial warranty. Service revenue, consisting of time and materials to perform the repairs, is recorded as services are rendered.
 
Determining the transaction price requires of level judgment, which is discussed by revenue category in further detail below.
 
Warranties are classified as either an assurance type or a service type warranty. A warranty is considered an assurance type warranty if it provides the customer with assurance that the product will function as intended for a limited period of time. An assurance type warranty is not accounted for as a separate performance obligation under the revenue model.
 
SCI Products include a five -year warranty. The first two years are considered as an assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. A service type warranty is either sold with a unit or separately for a unit for which the warranty has expired. A service type warranty is accounted as a separate performance obligation and revenue is recognized ratably over the life of the warranty.
 
The ReStore device is sold with a two-year warranty which is considered as assurance type warranty.
 
The Distributed Products are sold with assurance type warranty ranging between three years to ten years, depending on the specific product and part.
 
For AlterG Anti-Gravity Products, the Company offers customers extended warranty contracts that extend or enhance the technical support, parts, and labor coverage offered as part of the base warranty included with the Anti-Gravity system products. Extended warranty revenue is recognized ratably over the extended warranty coverage period. The Company offers a one-year assurance type warranty to customers in the U.S. and two years assurance type warranty for spare parts only to its international distributors. For these products, the Company determines standalone selling price based on the price at which the performance obligation is sold separately.

 

F - 15


 

Contract balances (in thousands):
 
 
 
December 31,
   
December 31,
 
 
 
2023
   
2022
 
Trade receivable, net of credit losses (1)
 
$
3,120
   
$
1,036
 
Deferred revenues (1) (2)
 
$
3,010
   
$
1,191
 
 
  (1)
Balance presented net of unrecognized revenue that was not yet collected.
 
  (2)
$435 thousands of the December 31, 2022 deferred revenue balance was recognized as revenue during the year ended December 31, 2023.
 
Deferred revenue which represent a contract liability, include unearned amounts related to service type warranty obligations as well as other advances and payments which the Company received from customers prior to satisfying the performance obligation, for which revenue has not yet been recognized. The Company's unearned performance obligations as of December 31, 2023 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $3.1 million, which will be fulfilled over one to five years.
 
  m.
Accounting for Share-Based Compensation:
 
The Company accounts for share-based compensation in accordance with ASC 718, “Compensation-Stock Compensation” (“ASC 718”). ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model (“OPM”). The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations.
 
The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. The Company account for forfeitures as they occur.
 
The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its share-option awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary share, expected share price volatility and the expected option term. Expected volatility is calculated based on actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options, or based on certain peer companies that the Company considered to be comparable, in case there is no sufficient trading volume to rely on market volatility. The expected option term is determined based on the simplified method, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.
 
The fair value of Restricted Stock Units (“RSUs”) granted is determined based on the price of the Company’s ordinary shares on the date of grant.
 
The Company accounts for options granted to consultants and other service providers under ASC 718. The fair value of these options was estimated using a Black-Scholes-Merton option-pricing model.
 
  n.
Warrants to Acquire Ordinary Shares:
 
During the twelve -month ended December 31, 2021, the Company issued warrants to acquire up to 15,083,611 ordinary shares. There were no issued warrants during the twelve months ended December 31, 2023 and 2022. The Company assessed the warrants pursuant to ASC 480 "Distinguishing Liabilities from Equity" and ASC 815 "Derivatives and Hedging" and determined that the warrants should be accounted for as equity and not as a derivative liability. Refer to Note 9f for additional information.
 
  o.
Research and Development Costs:
 
Research and development costs are charged to the consolidated statement of operations as incurred and are presented net of the amount of any grants the Company received for research and development in the period in which the grant was received.

 

F - 16


 

  p.
Income Taxes
 
The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”), using the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized.
 
ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits in its taxes on income. As of December 31, 2023, and 2022, the Company did not identify any significant uncertain tax positions.
 
  q.
Warranty provision:
 
For assurance-type warranty, the Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.
 
 
 
US Dollars
in
thousands
 
Balance at December 31, 2022
 
$
92
 
AlterG acquisition – see note 5
   
535
 
Provision
   
200
 
Usage
   
(479
)
Balance at December 31, 2023
 
$
348
 
 
  r.
Concentrations of Credit Risks:
 
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables.
 
The Company’s cash and cash equivalents are deposited in major banks in Israel, the United States and Germany. Such deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. The Company maintains cash and cash equivalents with diverse financial institutions and monitors the amount of credit exposure to each financial institution. The bank deposits are held in financial institutions which management believes are institutions with high credit standing, and accordingly, minimal credit risk from geographic or credit concentration exists with respect to these deposits.
 
The below table reflects the concentration of credit risk for the Company’s current customers as of December 31, 2023, to which substantial sales were made.
 
Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales.
 
 
 
December 31,
 
 
 
2023
   
2022
 
Customer A
   
*
)%
   
27
%
Customer B
   
*
)%
   
13
%
Customer C
   
-
     
13
%
Customer D
   
-
     
11
%
 
  *)
Less than 10%

 

F - 17


 

The allowance for credit losses is based on the Company's assessments of factors that may affect a customer's ability to pay. The Company regularly reviews the adequacy of the allowance for credit losses based on a combination of factors, including an assessment of the current customer's aging balance, the nature and size of the customer, the financial condition of the customer, and the amount of any receivables in dispute. The Company does not have any off-balance sheet credit exposure related to its customers. As of December 31, 2023, and 2022 trade receivables are presented net of $328 thousand and $26 thousand allowance for credit losses, respectively.
 
  s.
Accrued Severance Pay:
 
Pursuant to Israel’s Severance Pay Law, Israeli employees are entitled to severance pay equal to one month’s salary for each year of employment, or a portion thereof. All of the employees of the RRL elected to be included under section 14 of the Severance Pay Law, 1963 (“section 14”). According to this section, these employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet.
 
Total Company’s expenses related to severance pay amounted to $114 thousand , $113 thousand and $104 thousand for the years ended December 31, 2023, 2022 and 2021, respectively.
 
  t.
Fair Value Measurements:
 
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a three -tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The three -tiers are defined as follows:
 
 
Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities;
 
 
Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
 
 
Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.
 
The carrying amounts of cash and cash equivalents, short term deposits, trade receivables and trade payables approximate their fair value due to the short-term maturity of such instruments.
 
The following tables present information about the Company’s financial assets and liabilities that are measured in fair value on a recurring basis as of December 31, 2023 and December 31, 2022 (in thousands):
 
       
Fair value measurements as of
 
Description
 
Fair Value Hierarchy
 
December 31, 2023
   
December 31,
2022
 
Financial assets:
               
                 
Money market funds included in cash and cash equivalent
 
Level 1
 
$
2,550
   
$
-
 
Treasury bills included in cash and cash equivalent
 
Level 1
 

$

2,525
   

$

-
 
                     
Total Assets Measured at Fair Value
     
$
5,075
   
$
-
 
                     
Financial Liabilities:
                   
Earnout
 
Level 3
 
$
3,292
   
$
-
 
                     
Total liabilities measured at fair value
     
$
3,292
   
$
-
 

 

F - 18


 

The Company classifies cash equivalents within Level 1, because the Company uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair values.
 
The earnout was valued using a Monte Carlo simulation analysis, which is considered to be a Level 3 fair value measurement.
 
The following table summarizes the earnout liability activity as of December 31, 2023 (in thousands):
 
   
Earnout
   
Initial Measurement (August 11, 2023)
 
$
3,607
   
Change in fair value
   
(315)
   
Balance December 31, 2023
 
$
3,292
   
 
u. Basic and Diluted Net Loss Per Share:
 
Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding during the period.
 
Diluted loss per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus dilutive potential shares considered outstanding during the period.
 
v. Contingent liabilities
 
The Company accounts for its contingent liabilities in accordance with ASC 450, “Contingencies.” A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
 
With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.
 
w. Government grants
 
Royalty and non-royalty-bearing grants from the Israeli Innovation Authority (the “IIA”) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a reduction from research and development expenses (see Note 8c).

 

F - 19


 

x. Leases
 
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded at commencement date based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.
 
Leases with an initial term of 12 months or less are not recorded on the balance sheet.
 
Lessor accounting - Operating leases
 
A portion of the AlterG rental revenues for the AlterG Anti-Gravity systems are made through lease arrangements.
 
AlterG products are available for lease agreements ranging from 12 to 42 months. If the customer terminates the contract during the lease period, they are required to pay a cancellation fee. The lease period may be extended by an additional period as specified in the contract.
 
In determining the leases classification as a sales type or operating lease, the Company assesses, among other criteria: (i) the lease term to determine if it is for the major part of the economic life of the underlying equipment; and (ii) the present value of the lease payments to determine if they are equal to or greater than substantially all of the fair market value of the equipment at the inception of the lease AlterG Anti-Gravity systems. When these criteria are not met, the lease accounted for as operating leases and revenues are recognized over the term of the lease.
 
Under these arrangements, when the Company acts as the lessor for its product line, the Company accounted for the lease arrangements as operating leases in accordance with ASC 842, “Lease” (“ASC 842”).
 
The total rental revenue for the AlterG Anti-Gravity Products has amounted to $249 thousand from the time of acquisition through December 31, 2023.
 
y.  New Accounting Pronouncements
 
Recently Implemented Accounting Pronouncements
 
i.           Financial Instruments
 
In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. The Company adopted ASU 2016-13 as of January 1, 2023. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.
 
Recent Accounting Pronouncements Not Yet Adopted
 
 
i.
In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes - Improvements to Income Tax Disclosures” requiring enhancements and further transparency to certain income tax disclosures, most notably the tax rate reconciliation and income taxes paid. This ASU is effective for fiscal years beginning after December 15, 2024 on a prospective basis and retrospective application is permitted. The Company is currently evaluating the impact of the adoption of this standard.
 
 
ii.
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, “Segment Reporting” on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.

 

F - 20


 

NOTE 3:-
PREPAID EXPENSES AND OTHER CURRENT ASSETS
 
The components of prepaid expenses and other current assets are as follows (in thousands):
 
 
 
December 31,
 
 
 
2023
   
2022
 
Government institutions
 
$
253
   
$
81
 
Prepaid expenses
   
1,227
     
242
 
Advances to vendors
   
139
     
174
 
Other assets
   
747
     
152
 
 
               
 
 
$
2,366
   
$
649
 

 

NOTE 4:-
INVENTORIES
 
The components of inventories are as follows (in thousands):
 
 
 
December 31,
 
 
 
2023
   
2022
 
Finished products
 
$
3,157
   
$
2,421
 
Raw materials
   
2,496
     
508
 
 
               
 
 
$
5,653
   
$
2,929
 
 
During the twelve months ended December 31, 2023, 2022, and 2021, the Company recognized, at cost of revenues, reserves for excess and obsolete in the amount of $398 thousand, $502 thousand, and $252 thousand, respectively.

 

F - 21


 

NOTE 5:- BUSINESS COMBINATION
 
On August 11, 2023, pursuant to an Agreement and Plan of Merger among RRI, AlterG, Merger Sub, and Shareholder Representative Services LLC, RRI, August 8, 2023, the Company acquired AlterG and AlterG became a wholly owned subsidiary of the Company. AlterG develops, manufactures, and markets Anti-Gravity systems for use in physical and neurological rehabilitation and athletic training, both in the United States and internationally. The aggregate purchase price was a total of $19.0 million in cash, subject to working capital and other customary purchase price adjustments. Additional cash earnouts may be paid based upon a percentage of AlterG’s year-over-year future revenue growth over the next two years subject to working capital and other customary purchase price adjustments.
 
The total consideration transferred is as follows (in thousands):
 
Cash
 
$
18,493
 
Earnout payments
 
$
3,607
 
Total consideration
 
$
22,100
 
 
Earnout payments
 
The Company will pay an amount of cash equal to 65% of the amount, if any, by which AlterG revenue attributable to the first 12 months period exceeds revenue target ("first earnout payment"), and an amount in cash equal to 65% of the amount, if any, by which AlterG revenue attributable to the following 12 months period exceeds the revenue from the first 12 month period ("second earnout payment"). At the date of acquisition, management estimated fair value of the earnout payment based on the actual up to date performance of the acquired entity and the probability of the earn out payment occurrence to be at approximately $3.6 million. The Earn-out was accounted for as a liability and will be remeasured at each reporting period through the consolidated statement of operations.
 
The Company has accounted for the AlterG acquisition as a business combination. The Company has preliminarily allocated the purchase price of approximately $22.1 million fair values, and the excess of the purchase price over the aggregate fair values is recorded as goodwill.
 
The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date (in thousands):
 
Cash and cash equivalent
 
$
478
 
Restricted cash
   
51
 
Accounts receivable
   
1,773
 
Inventory
   
3,330
 
Prepaid expenses and other current assets
   
470
 
Right of use asset
   
1,151
 
Property and equipment, net
   
827
 
Other non-current assets
   
30
 
Goodwill
   
7,538
 
Intangible assets
   
14,133
 
Accounts payable
   
(2,082
)
Accrued compensation
   
(766
)
Other accrued liabilities
   
(1,059
)
Deferred revenue
   
(2,088
)
Warranty Obligations
   
(535
)
Leases Liability
   
(1,151
)
Total purchase consideration
 
$
22,100
 

 

F - 22


 

The following table presents the details of the intangible assets acquired at the date of AlterG acquisition (in thousands):
 
   
 
Estimated
   
Estimated Useful Life
 
   
Fair Value
   
(Years)
 
Trademark
 
$
795
     
3
 
Technology
   
6,161
     
4
 
Customer relationship - Warranty
   
201
     
2
 
Customer relationship - Rental
   
2,102
     
4
 
Customer relationship - Distribution
   
4,578
     
5
 
Backlog
   
296
     
1
 
 
Under the preliminary purchase price allocation, the Company allocates the purchase price to tangible and identified intangible assets acquired and liabilities assumed based on the preliminary estimates of their fair values. The fair values for the intangible assets acquired were primarily based on significant inputs that are not observable in the market and thus represent a Level 3 measurement in the fair value hierarchy. Customer relationships, distributor relationships, backlog, trademark and developed technology were valued using the income approach, based on estimated projections of expected cash flows to be generated by the assets, discounted to the present value at discount rates commensurate with perceived risk. The discounted cash flow analyses factor in assumptions on revenue and expense growth rates including estimates of customer growth and attrition rates, distributor growth and attrition rates, technology obsolescence, and relief from royalty projections. Additionally, these discounted cash flow analyses factor in expected amounts of working capital, fixed assets, assembled workforce and cost of capital for each intangible asset. Such estimates are subject to change during the measurement period which is not expected to exceed one year. Any adjustments to the preliminary purchase price allocation identified during the measurement period will be recognized in the period in which the adjustments are determined.
 
The Company incurred acquisition-related costs of $2.5 million included in General and administrative costs.
 
The table below presents the pro forma revenue and earnings of the combined business as if the acquisition had occurred as of January 1, 2022 (in thousands):
 
   
Twelve Months Ended
December 31,
 
   
2023
   
2022
 
Revenues
   
24,923
     
25,307
 
Net loss
   
(21,761
)
   
(28,369
)
 
The total revenues and net loss of AlterG, included in the consolidated income statement, since the acquisition date through December 31, 2023, amounted to 7,658 thousand and 249 thousand, respectively.
 
The pro forma financial information for all periods presented above has been calculated after adjusting the results of AlterG to reflect the business combinations accounting effects resulting from these acquisitions.
 
These proforma results reflect additional depreciation and amortization that would have been charged assuming the fair value adjustments to property, plant, and equipment and intangible asset occurred at the beginning of the period, along with consequential tax effects. The unaudited pro forma results have been prepared for comparative purposes only and are not necessarily indicative of what would have occurred had the business combinations been completed on January 1, 2022, nor it is necessarily indicative of future results of operations of the combined company. Furthermore, the unaudited pro forma financial information does not reflect the impact of any synergies resulting from the acquisition.

F - 23


 

NOTE 6:- GOODWILL AND OTHER INTANGIBLE ASSETS, NET
 
The Company has $7.5 million of goodwill related to its purchase of AlterG in the third quarter of fiscal year 2023, which has an indefinite life, and is not deductible for tax purposes.
 
As of December 31, 2023, the components of, and changes in, the carrying amount of intangible assets, net, were as follows (in thousands):
 
   
 
 
Cost
   
December 31, 2023 Accumulated
Amortization
   
 
Intangible Assets, Net
 
Trademark
   
795
     
(104
)
   
691
 
Technology
   
6,161
     
(604
)
   
5,557
 
Customer relationship - Warranty
   
201
     
(40
)
   
161
 
Customer relationship - Rental
   
2,102
     
(206
)
   
1,896
 
Customer relationship - Distribution
   
4,578
     
(358
)
   
4,220
 
Backlog
   
296
     
(296
)
   
-
 
Total Amortized Intangible Assets
   
14,133
     
(1,608
)
   
12,525
 

 

The estimated amortization expense is shown below (in thousands):

 

Fiscal 2024
                   
3,347
 
Fiscal 2025
                   
3,307
 
Fiscal 2026
                   
3,143
 
Fiscal 2027
                   
2,172
 
Fiscal 2028
                   
556
 
Total
                   
12,525
 
 
NOTE 7:-
PROPERTY AND EQUIPMENT, NET
 
The components of property and equipment, net are as follows (in thousands):
 
 
 
December 31,
 
 
 
2023
   
2022
 
Cost:
           
Computer equipment
 
$
1,690
   
$
743
 
Office furniture and equipment
   
468
     
308
 
Machinery and laboratory equipment
   
621
     
621
 
Field service units
   
4,166
     
1,816
 
Leasehold improvements
   
658
     
333
 
 
               
 
 
$
7,603
   
$
3,821
 
 
 
 
December 31,
 
 
 
2023
   
2022
 
Accumulated depreciation
   
6,341
     
3,625
 
 
               
Property and equipment, net
 
$
1,262
   
$
196
 
 
Depreciation expenses amounted to $239 thousand, $202 thousand, and $266 thousand for the years ended December 31, 2023, 2022 and 2021, respectively.

 

F - 24


 

NOTE 8:-
COMMITMENTS AND CONTINGENT LIABILITIES
 
  a.
Purchase commitment:
 
The Company has contractual obligations to purchase goods from its contract manufacturer as well as raw materials from different vendors. Purchase obligations do not include contracts that may be cancelled without penalty. As of December 31, 2023, non-cancellable outstanding obligations amounted to approximately $8.6 million.
 
  b.
Operating lease commitment:
 
  (i)
The Company operates from leased facilities in Israel, the United States and Germany. These leases expire between 2024 and 2025. A portion of the Company’s facilities leases is generally subject to annual changes in the Consumer Price Index (CPI). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred.
 
  (ii)
RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates in between 2024 and 2026 A subset of the Company’s cars leases is considered variable. The variable lease payments for such cars leases are based on actual mileage incurred at the stated contractual rate. RRL and RRG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $30 thousand as of December 31, 2023.
 
The Company’s future lease payments for its facilities and cars, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company’s consolidated balance sheets as of December 31, 2023 are as follows (in thousands):
 
2024
 
$
1,363
 
2025
   
674
 
2026
   
13
 
Total lease payments
   
2,050
 
Less: imputed interest
   
(147
)
Present value of future lease payments
   
1,903
 
Less: current maturities of operating leases
   
(1,296
)
Non-current operating leases
 
$
607
 
Weighted-average remaining lease term (in years)
   
1.92
 
Weighted-average discount rate
   
9.21
%
 
Total lease expenses for the years ended December 31, 2023, 2022 and 2021 were $976 thousand, $739 thousand, and $730 thousand, respectively.
 
  c.
Royalties:
 
The Company’s research and development efforts are financed, in part, through funding from the Israel Innovation Authority (“IIA”). Since the Company’s inception through December 31, 2023, the Company received funding from the IIA in the total amount of $2.6 million. Out of the $2.6 million in funding from the IIA, a total amount of $1.6 million were royalty-bearing grants, $400 thousand was received in consideration of 209 convertible preferred A shares, which converted after the Company’s initial public offering in September 2014 into ordinary shares in a conversion ratio of 1 to 1, while $570 thousand was received without future obligation. The Company is obligated to pay royalties to the IIA, amounting to 3% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required.
 
As of December 31, 2023, the Company paid royalties to the IIA in the total amount of $110 thousand.
 
Royalties expenses in cost of revenue were $17 thousand, $7 thousand and $14 thousand, for the years ended December 31, 2023, 2022 and 2021, respectively.
 
As of December 31, 2023, the contingent liability to the IIA amounted to $1.6 million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel.
 
Additionally, the License Agreement requires the Company to pay College (“Harvard”) royalties on net sales, see Note 10 below for more information about the Collaboration Agreement (as defined below) and the License Agreement (as defined below).

 

F - 25


 

  d.
Liens
 
As part of the Company’s restricted cash and other long-term assets, as of December 31, 2023, an amount of $709 thousand has been pledged as security in respect of a guarantee granted to a third party. Such deposit cannot be pledged to others or withdrawn without the consent of such third party.
 
  e.
Legal Claims:
 
Occasionally, the Company is involved in various claims such as product liability claims, lawsuits, regulatory examinations, investigations, and other legal matters arising, for the most part, in the ordinary course of business. While the outcome of any pending or threatened litigation and other legal matters is inherently uncertain, the Company does not believe the outcome of any of the matters will have a material adverse effect on the Company’s consolidated results of operation, liquidity or financial condition.

 

NOTE 9:-
SHAREHOLDERS’ EQUITY
 
  a.
Equity raise:
 
Follow-on offerings
 
On February 19, 2021, the Company entered into a purchase agreement with certain institutional and other accredited investors for the issuance and sale of 10,921,502 ordinary shares, par value NIS 0.25 per share at $3.6625 per ordinary share and warrants to purchase up to an aggregate of 5,460,751 ordinary shares with an exercise price of $3.6 per share, exercisable from February 19, 2021, until August 26, 2026. Additionally, the Company issued warrants to purchase up to 655,290 ordinary shares, with an exercise price of $4.578125 per share, exercisable from February 19, 2021, until August 26, 2026, to the Company February 2021 private placement offering.
 
On September 27, 2021, the Company signed a purchase agreement with certain institutional investors for the issuance and sale of 15,403,014 ordinary shares, par value NIS 0.25 per share, pre-funded warrants to purchase up to an aggregate of 610,504 ordinary shares and ordinary warrants to purchase up to an aggregate of 8,006,759 ordinary shares at an exercise price of $2.00 per share. The Pre-Funded Warrants have an exercise price of $0.001 per Ordinary Share and are immediately exercisable and can be exercised at any time after their original issuance until such pre-funded warrants are exercised in full. Each ordinary shares was sold at an offering price of $2.035 and each pre-funded warrant was sold at an offering price of $2.034 (equal to the purchase price per ordinary share minus the exercise price of the pre-funded warrant). The ordinary warrants are exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending five and one-half years from the date of issuance. All of the pre-funded warrants were exercised in full on September 27, 2021, and the offering closed on September 29, 2021. Additionally, the Company issued warrants to purchase up to 960,811 ordinary shares, with an exercise price of $2.5438 per share, exercisable from September 27, 2021, until September 27, 2026, to the Company September 2021 registered direct offering.
 
As of December 31, 2023, a total of 9,814,754 outstanding warrants with exercise prices ranging from $1.25 to $1.79 were exercised, for total gross proceeds of approximately $13.8 million. During the twelve months that ended December 31, 2023 no warrants were exercised.
 
  b.
Share option plans:
 
On March 30, 2012, the Company’s board of directors adopted the ReWalk Robotics Ltd. 2012 Equity Incentive Plan.
 
On August 19, 2014, the Company’s board of directors adopted the ReWalk Robotics Ltd. 2014 Incentive Compensation Plan or the “Plan”. The Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, cash-based awards, other stock-based awards and dividend equivalents to the Company’s and its affiliates’ respective employees, non-employee directors and consultants.

 

F - 26


 

Starting in 2014, the Company grants to directors and employees also RSU under this Plan. An RSU award is an agreement to issue shares of the company’s ordinary shares at the time the award is vested.
 
As of December 31, 2023 and 2022, the Company had reserved 1,018,945 and 2,934,679 shares of ordinary shares, respectively, available for issuance to employees, directors, officers, and non-employees of the Company.
 
The options generally vest over four years, with certain options granted to non-employee directors vesting over one year.
 
Any option or RSUs that are forfeited or cancelled before expiration becomes available for future grants under the Plan.
 
A summary of employee and non-employee shares options activity during the fiscal year ended 2023 is as follows:
 
 
 
Number
   
Weighted
average
exercise
price
   
Weighted
average
remaining
contractual
life (years)
   
Aggregate
intrinsic
value (in
thousands)
 
Options outstanding at the beginning of the year
   
43,994
   
$
41.27
     
4.39
   
$
-
 
Granted
   
-
     
-
     
-
     
-
 
Exercised
   
-
     
-
     
-
     
-
 
Forfeited
   
(10,823
)
   
52.78
     
-
     
-
 
 
                               
Options outstanding at the end of the year
   
33,171
   
$
37.51
     
4.39
   
$
-
 
 
                               
Options exercisable at the end of the year
   
33,171
   
$
37.51
     
4.39
   
$
-
 
 
There were no options granted during the fiscal year ended December 31, 2023, 2022 and 2021. The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders, which hold options with positive intrinsic value, exercised their options on the last date of the exercise period. During the years ended December 31, 2023, 2022 and 2021, no options were exercised.
 
A summary of employee and non-employee RSUs activity during the fiscal year ended 2023 is as follows:
 
 
 
Number of
shares
underlying
outstanding
RSUs
   
Weighted-
average
grant date
fair value
 
Unvested RSUs at the beginning of the year
   
2,755,057
     
1.16
 
Granted
   
2,258,370
     
0.66
 
Vested
   
(1,109,200
)
   
1.14
 
Forfeited
   
(131,813
)
   
1.13
 
 
               
Unvested RSUs at the end of the year
   
3,772,414
     
0.87
 
 
The weighted average grant date fair values of RSUs granted during the fiscal year ended December 31, 2023, 2022 and 2021, were $0.66, $1.00 and $1.69, respectively.
 
Total fair value of shares vested during the year ended December 31, 2023, 2022 and 2021 were $1,268 thousand, $860 thousand, and $802 thousand, respectively. As of December 31, 2023, there were $2.7 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2014 Plan. This cost is expected to be recognized over a period of approximately 2.9 years.
 

F - 27


 

The number of options and RSUs outstanding as of December 31, 2023 is set forth below, with options separated by range of exercise price:
 
Range of exercise price
 
Options and
RSUs
Outstanding
as of
December 31,
2023
 
 
Weighted
average
remaining
contractual
life
(years) (1)
 
 
Options
Exercisable
as of
December 31,
2023
 
 
Weighted
average
remaining
contractual
life
(years) (1)
 
RSUs only
 
 
3,772,414
 
 
 
-
 
 
 
-
 
 
 
-
 
$5.37 
 
 
12,425
 
 
 
5.24
 
 
 
12,425
 
 
 
5.24
 
$20.42- $33.75 
 
 
12,943
 
 
 
4.35
 
 
 
12,943
 
 
 
4.35
 
$50-$52.5 
 
 
6,230
 
 
 
3.46
 
 
 
6,230
 
 
 
3.46
 
$182.5-$524.25 
 
 
1,573
 
 
 
1.65
 
 
 
1,573
 
 
 
1.65
 
 
 
 
3,805,585
 
 
 
4.39
 
 
 
33,171
 
 
 
4.39
 
 
 
(1)
Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

 

  c.
Equity compensation issued to consultants:
 
The Company granted 32,895 RSUs during the fiscal year ended December 31, 2023, to non-employee consultants. As of December 31, 2023, there are 21,929 outstanding RSUs held by non-employee consultants.
 
  d.
Share-based compensation expense for employees and non-employees:
 
The Company recognized share-based compensation expense in the consolidated statements of operations as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Cost of revenue
 
$
9
   
$
16
   
$
10
 
Research and development, net
   
157
     
94
     
55
 
Sales and marketing
   
381
     
250
     
171
 
General and administrative
   
781
     
633
     
597
 
 
                       
Total
 
$
1,328
   
$
993
   
$
833
 

 

  e.
Treasury shares:
 
On June 2, 2022, the Company’s Board of Directors approved a share repurchase program to repurchase up to $8.0 million of its Ordinary Shares, par value NIS 0.25 per share. On July 21, 2022, the Company received approval from an Israeli court for the share repurchase program. The program was scheduled to expire on the earlier of January 20, 2023, or reaching $8.0 million of repurchases. On December 22, 2022, the Company’s Board of Directors approved an extension of the repurchase program, with such extension to be in the aggregate amount of up to $5.8 million. The extension was approved by an Israeli court on February 9, 2023, and it expired on August 9, 2023.
 
As of December 31, 2023, pursuant to the Company’s share repurchase program, the Company had repurchased a total of 4,022,607 of its outstanding ordinary shares at a total cost of $3.5 million.

 

F - 28


 

  f.
Warrants to purchase ordinary shares:
 
The following table summarizes information about warrants outstanding and exercisable as of December 31, 2023:
 
Issuance date
 
Warrants
outstanding
   
Exercise price
per warrant
   
Warrants
outstanding
and
exercisable
 
Contractual
term
 
 
(number)
         
(number)
 
 
December 31, 2015 (1)
   
4,771
   
$
7.500
     
4,771
 
See footnote (1)
December 28, 2016 (2)
   
1,908
   
$
7.500
     
1,908
 
See footnote (1)
February 25, 2019 (5)
   
45,600
   
$
7.187
     
45,600
 
February 21, 2024
April 5, 2019 (6)
   
408,457
   
$
5.140
     
408,457
 
October 7, 2024
April 5, 2019 (7)
   
49,015
   
$
6.503
     
49,015
 
April 3, 2024
June 5, 2019, and June 6, 2019 (8)
   
1,464,665
   
$
7.500
     
1,464,665
 
June 5, 2024
June 5, 2019 (9)
   
87,880
   
$
9.375
     
87,880
 
June 5, 2024
June 12, 2019 (10)
   
416,667
   
$
6.000
     
416,667
 
December 12, 2024
June 10, 2019 (11)
   
50,000
   
$
7.500
     
50,000
 
June 10, 2024
February 10, 2020 (12)
   
28,400
   
$
1.250
     
28,400
 
February 10, 2025
February 10, 2020 (13)
   
105,840
   
$
1.563
     
105,840
 
February 10, 2025
July 6, 2020 (14)
   
448,698
   
$
1.760
     
448,698
 
January 2, 2026
July 6, 2020 (15)
   
296,297
   
$
2.278
     
296,297
 
January 2, 2026
December 8, 2020 (16)
   
586,760
   
$
1.340
     
586,760
 
June 8, 2026
December 8, 2020 (17)
   
108,806
   
$
1.792
     
108,806
 
June 8, 2026
February 26, 2021 (18)
   
5,460,751
   
$
3.600
     
5,460,751
 
August 26, 2026
February 26, 2021 (19)
   
655,290
   
$
4.578
     
655,290
 
August 26, 2026
September 29, 2021 (20)
   
8,006,759
   
$
2.000
     
8,006,759
 
March 29, 2027
September 29, 2021 (21)
   
960,811
   
$
2.544
     
960,811
 
September 27, 2026
 
   
19,187,375
             
19,187,375
 
 
 
  (1)
Represents warrants for ordinary shares issuable upon an exercise price of $7.500 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2023.
 
  (2)
Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.
 
  (3)
Represents common warrants that were issued as part of the Company’s follow-on public offering in November 2018.
 
  (4)
Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on public offering in November 2018.
 
  (5)
Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on public offering in February 2019.
 
  (6)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019.
 
  (7)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering.

 

F - 29


 

  (8)
Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively.
 
  (9)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants.
 
  (10)
Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.
 
  (11)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants.
 
  (12)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of December 31, 2023, 3,740,100 warrants were exercised for total consideration of $4,675,125. During the twelve months that ended December 31, 2023, no warrants were exercised.
 
  (13)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of December 31, 2023, 230,160 warrants were exercised for total consideration of $359,625. During the twelve months that ended December 31, 2023, no warrants were exercised.
 
  (14)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in July 2020. As of December 31, 2023, 2,020,441 warrants were exercised for total consideration of $3,555,976. During the twelve months that ended December 31, 2023, no warrants were exercised.
 
  (15)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering.
 
  (16)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s private placement offering of ordinary shares in December 2020. As of December 31, 2023, 3,598,072 warrants were exercised for total consideration of $4,821,416. During the twelve months that ended December 31, 2023, no warrants were exercised.
 
  (17)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of December 31, 2023, 225,981 warrants were exercised for total consideration of $405,003. During the twelve months that ended December 31, 2023, no warrants were exercised.
 
  (18)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s private placement offering of ordinary shares in February 2021.
 
  (19)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement.
 
  (20)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in September 2021.
 
  (21)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.

 

NOTE 10:-
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT
 
On May 16, 2016, the Company entered into a Collaboration Agreement (as amended, the “Collaboration Agreement”) and an Exclusive License Agreement (as amended, the “License Agreement”) with Harvard. The Collaboration Agreement concluded on March 31, 2022.
 
Under the License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration.

 

F - 30


 

The License Agreement required the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The Harvard License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents.
 
As of December 31, 2023, the Company achieved three of the milestones which represent all development milestones under the License Agreement. The Company continues to evaluate the likelihood that the other milestones will be achieved on a quarterly basis.
 
The Company has recorded expenses in the amount of $29 thousand, $74 thousand, and $293 thousand as research and development expenses related to the License Agreement and to the Collaboration Agreement for the years ended December 31, 2023, 2022 and 2021, respectively. No withholding tax was deducted from the Company’s payments to Harvard in respect of the Collaboration Agreement and the License Agreement since this is not taxable income in Israel in accordance with Section 170 of the Israel Income Tax Ordinance 1961-5721.

 

NOTE 11:-
INCOME TAXES
 
The Company’s subsidiaries are separately taxed under the domestic tax laws of the jurisdiction of incorporation of each entity.
 
a. Corporate tax rates in Israel:
 
Presented hereunder are the tax rates relevant to the Company in the years 2021-2023:
 
The Israeli statutory corporate tax rate and real capital gains were 23% in the years 2021-2023.
 
b. Income (loss) before taxes on income is comprised as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Domestic
 
$
(19,638
)
 
$
(19,110
)
 
$
(12,780
)
Foreign
   
(2,507
)
   
8
     
138
 
 
 
$
(22,145
)
 
$
(19,102
)
 
$
(12,642
)
 
c. Taxes on income (benefit) are comprised as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Current
 
$
(12
)
 
$
151
   
$
123
 
Deferred
   
-
     
316
     
(29
)
 
                       
   
$
(12
)
 
$
467
   
$
94
 
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Domestic
 
$
-
   
$
-
   
$
-
 
Foreign
   
(12
)
   
467
     
94
 
 
                       
 
 
$
(12
)
 
$
467
   
$
94
 

 

F - 31


 

d. Deferred income taxes (in thousands):
 
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets as of December 31, 2023 and 2022 are derived from temporary differences.
 
In assessing the realization of deferred tax assets, the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. Based on the Company’s history of losses, the Company established a full valuation allowance for RRL.
 
Undistributed earnings of certain subsidiaries as of December 31, 2023 were immaterial. The Company intends to reinvest these earnings indefinitely in the foreign subsidiaries. As a result, the Company has not provided for any deferred income taxes.
 
 
 
December 31,
 
 
 
2023
   
2022
 
Deferred tax assets:
           
Carry forward tax losses
 
$
64,090
   
$
50,833
 
Research and development carry forward expenses-temporary differences
   
1,311
     
844
 
Accrual and reserves
   
849
     
392
 
Share based compensation
   
394
     
456
 
Credit tax carry forwards
   
1,714
     
-
 
Lease liabilities
   
480
     
214
 
Total deferred tax assets
   
68,838
     
52,739
 
Deferred tax liabilities:
               
Right-of-use asset
   
(470
)
   
(214
)
Intangible Assets
   
(3,015
)
   
-
 
Property and equipment
   
(144
)
   
-
 
Net deferred tax assets
   
65,209
     
52,525
 
Valuation allowance
   
(65,209
)
   
(52,525
)
 
               
Net deferred tax assets
 
$
-
   
$
-
 
 
The net changes in the total valuation allowance for each of the years ended December 31, 2023, 2022 and 2021, are comprised as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Balance at beginning of year
 
$
(52,525
)
 
$
(48,098
)
 
$
(42,941
)
Changes due to exchange rate differences
   
-
     
1,418
     
(1,488
)
Adjustment previous year loss
   
(5
)    
(14
)
   
-
 
Acquisition
   
(7,269
)
   
-
     
-
 
Additions during the year
   
(5,410
)
   
(5,831
)
   
(3,669
)
 
                       
Balance at end of year
 
$
(65,209
)
 
$
(52,525
)
 
$
(48,098
)

 

F - 32


 

e. Reconciliation of the theoretical tax expenses:
 
A reconciliation between the theoretical tax expense, assuming all income is taxed at the statutory tax rate applicable to income of the Company, and the actual tax expense (benefit) as reported in the consolidated statements of operations is as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Loss before taxes, as reported in the consolidated statements of operations
 
$
(22,145
)
 
$
(19,102
)
 
$
(12,642
)
 
                       
Statutory tax rate
   
23
%
   
23.0
%
   
23.0
%
 
                       
Theoretical tax benefits on the above amount at the Israeli statutory tax rate
 
$
(5,093
)
 
$
(4,393
)
 
$
(2,908
)
Income tax at rate other than the Israeli statutory tax rate
   
56
     
(2
)
   
7
 
Non-deductible expenses including equity-based compensation expenses and other 
   
-
     
262
     
102
 
Operating losses and other temporary differences for which valuation allowance was provided
   
5,410
     
5,375
     
3,669
 
Permanent differences
   
(342
)
   
(775
)
   
(784
)
Adjustment in respect of prior years
   
(43
)
   
-
     
-
 
Other
   
-
     
-
     
8
 
 
                       
Actual tax expense (benefit)
 
$
(12
)
 
$
467
   
$
94
 
 
f. Foreign tax rates:
 
Taxable income of RRI and AlterG was subject to tax at the rate of 21% in 2023, 2022 and 2021.
 
Taxable income of RRG was subject to tax at the rate of 30% in 2023, 2022, and 2021.
 
g. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Investment Law”):
 
Conditions for entitlement to the benefits:
 
Under the Investment Law, in 2012 the Company elected “Beneficiary Enterprise” status which provides certain benefits, including tax exemptions and reduced tax rates. Income not eligible for Beneficiary Enterprise benefits is taxed at a regular rate.
 
Income derived from Beneficiary Enterprise from productive activity will be exempt from tax for ten years from the year in which the Company first has taxable income, providing that 12 years have not passed from the beginning of the year of election. In the event of a dividend distribution from income that is exempt from company tax, as aforementioned, the Company will be required to pay tax of 10%-25% on that income.
 
In the event of distribution of dividends from the said tax-exempt income, the amount distributed will be subject to corporate tax at the rate ordinarily applicable to the Beneficiary Enterprise’s income. Tax-exempt income generated under the Company’s “Beneficiary Enterprise” program will be subject to taxes upon dividend distribution or complete liquidation.
 
The entitlement to the above benefits is conditional upon the Company’s fulfilling the conditions stipulated by the Law and regulations published thereunder.
 
h. Tax assessments:
 
RRL, RRI and RRG has had final tax assessments up to and including the 2017 tax year.

 

F - 33


 

AlterG files income tax returns in the United States and in various U.S. states.  AlterG returns for the years ended December 31, 2020 and later are generally subject to federal tax examination, while the AlterG returns for the years ended December 31, 2019 and later are generally subject to state tax examination.  However, the AlterG net operating losses and tax credits generally remain subject to tax examination and adjustment until they are utilized on a future tax return and the statute of limitations closes for that year.  Thus, the AlterG tax attributes generally remain open to federal and state tax examination and adjustment.
 
i. Net operating carry-forward losses for tax purposes:
 
As of December 31, 2023, RRL has carry-forward losses amounting to approximately $242.6 million, which can be carried forward for an indefinite period.
 
As of December 31, 2023, AlterG had approximately $31.4 million of federal net operating loss (“NOL”) carry forwards, and $47.2 million of state NOL carry forwards, which will begin to expire in 2025 and 2028, respectively.  The federal net operating losses from years beginning after January 1, 2018, of approximately $14.7 million may be carried forward indefinitely and losses prior to January 1, 2018 of approximately $16.7 million expire beginning in 2028 under prior law.
 
Internal Revenue Code Section 382 places a limitation ("Section 382 Limitation") on the amount of taxable income which can be offset by NOL carry forwards after a change in control (generally greater than 50% change in the value of the stock owned by 5% shareholders during the testing period) of a loss corporation. California has similar rules. On August 11, 2023, AlterG was involved in an equity transaction that constitutes a Section 382 change in ownership. The change in ownership limits the ability to utilize net operating loss carry forwards in future years. The 382-limitation impact on NOLs has been included in the current period provision. The Company may have had earlier Section 382 changes in ownership. This will be assessed upon realization of tax attributes.

 

F - 34


 

NOTE 12:-
FINANCIAL (EXPENSES) INCOME, NET
 
The components of financial (expenses) income, net were as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Foreign currency transactions and other
 
$
133
   
$
22
   
$
38
 
Interest Income
   
1,354
     
-
     
-
 
Bank commissions
   
(20
)
   
(22
)
   
(25
)
 
                       
 
 
$
1,467
   
$
*
)
 
$
13
 
 
*) Represent an amount lower than $1.

 

NOTE 13:-
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA
 
The Company manages its business on a basis of one reportable segment.
 
Total revenues from external customers on the basis of the Company's geographical areas are as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Revenue based on customer’s location:
                 
United States
   
7,636
     
2,303
     
2,519
 
Europe
   
5,044
     
3,057
     
3,381
 
Asia-Pacific
   
387
     
115
     
60
 
Rest of the world
   
787
     
36
     
6
 
 
                       
Total revenues
 
$
13,854
   
$
5,511
   
$
5,966
 
 
 
 
December 31,
 
 
 
2023
   
2022
 
Long-lived assets by geographic region:
           
Israel
 
$
529
   
$
757
 
United States
   
2,404
     
231
 
Germany
   
190
     
44
 
 
               
 
 
$
3,123
   
$
1,032
 
 
  (*)
Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.
 
Major customers data as a percentage of total revenue:
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Customer A
   
12.2
%
   
14.2
%
   
*
)
Customer B
   
*
)
   
*
)
   
11.0
%

 

  *)

Less than 10%

 

F - 35


 

NOTE 14:- BASIC AND DILUTED NET LOSS PER SHARE
 
The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share (in thousands, except share and per share data):
 
 
 
Year ended December 31,
 
 
 
2023
   
2022
   
2021
 
Net loss
 
$
(22,133
)
 
$
(19,569
)
 
$
(12,736
)
 
                       
Net loss attributable to ordinary shares
   
(22,133
)
   
(19,569
)
   
(12,736
)
Shares used in computing net loss per ordinary shares, basic and diluted
   
59,719,064
     
62,378,797
     
47,935,652
 
 
                       
Net loss per ordinary share, basic and diluted
 
$
(0.37
)
 
$
(0.31
)
 
$
(0.27
)
 
Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of ordinary shares and warrants outstanding would have been anti-dilutive.
 
For the twelve months ended December 31, 2023, the total number of ordinary shares related to the outstanding warrants and share option plans aggregated to 19,220,546, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect.
 
For the twelve months ended December 31, 2022, the total number of ordinary shares related to the outstanding warrants and share option plans aggregated to 19,464,888, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect.
 
NOTE 15:- RESTRUCTURING ACTIVITIES
 
On December 12, 2023, the Board of Directors of the Company approved a re-organization plan (the “2023 Reorganization Plan”) that included, among other things, downsizing approximately 15% of the Company’s workforce and adapting the Company's organizational structure, roles, and responsibilities accordingly.
 
During the year ended December 31, 2023, in connection with the 2023 Reorganization Plan, the Company recorded expenses of $670 thousand, for one time employee termination benefits and legal expenses. $175 thousand attributable to research and development, net, $70 thousand to sales and marketing and $425 thousand to General and administrative expenses. However, none of these amounts were paid in 2023. The Company does not expect to incur additional costs related to the 2023 Reorganization Plan.

 

F - 36


 
EX-21.1 2 exhibit_21-1.htm EXHIBIT 21.1


Exhibit 21.1
 
List of Subsidiaries of ReWalk Robotics Ltd.

Name of Subsidiary
 
Place of Incorporation
Lifeward, Inc.
 
Delaware, United States
Lifeward CA, Inc.
 
Delaware, United States
Lifeward GmbH
 
Germany
 

EX-23.1 3 exhibit_23-1.htm EXHIBIT 23.1


Exhibit 23.1

Kost Forer Gabbay & Kasierer
Menachem Begin 144,
Tel-Aviv 6492102, Israel
Tel: +972-3-6232525
Fax: +972-2-5622555
ey.com

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

(1)
Registration Statements (Form S-3 No. 333-231305, 333-260382 and 333-263984) of ReWalk Robotics Ltd.,
(2)
Registration Statements (Form S-1 No. 333-235931, 333-239733, 333-251454 and 333-254147) of ReWalk Robotics Ltd., and
(3)
Registration Statements (Form S-8 No. 333-199688, 333-221357, 333-230485, 333-239258 and 333-267284) pertaining to the ReWalk Robotics Ltd. 2006 Stock Option Plan, ReWalk Robotics Ltd. 2012 Equity Incentive Plan and ReWalk Robotics Ltd. 2014 Incentive Compensation Plan;

of our report dated February 27, 2024, with respect to the consolidated financial statements of ReWalk Robotics Ltd. included in this Annual Report (Form 10-K) of ReWalk Robotics Ltd. for the year ended December 31, 2023.

/s/ KOST FORER GABBAY & KASIERER
 
A Member of EY Global
 
 
February 27, 2024
 
Tel-Aviv


EX-31.1 4 exhibit_31-1.htm EXHIBIT 31.1


EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
EXCHANGE ACT RULE 13A-14(A)/15D-14(A)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Larry Jasinski, certify that:

1. I have reviewed this annual report on Form 10-K of ReWalk Robotics Ltd. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
/s/ Larry Jasinski
 
Larry Jasinski
 
Chief Executive Officer
 
(Principal Executive Officer)
 
 Date: February 27, 2024



EX-31.2 5 exhibit_31-2.htm EXHIBIT 31.2


EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
EXCHANGE ACT RULE 13A-14(A)/15D-14(A)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Mike Lawless, certify that:

1. I have reviewed this annual report on Form 10-K of ReWalk Robotics Ltd. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 
/s/ Mike Lawless
 
Mike Lawless
 
Chief Financial Officer
 
(Principal Financial Officer)
 
Date: February 27, 2024


EX-32.1 6 exhibit_32-1.htm EXHIBIT 32.1


 EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of ReWalk Robotics Ltd. (the “Company”) on Form 10-K for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Larry Jasinski, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
/s/ Larry Jasinski
 
Larry Jasinski
 
Chief Executive Officer
 
(Principal Executive Officer)
 
Date: February 27, 2024

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



EX-32.2 7 exhibit_32-2.htm EXHIBIT 32.2


EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of ReWalk Robotics Ltd. (the “Company”) on Form 10-K for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mike Lawless, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
/s/ Mike Lawless 
 
Mike Lawless 
 
Chief Financial Officer
 
(Principal Financial Officer)
 
Date: February 27, 2024

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



EX-101.SCH 8 lfwd-20231231.xsd XBRL SCHEMA FILE 0001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 0002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 0005 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 0006 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 0007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 0008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 0009 - Disclosure - GENERAL link:presentationLink link:definitionLink link:calculationLink 0010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 0011 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS link:presentationLink link:definitionLink link:calculationLink 0012 - Disclosure - INVENTORIES link:presentationLink link:definitionLink link:calculationLink 0013 - Disclosure - BUSINESS COMBINATION link:presentationLink link:definitionLink link:calculationLink 0014 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET link:presentationLink link:definitionLink link:calculationLink 0015 - Disclosure - PROPERTY AND EQUIPMENT, NET link:presentationLink link:definitionLink link:calculationLink 0016 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES link:presentationLink link:definitionLink link:calculationLink 0017 - Disclosure - SHAREHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 0018 - Disclosure - RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT link:presentationLink link:definitionLink link:calculationLink 0019 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 0020 - Disclosure - FINANCIAL EXPENSES (INCOME), NET link:presentationLink link:definitionLink link:calculationLink 0021 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA link:presentationLink link:definitionLink link:calculationLink 0022 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE link:presentationLink link:definitionLink link:calculationLink 0023 - Disclosure - RESTRUCTURING ACTIVITIES link:presentationLink link:definitionLink link:calculationLink 0024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 0025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 0026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) link:presentationLink link:definitionLink link:calculationLink 0027 - Disclosure - INVENTORIES (Tables) link:presentationLink link:definitionLink link:calculationLink 0028 - Disclosure - BUSINESS COMBINATION (Tables) link:presentationLink link:definitionLink link:calculationLink 0029 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables) link:presentationLink link:definitionLink link:calculationLink 0030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) link:presentationLink link:definitionLink link:calculationLink 0031 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables) link:presentationLink link:definitionLink link:calculationLink 0032 - Disclosure - SHAREHOLDERS' EQUITY (Tables) link:presentationLink link:definitionLink link:calculationLink 0033 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:definitionLink link:calculationLink 0034 - Disclosure - FINANCIAL EXPENSES (INCOME), NET (Tables) link:presentationLink link:definitionLink link:calculationLink 0035 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables) link:presentationLink link:definitionLink link:calculationLink 0036 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Tables) link:presentationLink link:definitionLink link:calculationLink 0037 - Disclosure - GENERAL (Details) link:presentationLink link:definitionLink link:calculationLink 0038 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:definitionLink link:calculationLink 0039 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 1) link:presentationLink link:definitionLink link:calculationLink 0040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 2) link:presentationLink link:definitionLink link:calculationLink 0041 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 3) link:presentationLink link:definitionLink link:calculationLink 0042 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 4) link:presentationLink link:definitionLink link:calculationLink 0043 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 5) link:presentationLink link:definitionLink link:calculationLink 0044 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 6) link:presentationLink link:definitionLink link:calculationLink 0045 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 0046 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) link:presentationLink link:definitionLink link:calculationLink 0047 - Disclosure - INVENTORIES (Details) link:presentationLink link:definitionLink link:calculationLink 0048 - Disclosure - INVENTORIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 0049 - Disclosure - BUSINESS COMBINATION (Details) link:presentationLink link:definitionLink link:calculationLink 0050 - Disclosure - BUSINESS COMBINATION (Details 1) link:presentationLink link:definitionLink link:calculationLink 0051 - Disclosure - BUSINESS COMBINATION (Details 2) link:presentationLink link:definitionLink link:calculationLink 0052 - Disclosure - BUSINESS COMBINATION (Details 3) link:presentationLink link:definitionLink link:calculationLink 0053 - Disclosure - BUSINESS COMBINATION (Details Textual) link:presentationLink link:definitionLink link:calculationLink 0054 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details) link:presentationLink link:definitionLink link:calculationLink 0055 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details 1) link:presentationLink link:definitionLink link:calculationLink 0056 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details Textual) link:presentationLink link:definitionLink link:calculationLink 0057 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details) link:presentationLink link:definitionLink link:calculationLink 0058 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Textual) link:presentationLink link:definitionLink link:calculationLink 0059 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details) link:presentationLink link:definitionLink link:calculationLink 0060 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 0061 - Disclosure - SHAREHOLDERS' EQUITY (Details) link:presentationLink link:definitionLink link:calculationLink 0062 - Disclosure - SHAREHOLDERS' EQUITY (Details 1) link:presentationLink link:definitionLink link:calculationLink 0063 - Disclosure - SHAREHOLDERS' EQUITY (Details 2) link:presentationLink link:definitionLink link:calculationLink 0064 - Disclosure - SHAREHOLDERS' EQUITY (Details 3) link:presentationLink link:definitionLink link:calculationLink 0065 - Disclosure - SHAREHOLDERS' EQUITY (Details 4) link:presentationLink link:definitionLink link:calculationLink 0066 - Disclosure - SHAREHOLDERS' EQUITY (Details Textual) link:presentationLink link:definitionLink link:calculationLink 0067 - Disclosure - RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT (Details) link:presentationLink link:definitionLink link:calculationLink 0068 - Disclosure - INCOME TAXES (Details) link:presentationLink link:definitionLink link:calculationLink 0069 - Disclosure - INCOME TAXES (Details 1) link:presentationLink link:definitionLink link:calculationLink 0070 - Disclosure - INCOME TAXES (Details 2) link:presentationLink link:definitionLink link:calculationLink 0071 - Disclosure - INCOME TAXES (Details 3) link:presentationLink link:definitionLink link:calculationLink 0072 - Disclosure - INCOME TAXES (Details 4) link:presentationLink link:definitionLink link:calculationLink 0073 - Disclosure - INCOME TAXES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 0074 - Disclosure - FINANCIAL EXPENSES (INCOME), NET (Details) link:presentationLink link:definitionLink link:calculationLink 0075 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details) link:presentationLink link:definitionLink link:calculationLink 0076 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 1) link:presentationLink link:definitionLink link:calculationLink 0077 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 2) link:presentationLink link:definitionLink link:calculationLink 0078 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details Textual) link:presentationLink link:definitionLink link:calculationLink 0079 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details) link:presentationLink link:definitionLink link:calculationLink 0080 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details Textual) link:presentationLink link:definitionLink link:calculationLink 0081 - Disclosure - RESTRUCTURING ACTIVITIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 lfwd-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 lfwd-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 11 lfwd-20231231_lab.xml XBRL LABEL FILE EX-101.PRE 12 lfwd-20231231_pre.xml XBRL PRESENTATION FILE GRAPHIC 13 image0.jpg GRAPHIC begin 644 image0.jpg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image00001.jpg GRAPHIC begin 644 image00001.jpg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end GRAPHIC 15 image1.jpg GRAPHIC begin 644 image1.jpg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end GRAPHIC 16 image00002.jpg GRAPHIC begin 644 image00002.jpg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end GRAPHIC 17 image2.jpg GRAPHIC begin 644 image2.jpg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end
GRAPHIC 18 image00003.jpg GRAPHIC begin 644 image00003.jpg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end XML 19 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2023
Feb. 27, 2024
Jun. 30, 2023
Cover [Abstract]      
Entity Central Index Key 0001607962    
Document Fiscal Period Focus FY    
Amendment Flag false    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2023    
Document Transition Report false    
Entity File Number 001-36612    
Entity Registrant Name ReWalk Robotics Ltd.    
Entity Incorporation State or Country Code L3    
Entity Tax Identification Number 00-0000000    
Entity Address, Address Line One 3 Hatnufa Street    
Entity Address, Address Line Two Floor 6    
Entity Address, City or Town Yokneam Illit    
Entity Address, Country IL    
Entity Address, Postal Zip Code 2069203    
City Area Code 972    
Local Phone Number 4.959.0123    
Title of 12(b) Security Ordinary Shares, par value NIS 0.25 per share    
Trading Symbol LFWD    
Name of Exchange on which Security is Registered NASDAQ    
Entity Well-Known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Auditor Attestation Flag false    
Entity Public Float     $ 35,050,478
Entity Common Stock, Shares Outstanding   59,480,132  
Auditor Name KOST FORER GABBAY &    
Auditor Location Tel-Aviv, Israel    
Auditor Firm Id 1281    
Document Financial Statement Error Correction [Flag] false    
XML 20 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
CURRENT ASSETS    
Cash and cash equivalents $ 28,083 $ 67,896
Trade receivable, net of credit losses of $328 and $26, respectively 3,120 1,036
Prepaid expenses and other current assets 2,366 649
Inventories 5,653 2,929
Total current assets 39,222 72,510
LONG-TERM ASSETS    
Restricted cash and other long-term assets 784 694
Operating lease right-of-use assets 1,861 836
Property and equipment, net 1,262 196
Intangible assets 12,525 0
Goodwill 7,538 0
Total long-term assets 23,970 1,726
Total assets 63,192 74,236
CURRENT LIABILITIES:    
Trade payables 5,069 1,950
Employees and payroll accruals 2,034 1,282
Deferred revenue 1,504 301
Current maturities of operating leases liability 1,296 564
Earnout liability 576 0
Other current liabilities 1,316 685
Total current liabilities 11,795 4,782
LONG-TERM LIABILITIES    
Earnout liability 2,716 0
Deferred revenues 1,506 890
Non-current operating leases liability 607 333
Other long-term liabilities 58 66
Total long-term liabilities 4,887 1,289
Total liabilities 16,682 6,071
COMMITMENTS AND CONTINGENT LIABILITIES
Shareholders’ equity:    
Ordinary share of NIS 0.25 par value-Authorized: 120,000,000 shares at December 31, 2023 and December 31, 2022; Issued: 64,132,706 and 63,023,506 shares at December 31, 2023 and December 31, 2022, respectively; Outstanding: 60,110,099 and 60,090,298 shares as of December 31, 2023 and December 31, 2022 respectively 4,487 4,489
Additional paid-in capital 281,109 279,857
Treasury Shares at cost, 4,022,607 and 2,933,208 ordinary shares at December 31, 2023 and December 31, 2022 respectively (3,203) (2,431)
Accumulated deficit (235,883) (213,750)
Total shareholders' equity 46,510 68,165
Total liabilities and shareholders' equity $ 63,192 $ 74,236
XML 21 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical)
$ in Thousands
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2022
USD ($)
shares
Statement of Financial Position [Abstract]    
Allowance for credit losses | $ $ 328 $ 26
Ordinary shares, authorized 120,000,000 120,000,000
Ordinary shares, issued 64,132,706 63,023,506
Ordinary shares, outstanding 60,110,099 60,090,298
Treasury stock common shares 4,022,607 2,933,208
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Income Statement [Abstract]      
Revenue $ 13,854 $ 5,511 $ 5,966
Cost of revenue 9,401 3,606 3,063
Gross profit 4,453 1,905 2,903
Operating expenses:      
Research and development, net 4,148 4,031 2,939
Sales and marketing 13,922 9,842 6,993
General and administrative 9,995 7,134 5,626
Total operating expenses 28,065 21,007 15,558
Operating loss (23,612) (19,102) (12,655)
Financial income, net 1,467 [1] 13
Loss before income taxes (22,145) (19,102) (12,642)
Taxes on income (benefit) (12) 467 94
Net loss $ (22,133) $ (19,569) $ (12,736)
Net loss per ordinary share, basic | (per share) $ (0.37) $ (0.31) $ (0.27)
Net loss per ordinary share, diluted | (per share) $ (0.37) $ (0.31) $ (0.27)
Weighted average number of shares used in computing net loss per ordinary share, basic | shares 59,719,064 62,378,797 47,935,652
Weighted average number of shares used in computing net loss per ordinary share, diluted | shares 59,719,064 62,378,797 47,935,652
[1] Represents an amount lower than $1.
XML 23 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Ordinary Share [Member]
Additional paid-in capital [Member]
Treasury Shares [Member]
Accumulated deficit [Member]
Total
Balance at Dec. 31, 2020 $ 1,827 $ 201,392 $ 0 $ (181,445) $ 21,774
Balance, shares at Dec. 31, 2020 25,332,225        
Share-based compensation to employees and non-employees $ 0 833 0 0 833
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees $ 31 (31) 0 0 0
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees, shares 398,164        
Issuance of ordinary shares in a "Best Efforts" offering, net of issuance expenses $ 832 35,489 0 0 36,321
Issuance of ordinary shares in a "Best Efforts" offering, net of issuance expenses, shares 10,921,502        
Exercise of pre-funded warrants and warrants $ 772 14,288 0 0 15,060
Exercise of pre-funded warrants and warrants, shares 10,425,258        
Issuance of ordinary shares in a "registered direct" offering, net of issuance expenses $ 1,199 26,932 0 0 28,131
Issuance of ordinary shares in a "registered direct" offering, net of issuance expenses, shares 15,403,014        
Net loss $ 0 0 0 (12,736) (12,736)
Balance at Dec. 31, 2021 62,480,163 4,661 278,903 (194,181) 89,383
Share-based compensation to employees and non-employees 0 993 0 0 993
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees $ 39 (39) 0 0 0
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees, shares 543,343        
Treasury shares at cost $ (211) 0 (2,431) 0 (2,642)
Treasury shares at cost (shares) (2,933,208)        
Net loss $ 0 0 0 (19,569) (19,569)
Balance at Dec. 31, 2022 $ 4,489 279,857 2,431 (213,750) 68,165
Balance, shares at Dec. 31, 2022 60,090,298        
Share-based compensation to employees and non-employees $ 0 1,328 0 0 1,328
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees $ 76 (76) 0 0 0
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees, shares 1,109,200        
Treasury shares at cost $ (78) 0 (772) 0 (850)
Treasury shares at cost (shares) (1,089,399)        
Net loss $ (0) 0 (0) (22,133) (22,133)
Balance at Dec. 31, 2023 $ 4,487 $ 281,109 $ (3,203) $ (235,883) $ 46,510
Balance, shares at Dec. 31, 2023 60,110,099        
XML 24 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)
$ in Thousands
12 Months Ended
Dec. 31, 2021
USD ($)
Best Offering [Member]  
Issuance expenses, amount $ 3,679
Registered Direct [Member]  
Issuance expenses, amount $ 3,215
XML 25 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash flows used in operating activities:      
Net loss $ (22,133) $ (19,569) $ (12,736)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 239 202 266
Amortization of intangible assets 1,608 0 0
Share-based compensation 1,328 993 833
Deferred taxes 0 316 (29)
Remeasurement of earnout liability (315) 0 0
Interest income (11) 0 0
Exchange rate fluctuations (45) 79 0
Changes in assets and liabilities:      
Trade receivables, net (311) (408) 99
Prepaid expenses, operating lease right-of-use assets and other assets (531) 94 592
Inventories (277) (117) 432
Trade payables 1,037 566 (884)
Employees and payroll accruals (14) 140 275
Deferred revenues (269) (34) 74
Operating lease liabilities and other liabilities (973) (153) (391)
Net cash used in operating activities (20,667) (17,891) (11,469)
Cash flows used in investing activities:      
Acquisition of a business, net of cash acquired (18,068) 0 0
Purchase of property and equipment (81) (25) (47)
Net cash used in investing activities (18,149) (25) (47)
Cash flows from financing activities:      
Issuance of ordinary shares in a private placement, net of issuance expenses paid in the amount of $3,679 [1] 0 0 36,321
Issuance of ordinary shares in a “registered direct” offering, net of issuance expenses in the amount of $3,215 [1] 0 0 28,131
Exercise of pre-funded warrants and warrants [1],[2] 0 0 15,060
Purchase of treasury shares (992) (2,500) 0
Net cash (used in) provided by financing activities (992) (2,500) 79,512
Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash 45 (79) 0
Increase (decrease) in cash, cash equivalents, and restricted cash (39,763) (20,495) 67,996
Cash, cash equivalents, and restricted cash at beginning of period 68,555 89,050 21,054
Cash, cash equivalents, and restricted cash at end of period 28,792 68,555 89,050
Supplemental disclosures of non-cash flow information      
Classification of other current assets to property and equipment, net 0 22 34
Classification of inventory to property and equipment 481 67 32
Amounts related to shares re-purchase not yet paid 0 142 0
ROU assets obtained from new lease liabilities 513 0 0
Supplemental disclosures of cash flow information:      
Cash paid for income taxes 126 113 40
Cash received from interest 1,341 0 0
Reconciliation of cash, cash equivalents and restricted cash as shown in the consolidated statements of cash flows      
Cash and cash equivalents 28,083 67,896 88,337
Restricted cash included in other long-term assets 709 659 713
Total Cash, cash equivalents, and restricted cash $ 28,792 $ 68,555 $ 89,050
[1] See Note 9a.
[2] See Note 9f.
XML 26 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Private Placement [Member]  
Issuance expenses paid $ 3,679
Registered Direct [Member]  
Issuance expenses paid $ 3,215
XML 27 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
GENERAL
12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GENERAL
NOTE 1:-
GENERAL
 
  a.
ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date.
 
  b.
RRL has three wholly-owned (directly and indirectly) subsidiaries: (i) ReWalk Robotics, Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012, (ii) ReWalk Robotics GMBH (“RRG”) incorporated under the laws of Germany on January 14, 2013, and (iii) AlterG, Inc. (“AlterG”) incorporated in Delaware on October 21, 2004 under the name of Gravus, Inc. On June 30, 2005, the Company re-incorporated in Delaware and changed its name to AlterG, Inc. in September 2005.
 
  c.
The Company is a medical device company that is designing, developing, and commercializing innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions. The Company’s initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury (collectively, the “SCI Products”). These devices are robotic exoskeletons that are designed for individuals with paraplegia that use the Company’s patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. These SCI Products allow individuals with spinal cord injury the ability to stand and walk again during everyday activities at home or in the community.
 
The Company has sought to expand the product offerings beyond the SCI Products through internal development and distribution agreements. The Company has developed its ReStore Exo-Suit device, which it began commercializing in June 2019. The ReStore is a powered, lightweight soft exo-suit intended for use during the rehabilitation of individuals with lower limb disability due to stroke. During the second quarter of 2020, the Company signed two separate agreements to distribute additional product lines in the United States. The Company is the exclusive distributor of the MYOLYN MyoCycle FES Pro cycles to United States (“U.S.”) rehabilitation clinics and for the MyoCycle Home cycles available to US veterans through VA hospitals. In the second quarter of 2020, the Company also became the exclusive distributor of the MediTouch Tutor movement biofeedback systems in the United States; however, due to unsatisfactory sales performance of the MediTouch product lines, the Company terminated this agreement as of January 31, 2023. We refer to the MediTouch and MyoCycle devices as the Company’s “Distributed Products.”
 
On August 11, 2023, pursuant to an Agreement and Plan of Merger among RRI, AlterG, Atlas Merger Sub, Inc., a wholly owned subsidiary of RRI (“Merger Sub”), and Shareholder Representative Services LLC, dated August 11, 2023, RRI acquired AlterG and AlterG became a wholly owned subsidiary of the Company.
 
For accounting purposes, RRI was considered the acquirer and AlterG was considered the acquiree. The acquisition was accounted for using the acquisition method of accounting. See Note 5 for additional information.
 
The Company made its first acquisition to supplement its internal growth when it acquired AlterG, a leading provider of AlterG Anti-Gravity systems for use in physical and neurological rehabilitation.  The Company paid a cash purchase price of $19.0 million at closing and additional cash earnouts may be paid based upon a percentage of AlterG’s year-over-year revenue growth over the two years following the closing. The AlterG Anti-Gravity systems use patented, NASA-derived Differential Air Pressure (“DAP”) technology to reduce the effects of gravity and allow people to rehabilitate with finely calibrated support and reduced pain.  The Company will continue to evaluate other products for distribution or acquisition that can broaden its product offerings further to help individuals with physical and neurological injury and disability.
 
The Company markets and sells its products directly to institutions and individuals and through third-party distributors. The Company sells its products directly primarily in the United States, through a combination of direct sales and distributors (depending on the product line) in Germany, Canada, and Australia, and primarily through distributors in other markets. In its direct markets, the Company has established relationships with clinics and rehabilitation centers, professional and college sports teams, and individuals and organizations in the spinal cord injury community, and in its indirect markets, the Company’s distributors maintain these relationships. RRI and AlterG market and sell products mainly in the United States. RRG markets and sells the Company’s products mainly in Germany and Europe.
 
  d.
The Company depends on one contract manufacturer to manufacture the ReWalk and the ReStore products in its portfolio, Sanmina. Reliance on this vendor makes the Company vulnerable to possible capacity constraints and reduces control over component availability, delivery schedules, manufacturing yields and costs.
 
  e.
For the full year ended December 31, 2023 the Company incurred a consolidated net loss of $22.1 million and has an accumulated deficit in the total amount of $235.9 million. The Company’s negative operating cash flow for the full year ended December 31, 2023 was $20.7 million. Our cash and cash equivalent on December 31, 2023 totalled $28.1 million. The Company has sufficient funds to support its operation for more than 12 months following the approval of its consolidated financial statements for the fiscal year ended December 31, 2023.
 
The Company expects to incur future net losses and the transition to profitability is dependent upon, among other things, the successful development and commercialization of the Company’s products and product candidates, the establishment of contracts for the distribution of new product lines, or the acquisition of additional product lines, any of which, or in combination, would contribute to the achievement of a level of revenue adequate to support the cost structure. Until the Company achieves profitability or generates positive cash flows, it will continue to need to raise additional cash. The Company intends to fund future operations through existing cash on hand, additional private and/or public offerings of debt or equity securities, cash exercises of outstanding warrants or a combination of the foregoing. In addition, the Company may seek additional capital through arrangements with strategic partners or from other sources and will continue to address its cost structure. Notwithstanding, there can be no assurance that the Company will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.
XML 28 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES
NOTE 2:-
SIGNIFICANT ACCOUNTING POLICIES
 
The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), applied on a consistent basis, as follows:
 
  a.
Use of Estimates
 
The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to inventories, fair values of share-based awards, contingent liabilities, provision for warranty, allowance for credit losses and sales return reserve. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
 
  b.
Financial Statements in U.S. Dollars:
 
The functional currency is the currency that best reflects the economic environment in which the Company and its subsidiaries operate and conduct their transactions. Most of the Company’s revenues and costs are incurred in U.S. dollar. In addition, the Company’s financing activities are incurred in U.S. dollars. The Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and each of its subsidiaries operate. Thus, the dollar is the Company’s and its subsidiary's functional and reporting currency.
 
Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are remeasured into U.S. dollars in accordance with ASC 830 “Foreign Currency Matters.” All transaction gains and losses of the remeasured monetary balance sheet items are reflected in the consolidated statements of operations as financing income or expenses as appropriate.

 

  c.
Principles of Consolidation:
 
The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances have been eliminated upon consolidation.
 
  d.
Cash Equivalents:
 
Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less, at the date acquired.
 
  e.
Inventories:
 
Inventories are stated at the lower of cost or net realizable value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence.
 
The Company periodically evaluates the quantities on hand relative to historical, current, and projected sales volume. Based on this evaluation, an impairment charge is recorded when required to write-down inventory to its net realized value.
 
Cost is determined as follows:
 
Finished products - based on raw materials and manufacturing costs on an average basis.
 
Raw materials - The weighted average cost method.
 
The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors, including historical usage rates and forecasted sales according to outstanding backlogs. Purchasing requirements and alternative usage are explored within these processes to mitigate inventory exposure. When recorded, the reserves are intended to reduce the carrying value of inventory to its net realizable value. If actual demand for the Company’s products deteriorates, or market conditions are less favourable than those projected, additional inventory reserves may be required.
 
  f.
Property and Equipment:
 
Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:
 
 
%
Computer equipment
20-33 (mainly 33)
Office furniture and equipment
6 - 10 (mainly 10)
Machinery and laboratory equipment
15
Field service units
20-50
Leasehold improvements
Over the shorter of the lease term
or estimated useful life
 
  g.
Business Combinations
 
The Company accounts for business combinations in accordance with ASC 805, “Business Combinations” (“ASC 805”). For business combinations accounted for under the acquisition method, ASC 805 requires recognition of assets acquired, liabilities assumed, and any non-controlling interest at the acquisition date, measured at their fair values as of that date. The Company determines the recognition of intangible assets based on the following criteria: (i) the intangible asset arises from contractual or other rights; or (ii) the intangible asset is separable or divisible from the acquired entity and capable of being sold, transferred, licensed, returned or exchanged.
 
The excess of the fair value of the purchase price over the fair values of the identifiable assets and liabilities is recorded as goodwill. Determining the fair value of the identifiable assets and liabilities requires management to use significant judgment and estimates including the forecasted revenue and revenues growth rates, discount rates, customer contract renewal rates and customer attrition rates. The process of estimating the fair values requires significant estimates, especially with respect to intangible assets. Management’s determination of fair value of assets acquired and liabilities assumed at the acquisition date is based on the best information available in the circumstances and incorporates management’s own assumptions and involves a significant degree of judgment.
 
Acquisition related costs include legal fees, consulting and success fees, and other non-recurring integration related costs. Acquisition-related costs are expensed as incurred.

 

  h.
Goodwill and Other Intangibles
 
For business combinations, the purchase prices are allocated to the tangible assets and intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition dates, with the remaining unallocated purchase prices recorded as goodwill.
 
The Company has no indefinite-lived intangible assets other than goodwill. Acquired identifiable finite-lived intangible assets include identifiable acquired technology, customer relationships, trademarks and backlog and are amortized on a straight-line basis over the estimated useful lives of the assets. The Company routinely reviews the remaining estimated useful lives of finite-lived intangible assets.
 
Goodwill is not amortized and is tested for impairment at least annually.
The Company operates as one reporting unit and the fair value of the reporting unit is estimated using quoted market prices of the Company’s stock in active markets. The Company tests goodwill for impairment annually in the fourth quarter and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable.
 
When testing goodwill for impairment, the Company may first perform a qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. The Company may elect to bypass the qualitative assessment and proceed directly to performing a quantitative analysis. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company recognizes an impairment of goodwill for the amount of this excess.
 
As of December 31, 2023, no impairments of goodwill have been recognized.
 
  i.
Impairment of Long-Lived Assets
 
The Company’s long-lived assets, including right-of-use (“ROU”) assets and identifiable intangible assets that are subject to amortization, are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2023, 2022 and 2021, no impairment losses have been recorded.
 
  j.
Restricted cash and Other long-term assets:
 
Other long-term assets include long-term prepaid expenses and restricted cash deposits for offices and cars leasing based upon the term of the remaining restrictions.
 
  k.
Treasury shares
 
The Company repurchased its ordinary shares and holds them as treasury shares. The Company presents the cost to repurchase treasury shares as a reduction of shareholders' equity.

 

  l.
Revenue Recognition:
 
The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to clinics and rehabilitation centres, professional and college sports teams, private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), and distributors.
 
The Company recognizes revenue in accordance with ASC 606, “Revenue Recognition” when, or as, control of the promised good or service is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company applies the following five steps:
 
  1.
Identify the contract with a customer
 
The Company generally considers a purchase order or a signed quote to be a contract with a customer. In evaluating the contract with a customer, the Company analyzes the customer’s intent and ability to pay the amount of promised consideration (credit risk) and considers the probability of collecting substantially all of the consideration.
 
  2.
Identify the performance obligations in the contract
 
At a contract’s inception, the Company assesses the goods or services promised in a contract with a customer and identifies the performance obligations.
 
  3.
Determine the transaction price
 
The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring products or services to the customer.
 
The Company does not offer extended payment terms beyond one year to customers.
 
  4.
Allocate the transaction price to performance obligations in the contract
 
If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.
 
  5.
Recognize revenue when or as the Company satisfies a performance obligation
 
Revenue is recognized when or as performance obligations are satisfied by transferring control of a promised good or service to a customer. Control either transfers over time or at a point in time, which affects when revenue is recorded.
 
The Company has elected to apply the practical expedient for financing component for transactions in which the difference between the payment date and the revenue recognition timing is up to 12 months.
 
Disaggregation of Revenue (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Product
 
$
10,681
   
$
4,175
   
$
4,916
 
Rental
   
1,033
     
859
     
533
 
Service and warranty
   
2,140
     
477
     
517
 
Total Revenues
 
$
13,854
   
$
5,511
   
$
5,966
 
 
Product revenue
 
Revenue from Products is comprised of sale of Anti-Gravity products, sale of systems products to rehabilitation facilities and sale of ReWalk Personal Exoskeleton systems to end users. Revenues generated from the sale of Products are recognized at a point in time, once the customer has obtained the legal title to the items purchased.
 
For systems sold to rehabilitation facilities, the Company includes insignificant training and considers the elements in the arrangement to be a single performance obligation. Therefore, the Company recognizes revenue for the system only when control is transferred after delivery and when the training has been completed, in accordance with the agreements terms with the customer.

 

For sales of ReWalk Personal Exoskeleton systems to end users, and for sales of ReWalk Personal or ReWalk Rehabilitation Exoskeleton systems to third party distributors, the Company does not provide training to the end user as this training is completed by the rehabilitation center or by the distributor that have previously completed the ReWalk Training program. Therefore, the Company recognizes revenue in such sales upon delivery.
 
The Company generally does not grant a right of return for its products. In rare circumstances when the Company provides a right of return for its products. the Company records reductions to revenue for expected future product returns based on the Company’s historical experience and estimates.
 
During 2023, the Company offered six products: (1) ReWalk Personal Exoskeletons, (2) ReWalk Rehabilitation Exoskeleton, (3) ReStore, (4) AlterG Anti-Gravity systems, (5) MyoCycle and (6) MediTouch. Due to unsatisfactory sales performance of the MediTouch product lines, the Company terminated this agreement as of January 31, 2023.
 
Rental revenue
 
Rental revenue for the AlterG Anti-Gravity systems is accounted for under ASC Topic 842, Leases. The Company rents its products to customers for a fixed monthly fee over the rental term, which typically ranges from 2 to 3 years. Rental revenues are recorded as earned on a monthly basis. See Note 2x for additional information.
 
For the SCI Products, the Company also offers a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee for a limited period prior to selling its products.
 
Service and warranties
 
The Company services its products after expiration of the initial warranty. Service revenue, consisting of time and materials to perform the repairs, is recorded as services are rendered.
 
Determining the transaction price requires of level judgment, which is discussed by revenue category in further detail below.
 
Warranties are classified as either an assurance type or a service type warranty. A warranty is considered an assurance type warranty if it provides the customer with assurance that the product will function as intended for a limited period of time. An assurance type warranty is not accounted for as a separate performance obligation under the revenue model.
 
SCI Products include a five -year warranty. The first two years are considered as an assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. A service type warranty is either sold with a unit or separately for a unit for which the warranty has expired. A service type warranty is accounted as a separate performance obligation and revenue is recognized ratably over the life of the warranty.
 
The ReStore device is sold with a two-year warranty which is considered as assurance type warranty.
 
The Distributed Products are sold with assurance type warranty ranging between three years to ten years, depending on the specific product and part.
 
For AlterG Anti-Gravity Products, the Company offers customers extended warranty contracts that extend or enhance the technical support, parts, and labor coverage offered as part of the base warranty included with the Anti-Gravity system products. Extended warranty revenue is recognized ratably over the extended warranty coverage period. The Company offers a one-year assurance type warranty to customers in the U.S. and two years assurance type warranty for spare parts only to its international distributors. For these products, the Company determines standalone selling price based on the price at which the performance obligation is sold separately.

 

Contract balances (in thousands):
 
 
 
December 31,
   
December 31,
 
 
 
2023
   
2022
 
Trade receivable, net of credit losses (1)
 
$
3,120
   
$
1,036
 
Deferred revenues (1) (2)
 
$
3,010
   
$
1,191
 
 
  (1)
Balance presented net of unrecognized revenue that was not yet collected.
 
  (2)
$435 thousands of the December 31, 2022 deferred revenue balance was recognized as revenue during the year ended December 31, 2023.
 
Deferred revenue which represent a contract liability, include unearned amounts related to service type warranty obligations as well as other advances and payments which the Company received from customers prior to satisfying the performance obligation, for which revenue has not yet been recognized. The Company's unearned performance obligations as of December 31, 2023 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $3.1 million, which will be fulfilled over one to five years.
 
  m.
Accounting for Share-Based Compensation:
 
The Company accounts for share-based compensation in accordance with ASC 718, “Compensation-Stock Compensation” (“ASC 718”). ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model (“OPM”). The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations.
 
The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. The Company account for forfeitures as they occur.
 
The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its share-option awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary share, expected share price volatility and the expected option term. Expected volatility is calculated based on actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options, or based on certain peer companies that the Company considered to be comparable, in case there is no sufficient trading volume to rely on market volatility. The expected option term is determined based on the simplified method, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.
 
The fair value of Restricted Stock Units (“RSUs”) granted is determined based on the price of the Company’s ordinary shares on the date of grant.
 
The Company accounts for options granted to consultants and other service providers under ASC 718. The fair value of these options was estimated using a Black-Scholes-Merton option-pricing model.
 
  n.
Warrants to Acquire Ordinary Shares:
 
During the twelve -month ended December 31, 2021, the Company issued warrants to acquire up to 15,083,611 ordinary shares. There were no issued warrants during the twelve months ended December 31, 2023 and 2022. The Company assessed the warrants pursuant to ASC 480 "Distinguishing Liabilities from Equity" and ASC 815 "Derivatives and Hedging" and determined that the warrants should be accounted for as equity and not as a derivative liability. Refer to Note 9f for additional information.
 
  o.
Research and Development Costs:
 
Research and development costs are charged to the consolidated statement of operations as incurred and are presented net of the amount of any grants the Company received for research and development in the period in which the grant was received.

 

  p.
Income Taxes
 
The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”), using the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized.
 
ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits in its taxes on income. As of December 31, 2023, and 2022, the Company did not identify any significant uncertain tax positions.
 
  q.
Warranty provision:
 
For assurance-type warranty, the Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.
 
 
 
US Dollars
in
thousands
 
Balance at December 31, 2022
 
$
92
 
AlterG acquisition – see note 5
   
535
 
Provision
   
200
 
Usage
   
(479
)
Balance at December 31, 2023
 
$
348
 
 
  r.
Concentrations of Credit Risks:
 
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables.
 
The Company’s cash and cash equivalents are deposited in major banks in Israel, the United States and Germany. Such deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. The Company maintains cash and cash equivalents with diverse financial institutions and monitors the amount of credit exposure to each financial institution. The bank deposits are held in financial institutions which management believes are institutions with high credit standing, and accordingly, minimal credit risk from geographic or credit concentration exists with respect to these deposits.
 
The below table reflects the concentration of credit risk for the Company’s current customers as of December 31, 2023, to which substantial sales were made.
 
Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales.
 
 
 
December 31,
 
 
 
2023
   
2022
 
Customer A
   
*
)%
   
27
%
Customer B
   
*
)%
   
13
%
Customer C
   
-
     
13
%
Customer D
   
-
     
11
%
 
  *)
Less than 10%

 

The allowance for credit losses is based on the Company's assessments of factors that may affect a customer's ability to pay. The Company regularly reviews the adequacy of the allowance for credit losses based on a combination of factors, including an assessment of the current customer's aging balance, the nature and size of the customer, the financial condition of the customer, and the amount of any receivables in dispute. The Company does not have any off-balance sheet credit exposure related to its customers. As of December 31, 2023, and 2022 trade receivables are presented net of $328 thousand and $26 thousand allowance for credit losses, respectively.
 
  s.
Accrued Severance Pay:
 
Pursuant to Israel’s Severance Pay Law, Israeli employees are entitled to severance pay equal to one month’s salary for each year of employment, or a portion thereof. All of the employees of the RRL elected to be included under section 14 of the Severance Pay Law, 1963 (“section 14”). According to this section, these employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet.
 
Total Company’s expenses related to severance pay amounted to $114 thousand , $113 thousand and $104 thousand for the years ended December 31, 2023, 2022 and 2021, respectively.
 
  t.
Fair Value Measurements:
 
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a three -tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The three -tiers are defined as follows:
 
 
Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities;
 
 
Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
 
 
Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.
 
The carrying amounts of cash and cash equivalents, short term deposits, trade receivables and trade payables approximate their fair value due to the short-term maturity of such instruments.
 
The following tables present information about the Company’s financial assets and liabilities that are measured in fair value on a recurring basis as of December 31, 2023 and December 31, 2022 (in thousands):
 
       
Fair value measurements as of
 
Description
 
Fair Value Hierarchy
 
December 31, 2023
   
December 31,
2022
 
Financial assets:
               
                 
Money market funds included in cash and cash equivalent
 
Level 1
 
$
2,550
   
$
-
 
Treasury bills included in cash and cash equivalent
 
Level 1
 

$

2,525
   

$

-
 
                     
Total Assets Measured at Fair Value
     
$
5,075
   
$
-
 
                     
Financial Liabilities:
                   
Earnout
 
Level 3
 
$
3,292
   
$
-
 
                     
Total liabilities measured at fair value
     
$
3,292
   
$
-
 

 

The Company classifies cash equivalents within Level 1, because the Company uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair values.
 
The earnout was valued using a Monte Carlo simulation analysis, which is considered to be a Level 3 fair value measurement.
 
The following table summarizes the earnout liability activity as of December 31, 2023 (in thousands):
 
   
Earnout
   
Initial Measurement (August 11, 2023)
 
$
3,607
   
Change in fair value
   
(315)
   
Balance December 31, 2023
 
$
3,292
   
 
u. Basic and Diluted Net Loss Per Share:
 
Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding during the period.
 
Diluted loss per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus dilutive potential shares considered outstanding during the period.
 
v. Contingent liabilities
 
The Company accounts for its contingent liabilities in accordance with ASC 450, “Contingencies.” A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
 
With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.
 
w. Government grants
 
Royalty and non-royalty-bearing grants from the Israeli Innovation Authority (the “IIA”) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a reduction from research and development expenses (see Note 8c).

 

x. Leases
 
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded at commencement date based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.
 
Leases with an initial term of 12 months or less are not recorded on the balance sheet.
 
Lessor accounting - Operating leases
 
A portion of the AlterG rental revenues for the AlterG Anti-Gravity systems are made through lease arrangements.
 
AlterG products are available for lease agreements ranging from 12 to 42 months. If the customer terminates the contract during the lease period, they are required to pay a cancellation fee. The lease period may be extended by an additional period as specified in the contract.
 
In determining the leases classification as a sales type or operating lease, the Company assesses, among other criteria: (i) the lease term to determine if it is for the major part of the economic life of the underlying equipment; and (ii) the present value of the lease payments to determine if they are equal to or greater than substantially all of the fair market value of the equipment at the inception of the lease AlterG Anti-Gravity systems. When these criteria are not met, the lease accounted for as operating leases and revenues are recognized over the term of the lease.
 
Under these arrangements, when the Company acts as the lessor for its product line, the Company accounted for the lease arrangements as operating leases in accordance with ASC 842, “Lease” (“ASC 842”).
 
The total rental revenue for the AlterG Anti-Gravity Products has amounted to $249 thousand from the time of acquisition through December 31, 2023.
 
y.  New Accounting Pronouncements
 
Recently Implemented Accounting Pronouncements
 
i.           Financial Instruments
 
In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. The Company adopted ASU 2016-13 as of January 1, 2023. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.
 
Recent Accounting Pronouncements Not Yet Adopted
 
 
i.
In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes - Improvements to Income Tax Disclosures” requiring enhancements and further transparency to certain income tax disclosures, most notably the tax rate reconciliation and income taxes paid. This ASU is effective for fiscal years beginning after December 15, 2024 on a prospective basis and retrospective application is permitted. The Company is currently evaluating the impact of the adoption of this standard.
 
 
ii.
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, “Segment Reporting” on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.
XML 29 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
PREPAID EXPENSES AND OTHER CURRENT ASSETS
12 Months Ended
Dec. 31, 2023
PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]  
PREPAID EXPENSES AND OTHER CURRENT ASSETS
NOTE 3:-
PREPAID EXPENSES AND OTHER CURRENT ASSETS
 
The components of prepaid expenses and other current assets are as follows (in thousands):
 
 
 
December 31,
 
 
 
2023
   
2022
 
Government institutions
 
$
253
   
$
81
 
Prepaid expenses
   
1,227
     
242
 
Advances to vendors
   
139
     
174
 
Other assets
   
747
     
152
 
 
               
 
 
$
2,366
   
$
649
 
XML 30 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORIES
12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
INVENTORIES
NOTE 4:-
INVENTORIES
 
The components of inventories are as follows (in thousands):
 
 
 
December 31,
 
 
 
2023
   
2022
 
Finished products
 
$
3,157
   
$
2,421
 
Raw materials
   
2,496
     
508
 
 
               
 
 
$
5,653
   
$
2,929
 
 
During the twelve months ended December 31, 2023, 2022, and 2021, the Company recognized, at cost of revenues, reserves for excess and obsolete in the amount of $398 thousand, $502 thousand, and $252 thousand, respectively.
XML 31 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATION
12 Months Ended
Dec. 31, 2023
Business Combinations [Abstract]  
BUSINESS COMBINATION
NOTE 5:- BUSINESS COMBINATION
 
On August 11, 2023, pursuant to an Agreement and Plan of Merger among RRI, AlterG, Merger Sub, and Shareholder Representative Services LLC, RRI, August 8, 2023, the Company acquired AlterG and AlterG became a wholly owned subsidiary of the Company. AlterG develops, manufactures, and markets Anti-Gravity systems for use in physical and neurological rehabilitation and athletic training, both in the United States and internationally. The aggregate purchase price was a total of $19.0 million in cash, subject to working capital and other customary purchase price adjustments. Additional cash earnouts may be paid based upon a percentage of AlterG’s year-over-year future revenue growth over the next two years subject to working capital and other customary purchase price adjustments.
 
The total consideration transferred is as follows (in thousands):
 
Cash
 
$
18,493
 
Earnout payments
 
$
3,607
 
Total consideration
 
$
22,100
 
 
Earnout payments
 
The Company will pay an amount of cash equal to 65% of the amount, if any, by which AlterG revenue attributable to the first 12 months period exceeds revenue target ("first earnout payment"), and an amount in cash equal to 65% of the amount, if any, by which AlterG revenue attributable to the following 12 months period exceeds the revenue from the first 12 month period ("second earnout payment"). At the date of acquisition, management estimated fair value of the earnout payment based on the actual up to date performance of the acquired entity and the probability of the earn out payment occurrence to be at approximately $3.6 million. The Earn-out was accounted for as a liability and will be remeasured at each reporting period through the consolidated statement of operations.
 
The Company has accounted for the AlterG acquisition as a business combination. The Company has preliminarily allocated the purchase price of approximately $22.1 million fair values, and the excess of the purchase price over the aggregate fair values is recorded as goodwill.
 
The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date (in thousands):
 
Cash and cash equivalent
 
$
478
 
Restricted cash
   
51
 
Accounts receivable
   
1,773
 
Inventory
   
3,330
 
Prepaid expenses and other current assets
   
470
 
Right of use asset
   
1,151
 
Property and equipment, net
   
827
 
Other non-current assets
   
30
 
Goodwill
   
7,538
 
Intangible assets
   
14,133
 
Accounts payable
   
(2,082
)
Accrued compensation
   
(766
)
Other accrued liabilities
   
(1,059
)
Deferred revenue
   
(2,088
)
Warranty Obligations
   
(535
)
Leases Liability
   
(1,151
)
Total purchase consideration
 
$
22,100
 

 

The following table presents the details of the intangible assets acquired at the date of AlterG acquisition (in thousands):
 
   
 
Estimated
   
Estimated Useful Life
 
   
Fair Value
   
(Years)
 
Trademark
 
$
795
     
3
 
Technology
   
6,161
     
4
 
Customer relationship - Warranty
   
201
     
2
 
Customer relationship - Rental
   
2,102
     
4
 
Customer relationship - Distribution
   
4,578
     
5
 
Backlog
   
296
     
1
 
 
Under the preliminary purchase price allocation, the Company allocates the purchase price to tangible and identified intangible assets acquired and liabilities assumed based on the preliminary estimates of their fair values. The fair values for the intangible assets acquired were primarily based on significant inputs that are not observable in the market and thus represent a Level 3 measurement in the fair value hierarchy. Customer relationships, distributor relationships, backlog, trademark and developed technology were valued using the income approach, based on estimated projections of expected cash flows to be generated by the assets, discounted to the present value at discount rates commensurate with perceived risk. The discounted cash flow analyses factor in assumptions on revenue and expense growth rates including estimates of customer growth and attrition rates, distributor growth and attrition rates, technology obsolescence, and relief from royalty projections. Additionally, these discounted cash flow analyses factor in expected amounts of working capital, fixed assets, assembled workforce and cost of capital for each intangible asset. Such estimates are subject to change during the measurement period which is not expected to exceed one year. Any adjustments to the preliminary purchase price allocation identified during the measurement period will be recognized in the period in which the adjustments are determined.
 
The Company incurred acquisition-related costs of $2.5 million included in General and administrative costs.
 
The table below presents the pro forma revenue and earnings of the combined business as if the acquisition had occurred as of January 1, 2022 (in thousands):
 
   
Twelve Months Ended
December 31,
 
   
2023
   
2022
 
Revenues
   
24,923
     
25,307
 
Net loss
   
(21,761
)
   
(28,369
)
 
The total revenues and net loss of AlterG, included in the consolidated income statement, since the acquisition date through December 31, 2023, amounted to 7,658 thousand and 249 thousand, respectively.
 
The pro forma financial information for all periods presented above has been calculated after adjusting the results of AlterG to reflect the business combinations accounting effects resulting from these acquisitions.
 
These proforma results reflect additional depreciation and amortization that would have been charged assuming the fair value adjustments to property, plant, and equipment and intangible asset occurred at the beginning of the period, along with consequential tax effects. The unaudited pro forma results have been prepared for comparative purposes only and are not necessarily indicative of what would have occurred had the business combinations been completed on January 1, 2022, nor it is necessarily indicative of future results of operations of the combined company. Furthermore, the unaudited pro forma financial information does not reflect the impact of any synergies resulting from the acquisition.
XML 32 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS, NET
12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS, NET
NOTE 6:- GOODWILL AND OTHER INTANGIBLE ASSETS, NET
 
The Company has $7.5 million of goodwill related to its purchase of AlterG in the third quarter of fiscal year 2023, which has an indefinite life, and is not deductible for tax purposes.
 
As of December 31, 2023, the components of, and changes in, the carrying amount of intangible assets, net, were as follows (in thousands):
 
   
 
 
Cost
   
December 31, 2023 Accumulated
Amortization
   
 
Intangible Assets, Net
 
Trademark
   
795
     
(104
)
   
691
 
Technology
   
6,161
     
(604
)
   
5,557
 
Customer relationship - Warranty
   
201
     
(40
)
   
161
 
Customer relationship - Rental
   
2,102
     
(206
)
   
1,896
 
Customer relationship - Distribution
   
4,578
     
(358
)
   
4,220
 
Backlog
   
296
     
(296
)
   
-
 
Total Amortized Intangible Assets
   
14,133
     
(1,608
)
   
12,525
 

 

The estimated amortization expense is shown below (in thousands):

 

Fiscal 2024
                   
3,347
 
Fiscal 2025
                   
3,307
 
Fiscal 2026
                   
3,143
 
Fiscal 2027
                   
2,172
 
Fiscal 2028
                   
556
 
Total
                   
12,525
 
XML 33 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY AND EQUIPMENT, NET
12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT, NET
NOTE 7:-
PROPERTY AND EQUIPMENT, NET
 
The components of property and equipment, net are as follows (in thousands):
 
 
 
December 31,
 
 
 
2023
   
2022
 
Cost:
           
Computer equipment
 
$
1,690
   
$
743
 
Office furniture and equipment
   
468
     
308
 
Machinery and laboratory equipment
   
621
     
621
 
Field service units
   
4,166
     
1,816
 
Leasehold improvements
   
658
     
333
 
 
               
 
 
$
7,603
   
$
3,821
 
 
 
 
December 31,
 
 
 
2023
   
2022
 
Accumulated depreciation
   
6,341
     
3,625
 
 
               
Property and equipment, net
 
$
1,262
   
$
196
 
 
Depreciation expenses amounted to $239 thousand, $202 thousand, and $266 thousand for the years ended December 31, 2023, 2022 and 2021, respectively.
XML 34 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENT LIABILITIES
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENT LIABILITIES
NOTE 8:-
COMMITMENTS AND CONTINGENT LIABILITIES
 
  a.
Purchase commitment:
 
The Company has contractual obligations to purchase goods from its contract manufacturer as well as raw materials from different vendors. Purchase obligations do not include contracts that may be cancelled without penalty. As of December 31, 2023, non-cancellable outstanding obligations amounted to approximately $8.6 million.
 
  b.
Operating lease commitment:
 
  (i)
The Company operates from leased facilities in Israel, the United States and Germany. These leases expire between 2024 and 2025. A portion of the Company’s facilities leases is generally subject to annual changes in the Consumer Price Index (CPI). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred.
 
  (ii)
RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates in between 2024 and 2026 A subset of the Company’s cars leases is considered variable. The variable lease payments for such cars leases are based on actual mileage incurred at the stated contractual rate. RRL and RRG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $30 thousand as of December 31, 2023.
 
The Company’s future lease payments for its facilities and cars, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company’s consolidated balance sheets as of December 31, 2023 are as follows (in thousands):
 
2024
 
$
1,363
 
2025
   
674
 
2026
   
13
 
Total lease payments
   
2,050
 
Less: imputed interest
   
(147
)
Present value of future lease payments
   
1,903
 
Less: current maturities of operating leases
   
(1,296
)
Non-current operating leases
 
$
607
 
Weighted-average remaining lease term (in years)
   
1.92
 
Weighted-average discount rate
   
9.21
%
 
Total lease expenses for the years ended December 31, 2023, 2022 and 2021 were $976 thousand, $739 thousand, and $730 thousand, respectively.
 
  c.
Royalties:
 
The Company’s research and development efforts are financed, in part, through funding from the Israel Innovation Authority (“IIA”). Since the Company’s inception through December 31, 2023, the Company received funding from the IIA in the total amount of $2.6 million. Out of the $2.6 million in funding from the IIA, a total amount of $1.6 million were royalty-bearing grants, $400 thousand was received in consideration of 209 convertible preferred A shares, which converted after the Company’s initial public offering in September 2014 into ordinary shares in a conversion ratio of 1 to 1, while $570 thousand was received without future obligation. The Company is obligated to pay royalties to the IIA, amounting to 3% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required.
 
As of December 31, 2023, the Company paid royalties to the IIA in the total amount of $110 thousand.
 
Royalties expenses in cost of revenue were $17 thousand, $7 thousand and $14 thousand, for the years ended December 31, 2023, 2022 and 2021, respectively.
 
As of December 31, 2023, the contingent liability to the IIA amounted to $1.6 million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel.
 
Additionally, the License Agreement requires the Company to pay College (“Harvard”) royalties on net sales, see Note 10 below for more information about the Collaboration Agreement (as defined below) and the License Agreement (as defined below).

 

  d.
Liens
 
As part of the Company’s restricted cash and other long-term assets, as of December 31, 2023, an amount of $709 thousand has been pledged as security in respect of a guarantee granted to a third party. Such deposit cannot be pledged to others or withdrawn without the consent of such third party.
 
  e.
Legal Claims:
 
Occasionally, the Company is involved in various claims such as product liability claims, lawsuits, regulatory examinations, investigations, and other legal matters arising, for the most part, in the ordinary course of business. While the outcome of any pending or threatened litigation and other legal matters is inherently uncertain, the Company does not believe the outcome of any of the matters will have a material adverse effect on the Company’s consolidated results of operation, liquidity or financial condition.
XML 35 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHAREHOLDERS' EQUITY
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
SHAREHOLDERS' EQUITY
NOTE 9:-
SHAREHOLDERS’ EQUITY
 
  a.
Equity raise:
 
Follow-on offerings
 
On February 19, 2021, the Company entered into a purchase agreement with certain institutional and other accredited investors for the issuance and sale of 10,921,502 ordinary shares, par value NIS 0.25 per share at $3.6625 per ordinary share and warrants to purchase up to an aggregate of 5,460,751 ordinary shares with an exercise price of $3.6 per share, exercisable from February 19, 2021, until August 26, 2026. Additionally, the Company issued warrants to purchase up to 655,290 ordinary shares, with an exercise price of $4.578125 per share, exercisable from February 19, 2021, until August 26, 2026, to the Company February 2021 private placement offering.
 
On September 27, 2021, the Company signed a purchase agreement with certain institutional investors for the issuance and sale of 15,403,014 ordinary shares, par value NIS 0.25 per share, pre-funded warrants to purchase up to an aggregate of 610,504 ordinary shares and ordinary warrants to purchase up to an aggregate of 8,006,759 ordinary shares at an exercise price of $2.00 per share. The Pre-Funded Warrants have an exercise price of $0.001 per Ordinary Share and are immediately exercisable and can be exercised at any time after their original issuance until such pre-funded warrants are exercised in full. Each ordinary shares was sold at an offering price of $2.035 and each pre-funded warrant was sold at an offering price of $2.034 (equal to the purchase price per ordinary share minus the exercise price of the pre-funded warrant). The ordinary warrants are exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending five and one-half years from the date of issuance. All of the pre-funded warrants were exercised in full on September 27, 2021, and the offering closed on September 29, 2021. Additionally, the Company issued warrants to purchase up to 960,811 ordinary shares, with an exercise price of $2.5438 per share, exercisable from September 27, 2021, until September 27, 2026, to the Company September 2021 registered direct offering.
 
As of December 31, 2023, a total of 9,814,754 outstanding warrants with exercise prices ranging from $1.25 to $1.79 were exercised, for total gross proceeds of approximately $13.8 million. During the twelve months that ended December 31, 2023 no warrants were exercised.
 
  b.
Share option plans:
 
On March 30, 2012, the Company’s board of directors adopted the ReWalk Robotics Ltd. 2012 Equity Incentive Plan.
 
On August 19, 2014, the Company’s board of directors adopted the ReWalk Robotics Ltd. 2014 Incentive Compensation Plan or the “Plan”. The Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, cash-based awards, other stock-based awards and dividend equivalents to the Company’s and its affiliates’ respective employees, non-employee directors and consultants.

 

Starting in 2014, the Company grants to directors and employees also RSU under this Plan. An RSU award is an agreement to issue shares of the company’s ordinary shares at the time the award is vested.
 
As of December 31, 2023 and 2022, the Company had reserved 1,018,945 and 2,934,679 shares of ordinary shares, respectively, available for issuance to employees, directors, officers, and non-employees of the Company.
 
The options generally vest over four years, with certain options granted to non-employee directors vesting over one year.
 
Any option or RSUs that are forfeited or cancelled before expiration becomes available for future grants under the Plan.
 
A summary of employee and non-employee shares options activity during the fiscal year ended 2023 is as follows:
 
 
 
Number
   
Weighted
average
exercise
price
   
Weighted
average
remaining
contractual
life (years)
   
Aggregate
intrinsic
value (in
thousands)
 
Options outstanding at the beginning of the year
   
43,994
   
$
41.27
     
4.39
   
$
-
 
Granted
   
-
     
-
     
-
     
-
 
Exercised
   
-
     
-
     
-
     
-
 
Forfeited
   
(10,823
)
   
52.78
     
-
     
-
 
 
                               
Options outstanding at the end of the year
   
33,171
   
$
37.51
     
4.39
   
$
-
 
 
                               
Options exercisable at the end of the year
   
33,171
   
$
37.51
     
4.39
   
$
-
 
 
There were no options granted during the fiscal year ended December 31, 2023, 2022 and 2021. The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders, which hold options with positive intrinsic value, exercised their options on the last date of the exercise period. During the years ended December 31, 2023, 2022 and 2021, no options were exercised.
 
A summary of employee and non-employee RSUs activity during the fiscal year ended 2023 is as follows:
 
 
 
Number of
shares
underlying
outstanding
RSUs
   
Weighted-
average
grant date
fair value
 
Unvested RSUs at the beginning of the year
   
2,755,057
     
1.16
 
Granted
   
2,258,370
     
0.66
 
Vested
   
(1,109,200
)
   
1.14
 
Forfeited
   
(131,813
)
   
1.13
 
 
               
Unvested RSUs at the end of the year
   
3,772,414
     
0.87
 
 
The weighted average grant date fair values of RSUs granted during the fiscal year ended December 31, 2023, 2022 and 2021, were $0.66, $1.00 and $1.69, respectively.
 
Total fair value of shares vested during the year ended December 31, 2023, 2022 and 2021 were $1,268 thousand, $860 thousand, and $802 thousand, respectively. As of December 31, 2023, there were $2.7 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2014 Plan. This cost is expected to be recognized over a period of approximately 2.9 years.
 
The number of options and RSUs outstanding as of December 31, 2023 is set forth below, with options separated by range of exercise price:
 
Range of exercise price
 
Options and
RSUs
Outstanding
as of
December 31,
2023
 
 
Weighted
average
remaining
contractual
life
(years) (1)
 
 
Options
Exercisable
as of
December 31,
2023
 
 
Weighted
average
remaining
contractual
life
(years) (1)
 
RSUs only
 
 
3,772,414
 
 
 
-
 
 
 
-
 
 
 
-
 
$5.37 
 
 
12,425
 
 
 
5.24
 
 
 
12,425
 
 
 
5.24
 
$20.42- $33.75 
 
 
12,943
 
 
 
4.35
 
 
 
12,943
 
 
 
4.35
 
$50-$52.5 
 
 
6,230
 
 
 
3.46
 
 
 
6,230
 
 
 
3.46
 
$182.5-$524.25 
 
 
1,573
 
 
 
1.65
 
 
 
1,573
 
 
 
1.65
 
 
 
 
3,805,585
 
 
 
4.39
 
 
 
33,171
 
 
 
4.39
 
 
 
(1)
Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

 

  c.
Equity compensation issued to consultants:
 
The Company granted 32,895 RSUs during the fiscal year ended December 31, 2023, to non-employee consultants. As of December 31, 2023, there are 21,929 outstanding RSUs held by non-employee consultants.
 
  d.
Share-based compensation expense for employees and non-employees:
 
The Company recognized share-based compensation expense in the consolidated statements of operations as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Cost of revenue
 
$
9
   
$
16
   
$
10
 
Research and development, net
   
157
     
94
     
55
 
Sales and marketing
   
381
     
250
     
171
 
General and administrative
   
781
     
633
     
597
 
 
                       
Total
 
$
1,328
   
$
993
   
$
833
 

 

  e.
Treasury shares:
 
On June 2, 2022, the Company’s Board of Directors approved a share repurchase program to repurchase up to $8.0 million of its Ordinary Shares, par value NIS 0.25 per share. On July 21, 2022, the Company received approval from an Israeli court for the share repurchase program. The program was scheduled to expire on the earlier of January 20, 2023, or reaching $8.0 million of repurchases. On December 22, 2022, the Company’s Board of Directors approved an extension of the repurchase program, with such extension to be in the aggregate amount of up to $5.8 million. The extension was approved by an Israeli court on February 9, 2023, and it expired on August 9, 2023.
 
As of December 31, 2023, pursuant to the Company’s share repurchase program, the Company had repurchased a total of 4,022,607 of its outstanding ordinary shares at a total cost of $3.5 million.

 

  f.
Warrants to purchase ordinary shares:
 
The following table summarizes information about warrants outstanding and exercisable as of December 31, 2023:
 
Issuance date
 
Warrants
outstanding
   
Exercise price
per warrant
   
Warrants
outstanding
and
exercisable
 
Contractual
term
 
 
(number)
         
(number)
 
 
December 31, 2015 (1)
   
4,771
   
$
7.500
     
4,771
 
See footnote (1)
December 28, 2016 (2)
   
1,908
   
$
7.500
     
1,908
 
See footnote (1)
February 25, 2019 (5)
   
45,600
   
$
7.187
     
45,600
 
February 21, 2024
April 5, 2019 (6)
   
408,457
   
$
5.140
     
408,457
 
October 7, 2024
April 5, 2019 (7)
   
49,015
   
$
6.503
     
49,015
 
April 3, 2024
June 5, 2019, and June 6, 2019 (8)
   
1,464,665
   
$
7.500
     
1,464,665
 
June 5, 2024
June 5, 2019 (9)
   
87,880
   
$
9.375
     
87,880
 
June 5, 2024
June 12, 2019 (10)
   
416,667
   
$
6.000
     
416,667
 
December 12, 2024
June 10, 2019 (11)
   
50,000
   
$
7.500
     
50,000
 
June 10, 2024
February 10, 2020 (12)
   
28,400
   
$
1.250
     
28,400
 
February 10, 2025
February 10, 2020 (13)
   
105,840
   
$
1.563
     
105,840
 
February 10, 2025
July 6, 2020 (14)
   
448,698
   
$
1.760
     
448,698
 
January 2, 2026
July 6, 2020 (15)
   
296,297
   
$
2.278
     
296,297
 
January 2, 2026
December 8, 2020 (16)
   
586,760
   
$
1.340
     
586,760
 
June 8, 2026
December 8, 2020 (17)
   
108,806
   
$
1.792
     
108,806
 
June 8, 2026
February 26, 2021 (18)
   
5,460,751
   
$
3.600
     
5,460,751
 
August 26, 2026
February 26, 2021 (19)
   
655,290
   
$
4.578
     
655,290
 
August 26, 2026
September 29, 2021 (20)
   
8,006,759
   
$
2.000
     
8,006,759
 
March 29, 2027
September 29, 2021 (21)
   
960,811
   
$
2.544
     
960,811
 
September 27, 2026
 
   
19,187,375
             
19,187,375
 
 
 
  (1)
Represents warrants for ordinary shares issuable upon an exercise price of $7.500 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2023.
 
  (2)
Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.
 
  (3)
Represents common warrants that were issued as part of the Company’s follow-on public offering in November 2018.
 
  (4)
Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on public offering in November 2018.
 
  (5)
Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on public offering in February 2019.
 
  (6)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019.
 
  (7)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering.

 

  (8)
Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively.
 
  (9)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants.
 
  (10)
Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.
 
  (11)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants.
 
  (12)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of December 31, 2023, 3,740,100 warrants were exercised for total consideration of $4,675,125. During the twelve months that ended December 31, 2023, no warrants were exercised.
 
  (13)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of December 31, 2023, 230,160 warrants were exercised for total consideration of $359,625. During the twelve months that ended December 31, 2023, no warrants were exercised.
 
  (14)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in July 2020. As of December 31, 2023, 2,020,441 warrants were exercised for total consideration of $3,555,976. During the twelve months that ended December 31, 2023, no warrants were exercised.
 
  (15)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering.
 
  (16)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s private placement offering of ordinary shares in December 2020. As of December 31, 2023, 3,598,072 warrants were exercised for total consideration of $4,821,416. During the twelve months that ended December 31, 2023, no warrants were exercised.
 
  (17)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of December 31, 2023, 225,981 warrants were exercised for total consideration of $405,003. During the twelve months that ended December 31, 2023, no warrants were exercised.
 
  (18)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s private placement offering of ordinary shares in February 2021.
 
  (19)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement.
 
  (20)
Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in September 2021.
 
  (21)
Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.
XML 36 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT
12 Months Ended
Dec. 31, 2023
Research and Development [Abstract]  
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT
NOTE 10:-
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT
 
On May 16, 2016, the Company entered into a Collaboration Agreement (as amended, the “Collaboration Agreement”) and an Exclusive License Agreement (as amended, the “License Agreement”) with Harvard. The Collaboration Agreement concluded on March 31, 2022.
 
Under the License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration.

 

The License Agreement required the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The Harvard License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents.
 
As of December 31, 2023, the Company achieved three of the milestones which represent all development milestones under the License Agreement. The Company continues to evaluate the likelihood that the other milestones will be achieved on a quarterly basis.
 
The Company has recorded expenses in the amount of $29 thousand, $74 thousand, and $293 thousand as research and development expenses related to the License Agreement and to the Collaboration Agreement for the years ended December 31, 2023, 2022 and 2021, respectively. No withholding tax was deducted from the Company’s payments to Harvard in respect of the Collaboration Agreement and the License Agreement since this is not taxable income in Israel in accordance with Section 170 of the Israel Income Tax Ordinance 1961-5721.
XML 37 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE 11:-
INCOME TAXES
 
The Company’s subsidiaries are separately taxed under the domestic tax laws of the jurisdiction of incorporation of each entity.
 
a. Corporate tax rates in Israel:
 
Presented hereunder are the tax rates relevant to the Company in the years 2021-2023:
 
The Israeli statutory corporate tax rate and real capital gains were 23% in the years 2021-2023.
 
b. Income (loss) before taxes on income is comprised as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Domestic
 
$
(19,638
)
 
$
(19,110
)
 
$
(12,780
)
Foreign
   
(2,507
)
   
8
     
138
 
 
 
$
(22,145
)
 
$
(19,102
)
 
$
(12,642
)
 
c. Taxes on income (benefit) are comprised as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Current
 
$
(12
)
 
$
151
   
$
123
 
Deferred
   
-
     
316
     
(29
)
 
                       
   
$
(12
)
 
$
467
   
$
94
 
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Domestic
 
$
-
   
$
-
   
$
-
 
Foreign
   
(12
)
   
467
     
94
 
 
                       
 
 
$
(12
)
 
$
467
   
$
94
 

 

d. Deferred income taxes (in thousands):
 
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets as of December 31, 2023 and 2022 are derived from temporary differences.
 
In assessing the realization of deferred tax assets, the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. Based on the Company’s history of losses, the Company established a full valuation allowance for RRL.
 
Undistributed earnings of certain subsidiaries as of December 31, 2023 were immaterial. The Company intends to reinvest these earnings indefinitely in the foreign subsidiaries. As a result, the Company has not provided for any deferred income taxes.
 
 
 
December 31,
 
 
 
2023
   
2022
 
Deferred tax assets:
           
Carry forward tax losses
 
$
64,090
   
$
50,833
 
Research and development carry forward expenses-temporary differences
   
1,311
     
844
 
Accrual and reserves
   
849
     
392
 
Share based compensation
   
394
     
456
 
Credit tax carry forwards
   
1,714
     
-
 
Lease liabilities
   
480
     
214
 
Total deferred tax assets
   
68,838
     
52,739
 
Deferred tax liabilities:
               
Right-of-use asset
   
(470
)
   
(214
)
Intangible Assets
   
(3,015
)
   
-
 
Property and equipment
   
(144
)
   
-
 
Net deferred tax assets
   
65,209
     
52,525
 
Valuation allowance
   
(65,209
)
   
(52,525
)
 
               
Net deferred tax assets
 
$
-
   
$
-
 
 
The net changes in the total valuation allowance for each of the years ended December 31, 2023, 2022 and 2021, are comprised as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Balance at beginning of year
 
$
(52,525
)
 
$
(48,098
)
 
$
(42,941
)
Changes due to exchange rate differences
   
-
     
1,418
     
(1,488
)
Adjustment previous year loss
   
(5
)    
(14
)
   
-
 
Acquisition
   
(7,269
)
   
-
     
-
 
Additions during the year
   
(5,410
)
   
(5,831
)
   
(3,669
)
 
                       
Balance at end of year
 
$
(65,209
)
 
$
(52,525
)
 
$
(48,098
)

 

e. Reconciliation of the theoretical tax expenses:
 
A reconciliation between the theoretical tax expense, assuming all income is taxed at the statutory tax rate applicable to income of the Company, and the actual tax expense (benefit) as reported in the consolidated statements of operations is as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Loss before taxes, as reported in the consolidated statements of operations
 
$
(22,145
)
 
$
(19,102
)
 
$
(12,642
)
 
                       
Statutory tax rate
   
23
%
   
23.0
%
   
23.0
%
 
                       
Theoretical tax benefits on the above amount at the Israeli statutory tax rate
 
$
(5,093
)
 
$
(4,393
)
 
$
(2,908
)
Income tax at rate other than the Israeli statutory tax rate
   
56
     
(2
)
   
7
 
Non-deductible expenses including equity-based compensation expenses and other 
   
-
     
262
     
102
 
Operating losses and other temporary differences for which valuation allowance was provided
   
5,410
     
5,375
     
3,669
 
Permanent differences
   
(342
)
   
(775
)
   
(784
)
Adjustment in respect of prior years
   
(43
)
   
-
     
-
 
Other
   
-
     
-
     
8
 
 
                       
Actual tax expense (benefit)
 
$
(12
)
 
$
467
   
$
94
 
 
f. Foreign tax rates:
 
Taxable income of RRI and AlterG was subject to tax at the rate of 21% in 2023, 2022 and 2021.
 
Taxable income of RRG was subject to tax at the rate of 30% in 2023, 2022, and 2021.
 
g. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Investment Law”):
 
Conditions for entitlement to the benefits:
 
Under the Investment Law, in 2012 the Company elected “Beneficiary Enterprise” status which provides certain benefits, including tax exemptions and reduced tax rates. Income not eligible for Beneficiary Enterprise benefits is taxed at a regular rate.
 
Income derived from Beneficiary Enterprise from productive activity will be exempt from tax for ten years from the year in which the Company first has taxable income, providing that 12 years have not passed from the beginning of the year of election. In the event of a dividend distribution from income that is exempt from company tax, as aforementioned, the Company will be required to pay tax of 10%-25% on that income.
 
In the event of distribution of dividends from the said tax-exempt income, the amount distributed will be subject to corporate tax at the rate ordinarily applicable to the Beneficiary Enterprise’s income. Tax-exempt income generated under the Company’s “Beneficiary Enterprise” program will be subject to taxes upon dividend distribution or complete liquidation.
 
The entitlement to the above benefits is conditional upon the Company’s fulfilling the conditions stipulated by the Law and regulations published thereunder.
 
h. Tax assessments:
 
RRL, RRI and RRG has had final tax assessments up to and including the 2017 tax year.

 

AlterG files income tax returns in the United States and in various U.S. states.  AlterG returns for the years ended December 31, 2020 and later are generally subject to federal tax examination, while the AlterG returns for the years ended December 31, 2019 and later are generally subject to state tax examination.  However, the AlterG net operating losses and tax credits generally remain subject to tax examination and adjustment until they are utilized on a future tax return and the statute of limitations closes for that year.  Thus, the AlterG tax attributes generally remain open to federal and state tax examination and adjustment.
 
i. Net operating carry-forward losses for tax purposes:
 
As of December 31, 2023, RRL has carry-forward losses amounting to approximately $242.6 million, which can be carried forward for an indefinite period.
 
As of December 31, 2023, AlterG had approximately $31.4 million of federal net operating loss (“NOL”) carry forwards, and $47.2 million of state NOL carry forwards, which will begin to expire in 2025 and 2028, respectively.  The federal net operating losses from years beginning after January 1, 2018, of approximately $14.7 million may be carried forward indefinitely and losses prior to January 1, 2018 of approximately $16.7 million expire beginning in 2028 under prior law.
 
Internal Revenue Code Section 382 places a limitation ("Section 382 Limitation") on the amount of taxable income which can be offset by NOL carry forwards after a change in control (generally greater than 50% change in the value of the stock owned by 5% shareholders during the testing period) of a loss corporation. California has similar rules. On August 11, 2023, AlterG was involved in an equity transaction that constitutes a Section 382 change in ownership. The change in ownership limits the ability to utilize net operating loss carry forwards in future years. The 382-limitation impact on NOLs has been included in the current period provision. The Company may have had earlier Section 382 changes in ownership. This will be assessed upon realization of tax attributes.
XML 38 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL EXPENSES (INCOME), NET
12 Months Ended
Dec. 31, 2023
Other Income and Expenses [Abstract]  
FINANCIAL EXPENSES (INCOME), NET
NOTE 12:-
FINANCIAL (EXPENSES) INCOME, NET
 
The components of financial (expenses) income, net were as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Foreign currency transactions and other
 
$
133
   
$
22
   
$
38
 
Interest Income
   
1,354
     
-
     
-
 
Bank commissions
   
(20
)
   
(22
)
   
(25
)
 
                       
 
 
$
1,467
   
$
*
)
 
$
13
 
 
*) Represent an amount lower than $1.
XML 39 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA
12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA
NOTE 13:-
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA
 
The Company manages its business on a basis of one reportable segment.
 
Total revenues from external customers on the basis of the Company's geographical areas are as follows (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Revenue based on customer’s location:
                 
United States
   
7,636
     
2,303
     
2,519
 
Europe
   
5,044
     
3,057
     
3,381
 
Asia-Pacific
   
387
     
115
     
60
 
Rest of the world
   
787
     
36
     
6
 
 
                       
Total revenues
 
$
13,854
   
$
5,511
   
$
5,966
 
 
 
 
December 31,
 
 
 
2023
   
2022
 
Long-lived assets by geographic region:
           
Israel
 
$
529
   
$
757
 
United States
   
2,404
     
231
 
Germany
   
190
     
44
 
 
               
 
 
$
3,123
   
$
1,032
 
 
  (*)
Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.
 
Major customers data as a percentage of total revenue:
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Customer A
   
12.2
%
   
14.2
%
   
*
)
Customer B
   
*
)
   
*
)
   
11.0
%

 

  *)

Less than 10%

XML 40 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
BASIC AND DILUTED NET LOSS PER SHARE
12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
BASIC AND DILUTED NET LOSS PER SHARE
NOTE 14:- BASIC AND DILUTED NET LOSS PER SHARE
 
The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share (in thousands, except share and per share data):
 
 
 
Year ended December 31,
 
 
 
2023
   
2022
   
2021
 
Net loss
 
$
(22,133
)
 
$
(19,569
)
 
$
(12,736
)
 
                       
Net loss attributable to ordinary shares
   
(22,133
)
   
(19,569
)
   
(12,736
)
Shares used in computing net loss per ordinary shares, basic and diluted
   
59,719,064
     
62,378,797
     
47,935,652
 
 
                       
Net loss per ordinary share, basic and diluted
 
$
(0.37
)
 
$
(0.31
)
 
$
(0.27
)
 
Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of ordinary shares and warrants outstanding would have been anti-dilutive.
 
For the twelve months ended December 31, 2023, the total number of ordinary shares related to the outstanding warrants and share option plans aggregated to 19,220,546, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect.
 
For the twelve months ended December 31, 2022, the total number of ordinary shares related to the outstanding warrants and share option plans aggregated to 19,464,888, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect.
XML 41 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
RESTRUCTURING ACTIVITIES
12 Months Ended
Dec. 31, 2023
Restructuring and Related Activities [Abstract]  
Restructuring and Related Activities Disclosure [Text Block]
NOTE 15:- RESTRUCTURING ACTIVITIES
 
On December 12, 2023, the Board of Directors of the Company approved a re-organization plan (the “2023 Reorganization Plan”) that included, among other things, downsizing approximately 15% of the Company’s workforce and adapting the Company's organizational structure, roles, and responsibilities accordingly.
 
During the year ended December 31, 2023, in connection with the 2023 Reorganization Plan, the Company recorded expenses of $670 thousand, for one time employee termination benefits and legal expenses. $175 thousand attributable to research and development, net, $70 thousand to sales and marketing and $425 thousand to General and administrative expenses. However, none of these amounts were paid in 2023. The Company does not expect to incur additional costs related to the 2023 Reorganization Plan.
XML 42 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Use of Estimates
  a.
Use of Estimates
 
The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to inventories, fair values of share-based awards, contingent liabilities, provision for warranty, allowance for credit losses and sales return reserve. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
Financial Statements in U.S. Dollars
  b.
Financial Statements in U.S. Dollars:
 
The functional currency is the currency that best reflects the economic environment in which the Company and its subsidiaries operate and conduct their transactions. Most of the Company’s revenues and costs are incurred in U.S. dollar. In addition, the Company’s financing activities are incurred in U.S. dollars. The Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and each of its subsidiaries operate. Thus, the dollar is the Company’s and its subsidiary's functional and reporting currency.
 
Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are remeasured into U.S. dollars in accordance with ASC 830 “Foreign Currency Matters.” All transaction gains and losses of the remeasured monetary balance sheet items are reflected in the consolidated statements of operations as financing income or expenses as appropriate.
Principles of Consolidation
  c.
Principles of Consolidation:
 
The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances have been eliminated upon consolidation.
Cash Equivalents
  d.
Cash Equivalents:
 
Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less, at the date acquired.
Inventories
  e.
Inventories:
 
Inventories are stated at the lower of cost or net realizable value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence.
 
The Company periodically evaluates the quantities on hand relative to historical, current, and projected sales volume. Based on this evaluation, an impairment charge is recorded when required to write-down inventory to its net realized value.
 
Cost is determined as follows:
 
Finished products - based on raw materials and manufacturing costs on an average basis.
 
Raw materials - The weighted average cost method.
 
The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors, including historical usage rates and forecasted sales according to outstanding backlogs. Purchasing requirements and alternative usage are explored within these processes to mitigate inventory exposure. When recorded, the reserves are intended to reduce the carrying value of inventory to its net realizable value. If actual demand for the Company’s products deteriorates, or market conditions are less favourable than those projected, additional inventory reserves may be required.
Property and Equipment
  f.
Property and Equipment:
 
Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:
 
 
%
Computer equipment
20-33 (mainly 33)
Office furniture and equipment
6 - 10 (mainly 10)
Machinery and laboratory equipment
15
Field service units
20-50
Leasehold improvements
Over the shorter of the lease term
or estimated useful life
Business Combinations
  g.
Business Combinations
 
The Company accounts for business combinations in accordance with ASC 805, “Business Combinations” (“ASC 805”). For business combinations accounted for under the acquisition method, ASC 805 requires recognition of assets acquired, liabilities assumed, and any non-controlling interest at the acquisition date, measured at their fair values as of that date. The Company determines the recognition of intangible assets based on the following criteria: (i) the intangible asset arises from contractual or other rights; or (ii) the intangible asset is separable or divisible from the acquired entity and capable of being sold, transferred, licensed, returned or exchanged.
 
The excess of the fair value of the purchase price over the fair values of the identifiable assets and liabilities is recorded as goodwill. Determining the fair value of the identifiable assets and liabilities requires management to use significant judgment and estimates including the forecasted revenue and revenues growth rates, discount rates, customer contract renewal rates and customer attrition rates. The process of estimating the fair values requires significant estimates, especially with respect to intangible assets. Management’s determination of fair value of assets acquired and liabilities assumed at the acquisition date is based on the best information available in the circumstances and incorporates management’s own assumptions and involves a significant degree of judgment.
 
Acquisition related costs include legal fees, consulting and success fees, and other non-recurring integration related costs. Acquisition-related costs are expensed as incurred.
Goodwill and Other Intangibles
  h.
Goodwill and Other Intangibles
 
For business combinations, the purchase prices are allocated to the tangible assets and intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition dates, with the remaining unallocated purchase prices recorded as goodwill.
 
The Company has no indefinite-lived intangible assets other than goodwill. Acquired identifiable finite-lived intangible assets include identifiable acquired technology, customer relationships, trademarks and backlog and are amortized on a straight-line basis over the estimated useful lives of the assets. The Company routinely reviews the remaining estimated useful lives of finite-lived intangible assets.
 
Goodwill is not amortized and is tested for impairment at least annually.
The Company operates as one reporting unit and the fair value of the reporting unit is estimated using quoted market prices of the Company’s stock in active markets. The Company tests goodwill for impairment annually in the fourth quarter and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable.
 
When testing goodwill for impairment, the Company may first perform a qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. The Company may elect to bypass the qualitative assessment and proceed directly to performing a quantitative analysis. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company recognizes an impairment of goodwill for the amount of this excess.
 
As of December 31, 2023, no impairments of goodwill have been recognized.
Impairment of Long-Lived Assets
  i.
Impairment of Long-Lived Assets
 
The Company’s long-lived assets, including right-of-use (“ROU”) assets and identifiable intangible assets that are subject to amortization, are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2023, 2022 and 2021, no impairment losses have been recorded.
Restricted Cash and Other Long-Term Assets
  j.
Restricted cash and Other long-term assets:
 
Other long-term assets include long-term prepaid expenses and restricted cash deposits for offices and cars leasing based upon the term of the remaining restrictions.
Treasury shares
  k.
Treasury shares
 
The Company repurchased its ordinary shares and holds them as treasury shares. The Company presents the cost to repurchase treasury shares as a reduction of shareholders' equity.
Revenue Recognition
  l.
Revenue Recognition:
 
The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to clinics and rehabilitation centres, professional and college sports teams, private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), and distributors.
 
The Company recognizes revenue in accordance with ASC 606, “Revenue Recognition” when, or as, control of the promised good or service is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company applies the following five steps:
 
  1.
Identify the contract with a customer
 
The Company generally considers a purchase order or a signed quote to be a contract with a customer. In evaluating the contract with a customer, the Company analyzes the customer’s intent and ability to pay the amount of promised consideration (credit risk) and considers the probability of collecting substantially all of the consideration.
 
  2.
Identify the performance obligations in the contract
 
At a contract’s inception, the Company assesses the goods or services promised in a contract with a customer and identifies the performance obligations.
 
  3.
Determine the transaction price
 
The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring products or services to the customer.
 
The Company does not offer extended payment terms beyond one year to customers.
 
  4.
Allocate the transaction price to performance obligations in the contract
 
If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.
 
  5.
Recognize revenue when or as the Company satisfies a performance obligation
 
Revenue is recognized when or as performance obligations are satisfied by transferring control of a promised good or service to a customer. Control either transfers over time or at a point in time, which affects when revenue is recorded.
 
The Company has elected to apply the practical expedient for financing component for transactions in which the difference between the payment date and the revenue recognition timing is up to 12 months.
 
Disaggregation of Revenue (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Product
 
$
10,681
   
$
4,175
   
$
4,916
 
Rental
   
1,033
     
859
     
533
 
Service and warranty
   
2,140
     
477
     
517
 
Total Revenues
 
$
13,854
   
$
5,511
   
$
5,966
 
 
Product revenue
 
Revenue from Products is comprised of sale of Anti-Gravity products, sale of systems products to rehabilitation facilities and sale of ReWalk Personal Exoskeleton systems to end users. Revenues generated from the sale of Products are recognized at a point in time, once the customer has obtained the legal title to the items purchased.
 
For systems sold to rehabilitation facilities, the Company includes insignificant training and considers the elements in the arrangement to be a single performance obligation. Therefore, the Company recognizes revenue for the system only when control is transferred after delivery and when the training has been completed, in accordance with the agreements terms with the customer.

 

For sales of ReWalk Personal Exoskeleton systems to end users, and for sales of ReWalk Personal or ReWalk Rehabilitation Exoskeleton systems to third party distributors, the Company does not provide training to the end user as this training is completed by the rehabilitation center or by the distributor that have previously completed the ReWalk Training program. Therefore, the Company recognizes revenue in such sales upon delivery.
 
The Company generally does not grant a right of return for its products. In rare circumstances when the Company provides a right of return for its products. the Company records reductions to revenue for expected future product returns based on the Company’s historical experience and estimates.
 
During 2023, the Company offered six products: (1) ReWalk Personal Exoskeletons, (2) ReWalk Rehabilitation Exoskeleton, (3) ReStore, (4) AlterG Anti-Gravity systems, (5) MyoCycle and (6) MediTouch. Due to unsatisfactory sales performance of the MediTouch product lines, the Company terminated this agreement as of January 31, 2023.
 
Rental revenue
 
Rental revenue for the AlterG Anti-Gravity systems is accounted for under ASC Topic 842, Leases. The Company rents its products to customers for a fixed monthly fee over the rental term, which typically ranges from 2 to 3 years. Rental revenues are recorded as earned on a monthly basis. See Note 2x for additional information.
 
For the SCI Products, the Company also offers a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee for a limited period prior to selling its products.
 
Service and warranties
 
The Company services its products after expiration of the initial warranty. Service revenue, consisting of time and materials to perform the repairs, is recorded as services are rendered.
 
Determining the transaction price requires of level judgment, which is discussed by revenue category in further detail below.
 
Warranties are classified as either an assurance type or a service type warranty. A warranty is considered an assurance type warranty if it provides the customer with assurance that the product will function as intended for a limited period of time. An assurance type warranty is not accounted for as a separate performance obligation under the revenue model.
 
SCI Products include a five -year warranty. The first two years are considered as an assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. A service type warranty is either sold with a unit or separately for a unit for which the warranty has expired. A service type warranty is accounted as a separate performance obligation and revenue is recognized ratably over the life of the warranty.
 
The ReStore device is sold with a two-year warranty which is considered as assurance type warranty.
 
The Distributed Products are sold with assurance type warranty ranging between three years to ten years, depending on the specific product and part.
 
For AlterG Anti-Gravity Products, the Company offers customers extended warranty contracts that extend or enhance the technical support, parts, and labor coverage offered as part of the base warranty included with the Anti-Gravity system products. Extended warranty revenue is recognized ratably over the extended warranty coverage period. The Company offers a one-year assurance type warranty to customers in the U.S. and two years assurance type warranty for spare parts only to its international distributors. For these products, the Company determines standalone selling price based on the price at which the performance obligation is sold separately.

 

Contract balances (in thousands):
 
 
 
December 31,
   
December 31,
 
 
 
2023
   
2022
 
Trade receivable, net of credit losses (1)
 
$
3,120
   
$
1,036
 
Deferred revenues (1) (2)
 
$
3,010
   
$
1,191
 
 
  (1)
Balance presented net of unrecognized revenue that was not yet collected.
 
  (2)
$435 thousands of the December 31, 2022 deferred revenue balance was recognized as revenue during the year ended December 31, 2023.
 
Deferred revenue which represent a contract liability, include unearned amounts related to service type warranty obligations as well as other advances and payments which the Company received from customers prior to satisfying the performance obligation, for which revenue has not yet been recognized. The Company's unearned performance obligations as of December 31, 2023 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $3.1 million, which will be fulfilled over one to five years.
Accounting for Share-Based Compensation
  m.
Accounting for Share-Based Compensation:
 
The Company accounts for share-based compensation in accordance with ASC 718, “Compensation-Stock Compensation” (“ASC 718”). ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model (“OPM”). The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations.
 
The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. The Company account for forfeitures as they occur.
 
The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its share-option awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary share, expected share price volatility and the expected option term. Expected volatility is calculated based on actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options, or based on certain peer companies that the Company considered to be comparable, in case there is no sufficient trading volume to rely on market volatility. The expected option term is determined based on the simplified method, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.
 
The fair value of Restricted Stock Units (“RSUs”) granted is determined based on the price of the Company’s ordinary shares on the date of grant.
 
The Company accounts for options granted to consultants and other service providers under ASC 718. The fair value of these options was estimated using a Black-Scholes-Merton option-pricing model.
Class Of Warrant Or Right [Policy Text Block]
  n.
Warrants to Acquire Ordinary Shares:
 
During the twelve -month ended December 31, 2021, the Company issued warrants to acquire up to 15,083,611 ordinary shares. There were no issued warrants during the twelve months ended December 31, 2023 and 2022. The Company assessed the warrants pursuant to ASC 480 "Distinguishing Liabilities from Equity" and ASC 815 "Derivatives and Hedging" and determined that the warrants should be accounted for as equity and not as a derivative liability. Refer to Note 9f for additional information.
Research and Development Costs
  o.
Research and Development Costs:
 
Research and development costs are charged to the consolidated statement of operations as incurred and are presented net of the amount of any grants the Company received for research and development in the period in which the grant was received.
Income Taxes
  p.
Income Taxes
 
The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”), using the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized.
 
ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits in its taxes on income. As of December 31, 2023, and 2022, the Company did not identify any significant uncertain tax positions.
Warranty Provision
  q.
Warranty provision:
 
For assurance-type warranty, the Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.
 
 
 
US Dollars
in
thousands
 
Balance at December 31, 2022
 
$
92
 
AlterG acquisition – see note 5
   
535
 
Provision
   
200
 
Usage
   
(479
)
Balance at December 31, 2023
 
$
348
 
Concentrations of Credit Risks
  r.
Concentrations of Credit Risks:
 
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables.
 
The Company’s cash and cash equivalents are deposited in major banks in Israel, the United States and Germany. Such deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. The Company maintains cash and cash equivalents with diverse financial institutions and monitors the amount of credit exposure to each financial institution. The bank deposits are held in financial institutions which management believes are institutions with high credit standing, and accordingly, minimal credit risk from geographic or credit concentration exists with respect to these deposits.
 
The below table reflects the concentration of credit risk for the Company’s current customers as of December 31, 2023, to which substantial sales were made.
 
Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales.
 
 
 
December 31,
 
 
 
2023
   
2022
 
Customer A
   
*
)%
   
27
%
Customer B
   
*
)%
   
13
%
Customer C
   
-
     
13
%
Customer D
   
-
     
11
%
 
  *)
Less than 10%

 

The allowance for credit losses is based on the Company's assessments of factors that may affect a customer's ability to pay. The Company regularly reviews the adequacy of the allowance for credit losses based on a combination of factors, including an assessment of the current customer's aging balance, the nature and size of the customer, the financial condition of the customer, and the amount of any receivables in dispute. The Company does not have any off-balance sheet credit exposure related to its customers. As of December 31, 2023, and 2022 trade receivables are presented net of $328 thousand and $26 thousand allowance for credit losses, respectively.
Accrued Severance Pay
  s.
Accrued Severance Pay:
 
Pursuant to Israel’s Severance Pay Law, Israeli employees are entitled to severance pay equal to one month’s salary for each year of employment, or a portion thereof. All of the employees of the RRL elected to be included under section 14 of the Severance Pay Law, 1963 (“section 14”). According to this section, these employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet.
 
Total Company’s expenses related to severance pay amounted to $114 thousand , $113 thousand and $104 thousand for the years ended December 31, 2023, 2022 and 2021, respectively.
Fair Value Measurements
  t.
Fair Value Measurements:
 
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a three -tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The three -tiers are defined as follows:
 
 
Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities;
 
 
Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
 
 
Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.
 
The carrying amounts of cash and cash equivalents, short term deposits, trade receivables and trade payables approximate their fair value due to the short-term maturity of such instruments.
 
The following tables present information about the Company’s financial assets and liabilities that are measured in fair value on a recurring basis as of December 31, 2023 and December 31, 2022 (in thousands):
 
       
Fair value measurements as of
 
Description
 
Fair Value Hierarchy
 
December 31, 2023
   
December 31,
2022
 
Financial assets:
               
                 
Money market funds included in cash and cash equivalent
 
Level 1
 
$
2,550
   
$
-
 
Treasury bills included in cash and cash equivalent
 
Level 1
 

$

2,525
   

$

-
 
                     
Total Assets Measured at Fair Value
     
$
5,075
   
$
-
 
                     
Financial Liabilities:
                   
Earnout
 
Level 3
 
$
3,292
   
$
-
 
                     
Total liabilities measured at fair value
     
$
3,292
   
$
-
 

 

The Company classifies cash equivalents within Level 1, because the Company uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair values.
 
The earnout was valued using a Monte Carlo simulation analysis, which is considered to be a Level 3 fair value measurement.
 
The following table summarizes the earnout liability activity as of December 31, 2023 (in thousands):
 
   
Earnout
   
Initial Measurement (August 11, 2023)
 
$
3,607
   
Change in fair value
   
(315)
   
Balance December 31, 2023
 
$
3,292
   
Basic and Diluted Net Loss Per Share
u. Basic and Diluted Net Loss Per Share:
 
Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding during the period.
 
Diluted loss per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus dilutive potential shares considered outstanding during the period.
Contingent liabilities
v. Contingent liabilities
 
The Company accounts for its contingent liabilities in accordance with ASC 450, “Contingencies.” A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
 
With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.
Government grants
w. Government grants
 
Royalty and non-royalty-bearing grants from the Israeli Innovation Authority (the “IIA”) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a reduction from research and development expenses (see Note 8c).
Leases
x. Leases
 
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded at commencement date based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.
 
Leases with an initial term of 12 months or less are not recorded on the balance sheet.
 
Lessor accounting - Operating leases
 
A portion of the AlterG rental revenues for the AlterG Anti-Gravity systems are made through lease arrangements.
 
AlterG products are available for lease agreements ranging from 12 to 42 months. If the customer terminates the contract during the lease period, they are required to pay a cancellation fee. The lease period may be extended by an additional period as specified in the contract.
 
In determining the leases classification as a sales type or operating lease, the Company assesses, among other criteria: (i) the lease term to determine if it is for the major part of the economic life of the underlying equipment; and (ii) the present value of the lease payments to determine if they are equal to or greater than substantially all of the fair market value of the equipment at the inception of the lease AlterG Anti-Gravity systems. When these criteria are not met, the lease accounted for as operating leases and revenues are recognized over the term of the lease.
 
Under these arrangements, when the Company acts as the lessor for its product line, the Company accounted for the lease arrangements as operating leases in accordance with ASC 842, “Lease” (“ASC 842”).
 
The total rental revenue for the AlterG Anti-Gravity Products has amounted to $249 thousand from the time of acquisition through December 31, 2023.
New Accounting Pronouncements
y.  New Accounting Pronouncements
 
Recently Implemented Accounting Pronouncements
 
i.           Financial Instruments
 
In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. The Company adopted ASU 2016-13 as of January 1, 2023. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.
 
Recent Accounting Pronouncements Not Yet Adopted
 
 
i.
In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes - Improvements to Income Tax Disclosures” requiring enhancements and further transparency to certain income tax disclosures, most notably the tax rate reconciliation and income taxes paid. This ASU is effective for fiscal years beginning after December 15, 2024 on a prospective basis and retrospective application is permitted. The Company is currently evaluating the impact of the adoption of this standard.
 
 
ii.
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, “Segment Reporting” on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.
XML 43 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Public Utility Property, Plant, and Equipment
 
%
Computer equipment
20-33 (mainly 33)
Office furniture and equipment
6 - 10 (mainly 10)
Machinery and laboratory equipment
15
Field service units
20-50
Leasehold improvements
Over the shorter of the lease term
or estimated useful life
Schedule of disaggregation of revenues
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Product
 
$
10,681
   
$
4,175
   
$
4,916
 
Rental
   
1,033
     
859
     
533
 
Service and warranty
   
2,140
     
477
     
517
 
Total Revenues
 
$
13,854
   
$
5,511
   
$
5,966
 
Schedule of contract balances
 
 
December 31,
   
December 31,
 
 
 
2023
   
2022
 
Trade receivable, net of credit losses (1)
 
$
3,120
   
$
1,036
 
Deferred revenues (1) (2)
 
$
3,010
   
$
1,191
 
 
  (1)
Balance presented net of unrecognized revenue that was not yet collected.
 
  (2)
$435 thousands of the December 31, 2022 deferred revenue balance was recognized as revenue during the year ended December 31, 2023.
Schedule of warranty provision
 
 
US Dollars
in
thousands
 
Balance at December 31, 2022
 
$
92
 
AlterG acquisition – see note 5
   
535
 
Provision
   
200
 
Usage
   
(479
)
Balance at December 31, 2023
 
$
348
 
Schedule of concentration of credit risk
 
 
December 31,
 
 
 
2023
   
2022
 
Customer A
   
*
)%
   
27
%
Customer B
   
*
)%
   
13
%
Customer C
   
-
     
13
%
Customer D
   
-
     
11
%
 
  *)
Less than 10%

 

Schedule of assets and liabilities measured at fair value
       
Fair value measurements as of
 
Description
 
Fair Value Hierarchy
 
December 31, 2023
   
December 31,
2022
 
Financial assets:
               
                 
Money market funds included in cash and cash equivalent
 
Level 1
 
$
2,550
   
$
-
 
Treasury bills included in cash and cash equivalent
 
Level 1
 

$

2,525
   

$

-
 
                     
Total Assets Measured at Fair Value
     
$
5,075
   
$
-
 
                     
Financial Liabilities:
                   
Earnout
 
Level 3
 
$
3,292
   
$
-
 
                     
Total liabilities measured at fair value
     
$
3,292
   
$
-
 

 

Schedule of warrants liability activity
   
Earnout
   
Initial Measurement (August 11, 2023)
 
$
3,607
   
Change in fair value
   
(315)
   
Balance December 31, 2023
 
$
3,292
   
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)
12 Months Ended
Dec. 31, 2023
PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]  
Schedule of prepaid expenses and other current assets
 
 
December 31,
 
 
 
2023
   
2022
 
Government institutions
 
$
253
   
$
81
 
Prepaid expenses
   
1,227
     
242
 
Advances to vendors
   
139
     
174
 
Other assets
   
747
     
152
 
 
               
 
 
$
2,366
   
$
649
 
XML 45 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORIES (Tables)
12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of inventories
 
 
December 31,
 
 
 
2023
   
2022
 
Finished products
 
$
3,157
   
$
2,421
 
Raw materials
   
2,496
     
508
 
 
               
 
 
$
5,653
   
$
2,929
 
XML 46 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATION (Tables)
12 Months Ended
Dec. 31, 2023
Business Combinations [Abstract]  
Schedule of total consideration
Cash
 
$
18,493
 
Earnout payments
 
$
3,607
 
Total consideration
 
$
22,100
 
Schedule of preliminary fair value of assets acquired and liabilities
Cash and cash equivalent
 
$
478
 
Restricted cash
   
51
 
Accounts receivable
   
1,773
 
Inventory
   
3,330
 
Prepaid expenses and other current assets
   
470
 
Right of use asset
   
1,151
 
Property and equipment, net
   
827
 
Other non-current assets
   
30
 
Goodwill
   
7,538
 
Intangible assets
   
14,133
 
Accounts payable
   
(2,082
)
Accrued compensation
   
(766
)
Other accrued liabilities
   
(1,059
)
Deferred revenue
   
(2,088
)
Warranty Obligations
   
(535
)
Leases Liability
   
(1,151
)
Total purchase consideration
 
$
22,100
 
Schedule of intangible assets acquired
 
   
 
Estimated
   
Estimated Useful Life
 
   
Fair Value
   
(Years)
 
Trademark
 
$
795
     
3
 
Technology
   
6,161
     
4
 
Customer relationship - Warranty
   
201
     
2
 
Customer relationship - Rental
   
2,102
     
4
 
Customer relationship - Distribution
   
4,578
     
5
 
Backlog
   
296
     
1
 
Schedule of pro forma revenue and earnings
   
Twelve Months Ended
December 31,
 
   
2023
   
2022
 
Revenues
   
24,923
     
25,307
 
Net loss
   
(21,761
)
   
(28,369
)
XML 47 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)
12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets
   
 
 
Cost
   
December 31, 2023 Accumulated
Amortization
   
 
Intangible Assets, Net
 
Trademark
   
795
     
(104
)
   
691
 
Technology
   
6,161
     
(604
)
   
5,557
 
Customer relationship - Warranty
   
201
     
(40
)
   
161
 
Customer relationship - Rental
   
2,102
     
(206
)
   
1,896
 
Customer relationship - Distribution
   
4,578
     
(358
)
   
4,220
 
Backlog
   
296
     
(296
)
   
-
 
Total Amortized Intangible Assets
   
14,133
     
(1,608
)
   
12,525
 
Schedule of future amortization expense
Fiscal 2024
                   
3,347
 
Fiscal 2025
                   
3,307
 
Fiscal 2026
                   
3,143
 
Fiscal 2027
                   
2,172
 
Fiscal 2028
                   
556
 
Total
                   
12,525
 
XML 48 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY AND EQUIPMENT, NET (Tables)
12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of components of property and equipment, net
 
 
December 31,
 
 
 
2023
   
2022
 
Cost:
           
Computer equipment
 
$
1,690
   
$
743
 
Office furniture and equipment
   
468
     
308
 
Machinery and laboratory equipment
   
621
     
621
 
Field service units
   
4,166
     
1,816
 
Leasehold improvements
   
658
     
333
 
 
               
 
 
$
7,603
   
$
3,821
 
 
 
 
December 31,
 
 
 
2023
   
2022
 
Accumulated depreciation
   
6,341
     
3,625
 
 
               
Property and equipment, net
 
$
1,262
   
$
196
 
XML 49 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENT LIABILITIES (Tables)
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of minimum royalty payments
2024
 
$
1,363
 
2025
   
674
 
2026
   
13
 
Total lease payments
   
2,050
 
Less: imputed interest
   
(147
)
Present value of future lease payments
   
1,903
 
Less: current maturities of operating leases
   
(1,296
)
Non-current operating leases
 
$
607
 
Weighted-average remaining lease term (in years)
   
1.92
 
Weighted-average discount rate
   
9.21
%
XML 50 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHAREHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of employee and non-employee shares options activity
 
 
Number
   
Weighted
average
exercise
price
   
Weighted
average
remaining
contractual
life (years)
   
Aggregate
intrinsic
value (in
thousands)
 
Options outstanding at the beginning of the year
   
43,994
   
$
41.27
     
4.39
   
$
-
 
Granted
   
-
     
-
     
-
     
-
 
Exercised
   
-
     
-
     
-
     
-
 
Forfeited
   
(10,823
)
   
52.78
     
-
     
-
 
 
                               
Options outstanding at the end of the year
   
33,171
   
$
37.51
     
4.39
   
$
-
 
 
                               
Options exercisable at the end of the year
   
33,171
   
$
37.51
     
4.39
   
$
-
 
Schedule of employee and non-employee RSUs activity
 
 
Number of
shares
underlying
outstanding
RSUs
   
Weighted-
average
grant date
fair value
 
Unvested RSUs at the beginning of the year
   
2,755,057
     
1.16
 
Granted
   
2,258,370
     
0.66
 
Vested
   
(1,109,200
)
   
1.14
 
Forfeited
   
(131,813
)
   
1.13
 
 
               
Unvested RSUs at the end of the year
   
3,772,414
     
0.87
 
Schedule of options and RSUs outstanding
Range of exercise price
 
Options and
RSUs
Outstanding
as of
December 31,
2023
 
 
Weighted
average
remaining
contractual
life
(years) (1)
 
 
Options
Exercisable
as of
December 31,
2023
 
 
Weighted
average
remaining
contractual
life
(years) (1)
 
RSUs only
 
 
3,772,414
 
 
 
-
 
 
 
-
 
 
 
-
 
$5.37 
 
 
12,425
 
 
 
5.24
 
 
 
12,425
 
 
 
5.24
 
$20.42- $33.75 
 
 
12,943
 
 
 
4.35
 
 
 
12,943
 
 
 
4.35
 
$50-$52.5 
 
 
6,230
 
 
 
3.46
 
 
 
6,230
 
 
 
3.46
 
$182.5-$524.25 
 
 
1,573
 
 
 
1.65
 
 
 
1,573
 
 
 
1.65
 
 
 
 
3,805,585
 
 
 
4.39
 
 
 
33,171
 
 
 
4.39
 
Schedule of non-cash share-based compensation expense
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Cost of revenue
 
$
9
   
$
16
   
$
10
 
Research and development, net
   
157
     
94
     
55
 
Sales and marketing
   
381
     
250
     
171
 
General and administrative
   
781
     
633
     
597
 
 
                       
Total
 
$
1,328
   
$
993
   
$
833
 
Schedule of warrants outstanding and exercisable
Issuance date
 
Warrants
outstanding
   
Exercise price
per warrant
   
Warrants
outstanding
and
exercisable
 
Contractual
term
 
 
(number)
         
(number)
 
 
December 31, 2015 (1)
   
4,771
   
$
7.500
     
4,771
 
See footnote (1)
December 28, 2016 (2)
   
1,908
   
$
7.500
     
1,908
 
See footnote (1)
February 25, 2019 (5)
   
45,600
   
$
7.187
     
45,600
 
February 21, 2024
April 5, 2019 (6)
   
408,457
   
$
5.140
     
408,457
 
October 7, 2024
April 5, 2019 (7)
   
49,015
   
$
6.503
     
49,015
 
April 3, 2024
June 5, 2019, and June 6, 2019 (8)
   
1,464,665
   
$
7.500
     
1,464,665
 
June 5, 2024
June 5, 2019 (9)
   
87,880
   
$
9.375
     
87,880
 
June 5, 2024
June 12, 2019 (10)
   
416,667
   
$
6.000
     
416,667
 
December 12, 2024
June 10, 2019 (11)
   
50,000
   
$
7.500
     
50,000
 
June 10, 2024
February 10, 2020 (12)
   
28,400
   
$
1.250
     
28,400
 
February 10, 2025
February 10, 2020 (13)
   
105,840
   
$
1.563
     
105,840
 
February 10, 2025
July 6, 2020 (14)
   
448,698
   
$
1.760
     
448,698
 
January 2, 2026
July 6, 2020 (15)
   
296,297
   
$
2.278
     
296,297
 
January 2, 2026
December 8, 2020 (16)
   
586,760
   
$
1.340
     
586,760
 
June 8, 2026
December 8, 2020 (17)
   
108,806
   
$
1.792
     
108,806
 
June 8, 2026
February 26, 2021 (18)
   
5,460,751
   
$
3.600
     
5,460,751
 
August 26, 2026
February 26, 2021 (19)
   
655,290
   
$
4.578
     
655,290
 
August 26, 2026
September 29, 2021 (20)
   
8,006,759
   
$
2.000
     
8,006,759
 
March 29, 2027
September 29, 2021 (21)
   
960,811
   
$
2.544
     
960,811
 
September 27, 2026
 
   
19,187,375
             
19,187,375
 
 
XML 51 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of loss before taxes on income
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Domestic
 
$
(19,638
)
 
$
(19,110
)
 
$
(12,780
)
Foreign
   
(2,507
)
   
8
     
138
 
 
 
$
(22,145
)
 
$
(19,102
)
 
$
(12,642
)
Schedule of taxes on income
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Current
 
$
(12
)
 
$
151
   
$
123
 
Deferred
   
-
     
316
     
(29
)
 
                       
   
$
(12
)
 
$
467
   
$
94
 
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Domestic
 
$
-
   
$
-
   
$
-
 
Foreign
   
(12
)
   
467
     
94
 
 
                       
 
 
$
(12
)
 
$
467
   
$
94
 
Schedule of deferred income taxes
 
 
December 31,
 
 
 
2023
   
2022
 
Deferred tax assets:
           
Carry forward tax losses
 
$
64,090
   
$
50,833
 
Research and development carry forward expenses-temporary differences
   
1,311
     
844
 
Accrual and reserves
   
849
     
392
 
Share based compensation
   
394
     
456
 
Credit tax carry forwards
   
1,714
     
-
 
Lease liabilities
   
480
     
214
 
Total deferred tax assets
   
68,838
     
52,739
 
Deferred tax liabilities:
               
Right-of-use asset
   
(470
)
   
(214
)
Intangible Assets
   
(3,015
)
   
-
 
Property and equipment
   
(144
)
   
-
 
Net deferred tax assets
   
65,209
     
52,525
 
Valuation allowance
   
(65,209
)
   
(52,525
)
 
               
Net deferred tax assets
 
$
-
   
$
-
 
Schedule of net changes in total valuation allowance
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Balance at beginning of year
 
$
(52,525
)
 
$
(48,098
)
 
$
(42,941
)
Changes due to exchange rate differences
   
-
     
1,418
     
(1,488
)
Adjustment previous year loss
   
(5
)    
(14
)
   
-
 
Acquisition
   
(7,269
)
   
-
     
-
 
Additions during the year
   
(5,410
)
   
(5,831
)
   
(3,669
)
 
                       
Balance at end of year
 
$
(65,209
)
 
$
(52,525
)
 
$
(48,098
)
Schedule of reconciliation between the theoretical tax expense and the actual tax expense (benefit)
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Loss before taxes, as reported in the consolidated statements of operations
 
$
(22,145
)
 
$
(19,102
)
 
$
(12,642
)
 
                       
Statutory tax rate
   
23
%
   
23.0
%
   
23.0
%
 
                       
Theoretical tax benefits on the above amount at the Israeli statutory tax rate
 
$
(5,093
)
 
$
(4,393
)
 
$
(2,908
)
Income tax at rate other than the Israeli statutory tax rate
   
56
     
(2
)
   
7
 
Non-deductible expenses including equity-based compensation expenses and other 
   
-
     
262
     
102
 
Operating losses and other temporary differences for which valuation allowance was provided
   
5,410
     
5,375
     
3,669
 
Permanent differences
   
(342
)
   
(775
)
   
(784
)
Adjustment in respect of prior years
   
(43
)
   
-
     
-
 
Other
   
-
     
-
     
8
 
 
                       
Actual tax expense (benefit)
 
$
(12
)
 
$
467
   
$
94
 
XML 52 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL EXPENSES (INCOME), NET (Tables)
12 Months Ended
Dec. 31, 2023
Other Income and Expenses [Abstract]  
Schedule of financial expenses, net
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Foreign currency transactions and other
 
$
133
   
$
22
   
$
38
 
Interest Income
   
1,354
     
-
     
-
 
Bank commissions
   
(20
)
   
(22
)
   
(25
)
 
                       
 
 
$
1,467
   
$
*
)
 
$
13
 
XML 53 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables)
12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Schedule of revenues within geographic areas
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Revenue based on customer’s location:
                 
United States
   
7,636
     
2,303
     
2,519
 
Europe
   
5,044
     
3,057
     
3,381
 
Asia-Pacific
   
387
     
115
     
60
 
Rest of the world
   
787
     
36
     
6
 
 
                       
Total revenues
 
$
13,854
   
$
5,511
   
$
5,966
 
Schedule of long-lived assets by geographic region
 
 
 
December 31,
 
 
 
2023
   
2022
 
Long-lived assets by geographic region:
           
Israel
 
$
529
   
$
757
 
United States
   
2,404
     
231
 
Germany
   
190
     
44
 
 
               
 
 
$
3,123
   
$
1,032
 
 
  (*)
Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.
Schedule of major customer data as a percentage of total revenues
 
 
 
Year Ended December 31,
 
 
 
2023
   
2022
   
2021
 
Customer A
   
12.2
%
   
14.2
%
   
*
)
Customer B
   
*
)
   
*
)
   
11.0
%

 

  *)

Less than 10%

XML 54 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
BASIC AND DILUTED NET LOSS PER SHARE (Tables)
12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of basic and diluted net loss per ordinary share
 
 
Year ended December 31,
 
 
 
2023
   
2022
   
2021
 
Net loss
 
$
(22,133
)
 
$
(19,569
)
 
$
(12,736
)
 
                       
Net loss attributable to ordinary shares
   
(22,133
)
   
(19,569
)
   
(12,736
)
Shares used in computing net loss per ordinary shares, basic and diluted
   
59,719,064
     
62,378,797
     
47,935,652
 
 
                       
Net loss per ordinary share, basic and diluted
 
$
(0.37
)
 
$
(0.31
)
 
$
(0.27
)
XML 55 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
GENERAL (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
General [Abstract]      
Net loss $ (22,133) $ (19,569) $ (12,736)
Accumulated deficit 235,883 213,750  
Negative cash flow from operations (20,667) (17,891) $ (11,469)
Cash and cash equivalents $ 28,083 $ 67,896  
XML 56 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Details)
12 Months Ended
Dec. 31, 2023
Property Plant And Equipment Useful Life Description Over the shorter of the lease term
Machinery and laboratory equipment [Member]  
Property and equipment estimated useful lives 15 years
Minimum [Member] | Computer equipment [Member]  
Property and equipment estimated useful lives 20 years
Minimum [Member] | Office furniture and equipment [Member]  
Property and equipment estimated useful lives 6 years
Minimum [Member] | Field service units [Member]  
Property and equipment estimated useful lives 20 years
Maximum [Member] | Computer equipment [Member]  
Property and equipment estimated useful lives 33 years
Maximum [Member] | Office furniture and equipment [Member]  
Property and equipment estimated useful lives 10 years
Maximum [Member] | Field service units [Member]  
Property and equipment estimated useful lives 50 years
XML 57 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Total Revenues $ 13,854 $ 5,511 $ 5,966
Product [Member]      
Total Revenues 10,681 4,175 4,916
Service And Warranty [Member]      
Total Revenues 2,140 477 517
Rental [Member]      
Total Revenues $ 1,033 $ 859 $ 533
XML 58 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Trade receivable, net of credit losses [1] $ 3,120 $ 1,036
Deferred revenues [1],[2] $ 3,010 $ 1,191
[1] Balance presented net of unrecognized revenue that was not yet collected.
[2] $401 thousands of the December 31, 2022 deferred revenue balance was recognized as revenue during the year ended December 31, 2023.
XML 59 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Details 3) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2023
Accounting Policies [Abstract]    
Balance at December 31, 2022 $ 92 $ 92
AlterG acquisition $ 535  
Provision   200
Usage   (479)
Balance at September 30, 2023   $ 348
XML 60 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Details 4) - Trade Receivables [Member] - Credit Concentration Risk [Member]
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Customer A [Member]    
Concentration Risk [Line Items]    
Concentration of credit risk [1] 27.00%
Customer B [Member]    
Concentration Risk [Line Items]    
Concentration of credit risk [1] 13.00%
Customer C [Member]    
Concentration Risk [Line Items]    
Concentration of credit risk 0.00% 13.00% [1]
Customer D [Member]    
Concentration Risk [Line Items]    
Concentration of credit risk 0.00% 11.00% [1]
[1] Less than 10%
XML 61 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Details 5) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial Assets $ 5,075 $ 0
Earnout [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial Liabilities 3,292 0
Fair Value, Inputs, Level 3 [Member] | Earnout [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial Liabilities 3,292 0
Money market funds [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial Assets 2,550 0
Treasury bills [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial Assets $ 2,525 $ 0
XML 62 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Details 6) - Earnout [Member]
$ in Thousands
2 Months Ended
Sep. 30, 2023
USD ($)
Fair Value Warrants Liability Activity [Line Items]  
Initial Measurement (August 11, 2023) $ 3,607
Change in fair value 315
Balance September 30, 2023 $ 3,292
XML 63 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Significant Accounting Policies Textual Abstract      
Inventory Write-down $ 398 $ 502 $ 252
Deferred revenue recognized $ 435    
Revenue Recognition Recognized the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $3.1 million, which will be fulfilled over one to five years.    
Severance Pay Monthly Deposit By Employees Percentage 8.33%    
Severance pay expense $ 114 113 104
Royalty expenses 17 $ 7 14
Rental Revenue For Anti Gravity Products $ 249    
Warrants and rights outstanding     $ 15,083,611
Minimum [Member]      
Significant Accounting Policies Textual Abstract      
Leases agreement term 12 years    
Maximum [Member]      
Significant Accounting Policies Textual Abstract      
Leases agreement term 42 years    
Re Store Product [Member]      
Significant Accounting Policies Textual Abstract      
Service policy 2 years    
SCI Products [Member]      
Significant Accounting Policies Textual Abstract      
Service policy 5 years    
XML 64 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]    
Prepaid Expenses To Government Institutions Current $ 253 $ 81
Prepaid expenses 1,227 242
Advances to vendors 139 174
Other assets 747 152
Prepaid expenses and other current assets $ 2,366 $ 649
XML 65 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Finished products $ 3,157 $ 2,421
Raw materials 2,496 508
Inventories $ 5,653 $ 2,929
XML 66 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORIES (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]      
Inventory write-down $ 398 $ 502 $ 252
XML 67 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATION (Details) - USD ($)
$ in Thousands
Aug. 08, 2023
Dec. 31, 2023
Business Acquisition [Line Items]    
Cash   $ 478
Alterg Inc [Member]    
Business Acquisition [Line Items]    
Cash $ 18,493  
Earnout payments 3,607  
Total consideration $ 22,100  
XML 68 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATION (Details 1) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Business Combinations [Abstract]    
Cash and cash equivalent $ 478  
Restricted cash 51  
Accounts receivable 1,773  
Inventory 3,330  
Prepaid expenses and other current assets 470  
Right of use asset 1,151  
Property and equipment, net 827  
Other non-current assets 30  
Goodwill 7,538 $ 0
Intangible assets 14,133  
Accounts payable (2,082)  
Accrued compensation (766)  
Other accrued liabilities (1,059)  
Deferred revenue (2,088)  
Warranty Obligations (535)  
Leases Liability (1,151)  
Total purchase consideration $ 22,100  
XML 69 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATION (Details 2)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Finite-Lived Intangible Assets [Line Items]  
Estimated Fair Value $ 14,133
Trademarks [Member]  
Finite-Lived Intangible Assets [Line Items]  
Estimated Fair Value $ 795
Estimated Useful Life (Years) 3 years
Technology [Member]  
Finite-Lived Intangible Assets [Line Items]  
Estimated Fair Value $ 6,161
Estimated Useful Life (Years) 4 years
Customer Relationship Warranty [Member]  
Finite-Lived Intangible Assets [Line Items]  
Estimated Fair Value $ 201
Estimated Useful Life (Years) 2 years
Customer Relationship Rental [Member]  
Finite-Lived Intangible Assets [Line Items]  
Estimated Fair Value $ 2,102
Estimated Useful Life (Years) 4 years
Customer Relationship - Distribution [Member]  
Finite-Lived Intangible Assets [Line Items]  
Estimated Fair Value $ 4,578
Estimated Useful Life (Years) 5 years
Backlog [Member]  
Finite-Lived Intangible Assets [Line Items]  
Estimated Fair Value $ 296
Estimated Useful Life (Years) 1 year
XML 70 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATION (Details 3) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Business Combinations [Abstract]    
Revenues $ 24,923 $ 25,307
Net loss $ (21,761) $ (28,369)
XML 71 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATION (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Aug. 08, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Business Acquisition [Line Items]        
Earnout payments $ 3,600      
Acquisition-related costs   $ 2,500    
Revenues   13,854 $ 5,511 $ 5,966
Alterg Inc [Member]        
Business Acquisition [Line Items]        
Aggregate purchase price in cash $ 19,000      
Description of Earnout payments The Company will pay an amount of cash equal to 65% of the amount, if any, by which      
Purchase price $ 22,100      
Revenues $ 7,658 $ 249    
XML 72 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]      
Cost $ 14,133    
Accumulated Amortization (1,608) $ 0 $ 0
Intangible Assets, Net 12,525    
Trademark      
Finite-Lived Intangible Assets [Line Items]      
Cost 795    
Accumulated Amortization (104)    
Intangible Assets, Net 691    
Technology [Member]      
Finite-Lived Intangible Assets [Line Items]      
Cost 6,161    
Accumulated Amortization (604)    
Intangible Assets, Net 5,557    
Customer relationship - Warranty      
Finite-Lived Intangible Assets [Line Items]      
Cost 201    
Accumulated Amortization (40)    
Intangible Assets, Net 161    
Customer relationship - Rental      
Finite-Lived Intangible Assets [Line Items]      
Cost 2,102    
Accumulated Amortization (206)    
Intangible Assets, Net 1,896    
Customer relationship - Distribution      
Finite-Lived Intangible Assets [Line Items]      
Cost 4,578    
Accumulated Amortization (358)    
Intangible Assets, Net 4,220    
Backlog      
Finite-Lived Intangible Assets [Line Items]      
Cost 296    
Accumulated Amortization (296)    
Intangible Assets, Net $ 0    
XML 73 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details 1)
$ in Thousands
Dec. 31, 2023
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Fiscal 2024 $ 3,347
Fiscal 2025 3,307
Fiscal 2026 3,143
Fiscal 2027 2,172
Fiscal 2028 556
Total $ 12,525
XML 74 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details Textual)
9 Months Ended
Sep. 30, 2023
USD ($)
Alterg Inc [Member]  
Goodwill [Line Items]  
Purchase of goodwill $ 7,500
XML 75 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY AND EQUIPMENT, NET (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 7,603 $ 3,821
Accumulated depreciation 6,341 3,625
Property and equipment, net 1,262 196
Computer equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 1,690 743
Office furniture and equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 468 308
Machinery and laboratory equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 621 621
Field service units [Member]    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 4,166 1,816
Leasehold improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 658 $ 333
XML 76 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY AND EQUIPMENT, NET (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Property And Equipment Net Textual Abstract      
Depreciation expenses $ 239 $ 202 $ 266
XML 77 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENT LIABILITIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
2023 $ 1,363  
2024 674  
2025 13  
Total lease payments 2,050  
Less: imputed interest (147)  
Present value of future lease payments 1,903  
Less: current maturities of operating leases (1,296) $ (564)
Non-current operating leases $ 607 $ 333
Weighted-average remaining lease term (in years) 1 year 11 months 1 day  
Weighted-average discount rate 9.21%  
XML 78 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENT LIABILITIES (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Commitments And Contingencies Liabilities [Abstract]      
Non-cancelable outstanding obligations $ 8,600    
Royalties expenses $ 17 $ 7 $ 14
Lease expiration, term These leases expire between 2024 and 2025.    
Restricted cash and other long-term assets $ 709    
Rent expenses $ 976 $ 739 $ 730
IPO [Member]      
Commitments And Contingencies Liabilities [Abstract]      
Description of conversion ratio ordinary shares in a conversion ratio of 1 to 1    
IIA [Member]      
Commitments And Contingencies Liabilities [Abstract]      
Total fund received $ 2,600    
Research And Development Royalty Bearing Grants $ 1,600    
Royalty Fees Percentage 3.00%    
Contingent liability $ 1,600    
Percentage Of Grant Received Considered To Determine Royalty Fees 100.00%    
Royalties expenses $ 110    
IIA [Member] | Convertible preferred A shares [Member]      
Commitments And Contingencies Liabilities [Abstract]      
Research And Development Amount Received In Consideration Of Convertible Preferred Shares $ 400    
Convertible preferred shares 209    
XML 79 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHAREHOLDERS' EQUITY (Details) - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Equity [Abstract]    
Number, Options outstanding at the beginning of the period 43,994  
Number, Granted 0  
Number, Exercised 0  
Number, Forfeited (10,823)  
Number, Options outstanding at the end of the period 33,171 43,994
Number, Options exercisable at the end of the period 33,171  
Average exercise price, Options outstanding at the beginning of the period $ 41.27  
Average exercise price, Granted 0  
Average exercise price, Exercised 0  
Average exercise price, Forfeited 52.78  
Average exercise price, Options outstanding at the end of the period 37.51 $ 41.27
Average exercise price, Options exercisable at the end of the period $ 37.51  
Average remaining contractual life (in years), Options outstanding at the beginning of the period 4 years 4 months 20 days 4 years 4 months 20 days
Average remaining contractual life (in years), Options exercisable at the end of the period 4 years 4 months 20 days  
XML 80 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHAREHOLDERS' EQUITY (Details 1) - Employee Stock Option And Restricted Stock Units Rsu [Member]
12 Months Ended
Dec. 31, 2023
$ / shares
shares
Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Nonvested Outstanding Roll Forward Abstract  
Unvested RSUs at the Beginning of the period | shares 2,755,057
Granted | shares 2,258,370
Vested | shares (1,109,200)
Forfeited | shares (131,813)
Unvested RSUs at the end of the period | shares 3,772,414
Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Exercise Price Roll Forward Abstract  
Unvested RSUs at the Beginning of the period | $ / shares $ 1.16
Granted | $ / shares 0.66
Share Based Compensation Arrangements By Share Based Payment Restricted Stock Options Vested In Period Weighted Average Exercise Price | $ / shares 1.14
Share Based Compensation Arrangements By Share Based Payment Restricted Stock Options Forfeited In Period Weighted Average Exercise Price | $ / shares 1.13
Unvested RSUs at the end of the period | $ / shares $ 0.87
XML 81 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHAREHOLDERS' EQUITY (Details 2) - Employee Stock Option [Member]
12 Months Ended
Dec. 31, 2023
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding 3,805,585
Options outstanding weighted average remaining contractual life (years) 4 years 4 months 20 days [1]
Options outstanding and exercisable 33,171
Options exercisable weighted average remaining contractual life (years) 4 years 4 months 20 days [1]
RSUs only [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding 3,772,414
Exercise Price Range One [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Investment Options Exercise Prices | $ / shares $ 5.37
Options outstanding 12,425
Options outstanding weighted average remaining contractual life (years) 5 years 2 months 26 days [1]
Options outstanding and exercisable 12,425
Options exercisable weighted average remaining contractual life (years) 5 years 2 months 26 days [1]
Exercise Price Range Two [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Range of exercise price, minimum | $ / shares $ 20.42
Range of exercise price, maximum | $ / shares $ 33.75
Options outstanding 12,943
Options outstanding weighted average remaining contractual life (years) 4 years 4 months 6 days [1]
Options outstanding and exercisable 12,943
Options exercisable weighted average remaining contractual life (years) 4 years 4 months 6 days [1]
Exercise Price Range Three [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Range of exercise price, minimum | $ / shares $ 50
Range of exercise price, maximum | $ / shares 52.5
$50-$52.5 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Range of exercise price, minimum | $ / shares 182.5
Range of exercise price, maximum | $ / shares $ 524.25
Options outstanding 6,230
Options outstanding weighted average remaining contractual life (years) 3 years 5 months 15 days [1]
Options outstanding and exercisable 6,230
Options exercisable weighted average remaining contractual life (years) 3 years 5 months 15 days [1]
$182.5-$524.25 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Options outstanding 1,573
Options outstanding weighted average remaining contractual life (years) 1 year 7 months 24 days [1]
Options outstanding and exercisable 1,573
Options exercisable weighted average remaining contractual life (years) 1 year 7 months 24 days [1]
[1] Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. 
XML 82 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHAREHOLDERS' EQUITY (Details 3) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Non-cash share-based compensation expense $ 1,328 $ 993 $ 833
Cost of revenue [Member]      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Non-cash share-based compensation expense 9 16 10
Research and development, net [Member]      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Non-cash share-based compensation expense 157 94 55
Sales and marketing, net [Member]      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Non-cash share-based compensation expense 381 250 171
General and administrative [Member]      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Non-cash share-based compensation expense $ 781 $ 633 $ 597
XML 83 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHAREHOLDERS' EQUITY (Details 4)
12 Months Ended
Dec. 31, 2023
$ / shares
shares
Class of Warrant or Right [Line Items]  
Warrants outstanding 19,187,375
Class Of Warrant Or Right Exercisable 19,187,375
Warrants To Purchase Ordinary Shares Issued On December Two Thousand Fifteen Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 4,771 [1]
Exercise price per warrant | $ / shares $ 7.5 [1]
Class Of Warrant Or Right Exercisable 4,771 [1]
Warrants To Purchase Ordinary Shares Issued On December Two Thousand Sixteen Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 1,908 [2]
Exercise price per warrant | $ / shares $ 7.5 [2]
Class Of Warrant Or Right Exercisable 1,908 [2]
Warrants To Purchase Ordinary Shares Issued On November Twenty Two Thousand Eighteen Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 45,600 [3]
Exercise price per warrant | $ / shares $ 7.187 [3]
Class Of Warrant Or Right Exercisable 45,600 [3]
Warrants Expitation Date Feb. 21, 2024 [3]
Warrants To Purchase Ordinary Shares Issued On November Twenty Two Thousand Eighteen One Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 408,457 [4]
Exercise price per warrant | $ / shares $ 5.14 [4]
Class Of Warrant Or Right Exercisable 408,457 [4]
Warrants Expitation Date Oct. 07, 2024 [4]
Warrants To Purchase Ordinary Shares Issued On February Twenty Five Two Thousand Nineteen Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 49,015 [5]
Exercise price per warrant | $ / shares $ 6.503 [5]
Class Of Warrant Or Right Exercisable 49,015 [5]
Warrants Expitation Date Apr. 03, 2024 [5]
Warrants To Purchase Ordinary Shares Issued On April Five Two Thousand Nineteen Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 1,464,665 [6]
Exercise price per warrant | $ / shares $ 7.5 [6]
Class Of Warrant Or Right Exercisable 1,464,665 [6]
Warrants Expitation Date Jun. 05, 2024 [6]
Warrants To Purchase Ordinary Shares Issued On April Five Two Thousand Nineteen One Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 87,880 [7]
Exercise price per warrant | $ / shares $ 9.375 [7]
Class Of Warrant Or Right Exercisable 87,880 [7]
Warrants Expitation Date Jun. 05, 2024 [7]
Warrants To Purchase Ordinary Shares Issued On June Five And Six Two Thousand Nineteen Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 416,667 [8]
Exercise price per warrant | $ / shares $ 6 [8]
Class Of Warrant Or Right Exercisable 416,667 [8]
Warrants Expitation Date Dec. 12, 2024 [8]
Warrants To Purchase Ordinary Shares Issued On June Five Two Thousand Nineteen Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 50,000 [9]
Exercise price per warrant | $ / shares $ 7.5 [9]
Class Of Warrant Or Right Exercisable 50,000 [9]
Warrants Expitation Date Jun. 10, 2024 [9]
Warrants To Purchase Ordinary Shares Issued On June Tweleve Two Thousand Nineteen Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 28,400 [10]
Exercise price per warrant | $ / shares $ 1.25 [10]
Class Of Warrant Or Right Exercisable 28,400 [10]
Warrants Expitation Date Feb. 10, 2025 [10]
Warrants To Purchase Ordinary Shares Issued On June Ten Two Thousand Nineteen Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 105,840 [11]
Exercise price per warrant | $ / shares $ 1.563 [11]
Class Of Warrant Or Right Exercisable 105,840 [11]
Warrants Expitation Date Feb. 10, 2025 [11]
Warrants To Purchase Ordinary Shares Issued On February Ten Two Thousand Twenty Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 448,698 [12]
Exercise price per warrant | $ / shares $ 1.76 [12]
Class Of Warrant Or Right Exercisable 448,698 [12]
Warrants Expitation Date Jan. 02, 2026 [12]
Warrants To Purchase Ordinary Shares Issued On February Ten Two Thousand Twenty One Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 296,297 [13]
Exercise price per warrant | $ / shares $ 2.278 [13]
Class Of Warrant Or Right Exercisable 296,297 [13]
Warrants Expitation Date Jan. 02, 2026 [13]
Warrants To Purchase Ordinary Shares Issued On July Six Two Thousand Twenty Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 586,760 [14]
Exercise price per warrant | $ / shares $ 1.34 [14]
Class Of Warrant Or Right Exercisable 586,760 [14]
Warrants Expitation Date Jun. 08, 2026 [14]
Warrants To Purchase Ordinary Shares Issued On July Six Two Thousand Twenty One Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 108,806 [15]
Exercise price per warrant | $ / shares $ 1.792 [15]
Class Of Warrant Or Right Exercisable 108,806 [15]
Warrants Expitation Date Jun. 08, 2026 [15]
Warrants To Purchase Ordinary Shares Issued On December Eight Two Thousand Twenty Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 5,460,751 [16]
Exercise price per warrant | $ / shares $ 3.6 [16]
Class Of Warrant Or Right Exercisable 5,460,751 [16]
Warrants Expitation Date Aug. 26, 2026 [16]
Warrants To Purchase Ordinary Shares Issued On December Eight Two Thousand Twenty One Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 655,290 [17]
Exercise price per warrant | $ / shares $ 4.578 [17]
Class Of Warrant Or Right Exercisable 655,290 [17]
Warrants Expitation Date Aug. 26, 2026 [17]
Warrants To Purchase Ordinary Shares Issued On February Twenty Six Two Thousand Twenty One Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 8,006,759 [18]
Exercise price per warrant | $ / shares $ 2 [18]
Class Of Warrant Or Right Exercisable 8,006,759 [18]
Warrants Expitation Date Mar. 29, 2027 [18]
Warrants To Purchase Ordinary Shares Issued On February Twenty Six Two Thousand Twenty One One Member  
Class of Warrant or Right [Line Items]  
Warrants outstanding 960,811 [19]
Exercise price per warrant | $ / shares $ 2.544 [19]
Class Of Warrant Or Right Exercisable 960,811 [19]
Warrants Expitation Date Sep. 27, 2026 [19]
[1] Represents warrants for ordinary shares issuable upon an exercise price of $7.500 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2022.
[2] Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.
[3] Represents common warrants that were issued as part of the Company’s follow-on public offering in November 2018.
[4] Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on public offering in November 2018.
[5] Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on public offering in February 2019.
[6] Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019.
[7] Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering.
[8] Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively.
[9] Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants.
[10] Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.
[11] Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants.
[12] Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of December 31, 2022, 3,740,100 warrants were exercised for total consideration of $4,675,125. During the twelve months that ended December 31, 2022, no warrants were exercised.
[13] Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of December 31, 2022, 230,160 warrants were exercised for total consideration of $359,625. During the twelve months that ended December 31, 2022, no warrants were exercised.
[14] Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. As of December 31, 2022, 2,020,441 warrants were exercised for total consideration of $3,555,976. During the twelve months that ended December 31, 2022, no warrants were exercised.
[15] Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering.
[16] Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. As of December 31, 2022, 3,598,072 warrants were exercised for total consideration of $4,821,416. During the twelve months that ended December 31, 2022, no warrants were exercised.
[17] Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of December 31, 2022, 225,981 warrants were exercised for total consideration of $405,003. During the twelve months that ended December 31, 2022, no warrants were exercised.
[18] Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021.
[19] Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.
XML 84 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHAREHOLDERS' EQUITY (Details Textual)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Sep. 27, 2021
₪ / shares
shares
Feb. 19, 2021
₪ / shares
shares
Feb. 19, 2021
₪ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
$ / shares
Dec. 31, 2015
$ / shares
Dec. 31, 2023
₪ / shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
₪ / shares
shares
Dec. 22, 2022
USD ($)
Jul. 21, 2022
USD ($)
Jun. 02, 2022
₪ / shares
Jun. 02, 2022
USD ($)
Sep. 27, 2021
$ / shares
shares
Feb. 19, 2021
$ / shares
shares
Dec. 28, 2016
USD ($)
Shareholders Equity Textual Abstract                                  
Per share value of stock repurchase authorized | ₪ / shares               ₪ 0.25   ₪ 0.25              
Options granted (in shares)       0                          
Warrants to purchase ordinary shares       32,895                          
Warrants outstanding                 19,187,375                
Total number of warrants outstanding                 9,814,754                
Proceeds From Warrant Exercises | $       $ 13,800                          
Minimum [Member]                                  
Shareholders Equity Textual Abstract                                  
Exercise price per share | $ / shares                 $ 1.25                
Maximum [Member]                                  
Shareholders Equity Textual Abstract                                  
Exercise price per share | $ / shares                 $ 1.79                
Kreos Capital V [Member]                                  
Shareholders Equity Textual Abstract                                  
Warrants grant date             Dec. 31, 2015                    
Warrants Exercisable Descrition             currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2023.                    
Restricted Stock Units (RSUs) [Member]                                  
Shareholders Equity Textual Abstract                                  
Weighted average grant date fair value, restricted stock units (in USD per share) | $ / shares       $ 0.66 $ 1 $ 1.69                      
Employee Stock Option [Member]                                  
Shareholders Equity Textual Abstract                                  
Shares reserved for future issuance (in shares)                 1,018,945 2,934,679              
Unrecognized cost of shares | $                 $ 2,700                
Expected term of shares       2 years 10 months 24 days                          
Total fair value of shares vested | $       $ 1,268 $ 860 $ 802                      
Private Placement [Member]                                  
Shareholders Equity Textual Abstract                                  
Issuance expenses | $       3,679                          
Purchase agreement with certain institutional investors [Member]                                  
Shareholders Equity Textual Abstract                                  
Issuance of ordinary shares (in shares) 15,403,014                                
Per share value of stock repurchase authorized | ₪ / shares ₪ 0.25                                
Exercise price per share | $ / shares                             $ 2    
Number of warrants issued 8,006,759                           8,006,759    
Description of underwriting agreement The Pre-Funded Warrants have an exercise price of $0.001 per Ordinary Share and are immediately exercisable and can be exercised at any time after their original issuance until such pre-funded warrants are exercised in full. Each ordinary shares was sold at an offering price of $2.035 and each pre-funded warrant was sold at an offering price of $2.034 (equal to the purchase price per ordinary share minus the exercise price of the pre-funded warrant).                                
Purchase agreement with certain institutional investors [Member] | Additionally Warrants Issued [Member]                                  
Shareholders Equity Textual Abstract                                  
Issuance of ordinary shares (in shares) 610,504                                
Exercise price per share | $ / shares                             $ 2.5438    
Number of warrants issued 960,811                           960,811    
Purchase Agreement With Certain Institutional Accerdited Investors Member                                  
Shareholders Equity Textual Abstract                                  
Issuance of ordinary shares (in shares)   10,921,502                              
Shares issued price per share | $ / shares                               $ 3.6625  
Per share value of stock repurchase authorized | ₪ / shares   ₪ 0.25 ₪ 0.25                            
Exercise price per share | $ / shares                               $ 3.6  
Number of warrants issued   5,460,751 5,460,751                         5,460,751  
Warrants Exercisable Descrition     exercisable from February 19, 2021, until August 26, 2026                            
Purchase Agreement With Certain Institutional Accerdited Investors Member | Additionally Warrants Issued [Member]                                  
Shareholders Equity Textual Abstract                                  
Exercise price per share | $ / shares                               $ 4.578125  
Number of warrants issued   655,290 655,290                         655,290  
Warrants Exercisable Descrition     exercisable from February 19, 2021, until August 26, 2026                            
Certain institutional purchasers [Member] | Offering of ordinary shares in February 2020 [Member]                                  
Shareholders Equity Textual Abstract                                  
Number of warrants issued                   3,740,100              
Proceeds From Warrant Exercises | $         4,675,125                        
Certain institutional purchasers [Member] | Offering of ordinary shares in February 2020 Two [Member]                                  
Shareholders Equity Textual Abstract                                  
Number of warrants issued                   230,160              
Proceeds From Warrant Exercises | $         359,625                        
Certain institutional purchasers [Member] | Offering of ordinary shares in July 2020 [Member]                                  
Shareholders Equity Textual Abstract                                  
Number of warrants issued                   2,020,441              
Proceeds From Warrant Exercises | $         3,555,976                        
Certain institutional purchasers [Member] | Offering of ordinary shares in December 2020 [Member]                                  
Shareholders Equity Textual Abstract                                  
Number of warrants issued                   3,598,072              
Proceeds From Warrant Exercises | $         4,821,416                        
Certain institutional purchasers [Member] | December 2020 private placement [Member]                                  
Shareholders Equity Textual Abstract                                  
Number of warrants issued                   225,981              
Proceeds From Warrant Exercises | $         $ 405,003                        
Kreos Capital [Member]                                  
Shareholders Equity Textual Abstract                                  
Exercise price per share | $ / shares             $ 7.5                    
Drawdown amount under loan agreement | $                                 $ 8,000
Share Repurchase Program [Member]                                  
Shareholders Equity Textual Abstract                                  
Shares issued price per share | ₪ / shares                         ₪ 0.25        
Issuance expenses | $       $ 3,500                          
Number of ordinary shares repurchased, amount | $                     $ 5,800 $ 8,000   $ 8,000      
Outstanding ordinary shares repurchased, shares                 4,022,607                
XML 85 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Research Collaboration Agreement And License Agreement Textual Abstract      
Research and development, net $ 4,148 $ 4,031 $ 2,939
License Agreement and Collaboration Agreement [Member]      
Research Collaboration Agreement And License Agreement Textual Abstract      
Research and development, net $ 29 $ 74 $ 293
XML 86 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Domestic $ (19,638) $ (19,110) $ (12,780)
Foreign (2,507) 8 138
Loss before income taxes $ (22,145) $ (19,102) $ (12,642)
XML 87 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES (Details 1) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Current $ (12) $ 151 $ 123
Deferred 0 316 (29)
Taxes on income (12) 467 94
Domestic 0 0 0
Foreign (12) 467 94
Taxes on income $ (12) $ 467 $ 94
XML 88 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES (Details 2) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:        
Carry forward tax losses $ 64,090 $ 50,833    
Research and development carry forward expenses-temporary differences 1,311 844    
Accrual and reserves 849 392    
Share based compensation 394 456    
Credit tax carry forwards 1,714 0    
Lease liabilities 480 214    
Total deferred tax assets 68,838 52,739    
Deferred tax liabilities:        
Right-of-use asset (470) (214)    
Intangible Assets (3,015) 0    
Property and equipment (144) 0    
Net deferred tax assets 65,209 52,525    
Valuation allowance (65,209) (52,525) $ (48,098) $ (42,941)
Net deferred tax assets $ 0 $ 0    
XML 89 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES (Details 3) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Balance at beginning of year $ (52,525) $ (48,098) $ (42,941)
Valuationallowancedeferred Tax Asset Changes Due To Exchange Rate Differences Amount 0 1,418 (1,488)
Adjustment previous year loss (5) (14) 0
Acquisition (7,269) 0 0
Additions during the year (5,410) (5,831) (3,669)
Balance at end of year $ (65,209) $ (52,525) $ (48,098)
XML 90 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES (Details 4) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Loss before taxes, as reported in the consolidated statements of operations $ (22,145) $ (19,102) $ (12,642)
Statutory tax rate 23.00% 23.00% 23.00%
Theoretical tax benefits on the above amount at the Israeli statutory tax rate $ (5,093) $ (4,393) $ (2,908)
Income tax at rate other than the Israeli statutory tax rate 56 (2) 7
Non-deductible expenses including equity-based compensation expenses and other 0 262 102
Operating losses and other temporary differences for which valuation allowance was provided 5,410 5,375 3,669
Permanent differences (342) (775) (784)
Adjustment in respect of prior years (43) 0 0
Other 0 0 8
Actual tax expense (benefit) $ (12) $ 467 $ 94
XML 91 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES (Details Textual) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Jan. 01, 2018
Income Taxes [Abstract]          
Statutory tax rate 23.00% 23.00% 23.00%    
Beneficiary enterprise from productive activity, tax exemption period 10 years        
Beneficiary Enterprise From Productive Activity Maximum Time From Period Of Election For Tax Exemption 12 years        
Minimum [Member]          
Income Taxes [Abstract]          
Beneficiary enterprise from productive activity, tax rate on dividend distributions from tax exempt income 10.00%        
Maximum [Member]          
Income Taxes [Abstract]          
Beneficiary enterprise from productive activity, tax rate on dividend distributions from tax exempt income 25.00%        
Israel Tax Authority [Member]          
Income Taxes [Abstract]          
Statutory tax rate   23.00% 23.00% 23.00%  
Re Walk Robotics Inc [Member]          
Income Taxes [Abstract]          
Statutory tax rate 21.00% 21.00% 21.00%    
Carry-forward losses $ 242.6        
Rewalk Robotics Gmbh [Member]          
Income Taxes [Abstract]          
Statutory tax rate 30.00% 30.00% 30.00%    
Alterg Inc [Member]          
Income Taxes [Abstract]          
Carry-forward losses $ 31.4        
Operating loss carry forwards prior period         $ 16.7
Net operating carry forward losses expiration term 2025 and 2028        
Alterg Inc [Member] | Federal [Member]          
Income Taxes [Abstract]          
Carry-forward losses         $ 14.7
Alterg Inc [Member] | State [Member]          
Income Taxes [Abstract]          
Carry-forward losses $ 47.2        
XML 92 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL EXPENSES (INCOME), NET (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Other Income and Expenses [Abstract]      
Foreign currency transactions and other $ 133 $ (22) $ 38
Interest Income 1,354 0 0
Bank commissions (20) (22) (25)
Financial (expenses) income, net $ 1,467 $ 13
XML 93 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue, Major Customer [Line Items]      
Total revenues $ 13,854 $ 5,511 $ 5,966
United States [Member]      
Revenue, Major Customer [Line Items]      
Total revenues 7,636 2,303 2,519
Europe [Member]      
Revenue, Major Customer [Line Items]      
Total revenues 5,044 3,057 3,381
Asia Pacific [Member]      
Revenue, Major Customer [Line Items]      
Total revenues 387 115 60
Rest Of World [Member]      
Revenue, Major Customer [Line Items]      
Total revenues $ 787 $ 36 $ 6
XML 94 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 1) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets $ 3,123 $ 1,032
Israel [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets 529 757
United States [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets 2,404 231
Germany [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Long-lived assets $ 190 $ 44
XML 95 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 2) - Sales Revenue, Net [Member] - Customer Concentration Risk [Member]
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Customer A [Member]      
Revenue, Major Customer [Line Items]      
Concentration risk 12.20% 14.20% [1]
Customer B [Member]      
Revenue, Major Customer [Line Items]      
Concentration risk [1] [1] 11.00%
[1] Less than 10%
XML 96 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details Textual)
12 Months Ended
Dec. 31, 2023
segment
Geographic Information And Major Customer And Product Data [Abstract]  
Number of reportable segments 1
XML 97 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
BASIC AND DILUTED NET LOSS PER SHARE (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2023
₪ / shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
₪ / shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
₪ / shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Earnings Per Share [Abstract]            
Net loss | $   $ (22,133)   $ (19,569)   $ (12,736)
Net loss attributable to ordinary shares | $   $ (22,133)   $ (19,569)   $ (12,736)
Weighted average number of shares used in computing net loss per ordinary share, basic | shares   59,719,064   62,378,797   47,935,652
Weighted average number of shares used in computing net loss per ordinary share, diluted | shares   59,719,064   62,378,797   47,935,652
Net loss per ordinary share, basic | (per share) ₪ (0.37) $ (0.37) ₪ (0.31) $ (0.31) ₪ (0.27) $ (0.27)
Net loss per ordinary share, diluted | (per share) ₪ (0.37) $ (0.37) ₪ (0.31) $ (0.31) ₪ (0.27) $ (0.27)
XML 98 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
BASIC AND DILUTED NET LOSS PER SHARE (Details Textual) - shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]    
Shares Excluded from Diluted Loss per Share - Anti-Dilutive 19,220,546 19,464,888
XML 99 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
RESTRUCTURING ACTIVITIES (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Dec. 12, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Restructring Activities [Line Items]        
Research and development, net   $ 4,148 $ 4,031 $ 2,939
Sales and marketing   13,922 $ 9,842 $ 6,993
2023 Reorganization Plan [Member]        
Restructring Activities [Line Items]        
Workforce Percentage 15.00%      
Amount of employee termination benefits and legal expenses   670    
Research and development, net   175    
Sales and marketing, net   70    
Sales and marketing   $ 425    
EXCEL 101 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

M9)1JGDKO[YYO[QY_3NYL9.IZ PH3*$_05/3H5R1!K,!)/G_RA]ZW/K?_B6S+>]AY#P^Q)[>$$7U1,E0*GE6IZCW-AB*R M%*8"K)+0C\YB=[7I8C\I& 1^E[2E;M"I&QQ4-\6UOM<*!,&T5UD#'VXM>C'< M4;:?%'GG_<*B3EAT4-CZRA#HE17M[44TC,(=6?M)P45PL:/+W7C%IH+^P&)) MF$04%AKFG9YIO&BJ4A,H7MJ'/>=*EPG;S74A!V$2]/R"<[4.3*WH?@W)/U!+ M P04 " #S25M839[-,'8" "$!@ &0 'AL+W=O*!E\;7ON?<>X^;D[@1\EX5 !H]E(RKD5=H79UBK+("2J*. M1 7^?XQ+0KF7Q&YO(I-8U)I1#A.)5%V61#Z. M@8EFY 7>>F-*EX6V&SB)*[*$&>C;:B)-A'N6G); %14<25B,O+/@-!W8?)=P M1Z%1&VMD)YD+<6^#RWSD^;8A8)!IRT#,8P7GP)@E,FW\ZSB]OJ0%;J[7[#_< M[&:6.5%P+MAOFNMBY)UX*(<%J9F>BN8G=/,,+5\FF'*_J&ESAT,/9;72HNS MIH.2\O9)'CH=-@#!\0Y V '"EX#!#D#4 :+W @8=P$F-VU&<#BG1)(FE:)"T MV8;-+IR8#FW&I]Q>^TQ+7UW<7US>_II<7,[2?@B:4*70##[HF[ = MHMM9BO;W#M >HAS=%*)6A.;H&G[X<';TP3]?<0.;YHUSWP M%7 MY"-*J=/ MP;'_?9M8'TF6?A#9,R$'O9"#M]@WA&PDU7"8BX9O4Z]E&3H6ZXVK)/IV$N/5 MIBBO>U@1:5&ULK99K;YLP%(;_BL6JJ96V<$L(ZPA2+IT6:;VH M:;\X#AN-@2]D]3P $>LS2G(^, M1(CBU#1YE$"&>8\6D,N9%649%K++UB8O&.!8B[+4="S+,S-,>":K!.A!LPP*/ :%B!NBRLF>V;C$I,,\)O EN^TD2)94GJO.O-X9%@J(4@A$LH!R]L&II"FRDBF M\5![&DU()=QM/[O_T.R298DY3&GZA\0B&1F^@6)8X3(5UW3[$VJ>@?*+:,KU M%6VKM0//0%')!CU9*&Y.HM+@23LT3J1#BY7M[&^^!S%[0NPV]V^4> M3C%/V@ [5>\%K,P&VDS]3#9A?^@'YJ8E[WZ3=[\S[W$J@*W1/(_0W3ED2V"M M[ZG3Y+T8!S)[P3MH> >'WZ6#0](?R.P%O=?0>Q_:I=Z;C67[_6]NL[6JS#N] M/YCYL,E\V)GY&6:Y+)FHP$^RXHG6WV7EX.U0N)XU? 71&>:#$'X#X7="W%"! M4Q116;%C8%CMO38._\W;,VMWE!F MPZKZ774$+70)7%(A"ZIN)O+( TPMD/,K2L5S1U75YA 5_@-02P,$% @ M\TE;6#-!$VPS! O!$ !D !X;"]W;W)K&UL MM9A=;Z,X%(;_BL6.5C/2I& ((>DFD=IT9S?23%LU[<[%:B\<)F%A;*=-+VQ;A%F(B+E@* MB;JS9CPF4IWRC2U2#F25&\61[3K.P(X)3:SI.+]VSZ=CELF()G#/D7POG5I53&UX M>/SJ_5,.KV"61,",15_I2FXGUM!"*UB3+)(/;/\WE$"^]A>R2.2_:%^,]=7@ M,!.2Q:6QRB"F2?%/GLL'<6" ^T<,W-+ _5D#KS3PR34#807R,,? MD>NX7H?Y[.?-W;?FMH*NR-V*W,W]>]XBY%2D*86&I)"> [L*:__X8'SA]=N+_(V1MXKX+W3-ZG,R*V M2$TC"O4!?,_HCD20R"[HPI.?>])=83?M!\.QO3MD,48[D:5?L?2-+ ^@9HR& M$@J:+H3"P> P<<- F.,$PG\BL W$ER%(7UE;"D]^,:*UV]64+-&C.'.Q7G8#>!C3A_,;;:TRCJ3!^W MT@]\KZDDY:A#N:D9WV95*STV:JGJ2Y(D&ZK:JNGINNWB[V.OV5_-H4Y]P+5N M8[-P5U*1DI=C.E&Z."3IN<[0;9*<0[1QK=K8+-N*A&=:LUFL^VV^_^JD:8MW M+Q@,FC#GT&]<"S@V*WBQC$F)%%&RI!&5%+HKK2WD/>SXHR;2.:0Q6=B_$LY)HD3C;AG13;'1[Z1I MBWC/]_PFS#ED'-ZQ!R+A52*H/)(*N@!]O!*.6,K@N=EH*^$L%W3YXM=;?-;X0OJ'J/3&"M7+O M7 0J'5Y\*BA.)$OSM^TED^K=/3_< E%<>H"ZOV9,OI[H%_CJ@\WT?U!+ P04 M " #S25M8S86]_O # #>$P &0 'AL+W=O^ZQ[XE/[/Y2R!>5 &CT*TNY&GB)UO-SWU=1 AE5 M9V(.W#R9"IE1;9IRYJNY!!KG05GJDR!H^QEEW O[^;T'&?;%0J>,PX-$:I%E M5+X-(17+@8>]]QN/;)9H>\,/^W,Z@S'HY_F#-"V_1(E9!EPQP9&$Z<"[P.=# MTK4!>8^O#)9J[1K9H4R$>+&-43SP LL(4HBTA:#F[Q4N(4TMDN'QBB&*5VD^E$L_X'5@%H6+Q*IRG_1LNC; M-)VCA=(B6P4;!AGCQ3_]M9J(M0!"-@2050#)>1>)U26I#_6B58%@D(!L28(+N!->)0M<\AOC_ +YA6U(F[Y2' MQ(EX!=$9:N"_$ E( SV/K]#)IU,';J.\,XT_#YUJ@D1B.N*9^Q M20KH0BG0"OVX-?W12$.F_JV;A@*\60]N7ZYS-:<1##SS]BB0K^"%?_Z!V\'? M#NK-DGK3A1Y>*\V,0@WO&\HD^DK3!=1Q+%!:.8I]7U]#W,2-1M]_K4G>*I.W MG,F?)(W-4F&6$?3C#K()R-KY<8+L.3_MDF+[F*5M'X%ZIZ3>.4AI.Q]*V^FU MZ@O;+5-W=TS]K&"Z2-$MFP(Z^0Y4JM,Z#FZX!GJSD8XYZ97$>F[%091PD8K9 MFU-Q3I ]RX:#:F$-CJFY%?J!V:_9 CZ([%8PZ[IKXS:N%QXF57IR6.EMP6MN MU1ZN; ([E_+P,G=ED.@14FH_+53"YN@;E9)R[5:D&WG?HE8N@9M'E:33A/9E M7]D,=OO,SI)L?9 D"38ILG(0[%SE]U"D&X]L5V1E$=CM$?6*? 13X=2M1R?N MOA6M_ 5WCZI'I]_LR[XR(>QVH9WUV/NH1QR0>D&2RE^(TP%^7Y!;\+8OD:1R M#^)VCWI!?D973&G))HM\0^82IAM_S]*2RGX(.:8PB=.,]F5?&11Q&]2NPES! MK NSV>IT-PBSG43XZ\=N9B%;I8?+"D4 MB077Q>E+>;<\O+HHCFRJ[L7)UQV5,\852F%J0H.SCID461PF%0TMYOD!SD1H MLZKFEPF8/;>T'&ULK57);MLP$/T50@V* M!&BBS7*6V@*\)*@/<8(X;@]%#[0TMHA0I$I2=OKW)2E9M5W9Z*$7B1S.>_-F M-!SU-ER\R0Q H?><,MEW,J6*.]>5208YEE>\ *9/EESD6.FM6+FR$(!3"\JI M&WA>U\TQ84[SF:1]QS." M@$*B# /6KS6,@%)#I&7\K#F=)J0![JZW[ \V=YW+ DL8^.8+U/E8@0FGTC[1IO*-M'-22L7S&JP5Y(15;_Q>UV$'X'>/ ((:$!P" M.D< 80T(;:*5,IO6&"L<]P3?(&&\-9M9V-I8M,Z&,/,59TKH4Z)Q*A[.9Y/I M_6R&1D^/P\ET\#IYFJ+S,2A,J$3A!;I$\]D8G9]=H#-$&'K->"DQ2V7/53J\ M(7&3.M2P"A4<">4'Z)$SE4ETSU)(]PEA!2+EME17\%O S\ZZY_H*O- M[2;LWAX(31 DOF:I:NK$VXV]@;_V!?:C'8C7%_M!4,_41BQ71 M+45AJ2F]JVLM2E1SJMHH7MBKON!*#PZ[S/1H!V$<]/F2<[7=F #-SR+^#5!+ M P04 " #S25M8SPN@XP@$ !N$P &0 'AL+W=OU ^^_73FA*($1EY!M('+_/L=\3.[8'6\I^\A!1P$L2IWQHA$)DUZ;) M@Q 3PB]IAJE\LJ(L(4+>LK7),X9D68B2V'0LRS,3$J7&:%"4W;/1@.8BCE*\ M9\#S)"'L=8PQW0X-VW@K>(C6H5 %YFB0D37.43QE]TS>F15E&268\HBFP' U M-&[L:]]VE*"H\4^$6[YW#:HK"TI_JIO9/L^]W )^G*$@4R MA'.X"9[SB$?%2V3MA4)\S7!*OEI5OEI=M&'_F$I7*BAHR\RGE6- V<<4EP"X*:X3>C MCF=9 W.S;V]KF'/MU0GS-<%J]KJ5O6ZKO7MO^U>&,1&XA(#R9I];4>>^[NY1 MTASW,&E3G1%]3;":SU[EL]?J\P-N,,VQT=96Y;FVEC!OSU:[TW.[![YZ1^:[ MKFW7*_D-E?J>5U6J^7!5^7#5_K[% MD:9FD /VXQ62!KG%A;(>=:HA,VU0GS M-<%JF>A5F>CI_^#U=.9%)VRJ$^9K@M7RTJ_RTF\?(>LUP[675SH[Z;Z[5Y[;.S3WN);3[1^L8-I; M<;9GFFBE9^;>N4(BESO%@0Z7ZVHYB,OM>55:'1K=%$\8\J3 MJ%O"UE'*(<:51%J75](M5A[NE#>"9L7IQ8(*09/B,D2R1*8JR.&ULM9I=;^(X%(;_BL6.5C/2M,0V7^U2)$HZ,TC]4MO9 M7HSV(H +49.8M4V9[J]?)] 8)ZG5H,--2T+.Z_A))8+QA3Z'4>) M/&LLE%J>-IMRNF!Q((_YDB7ZG2SUG$UV<-W'C;<1?.%RK=T1STE\&PYE:G#5Z M#31C3\$J4G=\_8-M)]1.\Z8\DME?M-X7EVAX[:.;AQ\7=VA\_3"\_CX^O[Q P_O[ MBX?[K^CZX@%]]ID*PDA^04?HY[V//G_Z@CZA,$$/"[Z203*3_:;29Y3F-J?; MT<\WHY-W1L<$7?%$+22Z2&9L9@(XJ^(>(16G-#H MX^6DHMS_>#EVS(;F5X=F>?2=O&]A$BIV=*D?C1D:)RI(YN$D8F@H)5,2_;K4 MQZ.Q8K'\IPK^)KQ5'9YVE%.Y#*;LK*%;AF3BA34&?_Z!.]Y?5> @PWR@, MJ M*X?:EMF/:6X4WI,05T:*LU&86P:P^DTKO#I3KG#.P>LC0X6X8":.E2:#<>X.G;+^BC[GH<))%B4W31R$2[1$7H,A @2 M]5J)"53B0=-\J#0;I_%X?%"1QZ F#YKF0Z799(W,X_UL'I=UGGBE=@_J\U!I M]K>,1N@)G-"3"J%O%;X:&;G'JTL'*LVF8WR>0/D\*?M\613K=^PA4[T'3?*@T&ZG1>W)0O2>@>@^:YD.EV62- MWI/]])Z4];[5[A9__G.'UT9Q"+^GQN\IG-_3"K^G[2(>]X"U?T _A.!3(_@4 M2O!I6?!;A!0__;B'JPWG$(9/C>%3M^&?!]/GB,\K:8"J/&B:#Y5F4]M9ZG+8 MM2ZPBUU@5[L<0N6I47FZG\K3"I4OV9@[NS:)0Y@\-29/X4R>5IE\&0^HR4.E MV7B,R5,HD]\&.=;ZC-QCU28#JO'-G0636L[GV<)3B:9\E:C-6L-\;[ZX=9@M MZ2SL/\>G_F:)JHG9K)B]"L0\3"2*V)..](Z[FI78+$+=;"B^S)9E3KC2GQ"R MEPL6S)A(#]#O/W&NWC;2 ?*EP(/_ 5!+ P04 " #S25M8[DZ2:8D" !Y M!@ &0 'AL+W=O*/\[[/.4E\ M$I=BJ6MEP+)%DERIGM M.4YHYX065A)7:X\BB?E&,5K@HP"YR7,B_@V0\;)GN=;[PA-=KI19L)-X398X M1?6\?A1Z9CB;UN\1L:,D4[C[\[3:I!&N#]^=[^I:M>US(G$:\Y>:*96/:MK088+ MLF'JB9=WN*LG,'XI9[*Z0EG'AM\M2#=2\7PGUAGDM*COY&WW'/8$GG=$X.T$ M7I5W#:JR'!)%DECP$H2)UFYF4)5:J75RM# O9:J$WJ5:IY+;AX?AR_C^'OJ3 M(3S,[D9/,)[,^I/;\>!^!/WI=#2;7L!D-(/S(2I"F03W&YP!+6"VXAM)BDS& MMM*9&#\[W5$'-=4[0AUB>@F^>P&>X_GP/!W"^=FWCS:V+J2IQFNJ\2I?_U@U MG&43CO%G),K MN28I]BQ]$"2*+5K)UR]NZ/SXI :_J<'_S#VYT4D29IY,IRVU6AQ48G/BMHGO M=Z+8WK8@.PVR&PO=V]R:W-H M965T^[[OO[-P%%1>O,D54\):Q7 Z<5*GB MQG5EG&)&9(<7F.N3#1<94=H46U<6 DEB01ES?<^[[O?L/VSMNI8UD7C+V3--5#IPOCJ0X(:43"UY=8]-/59@S)FT7ZCJV"N= M,2ZEXED#UG9&\WHE;\T]' !\_PC ;P"^U5TGLBK'1)$P$+P"8:(UF]G84BU: MBZ.Y>91("7U*-4Z%=X^/X^?I; ;#^1@>5_>3)4SGJ^'\;CJ:36 819-5= 'S MR0K@;(R*4"9AA6^J).P\<)568'C>JU3")$\P^1?O:N6M M?'\O?^2?)(RPZ$#7NP#?\[OP%(WA[//Y"=YN>RU=R]L[PCMD"L46IGD,+P^8 MK5'\^JC:DR2FGVYD06(<.+IA)(H=.N&73Y=7WO<3$GNMQ)YE[QY[.]STO M<'>'N=V#WSS3SV.;64+,RUS5?WSK;>?%L&Z3O^'UL'D@8DMS"0PW&NIUKG5J M43=P;2A>V*99&ULM5AM M;]HZ%/XK5NYTM4E=$R<0H!>0.F!:I;5C?=DT3?>#"0>PEL29[<#V[V?)K)B M/"!2#?G:%!$'LDR2 M^T+,ABZ=,0YAR). @(__T.?+8; M&=AXO'%+UQNI;YCC8436< ?R(9IS-3)SE"4-(!24A8C#:F1F$).(+ MA9TH72-=RH*Q'WIPM1P9EF8$/GA20Q#ULX4)^+Y&4CQ^9J!&_DZ=6+Y^1'^? M%*^*61 !$^9_I4NY&1E] RUA16)?WK+=!\@*ZFH\C_DB^8MV::SK&,B+A61! MEJP8!#1,?\FOK!&E!-QY(L'.$NSG)CA9@I,4FC)+RIH22<9#SG:(ZVB%IB^2 MWB39JAH:ZFF\DUP]I2I/CN>WG^:SV_MOZ/)FBF:?'Z[FU[.;^S-T,[M'KZ<@ M"?7%&_06/=Q-T>M7;] K1$-TOV&Q(.%2#$VI.&@DT\O>]RY]G_W$^Z;@G2,' MGR';LIV:],GST^UJNJDJS\NW\_+M!,]YJGRN%@27O\_0W">A1*HH-/L9TT@I M5:+O'U4XNI(0B/_K2DVQ._78>@%>B(AX,#+4"A/ MV",__T'N]9_=86W!%9I M@Y.WP6E"+[4ARML CVTX0VO.1.U1\*7GQ4'L$PE+M6A51SQ*]+901S)%>9# MKH.<[Z"1[Z?5BGJ 5C$/J8PY5 DW2K<1^-@Y:PFLT@-L%9]MZX3BS1&8W-T*UI"J[:B,#6XV=6\6,DU%L?>=SA_ M":I2+BP.;O8X[RGX2Z1;H3?E6&W)HEFZC7!'SU=+:-7B"^.$W5-*MU4GU19: MM16%E\*-'N7ETNT=;L+8=?>U>QB%^_@)WXL+YX.;K<]'( (V3 F8!A%G6]!D M_Z+?1L2C)ZTEM&K]A9/"@U/JMU4[U19:]1B@\%-VHTEYL7XSV/)_MVYWWT34 M!#G.O@TV2X2N?IH50ZD"Q*SG463$H6))<;($O@ M.D ]7S$F'P?ZJ"@_&AS_ 5!+ P04 " #S25M8A_O3\8L" "A!@ &0 M 'AL+W=O\[UN<:'<"OD@\H M--D5.5=#)].ZO')=E6104'4N2N"XLA*RH!I#N795*8&F%E3DKN]Y [>@C#M1 M:.=F,@I%I7/&82:)JHJ"RJ+0U)8T2K7<['] 8V> M"\.7B%S9)]G6N9=8,:F4%D4#QKA@O'[37=.' T!O< 3@-P#_):!_!! T@."M M@'X#L*UV:RFV#S'5- JEV!)ILI'-#&PS+1KE,VZ._4Y+7&6(T]%L_G,VF2_^ MDM$T)I-?]S>SV\ET<4:FDP4YC4%3EBNR@)VN:/Z)?";W=S$Y/?E$3@CC9)&) M2E&>JM#5N!?#Z"9-W7%=US]2M^>36\%UILB$IY ^)W!11*O$WRL9^Z\RQI"< MDZ!W1GS/#SHV=/UVN-\!C]\.[[VB)FC/);!\P;%SD7BSI7XB(YZ2R6/%2KQK MFDS1")K3(*.ETA+O35?S:_)^-[FQDBM5T@2&#GJ% KD!)_KXH3?POG4U[CW) MXG];4?MO4_FOL>$A(FC!J'0=V:)T*.K_=FN;"TACCW$1^\#5T-X==ZR-L0ZT**T%K$4&@W'#C/\AX T";B^$D+O U.@_2M% M_P!02P,$% @ \TE;6,W7D.*1 P : P !D !X;"]W;W)K&ULK5=A;YLZ%/TK%INF5GHI&!+2= E2F^R]%ZG-JB7;/DS[ MX,)-8@UPGFV2]=^_:T@I)816T;XD&'S./>=>8U^&.R%_J36 )K^3.%4C:ZWU MYLJV5;B&A*D+L8$4GRR%3)C&H5S9:B.!13DHB6W7<7P[83RU@F%^[UX&0Y'I MF*=P+XG*DH3)QQN(Q6YD4>OIQA>^6FMSPPZ&&[:".>BOFWN)([MDB7@"J>(B M)1*6(^N:7HVI:P#YC&\<=JIR38R5!R%^F<$T&EF.400QA-I0,/S;PACBV#"A MCO_VI%89TP"KUT_L?^?FTZ?7(NK1(!$N6Q?J+V/T+>T,]PQ>* M6.6_9%?,[7'N#E1@ME MN:T)TRP82K$CTLQ&-G.1YR9'HQN>FC+.M<2G''$Z&'^^NYLN[C[-%G-R/9N0 M\>?98CK[!\?D=GI],[V=+J:?YN1L IKQ6)V3#ODZGY"S]^?D/>$I6:Q%IE@: MJ:&M48XAM<-]Z)LBM'LD] 3""^+1OXCKN%X#?/QVN/L2;F,2RDRX92;Y$/K\R'U\8>'*G*38'JY2BS26P# MZODX$^_UN37Z7NWFNZ>TVZ>P>Z M:3W=K<0GRO9+V7ZK[(70+"8QX%Y*-NPQ?X&:;/@'-ERGY]2,M(8ZT4B_--)O M-7(+2ET1GFPR#1'N;1HPAFZRTC^PTJ'=?LU*:[ 3K5R65BY;K=P;RE23+8LS M(&))EIDV6]?K5;H\7&P#I[[<6H.?:&U06AN\H4IA)J4QB.=X)KDV.S2ZQ.9& M,K-I%T8;#0X::N<._)K#P<$FU^GYSYO%"^74>3YKG5;M,Y%VGI2_1>N>KBK# M=^KKK&&2YWE'I%;: MHJ]7O>_T#485O4N0)LV4Q36.HE^'8DY P[@$=@4ITW MRF\/07,HH90D>-2N%:$D8H^-C4 KT8D+CCXW!K3UG#W,183-@,BPB%A!:'1> M$ XJ-7$NG(%+Z[7[HP>\76D#30]^Q^2*IPH+MD1ZYZ*/:T06;6TQT&*3=X8/ M0F.?F5^N\5, I)F SY="Z*>!:3;+CXO@?U!+ P04 " #S25M81FQ'=GT% M #5'0 &0 'AL+W=O\B I#H*8E3<=F*I%Q?M-LBC" AXI2M(55/EHPG1*I+ MOFJ+-0>RR(R2N.U[7J^=$)JV1L/LWCT?#=E&QC2%>X[$)DD(?[Z"F.TN6[CU MZ^8M I##IO->@6!MV,F7PJ&0\!D60T MY&R'N.ZMT'0C(S.S5M.GJ7[OCY*KIU39R='D[N9F.KOY=#M[1./; $WN;F?3 MVR_J&EU/QU?3Z^EL^ND1O0] $AH+-(,GN2'Q!W2"OCX&Z/V[#^@=HBF:16PC M2+H0P[94;FGP=EBX<)6[X+_B O;1#4ME)-"G= &+.D!;S:>(HZ^"/R/;]C<&CR=G/?8!Z\W1Q;9M,I7U$GP^N\]HI8DE"IUIH4:)PNT$21 M1=,5I"$%@:XIF=.82MW^-IX+R=52^L?T%O)1NN91='ZY$&L2PF5+)1 !? NM MT>^_X9[WAXE!EV"!([ :N]V2W:X-?73+TI.0I"'$9!X#4JE12!7'BF#$YC%= M$9V>C%&=XYYEN#J];D>#GN<-V]M]GJR#'\N3([ :3VD(,')RUN $]P\8:78YZ!$80+IEEYKSO=+YGM7Y:U!;@W:<\NQ]?D02>&*: M@!UG%BE>4:S11 X': YR!Y#JU=Y%*G)TX^S4M&:LV,?&@B.P&IW]DLZ^/19 MI1D:2EB@D(@HFS63$7 4LW1UHKE%1 B0QACI-P/ .S\($NOXQU+E"*Q&U:"D M:O #JE)I73&#!AOG_=X!&\T^_->>E[^=6WZ?W=^C;#21SX,8- MQ6I][(;B$BQP!%9C#7N5I/)^R89=#..(8*=H@2NT.L5[JA5;0S, $7*ZSDH' MMD0A2[? \UI$)W@CFW9$QM6>KRH?)"*B/-::EC1P]5@828:PD6'K"$S;%_]T;%W\=O.C@],E6N *K4Y=I=?QKQ'LV*EB=XH6N$*K4UR)=FQ7 M[3,F28R6&\4NAQ#H]K!N+!AL:G2_J='M8QW-S,]0Z;B2Z?@'.EUA$AY&6>0% ML(68K74HHES /Z,K]5A7-U\X20':=BWQ5:G9U*[F.[WB\3F$1QD;V>C=0T MI;TI<)R*>U=H=6HJ>8_M^KZ*%72WS-<4>B@RDD[\@BZ J^:,J<6H"R-EC_:C MSZ'QMF\+!4@MNG CN)S6$:[0ZE\QJT+" MMZKHF@9#_^EP4FI44OV=2HVW!*XC:_RB6&UJS3[0L5+"*5K@"JU.2[RJ2<8)V^PGS&E:YLSL.YW.J?M1?U]&_6,6 M\\;WX#?21+>Q!]D=/IK>GU%O^%6]X5O%]LB<%\3K#.5PO7U5W/@"9Q_S:(:< ME@OMO?.N!/@J.S<4JEI7P92?$I5WR[/)<78B=W#_"E\$^0EC!9,?>-X0OJ*I M0#$L%:1WVE?QQ/,SQ/Q"LG5VJC9G4K(D:T9 5.#J#NKYDC'Y&PO=V]R:W-H965T0RRXAXNH:4KX<.=C8#]W2^4&; C08YF<,#J,_YG=!W;JV2T R8I)PA M ;.A,\)78QP:@V+&GQ36'N]4;]YP)>PTR)A#%/_Z*)6@R=GH,2F)%EJN[Y^A8JH([1BWDJ MBT^TKN9Z#HJ74O&L,M819)25W^2Q2L2.@=\Y8>!7!OZY!D%E$!2@960%U@U1 M)!H(OD;"S-9JYJ+(36&M:2@SC_%!"?TKU78J>K@=W4]N/_UZ,[E_^!%-?O_\ MX8^_T9L;4(2F\BUZC[Y'+I(+(D .7*4=&C,WKL2O2W'_A#CVT4?.U$*B"4L@ MV1=P=:1UN/XFW&O?JG@#<0L%^!WR/3\X$M#X?'/?$DY09R\H]((3>I.O2ZJ> MT#^CJ51"OY'_'LM1*=$^+F&6Z97,20Q#1Z]#"6(%3O3#=[CK_72,[T)B>[3M MFK9M4X]^6V93$._0I]RL0(ET59"*L(2R.2(*J06@*N(IA,\0WF.O9PK$'H?5 M4T..7LW1^[]K!UCR\JKI/4,- ASB ]+GL_;7UAY"OT;HOPH!RK>*3%-X%4+_ M+ 1K+ T?%O:V_XJ>E76T J&[F VCQA$TADN5OLIYN/M\<,L/#U)@C[%I#G8Z M ]PH!Y9R6"G:BHG=:5,H?POE-X*RELA*TXIE==L4:]N'8.L?_TDL:]FL-,UK M5G-U_%;8.V3[%DT'WG8=V-YV-%B+9]6ARNT>?A"V.H>5J)IW>K7N)R 20!82;HWV>Z&^Y>)81HH*7-&%R8$5* M9=>V+8,(4RI;/$.FORRY2*G22[&R92:0AKE0FMBNXW3ME,;,&O;SO:D8]OE: M)3'#J0"Y3E,J=F-,^'9@$6N_,8M7D3(;]K"?T17.42VRJ= KN](2QBDR&7,& M I<#:T2NQZ1M!/(3'V+EL*:01JSXDE?2D<<"7CN&0&W%'!SW@50SO*6*CKL"[X% M84YK;>8E-S67UN1B9FYEKH3^&FLY-9S?C6:3N\=WMY/9_'N8_+:X?_\[_'"+ MBL:)!/(CO(%)FB5\APASQ8-G>,QR=XY8"#.42L2!PK#\MF"QDC"3:_CC =,G M%'_V;:59&BP[*!F-"T;N&4;$A0?.5"1APD(,_Z[ UN95-KI[&\=NH\9;#%K@ MD9_ =5P/O@4;9$0%RO+1@.!57O1R!.^<%XTB&.OH".&&ISIE)"V\) 1E*]1A MK&"\@^-S4[K+MT=;*L+2JS)WZ^33.E8[N&?:NVMS1L*CBE# ^XBRZN2OG&VT M_[6FQ[62BK(P9BN8\20!':^YTM&3UJ#CONX2"H/:]0:96G M,QK@P-+)+E%L MT!I^]PWI.C\WN*M=N:O=I'VXV#.?S1<2J )M'8QQ%3-F;.#+?"-#$?,0/M=> M4V%$ =/-84S]V0Q=O]-Q.G[?WM3PZU3\.HW\?M&79N@U07=.H=U.S_.=>NAN M!=UMA/Y0.*8)N7N"_(80YTK7X7IHOX+V&Z%UU"PQOH3NUZ![I$>\>O!>!=[[ M]R&!.AE>'PR]$V:>[[MMTJYG=E4QN_J?Y/;'O,7HS=$&A6Z9,'E!$<028:JK M,+X^]Z^^0NX3Y]!QG"^9_8=Z7=M+"BS_Z-9)BW3KKYP<=47RR@IP ;[LKLX1 MOM/JGL-W#_AN(_YK@DZ>B[J3MKP/J[*XW#.8%MZ]%%$7S7=/S=?N/Y-QY-!. M26/[^4KF'PK<%_2 5^N!,]60'#HD^0\MLJX>7J#7/DD/I]7[9WNTC^;'%,4J MGY(E!'S-5#%*5KO5)#XJYL_#\6*,?Z!")[*$!)=:U&GYND^*8C(N%HIG^33Z MQ)6>;?/72/^;0&$.Z.]+SM5^80"J_R?#OP!02P,$% @ \TE;6*TF_O7G M!0 LB, !D !X;"]W;W)K&ULQ5IK;]LV%/TK MA!=L+9!:XD-VDCD&$B=# K1HEK0;AJ(?&(FVA.KAD72< /OQ(R59=&J)LF,; M_A+KQ7/OY>4]1U?A8)[Q'R)D3(+G)$[%>2>4C8BG!^1/ M_!6QN5@Z!CJ4QRS[H4]N@_..JSUB,?.EAJ#JYXF-6!QK).7'OR5HI[*I!RX? M+]#_R(-7P3Q2P499_'<4R/"\<](! 1O362SOL_D-*P/*'?2S6.1_P;Q\UNT M?R9DEI2#E0=)E!:_]+FMY)][ >:JQ[E76O4VM M@WE>>FJBZ1/CBDH46V@^TK=\M6ZXJOP9C4$7AZ0%Y MZ70/D4'7*).["V8J45[50+^/""3U50"7I!%:':B=L\]JQJS:9\5\ZZ0AXS,Z MX((HC>\X."/"T*J$P]OTB0F9Q[18'*_#$."_)?FOC:"PT%]:+5X7]QN6BA%1 MN!,5A:LR"A%!#2(*C8K"@\EHBV6OI&Q447:OD;);H.R<#8V2PKU(*5S54EMN MC)C"@ZEIB^6-V2EU'PH+C<3"0VHLW(?((B.RR"ZR MA9/9>+$\&9AJYX]UKQDELZ254$O\94)%;I>@^K)!1GR177R;'://ZSD&5QS# MN-MOJ&=D%!9916Y=JB]17M/)*<$-YHT&(KL&[I'J6RROO)TWLTD+DIU-D%%= MM+'JKL/TJ$Z%FU-C5!BMI\)[8/H6RYND9AL11D:$D5V$ZXD^Y,S^]FQ'?2L; M&JU&_0-2/;)J[%N#,]J+6KK9K:F^P/>6WYW=AJ(QZHJL K<#GB_P(5QV"W4; M>!X;9<1V93SRW ]'&LBZ8.T@;\PI-BJ)X2&_2^ZCE\5&:;%=:;=>L"7^JZ4! M3YK7QM+78+N ;;UH<4T;BDBWJ=O 1A+Q3AI1O"J!/80;BAD;!<0'ZT-;+.-2 M ;V% D*O40);H.P2B(T$XKWTH7BU#[6DQD@;/E@;VF)YH]1LTX9B(X78+H5' M.0MH>MZ/4;7M>)T4YB[S#W M2%8MEF%>$:!??9N:K&\ M26:VZ7&)%O375XS($JL^U5>E,C>BL3^+:?[?>?5JLN:$2<83$&1,@#23($K] M>!8P($-%(?J_7S*D4D%Q!B:*=!3<,9B'D1^"4,&J):)&!&RL8"5;@>TV4X6S MM&,A87R2;^00"F&6RN*_Q]75:K/(1;Y%XJ?KE_!L!.NNH[-1W?,7A)R-U.S7 MW?$6^U$O,L2+#2+%B&ULQ5AM;]LV$/XKA%9L+9!$;Y9L M9[8!)_*6 ,V6VR?#/#26Y,1FKLEDY&9,/3)(=;BM@FRS#]>@$IV8T-VW@:F">KF,L!0IA))K.-+"6I4!',/69P2=*_DHC' M8V-@H B6>)/R.=E=01F0)_%"DC+UBW:%;7]HH'##.,E*9[&"+,F+?_Q8$G'@ M( )M=W!*!Z?IT'O&P2T=W)?_D;O ^ X21ER/Z!3=+<( MT/MW'] [E.3H4TPV#.<1&YE<3"]!S+"+=YX6?^%T(@80GB'7/D&.Y;@M"[I\N;O3XAZ\W-WNB,:MML)5>.YS6Q%C M"J7)\PY6^,0QH8X0AC0+1B3'W^P?>OG-FYU@@6:P&J\ M]RK>>UWHD]](?AIB%B-VL $AR2396!U.4!#?1FD![2EH><9N)[;K#$;F]I"J M8Z/AT*W;!,=<)%F@"J_'>KWCO?S])%M#^H=H:>CRVL/V&'%M, MK'8U#JJ8!ITQS05+F(:Q2I5(2#(EZR*)@"?YZO_UV8WYVD31BA;H0JOSZ>SY=-Y8I.4"=)&O$RW0 MA58G?_^>L#NOS=^H4_=(7N[ ;NKTV,CQK*90CXWLOOV,4O>7=KO[UOXKY$!Q MJO(&1^)EG#!.L2PB=&NU$_75Z:(3+="%5F=T_UJPO;?6JM97AE:T0!=:G?S] M0\/NO$]_HU;]H\=C_UBKQT:^VWR%MAAYPWY#J^9!N2D#NE)E.R96*W*@*-Y4 MHU5I<*H*8HWQ"UDR5&6L/4Q1;[S!=)7D#*6P%)#665^LB!8EO*+#R5H5M>X) MYR13S1AP!%0:B.]+0OA31TY0%5(G_P%02P,$% @ \TE;6,RCJ;$J#P MPG$ !D !X;"]W;W)K&ULQ5UM<]LV$OXK&#?7 M2V9T- &^Y\4SCI-,TTN:7)RV"XO6J:GS+;]TV6<9"=G+^6QS\79RWQ=I4G&/Q>D7"^7 M<7'WFJ?YYM4)/=D=^)+<+"IQX/3LY2J^X9>\^G7UN8!OIWLI\V3)LS+),U+P MZU\EO"-V7C,Q&V7.7YG^++^_FK$UNHQ%,^JX2,&/[=\@N> MID(4*/*?6NK)OE%Q8?/S3OH[:3U8+527A"YOPZ7J?5EWSS M$Z\M\H2\69Z6\B_9U.?:)V2V+JM\65\,&BR3;/L__E9[HG&!P^ZY@-47L-8% MU+GG J>^P)&&;C639KV)J_CL99%O2"'.!FGB@_2-O!JL23+1CY=5 ;\F<%UU M=OG3^9>W/WWZ\.;ME\N_D[?_^O7]UW^3IV]X%2=I2=QG+T\K:$6<>SJK);[> M2F3W2*2,?,RS:E&2M]FQW93L?73"OQ#9]9Q*$3PFSFD"?DE)2+ MN.!E_4_3@K/W@B-;<.YIX2*-RY+DU^3WN"CBK")Y0>20)M,/<"IY7_%E^4>? M+[9RW7ZY(@B?EZMXQE^=0)25O+CE)V<__D!]^X5&:W>OM:N3?E8K"XJOJ[** MLWF2W?3IN)7B2RDBKF_/:$3#P F\EZ>W/>U[^_8];?M;KWU27ONT\]K;;[R8 M)65\E?(^A;P'*N3O%?*/<\C7G'Q>%[,%Q#\8)\W>3DZR)?E^!#\BZYKCC/R$?Y6Y_Z6B4&]GFP-S$P-%(# UJ'>ZW# M449JV!D8;A#0_:"0)UWHFYK2/S0*1WN%(ZV4>@!SLBJ2&?R%0;*I'?Z_!@+U MV; 53%G#B,#R6C;H6]?;0&V%[;:9 *WE(AV!M(Y8T6 H:CZJ+Y-O2%3KM1@8 M()0I*YFAP*X%CZRXHDZJY;BC8[L64_K&IDP[IA1S4CUU/B*^:\E( M@"/M(W8H!J:&*)CV<7"W-_2M(U8HVJ:C\O8O^>TNPGE6W1T&^EMA/1+I)@B< M*@:GIBB,4/Q.3N2S]]^6R55+&?S,'?MUUPOZAV_L@B# MF:&8&KH] BX0 8A-BKV9EF3-(-@G (/[44ROT4 P8(KVF:DI,S,Q9V:*^MDX MLV;6G3:[=NAZ[>!'FINZVA&FF)[IN?81,%9+#AJ6>!9UVW8@7*^W0W$]TW/] ME&?9I5%B!WH8$PO 3%*,3P[DN&/@S& WV(M M?JEA[%URRP^Q[!=H ,G&]"H-A0.5'K#(%(YI67^@XH[*!AP]'1^+8TX/^4;;3M@2A?+TEBO(=/>4/!K):+MHA M^N81,QJ5[R.G[T?@&"+J?%4('',T.(9(0(Q2'.\E$_KS.!7YX.OY"9 MOM8H5W&[>R2WCX1?^IFD7IFA-S%52N!20QCFFBC9NRH#<(^<]&/W7[N$'P9A MV"Z_(*U- ^W84H3OZCGV$0A62S[(P"*K>=NVM@1A>;TEC=O?>I8?C&%N=VK? MVR'(S%YOAN)P5S^S?@B"(:*.0#!$ F*4XG=WU)(^*,ZW ':^O5GWX$1,K\]0 M+%!Y@6NJJ.^:*.J[*A%PQRGJNSU%?>K[?KO\@C0W#;7C2]&^:ZRJ7TOVFM/( MMA$(S6N-\!3->X8*^E[/G+ZO,Y#V$3L4@WOC5?0147*M%V4: $,$(#8I@K 'LH<.GU&!C_GDH'/%-U?,]$'=]3[.^-4\?WNF3OV7;GYA?2VC32#JO& MDCEC9?Q:,C)_1-I'[%#\[ADJXWO="7UO=R#3>;T9BK:]\:KXB"B9>U%;AUS( MU%YODV)T;]0BOD2NKQN>\B'@9:)X[ZDLP#-5O/=,%.]]Q?S^.,5[OTOT+'0[ MT8*T-J6V;FCYBNA]8]7[6G+S)B2U6!N]D/8Q0Q2[^X:*]WYW+M_;($2774NSPR^O#+T0 9I1B=G_4ZOT6P "F'@I>>C6&8H!*!7Q3M7O? M1.W>;ZRR'Z=V[_?4[FT/HJ4=+ C74^U"8E^1O6^L=E]+/JA\4$0TP M4Q3'^X;*]WY/^;ZW3[!5]GI#%(/[XY7O$5%' !BV[%YK5*#8/1BU?*^64;1! MK%Y7<3^$Z149^BR*R@<"4Z7[P$3I/E#\'XQ3N@]Z[M6[H1^U%THCS4VI=J5T MH/@^,%:\KR4?)F!!N_*%M(\9HC@^,%2[#WJ6Y?7V"#*?1PQ1+!Z,5[U'1/T< MR^I]7?SR^Q ,D8!9I2@^&+5\CR*8_@:D7IFA8-!XI,[8,W4F:O>!R@*"<6KW M09?T6>2SJ%TN1IJ;4NUJZ4"1?F"L>!_T+,EG%@LZX8]1O=:44%%]:*B$'_;, M[/OZ!&D?,T11>3A>#1\1=02.(1(PJQ3/AR-7\=.[[MU'- O3*S'TV5J5%(2F M2OBAB1)^J)* <)P2?MA3P@_]P&]/6I#FIE2[3#I4G!\:*^*'W;7XU'+::_&1 M]C%#%,V'AJKX84\5O[='L*F]WA!%X>%X=7Q$5+V&(M2A%S;+UUO5>&I^Y$J^ M!KWT&9A>D:% H!*"T%0=/S11QX\4_4?CU/&C+MM3.PSM]O0+:6Y*M0ND(\7V MD;%"?M2S#!\FDA%KFX)1O-X41?&1H5)^U)W;]_<)-K?7&Z)H/!JOEH^(.@+# M$ F858KCHU&+^?O=&^13D _,P_2J# 4#E19$I@KZD8F"?J32@&B<@G[4P_JN M;P=>>V<0I+TIU:Z3CA3M1\8J^E'/:GS'ZL0^QO1Z0Q331X;J^5%W:G]/EV!S M>[TEC8USQBOH(Z+.US<68;X.Q+!9OM8H:C=WTAFUI'\$C.D3,D2?H7L]V(U= M=VQ3M?V=Y+%U9PW=QRGO[^0TP\?W/!9U]JI &IQ2[;II:C>VT[&-E?AWH@]R M,]?R.M4Q3 ?4G,9&.[:A0O].\!%]@TW[$6,:N^W8XQ7[,5DXNF$24,,:&_#8 MANK]6RP;-NE$E!J,$XV=>&QC6_'81O;BL1N;\=@C[<9C=U.$T+;]P(LZ@83E M"-JUU=1N[,ECF]N4Q^ZNWV_//;'F,4N:6^P9VV.O9Y.]>_H%W6@/L::YU=YX M=P$P61_C @ NV@)8S"N%MVZS>FY[1L% MF ZH.8T4 =FD[Q% URT;W-,W6-D ,:9!_/JM\AZ()O!+LESR>0(C"!H M7\'A6@_06>Z1+[4&,3%9\N*&%Q/Y2YXF<_G31$@"_8N;.$O^NS^[:8DT6:I9 MY?)T\6,9;W5/H7NR4O90G*;B2+F^$HA9)?#]3AX4YT,,)_ M#@<+ @Y+@.7@;.BF4FHICU<+<'LL/0>R\TT&O2;:2\ %,)H.94[ X[-T+:!; MBJY@D)3QMANE^\7P:9PO>IP&+^KMW:&).;1]Z-2FB$T"IHFSR#*'?I:J>?;? M=DK H_=Q MM(CGY$HL--_%"HPW*;L5 8Q94]:,Q%F^7 K]=X) \VH;1LDV#P$Q8CSN]'P2 M6C99@K7"ZGD1;^;@>!BK\UK9#R(6SF\*SI<@O_9K/I,#_S D62A#TK?()>< M!'F5Y14G5&+"/CR25#@#7+$LK:GS&,W;'7L-PR;?_ -$K-97,'+AO&M>B!Y( M&GLC@H:A-74?U' ]/J13-@6@"8R<6%ZW@O#8AM7U-G02B#<1^-#D8W7T>@'V M/N5D-)3B4=%5"KF3[*SX1O[MT30!28/UW*>QH&=D3?VC]9P!*L>)B,\20F(M MM ' 7M6),S@U$?$/,7D+D->PXQXE"WZ3E- 9('R>% #A2DL8(AT6VNUHLM4Z M>)!WQ_"I:EVCN34-'^G.)+OE997OO+E+#O><&^]C.:^?#:$PJIY]X2 M:81B78GKN4@L16:5 /LTZ@G[L0/O EEGD7>K*4VDMXW/ 487FY?5R,=P\4[ M:_K:S_+[&K;$:L7O/5X.W-;O<(TS&>2O,$L?Y$K'BR:^*4>ZWV/(YNOBX8PD M%U)Z])ACIUXGC>) M^,:Q^6I(R#:;7+M"Q*OTM6(OJ\#R^U?:X2 M9@R;O"BV]32Y22OG=_'ZJ@"_:^(M=IX^5ULC0BWNDGM%AGU?9=9/NC^Q<' MGLNWY;6.OQ8O%.P[SIY?])U_3FDH7D$8]O\6[5]/>*K4VK[=\&-55Y5^5)^7/ 8AJLX 7X74^[=%]' _K6-9_\' M4$L#!!0 ( /-)6UBAFT,\ZAL *S> 0 9 >&PO=V]R:W-H965TB<7MZTIEL&XFKTR0S:72_2VEWY\R9\T ! MV=84D"N).-G3%W\D$ AA+$/Z]9,$8_19 ID_8FG]UGK[D&9_YG=Q7 A?%_-E M_N[BKBCNWUQ=Y=.[>!'EE^E]O"Q_?'^[?H^/WO_-ET5\V09^YF0KQ:+*/OV:SQ/']Y=B!?;.\+D]JZH[KAZ M__8^NHT_Q<7O]WY6_G2U4V;)(E[F2;H4LOCFW<4'\4TX&54;K!_Q[R1^R/=N M"]53^9RF?U8_&+-W%[UJC^)Y/"TJ(BK_^Q)_C.?S2BKWXZ\:O=BU66VX?WNK MJ^LG7SZ9SU$>?TSG?R2SXN[=Q>1"F,4WT6I>A.F#'M=/:%AYTW2>K_\5'NK' M]BZ$Z2HOTD6]<;D'BV2Y^3_Z6K\0IVP@U1M(!QOTI2V&!0 M;S XV&#PU"X-ZPV&A[O4?V*#4;W!Z-0-QO4&XU-?I4F]P>1@ VGXQ ;7]0;7 MISYIL;<]/#SR3^_8]M"+ZV-_M7DKKM_'K&NABLMR_?OLFRJEN?BJS\;5)N5[S_I'\(%=VS927\]-^"$OQN M_/8_PBLY+J)DG@N_Q5^+533_6?A1N!+RNRB+YH"QG\>S(]LHSVTL=P%7Y0NQ> M#6G[:OPJ=8J?XOM+01J_%J2>) H__3#ICZ1?FJ>^^>_(CG[L9M7X\Z4@7I_- MRB_#*MVL'$\OA;ZX9OO"[Y]DX=6/K;^ )V'U=%@Z A\1M=-%\311/UD4A]V2 M<<[+>'ATCGCF2QT6ZYS#F) M)WG$\\[QGMXM_YR"<\K!#,ZI":> X2F'<;)^0XR./]%6J>WO/GCZ:[?_U#.O M]NKL_PW^7TTC=]=E*?Q M>9Q]B2_>__2#..K]=.GO_3C;?"X(7Z+Y*A;2&Z'\RC']4\CB^U4VO8OR6(A6 MQ5V:)?^)9\+?IWQN_MK9Y+D%FL1D$E-(3"4QC<1T$C,VF+C1JAZU+^][E]+P M[=67_ZK[MA3CKKZ6]I M$# M@_)*-FJ3F$-B+HEY).:36$!B(82URNOUKKQ>=U^NRM)I',]R0&6][&(3[+)F6_^Y&S?[='1#ZM=L]NRZ3FHQJ"JJIJ*:AFHYJ M!JJ9M3;>[P-Z--C50MNT4 M"#0'AFHRJBFHIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%E):NP0WP; J M$?,2/1$#M"R3FHQJ"JJIJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%E-8N MRTVX3.Q.EWU_3P0:-$,U&=445%-134,U'=4,5#-KK=T3,;X^[(E 0V>HYJ": MBVH>JOFH%J!:2&GM>MN$S\3N])F5Q6DN?(SNDVI@[[^[>R30R!FJR:BFH)J* M:AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%I(:>U2W$35Q/'+]$B@X354DU%- M0345U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+60TMIEN4F\B=V1MUV$>#WA MC3"+BOAH%48C;J@FHYJ":BJJ::BF/_.7L9M6=CV5[M'"BX;;4,U"-1O5'%1S M4)LLG-@=AML5WKI/./H\CP4YSJ=94LU =K0(HTDX5)-1 M34$U%=4T5-.?^2N9KK(L7A;S;T*\]V=234KW4'Z7JF92JN;POX^RXF=AM2R2 MN5#0K^WGE=Z6&WV*BE_DRP6\2PI/_/+!NZS MI+R[2-?"-%VN5T)9KTU2,I&PB+/;.'N]_DTZ3V;K7[VNI"Q.L]MHF?QG]^A* M^)@N[J/E-^$A*>XVNUFDZX=7O\RCS;[/DVF\S-<3ET;S>75/OOI<)>V+I/SY MV_K.ZO%1GL=5##_;SH9]T$A%5_^GY9V94+Y@U;?+\M'WY9?-]5ZN[R_NHF7Y M3*I7KK33AV4\6[>7E"]!]NW ?%V^XM/YJHK\K^GR"^HRCS:+M:Q?_F1ZM__X MGWZ82.+XEWJB[NT7W=:+ND\\).53JQXE+-(LWNS:L/=?VYWXDA:;AF="7+[B MZ2(I_URJ)5QV3SU?95^2+]6#ZJ<;W11Q=MC.I>"FR[C>IGRA=S,:W$4SX7,< M+[=_5^5+$:WMYH^EGJK^\NA'/QK01#4+U6Q4KKF]7HLPJOPT^_YSYW7*+KA<\\ 4$U&-0755%33 M4$U'-0/53%2S4,U&-0?57%3S4,U'M0#50DIK%^8FORF]3'Y30O.;J":CFH)J M*JIIJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C6H!J(:6UR[+4E.7N_.8?Z\5+JV^H M7^(LNHWWKE4(-U&2;58_>2UDS7GU9AF4U>:\NEKQ\)/A@Q*".[KR!:B:J6:AFHYJ# M:BZJ>:CFHUJ :B&EM:MJD]*4NE.:RN)^GGZ+X[H/8K/P27?O YK91#49U114 M4U%-0S4=U0Q4,U'-0C4;U1Q4U -5"2FM7VB9Z*74O$ZA\O8_75\6* M.%LT5?9HA473EJ@FHYKRS&LF"=_B*,L%L2TZW&0MI5.6%VQ&+.R=\'Z)\ZI M/W7>BZ8O44U&-:766@,-I-'D<#C"XT=-1KW# 0E''M23#LWJV 0BI>=6!TR^5".Z_'G9QB)>%MUC$= L)*K) MJ*:@FHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6DAIK6+<;R)J_=Z+C$7H MHP$U5)-134$U%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"UD-+:9;D)J/4[ MDQ;OC>V @_CK?35QPI-7RKJ=L^LPFDA#-:76]B]A]Q]=OU;1-C54TU'-0#43 MU2Q4LU'-0347U3Q4\U$M0+60TMKU56KJ:W?2S%]ET[LHCX7H-HLWG1#K^6NF M<59$237Q2UXDQ:I*2I0GPLFRZK9-RS/DKIZ*[B;/+L5HE@S5%%1344U#-1W5 M#%0S4'@UZ_)P[:W^H_=N_#V567U!144U%-0S4=U0Q4,U'-0C4; MU1Q4+4O_L7O7SB[&:"P-U514TU!-1S4#U4Q4 MLU#-1C4'U5Q4\U#-1[4 U4)*:Q?C)N#6[PZX??=BK]WNV5T3:,P-U1144U%- M0S4=U0Q4,U'-0C4;U1Q44)[VZ)@VIVAGAVM,".'_4P3'J]T7AX?7A.BP;84$U!-175-%3347^=;KX53_[Z];M+\P4O7[:6E^CO?7M2DV"_@DB[A9)">7@A)-[Q[U<3]$N9!7 MR_NL6R^?U4V<5:]D\R2ERUY_N%GA)SK:X(G&0'@5_U5=[:Q7&=IU]#1?.]H[ M)RR2Y2K?+!3UZ+5?"X]VY>=CBP!][#[P9W\ZHD%"5%-134,U'=4,5#-1S4(U M&]4<5'-1S4,U']4"5 LIK?T1VD08^\]$&/_A\$'A;^'#;)9L?E]^M.T^*XWU M5YGN889H(!+59%134$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"VDM%9I M'S2!R,'+!"(':" 2U6144U!-134-U714,U#-1#4+U6Q4L'U -5"2FO77*FIN=TAR>\>U]+MGGTNC"8A44U!-175 M-%334]2:B>'ABBV8644U!-175-%334U -5"2FN7Y2;=..A.-_Z3*V]HOK'6VHM=7DOB\'"Q#QEM5T$U%=4T M5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"UD-+:5;>).0ZZ8X[U8M2;SM_S+\"A MJ_NAFHQJ"JJIJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J0:VU+N?U+T>CP]F% M0JK9=MUMPI&#[A#CBTRLU-WFV>5XHSTS39-\VL,4=-]45--034U -5"2FM7V28_-^C.SWW_R#(T_(9J,JHIJ*:BFH9J.JH9 MJ&:BFH5J-JHYJ.:BFH=J/JH%M29*[1/;P[/:EPBU#9M0V[ SG7'>L+)NZ]P: M6VO[O;;#P:@W'AZ,0Y%/?:""[I^*:AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6 MG/J&#JEFV\6QB98-NZ-EN\D7E+T)AC:3)%7CQ(Z62'35/523GWFV^[,HW63I M0E#CS]FJNJ8G7K\6I)XDOJZG1_JPNEWEA2"-UG>/CIVDHGNNHIJ&:CJJ&:AF MHIJ%:C:J.:CFHIJ':CZJ!:@64EJ[7DM-O3YQ[;Y_.L;WG\S"T[V/9W\"H!$W M5%-0344U#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+:2T=HUO:CFHUI0:^)^]_3@ MB(^&I%$-MXMNDXL;=J_U=][%.S0,5VNMJ=.&0^FZ=WCM[K3'*>C>J:BF MH9J.:@:JF:AFH9J-:@ZJN:CFH9J/:L&)[^>0:K5=&9MHVK [FO8]5^[02!JJ MR<\\6_;*'1IJ0S4-U714,U#-1#4+U6Q4MU7ZE#LW"H)J.:@FHJJFFHIJ.: M@6HFJEFH9J.:@VHNJGFHYJ-:@&HAI;5K>A.8&TY>YDH=FHE#-1G5%%1344U# M-1W5#%0S4IS&:JD,U&=44 M5%-134,U'=4,5#-1S:JU_<[*_GC0$WL'O94VVJR#:BZJ>:CFHUJ :B&EMT@[NY&[]^OLDHU&_E!-0345U314TU'-0#43U2Q4LU'-0347U3Q4\U$M M0+60TMIU76KJNO0BW<@C-(>':C*J*:BFHIJ&:CJJ&:AFHIJ%:C:J.:CFHIJ' M:CZJ!:@64EJ[+#FE2 MOU<^^J 7&6W50347U3Q4\U$M0+60TMI5MHG5E3=?HA>Y4SV[WI*:C&H*JJFU MUKI@-+Q^-!6UAK:JHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&EM>MMDZ@;=2?J MP$YDI034$U%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1 M+4"UD-+:];S) 8Y&+]-YC(8!44U&-0755%334$U'-0/53%2S4,U&-0?57%3S M4,U'M0#50DIKE^4F[C?JCON=UWF,QO10348U!=545--034:CFHUJ :B&EM'38?8QFZU#-0#43U2Q4LU'-0347U3Q4\U$M0+60TMH%M\G6 MC;JS=6#WL1Q/-U/1/]^%C&;T4$U&-0755%334$U'-0/53%2S4,U&-0?57%3S M4,U'M0#50DIKU?1Q$^0;]UZD"WF,)OE0348U!=545--034U -5"2FN7Y2;N-^Z.^YW5A=QMG5V+T8@>JBFHIJ*:AFHZJAFH M9J*:56L'HQ(GO;%TT(6,-NN@FHMJ'JKYJ!:@6DAI[3(K-67VF27UOJ\+N5L] MN^"BX3M44U!-K;76-!8321R(AUW(:+,ZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H M%E):N^ VN;IQ=Z[NG"[D=A_Q?99\B8I8N)^7>[=>_+2KU[A[-\ZNT&@D#]44 M5%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 LIK5W&F^!>>?-%>HT':%DF M-1G5%%1344U#-1W5#%0S4&O5[_L,\8C=.AFH%J M)JI9J&:CFH-J+JIYJ.:C6H!J(:6UZVT3IQMWQ^FL+$YSX6-TGQ31O+O7%\W2 MH9J,:@JJJ:BFH9J.:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA936+L1-X&[\,DO> MC='$':K)J*:@FHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6DAI[;+GL+TK9+;A.'FW3'X=8]#T(8;P<* M"WZ6WF;1HK,WN-L\N]:BL3A44U!-134-U714,U#-1#4+U6Q4 MJOFH%J!:2&GMLMPD[";=";M/]1QKZW&_1[J$?_IATA])OW1V#'U -5"2FO7 MWB865][LJKU&672C95EPXZ_W\;)C+'"W-/>&:C*J*:BFHIJ&:CJJ&:AFHIJ%:G:M[7\Z#R>'G\[.D4>U+NK4 M-15-LYW4IH^V&:!:2&GM6MFDU";=*35O5>1%M)RMYV#OJI8=W0!H8@W59%13 M4$U%-0W5=%0S4,VLM=;T<#U)&O7&[;>]A39KHYJ#:BZJ>:CFHUJ :B&E;8KO M57X7QX4<%='[MXLXNXT_QO-Y+DRKT\SJ,VKOWK*VWI3%67SS0;JX>G3_K^(; M63QROR*^T8_=;XAOS&/WN^(;;WW_5;,[[]_>1[>Q$V6WR3(7YO%-N6N]RRHK MG26W=[L?BO3^W85X(7Q.BR)=K&_>Q=$LSJH'E+^_2=-B^T/5P$.:_;E^^N__ M'U!+ P04 " #S25M800#85P # !V"@ &0 'AL+W=OWV,.W!)!<2 M-;$SVT#W[V[H>R91P "O:0)X3TM$B*[T74> M1)!B?DDS(/+)@K(4"SEE2YUG#'"8@])$MPRCK:F-NE*Y'$!!X8 MXJLTQ>Q/'Q*ZZ6FFMEV8QLM(J 7=[69X"3,03]D#DS.]8@GC% B/*4$,%CW- M,V_\CHK/ [['L.$[8Z24S"E]5I.[L*<9*B%((!"* '<_0=ZWZ7 X'DX>D3?QT>AN,)S,ACNKYSX('"?\$_J,GF8^.C_[A,Y03-!C M1%<5 MXRT9@"Q$@3P2HE$!$KG"!OS@6395;W8HJ-G?J-UM:V7 4T!41Q?>K6JV:)R_O&0[6 M^[*I*GJ@5YJB(QMCMHP)1PDL)*5QV9$9L:++*2:"9OEW?TZ%["+R820;0V J M0#Y?4"JV$[5!U6JZ?P%02P,$% @ \TE;6-,)7]S' @ 0@ !D !X M;"]W;W)K&ULK55=;YLP%/TK%JNF5EH+&$*[+D%* M0J=56K>J:;=)TQXQ%W^5P5E,&]0')>ED3\&T#!ESW'=]8'#W2:*W/@QMT9F<((U-/L7NB= MVZADM 0F*6=(P*3G]/WK)#)X"_A!82DWULAD,N;\V6QNLY[C&4-00*J, M&/ M!0RA*(R0MO&WUG2:D(:XN5ZK?[:YZUS&1,*0%S]IIO*><^6@#"9D7J@'OOP" M=3X=HY?R0MI?M*RPH0:GO)Z MNG\DFZ"Y@,#J!8H?]W'=)=B;?8K M8K09$'>\RQWW^ZB=_))]A+]1@RW74>,Z.NKZ*Y<2C4$/(-"=POZ7%5E!:Z>( M]NN&L1]V=O)H@>E;\/!.,FTP'(5X)Q]WHSF6(*9VR$B4\CE35=-I3ILYUK?M M>^=\H.=;-8Y>9*KA>$?$E#*)"IAH2>_B4IL2U<"I-HK/; L>D:# M, #]?L*Y6F],@&;JQ_\!4$L#!!0 ( /-)6U@Z66>E^@( @* 9 M>&PO=V]R:W-H965T**K8"J)W/&4RQ5ER],L>* XYR4)J9C6;Z98D*- M8)"/W?-@P#*9$ KW'(DL33'_,X:$;8:&;6P''LAB*?6 &0Q6> %3D$^K>ZYZ M9J42DQ2H((PB#O.A,;*OP[[&YX!O!#9BIXWT3&:,/>O.;3PT+&T($HBD5L#J M;PT32!(MI&S\+C6-JJ0F[K:WZI_RN:NYS+" "4N^DU@NAT;/0#',<9;(![;Y M#.5\.EHO8HG(?]&FP'8L T69D"PMR"5!"]/IIA*GD.()0X&G&T0UVBEIAMYF#E;39]0O>Q3R=53HG@RN/TR M^7IW@QY'/VZFZ#P$B4DBD'V!+M'3-$3G9Q?H#!&*'I582!(UN>Z^FOBKB+ -L6>X5QGNM1I61YPZP&B3W]X) M*=947Z*'XR/U36GN)7\DRGN2'>8+P@5*(&YDK2NNLH0+^X=14>R57X2SYA4 MYWK>7*JK&G -4,_GC,EM1Q>H+G_!7U!+ P04 " #S25M81*$O]'P$ !N M%P &0 'AL+W=O[GXZ M/J*.=YP=*?M1[##FX#E+\V)N[3C?7]MV$>]PAHHKNL>YN+.A+$-P9 M1DGIE*6VZSBAG2&26XM9>>V.+6;TP%.2XSL&BD.6(?;R$:?T.+>@]7KAGFQW M7%ZP%[,]VN('S+_M[Y@XLQN5A&0X+PC- <.;N74#KU"C\79,9!# M65/Z0Y[<)G/+D1'A%,=<2B#Q\X27.$VEDHCC9RUJ-<^4CN?'K^J?RL&+P:Q1 M@9W)A9(\ 8=4GY/CW_A>D"!U(MI6I3_P;&R'3L6B \%IUGM+"+( M2%[]HN<:Q)D#]-]P<&L']U('KW;P+G7P:P?_4H>@=BB';E=C+\%%B*/%C-$C M8-):J,F#DG[I+7B17$Z4!\[$72+\^.+VR_+KYQ5XO/EW]0#>1Y@CDA; _0!& MX-M#!-Z_^P#> 9*#QQT]%"A/BIG-Q6.ELQW7C_A8/<)]XQ$1CJ^ !_\ KN-Z M&O?EY>ZNQCVZW!UJW%>7NSMM=UN@;GB[#6^WU//>U-M@QG ".'H&J"@P+ZYU M2"L57Z\BL\=UL44BP:4FPUD%CK57C-J_!, MZHLE8NP%B%Q[1*QZ'RD5+T0[PRNEH%22N?=I$?K.5$R(IW/.JE7@3#RO;149 MH^H+<""Q%D"_ >@; =X+1<3B'1!Y023G)['J[,4:PD'<(HN?Q:HFN(XXSO:4 MB>4()&0C/@.,IB^X@<1:X,(&7&@$][!##)>E1 )BFLF9 MB&2%HH,7:L!T9M12M?&#L //&%%?> .)M>"-&WAC0&(M>),&WL0([V\L)AU("5J3E'"B_UXGZG2:=%<5 MU<;M".O4Y6 MC(QA]24XD%B+('1.);US>8UY-@&UA6:M-5"E.:A:-*C::BBU]ELY:[2@N5J2 M+>N(;D8'D1;*.:U]'5"9K2-_W$T).BLU*9@#ZHUO(+4VOE/?!(V]P.(VYRC? MDG6*PBI V"VKEQHKA=^@7'K/FD$[$/ML MJU+N1']&;$OR J1X(^2=J[$8&*LV=ZL33O?E[N6:%=>ED3@@E5_E[DL)D[B0(XKTE3R@>W^ MP+V?@=;+6"7,?]CML9X#62,DJ_=D%4%=TO:7/._S<$#PXS.$8$\(^H3H#"'< M$\+7$J(](3*9::V8/*1$DNF8LQUPC59J^L$DT["5_9+J;7^47+TM%4]./_RY M^.ON%IYF_]P^PKL4)2DK >%[N(*/CRF\>_L>WD))X:E@C2 T%V-7JF4UV[E]P$W9;$!J]\-P6T(S5"$_D&=)29!43#4?X/%L*R=6U^&++>*L8 MV15UJ;@1&Y+AQ%&U0"#?HC/]Y8T?>[_9LO4SQ=*?)':4R:C+9'1)?3HG%:$9 M I&PQ'5):4G7P%;P PFW9;%5&Q@U71^WTZM!H/[&[O8P/Q98E'BCY!B6VF#! M*/([V)&G0>=I<-'3)U(U1)=(4JD2K>VIJH:<8VY.S$P(]6U8%(2N44#:J'/$ MX/8Y,Q/P0"2J0[52!%1, ;.:-53:#^&(.9OE750G5QT:".C7;4I4BLZ>@[HJU(,6G4?0WU0+QHYZ94XQG-S+L MC PO&\F^-Z4H]7;:PAZ>QC0,XE$O\E-4;Z?22XBCN),N[N1_-B W00O(&ZXO ME2SP[*U*+,F/_/YILJ&2T.\YL:#"^" C1VY&G9O1:\L$TOQ2@1B=7NEX$'C] M';' +'4DM<".ZTCKQCWXFM?(UZ8K$I#IF]M^([O9KO&:F7ZC-S]7#5G;/_TG MTW9S=X2K\BB@PI62]*Z'*BC>=DCM0+*-Z1F63*H.Q#P6JJE$K@'J_8HQ^3+0 M"W1MZO1?4$L#!!0 ( /-)6UAPKEI::P0 )D. 9 >&PO=V]R:W-H M965TD[.3O.Y04V99H)2CVQ9:H,T.>0W(NDQT7W^0:0)'G+,WE MU%HKM;FR;1FO(:/RDF\@QR]++C*J\%6L;+D10)/2*$MMSW%".Z,LMV:3L">339T!8^@OFX>!+[9C9>$ M99!+QG,B8#FUYNY5Y/K:H$3\P6 G#YZ)IK+@_)M^N4NFEJ-7!"G$2KN@^+>% M&TA3[0G7\;UV:C5S:L/#YU?OOY;DDNI-;)( DM:I.H+W_T& M-:&!]A?S5):_9%=C'8O$A50\JXUQ!1G+JW_Z7 MQ8."&)PR\VL!K&P0G#/S: MP'^O05 ;!*4R%952AX@J.IL(OB-"H]&;?BC%+*V1/LOUOC\J@5\9VJG9W:>; MS_>WY&G^U^TC.8M 499*$IR3"_+U,2)G'\[)!\)R\K3FA:1Y(B>VPFFUL1W7 M4UQ74W@GIG ]CU&$%\2W_U(/,?S#0NZ M>;^Y9S"/WF_N]K#QFRWP2W_^J2W(8YX!>:+/)&(R3KDL!)"_YPNI!%Z+?TR* M5QX#LT<=*Z[DAL8PM3 82!!;L&8__^2&SB\FM7ZDL^@'.3M2,FB4#/J\SW[G M4I(%8#0$HN@SR(^$2HQ.&RX4)/H8JS60F.>2IRRA>DPJ_,,XIB3A2X+A5% = MCXS'O)I\4$ZNX^EV=N%Y;C"8V-M#.0TP=^PZWC$L,L&\,-C#CB08-!(,>B5X M1#Z%XN)%"T"0#)B85#Y&!W,[E_HF'?%X#RAZ W3$(6PXA+T6-G9)9@V$@P[)6@C@F: Q+4- A'F@*YTOQ_$*YF"P\6.0A;;+N0B_:1[4*& M9IJCAN:HE^8GGE]@2B@P^2]2(/",Y8P$B3]U#]7H08I8L _HD$P M(&'$PBJ,)&RY! %YC-\QJI'=FL5KLJ5I46E 4ZS;*'XF.PQT&\&WK)-A*QW& MW0,0N&TI#"!_V IO41?DA^'8+(;K[,L0IU>.!\ B+L[G,DW^Q<--)1:<<3',;+')U>MD(AIOX E28J;G= MY03MH&0 .6U:?9!C3MZ>D]=_7$]=L-JN[X:]#8D,D!,1U-V756YOK3&;QZJH M,T@=*\A9G4K.C4Q\4T9N<^F"@G#89M,%C=NGRCZHV3,0J[+WD1CB,*E5E7 S MVO17\[*K:(U?Z[ZK[ 7V;JJF[9Z*%CL/U!+ P04 " #S25M8J($A#+\& "I M/0 &0 'AL+W=O;]1/&0E]2I>+Z5ZENV$D*371*GV45GI?7ZK-?+YBN1A%E7KD5J?EE*E83: MG*J'7K96(EP404G$4=J9G!?7;M3D7&YT'*7B1I%LDR2A>KH2L=Q> M=+S.\X7;Z&&E\PN]R?DZ?!!W0G]>WRASUCM0%E$BTBR2*5%B>=&Y],ZX[^3L^ZT,K]& M)DY//GRD/V7E/FWOGA-Z\O,_5_C[TE?MXE%S+5*\RPM*%6-B GJGTH>;TN>97U$D, MQ+Q+?.\=H7WJUU1HVCR-*@'Y7GP+%N', M<<'()Z/'2;^;CZK'EVHU*10T*<2<56[;NB"8U;K#0^L.G:U[)5*QC.:1F92) M2+50:Q5E@BR53,A:R<6FF#CW\V>DG]X5(HB=2-;%O+H6*I*+.D'NU2&9"U4Z?3D+;Z1,)"Y PAH1Q$,S2='S0=(Q:&8V1TB)A M 1+&D# .@EG2GAZD/<7/W?D"BIALO3#7%B)=F /3):+9)L_8V3ZXFN/-.U/> M?>IZRVG-.LD[6G YZ]^V$R!A# GC()C5";Q^]0+<=V?M6.7G:'1UG< M_0BM.P.2QJ TCJ+9G:$RL3RGD3+YD*E0Q,5+U.5&KZ3*W[V<:1UJ9D%I 93& MH#2.HMDZ5XZ6-X"E=:33-(72 BB-06D<1;,5KEPUS^UO-3,MW9#6X@Z;V)N- M2K%&I3BJ_G8C5R:6YW:+;@7Y$L;?R*V<21W-,V+&E3M=(IV:*9060&D,2N,H MFJUSY4IY)[!T";6GH+0 2F-0&D?1;(4KC\IS^B1-T^6X+BD=>PZ-2@6-2C%W MM5LW\OB+MJ$#VAT=-S34 MW8'2&)3&433[,X'*X*%N@^=6;*UI[I=DMG+.VRP(I050&H/2.(IFZURY M/13F]E"HVP.E!5 :@](XBF8K7+D]U.WV-)OG:)TK<_PM0Y-"09-"S%WGUBW\ M/2P46EDHU&VA7,9:J(?_?!-P4UJ/'ZAQ J4Q*(VC:+:ZE7%"8<8)A1HG4%H MI3$HC:-HML*5<4+=QDG316J)L1:IOM<='&=)Z,=$4!J#TCB*9NM6>3'4[<5\ M6@LSG47I0Z$9F>'$:! MK6;EN%#WAT ?A2;RH*@E9CDFB=BMH_QWF1(SXR:UJKIO0OMT2,)TD7]"/*[5 M$6J_0&D,2N,HFBUW9;]0M_U2LV@B?Q,N%J8'Q.YU%/2;(2@M@-(8E,91-%OP MR@JBI[!U%-))F4)I 93&H#2.HMG;(2K/R'=[1DW746Y,Z^T04*L(2F-0&B]I M]LP[>&WF]2L/R'*E5K> MV;8,8\BHO.%+8/ADSD5&%6[%PI9+ 30R3EEJN_6Z;V7*%&2 9,)9T3 MO&-UG;M!2]L;@^\);.3.FNA,9IR_ZLTHZEAU30A2")5&H/BWACZDJ09"&G\* M3*L,J1UWUUOT>Y,[YC*C$OH\_9%$*NY8MQ:)8$Y7J7KBFZ]0Y-/4>"%/I?DE MF]S61^-P)17/"F=DD"4L_Z=OA0X[#HY_PL$M'-Q#A\8)!Z]P\#[JT"@<&D:9 M/!6CPX J&K0%WQ"AK1%-+XR8QAO33YA^[5,E\&F"?BJX'XV[X_ZH^XT,?TZ& MX^EP2FJC.%.Q)$,60;0/8&,&91KN-HV>>Q9Q .$-\9PKXM9= MKX)0_^/N;H7[X./NSIELO/*E> ;/.X'WJ&(09,1"G@%!B"6^E!53>=,M3\O9WC4C[>"\AS,_']'_8/(/A@&PO=V]R:W-H965TB!5DF -MVM9O_]-@V# M@@SE5'I>%)I[#O<>^N#U]HZ4_>!;0@3X%4<)[QM;(7:WILG]+8DQOZ$[DL@K M:\IB+.0IVYA\QP@.%"B.3-NR/#/&86(,>FIMQ@8]NA=1F) 9 WP?QYC]=TNP;T'A:F(>;K4@7S$%OAS=D0<1J-V/RS"Q8@C F"0]I AA9]XTAO$702P$J MXI^0'/G9,4A+>:3T1WHR#OJ&E69$(N*+E ++KP,9D2A*F60>/W-2H[AG"CP_ M?F+_J(J7Q3QB3D8T^AH&8MLW.@8(R!KO(S&GQ\\D+\A-^7P:"R:NAQ(G!I_OII_EP]GD\ N.'C]/Y9+@< M3Q_ \ &!R?#+= Y&J\5R.KF?JZ79?(I6HR5 P^40O$-$X##B[\&?8+5 X-W; M]^ M"!.PW-(]QTG >Z:0*:8W,OT\G;LL'?N9=* -)C016P[NDX $90)3UE84 M:#\5>&5ZZ M 722(4UD)?V\0C_O5>SDZ513)QG21%92LUVHV?Y-.V5X[\P#;<_Q*FZZ#+(= MRZFXJ2;(A=UZ-W6*_#N-^=_OF>RG&FW42/#2!Z^3#&DB*PG7+83KOHJ-NCK5 MU$F&-)&5U(36J2>S?M-(.<'Y_G>M5O5WJ2;*L=QVQ4IU44X'UGL)GC66L+&( M(0\QF&$_7(=^HZ>:>5ZZ#;2R(5UL90WMDX;VJQ@KI]4EJ4XVI(NM+.FI@8:- M'>4UWG(N_=!I5ZUU&02A6W7699!G/>.K4\\*FYO6.>$"3-?@*V51T&RL1J(7 M[P*=;$@76UG$4]\,W='FD0NXN=;@E." L#9#7UY2*IY/T!L6P M;_ _4$L#!!0 ( /-)6UAF=VY', , %<- 9 >&PO=V]R:W-H965T M+C1!\,%&A/#8_6#VPP@7 M:&P[[,P ^N]W9JB5:FTT-O$+=*;WGKGGW%.X;6PIN^=+1 $/81#QIK$48G5J MFGRZQ)#P$[K"2-Z94Q82(9=L8?(50S+326%@.I95,4/B1X;7T'L#YC7H6@1^ MA ,&?!V&A#V>84"W3<,VGC:&_F(IU(;I-59D@2,4D]6 R969H,S\$"/NTP@8 MSIM&RSYMVXY*T!&_?=SRO6M05.XHO5>+[JQI6*HB#' J% 217QML8Q H)%G' MOQC42,Y4B?O73^@7FKPD=Z_'+8&5]TV=&\N^L->:]SM MWT#KI@.]UJ_^$-J3T;C?.Q_JK<&PWYFTQ]!IC5MPV$%!_("#?03',!EUX/#@ M" [ CV"\I&M.HAEOF$(6J8XRIW%!9[N"G#<*ZN#T!%S[!SB6XV:DM]^?[J33 M32E-HH^3Z.-H//<-O"%N,%HCASFC(9P_"&01":"M.X.,@V0)US1:'%]+.\Z@ MQ3D*#K?7$@>Z D/^-TN#W:&E[$/5HWO*5V2*34,^FQS9!@WO^S>[8OW,4J0@ ML)0^;J*/FX?N:>J!IDXT]2RV.XBRAE"_*QO/M55S-_LL7@?9ENLD0:GJ2DEU MI=SJNIP1#."VA^$=LLQ.Y )\M!,%@:6XEA.NY:]P:KE(?0H"2^E32?2I?-ZI M.XC*G@G+3OV%45_'5,O5;)]6D]JJN;5-(E_(ND:""-G /+OFXGRT'06!I2C7 M$LJUK[!KK4A]"@)+Z5-/]*E_WJ[U5U9T2E;IA5\S@EP[VZ^V]3PV6+GE7:*< MH:+'7*_F0WRT&46AI0GOS4GV5_@U/K4HC0I"2VOT/"O9N:/&^SP;8Z3^Z.O6 M"\]F!)5*+SQK[DV]ZI6C1]C"CS@$.)=)UDE59K/=%+];"+K2@_ =%;)G^G(I MWWR0J0!Y?TZI>%JHV3IYE_+^ U!+ P04 " #S25M8:]_)X6$# #I#0 M&0 'AL+W=OO,7T*$V25902Q&YH1&F(LN7>AL10'/%"@*=<(,'!)^#69\V=:N-#2# M.5Z'W"/;&T@3JDD^GX1,_:)MZFMHR%\S3J(4+"*(@CCYXI=4B#V 63\!L%* M=0RHG !44D#E&% ] :BF@.JY,]120.W<&>HIH'[N#(T4T%"+E:BKEJ:'.>ZT M*-DB*KT%FVRH]55HL2)!++?B':=B-! XWAGT)P//GMX,'30>,AYN+N?C/J>,DV]2>_!N4<]^]Y&[WO <1 R9'U ']$=#H$A#S80 MK^$"C445/8X@>@+Z38PZ*A.@R"&Q#S&G6&U$+V#/F5M+YR(A&9;NI\%WD^"M M$\&;%AJ1F"\9ZL;!=E4LL6M*+[J";Y,=;M0Y$(2>18VV0K[T-;$8<> ;D#KO'MCUHU/>0*5 M2>:61'8@7C43KZK8*R?$R[;R"'\G]'4'/]X*1S3D$+%<-:MEJEDFF5L2V8&: MM4S-6O%6/*A[*NH^3[N$XUIQR#_13<>X-&4E;?9%R?6J'GFYA?'D9XMR8AH4 MY_5H?BM0IYZI4S^O4+N%A5I(\K=;JTPRMR2R _$:F7B-_U*HC3+5+)/,+8GL M0,VK3,VK$@JUD./\XG**8_FMN!*M2YJ\_R^3NPGHZO#P,;.SYT#S:^W(8!JO MUS+C3[/? F.(+W&,3.-MWLKJ>]<^L>$7ZD;/D$_6,4_*)[-FKP9;W96/[%WY MFLBS6TTGS[]G-?MY=M=J#O+L]G5S<)UG-XW=,T9_32!Y!(TP700Q0R',13+& M94.&PO=V]R:W-H965TQCVH-B,K566/$E. MNK^?)"=>!K1YL26*/#R'(A7MI7K6):*!EXH+/2*E,?5-$.BLQ(KJ"UFCL"=; MJ2IJ[%85@:X5TMP'53P(>[VKH*),D#CRMI6*(]D8S@2N%.BFJJCZ,T8N]R/2 M)T=#RHK2.$,01S4M\!'-4[U2=A=T*#FK4&@F!2CWR_LT63W,)C!;W"W3>;*>+1>0+*8P3[XN4Y@\/:Z7\]O4FU;IOI&]'\)<"E-JN!4YYO\#!%9* MIR<\ZAF'9Q&GF%W H/\)PEXX (V%;2!S!G?0U6G@<0=OU0EEH6A=L@QFHIT% MUU2)R&%.?TD%$W]7J+QII63>9 ;&ULO5A=CYLX%/TK%AU54VEV"! @3)-(R4#2D=K9:#+3/JSVP0E.8A7LK&V2 MKK0_?FT@-!] R0KM2^*/>\^YON=BC/M[RK[S#4("_(@CP@?:1HCM@Z[SY0;% MD-_3+2)R9D59#(7LLK7.MPS!,'6*(]WL=!P]AIAHPWXZ-F/#/DU$A F:,<"3 M.(;L[S&*Z'Z@&=IAX 6O-T(-Z,/^%J[1'(FW[8S)GEZ@A#A&A&-* $.K@38R M'J:>LD\-OF*TYT=MH%:RH/2[ZCR% ZVC D(16@J% .7?#CVB*%) ,HR_/<64808Y+]PQ]Y'HX<3+O"PQ M]!/#\6C^] A&SS[PGSZ_O08^> Y>P>??YW,P"U[ _-/H)0"W/A(01_P#N $Z MX!O($ >8@#>"!;^3@[+]NJ$)AR3D?5W(N!2ZOLQC&&S'/-C$7I)A(_7X+W-?7![ MU8!45;J5,5@53 !G!9,W! M##$P5ZC@C]&""R9WP3_+BC6#ZY;#J3?# ]_")1IH) (N(@0$!92%F,ACU6$KJ9"R%OU:*>UF4K;)&91PEDG9)N>TC+-:2J>0 MTJF5\EMZ8D0A@#O$Y $8D"1>R.V:K@X:)ES.RF/&DL;;1,C]')"#_%ME>"+Y MG3J=XJ44OO+U-*X-Z%KU,S#G*"NVYQI>Q^F>Z=\F:W#)ZIB6VW,]]ZP"VF2= M7K)V7<^R'=LLKP&WJ 'W_ZV!$$>)PJNK@MJ0KJT"MVD5M,D:7+)65$&;K--+ MUOHJZ!55T&NVJ=<]U;=J,AW[4"9JQF!TCS>ISKUUEH_'S,RMM_(KP(Q3LZ < M[,QJ4@YFGG%.2\&.K$XRZQ69]?Y[9G\^*[_(K=>V'.P\M^5@ M%[DM!;O(K7[T11TCMDXO2[C<>1(BLL_08K2XCQFEUQ!GXV/C89I=J_R$R2YY MOD"VQH2#"*TD9.?>E2]5EEV<9!U!M^EW^X(*0>.TN4$P1$P9R/D5I>+0403% M[=7P7U!+ P04 " #S25M8R(3PRH4" #K8F>T ^_>S']A+[[/N^N^^3O$3*Q'7A=[W PH^M"VP,_32JRQCGJQVHJC>6W+$M:(E=4<)"X&GC# M[M4XLO[.X1O%K3K:@U6R$.+)&C?+@=>Q"2'#7%L&8I8-CI$Q2V32^+7G]-J0 M%GB\/[!_<=J-E@51.!;L.UWJ8N#U/5CBBM1,S\3V&O=Z>I8O%TRY+VP;W[CG M05XK+OPQ&@&Y\!!'M \!(0G0&$>T#HA#:9.5D9T21-I-B" MM-Z&S6Y<;1S:J*'P\7H HB426^-EE8+C_?1QPU$8,S$;L!W FN M"P43OL3E9==SFKS=/"2HH2,LIJ;8Q;H114;4DN8,@U MO7"WII%/U:4)%KM@=AIMTNZG(.CTHCCQ-\>:3SE&<=3O]UO'1H]_U"@ERK6; M'PIR47/=_&_M:3NBAJXS7YR/S.AJ)LU?FF;NW1&YIEP!PY6A[%Q^-)-"-K.D M,;2H7#LNA#;-[;:%&;\HK8.Y7PFA#X8-T [T] ]02P,$% @ \TE;6. S MH&ULM9AMC]HX M$,>_BI6KJE;J;9YXRA:06)*[(G5/"-CV174O3!A(M(G-V0:V_?2UDVR60(A M\KV!/'A^X_E//)FX?Z#LF4< KVD">$#(Q)B>V^:/(P@Q?R.;H'(.VO*4BSD M*=N8?,L KS*C-#$=R^J8*8Z),>QGUZ9LV*<[D<0$I@SQ79IB]O,!$GH8&+;Q M>F$6;R*A+IC#_A9O8 [B:3ME\LPL*:LX!<)C2A"#]< 8V?>![2B#;,2W& [\ MZ!BI4):4/JN3R6I@6&I&D$ H% ++OSV,(4D42<[COP)JE#Z5X?'Q*_VO+'@9 MS!)S&-/D>[P2T<#H&6@%:[Q+Q(P>OD 14%OQ0IKP[!<=\K$=ST#AC@N:%L9R M!FE,\G_\4@AQ9&"W+A@XA8%S:M"Y8. 6!NZU'EJ%0>M:@W9AD(5NYK%GPOE8 MX&&?T0-B:K2DJ8-,_#'Y M-EE,@CE"'WP0.$XX6L"+V.'D(_H3/[5N>#5=M C)2+B*" K6%4!I@RAC,-YC>/!:23Z$-XAV_F$',MQZR9T MA;EK7S3WKS=W:LR#Z\WM!C'<,JENQG,O)16X8+M0L)ALT$@MQ5C$P-&/KW(@ MF@A(^;\ULWS(J:UZJBI9]WR+0Q@8LB9Q8'LPAN__L#O6YSK!=<)\G;! $ZR2 MFE:9FE837:4&, LC)!>.+&A[6:FWLNZ*3XB J,M)(^[6G.2P=@93KY#]L&6W M>GUS?ZQUS2#+M:N#@O-!CN=ZY:"*-NU2FW:C-G.Y]9+TBDEZ31*HLH1FH%L!#") M?^'LW3I-,$$_'B%= JM=QHW(6P72"?-UP@)-L$I>NF5>NO]+A>WJ3(U.F*\3 M%FB"55+3*U/3:UPRWV5C*AOH$- 4Y"\1LM^M2T5.Z1TM5^O.;E?7]+C1U:T2 MZX0%FF 5B;U28J]1XE%*=T0@ND:0;A/Z$P )8+([S0O4$@BL8Y&7\@0V.$'P M(K]L.-2UB@^-OFY=$]Y9/>]TK9-JKM-AH E6R8-MO77OEMYVHIEWJ]H%K?+Z M[)ZL(5^KRT 7K2KXT>>2?6N/U@ M,^5FE9WS[MZ)UN@QTT7*9S:.]@!38)MN$X2A4%3O_G"ZOEAL]HVQ[X^3Z M6&T 97L,;YA\]^@1LTU,N"SM:XFT[KI2+99OR.0G@FZS'8 5, M#9#WUY2*UQ/EH-P6&_X&4$L#!!0 ( /-)6UA'=:WW=P, -L7 - M>&POCNC5#F+ ME(NB[\Z4RC]X7C&9T904%UE.A?8DF4R)TETY]8I<4A(7 $JYUVZU0B\E3+B# MGIBGUZDJG$DV%ZKO^JW:YIC+YUA;P_>N8_B&64S[[MW9VQ_S3%V]<ON_&K;?E8ZSEW/2GJY!^E%"^?5/HPZW*0NAY]J(@,\Q6 ="TQ':9#0PU7X)W9A@E]^WD?W[]QM>O<3ZU@IWVGMIWBT?I@WWI MGPI0A?"JC33H)9EH]E/@&H/60%+JW!/>=X>$L[%D@$I(ROC2F-M@F&0\DX[2 M&UF+\L%2/!BW;WJPQRN>E(E,EK%-!/,[KH9O.58]$,@XKP6V76,8]'*B%)7B M6G?*P:7QDQ.OD[#Y3G^9Z.J+L0\'0&TD3MBC[BZ06@+'[.#O)<[[\R-E4 MI-1,?N^ @QY9X9Q9)MF#C@:E,M$&*EWGGDK%)NN6GY+D([I0JW):)+CF]A%J M_K=YGE)!)>'KHG7M'W*67ZRX.C"\AN;RMK*MV"HRZ!R^QNJ0=.@BPV,0>03+ M'42'K[$ZZ!ZZR&/(9.?5[NS/$>D?@\CV,8@,#E*D5QU\UT[7&V?KVNK .TS? M_0;O3;P)ZHSGC"LFJMZ,Q3$5CX[8FEZ1,:>;_'I\3!,RYVI4._MNT_Y*8S9/ MHWK4#22B&M6TO\#T_+!^@=*QF(CI@L;#JBNGX[+IZ(:.6GT L.VY+C]V#X8Q M/KL'?%@<3 &&,2@LSO\TGRXZ'^/#M'6MGBZ*Z:(8@[)YAN47BV/'1/ICGVD4 M!4$88AD=#JT*AEC>PA#^[&R8-D!@<2#2\W*-KS9>(;OK %O3716"S12O1&RF M>*[!8\\;(*+(OMI8'$!@JX#5#L2WQX&:LF." %85TX;M8-P319@':M%>HV&( M9">$KWU]L%T2!%%D]X#/KB (, _L1MR#*0 -F"<(RN?@UO/(6SVGO.;?^8._ M4$L#!!0 ( /-)6UB7BKL

-8?20$3;8T.P6BP^0"X99K>] M9!:G;2JMUS&=:-94P)O:L"'@!9]NKB-BD0<40 M 6F[_?4[X*8][+*O]N:$*YL/X8>!F>><,^.W7ZKZTUU5?1)?CT797,X>VO;Q MS7S>[!^R8]K\5CUFI3IR7]7'M%6;]<=Y\UAGZ:%YR++V6,RU\W-K?DSS?:E^7F\VQ2?\R:_RXN\_>MRUG\OLIDXYF5^ MS+]EA\O9^4PT#]67357GWZJR38MX7U=%<3E;G [<9'6;[_^U.^X@D_2NZ?>T MZ5V4*I#+F76N+GB?UTW;G]%?/U6,GS-U\FGKJ:VN\J+-ZE7:9NNZ>GK,RX_= M9=1=S,EM].WP_'EJQ#?U_VG&ZOX^WV>K:O]TS,KVU(YU5G2 9?.0/S8S4:;' M['+V?(I(RX/PRE8UDI#EZ5+JW.Y.U4_+P^FN6X5+VK!^DZL#M3STX'R0;AC$ MH2]73N*MQ-+QG<#U1+SQO"0F@!H U"8#%&?;E$#J %)_0<@X41_77J PRL1 M;KV(0!H TN"%''*Y&R=8>[&0@6I-)_(V!-($D.:$D+<:@;0 I#79XW:=F+:D M#2#M"2$'+7D!("]X(==>X$6.3V!> YC7S.^>7 ?R2KI.D C'=<-=D,A@+;:J M%5WIT?%P<8Y&['->S&WD;1VY$M[[K1?$JG' LWO%[*P$ED&% V9) %LT+68;CZ4_H^>9HR M2-3P)Y>^)QR*B1RR8);(-NJ$EGSH,;T_=G+;C2J_BL!+*"(RR()9(>KA7LOD M--AUE&H@[/JQVA:^=)84$SEDP2R1DW5#?^5%\2]]4R8?*!M2QX+9'9$7>T[D M;E3;^;ZS#*.^JPAG'7F=12@FDL>"V1XR4,_:$XGS?CC&((3!WY1F?V#0U\1N%@+8Q9-C "&CYH)!N=638P AIB(MGH MS+*!$= 0$\E&9Y;-]T*..%ME;9H7P[<1F49G-@V.*0R*B5RC,[L&8YH4$[E& MG[)$=FO10C=RC<'L&HQI4TSD&H/;-1#S@F(BVQC,ML&8KRDF\HXQ89)SVU=L M?V#"69@)DYS;OF+[ Q-YQY@TR:&YF(&\8[QDDC/B'@.YQV!VSQB<2+*O[5-: M#""1>0QF\XRG8F--B<1C,(L'4@K::TPD'I-9/!B31FLF$H_)75:#F+1SFT@\ MY@3S->(G)\5$XC&GG+H9#)4F$H_)G?! 3!H)FW ! +-X,":-A$TD'I-9/+#J MLLHH)E*0R:P@B#E('TTD(9-90K@X-.A"R$(FLX4P)NU"%K*0Q9W^C-:P1I1N M(0E9DU3:QI1N(0E9W-D/Q!RL2$(2LKBS'XA)>Y"%)&1Q9S\0<]"#D(0L[F5H M$),N=;#@.C1F"<%Y^N%J.20ABST/HN7JL7$(N<=ZP54$9/P9\"'I6,S2&>?3 M*)^-;&,SVV:<3Q_P(<_8[ O1QOB, 1\2C/VBDSF@3& CO]B3SNI0O]C(+_:D MLSH#3.07FSO)@9A4@S;RB\T^JX,P:2YFPY7.S'[!F'16PD:BL;DK;7 J;_!N M(M_8W*4VB$G?S0NDG0MF[?S7FJOO!2**B>QS@^^I6%FF%VJPOOGXK"5?O"TJ_2P_._BY[_&?7N;U!+ P04 M" #S25M8JYPQ2VX" #:+P &@ 'AL+U]R96QS+W=O3L.JVHWC^4==#^M=.;;#0W/T\E_^9V&TV^W7YV:U_ M'\MI_,?@^D_7OP^[4L9J\=KVVS*NJOKC<-L]U-=->KA,KA8O;ZNJ?WE+53UW MD$"0S!^4(2C/'Z00I/,'&039_$$.03Y_4$!0S!_40% S?] C!#W.'Y26*..2 M(&F"-8'6";E.!%XG!#L1B)V0[$1@=D*T$X':"=E.!&XGA#L1R)V0[D1@=T*\ M$X'>@GH+@=Z">@N!WC)YV";06U!O(=!;4&\AT%M0;R'06U!O(=!;4&\AT%M0 M;R'06U!O(= [H]Z90.^,>F<"O3/JG0GTSI.7)01Z9]0[$^B=4>],H'=&O3.! MWAGUS@1Z9]0[$^B=4>],H+>BWDJ@MZ+>2J"WHMY*H+>BWDJ@MTY>=A/HK:BW M$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z&VHMQ'H;:BW$>AMJ+<1Z&VHMQ'H;:BW M$>AMDX^5!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>COJ[01Z.^KM!'H[ZNT$>COJ M[01Z.^KM!'H[ZNT$>OOD9Q,"O1WU=@*]'?5V KT=]78"O0/U#@*] _4. KT# M]0X"O0/U#@*] _4. KT#]0X"O0/U#@*]8_*S(('>@7H'@=Z!>@>!W@WJW1#H MW:#>S7?J/8R?AS+<>K[6>/WOI'J\G%MNE[\NOW9.;L(5Y_J^8GC^"U!+ P04 M " #S25M81.3?6!X" "7+@ $P %M#;VYT96YT7U1Y<&5S72YX;6S- MVM].VS 4!O!7J7*+&M?_RT2YV;C=N-@+>,DIC9K$EFV@O/V<%) VL0I4I'TW MC5K;YSOQD7Y7O?KY%"@M#D,_IDVURSE\82PU.QIL3>5" MZ+O&Y;+.'L;VKY3ES_UXH!B[EA:W+N;O M;BB[V*%G*3_UE.K3)=[HT6^W74.M;^Z'QG)='H92B&*N3O]BJ^)I?39[T?3M%MJWYE= MKO?1Q_T\C\3FQ_EW_.>,7^M_L \!TH<$Z4.!]*%!^C @?5B0/M8@?5R"],%7 M*(V@B,I12.4HIG(45#F*JAR%58[B*D>!E:/(*E!D%2BR"A19!8JL D56@2*K M0)%5H,@J4&05*+)*%%DEBJP215:)(JM$D56BR"I19)4HLDH4626*K I%5H4B MJT*15:'(JE!D52BR*A19%8JL"D56A2*K1I%5H\BJ4635*+)J%%DUBJP:15:- M(JM&D56CR&I09#4HLAH460V*K 9%5H,BJT&1U:#(:E!D-2BR6A19+8JL%D56 MBR*K19'5HLAJ462U*+):%%DMBJQK%%G7_U/67][O/SE^?M:#Z\:7?#;_'_WZ M-U!+ 0(4 Q0 ( /-)6U@'04UB@0 +$ 0 " 0 M !D;V-0&UL4$L! A0#% @ \TE;6$*8_&GO *P( M !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% M @ \TE;6)E&PO=V]R:W-H965T&UL4$L! A0#% M @ \TE;6%2A_'(F!P /1\ !@ ("!&Q 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ \TE;6#\&)4=+!P M:BX !@ ("!1" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \TE;6-J;S3%T @ Y@4 !@ M ("!L30 'AL+W=O&PO=V]R:W-H965T%O !X;"]W;W)K M&UL4$L! A0#% @ \TE;6&")Y[3G @ %@8 M !D ("!T'( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \TE;6$(F&PO=V]R:W-H965T M&UL4$L! A0# M% @ \TE;6';\QLU;!0 O0P !D ("!P*, 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ \TE;6#O* M@1OP P 9 @ !D ("!G+D 'AL+W=O&PO=V]R:W-H965T;! !X;"]W;W)K&UL4$L! A0#% @ \TE;6+"-*SHF+0 59, !D M ("!ZL4 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ \TE;6,"Y<'=: @ #P4 !D ("! M%OP 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ \TE;6):OHU/G @ *@8 !D ("!O08! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \TE;6 9^H4#= M!0 2@\ !D ("!V1,! 'AL+W=O""LR:$" "#!0 &0 M@('M&0$ >&PO=V]R:W-H965T&UL4$L! A0#% @ \TE;6*#06"72 @ (P8 !D M ("!Q2 ! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ \TE;6/0;.,84 P /@L !D ("!C2H! M 'AL+W=O&PO=V]R:W-H965TZ ( .P( 9 M " @28Q 0!X;"]W;W)K&UL4$L! A0#% @ M\TE;6/R&PO=V]R:W-H965T&UL4$L! A0#% @ \TE;6$V>S3!V @ A 8 !D M ("![TD! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ \TE;6,V%O?[P P WA, !D ("!\5,! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \TE; M6%,%]R!Z!0 %BP !D ("!#E\! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \TE;6*$$=ICQ P )A0 M !D ("!#VH! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \TE;6$9L1W9]!0 U1T !D M ("!P70! 'AL+W=O@$ >&PO=V]R:W-H965T M&UL4$L! A0# M% @ \TE;6*TF_O7G!0 LB, !D ("!>((! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ \TE;6*&; M0SSJ&P K-X! !D ("!-9P! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \TE;6#I99Z7Z @ " H !D M ("!B[X! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ \TE;6'"N6EIK! F0X !D ("! M',H! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ \TE;6,]4?S?C P ^!, !D ("!^]@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \TE;6. SHT! 'AL+W=O&PO&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #S25M81.3?6!X" "7+@ M$P @ 'Z_@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 ..60!9 &88 !) 0( ! end XML 102 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 103 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 105 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 260 395 1 true 104 0 false 6 false false R1.htm 0001 - Document - Document and Entity Information Sheet http://www.rewalk.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 0002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.rewalk.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.rewalk.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.rewalk.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0005 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Sheet http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Statements 5 false false R6.htm 0006 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) Sheet http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquityParenthetical STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 0007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlowsParenthetical CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Statements 8 false false R9.htm 0009 - Disclosure - GENERAL Sheet http://www.rewalk.com/role/General GENERAL Notes 9 false false R10.htm 0010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.rewalk.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 0011 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS Sheet http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssets PREPAID EXPENSES AND OTHER CURRENT ASSETS Notes 11 false false R12.htm 0012 - Disclosure - INVENTORIES Sheet http://www.rewalk.com/role/Inventories INVENTORIES Notes 12 false false R13.htm 0013 - Disclosure - BUSINESS COMBINATION Sheet http://www.rewalk.com/role/ACQUISITIONOFALTERG BUSINESS COMBINATION Notes 13 false false R14.htm 0014 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET Sheet http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET GOODWILL AND OTHER INTANGIBLE ASSETS, NET Notes 14 false false R15.htm 0015 - Disclosure - PROPERTY AND EQUIPMENT, NET Sheet http://www.rewalk.com/role/PropertyAndEquipmentNet PROPERTY AND EQUIPMENT, NET Notes 15 false false R16.htm 0016 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES Sheet http://www.rewalk.com/role/CommitmentsAndContingentLiabilities COMMITMENTS AND CONTINGENT LIABILITIES Notes 16 false false R17.htm 0017 - Disclosure - SHAREHOLDERS' EQUITY Sheet http://www.rewalk.com/role/ShareholdersEquity SHAREHOLDERS' EQUITY Notes 17 false false R18.htm 0018 - Disclosure - RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT Sheet http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreement RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT Notes 18 false false R19.htm 0019 - Disclosure - INCOME TAXES Sheet http://www.rewalk.com/role/IncomeTaxes INCOME TAXES Notes 19 false false R20.htm 0020 - Disclosure - FINANCIAL EXPENSES (INCOME), NET Sheet http://www.rewalk.com/role/FinancialExpensesIncomeNet FINANCIAL EXPENSES (INCOME), NET Notes 20 false false R21.htm 0021 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Sheet http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductData GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Notes 21 false false R22.htm 0022 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE Sheet http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHARE BASIC AND DILUTED NET LOSS PER SHARE Notes 22 false false R23.htm 0023 - Disclosure - RESTRUCTURING ACTIVITIES Sheet http://www.rewalk.com/role/RESTRUCTRINGACTIVITIES RESTRUCTURING ACTIVITIES Notes 23 false false R24.htm 0024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 24 false false R25.htm 0025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.rewalk.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.rewalk.com/role/SignificantAccountingPolicies 25 false false R26.htm 0026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Sheet http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsTables PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Tables http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssets 26 false false R27.htm 0027 - Disclosure - INVENTORIES (Tables) Sheet http://www.rewalk.com/role/InventoriesTables INVENTORIES (Tables) Tables http://www.rewalk.com/role/Inventories 27 false false R28.htm 0028 - Disclosure - BUSINESS COMBINATION (Tables) Sheet http://www.rewalk.com/role/ACQUISITIONOFALTERGTables BUSINESS COMBINATION (Tables) Tables http://www.rewalk.com/role/ACQUISITIONOFALTERG 28 false false R29.htm 0029 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables) Sheet http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables) Tables http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET 29 false false R30.htm 0030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) Sheet http://www.rewalk.com/role/PropertyAndEquipmentNetTables PROPERTY AND EQUIPMENT, NET (Tables) Tables http://www.rewalk.com/role/PropertyAndEquipmentNet 30 false false R31.htm 0031 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables) Sheet http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesTables COMMITMENTS AND CONTINGENT LIABILITIES (Tables) Tables http://www.rewalk.com/role/CommitmentsAndContingentLiabilities 31 false false R32.htm 0032 - Disclosure - SHAREHOLDERS' EQUITY (Tables) Sheet http://www.rewalk.com/role/ShareholdersEquityTables SHAREHOLDERS' EQUITY (Tables) Tables http://www.rewalk.com/role/ShareholdersEquity 32 false false R33.htm 0033 - Disclosure - INCOME TAXES (Tables) Sheet http://www.rewalk.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://www.rewalk.com/role/IncomeTaxes 33 false false R34.htm 0034 - Disclosure - FINANCIAL EXPENSES (INCOME), NET (Tables) Sheet http://www.rewalk.com/role/FinancialExpensesIncomeNetTables FINANCIAL EXPENSES (INCOME), NET (Tables) Tables http://www.rewalk.com/role/FinancialExpensesIncomeNet 34 false false R35.htm 0035 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables) Sheet http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataTables GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables) Tables http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductData 35 false false R36.htm 0036 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Tables) Sheet http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHARETables BASIC AND DILUTED NET LOSS PER SHARE (Tables) Tables http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHARE 36 false false R37.htm 0037 - Disclosure - GENERAL (Details) Sheet http://www.rewalk.com/role/GeneralDetails GENERAL (Details) Details http://www.rewalk.com/role/General 37 false false R38.htm 0038 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.rewalk.com/role/SignificantAccountingPoliciesDetails SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.rewalk.com/role/SignificantAccountingPoliciesTables 38 false false R39.htm 0039 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 1) Sheet http://www.rewalk.com/role/TestrereDetails SIGNIFICANT ACCOUNTING POLICIES (Details 1) Details http://www.rewalk.com/role/SignificantAccountingPoliciesTables 39 false false R40.htm 0040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 2) Sheet http://www.rewalk.com/role/TestrereDetails1 SIGNIFICANT ACCOUNTING POLICIES (Details 2) Details http://www.rewalk.com/role/SignificantAccountingPoliciesTables 40 false false R41.htm 0041 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 3) Sheet http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails6 SIGNIFICANT ACCOUNTING POLICIES (Details 3) Details http://www.rewalk.com/role/SignificantAccountingPoliciesTables 41 false false R42.htm 0042 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 4) Sheet http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2 SIGNIFICANT ACCOUNTING POLICIES (Details 4) Details http://www.rewalk.com/role/SignificantAccountingPoliciesTables 42 false false R43.htm 0043 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 5) Sheet http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4 SIGNIFICANT ACCOUNTING POLICIES (Details 5) Details http://www.rewalk.com/role/SignificantAccountingPoliciesTables 43 false false R44.htm 0044 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 6) Sheet http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails5 SIGNIFICANT ACCOUNTING POLICIES (Details 6) Details http://www.rewalk.com/role/SignificantAccountingPoliciesTables 44 false false R45.htm 0045 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Sheet http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Details http://www.rewalk.com/role/SignificantAccountingPoliciesTables 45 false false R46.htm 0046 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Sheet http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Details http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsTables 46 false false R47.htm 0047 - Disclosure - INVENTORIES (Details) Sheet http://www.rewalk.com/role/InventoriesDetails INVENTORIES (Details) Details http://www.rewalk.com/role/InventoriesTables 47 false false R48.htm 0048 - Disclosure - INVENTORIES (Details Textual) Sheet http://www.rewalk.com/role/INVENTORIESNarrativeDetails INVENTORIES (Details Textual) Details http://www.rewalk.com/role/InventoriesTables 48 false false R49.htm 0049 - Disclosure - BUSINESS COMBINATION (Details) Sheet http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails BUSINESS COMBINATION (Details) Details http://www.rewalk.com/role/ACQUISITIONOFALTERGTables 49 false false R50.htm 0050 - Disclosure - BUSINESS COMBINATION (Details 1) Sheet http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1 BUSINESS COMBINATION (Details 1) Details http://www.rewalk.com/role/ACQUISITIONOFALTERGTables 50 false false R51.htm 0051 - Disclosure - BUSINESS COMBINATION (Details 2) Sheet http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2 BUSINESS COMBINATION (Details 2) Details http://www.rewalk.com/role/ACQUISITIONOFALTERGTables 51 false false R52.htm 0052 - Disclosure - BUSINESS COMBINATION (Details 3) Sheet http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails3 BUSINESS COMBINATION (Details 3) Details http://www.rewalk.com/role/ACQUISITIONOFALTERGTables 52 false false R53.htm 0053 - Disclosure - BUSINESS COMBINATION (Details Textual) Sheet http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails BUSINESS COMBINATION (Details Textual) Details http://www.rewalk.com/role/ACQUISITIONOFALTERGTables 53 false false R54.htm 0054 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details) Sheet http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details) Details http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables 54 false false R55.htm 0055 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details 1) Sheet http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1 GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details 1) Details http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables 55 false false R56.htm 0056 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details Textual) Sheet http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETNarrativeDetails GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details Textual) Details http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables 56 false false R57.htm 0057 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details) Sheet http://www.rewalk.com/role/PropertyAndEquipmentNetDetails PROPERTY AND EQUIPMENT, NET (Details) Details http://www.rewalk.com/role/PropertyAndEquipmentNetTables 57 false false R58.htm 0058 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Textual) Sheet http://www.rewalk.com/role/PropertyAndEquipmentNetDetailsTextual PROPERTY AND EQUIPMENT, NET (Details Textual) Details http://www.rewalk.com/role/PropertyAndEquipmentNetTables 58 false false R59.htm 0059 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details) Sheet http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails COMMITMENTS AND CONTINGENT LIABILITIES (Details) Details http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesTables 59 false false R60.htm 0060 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Textual) Sheet http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual COMMITMENTS AND CONTINGENT LIABILITIES (Details Textual) Details http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesTables 60 false false R61.htm 0061 - Disclosure - SHAREHOLDERS' EQUITY (Details) Sheet http://www.rewalk.com/role/ShareholdersEquityDetails SHAREHOLDERS' EQUITY (Details) Details http://www.rewalk.com/role/ShareholdersEquityTables 61 false false R62.htm 0062 - Disclosure - SHAREHOLDERS' EQUITY (Details 1) Sheet http://www.rewalk.com/role/ShareholdersEquityDetails1 SHAREHOLDERS' EQUITY (Details 1) Details http://www.rewalk.com/role/ShareholdersEquityTables 62 false false R63.htm 0063 - Disclosure - SHAREHOLDERS' EQUITY (Details 2) Sheet http://www.rewalk.com/role/ShareholdersEquityDetails2 SHAREHOLDERS' EQUITY (Details 2) Details http://www.rewalk.com/role/ShareholdersEquityTables 63 false false R64.htm 0064 - Disclosure - SHAREHOLDERS' EQUITY (Details 3) Sheet http://www.rewalk.com/role/ShareholdersEquityDetails3 SHAREHOLDERS' EQUITY (Details 3) Details http://www.rewalk.com/role/ShareholdersEquityTables 64 false false R65.htm 0065 - Disclosure - SHAREHOLDERS' EQUITY (Details 4) Sheet http://www.rewalk.com/role/ShareholdersEquityDetails4 SHAREHOLDERS' EQUITY (Details 4) Details http://www.rewalk.com/role/ShareholdersEquityTables 65 false false R66.htm 0066 - Disclosure - SHAREHOLDERS' EQUITY (Details Textual) Sheet http://www.rewalk.com/role/ShareholdersEquityDetailsTextual SHAREHOLDERS' EQUITY (Details Textual) Details http://www.rewalk.com/role/ShareholdersEquityTables 66 false false R67.htm 0067 - Disclosure - RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT (Details) Sheet http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreementDetails RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT (Details) Details http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreement 67 false false R68.htm 0068 - Disclosure - INCOME TAXES (Details) Sheet http://www.rewalk.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://www.rewalk.com/role/IncomeTaxesTables 68 false false R69.htm 0069 - Disclosure - INCOME TAXES (Details 1) Sheet http://www.rewalk.com/role/IncomeTaxesDetails1 INCOME TAXES (Details 1) Details http://www.rewalk.com/role/IncomeTaxesTables 69 false false R70.htm 0070 - Disclosure - INCOME TAXES (Details 2) Sheet http://www.rewalk.com/role/IncomeTaxesDetails2 INCOME TAXES (Details 2) Details http://www.rewalk.com/role/IncomeTaxesTables 70 false false R71.htm 0071 - Disclosure - INCOME TAXES (Details 3) Sheet http://www.rewalk.com/role/IncomeTaxesDetails3 INCOME TAXES (Details 3) Details http://www.rewalk.com/role/IncomeTaxesTables 71 false false R72.htm 0072 - Disclosure - INCOME TAXES (Details 4) Sheet http://www.rewalk.com/role/IncomeTaxesDetails4 INCOME TAXES (Details 4) Details http://www.rewalk.com/role/IncomeTaxesTables 72 false false R73.htm 0073 - Disclosure - INCOME TAXES (Details Textual) Sheet http://www.rewalk.com/role/IncomeTaxesDetailsTextual INCOME TAXES (Details Textual) Details http://www.rewalk.com/role/IncomeTaxesTables 73 false false R74.htm 0074 - Disclosure - FINANCIAL EXPENSES (INCOME), NET (Details) Sheet http://www.rewalk.com/role/FinancialExpensesIncomeNetDetails FINANCIAL EXPENSES (INCOME), NET (Details) Details http://www.rewalk.com/role/FinancialExpensesIncomeNetTables 74 false false R75.htm 0075 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details) Sheet http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details) Details http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataTables 75 false false R76.htm 0076 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 1) Sheet http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails1 GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 1) Details http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataTables 76 false false R77.htm 0077 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 2) Sheet http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2 GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 2) Details http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataTables 77 false false R78.htm 0078 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details Textual) Sheet http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetailsTextual GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details Textual) Details http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataTables 78 false false R79.htm 0079 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details) Sheet http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails BASIC AND DILUTED NET LOSS PER SHARE (Details) Details http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHARETables 79 false false R80.htm 0080 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details Textual) Sheet http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHARENarrativeDetails BASIC AND DILUTED NET LOSS PER SHARE (Details Textual) Details http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHARETables 80 false false R81.htm 0081 - Disclosure - RESTRUCTURING ACTIVITIES (Details Textual) Sheet http://www.rewalk.com/role/RESTRUCTRINGACTIVITIESNarrativeDetails RESTRUCTURING ACTIVITIES (Details Textual) Details http://www.rewalk.com/role/RESTRUCTRINGACTIVITIES 81 false false All Reports Book All Reports lfwd-20231231.xsd lfwd-20231231_cal.xml lfwd-20231231_def.xml lfwd-20231231_lab.xml lfwd-20231231_pre.xml zk2431037.htm image0.jpg image00001.jpg image00003.jpg image1.jpg image2.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 108 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "zk2431037.htm": { "nsprefix": "lfwd", "nsuri": "http://www.rewalk.com/20231231", "dts": { "schema": { "local": [ "lfwd-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "lfwd-20231231_cal.xml" ] }, "definitionLink": { "local": [ "lfwd-20231231_def.xml" ] }, "labelLink": { "local": [ "lfwd-20231231_lab.xml" ] }, "presentationLink": { "local": [ "lfwd-20231231_pre.xml" ] }, "inline": { "local": [ "zk2431037.htm" ] } }, "keyStandard": 310, "keyCustom": 85, "axisStandard": 25, "axisCustom": 2, "memberStandard": 40, "memberCustom": 63, "hidden": { "total": 12, "http://xbrl.sec.gov/dei/2023": 4, "http://www.rewalk.com/20231231": 2, "http://fasb.org/us-gaap/2023": 6 }, "contextCount": 260, "entityCount": 1, "segmentCount": 104, "elementCount": 711, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 811, "http://xbrl.sec.gov/dei/2023": 38 }, "report": { "R1": { "role": "http://www.rewalk.com/role/DocumentAndEntityInformation", "longName": "0001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.rewalk.com/role/ConsolidatedBalanceSheets", "longName": "0002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R3": { "role": "http://www.rewalk.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations", "longName": "0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:CostOfRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R5": { "role": "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity", "longName": "0005 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "shortName": "STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquityParenthetical", "longName": "0006 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)", "shortName": "STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_20210101to20211231_usgaapSubsidiarySaleOfStockAxis_lfwdBestOfferingMember", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20210101to20211231_usgaapSubsidiarySaleOfStockAxis_lfwdBestOfferingMember", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows", "longName": "0007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R8": { "role": "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "longName": "0008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_usgaapSubsidiarySaleOfStockAxis_lfwdRegisteredDirectMember", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R9": { "role": "http://www.rewalk.com/role/General", "longName": "0009 - Disclosure - GENERAL", "shortName": "GENERAL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.rewalk.com/role/SignificantAccountingPolicies", "longName": "0010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssets", "longName": "0011 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "lfwd:PrepaidExpenseAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "lfwd:PrepaidExpenseAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.rewalk.com/role/Inventories", "longName": "0012 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.rewalk.com/role/ACQUISITIONOFALTERG", "longName": "0013 - Disclosure - BUSINESS COMBINATION", "shortName": "BUSINESS COMBINATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET", "longName": "0014 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.rewalk.com/role/PropertyAndEquipmentNet", "longName": "0015 - Disclosure - PROPERTY AND EQUIPMENT, NET", "shortName": "PROPERTY AND EQUIPMENT, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.rewalk.com/role/CommitmentsAndContingentLiabilities", "longName": "0016 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.rewalk.com/role/ShareholdersEquity", "longName": "0017 - Disclosure - SHAREHOLDERS' EQUITY", "shortName": "SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreement", "longName": "0018 - Disclosure - RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT", "shortName": "RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.rewalk.com/role/IncomeTaxes", "longName": "0019 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.rewalk.com/role/FinancialExpensesIncomeNet", "longName": "0020 - Disclosure - FINANCIAL EXPENSES (INCOME), NET", "shortName": "FINANCIAL EXPENSES (INCOME), NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductData", "longName": "0021 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA", "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHARE", "longName": "0022 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE", "shortName": "BASIC AND DILUTED NET LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIES", "longName": "0023 - Disclosure - RESTRUCTURING ACTIVITIES", "shortName": "RESTRUCTURING ACTIVITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies", "longName": "0024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.rewalk.com/role/SignificantAccountingPoliciesTables", "longName": "0025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsTables", "longName": "0026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "lfwd:PrepaidExpenseAndOtherAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "lfwd:PrepaidExpenseAndOtherAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.rewalk.com/role/InventoriesTables", "longName": "0027 - Disclosure - INVENTORIES (Tables)", "shortName": "INVENTORIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.rewalk.com/role/ACQUISITIONOFALTERGTables", "longName": "0028 - Disclosure - BUSINESS COMBINATION (Tables)", "shortName": "BUSINESS COMBINATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables", "longName": "0029 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.rewalk.com/role/PropertyAndEquipmentNetTables", "longName": "0030 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)", "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesTables", "longName": "0031 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "lfwd:ScheduleOfMinimumRoyaltyPaymentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "lfwd:ScheduleOfMinimumRoyaltyPaymentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.rewalk.com/role/ShareholdersEquityTables", "longName": "0032 - Disclosure - SHAREHOLDERS' EQUITY (Tables)", "shortName": "SHAREHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.rewalk.com/role/IncomeTaxesTables", "longName": "0033 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.rewalk.com/role/FinancialExpensesIncomeNetTables", "longName": "0034 - Disclosure - FINANCIAL EXPENSES (INCOME), NET (Tables)", "shortName": "FINANCIAL EXPENSES (INCOME), NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataTables", "longName": "0035 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables)", "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHARETables", "longName": "0036 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Tables)", "shortName": "BASIC AND DILUTED NET LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "lfwd:BasicAndDilutedNetLossPerOrdinaryShareTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "lfwd:BasicAndDilutedNetLossPerOrdinaryShareTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.rewalk.com/role/GeneralDetails", "longName": "0037 - Disclosure - GENERAL (Details)", "shortName": "GENERAL (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails", "longName": "0038 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "lfwd:PropertyPlantAndEquipmentUsefulLifeDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "div", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "lfwd:PropertyPlantAndEquipmentUsefulLifeDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "div", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.rewalk.com/role/TestrereDetails", "longName": "0039 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 1)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_srtProductOrServiceAxis_usgaapProductMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "div", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R40": { "role": "http://www.rewalk.com/role/TestrereDetails1", "longName": "0040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 2)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:AccountsReceivableNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "lfwd:ScheduleOfContractBalancesTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "us-gaap:AccountsReceivableNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "lfwd:ScheduleOfContractBalancesTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails6", "longName": "0041 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 3)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_20221231", "name": "lfwd:WarrantyProvisionBalance", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "lfwd:ScheduleOfWarrantyProvisionTableTextBlock", "div", "div", "us-gaap:StandardProductWarrantyPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20230930", "name": "lfwd:BusinessCombinationRecognizedWarrantProvision", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "lfwd:ScheduleOfWarrantyProvisionTableTextBlock", "div", "div", "us-gaap:StandardProductWarrantyPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R42": { "role": "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2", "longName": "0042 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 4)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details 4)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_20220101to20221231_srtMajorCustomersAxis_lfwdCustomerAMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapAccountsReceivableMember_usgaapConcentrationRiskByTypeAxis_usgaapCreditConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "div", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20220101to20221231_srtMajorCustomersAxis_lfwdCustomerAMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapAccountsReceivableMember_usgaapConcentrationRiskByTypeAxis_usgaapCreditConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "div", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4", "longName": "0043 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 5)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details 5)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_20230930_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230930_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails5", "longName": "0044 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details 6)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details 6)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_20230811_usgaapFairValueByLiabilityClassAxis_lfwdEarnoutMember", "name": "lfwd:WarrantsLiabilityActivity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "lfwd:ScheduleOfWarrantsLiabilityActivityTableTextBlock", "div", "div", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230811_usgaapFairValueByLiabilityClassAxis_lfwdEarnoutMember", "name": "lfwd:WarrantsLiabilityActivity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "lfwd:ScheduleOfWarrantsLiabilityActivityTableTextBlock", "div", "div", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual", "longName": "0045 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Textual)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:InventoryWriteDown", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "lfwd:ScheduleOfContractBalancesTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R46": { "role": "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "0046 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_20231231", "name": "lfwd:PrepaidExpensesToGovernmentInstitutionsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "div", "div", "div", "lfwd:PrepaidExpenseAndOtherAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "lfwd:PrepaidExpensesToGovernmentInstitutionsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "div", "div", "div", "lfwd:PrepaidExpenseAndOtherAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.rewalk.com/role/InventoriesDetails", "longName": "0047 - Disclosure - INVENTORIES (Details)", "shortName": "INVENTORIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.rewalk.com/role/INVENTORIESNarrativeDetails", "longName": "0048 - Disclosure - INVENTORIES (Details Textual)", "shortName": "INVENTORIES (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:InventoryWriteDown", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails", "longName": "0049 - Disclosure - BUSINESS COMBINATION (Details)", "shortName": "BUSINESS COMBINATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "div", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230808_usgaapBusinessAcquisitionAxis_lfwdAltergIncMember", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "td", "tr", "table", "div", "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock", "div", "div", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R50": { "role": "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1", "longName": "0050 - Disclosure - BUSINESS COMBINATION (Details 1)", "shortName": "BUSINESS COMBINATION (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "div", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "lfwd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "div", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R51": { "role": "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2", "longName": "0051 - Disclosure - BUSINESS COMBINATION (Details 2)", "shortName": "BUSINESS COMBINATION (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapTrademarksMember", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R52": { "role": "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails3", "longName": "0052 - Disclosure - BUSINESS COMBINATION (Details 3)", "shortName": "BUSINESS COMBINATION (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock", "div", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock", "div", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails", "longName": "0053 - Disclosure - BUSINESS COMBINATION (Details Textual)", "shortName": "BUSINESS COMBINATION (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_20230801to20230808", "name": "lfwd:EarnOutPaymentOfBusinessCombination", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "div", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230801to20230808", "name": "lfwd:EarnOutPaymentOfBusinessCombination", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "span", "span", "span", "span", "div", "div", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails", "longName": "0054 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapTrademarksMember", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R55": { "role": "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1", "longName": "0055 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details 1)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETNarrativeDetails", "longName": "0056 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details Textual)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_20230101to20230930_usgaapBusinessAcquisitionAxis_lfwdAltergIncMember", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-2", "ancestors": [ "span", "span", "span", "span", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20230930_usgaapBusinessAcquisitionAxis_lfwdAltergIncMember", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-2", "ancestors": [ "span", "span", "span", "span", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails", "longName": "0057 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)", "shortName": "PROPERTY AND EQUIPMENT, NET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.rewalk.com/role/PropertyAndEquipmentNetDetailsTextual", "longName": "0058 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Textual)", "shortName": "PROPERTY AND EQUIPMENT, NET (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": null }, "R59": { "role": "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails", "longName": "0059 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "lfwd:ScheduleOfMinimumRoyaltyPaymentsTableTextBlock", "div", "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "lfwd:ScheduleOfMinimumRoyaltyPaymentsTableTextBlock", "div", "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual", "longName": "0060 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Textual)", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "div", "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "div", "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.rewalk.com/role/ShareholdersEquityDetails", "longName": "0061 - Disclosure - SHAREHOLDERS' EQUITY (Details)", "shortName": "SHAREHOLDERS' EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_20221231", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R62": { "role": "http://www.rewalk.com/role/ShareholdersEquityDetails1", "longName": "0062 - Disclosure - SHAREHOLDERS' EQUITY (Details 1)", "shortName": "SHAREHOLDERS' EQUITY (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_20221231_usgaapAwardTypeAxis_lfwdEmployeeStockOptionAndRestrictedStockUnitsRsuMember", "name": "lfwd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20221231_usgaapAwardTypeAxis_lfwdEmployeeStockOptionAndRestrictedStockUnitsRsuMember", "name": "lfwd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.rewalk.com/role/ShareholdersEquityDetails2", "longName": "0063 - Disclosure - SHAREHOLDERS' EQUITY (Details 2)", "shortName": "SHAREHOLDERS' EQUITY (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_20231231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.rewalk.com/role/ShareholdersEquityDetails3", "longName": "0064 - Disclosure - SHAREHOLDERS' EQUITY (Details 3)", "shortName": "SHAREHOLDERS' EQUITY (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.rewalk.com/role/ShareholdersEquityDetails4", "longName": "0065 - Disclosure - SHAREHOLDERS' EQUITY (Details 4)", "shortName": "SHAREHOLDERS' EQUITY (Details 4)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "lfwd:ClassOfWarrantOrRightExercisable", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R66": { "role": "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual", "longName": "0066 - Disclosure - SHAREHOLDERS' EQUITY (Details Textual)", "shortName": "SHAREHOLDERS' EQUITY (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "NIS_per_Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "NIS_per_Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreementDetails", "longName": "0067 - Disclosure - RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT (Details)", "shortName": "RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_lfwdAgreementAxis_lfwdLicenseAgreementAndCollaborationAgreementMember", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R68": { "role": "http://www.rewalk.com/role/IncomeTaxesDetails", "longName": "0068 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.rewalk.com/role/IncomeTaxesDetails1", "longName": "0069 - Disclosure - INCOME TAXES (Details 1)", "shortName": "INCOME TAXES (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.rewalk.com/role/IncomeTaxesDetails2", "longName": "0070 - Disclosure - INCOME TAXES (Details 2)", "shortName": "INCOME TAXES (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.rewalk.com/role/IncomeTaxesDetails3", "longName": "0071 - Disclosure - INCOME TAXES (Details 3)", "shortName": "INCOME TAXES (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "C_20221231", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "lfwd:ValuationallowancedeferredTaxAssetChangesDueToExchangeRateDifferencesAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R72": { "role": "http://www.rewalk.com/role/IncomeTaxesDetails4", "longName": "0072 - Disclosure - INCOME TAXES (Details 4)", "shortName": "INCOME TAXES (Details 4)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R73": { "role": "http://www.rewalk.com/role/IncomeTaxesDetailsTextual", "longName": "0073 - Disclosure - INCOME TAXES (Details Textual)", "shortName": "INCOME TAXES (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "lfwd:BeneficiaryEnterpriseFromProductiveActivityTaxExemptionPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R74": { "role": "http://www.rewalk.com/role/FinancialExpensesIncomeNetDetails", "longName": "0074 - Disclosure - FINANCIAL EXPENSES (INCOME), NET (Details)", "shortName": "FINANCIAL EXPENSES (INCOME), NET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails", "longName": "0075 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details)", "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_srtStatementGeographicalAxis_countryUS", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R76": { "role": "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails1", "longName": "0076 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 1)", "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:NoncurrentAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "us-gaap:NoncurrentAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2", "longName": "0077 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 2)", "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "C_20230101to20231231_srtMajorCustomersAxis_lfwdCustomerAMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231_srtMajorCustomersAxis_lfwdCustomerAMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetailsTextual", "longName": "0078 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details Textual)", "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails", "longName": "0079 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details)", "shortName": "BASIC AND DILUTED NET LOSS PER SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "NIS_per_Share", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "us-gaap:EarningsPerShareDiluted", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } }, "R80": { "role": "http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHARENarrativeDetails", "longName": "0080 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details Textual)", "shortName": "BASIC AND DILUTED NET LOSS PER SHARE (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "lfwd:NumberOfSharesExcludedFromDilutedLossPerShareAntiDilutive", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20230101to20231231", "name": "lfwd:NumberOfSharesExcludedFromDilutedLossPerShareAntiDilutive", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIESNarrativeDetails", "longName": "0081 - Disclosure - RESTRUCTURING ACTIVITIES (Details Textual)", "shortName": "RESTRUCTURING ACTIVITIES (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "C_20230101to20231231", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20231201to20231212_usgaapPlanNameAxis_lfwdTwoZeroTwoThreeReorganizationPlanMember", "name": "lfwd:WorkforcePercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2431037.htm", "unique": true } } }, "tag": { "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Sale of stock price per share", "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time." } } }, "auth_ref": [ "r145" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Trade payables", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26", "r743" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Trade Receivables [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r699" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/TestrereDetails1" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Trade receivable, net\u00a0of credit losses", "verboseLabel": "Trade receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r644", "r698", "r749", "r851" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Trade receivable, net", "verboseLabel": "Trade receivable, net of credit losses of $328 and $26, respectively", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r282", "r283" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r63", "r195", "r575" ] }, "lfwd_AcquisitionDeferredTaxAssetAdjustmentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "AcquisitionDeferredTaxAssetAdjustmentsAmount", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "label": "Acquisition, Deferred Tax Asset, Adjustments, Amount", "documentation": "Represents the acquisition, deferred tax asset, adjustments, amount.", "verboseLabel": "Acquisition" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r108", "r743", "r856" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r420", "r421", "r422", "r611", "r781", "r782", "r783", "r834", "r857" ] }, "lfwd_AdditionallyWarrantsIssuedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "AdditionallyWarrantsIssuedMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Additionally Warrants Issued [Member]", "label": "Additionally Warrants Issued [Member]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r184", "r185", "r186", "r187", "r188", "r227", "r228", "r229", "r230", "r239", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r323", "r420", "r421", "r422", "r447", "r448", "r449", "r450", "r464", "r465", "r466", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r503", "r504", "r506", "r507", "r508", "r509", "r518", "r519", "r520", "r521", "r522", "r523", "r533", "r534", "r535", "r536", "r537", "r548", "r549", "r550", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-based compensation to employees and non-employees", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r77", "r78", "r387" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Issuance expenses, amount", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r14", "r143" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "srt_AfricaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AfricaMember", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails" ], "lang": { "en-us": { "role": { "label": "Africa [Member]" } } }, "auth_ref": [ "r859", "r860", "r861", "r862" ] }, "lfwd_AggregateNumberOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "AggregateNumberOfOrdinaryShares", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of ordinary shares.", "label": "Aggregate number of ordinary shares" } } }, "auth_ref": [] }, "lfwd_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "AgreementAxis", "presentation": [ "http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreementDetails", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Agreement Axis", "label": "Agreement [Axis]" } } }, "auth_ref": [] }, "lfwd_AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "AgreementDomain", "presentation": [ "http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreementDetails", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails3" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "Non-cash share-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r418", "r427" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "verboseLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r202", "r284", "r298" ] }, "lfwd_AllowanceForSalesReturns": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "AllowanceForSalesReturns", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Allowance for Sales Returns", "label": "Allowance For Sales Returns", "verboseLabel": "Net of sales return reserve" } } }, "auth_ref": [] }, "lfwd_AltergIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "AltergIncMember", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails", "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETNarrativeDetails", "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Information about AlterG Inc.", "label": "Alterg Inc [Member]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails" ], "lang": { "en-us": { "role": { "negatedNetLabel": "Accumulated Amortization", "verboseLabel": "Accumulated Amortization", "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r57", "r60" ] }, "lfwd_AmountOfAdditionalCashEarnouts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "AmountOfAdditionalCashEarnouts", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Amount Of Additional Cash Earnouts", "documentation": "Information about amount of additional cash earnouts.", "terseLabel": "Amount of additional cash earnouts" } } }, "auth_ref": [] }, "lfwd_AmountOfEmployeeTerminationBenefitsAndLegalExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "AmountOfEmployeeTerminationBenefitsAndLegalExpenses", "presentation": [ "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Amount Of Employee Termination Benefits And Legal Expenses", "documentation": "Represents the amount of employee termination benefits and legal expenses.", "verboseLabel": "Amount of employee termination benefits and legal expenses" } } }, "auth_ref": [] }, "lfwd_AmountOfWarrantProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "AmountOfWarrantProvision", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails6" ], "lang": { "en-us": { "role": { "label": "Amount Of Warrant Provision", "documentation": "It represents amount of warrant provision.", "verboseLabel": "Provision" } } }, "auth_ref": [] }, "lfwd_AmountOfWarrantProvisionUsage": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "AmountOfWarrantProvisionUsage", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails6" ], "lang": { "en-us": { "role": { "label": "Amount Of Warrant Provision Usage", "documentation": "It represents amount of warrant provision usage.", "verboseLabel": "Usage" } } }, "auth_ref": [] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails" ], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r859", "r860", "r861", "r862" ] }, "us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionContingentConsiderationTableTextBlock", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGTables" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of total consideration", "documentation": "Tabular disclosure of contingent consideration in asset acquisition." } } }, "auth_ref": [ "r833" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r160", "r198", "r220", "r261", "r268", "r273", "r287", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r468", "r470", "r505", "r569", "r649", "r743", "r756", "r796", "r797", "r841" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r190", "r207", "r220", "r287", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r468", "r470", "r505", "r743", "r796", "r797", "r841" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "verboseLabel": "Financial Assets", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r92" ] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent", "totalLabel": "Total long-term assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r220", "r287", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r468", "r470", "r505", "r796", "r797", "r841" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LONG-TERM ASSETS" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm Id", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r760", "r761", "r762" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r760", "r761", "r762" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r760", "r761", "r762" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1", "http://www.rewalk.com/role/ShareholdersEquityDetails2", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r389", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r413", "r414", "r415", "r416", "r417" ] }, "lfwd_BacklogMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BacklogMember", "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails" ], "lang": { "en-us": { "role": { "label": "Backlog [Member]", "terseLabel": "Backlog", "documentation": "Information about Backlog." } } }, "auth_ref": [] }, "lfwd_BankCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BankCommissions", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/FinancialExpensesIncomeNetDetails": { "parentTag": "lfwd_FinancialExpensesAndIncomeNet", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/FinancialExpensesIncomeNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of bank commissions.", "label": "Bank commissions", "negatedLabel": "Bank commissions" } } }, "auth_ref": [] }, "lfwd_BasicAndDilutedNetLossPerOrdinaryShareTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BasicAndDilutedNetLossPerOrdinaryShareTableTextBlock", "presentation": [ "http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHARETables" ], "lang": { "en-us": { "role": { "label": "Basic And Diluted Net Loss Per Ordinary Share [Table Text Block]", "documentation": "Tabular disclosure of basic and diluted net loss per ordinary share.", "verboseLabel": "Schedule of basic and diluted net loss per ordinary share" } } }, "auth_ref": [] }, "lfwd_BeneficiaryEnterpriseFromProductiveActivityMaximumTimeFromPeriodOfElectionForTaxExemption": { "xbrltype": "durationItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BeneficiaryEnterpriseFromProductiveActivityMaximumTimeFromPeriodOfElectionForTaxExemption", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Beneficiary Enterprise from Productive Activity, Maximum Time from Period of Election for Tax Exemption", "label": "Beneficiary Enterprise From Productive Activity Maximum Time From Period Of Election For Tax Exemption", "verboseLabel": "Beneficiary enterprise from productive activity, maximum time from period of election for tax exemption" } } }, "auth_ref": [] }, "lfwd_BeneficiaryEnterpriseFromProductiveActivityTaxExemptionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BeneficiaryEnterpriseFromProductiveActivityTaxExemptionPeriod", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Beneficiary Enterprise from Productive Activity, Tax Exemption Period", "label": "Beneficiary Enterprise From Productive Activity Tax Exemption Period", "verboseLabel": "Beneficiary enterprise from productive activity, tax exemption period" } } }, "auth_ref": [] }, "lfwd_BeneficiaryEnterpriseFromProductiveActivityTaxRateOnDividendDistributionsFromTaxExemptIncome": { "xbrltype": "percentItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BeneficiaryEnterpriseFromProductiveActivityTaxRateOnDividendDistributionsFromTaxExemptIncome", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Beneficiary Enterprise from Productive Activity, Tax Rate on Dividend Distributions from Tax Exempt Income", "label": "Beneficiary Enterprise From Productive Activity Tax Rate On Dividend Distributions From Tax Exempt Income", "verboseLabel": "Beneficiary enterprise from productive activity, tax rate on dividend distributions from tax exempt income" } } }, "auth_ref": [] }, "lfwd_BestOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BestOfferingMember", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Best Offering [Member]", "label": "Best Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails", "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r462", "r739", "r740" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails", "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r84", "r85", "r462", "r739", "r740" ] }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Transaction Costs", "terseLabel": "Amount of additional cash earnouts", "verboseLabel": "Earnout payments", "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails", "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r462" ] }, "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGTables" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table Text Block]", "terseLabel": "Schedule of pro forma revenue and earnings", "documentation": "Tabular disclosure of the nature and amount of any material, nonrecurring adjustments directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information)." } } }, "auth_ref": [ "r18" ] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails3" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net loss", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r460", "r461" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails3" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenues", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r460", "r461" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition-related costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r83" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails", "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred", "terseLabel": "Total consideration", "verboseLabel": "Purchase price", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r2", "r3", "r12" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERG" ], "lang": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "terseLabel": "BUSINESS COMBINATION", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r154", "r463" ] }, "lfwd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "documentation": "The amount of accrued compensation recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Compensation", "negatedLabel": "Accrued compensation", "terseLabel": "Accrued compensation" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 90.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "negatedLabel": "Leases Liability", "terseLabel": "Leases Liability", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation", "documentation": "Amount of lease obligation assumed in business combination." } } }, "auth_ref": [ "r87" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails", "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash", "verboseLabel": "Cash and cash equivalent", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r87" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 100.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r87" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 70.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r87" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 80.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts payable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Accounts payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r87" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 150.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "terseLabel": "Deferred revenue", "negatedLabel": "Deferred revenue", "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r87" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 120.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r87" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r86", "r87" ] }, "lfwd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "documentation": "The amount of other accrued liabilities recognized as of the acquisition date.", "negatedLabel": "Other accrued liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed Other Accrued Liabilities", "terseLabel": "Other accrued liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 130.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r87" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 110.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment, net", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r86", "r87" ] }, "lfwd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "documentation": "The amount of restricted cash recognized as of the acquisition date.", "terseLabel": "Restricted cash", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash" } } }, "auth_ref": [] }, "lfwd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Asset", "documentation": "The amount of Right of use asset recognized as of the acquisition date.", "terseLabel": "Right of use asset" } } }, "auth_ref": [] }, "lfwd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantyObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantyObligations", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 40.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed Warranty Obligations", "negatedLabel": "Warranty Obligations", "documentation": "The amount of warranty obligations recognized as of the acquisition date.", "terseLabel": "Warranty Obligations" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total purchase consideration", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r87" ] }, "lfwd_BusinessCombinationRecognizedWarrantProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "BusinessCombinationRecognizedWarrantProvision", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails6" ], "lang": { "en-us": { "role": { "label": "Business Combination Recognized Warrant Provision", "documentation": "It represents business combination recognized warrant provision.", "verboseLabel": "AlterG acquisition" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeDescription", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Description", "terseLabel": "Description of Earnout payments", "documentation": "In a business combination achieved in stages, this element represents a narrative description of the history, developments, or effect of the acquisition relative to the percentage of equity in the acquiree held by the acquirer immediately before the acquisition date. Such description may describe any gain recognized as a result of the acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Business Combinations Policy [Policy Text Block]", "verboseLabel": "Business Combinations", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r82" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets", "http://www.rewalk.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r39", "r193", "r716" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r40" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "totalLabel": "Total Cash, cash equivalents, and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r39", "r127", "r217" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase (decrease) in cash, cash equivalents, and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r127" ] }, "lfwd_CertainInstitutionalPurchasersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CertainInstitutionalPurchasersMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Certain institutional purchasers [Member]", "label": "Certain institutional purchasers [Member]" } } }, "auth_ref": [] }, "lfwd_ChangeInFairValueOfWarrantsLiabilityActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ChangeInFairValueOfWarrantsLiabilityActivity", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails5" ], "lang": { "en-us": { "role": { "label": "Change In Fair Value Of Warrants Liability Activity", "documentation": "It represents change in fair value of warrants liability activity.", "verboseLabel": "Change in fair value" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r183", "r199", "r200", "r201", "r220", "r243", "r244", "r246", "r248", "r255", "r256", "r287", "r336", "r338", "r339", "r340", "r343", "r344", "r349", "r350", "r352", "r355", "r362", "r505", "r605", "r606", "r607", "r608", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r636", "r658", "r676", "r691", "r692", "r693", "r694", "r695", "r767", "r778", "r784" ] }, "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Warrants grant date", "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format." } } }, "auth_ref": [ "r363" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "lfwd_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ClassOfWarrantOrRightExercisable", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Exercisable", "label": "Class Of Warrant Or Right Exercisable", "verboseLabel": "Warrants outstanding and exercisable" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Warrant exercise price", "terseLabel": "Exercise price per share", "verboseLabel": "Exercise price per warrant", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r363" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Warrant to purchase one ordinary share", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "positiveTerseLabel": "Warrants to acquire common stock", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of warrants issued", "verboseLabel": "Warrants to purchase common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r363" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Warrants outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "lfwd_ClassOfWarrantOrRightPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ClassOfWarrantOrRightPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for warrants or rights.", "label": "Class Of Warrant Or Right [Policy Text Block]", "verboseLabel": "Warrants to Acquire Ordinary Shares" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r68" ] }, "lfwd_ClassificationOfInventoryToPropertyAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ClassificationOfInventoryToPropertyAndEquipmentNet", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Classification of Inventory to Property and Equipment, Net", "label": "Classification Of Inventory To Property And Equipment Net", "verboseLabel": "Classification of inventory to property and equipment" } } }, "auth_ref": [] }, "lfwd_ClassificationOfOtherCurrentAssetsToPropertyAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ClassificationOfOtherCurrentAssetsToPropertyAndEquipmentNet", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Classification of other net current assets to property and equipment", "label": "Classification of other current assets to property and equipment, net" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENT LIABILITIES", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r31", "r96", "r570", "r635" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilities" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r140", "r330", "r331", "r700", "r792" ] }, "lfwd_CommitmentsAndContingenciesLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CommitmentsAndContingenciesLiabilitiesAbstract", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Contingent liabilities", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r64", "r701" ] }, "lfwd_CommonStockAggregateOfferingPriceAuthorizedUnderEquityDistributionAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CommonStockAggregateOfferingPriceAuthorizedUnderEquityDistributionAgreement", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Common Stock, Aggregate Offering Price Authorized Under Equity Distribution Agreement", "label": "Common Stock Aggregate Offering Price Authorized Under Equity Distribution Agreement", "verboseLabel": "Aggregate offering price" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Shares reserved for future issuance (in shares)", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r32" ] }, "lfwd_CommonStockIssuanceCostsUnderEquityDistributionAgreementAsPercentOfGrossProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CommonStockIssuanceCostsUnderEquityDistributionAgreementAsPercentOfGrossProceeds", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Stock issuance costs under equity distribution agreement as a percent of gross proceeds.", "label": "Common Stock Issuance Costs Under Equity Distribution Agreement As Percent Of Gross Proceeds", "verboseLabel": "Stock issuance costs under equity distribution agreement as a percent of gross proceeds" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Ordinary Share [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r746", "r747", "r748", "r750", "r751", "r752", "r753", "r781", "r782", "r834", "r855", "r857" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Ordinary shares, par value per share", "verboseLabel": "Per share value of stock repurchase authorized", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r107" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r107", "r636" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r107" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r107", "r636", "r655", "r857", "r858" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock Value", "terseLabel": "Ordinary share of NIS 0.25 par value-Authorized: 120,000,000 shares at September 30, 2022 and December 31, 2021; Issued: 62,901,945 and 62,480,163 shares as of September 30, 2022 and December 31, 2021 respectively; Outstanding: 62,717,316 and 62,480,163 shares as of September 30, 2022 and December 31, 2021 respectively", "verboseLabel": "Ordinary share of NIS 0.25 par value-Authorized: 120,000,000 shares at December 31, 2023 and December 31, 2022; Issued: 64,132,706 and 63,023,506 shares at December 31, 2023 and December 31, 2022, respectively; Outstanding: 60,110,099 and 60,090,298 shares as of December 31, 2023 and December 31, 2022 respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r107", "r571", "r743" ] }, "lfwd_CommonUnitsAndPreFundedUnits1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CommonUnitsAndPreFundedUnits1Member", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Common units and pre-funded units one [Member]", "label": "Common Units And Pre Funded Units 1 [Member]", "verboseLabel": "Common units and pre-funded units one [Member]" } } }, "auth_ref": [] }, "lfwd_CommonUnitsAndPreFundedUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CommonUnitsAndPreFundedUnitsMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Common units and pre-funded units [Member]", "label": "Common units and pre-funded units [Member]" } } }, "auth_ref": [] }, "lfwd_CommonUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CommonUnitsMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Common units [Member]", "label": "Common units [Member]" } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Computer equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r48", "r50", "r94", "r95", "r281", "r699" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r48", "r50", "r94", "r95", "r281", "r600", "r699" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r48", "r50", "r94", "r95", "r281", "r699", "r770" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentrations of Credit Risks", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r98", "r174" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r699" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2" ], "lang": { "en-us": { "role": { "label": "Concentration of credit risk", "verboseLabel": "Concentration risk", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r48", "r50", "r94", "r95", "r281" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r47", "r48", "r50", "r51", "r94", "r159", "r699" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r48", "r50", "r94", "r95", "r281", "r699" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r91", "r720" ] }, "lfwd_ContingentLiabilityRelatedToGrantsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ContingentLiabilityRelatedToGrantsReceived", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Represents the contingent liability related to grant received as of the balance sheet date.", "label": "Contingent Liability Related To Grants Received", "verboseLabel": "Contingent liability" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockDescription", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Description of conversion ratio", "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r42", "r43", "r44" ] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockMember", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Convertible preferred A shares [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": [ "r349", "r350", "r352", "r750", "r751", "r752", "r753" ] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Convertible preferred shares", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r24", "r65", "r106", "r142", "r358" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of revenues", "verboseLabel": "Cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r122", "r220", "r287", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r505", "r796" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails3" ], "lang": { "en-us": { "role": { "label": "Cost of revenue [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditConcentrationRiskMember", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Credit Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement." } } }, "auth_ref": [ "r159" ] }, "lfwd_CumulativeEffectToAccruedDeficitFromAdoptionOfNewStandards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CumulativeEffectToAccruedDeficitFromAdoptionOfNewStandards", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect To Accrued Deficit From Adoption Of New Standards" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails1": { "parentTag": "lfwd_TaxesOnIncome", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Current", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r153", "r446", "r454", "r780" ] }, "lfwd_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CustomerAMember", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2" ], "lang": { "en-us": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]", "verboseLabel": "Customer A [Member]", "terseLabel": "Customer A [Member]" } } }, "auth_ref": [] }, "lfwd_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CustomerBMember", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2" ], "lang": { "en-us": { "role": { "documentation": "Customer B [Member]", "label": "Customer B [Member]" } } }, "auth_ref": [] }, "lfwd_CustomerCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CustomerCMember", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2" ], "lang": { "en-us": { "role": { "documentation": "Customer C [Member]", "label": "Customer C [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r49", "r281" ] }, "lfwd_CustomerDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CustomerDMember", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2" ], "lang": { "en-us": { "role": { "documentation": "Customer D [Member]", "label": "Customer D [Member]" } } }, "auth_ref": [] }, "lfwd_CustomerRelationshipDistributionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CustomerRelationshipDistributionMember", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2" ], "lang": { "en-us": { "role": { "documentation": "The member stands for Customer relationship - Distribution.", "label": "Customer Relationship - Distribution [Member]" } } }, "auth_ref": [] }, "lfwd_CustomerRelationshipRentalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CustomerRelationshipRentalMember", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationship - Rental", "label": "Customer Relationship Rental [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [] }, "lfwd_CustomerRelationshipWarrantyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "CustomerRelationshipWarrantyMember", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "terseLabel": "Customer relationship - Warranty", "label": "Customer Relationship Warranty [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails" ], "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "terseLabel": "Customer relationship - Distribution", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r90" ] }, "country_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "DE", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails1" ], "lang": { "en-us": { "role": { "label": "Germany [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCollateralAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCollateralAmount", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Drawdown amount under loan agreement", "documentation": "Amount of assets pledged to secure a debt instrument." } } }, "auth_ref": [ "r97" ] }, "lfwd_December2020PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "December2020PrivatePlacementMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "December 2020 private placement [Member]", "label": "December 2020 private placement [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of prepaid expenses and other current assets", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "lfwd_DeferredIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "DeferredIncomeTax", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails1": { "parentTag": "lfwd_TaxesOnIncome", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "documentation": "Deferred Income Tax.", "negatedLabel": "Deferred", "label": "Deferred Income Tax" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 70.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred taxes", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r9", "r153", "r180", "r453", "r454", "r780" ] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/TestrereDetails1" ], "lang": { "en-us": { "role": { "label": "Deferred revenues and advance payments", "verboseLabel": "Deferred revenue", "terseLabel": "Deferred revenues", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r773" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred revenues", "verboseLabel": "Deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r772" ] }, "us-gaap_DeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue, Noncurrent", "verboseLabel": "Deferred revenues", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r773" ] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible Assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Net deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r441" ] }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGrossAbstract", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Research and development carry forward expenses-temporary differences", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r81", "r831" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net", "totalLabel": "Total deferred tax assets", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r830" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r830" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Carry forward tax losses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r81", "r831" ] }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Property, Plant and Equipment", "terseLabel": "Property and equipment", "negatedLabel": "Property and equipment", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards", "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total", "terseLabel": "Credit tax carry forwards", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r80", "r81", "r831" ] }, "lfwd_DeferredTaxAssetsTaxDeferredExpenseLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "DeferredTaxAssetsTaxDeferredExpenseLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.", "label": "Deferred Tax Assets Tax Deferred Expense Lease Liabilities", "verboseLabel": "Lease liabilities" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Accrual and reserves", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r81", "r831" ] }, "lfwd_DeferredTaxAssetsTaxDeferredExpenseShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "DeferredTaxAssetsTaxDeferredExpenseShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of deferred tax assets tax deferred expense share based compensation.", "label": "Deferred Tax Assets Tax Deferred Expense Share Based Compensation", "verboseLabel": "Share based compensation" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2", "http://www.rewalk.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "negatedPeriodEndLabel": "Balance at end of year", "negatedPeriodStartLabel": "Balance at beginning of year", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r442" ] }, "lfwd_DeferredTaxExpenseEffectOfChangeInTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "DeferredTaxExpenseEffectOfChangeInTaxRate", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of deferred tax expense effect of change in tax rate.", "label": "Deferred Tax Expense Effect Of Change In Tax Rate" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "lfwd_DeferredTaxLiabilitiesRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails2": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right-of-use asset.", "negatedLabel": "Right-of-use asset", "label": "Deferred Tax Liabilities Right Of Use Asset" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows", "http://www.rewalk.com/role/PropertyAndEquipmentNetDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Depreciation", "verboseLabel": "Depreciation expenses", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r62" ] }, "lfwd_DescriptionOfIncomeTaxLawForEncouragementOfCapitalInvestments": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "DescriptionOfIncomeTaxLawForEncouragementOfCapitalInvestments", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Description of income tax law for encouragement of capital investments.", "label": "Description of income tax law for encouragement of capital investments" } } }, "auth_ref": [] }, "lfwd_DescriptionOfUnderwritingAgreement": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "DescriptionOfUnderwritingAgreement", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Description of underwriting agreement.", "label": "Description of underwriting agreement" } } }, "auth_ref": [] }, "lfwd_DescriptionOfWainwrightOrItsDesigneesWarrantsToPurchase": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "DescriptionOfWainwrightOrItsDesigneesWarrantsToPurchase", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Description of wainwright or its designees warrants to purchase.", "label": "Description of wainwright or its designees warrants to purchase" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r760", "r761", "r762" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r760", "r761", "r762", "r764" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r763" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "lfwd_EarnOutPaymentOfBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "EarnOutPaymentOfBusinessCombination", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of earn out payment.", "label": "Earn Out Payment Of Business Combination", "terseLabel": "Earnout payments" } } }, "auth_ref": [] }, "lfwd_EarnOutRemeasured": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "EarnOutRemeasured", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Earn Out Remeasured", "documentation": "Information about earnout remeasured.", "terseLabel": "Remeasurement of earnout liability" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails", "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per ordinary share, basic and diluted", "terseLabel": "Net loss per ordinary share, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r215", "r231", "r232", "r233", "r234", "r235", "r241", "r243", "r246", "r247", "r248", "r252", "r493", "r494", "r565", "r579", "r722" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails", "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per ordinary share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r215", "r231", "r232", "r233", "r234", "r235", "r243", "r246", "r247", "r248", "r252", "r493", "r494", "r565", "r579", "r722" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r45", "r46" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHARE" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "BASIC AND DILUTED NET LOSS PER SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r240", "r249", "r250", "r251" ] }, "lfwd_EarnoutLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "EarnoutLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Earnout Liability Current", "documentation": "Represent the amount of Earnout liability current", "verboseLabel": "Earnout liability" } } }, "auth_ref": [] }, "lfwd_EarnoutMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "EarnoutMember", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4", "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails5" ], "lang": { "en-us": { "role": { "label": "Earnout [Member]", "documentation": "This member stands for Earnout.", "verboseLabel": "Earnout [Member]" } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r511" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails4", "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Statutory tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r223", "r436", "r456" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Employees and payroll accruals", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails3" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Unrecognized cost of shares", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r419" ] }, "lfwd_EmployeeStockOptionAndRestrictedStockUnitsRsuMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "EmployeeStockOptionAndRestrictedStockUnitsRsuMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "documentation": "Represents details pertaining to employee share option and RSU.", "label": "Employee Stock Option And Restricted Stock Units Rsu [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "lfwd_EmployeesAndNonEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "EmployeesAndNonEmployeesMember", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Employees and non- employees [Member]", "label": "Employees and non- employees [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r758" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual", "http://www.rewalk.com/role/IncomeTaxesDetailsTextual", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r758" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r758" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r765" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r758" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r758" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r758" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r758" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-Known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r766" ] }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EntityWideRevenueMajorCustomerLineItems", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails", "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2" ], "lang": { "en-us": { "role": { "label": "Revenue, Major Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r186", "r211", "r212", "r213", "r224", "r225", "r226", "r228", "r236", "r238", "r254", "r291", "r297", "r364", "r420", "r421", "r422", "r449", "r450", "r475", "r477", "r478", "r479", "r480", "r482", "r492", "r512", "r513", "r514", "r515", "r516", "r517", "r537", "r590", "r591", "r592", "r611", "r676" ] }, "lfwd_EquityExchangeProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "EquityExchangeProgramMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Equity Exchange Program [Member]", "label": "Equity Exchange Program [Member]" } } }, "auth_ref": [] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails" ], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "auth_ref": [ "r859", "r860", "r861", "r862" ] }, "lfwd_ExerciseOfPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ExerciseOfPreFundedWarrants", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Exercise of pre-funded warrants and warrants.", "label": "Exercise Of Pre Funded Warrants", "verboseLabel": "Exercise of pre-funded warrants and warrants", "terseLabel": "Exercise of pre-funded warrants and warrants" } } }, "auth_ref": [] }, "lfwd_ExerciseOfPreFundedWarrantsAndWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ExerciseOfPreFundedWarrantsAndWarrantsShares", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares exercise of pre-funded warrants and warrants.", "label": "Exercise of pre-funded warrants and warrants, shares" } } }, "auth_ref": [] }, "lfwd_ExerciseOfPreFundedWarrantsAndWarrantsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ExerciseOfPreFundedWarrantsAndWarrantsValue", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of exercise of pre-funded warrants and warrants.", "label": "Exercise Of Pre Funded Warrants And Warrants Value", "verboseLabel": "Exercise of pre-funded warrants and warrants" } } }, "auth_ref": [] }, "lfwd_ExercisePriceOrdinaryShares": { "xbrltype": "perShareItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ExercisePriceOrdinaryShares", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Exercise price ordinary shares.", "label": "Exercise Price Ordinary Shares" } } }, "auth_ref": [] }, "lfwd_ExercisePriceRangeFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ExercisePriceRangeFiveMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "documentation": "Represents information by five range of option prices pertaining to options granted.", "label": "Exercise Price Range Five [Member]", "verboseLabel": "$182.5-$524.25 [Member]" } } }, "auth_ref": [] }, "lfwd_ExercisePriceRangeFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ExercisePriceRangeFourMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "documentation": "Represents information by four range of option prices pertaining to options granted.", "label": "Exercise Price Range Four [Member]", "verboseLabel": "$50-$52.5 [Member]" } } }, "auth_ref": [] }, "lfwd_ExercisePriceRangeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ExercisePriceRangeMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range [Member]", "label": "Exercise Price Range [Member]", "verboseLabel": "RSUs only [Member]" } } }, "auth_ref": [] }, "lfwd_ExercisePriceRangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ExercisePriceRangeOneMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "documentation": "Represents information by one range of option prices pertaining to options granted.", "label": "Exercise Price Range One [Member]", "verboseLabel": "5.37 [Member]" } } }, "auth_ref": [] }, "lfwd_ExercisePriceRangeThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ExercisePriceRangeThreeMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "documentation": "Represents information by three range of option prices pertaining to options granted.", "label": "Exercise Price Range Three [Member]", "terseLabel": "$37.14-$38.75 [Member]" } } }, "auth_ref": [] }, "lfwd_ExercisePriceRangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ExercisePriceRangeTwoMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "documentation": "Represents information by two range of option prices pertaining to options granted.", "label": "Exercise Price Range Two [Member]", "verboseLabel": "$20.42- $33.75 [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r497", "r498", "r501" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r497", "r498", "r501" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "verboseLabel": "Schedule of assets and liabilities measured at fair value", "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances." } } }, "auth_ref": [ "r19", "r92", "r93", "r158" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r15" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r92", "r93" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r345", "r377", "r378", "r379", "r380", "r381", "r382", "r498", "r540", "r541", "r542", "r728", "r729", "r736", "r737", "r738" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4", "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails5" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r93", "r157" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r497", "r498", "r499", "r500", "r502" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r345", "r377", "r382", "r498", "r540", "r736", "r737", "r738" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r345", "r377", "r378", "r379", "r380", "r381", "r382", "r498", "r542", "r728", "r729", "r736", "r737", "r738" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4", "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails5" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r15" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r345", "r377", "r378", "r379", "r380", "r381", "r382", "r540", "r541", "r542", "r728", "r729", "r736", "r737", "r738" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "verboseLabel": "Fair Value, Measurements, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r496", "r502" ] }, "lfwd_FairValueWarrantsLiabilityActivityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "FairValueWarrantsLiabilityActivityLineItems", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails5" ], "lang": { "en-us": { "role": { "label": "Fair Value Warrants Liability Activity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "lfwd_FairValueWarrantsLiabilityActivityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "FairValueWarrantsLiabilityActivityTable", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails5" ], "lang": { "en-us": { "role": { "label": "Fair Value Warrants Liability Activity [Table]", "documentation": "Disclosure of information about fair value warrants liability activity." } } }, "auth_ref": [] }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails1": { "parentTag": "lfwd_TaxesIncome", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Federal Income Tax Expense (Benefit), Continuing Operations", "verboseLabel": "Domestic", "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r221", "r435" ] }, "lfwd_FeesAndOtherRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "FeesAndOtherRelatedExpenses", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "The amount of fees and other related expenses.", "label": "Fees and other related expenses" } } }, "auth_ref": [] }, "lfwd_FieldServiceUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "FieldServiceUnitsMember", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Field service units [Member]", "label": "Field service units [Member]" } } }, "auth_ref": [] }, "lfwd_FinancialExpensesAndIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "FinancialExpensesAndIncomeNet", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/FinancialExpensesIncomeNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/FinancialExpensesIncomeNetDetails" ], "lang": { "en-us": { "role": { "label": "Financial Expenses And Income Net", "documentation": "Represents the Financial Expenses And Income Net.", "totalLabel": "Financial (expenses) income, net", "verboseLabel": "Financial expenses (income), net", "negatedLabel": "Financial income, net", "negatedTotalLabel": "Financial (expenses) income, net" } } }, "auth_ref": [] }, "lfwd_FinancialExpensesIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "FinancialExpensesIncomeNet", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregate amount of financial expense or income from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Financial expenses (income), net", "totalLabel": "Financial (expenses) income, net", "verboseLabel": "Financial expenses (income), net", "negatedLabel": "Financial income, net", "negatedTotalLabel": "Financial (expenses) income, net" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Estimated Useful Life (Years)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed." } } }, "auth_ref": [ "r58" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Fiscal 2028", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Fiscal 2023 (period remaining)", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r135" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Fiscal 2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r135" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Fiscal 2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r135" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Fiscal 2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r135" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Fiscal 2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r135" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r317", "r319", "r320", "r321", "r547", "r551" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r547" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r58", "r59" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails1" ], "lang": { "en-us": { "role": { "positiveTerseLabel": "Estimated Fair Value", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible Assets, Net", "totalLabel": "Total", "verboseLabel": "Cost", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r134", "r547" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Estimated Fair Value", "verboseLabel": "Cost", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r318" ] }, "lfwd_FixedCommissionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "FixedCommissionAmount", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Fixed commission amount.", "label": "Fixed commission amount" } } }, "auth_ref": [] }, "lfwd_FixedCommissionRate": { "xbrltype": "percentItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "FixedCommissionRate", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Fixed commission rate.", "label": "Fixed commission rate" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Authority [Member]", "verboseLabel": "Federal [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionLossBeforeTax", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Loss, before Tax", "terseLabel": "Exchange rate fluctuations", "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement." } } }, "auth_ref": [ "r837", "r838" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Financial Statements in U.S. Dollars", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r510" ] }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails1": { "parentTag": "lfwd_TaxesIncome", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Foreign Income Tax Expense (Benefit), Continuing Operations", "verboseLabel": "Foreign", "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations." } } }, "auth_ref": [ "r221" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Office furniture and equipment [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "lfwd_GeneralAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "GeneralAbstract", "presentation": [ "http://www.rewalk.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "label": "General [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r124", "r660" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails3" ], "lang": { "en-us": { "role": { "label": "General and administrative [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r120" ] }, "lfwd_GeographicInformationAndMajorCustomerAndProductDataAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "GeographicInformationAndMajorCustomerAndProductDataAbstract", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Geographic Information And Major Customer And Product Data [Abstract]" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 40.0 }, "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 140.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails1", "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Goodwill", "verboseLabel": "Goodwill", "terseLabel": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r196", "r305", "r564", "r727", "r743", "r789", "r790" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill, Acquired During Period", "terseLabel": "Purchase of goodwill", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r308", "r727" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r133" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "verboseLabel": "Goodwill and Other Intangibles", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r11", "r56" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r727" ] }, "lfwd_GovernmentGrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "GovernmentGrantsPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for government grants.", "label": "Government Grants [Policy Text Block]", "verboseLabel": "Government grants" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r121", "r220", "r261", "r267", "r272", "r275", "r287", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r505", "r724", "r796" ] }, "lfwd_GuarantorObligationsCollateralPledged": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "GuarantorObligationsCollateralPledged", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Guarantor obligations as collateral pledged.", "label": "Guarantor Obligations Collateral Pledged", "verboseLabel": "Amount pledged as security" } } }, "auth_ref": [] }, "country_IL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "IL", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails", "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails1" ], "lang": { "en-us": { "role": { "label": "Israel [Member]" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IPOMember", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Attestation Flag" } } }, "auth_ref": [ "r760", "r761", "r762" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Impairment losses", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r9", "r61", "r138" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r139" ] }, "lfwd_ImputedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ImputedInterest", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Less: imputed interest.", "negatedLabel": "Less: imputed interest", "label": "Imputed Interest", "verboseLabel": "Less: imputed interest" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r222", "r455" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://www.rewalk.com/role/IncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations", "http://www.rewalk.com/role/IncomeTaxesDetails", "http://www.rewalk.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Loss before taxes, as reported in the consolidated statements of operations", "totalLabel": "Loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r118", "r163", "r261", "r267", "r272", "r275", "r566", "r577", "r724" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r222", "r455" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails3" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r322", "r327", "r661" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails3" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "auth_ref": [ "r327", "r661" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "INCOME TAXES", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r223", "r431", "r437", "r438", "r444", "r451", "r457", "r458", "r459", "r610" ] }, "lfwd_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement1": { "xbrltype": "percentItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement1", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.", "label": "Income Tax Examination Likelihood Of Unfavorable Settlement 1", "verboseLabel": "Maximum percentage of likely to be realized upon ultimate settlement" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Taxes on income", "verboseLabel": "Taxes on income (benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r169", "r181", "r237", "r238", "r264", "r435", "r452", "r580" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r210", "r433", "r434", "r438", "r439", "r443", "r445", "r604" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails4": { "parentTag": "us-gaap_OtherTaxExpenseBenefit", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Operating losses and other temporary differences for which valuation allowance was provided", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r829" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails4": { "parentTag": "us-gaap_OtherTaxExpenseBenefit", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Permanent differences", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r432", "r436" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails4": { "parentTag": "us-gaap_OtherTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Income tax at rate other than the Israeli statutory tax rate", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r829" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails4": { "parentTag": "us-gaap_OtherTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Theoretical tax benefits on the above amount at the Israeli statutory tax rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r436" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails4": { "parentTag": "us-gaap_OtherTaxExpenseBenefit", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Non-deductible expenses including equity-based compensation expenses and other", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r829" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails4": { "parentTag": "us-gaap_OtherTaxExpenseBenefit", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r829" ] }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails4": { "parentTag": "us-gaap_OtherTaxExpenseBenefit", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount", "terseLabel": "Adjustment in respect of prior years", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)." } } }, "auth_ref": [ "r829" ] }, "lfwd_IncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "IncomeTaxesAbstract", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r38", "r41" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 120.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Trade payables", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 100.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade receivables, net", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInDeferredLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredLiabilities", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 110.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Liabilities", "terseLabel": "Deferred revenues", "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 140.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Employees and payroll accruals", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 130.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 80.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Operating lease liabilities and other liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 90.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses, operating lease right-of-use assets and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r8" ] }, "lfwd_IntangibleAssetsNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "IntangibleAssetsNonCurrent", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Non Current", "documentation": "Represent the amount of Intangible assets", "verboseLabel": "Intangible assets" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/FinancialExpensesIncomeNetDetails": { "parentTag": "lfwd_FinancialExpensesAndIncomeNet", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/FinancialExpensesIncomeNetDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense", "verboseLabel": "Financial expenses related to loan agreement with Kreos", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r125", "r346", "r347", "r730", "r731" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 50.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Income (Expense), Net", "negatedLabel": "Interest income", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r165" ] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOther", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/FinancialExpensesIncomeNetDetails": { "parentTag": "lfwd_FinancialExpensesAndIncomeNet", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/FinancialExpensesIncomeNetDetails" ], "lang": { "en-us": { "role": { "label": "Interest Income, Other", "terseLabel": "Interest Income", "negatedLabel": "Interest Income", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "lfwd_InterestReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "InterestReceived", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Received", "documentation": "Represent the amount Cash received from interest", "terseLabel": "Cash received from interest" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/Inventories" ], "lang": { "en-us": { "role": { "label": "INVENTORIES", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r299" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Finished products", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r774" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 30.0 }, "http://www.rewalk.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets", "http://www.rewalk.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Inventories", "totalLabel": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r204", "r717", "r743" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r171", "r192", "r203", "r299", "r300", "r302", "r545", "r721" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r775" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/INVENTORIESNarrativeDetails", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Inventory Write-down", "verboseLabel": "Inventory write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r301" ] }, "lfwd_InvestmentOptionsExercisePrices": { "xbrltype": "perShareItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "InvestmentOptionsExercisePrices", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "documentation": "Exercise price.", "label": "Investment Options Exercise Prices", "verboseLabel": "Exercise price" } } }, "auth_ref": [] }, "lfwd_IsraelInnovationAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "IsraelInnovationAuthorityMember", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Israeli Innovation Authority [Member]", "label": "Israel Innovation Authority [Member]", "terseLabel": "IIA [Member]" } } }, "auth_ref": [] }, "us-gaap_IsraelTaxAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IsraelTaxAuthorityMember", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Israel Tax Authority [Member]", "documentation": "Designated tax department of the government of Israel." } } }, "auth_ref": [] }, "lfwd_IsraeliMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "IsraeliMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Israeli Member", "label": "Israeli [Member]" } } }, "auth_ref": [] }, "lfwd_IssuanceOfOrdinarySharesInPrivatePlacementNetOfIssuanceExpensesPaidInAmountOf3582": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "IssuanceOfOrdinarySharesInPrivatePlacementNetOfIssuanceExpensesPaidInAmountOf3582", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares in a private placement, net of issuance expenses paid in the amount.", "label": "Issuance Of Ordinary Shares In Private Placement Net Of Issuance Expenses Paid In Amount Of 3582", "verboseLabel": "Issuance of ordinary shares in a private placement, net of issuance expenses paid in the amount of $3,679", "terseLabel": "Issuance of ordinary shares in a private placement, net of issuance expenses paid in the amount of $3,679" } } }, "auth_ref": [] }, "lfwd_KreosCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "KreosCapitalMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Kreos Capital [Member]", "label": "Kreos Capital [Member]" } } }, "auth_ref": [] }, "lfwd_KreosCapitalVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "KreosCapitalVMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Kreos Capital V [Member]", "label": "Kreos Capital V [Member]" } } }, "auth_ref": [] }, "srt_LatinAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LatinAmericaMember", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails" ], "lang": { "en-us": { "role": { "label": "Latin America [Member]" } } }, "auth_ref": [ "r859", "r860", "r861", "r862" ] }, "lfwd_LeaseAgreementsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "LeaseAgreementsTerm", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Lease Agreements Term", "documentation": "Represents the amount of lease agreements term.", "verboseLabel": "Leases agreement term" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r137" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual", "http://www.rewalk.com/role/IncomeTaxesDetailsTextual", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r526" ] }, "us-gaap_LesseeOperatingLeaseDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseDescription", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Lease expiration, term", "documentation": "Description of lessee's operating lease." } } }, "auth_ref": [ "r527" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r531" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2022", "terseLabel": "2023", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r531" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2024", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r531" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2023", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r531" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Present value of future lease payments", "totalLabel": "Present value of future lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r531" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r27", "r220", "r287", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r469", "r470", "r471", "r505", "r634", "r723", "r756", "r796", "r841", "r842" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r112", "r162", "r573", "r743", "r779", "r787", "r836" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r29", "r191", "r220", "r287", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r469", "r470", "r471", "r505", "r743", "r796", "r841", "r842" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES", "terseLabel": "CURRENT LIABILITIES:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure", "verboseLabel": "Financial Liabilities", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r92" ] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r23", "r102", "r103", "r104", "r105", "r220", "r287", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r469", "r470", "r471", "r505", "r796", "r841", "r842" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LONG-TERM LIABILITIES" } } }, "auth_ref": [] }, "lfwd_LicenseAgreementAndCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "LicenseAgreementAndCollaborationAgreementMember", "presentation": [ "http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "License Agreement and to the Collaboration Agreement member.", "label": "License Agreement and Collaboration Agreement [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataTables" ], "lang": { "en-us": { "role": { "label": "Schedule of long-lived assets by geographic region", "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets." } } }, "auth_ref": [ "r21" ] }, "lfwd_LongTermEarnoutLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "LongTermEarnoutLiability", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long Term Earnout Liability", "documentation": "Represent the amount of Earnout Liability non current", "verboseLabel": "Earnout liability" } } }, "auth_ref": [] }, "lfwd_MachineryAndLaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "MachineryAndLaboratoryEquipmentMember", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Machinery and laboratory equipment [Member]", "label": "Machinery and laboratory equipment [Member]" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r281", "r735", "r799", "r852", "r853" ] }, "us-gaap_MarketingAndAdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketingAndAdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Marketing and Advertising Expense", "verboseLabel": "Sales and marketing, net", "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising." } } }, "auth_ref": [ "r124" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r332", "r333", "r334", "r335", "r384", "r544", "r587", "r626", "r627", "r682", "r684", "r686", "r687", "r689", "r711", "r712", "r725", "r732", "r741", "r745", "r798", "r843", "r844", "r845", "r846", "r847", "r848" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r332", "r333", "r334", "r335", "r384", "r544", "r587", "r626", "r627", "r682", "r684", "r686", "r687", "r689", "r711", "r712", "r725", "r732", "r741", "r745", "r798", "r843", "r844", "r845", "r846", "r847", "r848" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "verboseLabel": "Money market funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r800" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails2", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "auth_ref": [ "r281", "r735", "r799", "r852", "r853" ] }, "lfwd_NetAggregateProceedsOfAfterDeductingFeesAndOtherRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "NetAggregateProceedsOfAfterDeductingFeesAndOtherRelatedExpenses", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "The net aggregate proceeds of the first tranche closing after deducting fees and other related expenses in the amount of approximately.", "label": "Net aggregate proceeds of after deducting fees and other related expenses" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r216" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r216" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows used in investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows", "http://www.rewalk.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "label": "Negative cash flow from operations", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r127", "r128", "r129" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 30.0 }, "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails", "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows", "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations", "http://www.rewalk.com/role/GeneralDetails", "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss attributable to ordinary shares", "terseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r119", "r129", "r164", "r189", "r208", "r209", "r213", "r220", "r227", "r231", "r232", "r233", "r234", "r237", "r238", "r245", "r261", "r267", "r272", "r275", "r287", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r494", "r505", "r578", "r657", "r674", "r675", "r724", "r754", "r796" ] }, "lfwd_NetOperatingCarryForwardLossesExpirationTerm": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "NetOperatingCarryForwardLossesExpirationTerm", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Net Operating Carry Forward Losses Expiration Term", "documentation": "Net operating carry forward losses expiration term", "verboseLabel": "Net operating carry forward losses expiration term" } } }, "auth_ref": [] }, "lfwd_NetOperatingCarryForwardLossesTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "NetOperatingCarryForwardLossesTerms", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Net operating carry-forward losses, terms.", "label": "Net operating carry-forward losses, terms" } } }, "auth_ref": [] }, "lfwd_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionsQuantification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionsQuantification", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Addition of lease assets and liabilities related to operating leases.", "label": "New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoptions Quantification", "verboseLabel": "Addition of lease assets and liabilities related to operating leases" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of non-cash flow information" } } }, "auth_ref": [] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails1" ], "lang": { "en-us": { "role": { "label": "Long-lived assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r280" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Number of reportable segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r785" ] }, "lfwd_NumberOfSharesExcludedFromDilutedLossPerShareAntiDilutive": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "NumberOfSharesExcludedFromDilutedLossPerShareAntiDilutive", "presentation": [ "http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Shares Excluded From Diluted Loss Per Share Anti Dilutive", "documentation": "Represents the shares excluded from diluted loss per share anti dilutive.", "verboseLabel": "Shares Excluded from Diluted Loss per Share - Anti-Dilutive" } } }, "auth_ref": [] }, "lfwd_NumberOfWarrantsOutstandingTotal": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "NumberOfWarrantsOutstandingTotal", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Total number of warrants outstanding.", "label": "Number Of Warrants Outstanding Total", "terseLabel": "Total number of warrants outstanding" } } }, "auth_ref": [] }, "lfwd_OfferingOfOrdinarySharesInDecember2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "OfferingOfOrdinarySharesInDecember2020Member", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Offering of ordinary shares in December 2020 [Member]", "label": "Offering of ordinary shares in December 2020 [Member]" } } }, "auth_ref": [] }, "lfwd_OfferingOfOrdinarySharesInFebruary2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "OfferingOfOrdinarySharesInFebruary2020Member", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Offering of ordinary shares in February 2020 [Member]", "label": "Offering of ordinary shares in February 2020 [Member]" } } }, "auth_ref": [] }, "lfwd_OfferingOfOrdinarySharesInFebruary2020TwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "OfferingOfOrdinarySharesInFebruary2020TwoMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Offering of ordinary shares in February 2020 Two [Member]", "label": "Offering of ordinary shares in February 2020 Two [Member]" } } }, "auth_ref": [] }, "lfwd_OfferingOfOrdinarySharesInJuly2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "OfferingOfOrdinarySharesInJuly2020Member", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Offering of ordinary shares in July 2020 [Member]", "label": "Offering of ordinary shares in July 2020 [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r261", "r267", "r272", "r275", "r724" ] }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncomeLeasePayments", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Rent expenses", "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r253", "r532" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails", "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: current maturities of operating leases", "label": "Current maturities of operating leases", "terseLabel": "Current maturities of operating leases liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r525" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails", "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current operating leases", "terseLabel": "Non-current operating leases liability", "totalLabel": "Non-current operating leases", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r525" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r524" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r530", "r742" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term (in years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r529", "r742" ] }, "lfwd_OperatingLeasesMaximumPenaltiesPayableOnEarlyReleaseOfAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "OperatingLeasesMaximumPenaltiesPayableOnEarlyReleaseOfAgreement", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Represents the maximum amount of penalties payable on early release of lease agreement.", "label": "Operating Leases Maximum Penalties Payable On Early Release Of Agreement" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Carry-forward losses", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r80" ] }, "us-gaap_OperatingLossCarryforwardsExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsExpirationDate", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards, Expiration Date", "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format." } } }, "auth_ref": [ "r80" ] }, "lfwd_OperatingLossCarryforwardsPriorPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "OperatingLossCarryforwardsPriorPeriod", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards Prior Period", "documentation": "Represents the amount of operating loss carryforwards prior period.", "verboseLabel": "Operating loss carry forwards prior period" } } }, "auth_ref": [] }, "us-gaap_OrderOrProductionBacklogMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrderOrProductionBacklogMember", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2" ], "lang": { "en-us": { "role": { "label": "Order or Production Backlog [Member]", "terseLabel": "Backlog [Member]", "documentation": "Orders, production or production backlog arising from contracts such as purchase or sales orders acquired in a business combination." } } }, "auth_ref": [ "r89" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/General" ], "lang": { "en-us": { "role": { "label": "GENERAL", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r101", "r156", "r601", "r602" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r206", "r743" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Restricted cash and other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r197" ] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsLineItems", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsTable", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/FinancialExpensesIncomeNetDetails": { "parentTag": "lfwd_FinancialExpensesAndIncomeNet", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/FinancialExpensesIncomeNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign currency transactions and other", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "verboseLabel": "Foreign currency transactions and other", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/FinancialExpensesIncomeNet" ], "lang": { "en-us": { "role": { "label": "FINANCIAL EXPENSES (INCOME), NET", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r146", "r149" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r28", "r743" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r30" ] }, "us-gaap_OtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermDebt", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Other Long-Term Debt", "terseLabel": "Restricted cash and other long-term assets", "totalLabel": "Other Long-Term Debt, Total", "documentation": "Amount of long-term debt classified as other." } } }, "auth_ref": [ "r23", "r161", "r850" ] }, "us-gaap_OtherTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails4": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Other Tax Expense (Benefit)", "totalLabel": "Actual tax expense (benefit)", "documentation": "Amount of other income tax expense (benefit)." } } }, "auth_ref": [ "r221", "r828", "r832" ] }, "lfwd_PaymentToRepurchaseOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "PaymentToRepurchaseOfShares", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment To Repurchase Of Shares", "documentation": "Represent amount of cash out flow of shares repurchased not yet paid.", "terseLabel": "Amounts related to shares re-purchase not yet paid" } } }, "auth_ref": [] }, "lfwd_PaymentsForPurchaseOfTreasuryStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "PaymentsForPurchaseOfTreasuryStock", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount represents for Payments For Purchase Of Treasury Stock.", "negatedLabel": "Purchase of treasury shares", "label": "Payments For Purchase Of Treasury Stock" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Royalties paid", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Issuance expenses paid", "verboseLabel": "Issuance expenses", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r36" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Gross", "verboseLabel": "Cash and cash equivalent", "terseLabel": "Aggregate purchase price in cash", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r35", "r467" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition of a business, net of cash acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r35" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r126" ] }, "lfwd_PercentageOfGrantReceivedConsideredToDetermineRoyaltyFees": { "xbrltype": "percentItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "PercentageOfGrantReceivedConsideredToDetermineRoyaltyFees", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of grant received considered to determine royalty fees.", "label": "Percentage Of Grant Received Considered To Determine Royalty Fees" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826" ] }, "us-gaap_PostemploymentBenefitPlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PostemploymentBenefitPlansPolicy", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accrued Severance Pay", "documentation": "Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans." } } }, "auth_ref": [ "r375" ] }, "us-gaap_PostemploymentBenefitsPeriodExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PostemploymentBenefitsPeriodExpense", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Severance pay expense", "documentation": "Period expense related to postemployment benefits." } } }, "auth_ref": [] }, "lfwd_PreFundedUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "PreFundedUnitsMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Pre-funded units [Member]", "label": "Pre-funded units [Member]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 20.0 }, "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets", "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets", "verboseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r776" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]" } } }, "auth_ref": [] }, "lfwd_PrepaidExpenseAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "PrepaidExpenseAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssets" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for prepaid expenses and other current assets.", "label": "Prepaid Expense And Other Assets Disclosure Text Block", "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r205", "r303", "r304", "r718" ] }, "lfwd_PrepaidExpensesToGovernmentInstitutionsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "PrepaidExpensesToGovernmentInstitutionsCurrent", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance to government institutions.", "label": "Prepaid Expenses To Government Institutions Current" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual", "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Issuance of ordinary shares in a private placement, net of issuance expenses in the amount of $959", "verboseLabel": "Total gross proceeds received from the follow-on public offering", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r6" ] }, "lfwd_ProceedsFromIssuanceOfRegistrationCostTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ProceedsFromIssuanceOfRegistrationCostTwo", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares in a \"registered direct\" offering, net of issuance expenses in the amount.", "label": "Proceeds From Issuance Of Registration Cost Two", "terseLabel": "Issuance of ordinary shares in a \u201cregistered direct\u201d offering, net of issuance expenses in the amount of $3,215" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRoyaltiesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRoyaltiesReceived", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Total fund received", "documentation": "Cash received for royalties during the current period." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Gross proceeds", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Proceeds From Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r777" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.rewalk.com/role/TestrereDetails" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r733" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual", "http://www.rewalk.com/role/TestrereDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r277", "r546", "r581", "r582", "r583", "r584", "r585", "r586", "r714", "r733", "r744", "r771", "r793", "r794", "r799", "r852" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual", "http://www.rewalk.com/role/TestrereDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r277", "r546", "r581", "r582", "r583", "r584", "r585", "r586", "r714", "r733", "r744", "r771", "r793", "r794", "r799", "r852" ] }, "lfwd_PropertyAndEquipmentNetTextualAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "PropertyAndEquipmentNetTextualAbstract", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Property And Equipment Net Textual Abstract" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Axis]", "verboseLabel": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNet" ], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT, NET", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r136", "r175", "r178", "r179" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r137", "r194", "r576" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets", "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r568", "r576", "r743" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r10", "r175", "r178", "r574" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of components of Property and Equipment, Net", "terseLabel": "Schedule of components of property and equipment, net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r137" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "lfwd_PropertyPlantAndEquipmentUsefulLifeDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "PropertyPlantAndEquipmentUsefulLifeDescription", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment Useful Life Description", "documentation": "Property plant and equipment useful life description." } } }, "auth_ref": [] }, "lfwd_PurchaseAgreementWithCertainInstitutionalAccerditedInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "PurchaseAgreementWithCertainInstitutionalAccerditedInvestorsMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Purchase agreement with certain institutional and accredited investors [Member]", "label": "Purchase Agreement With Certain Institutional Accerdited Investors Member" } } }, "auth_ref": [] }, "lfwd_PurchaseAgreementWithCertainInstitutionalInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "PurchaseAgreementWithCertainInstitutionalInvestorsMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Purchase agreement with certain institutional investors [Member]", "label": "Purchase agreement with certain institutional investors [Member]" } } }, "auth_ref": [] }, "lfwd_PurchaseAgreementWithCertainInstitutionalInvestorsOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "PurchaseAgreementWithCertainInstitutionalInvestorsOneMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Purchase agreement with certain institutional investors [Member]", "label": "Purchase Agreement With Certain Institutional Investors One Member", "verboseLabel": "Purchase agreement with certain institutional investors [Member]" } } }, "auth_ref": [] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Non-cancelable outstanding obligations", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual", "http://www.rewalk.com/role/IncomeTaxesDetailsTextual", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "verboseLabel": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r332", "r333", "r334", "r335", "r376", "r384", "r414", "r415", "r416", "r543", "r544", "r587", "r626", "r627", "r682", "r684", "r686", "r687", "r689", "r711", "r712", "r725", "r732", "r741", "r745", "r748", "r791", "r798", "r844", "r845", "r846", "r847", "r848" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual", "http://www.rewalk.com/role/IncomeTaxesDetailsTextual", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r332", "r333", "r334", "r335", "r376", "r384", "r414", "r415", "r416", "r543", "r544", "r587", "r626", "r627", "r682", "r684", "r686", "r687", "r689", "r711", "r712", "r725", "r732", "r741", "r745", "r748", "r791", "r798", "r844", "r845", "r846", "r847", "r848" ] }, "lfwd_ReStoreProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ReStoreProductMember", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "ReStore product [Member]", "label": "Re Store Product [Member]" } } }, "auth_ref": [] }, "lfwd_ReWalkRoboticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ReWalkRoboticsIncMember", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the ReWalk Robotics Inc., a wholly-owned subsidiary of the entity.", "label": "Re Walk Robotics Inc [Member]" } } }, "auth_ref": [] }, "lfwd_RegisteredDirectMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RegisteredDirectMember", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Registered Direct.", "label": "Registered Direct [Member]" } } }, "auth_ref": [] }, "lfwd_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RegisteredDirectOfferingMember", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Registered Direct [Member]", "label": "Registered Direct Offering Member", "verboseLabel": "Registered Direct [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r383", "r538", "r539", "r629", "r630", "r631", "r632", "r633", "r654", "r656", "r681" ] }, "lfwd_RelatedPartyTransactionOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RelatedPartyTransactionOwnershipPercentage", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Related party transaction, ownership percentage.", "label": "Related Party Transaction Ownership Percentage" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r383", "r538", "r539", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r629", "r630", "r631", "r632", "r633", "r654", "r656", "r681", "r840" ] }, "lfwd_RentalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RentalMember", "presentation": [ "http://www.rewalk.com/role/TestrereDetails" ], "lang": { "en-us": { "role": { "label": "Rental [Member]", "documentation": "The member stands for rental." } } }, "auth_ref": [] }, "lfwd_RentalRevenueForAntiGravityProducts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RentalRevenueForAntiGravityProducts", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Rental Revenue For Anti Gravity Products", "documentation": "Represents the amount of rental revenue for anti-gravity products.", "verboseLabel": "Rental revenue for anti-gravity products" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAbstract", "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "auth_ref": [] }, "lfwd_ResearchAndDevelopmentAmountReceivedInConsiderationOfConvertiblePreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ResearchAndDevelopmentAmountReceivedInConsiderationOfConvertiblePreferredShares", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Represents the portion of aggregate amount received in consideration of convertible preferred shares by the entity to fund research and development activity.", "label": "Research And Development Amount Received In Consideration Of Convertible Preferred Shares" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "presentation": [ "http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r430", "r827" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations", "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIESNarrativeDetails", "http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "verboseLabel": "Research and development, net", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r100", "r429", "r849" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails3" ], "lang": { "en-us": { "role": { "label": "Research and development, net [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r428" ] }, "lfwd_ResearchAndDevelopmentRoyaltyBearingGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ResearchAndDevelopmentRoyaltyBearingGrants", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Represents the portion of aggregate amount received as royalty bearing grants by the entity to fund research and development activity.", "label": "Research And Development Royalty Bearing Grants" } } }, "auth_ref": [] }, "lfwd_ResearchCollaborationAgreementAndLicenseAgreementTextualAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ResearchCollaborationAgreementAndLicenseAgreementTextualAbstract", "presentation": [ "http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Research Collaboration Agreement And License Agreement Textual Abstract" } } }, "auth_ref": [] }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreement" ], "lang": { "en-us": { "role": { "label": "RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT", "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period." } } }, "auth_ref": [ "r166", "r430" ] }, "lfwd_RestOfWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RestOfWorldMember", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails" ], "lang": { "en-us": { "role": { "label": "Rest Of World [Member]", "documentation": "Rest of the world member." } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents, Current", "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r39", "r193", "r217" ] }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash included in other long-term assets", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r39", "r170", "r217" ] }, "lfwd_RestrictedCashAndOtherLongTermAssets": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RestrictedCashAndOtherLongTermAssets", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for other long term assets.", "label": "Restricted Cash And Other Long Term Assets", "verboseLabel": "Restricted Cash and Other Long-Term Assets" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "lfwd_RestructringActivitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RestructringActivitiesLineItems", "presentation": [ "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Restructring Activities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIES" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r324", "r325", "r326", "r328", "r329" ] }, "lfwd_RestructuringAndRelatedActivitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RestructuringAndRelatedActivitiesTable", "presentation": [ "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring And Related Activities [Table]", "documentation": "Disclosure of information about Restructuring activity." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets", "http://www.rewalk.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r109", "r143", "r572", "r594", "r599", "r609", "r637", "r743" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r186", "r224", "r225", "r226", "r228", "r236", "r238", "r291", "r297", "r420", "r421", "r422", "r449", "r450", "r475", "r478", "r479", "r482", "r492", "r590", "r592", "r611", "r857" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Deferred revenue recognized", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r262", "r263", "r266", "r270", "r271", "r277", "r279", "r281", "r373", "r374", "r546" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r182", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r713" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataTables" ], "lang": { "en-us": { "role": { "label": "Schedule of revenues within geographic areas", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r20" ] }, "lfwd_RevenueObligationAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RevenueObligationAxis", "presentation": [ "http://www.rewalk.com/role/TestrereDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue Obligation [Axis]", "label": "Revenue Obligation [Axis]" } } }, "auth_ref": [] }, "lfwd_RevenueObligationDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RevenueObligationDomain", "presentation": [ "http://www.rewalk.com/role/TestrereDetails" ], "lang": { "en-us": { "role": { "label": "Revenue Obligation [Domain]" } } }, "auth_ref": [] }, "lfwd_RevenueRecognitionRecognized": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RevenueRecognitionRecognized", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Revenue Recognition Recognized", "label": "Revenue Recognition Recognized" } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of disaggregation of revenues", "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [ "r768" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails", "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations", "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails", "http://www.rewalk.com/role/TestrereDetails" ], "lang": { "en-us": { "role": { "positiveLabel": "Revenue", "label": "Revenues", "terseLabel": "Total revenues", "verboseLabel": "Total Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r214", "r220", "r262", "r263", "r266", "r270", "r271", "r277", "r279", "r281", "r287", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r505", "r566", "r796" ] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails1" ], "lang": { "en-us": { "role": { "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "lfwd_RewalkRoboticsGmbhMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RewalkRoboticsGmbhMember", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "ReWalk Robotics GMBH", "label": "Rewalk Robotics Gmbh [Member]" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "ROU assets obtained from new lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r528", "r742" ] }, "lfwd_RoyaltyBearingGrantsExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RoyaltyBearingGrantsExpenses", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Represents the expenses related to royalty bearing grants.", "label": "Royalty-bearing grants expenses" } } }, "auth_ref": [] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Royalty expenses", "verboseLabel": "Royalties expenses", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r123" ] }, "lfwd_RoyaltyFeesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RoyaltyFeesPercentage", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of royalty fees.", "label": "Royalty Fees Percentage" } } }, "auth_ref": [] }, "lfwd_RrlAndRrgMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "RrlAndRrgMember", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "RRL and RRG [Member]", "label": "RRL and RRG [Member]" } } }, "auth_ref": [] }, "lfwd_SCIProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "SCIProductsMember", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "SCI Products [Member]", "label": "SCI Products [Member]" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual", "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual", "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2" ], "lang": { "en-us": { "role": { "label": "Sales Revenue, Net [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r281", "r769" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails", "http://www.rewalk.com/role/ACQUISITIONOFALTERGNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r84", "r85", "r462" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of taxes on income", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r152" ] }, "lfwd_ScheduleOfContractBalancesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ScheduleOfContractBalancesTableTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of of Contract balances.", "label": "Schedule Of Contract Balances [Table Text Block]", "verboseLabel": "Schedule of contract balances" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of deferred income taxes", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r151" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation between the theoretical tax expense and the actual tax expense (benefit)", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r150" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails3" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r76" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of non-cash share-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r76" ] }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails", "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails2" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers." } } }, "auth_ref": [ "r131" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Schedule of intangible assets acquired", "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r58", "r59", "r547" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r58", "r59" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r727" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of loss before taxes on income", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r780" ] }, "lfwd_ScheduleOfIncomeTaxLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ScheduleOfIncomeTaxLineItems", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Schedule of Income Tax Line Items", "label": "Schedule Of Income Tax Line Items" } } }, "auth_ref": [] }, "lfwd_ScheduleOfIncomeTaxTable": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ScheduleOfIncomeTaxTable", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about income tax.", "label": "Schedule of Income Tax [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.rewalk.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of inventories", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r25", "r113", "r114", "r115" ] }, "lfwd_ScheduleOfMinimumRoyaltyPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ScheduleOfMinimumRoyaltyPaymentsTableTextBlock", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the Minimum Royalty Payments.", "label": "Schedule Of Minimum Royalty Payments Table Text Block", "terseLabel": "Schedule of minimum royalty payments" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.rewalk.com/role/FinancialExpensesIncomeNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of financial expenses, net", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.rewalk.com/role/PropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Public Utility Property, Plant, and Equipment [Table Text Block]", "terseLabel": "Public Utility Property, Plant, and Equipment", "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": [ "r99" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of preliminary fair value of assets acquired and liabilities", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r155" ] }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "presentation": [ "http://www.rewalk.com/role/ResearchCollaborationAgreementAndLicenseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements." } } }, "auth_ref": [ "r430", "r827" ] }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataTables" ], "lang": { "en-us": { "role": { "label": "Schedule of major customer data as a percentage of total revenues", "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails1" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r55", "r117" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r386", "r388", "r389", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r413", "r414", "r415", "r416", "r417" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r69" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of options and RSUs outstanding", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": [ "r69" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of employee and non-employee shares options activity", "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Goods and Nonemployee Services Transaction [Table]", "documentation": "Details pertaining to each transaction in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting made, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows." } } }, "auth_ref": [ "r167", "r168" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of employee and non-employee RSUs activity", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrants outstanding and exercisable", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r68" ] }, "lfwd_ScheduleOfWarrantsLiabilityActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ScheduleOfWarrantsLiabilityActivityTableTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Warrants Liability Activity [Table Text Block]", "documentation": "Tabular disclosure of schedule of warrants liability activity.", "verboseLabel": "Schedule of warrants liability activity" } } }, "auth_ref": [] }, "lfwd_ScheduleOfWarrantyProvisionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ScheduleOfWarrantyProvisionTableTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Warranty Provision [Table Text Block]", "verboseLabel": "Schedule of warranty provision", "documentation": "Tabular disclosure of warranty provision." } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of future amortization expense", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r59" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of concentration of credit risk", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r47", "r48", "r50", "r51", "r94", "r159" ] }, "us-gaap_SecuritiesLoanedMeasurementDifferenceDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuritiesLoanedMeasurementDifferenceDescription", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Description of tranche consisting", "documentation": "Description of measurement difference between recognized amounts and resulting measurement differences for securities loaned." } } }, "auth_ref": [ "r116" ] }, "lfwd_SecuritiesPurchaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "SecuritiesPurchaseAgreementsMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreements [Member]", "label": "Securities Purchase Agreements [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r757" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Name of Exchange on which Security is Registered", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r759" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails", "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails1" ], "auth_ref": [ "r279", "r280", "r623", "r624", "r625", "r683", "r685", "r688", "r690", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r715", "r734", "r748", "r799", "r852" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductData" ], "lang": { "en-us": { "role": { "label": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r257", "r258", "r259", "r260", "r261", "r265", "r269", "r273", "r274", "r275", "r276", "r277", "r278", "r281" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations", "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails3" ], "lang": { "en-us": { "role": { "label": "Sales and marketing, net [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r120" ] }, "lfwd_ServiceAndWarrantyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ServiceAndWarrantyMember", "presentation": [ "http://www.rewalk.com/role/TestrereDetails" ], "lang": { "en-us": { "role": { "label": "Service And Warranty [Member]", "documentation": "The member stands for Service and warranty." } } }, "auth_ref": [] }, "lfwd_SeverancePayMonthlyDepositByEmployeesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "SeverancePayMonthlyDepositByEmployeesPercentage", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of monthly deposit required by employees as per the severance pay law.", "label": "Severance Pay Monthly Deposit By Employees Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, restricted stock units (in USD per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r404" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "label": "RSUs outstanding", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r401", "r402" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r405" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r386", "r388", "r389", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r413", "r414", "r415", "r416", "r417" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "label": "Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r16" ] }, "lfwd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedOutstandingRollForwardAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedOutstandingRollForwardAbstract", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Nonvested Outstanding Roll Forward Abstract" } } }, "auth_ref": [] }, "lfwd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageExercisePriceRollForwardAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageExercisePriceRollForwardAbstract", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Exercise Price Roll Forward Abstract" } } }, "auth_ref": [] }, "lfwd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstandingNumber", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options and Equity Instruments Other than Options, Outstanding, Number", "periodEndLabel": "Unvested RSUs at the end of the period", "periodStartLabel": "Unvested RSUs at the Beginning of the period", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Outstanding Number" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Number, Options exercisable at the end of the period", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r395" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Average exercise price, Options exercisable at the end of the period", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r395" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number, Forfeited", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r399" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Number, Granted", "verboseLabel": "Options granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r397" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, options (in USD per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r407" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value (in thousands), Options outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r69" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number, Options outstanding at the end of the period", "periodStartLabel": "Number, Options outstanding at the beginning of the period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r393", "r394" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Average exercise price, Options outstanding at the end of the period", "periodStartLabel": "Average exercise price, Options outstanding at the beginning of the period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r393", "r394" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1", "http://www.rewalk.com/role/ShareholdersEquityDetails2", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r389", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r413", "r414", "r415", "r416", "r417" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Average exercise price, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r398" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Average exercise price, Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r399" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Average exercise price, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r397" ] }, "lfwd_ShareBasedCompensationArrangementsByShareBasedPaymentRestrictedStockOptionsForfeitedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentRestrictedStockOptionsForfeitedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options forfeited.", "label": "Share Based Compensation Arrangements By Share Based Payment Restricted Stock Options Forfeited In Period Weighted Average Exercise Price" } } }, "auth_ref": [] }, "lfwd_ShareBasedCompensationArrangementsByShareBasedPaymentRestrictedStockOptionsGrantedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentRestrictedStockOptionsGrantedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options granted.", "label": "Share Based Compensation Arrangements By Share Based Payment Restricted Stock Options Granted In Period Weighted Average Exercise Price", "verboseLabel": "Granted" } } }, "auth_ref": [] }, "lfwd_ShareBasedCompensationArrangementsByShareBasedPaymentRestrictedStockOptionsVestedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentRestrictedStockOptionsVestedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options vested.", "label": "Share Based Compensation Arrangements By Share Based Payment Restricted Stock Options Vested In Period Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounting for Share-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r385", "r392", "r411", "r412", "r413", "r414", "r417", "r423", "r424", "r425", "r426" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r74" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "label": "Range of exercise price, minimum", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "label": "Options outstanding and exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r72" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "label": "Options outstanding", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "label": "Range of exercise price, maximum", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionLineItems", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Share-based Goods and Nonemployee Services Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "lfwd_ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ShareRepurchaseProgramMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Share repurchase program [Member]", "label": "Share Repurchase Program [Member]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Expected term (in years)", "verboseLabel": "Expected term of shares", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r413" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value (in thousands), Options exercisable at the end of the period", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r69" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Average remaining contractual life (in years), Options exercisable at the end of the period", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r69" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Average remaining contractual life (in years), Options outstanding at the beginning of the period", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r147" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Total fair value of shares vested", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r408" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "label": "Options exercisable weighted average remaining contractual life (years)", "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r148" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails2" ], "lang": { "en-us": { "role": { "label": "Options outstanding weighted average remaining contractual life (years)", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r147" ] }, "lfwd_SharebasedCompensationSharesAuthorizedUnderStockOptionsPlansExercisePriceRangeOutstandingOptionsAndEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionsPlansExercisePriceRangeOutstandingOptionsAndEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails1" ], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Options Plans, Exercise Price Range, Outstanding Options and Equity Instruments Other than Options, Weighted Average Exercise Price", "periodEndLabel": "Unvested RSUs at the end of the period", "periodStartLabel": "Unvested RSUs at the Beginning of the period", "label": "Sharebased Compensation Shares Authorized Under Stock Options Plans Exercise Price Range Outstanding Options And Equity Instruments Other Than Options Weighted Average Exercise Price" } } }, "auth_ref": [] }, "lfwd_ShareholdersEquityTextualAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ShareholdersEquityTextualAbstract", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Shareholders Equity Textual Abstract" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Shares issued price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "lfwd_Sharesissuedduringperiodvaluetreasurystock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "Sharesissuedduringperiodvaluetreasurystock", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The amount represent shares issued during period value treasury stock.", "label": "Sharesissuedduringperiodvaluetreasurystock", "terseLabel": "Treasury shares at cost" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r130", "r218" ] }, "lfwd_SignificantAccountingPoliciesTextualAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "SignificantAccountingPoliciesTextualAbstract", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies Textual Abstract" } } }, "auth_ref": [] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyPolicy", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Warranty", "verboseLabel": "Warranty Provision", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": [ "r795" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "verboseLabel": "State [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r183", "r199", "r200", "r201", "r220", "r243", "r244", "r246", "r248", "r255", "r256", "r287", "r336", "r338", "r339", "r340", "r343", "r344", "r349", "r350", "r352", "r355", "r362", "r505", "r605", "r606", "r607", "r608", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r636", "r658", "r676", "r691", "r692", "r693", "r694", "r695", "r767", "r778", "r784" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r33", "r186", "r211", "r212", "r213", "r224", "r225", "r226", "r228", "r236", "r238", "r254", "r291", "r297", "r364", "r420", "r421", "r422", "r449", "r450", "r475", "r477", "r478", "r479", "r480", "r482", "r492", "r512", "r513", "r514", "r515", "r516", "r517", "r537", "r590", "r591", "r592", "r611", "r676" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails", "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails1" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r279", "r280", "r623", "r624", "r625", "r683", "r685", "r688", "r690", "r697", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r715", "r734", "r748", "r799", "r852" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails", "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity", "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquityParenthetical", "http://www.rewalk.com/role/TestrereDetails" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r224", "r225", "r226", "r254", "r546", "r603", "r622", "r628", "r629", "r630", "r631", "r632", "r633", "r636", "r639", "r640", "r641", "r642", "r643", "r645", "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r656", "r659", "r660", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r676", "r749" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "http://www.rewalk.com/role/SignificantAccountingPoliciesDetails", "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity", "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquityParenthetical", "http://www.rewalk.com/role/TestrereDetails" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r224", "r225", "r226", "r254", "r546", "r603", "r622", "r628", "r629", "r630", "r631", "r632", "r633", "r636", "r639", "r640", "r641", "r642", "r643", "r645", "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r656", "r659", "r660", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r676", "r749" ] }, "lfwd_StockIssuedDuringPeriodShareOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodShareOrdinaryShares", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Issuance of ordinary shares, shares.", "label": "Stock Issued During Period Share Ordinary Shares" } } }, "auth_ref": [] }, "lfwd_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesInNetOfWarrantExerciseIssuanceExpenses": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesInNetOfWarrantExerciseIssuanceExpenses", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issuance of ordinary shares in a \"Warrant exercise\" agreement, net of issuance expenses in the amount.", "label": "Stock Issued During Period Shares Issuance Of Ordinary Shares In Net Of Warrant Exercise Issuance Expenses" } } }, "auth_ref": [] }, "lfwd_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesInRegisteredDirectNetOfIssuanceExpenses": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesInRegisteredDirectNetOfIssuanceExpenses", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issuance of ordinary shares in a \"Registered Direct\" offerings , net of issuance expenses in the amount.", "label": "Stock Issued During Period Shares Issuance Of Ordinary Shares In Registered Direct Net Of Issuance Expenses" } } }, "auth_ref": [] }, "lfwd_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesInRegisteredDirectNetOfIssuanceExpenses1": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesInRegisteredDirectNetOfIssuanceExpenses1", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of further shares issuance of ordinary shares in a registered direct offerings, net of issuance expenses in the amount.", "label": "Stock Issued During Period Shares Issuance Of Ordinary Shares In Registered Direct Net Of Issuance Expenses1", "terseLabel": "Issuance of ordinary shares in a \"registered direct\" offering, net of issuance expenses, shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Issuance of ordinary shares (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r14", "r106", "r107", "r143", "r605", "r676", "r692" ] }, "lfwd_StockIssuedDuringPeriodSharesOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodSharesOrdinaryShares", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issuance of ordinary shares in a \"best efforts\" offering, net of issuance expenses in the amount.", "label": "Stock Issued During Period Shares Ordinary Shares" } } }, "auth_ref": [] }, "lfwd_StockIssuedDuringPeriodSharesOrdinaryShares1": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodSharesOrdinaryShares1", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of further shares issuance of ordinary shares in a \"best efforts\" offering, net of issuance expenses in the amount.", "label": "Stock Issued During Period Shares Ordinary Shares1", "terseLabel": "Issuance of ordinary shares in a \"Best Efforts\" offering, net of issuance expenses, shares" } } }, "auth_ref": [] }, "lfwd_StockIssuedDuringPeriodSharesPrivatePlacement": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodSharesPrivatePlacement", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period under private placement.", "label": "Stock Issued During Period Shares Private Placement" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of ordinary shares upon vesting of RSUs by employees and non-employees, shares", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r14", "r106", "r107", "r143" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Number, Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r14", "r106", "r107", "r143", "r398" ] }, "lfwd_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesInNetOfWarrantExerciseIssuanceExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesInNetOfWarrantExerciseIssuanceExpenses", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of issuance of ordinary shares in a \"Warrant exercise\" agreement, net of issuance expenses in the amount.", "label": "Stock Issued During Period Value Issuance Of Ordinary Shares In Net Of Warrant Exercise Issuance Expenses" } } }, "auth_ref": [] }, "lfwd_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesInRegisteredDirectNetOfIssuanceExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesInRegisteredDirectNetOfIssuanceExpenses", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of issuance of ordinary shares in a \"Registered Direct\" offerings , net of issuance expenses in the amount.", "label": "Stock Issued During Period Value Issuance Of Ordinary Shares In Registered Direct Net Of Issuance Expenses" } } }, "auth_ref": [] }, "lfwd_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesInRegisteredDirectNetOfIssuanceExpenses1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesInRegisteredDirectNetOfIssuanceExpenses1", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of further issuance of ordinary shares in a registered direct offerings, net of issuance expenses in the amount.", "label": "Stock Issued During Period Value Issuance Of Ordinary Shares In Registered Direct Net Of Issuance Expenses1", "terseLabel": "Issuance of ordinary shares in a \"registered direct\" offering, net of issuance expenses" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r14", "r106", "r107", "r143", "r611", "r676", "r692", "r755" ] }, "lfwd_StockIssuedDuringPeriodValueNewIssuesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodValueNewIssuesGross", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, New Issues, Gross", "label": "Stock Issued During Period Value New Issues Gross" } } }, "auth_ref": [] }, "lfwd_StockIssuedDuringPeriodValueOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodValueOrdinaryShares", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of issuance of ordinary shares in a \"best efforts\" offering, net of issuance expenses.", "label": "Stock Issued During Period Value Ordinary Shares" } } }, "auth_ref": [] }, "lfwd_StockIssuedDuringPeriodValueOrdinaryShares1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodValueOrdinaryShares1", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of further issuance of ordinary shares in a \"best efforts\" offering, net of issuance expenses.", "label": "Stock Issued During Period Value Ordinary Shares1", "terseLabel": "Issuance of ordinary shares in a \"Best Efforts\" offering, net of issuance expenses" } } }, "auth_ref": [] }, "lfwd_StockIssuedDuringPeriodValuePrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "StockIssuedDuringPeriodValuePrivatePlacement", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period under private placement.", "label": "Stock Issued During Period Value Private Placement" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of ordinary shares upon vesting of RSUs by employees and non-employees", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r73", "r106", "r107", "r143" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Number of ordinary shares repurchased, amount", "verboseLabel": "Authorized value of stock repurchased", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Outstanding ordinary shares repurchased, shares", "verboseLabel": "Authorized number of stock repurchased", "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets", "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance", "periodStartLabel": "Balance", "label": "Equity, Attributable to Parent", "totalLabel": "Total shareholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r107", "r110", "r111", "r132", "r638", "r655", "r677", "r678", "r743", "r756", "r779", "r787", "r836", "r857" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity:", "verboseLabel": "SHAREHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "SHAREHOLDERS' EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r141", "r219", "r348", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r360", "r361", "r364", "r483", "r679", "r680", "r696" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Reverse share split, description", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r144" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.rewalk.com/role/CommitmentsAndContingentLiabilitiesDetailsTextual", "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual", "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of net changes in total valuation allowance", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r79" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash as shown in the consolidated statements of cash flows" } } }, "auth_ref": [] }, "lfwd_SupplementalDisclosuresOfCashFlowInformation": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "SupplementalDisclosuresOfCashFlowInformation", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Supplemental Disclosures of Cash Flow Information.", "verboseLabel": "Supplemental disclosures of cash flow information:" } } }, "auth_ref": [] }, "us-gaap_Supplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Supplies", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Advances to vendors", "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r719", "r726", "r788" ] }, "lfwd_TaxesIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "TaxesIncome", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "documentation": "Taxes on income.", "label": "Taxes Income", "totalLabel": "Taxes on income" } } }, "auth_ref": [] }, "lfwd_TaxesOnIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "TaxesOnIncome", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/IncomeTaxesDetails1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "documentation": "Taxes on income.", "label": "Taxes On Income", "totalLabel": "Taxes on income" } } }, "auth_ref": [] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails" ], "lang": { "en-us": { "role": { "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r22" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r786", "r839" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TrademarksMember", "presentation": [ "http://www.rewalk.com/role/ACQUISITIONOFALTERGDetails2", "http://www.rewalk.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademark", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r88" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.rewalk.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "lfwd_TreasurySharesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "TreasurySharesPolicyTextBlock", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Represents the accounting policy for treasury shares.", "label": "Treasury Shares [Policy Text Block]", "terseLabel": "Treasury shares" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock common shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r66" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.rewalk.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.rewalk.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury Shares at cost, 4,022,607 and 2,933,208 ordinary shares at December 31, 2023 and December 31, 2022 respectively", "label": "Treasury Stock, Common, Value", "terseLabel": "Treasury Shares at cost, 184,629 ordinary shares", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r34", "r66", "r67" ] }, "us-gaap_TreasuryStockPreferredMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockPreferredMember", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Preferred [Member]", "verboseLabel": "Treasury Shares [Member]", "documentation": "Previously issued preferred shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r66" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury shares at cost (shares)", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r14", "r107", "r143" ] }, "lfwd_TwoZeroTwoThreeReorganizationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "TwoZeroTwoThreeReorganizationPlanMember", "presentation": [ "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Two Zero Two Three Reorganization Plan [Member]", "documentation": "2023 Reorganization Plan", "verboseLabel": "2023 Reorganization Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r184", "r185", "r186", "r187", "r188", "r227", "r228", "r229", "r230", "r239", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r323", "r420", "r421", "r422", "r447", "r448", "r449", "r450", "r464", "r465", "r466", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r503", "r504", "r506", "r507", "r508", "r509", "r518", "r519", "r520", "r521", "r522", "r523", "r533", "r534", "r535", "r536", "r537", "r548", "r549", "r550", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ] }, "lfwd_TypeOfCurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "TypeOfCurrencyAxis", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Type of Currency [Axis]", "label": "Type Of Currency [Axis]" } } }, "auth_ref": [] }, "lfwd_TypeofCurrencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "TypeofCurrencyDomain", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails", "http://www.rewalk.com/role/GeographicInformationAndMajorCustomerAndProductDataDetails1" ], "lang": { "en-us": { "role": { "label": "United States [Member]" } } }, "auth_ref": [] }, "us-gaap_USTreasuryAndGovernmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryAndGovernmentMember", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails4" ], "lang": { "en-us": { "role": { "label": "US Treasury and Government [Member]", "verboseLabel": "Treasury bills [Member]", "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r567", "r736", "r854" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r52", "r53", "r54", "r172", "r173", "r176", "r177" ] }, "lfwd_ValuationAllowanceDeferredTaxAssetAdjustmentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ValuationAllowanceDeferredTaxAssetAdjustmentsAmount", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "documentation": "Valuation Allowance, Deferred Tax Asset, Adjustments, Amount", "negatedLabel": "Adjustment previous year loss", "label": "Valuation Allowance, Deferred Tax Asset, Adjustments, Amount" } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "negatedLabel": "Additions during the year", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r440" ] }, "lfwd_ValuationallowancedeferredTaxAssetChangesDueToExchangeRateDifferencesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "ValuationallowancedeferredTaxAssetChangesDueToExchangeRateDifferencesAmount", "crdr": "debit", "presentation": [ "http://www.rewalk.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "documentation": "Valuation Allowance, Deferred Tax Asset, Changes Due Exchange Rate Differences, Amount", "label": "Valuationallowancedeferred Tax Asset Changes Due To Exchange Rate Differences Amount" } } }, "auth_ref": [] }, "lfwd_WarrantExerciseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantExerciseMember", "presentation": [ "http://www.rewalk.com/role/ConsolidatedStatementsOfCashFlowsParenthetical", "http://www.rewalk.com/role/StatementsOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Warrant Exercise.", "label": "Warrant Exercise [Member]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "verboseLabel": "Warrants and rights outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Service policy", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r835" ] }, "lfwd_WarrantsExercisableDescrition": { "xbrltype": "stringItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsExercisableDescrition", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Warrants exercisable, description.", "label": "Warrants Exercisable Descrition" } } }, "auth_ref": [] }, "lfwd_WarrantsExpitationDate": { "xbrltype": "dateItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsExpitationDate", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "Warrants Expitation Date.", "label": "Warrants Expitation Date" } } }, "auth_ref": [] }, "lfwd_WarrantsLiabilityActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsLiabilityActivity", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails5" ], "lang": { "en-us": { "role": { "documentation": "It represents warrants liability activity.", "verboseLabel": "Warrants liability activity", "label": "Warrants Liability Activity", "periodStartLabel": "Initial Measurement (August 11, 2023)", "periodEndLabel": "Balance September 30, 2023" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinaryShares", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Warrants to purchase ordinary shares.", "label": "Warrants to purchase ordinary shares" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Warrants To Purchase Ordinary Shares[Member]", "label": "Warrants To Purchase Ordinary Shares Issued Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "April 5, 2019 [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On April Five Two Thousand Nineteen Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenOneMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "April 5, 2019 One [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On April Five Two Thousand Nineteen One Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "December 8, 2020 [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On December Eight Two Thousand Twenty Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyOneMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "December 8, 2020 One [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On December Eight Two Thousand Twenty One Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnDecemberTwoThousandFifteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnDecemberTwoThousandFifteenMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "Warrants to Purchase Ordinary Shares Issued on December Two Thousand Fifteen [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On December Two Thousand Fifteen Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnDecemberTwoThousandSixteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnDecemberTwoThousandSixteenMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "Warrants to Purchase Ordinary Shares Issued on December Two Thousand Sixteen [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On December Two Thousand Sixteen Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "February 10, 2020 [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On February Ten Two Thousand Twenty Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyOneMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "February 10, 2020 One [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On February Ten Two Thousand Twenty One Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentyFiveTwoThousandNineteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentyFiveTwoThousandNineteenMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "February 25, 2019 [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On February Twenty Five Two Thousand Nineteen Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "February 26, 2021 [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On February Twenty Six Two Thousand Twenty One Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneOneMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "February 26, 2021 One [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On February Twenty Six Two Thousand Twenty One One Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "July 6, 2020 [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On July Six Two Thousand Twenty Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyOneMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "July 6, 2020 One [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On July Six Two Thousand Twenty One Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnJuneFiveAndSixTwoThousandNineteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnJuneFiveAndSixTwoThousandNineteenMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "June 5, 2019 and June 6, 2019 [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On June Five And Six Two Thousand Nineteen Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnJuneFiveTwoThousandNineteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnJuneFiveTwoThousandNineteenMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "June 5, 2019 [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On June Five Two Thousand Nineteen Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnJuneTenTwoThousandNineteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnJuneTenTwoThousandNineteenMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "June 10, 2019 [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On June Ten Two Thousand Nineteen Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnJuneTweleveTwoThousandNineteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnJuneTweleveTwoThousandNineteenMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "June 12, 2019 [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On June Tweleve Two Thousand Nineteen Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnNovemberTwentyTwoThousandEighteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnNovemberTwentyTwoThousandEighteenMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "November 20, 2018 [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On November Twenty Two Thousand Eighteen Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnNovemberTwentyTwoThousandEighteenOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnNovemberTwentyTwoThousandEighteenOneMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "November 20, 2018 One [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On November Twenty Two Thousand Eighteen One Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnSeptemberTwentyNineTwoThousandTwentyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnSeptemberTwentyNineTwoThousandTwentyOneMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "September 29, 2021 [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On September Twenty Nine Two Thousand Twenty One Member" } } }, "auth_ref": [] }, "lfwd_WarrantsToPurchaseOrdinarySharesIssuedOnSeptemberTwentyNineTwoThousandTwentyOneOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantsToPurchaseOrdinarySharesIssuedOnSeptemberTwentyNineTwoThousandTwentyOneOneMember", "presentation": [ "http://www.rewalk.com/role/ShareholdersEquityDetails4" ], "lang": { "en-us": { "role": { "documentation": "September 29, 2021 One [Member]", "label": "Warrants To Purchase Ordinary Shares Issued On September Twenty Nine Two Thousand Twenty One One Member" } } }, "auth_ref": [] }, "lfwd_WarrantyProvisionBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WarrantyProvisionBalance", "crdr": "credit", "presentation": [ "http://www.rewalk.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails6" ], "lang": { "en-us": { "role": { "label": "Warranty Provision Balance", "documentation": "Represents the amount of Warranty provision balance.", "periodStartLabel": "Balance at December 31, 2022", "periodEndLabel": "Balance at September 30, 2023" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails", "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of shares used in computing net loss per ordinary share, diluted", "verboseLabel": "Shares used in computing net loss per ordinary shares, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r242", "r248" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.rewalk.com/role/BASICANDDILUTEDNETLOSSPERSHAREDetails", "http://www.rewalk.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares used in computing net loss per ordinary share, basic and diluted", "terseLabel": "Weighted average number of shares used in computing net loss per ordinary share, basic", "verboseLabel": "Shares used in computing net loss per ordinary shares, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r241", "r248" ] }, "lfwd_WorkforcePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "WorkforcePercentage", "presentation": [ "http://www.rewalk.com/role/RESTRUCTRINGACTIVITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Workforce Percentage", "documentation": "Represents the percentage of workforce.", "verboseLabel": "Workforce Percentage" } } }, "auth_ref": [] }, "lfwd_YaskawaElectricCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rewalk.com/20231231", "localname": "YaskawaElectricCorporationMember", "presentation": [ "http://www.rewalk.com/role/SignificantAccountingPoliciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "YEC [Member]", "label": "Yaskawa Electric Corporation Member" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(3)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "b", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)-(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "980", "SubTopic": "20", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481834/980-20-45-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-6" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481138/505-30-25-5" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "610", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//610/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//720/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "985", "SubTopic": "730", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//985-730/tableOfContent" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-4" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r767": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 109 0001178913-24-000730-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001178913-24-000730-xbrl.zip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�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

  •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Ë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

    8S@B0#E'),0L12(?#M8FE_+WA6!9N^/0,K3?TW1BZ00\KG3;GPN.2 MQ4]+DQM'5+^8)KE.^O3A'/00=\Q=-&?"*72-=OX4"W@Z@$@/@8*M/Y%?GH/^ MW%W]E4D<@/ 50PKFXQ"*PD-[]79K1_2H>[11-\8R%3\1(BA[JCLB)&(V+P,X8CDC[-V_14\ZCKZ,' MNE#W'-H'4_>\N4L>K3_B_I$O$TB:&RZ?Y"MP,,9G*QI7) %@0@HO$:)[C.:D M$R(26Q!\HW_&+AH(GD*, 3PL["RQ#Q8E!5P%!$T'/0O-"=I/"%/(E\&LL) 0 MS"J0#K!=P[5)MT3;=QT+.(B#8S.@'0<1:Y^##I)H=)K2%=N'%YA@Y&"UT*-H M!TF\Z!@<\"/3/@X\HD7%4\1'&)%"YNX,;R&Z20"#^*HD$L+QF,I^-D;*#6B[ MSZP)D:&76(+#BQI@L.T@,1O+3?3QG/OST4WC#$]JN40<2H5(QX"CN4OC8Q!/ MAOUW7=/[[FUDM:BKZQI&W<&&0APD5H> L80>W"-Z8F&")4,Y!T-,++&+H^G M5[14-KJ5@$E8!^B<]/%1;:*AP&?<-L,@?3MU0H44EZ;XO V[PGJ&Y7C!/3=. MBTH5P5+JEN?$!O"L6W/=CVZ^3D8'(VQA[JX_ W(8UH4!!TN/*SOK!HU/@$5HF? X0.P9 :$WQ*J&5 MB\'S8R3^QO0VKFCDP*%76$8R<),/&^'JT$-W2E<' M=\N>SFTSWK$9'Z+AUSK"#"* NPX51) DZF+<"E3QZ 3?*&T$8HT+EQ^UTM/[ M<>7K0,JFM\??F&@\,!!S=?\"O)<^!,86@K<4*4A#Z3@,D8<'\Z'@&]QXO6"$ M[OY>_H#PZ-FQG@,ACXC])C$>&+A+-!)E"$)Z\\?_T..==)0F7R)6(OGJ17^+(T) M8T%Z8 12$GJ. $AG^6B 21N&!VA#2' .'RM!Y$,AM<_&)D7#6W]#3 "VG%< M3^Z6$W2,1Q>]!;N;%BFSX=_<@Q#WBGF(_S 6_;9\#P0;LZ-CZY+>G.61*_70DU4I1S+:\P\1*J"34:YRHO M-[&_JQ8)YO8?..Y)RVPHF5F>F4LM-Y1(#'2O":/GJ,45TN MOH8>DB)G<:&9JG-9Q:7F2;"U5B4[2$\AF_.(] ZDHN"4,""':E4:K21F.Z9^ M66RU<2EL>U31]'1LZ GLPE,X(MK$"#Z;!D1Z50CQIA>B_-_8)31!RH[SB)8] M<)X0BR_U)$-W2FZG4RNK;O@+,WTPEI^1*HPVRYE2K1>B,?BF-S;A:.F!4ZAC M7644.O"I_0O?&T_=' 4.[B55)IHN?"5.]D#?1@A#0\)@GX4#! ^+#!&8>TON!KX;S.(]$D7W1^[Q\GX MT)P"=0SO&'J(3G\1Z':!>9&X%Q:+NVD/T$^0?/I&;=AX,)8YAB$#AP\^Q]F# M9!,"_1SO";;23^>6CTU\&QZZ\)3H)'K!65:JR:JAF^*/9BZ9KD/C"=;?;N&# MU*FJB33YP"MC.39ZB63JP/)H!%:\9<='I*[C*ZG'9^TZ!V0\O.K%-A,_-?8P M>OL3SD-8NO$1)_[R AX0#%Y#Q,96F-"XL^I^"LWA"SY*R5GXBY&)ULHV_(T, M^X+ )&8T"_T8@7,,%V4DWG?/FT]G2RQ.#(#!V&#,F[J&,T,?>9R]UC(BY=[X MPX@G 0'/".(3@G@^4CUK/9]'7@S#\8AG(UQ'')_CZL,!D/>[\X+]=)W1"#O(:3QK1EF0]5@@JDQA[,.^6')" M<,VJ;">=0QWN^(19.*^CDSH\I**C>=,IY:4_$H6%]WI=0(" U1L<+8.#$$@, MP)+O? K]B3-R+.?IC8:R!7YY/(O(F:1;1A3.%G/#4V41N\Q\&AY#! '#F".] M((I,)!J<1>+/D4:I!^.*;GW0,4L/_<>WU2 ^+*)'000T%A&')H0RR&BM]+0< M\1 <_^AF=E@G)95.S.5^EN7^^IC&+^>>27@-D?%C "0>24&0I$_@7Z$BP,HJ M+!V0BT&H'^EI":7M$ MS.?&?^?F(K6O@P/.?@,]VS@'2 7 $C;)Z!N3P+:X7P-=_),LGTL S=,BGH"X M27S9D^!/B'-A\23B6G@,I1!C(84$IKG8I31SD,Z>IBY%[OP@>%^WG\P@_0$G MH5)'#-$-'/"3I"Z&* 2>#C(1C\0>HL,(&A.;J"Y"Y/<)W #HLHDY$[#9-X*WY'?H0^4Z(,@E8ADA7+AGV7AO[)+ MN]WH3_7<>*B[;KH J[J1C9LPHTL8<)75B%4_"'>-6_07=\44/[<-A/NZ24WC MZ]7G59-&!,/'-LDOBWQ)@H@,1&$']ZF+>S8THS%_W818L?GU3,!!'W M'-!,*S+%82H98 MV"GP"4.0LQ&$[CTP9/KO.#\ M26I8H6FJF\9+E@;=]D5W1V>6XWRGF578IS*W<'PZT$E2%9U5L/;H:+"=*4X8 MM8F9YSLD/F7J%#]UOPJ7^[@.4$/; O?P< ]/Y?8D[N$)?0VCO4[[/1TV- UU MC5@1=]VLZ8U>NAU MBV"RK4+.:KQ($$\7YJ$NIDXEE2BGS5@TC?&7PT/.,;H0&0(G?Y&,:[PD@2MH M;^=5&&R"OXN";L@B+*6;+>)Q@KPST_/#E&+T$MT&WX0DIB5"=U;EZ\4%4V<$ M+2&J3K2ZA4B8GM4UJ'(;1&&D09:PZ/BBV/@RI)PNNV] ;I)2=MMZDQZY M HMS>"4%=IG0XTFLUAF\"%8IMK_OOF!![?/B%_LDC6YE MKSVX9VD^ZTKO@L[=-1A^NQSVKGN=0:\[W,@NY8__JG\W[-_VKCL/W6L0])8& MM+GTHMCWMI[3"31D;XZDV!W2)JVH5*L;GVRK8QKSEM#T][_WEEX#^G M1J!8MGO(W MDB' TEIF_I.[$C";K[23!/$(>QQ"3IJW-G@NW7CO#@T,SPYOR MZSOI758#71]/L_2PQHZ'!3 =/"M8=T#G'UV?K]6U;C.9&G(7+Y1(D<"_B5(FY.)*40B5PI(CD. =>V M=91%%:EY2@O]1],^Y+"5N>Q<9SC$0FN.>W?$8F7!<;D^/;>YYX5V?#/RW(SC M4.5X(2H/3??;8(!;25&[>3WGN4J+7)5VO=H77*_!3 MW;A!79+UCBHM=%3-O;,G79]=8";IV"/\I[O@D(Y_I;LN#M7 29!KG>/$<07F MMDD__#:\1FN.%@7=6WD'1M PI[KE_?KN#+TC@<"XR_:K?V'/IVAW#CNM3-_],=S*^B*Y0VB9U_1*OZYGG2*W$K0*'D#5OW+ISI)JWD97M!IBK)<(F:$='D&+:% M8&8TU5RQJK)4E@[/VJMX%A!GE](FT@W[F# [A!Z+..-E06G45AVL)G,P,HQ3 MY5%5S(9',[39J.VZH8<& M<6=+7;]*0:XC!E8%Z$J8NT)Z>T-:4JYRA"8TM)*\4F6'=7)F.TUF2YC.=S!; MAJ9CH2V7)!(P%AZ[50*HK)SZX/BZ589Q(MM%+!SEF%68]=KNE\G[P"^[=_]=O;0'7P%^:<@,N*\8608N?B0F%@>[H/D]%,I#QD7 MYKAP4(G%Y/O%A;EM]=R@Y[LFZ>!@A!FK-)C/1&IW&)*&> Q]L??/$AP)M<# M7Q):#:F*B4CLD2KGAL.X(9&5MR\W9'?4MGA27B5EN7O7033CTTY1N-C4##>7 M)"4-V):4N([ -%VE [ U:7B4'.\MW?8[]J@;4F3>M6FMWV\;04GI:2$RAJJBHF](V0N//UVPN:DJQO63E^XCEI MG/DKROR:I#2T1+3 %N:OL@A4Z42TJE3WH7G[I<0A\MHCIU1[1$O6M2XRYE!6 MA':3G8Q:9@03SG'UY;ADH?PB(PHEH;FF7GPU&:Y:L0^Y9CVQHLFPJJ14?'FX MHYS33Z6\N2M8K[*M:)6G7FU9F/R$/?10,'+FV*O-OE!55D.QZJY8.C%T0QFU M7-6]AB)(;3;JIVUDO*+5/8X ' '*08 -E=3R+:&F"G)9@?:9(T!<6/HA^ W M$J*?[:D-;KO\TU1WGTS[S'=F%X@LPK?!1#802D1%!_UZ YD!2F> $%J*&S], M(- -PYFB^^.^E,!V?-PXQT4?([I$=/;D(@%LIKND :$_@1[$]$=,/CK.S1^; MMFX;)KK(\]$'.%K3.]](+T>NXM9=,2RHNYA&)BGN]$.2]5/_:/EG ?V*XC]6 M'HNV;;;_GJW01@S_#+2TT%T9E[),/Q25;O[Y8TL6I4]GP5_U\\=9L N?)VXX MI@! Z?A%Q&V)!22HBK^)S3'8,&P=HCK.CQ2NDLI/^,5,?X)GCR[4OY_I8S2# M"]UZT=^\E8F0D7^,+=FN[?B4&FY#JIE%NQXCH)2T21[V0C]X=*Q1=5E^T/VS M<_L'&/0O^P^]JR&X?;@^!YV[:S#\=CGL7?(8C5/QPTJW5820X_8$#+"H[:7]^)[\A[?):&[]?,[.>5 MJ?V<&K,L./97<&*!)>^6#F-BR9!RL>^"E.62) MDF=0.3QT#0TX?43,H4A"GA(I8XZ0TR1R^42)'!MT*D7O97YE"CN=2Y[M[T')&-3H?OWSJ#[>__VNCL88FU-:GX"W?_[UGOX=Y[[ MFZ^_;"=7ENJM8\[)RS>#78\ID^;CJV^#0??N <2PY")/M,B/^/(CK$(Y^/06 MJ%JA77D$)KCZ"(*9_H9M*KP";16VK"P_9577*YV7,E$PKV,8:+*^=T]YHXBL M>TT0&[7MG,WA@L-%%=8K'5PD*@JFAHLL8^S;6DE)+:SK.XS7^^E.9Y;S!G&$ M O:3Z6^N8UDX@,&=HZWGQ7].H=Y) E(2-?Y"*AE "X>HW)KZHVF9O@D+:4(K M"Z)24E7P<@0-SA&,<40C4>CB$([(\KR56R5%%;-QEE96IKN&8XCH8P1<^ SM M.61;1F)&<6$UUZD*V)5(> ]I<$!)L) J?H(FUK:Q1S7Y@9%AG"Q;)K+B4[-E M=G*$(I;4#H-K[,!*Y!*W[@>?XI:BY;LL;?4 M;"146MZ*D0#DLDJ"LP-FAV1[NWW9(;N35VM4TJ)U\OI[5W=M9^X7?+1R M3>&$-(5$L4U%TJ3E6OP!%19Z@&O-VG;TJ"8_,#*,DV5+351$]4"VK'(]W.KH M[E4I?DO:+(.@&&(D6I@%14'R:IRG5(VSD2B#1*BO8)>^)"@2&T51>!5% M\%VB^%!ZOLO.[-!HE=1*B['\QWJV%J*U'1F2(UA1D'B[$59)-AUV)AP918LK MDM!LLX.<[%I$. 9P#,@) Q+>FX)%)U5HEA5S6>D.1,>37*Y]!$[+39O[M+A; MO:;[=?*>W]O^W6]G#]W!UWB5"+8-[MS-5(7EX6Y*3C^5Z&CR43F1[&R7*F MU)*EQJ&/YJJ%X%)#1SXOFG&1V42-1MF\EG[>@!O,XTY[GV57E$;7DA$1% MNGTX(3N';:M=4DDZ-@[+RHIKB#S.PABVDE/:N49P0AI! L<29? VY L7=+(W MQ&9=%81J,@8CPSA5_FPFBO(=PI\9%M-1E+KRYVDFY%D.&JH/W2D+H?2LA,@R M&_[*)"&E [)$A;[5U*"") RMQ4Q\*S/AZYSOZLMWB1)\>_%=AEEY=4F%Y4EY MFY+RF)(E6%&;>$H.JT2;#C\3I02*%UE4H=4JR2S"$_,X"G 4$)N)P@;%"U"X M'T))[##NMDY3_:]? M>P]?NWE/ MH>U['7MTA<@*'=G0-O902EX]\\(VK5_?^>XKJK)Y*NS*5C>4']A:3[U=5Y3VRK*8]@K9_<1; 51S!I.:Y4A2"]=V1 M:>ON&_ (E#EC<-<;@JVV$$64)45JRHK4;K02:;78%N+80]\QOM_K;M\=^KH/ M1__2K3F\ARX!S!0V$32(OV;0_2NX?N&#[-W=['!"IO.1)LJ.'#;N51OE$>,6 MT1:O,?NL? !FN@N>\:C..G-_XKB( $87NS=,%36EH6JRO&WB9-3>XKXI-HJ0 MC9?'#B4**NPWT-6=.62@DBP*:"CX7[![:^@3@.Z#:VC Z2-T@2(AB$!C ;H] M2GPJ?P(]SYNGVCY%DN2VVI;51!9:8E7H/7-:D88J2(HL--=4C2)S3#<1K8&P MX_")9$&##45 UI;_@KLO9$"0-?/(/KY,[3>/H'^W/=\=*5I/Z5C30U[2[1$ MADQB26(WSFN#14&2$,6WDQ'RJ3<8_6DVE42D_YZSR627\4Q$06XGP"&2^P/^1B=E$%;$9:5[1UM]4E MC$UL2FHS:5;;9R99F%QDH:TH@BRNL;@X2[Z&PPUL; N\7,]C&BW>I[%@2DU- M%5N)2HMK>"E_*PQFIEK4BBUWWS^PO6(<-6J &BU1:B8K'.V!&AD*M(*JE)2* M>[JH<6J5KSN&,9_.+1PH@6AS;!JFSU0I4EYYE_'*N^MA-6$B2"@U ^CK:'PC MW&P/$8(7(\1K2H=YBF3 0RN(+D,HJVA"JU62='940=XJP2J'"0X3*6"BG8A% M/ @F,I/!8C A*4)3*ZG!V,G 1+4,H3R?JY)J*!/+PX-<./U4*B:C*@HMK0/J M;"D3-_M& %9*^?\MR6M,)JI58LG;2ZK7->QQX5K"\V%$%J ML]'A82-+%JTOI M*6UE^R*:"%X$"Q/;TG=?,#]]3D4Z=!@O](-'!&2Y,,N@^V?G]@\PZ%_V'WI7 M0W#[<'U..A@,OUT.>]>]SF!;WX+RQW_5OQOV;WO7G8+1U9=(C[F0]R<=;F87;-UFDC[GC: MLB@9+'S@%SEDC9)'3SE,]&]T*@%HC^!RWEV>,AMC+HC3)'CY1.D=&T,J1=R< M2$HA$ID3"2>2740B58I(LG K-=1RBB(76=9] )^A/8=L9TLRXM,LVTQ:EF&Y MJNN5SJR<*#P9L,3:^B>B)$J^DVT;<45H:6H=\I<985)&AL&QHDKKE0XK$C4Q MMV"%'&%%=DXG3="D6I0Z8(1'&1D&AXHJK5 MKD;0(-;N,C"'LJ3,73D>\7"[!2IU/)WDI-))UO34\?S^. "W@E2FMJ"*)8E! M95LS.=^=)M^MZ2&TG>_R4#\4H;&FB1#G.\YW->4[25S3]&\[W^4ARRN"V*AB MY:V3<*.D6%P^N%&M_5RY&^NXWE@YCIC7A*8:R#9 M:R")HDF$X.X)O15D;U,%5:N+_L&YCG-="JY+E$W:SG5Y6-LDH2W6I7 2YSK. M=2FX+E'^83O7Y6%KDQ'7U>6LX[:V:BF9C R#Z[H5W3A&AL'IIZ(;Q\@P./UD M=G)7V;#6GT%7]W$]%_@Z@[8'O0O>0?YPWBEK6KS/.=\OOE\,[%[:Y@6MKG$]SY-,UB>/[\6D>3B-5$.O1#+L^#,+(,$Z63]_' MISFYF91V7?F46Z_>?1DBHJ"]'= (OD-LQ^+6J\RUZRK@3R(3? @M-+PG!#]? M0](H5IB7%*$ME]37@-N<.%=@KD@D$N_%%7F(SFVAI7*FJ,HC:LD4B2S?O9@B M#SFU(;3;)85#L2&#K@G*JKL!_#=H0]PP PNO^FAJVJ;G8T_L<\^ K@JY3(Y@Y('>%K9XG0BY7'VPADV8GT9M>.QY&!(T-.R)#,LMH; M&?+029J"I)14&Y8C T<&C@Q(DSH>&?*I[]B0V:G%Q'T*Q>:IG);IAIT8.O86 MD^\7WZ_Z[!>/44W9\M;Q=0LXB0P)M@,(>#A-#>3A1(YVE*<3",!%-4Z16X+8 M*,ELQJXFS)GSE)DS$3N>ACGS,%S)DB"*39,!(RG82 M)FA:;;,YN*6(:[+E:[+L+2;?+[Y?]=DO'M^506$-R_&*,1EQ_RSWS^Y-I^_3 MB=6)_*Z(OGNVX4SA+2+R8DQ2P$.+ARY#ZJ\B-*22@LES=\^62Q4?*K>('+ X M8,4!*Y$0E@ZPPM)M\OOE_UV2]N;CWX.+TQ;=TV3-T")I&6BJLCR74" MKA-D$\OP^NA:U&@J2XHD:6U):36C> 9K_#*ZB,@\#&:@NL$=+*A+64PU$-1& M2:%'/&F.PT/-X2'^JS,/&F?FZ]G$'*&C]B(!$YJHB)KZ[LLOJ\Q7:1ZLDG;. MPB)R;#@5;$AC392EP\6&?"V*[+1]XT&2W&IW"E8%]A:3[Q??K_KL%T^G32>X M8 (1(3H"!D0[X^BM/IV5"9*ZJ-+S>N1ZJR*HH(PD6:<>BJK03#O:%7_W& M=:97Z)&F/4="8N!X=VSODE KO>X!TVKWU7=UI%X@>=I]Z_EPZMTY-I:@78?4 M$.TA6=J%7N'6.%D6)+46:;JGH/=S,#HE,$KHYHGD_F*!J+8ACAR(JH4 C SC M=($H46_1&IJ>O[+HU!5FYW>!]P15VQ(!K?_Y&7_86)Y>*E%3C^?O,R&:L7-AG?0+ZUZV):URT\)00\%(V?^:,$*"/L_Y;DM:;6C2JU82OME M(E '\4&)5<9D05+8B%K?R)/<IL-%NL[Z@Q8WDU;(.,3(,;J2JZ,8Q,@Q./Q7=.$:& MP>F'&\FW&\G!#+H@#$0'WD1WH0 >=<\T@&Z/P,BTYCX<,25,<@6/*WBYY;UJ MHJBVD9;72(0#=W771N3IW4-WB-GDFK+&7H;UN][P+\1P?Y$;1(J?&%?\Y+1Z M7ZJIM"2UV4Q$+JY.Y1+S>VD3$<^5=:&,7)_E1CB.T1RC-V"TW%Y3_#\]1F_V M(Q2/T8K8D*1#,;J8B2",ECA&C&,3(,3C\5W3A&AL'IA_N%UHL_?Y+[PQ'0 MT2ST)PB0O/F(741CZASRP-Q#WYHVVM3I;$Y:M=OB%!QXZ@X\B*V2QOOC M@6>S63\_X%$T54I463T6>+*=2$,6E&9+:+9K8>GBP,.!YV#@D66YE;!('P\\ MFVW5^0&/*BK)\L[' D^V$U&;0EO1A(:VKAI?+8 GKA#_$'R@(X:AGVUG@H3% MN'">>9A H!M8)]7M-Z*4.CZZ&FTTTCV1NNK#)U>WP$QW?:S+^A/H04PSI$:6 MCA7><=0+%U&6#Z=(&_?.-VXEZ^OQRP)%TJ?.W,::_ M2 MX_T)^N0GZ= %".CH\RR\A-HS+LB,PM6919?%[A40N"C^([2!^,Z,_FYQMVW+ M .@Z +(0GY97,WY>&!#76 X?$K"1LC"]X,?2';CYYX\M),9\.@O^-O#0Z5)\ MGKCAF((#AXY?1.QH6%!W,1=.@EN24PA_$YMCL&JXC!NQI^D)JV5[8MH(G@1+$QL M2]]]P8#R.17IT&&\T \>'6N4"W<,NG]V;O\ @_YE_Z%W-02W#]?GH'-W#8;? M+H>]ZUYGT.L.#R+]8L8_?.@\=+]V[QZ&H'\#KG[OW/W6'8+>'1C^WAET?^_? M7G<'0TRM4O,3Z/[?M][#O^F#\/E+W_]%,-%\[=C&Q''?)0XM]B;][7QXCH0X MR])=#QL@_8DS]Y ,X('W\-6 ,Y^:' &"XG^TZ@RKAQ?B,,RWPV=CQL&5] M(5CWH(3FP874ETZ:"'$":%C&//IW-)S=BQS6J@ +3PX?D6/ M-:*X3-#=H>L%:ENEJ/FX8)K35$AV<6%=%1)JR*\4>7,R*>%@)]9H3B:<3+:2 MB:'/S-VG/J>34Z<3ZC;F9,+)9"N9C.#8-$Q^[' ZV4XG\+]STZ^6]2F+A >Y MQ5BJ8@Y;>ZE;NFU H'LX4.0:&I D0"@2FILHBVRW0F8D"X?=)"4&(_M6ZPLW MY=50N#1Q>R(.36]X!KTX=2QA[YC?/]* M*/S( #E9$Q1%%F19JT/W\/IP$2/#.%EF3L2U$I8+;+V4/W/FYL-[7$I":VU) M"<[.G)U/E)W50MAY$:5QKYNCGGU%K5P9LC8:DJ"T2VHMSYF;Z6&<"G.'>2B* M*$NJJ&JRTFXT$TG$N3!X&+]";G[OPC%T73@ZG+_'YBL?=ES/.U"QQ M$R/#J"%3IVO74Q!'#Z"OHTF/PIIPV9W5L58_+4E0U5HHV.523C&%.#GNU!-W MTL%.HNIZ>MC)1L*7A&9S77T.EBF_<&]&E3T5Q"Q\]JCC@DPX\Q7:GDX(TG< MG,XLYPWB%%A[!! !G$6?%$(!!>!:&9C%)!Z=E;>CN9(ZZ?" M= Q'UW,7T2K%2QJ$'O8Y6T;8PLQSAT2F*^V6(*VM5,\R;_&H&,[U^7%]*]%@ M8@/7$]&H9*8_7-A:V[26H MJF)4*GNL(K80GC &4S5T?W 1A>EAG"K[M\26J+$FI=3*P<(9G^EAG";C:Z*L M:LUD/ZL\&)_S+8^I/\A_8]I ![@\KRQ^NH2>#[IC1",^J=@K2Y_03Y!Z**1"IOZ()YPFE=.9[OI3\;YX^> M.3+1$@P1B_3'Y(;D7+3&+R.\!/U@REG:[(1&LYU@,?!>*D;YY)$ K)FJHY(+ MF.BV>Z?"9B?TG<2T6TH2A;8L">CDJV(\ 'NTS]GK,/;2TK 7$;C*XJYC@FTX ML]=)LE="7FSEQUK9R'D-09%+"J1AP[A=]P2&[BMT#=,C M!O"9"\_&:*9P!%YTU]41 ),4A>C->^G#>YD'!7'G8-ZXV%["Q9!&^V,D7-\0 M OTS(,F.';TE;LBJV6TPP?:U\")S=F1[&J;![0KY7\F/U;.1R31 ;8EUYE@?U MIP_J=^&3Z?D0R7U@9+K0\/./[&\G&LHQ$-D_B-;AFBQ#+E'^LI1L9,.C_$_5 M\]U.%89,73HAR??'RT[PGKU*N'<0T6YX>3=@5<;3 C1!%15!E$HJ6,4C43@_ M8GY,'^15&78\IA&RU.;1S55Y1"WYL5E-?BR@DW%#:/,T'\Z<9;HQE(;:J.B! M64._!^=*SI78SZ"*;25]0#537%DKQP3GQY/DQX0(VV:(%[,1/5N"5%9943:\ M C,=R??VTQG]XD*>O=8^00)1'+ #2B M / _']CUN.8\^'+1N)A^P%F29N[" . MHI."/0,W TH!AP\.'QP^\/_59J(W;'[PD;D]GD,)AQ(.)>5#B:HI6KLM%P@E M-?0<<"3A2%)O)$G5)TH6&\7!2':NCLV]GR19:"J-FF)*N0153+PNQSJ.=7EA MW;'&&PY5M80JGCCS[LNE;I$L%]W#&2W7T"!G,U DM/,BK@/'4S5.SH\OB^L[ MAD\<"YTE'I7TUJ$F$Y'<#5E06Z(@-90JNNW9(W#.0P?QT(8.EUGS4/[1UZK0 M:%0R H8].N>L=)#94Y64ABH7PDY96SR3 67-EM 6^=%4E4?LS4^Y3XOO5XWP M+YT!0Y(* ;]"[+1M59!:S,L353)CL,>$G,\/4QF.D'&R::;6%I16)6437OL_ M'1V2)(NS1]Q2&>W1HJ8.0=@! !' 6?<)VI21>0XQI)TTQP>KL M1G%PNJXG7:>*_E35AI@,'D]5 0Q#-4'JJQA0#R 2 SQ$L$/H/IL&I"EU V@X M3S:YRZ:Z>G+DTI1/-!Z=(P33PS@5A$A(_4JET2%_!T2[79)*P@&#Z6&<"F D MW"&RI#42%L%*@48- \LY6# ]C%,%B[:BMEN)6.]*@46M*N5PF&!Z&*<"$PDE MY+ BY;E"!%<>>-W_8^K^S]%1 IZAYZ-# W\_&'[SP.-;Z7X.[G=E#?P2*;5; MB].3_UZNHEYA)M=#2LYKJB(H:B4]N^RQ .>RP[@LH85LJP]8,I,=T?:$5Y&O MRB,JQF4I8P43SL:2V2QW!\$BN)!]WN-QA8P_HF*8D,YAH$B*O#ZVL#Q8J*$+ M@!_!G-VPR5V358VU4[A61G3.:)S11 V]D$0Q$3V3!Z.=))_PF/ITM!I*,J'= M6??15GD^VUX&[K1CVFFW7M* MI+14A06, M#*.&J'6,!"-J4EL160"M6CF?N.C"]#!J" )'B"Z:V!2U5C,_>TO6,D=#E>O MUE62.;+R\ZWI+5!EMU[97:"+0.HTS4%*@>HC!E8NZY76F;DQ:!KO*4DLID%WKZ*C@K,M9MX08& MV1B<S=69<%P_JVC@V"UB@IL?(H'JZ2#8YC"\>6--BR=R?;7,WU M'!HJ9)ZO>QK.]DZV,MM.).Z!9=H#F\8!*[9%I94LYDV=K?VY[_FZC1%K'4B7 M7!ZJ(0IH](+9U#"C'M;!O'2OT9J>RVVAI34YZ'#0X:!3WGIM#V.-/%^RU)2+$7#R M;_;.4VBJ8TKG<,CAL'PX3 AAB49/N4!A$8Y$65*$IB9R/.1XR/&0X^%A.NGZ M,K:IX# 3D:[1$J2&5@<,XRUEUM,A<=B/)L2=P&N 5]M-JUA[@UG3LZT"7GWW&D\5.12!D>*BJ TEB<#K MXYZ.;D2>CU'OD$P329#$MB"+M8@"J \?,C(,#@=+<-!:'X!];&^[DDW\"4QH M-C@8L,2%C RCAF"P.P)Z&QJLCP0L#PT*;.Q>#XC@48,F<,6I3UA)6 MI))AJH;N%2ZY,#V,TV1_3115-(M$];.2V;]6#AS.^$P/XU09'Z=L:FEMET@^VBK/YY'Y-7-RIS.C*$I;%1/EN):T >I&Z1A(>D J M ,6=)S"3*?$0+!P#&'U$Q $B7 M2)5QVW:&W",,Z#$\@+3N3);NE,VZ'SH[UOTM!VZSI,ZD_,3E8,#PB9MUFW%N MZN='[4EP5YJC-OO^W3DD6"S.R%99Y;WJ>49F9=1?TRNE[BDA97?O9L4?FJ8A M$K-.TYP'7RX4E-8IG-T@ LY'G(\R5U)D26I(JB9+8B(R<5?S-':*(2U$+':Z MJ7(F4'X[4T8G H81#"8<2;-II2P5"28YY$%PZX9#"(:5T M8[&J2J+<5EJKJ:,'M*1GP0FSI9.$+$B*4E.HJ9*!FH5%Y!#((3 %!#:/A$". M8+5$L)Q<;"I:U"J[SRYUBQ14TSU<,^T:&N04!XJ$B $Q1!ETNF5)\SL T$/! MR)D_6G 91,M']SU'QK9"3)%;$QL-+8G8H@BRR84S9CY.K9"CA",,1YBC! M87WYTJQ!IQ#WDZ()K18'' XX''#8550.ZQ2>7=<9M2%H4DGI4)GK%W$WR0_! M!SHB(OK9=L(([Q?-M/B#2_H 5M8]?I]PM8B712;/"<>Q$!&?/U(0AJ!L6GKMF&BB[Q09/(.78^ Z3_/PDNH2_)B:3]GT66Q M>P5H)(K_"-V8OC.COUO<;=NJ +HL@*S+I^7%C1]X!IH?=,.'!)BG++RG^+%T M0V[^^6-+%J5/9\'?)AXZ78K/$S<<4W!BTO&+"#L-"^HNALQ)<$MRC.)O8G,, M5@V[TZD/_4=Z$B6=Z^$7,_T)GCTB+?G[F3Y&,[C0K1?]S5N9"!GYQR^K&Q N MYLK5^)/4E+:R?1%-!"^"A8EMZ;LO&/VW$0Q]^ O]X!$=MN^^#+I_=F[_ (/^ M9?^A=S4$MP_7YZ!S=PV&WRZ'O>M>9]#K#A?/WN_F5_V[8?^V=]UYZ*(;/J _ M7[MW#T/0OP%7G>'OX.:V_^>0\B&1'O"'Y+._"".9KQW;F#CNNP1?[#F.;^?# MHA'$512_GBEET;@DRFEO M\Z-D]DF/1A(Q2F=\Y[;OG,QWKJ([)S&[J>:SQWYG M\;C4BL-/ARS(GO7M,A[R>N]OPNV2Z+C 9IY-YN28&A@.7?\/G(=.A8<2\5F[ M>$B.>$C.GH>DMJ UU@5*,L-#'S@OU)87M'UY08IX0!RQP^FY H^K CTG2FGMH.<<;.E?Y 9;]O/J6PB6 MDVD6 ?WISZU@1<%9UR34E5&G)+;B?* L4)IC_N1>32(=12D"PH"0VQM09M,B95KL>S MR"SIB%=IM!N)F*6]B3<#P6]79Q9.IJ4_KD0RU51%2VC7>Y-I!O)Q%Z M=Y09XF:7Y#B%IZ5P=6\*+\"QRC"%GX3]KH=+[$'/!R;1%;@!KPH:8)+CU98F M;1'@0L4PW&VJ& 9:X1W,R:*7=+Q*3"' J=1;J0RU'T7L"4O?'L1>:U&N,L3' M:3TMK2JV%.AX\AVFK^VI,=/L) E?W(1A;<\.?$U=]<0Y:KM"E0H&T M\EVCD4J^NW%<='?[:NZZT#;>'ES=]NB-<5FQ2XB8&+L#BK;=792B2,T!:!D@(@X7[RRT8ZQL+$?L%Z3E)"S$ W1Y%<4:\.'%A(BR+Q4U967"^OWQ_^?[6 M1,]B5[+A@A07E/G^5G?!^?YR1>A@1>C!U4<0=W&!YK/^:.$R9S;TN?+#EOU^ MNQM7$65)D12Y(2JRO"8FSW"A[L%K2/_V[(YAH('YWB#:]8+B\Y32 O166BZ+ MLU?NNZTRZ2><5(D*0 >2?1XN6G5M-45F'%6O0MGNCD"D,9M(AEOT8_/PI0#"-&?.>.SN0?C%G''GT WJE7, M?;HL1?BF.QD;B2I+2=@(Z"-,ZP_">SOVJ(^WO]#:PYK"13578$MFXS6_AV)WI;\2KRVUW5=3A$HTT-UO\[^E&DUTO MK,V%J+!UO%6&^#BM)V@]T63S8%K/0Y#3&&N_61G2.RE*3Z.+:Y*F--4TZDI* M$_2>(I!A+WK/HW.:W&2Z_M:)&@"CSFDN?(;VG-L JZ@M*G)#:S5;*0R! MX7:7*.')C;*"?U?2.R3$$#RM8O9KL4A\/'H MN"/HQ@8 /,$;^76?9(GL[94GL'?6#HW@3,/3C")4D7V=EX\Y]+E\\S4.\S MAXL\; !Y#S)K3$L4/4&4=(4(Z=YUGLT1'%V^??-PE_8(TSH1.15N&Q:%1B/C M:-'L4>TXBQGGLCIR62L197,4E^4KG#>%%ONR ^WK>^@PTV&(TMY\6+S$:F M_0R]%;-1<7UL3CL&A,4"YJPL.-]?OK]\?UF*76)(V^H8_YV;GDDL \X8Z.!Q M[J&+/-J( ']$7",ZOLR%(ZZ6L97%DK+!O"(JFI:BP?R]_C9%).0].!VZX9*:)JU<(\&0^-83O1-!&\OLX+R9-+>4+.*I ETMPW!/SU M0GHJ+WA=:@F2RGS 'T][XUR6X+)$"O=17)9K\#K[ CGG,,YA"0Y+)&\?Q6'Y M=NI@7C*O5EHI0^;O@H/6>; 0:\%"K"PXWU^^OWQ_>;#?KJ#UL>M,P=BT==LH M*V+]M(,[6,S<8&7!^?[R_>7[RU+P$4.J5L_SYNC4(I%&CHL48-U] ]Y$=Z&' M_1\ZF+GFL^Y#,+/0BF+'6Q3*;H8_A;37N@=P W;\*W\"@3Y%,R'7_93&]*!( MB9I6H2^P/Q[ZCO$]'.F5XZWMY+YB-/]K[N&[#.>/GCDRT:R&N@6#6W5>32_X M_IY.[SZO4I6)-0SO+P;\,L]8I>>W2&,TA\K&@[@RL,7 MQ&X :&7HD[/#_$)E]],V"&2+SF@S5]'YWG4,"$?>C>M, M%TA-20K79'-L3*H/+\ZIR>25H3M.YJLR>4ML-1:AB$>3>:UE[#9&CT=R\HONNCJ25DF2;?0& MB7OO96ZMK9P^+BD*NJ?47CX*PZWOC^]=>$/V_<]@IT]-QJL,I7'"3FC:S2.( MNM82766HC!-U@JA;1Q!U'O*;I EB0ZP6>9]JTF:\6(J/NU_-([,H3]4\^127 MU1;TDMR0&RLVDL!4?>.X(2WUQP\!)1&3W]8FK_ :@R=?L6D%EF1511PFI4P2OPEIJKQB)Q60J'EA-,YFJ_8P M)6V;SG0LEF^EDRI(V)S)3HG)TO%8ML=8'E;H9EO0I*H=8"<:G,L;;9YXNB@K M"\[WE^\OWU^6#$,,68&ZXS$T2%Y']]68Z/83!"[.[J:O/8"$)2P"">2_ !=; M?D9R2Q@8-X">[YJ&#T?D>QX85X%0B]7 .$E2UEAP*%WTQR%5#!!1]&V\R?C? M&!TL2( TKK%'RQ_$KBS(9ZIF7&B3!R'5D#-2&3?5EJ2TVXD:L\6P1JXFFC5E M*!CBD1P[_G'VR.K@0-PA(P9)-&PHACO8]F)R^TD6RTA>?<#) MR :11HGC$BY(1"#BJ+L01XTBQ='3UMTR]B@VM88H)>31HP#D'KJF,PH)ZCH@ M)_3>FF/39QRJ*'P5[954VD*SH3 %0KP+;R6X)^'$2+0F*YUS\G4VBH+:9DOC MXYS#&.>D8YR$)%LZX^3A06PT!:32LLPO/$(O7D\ZI:@+=!\\0G1+&T?LX51F M0G\\8(\'.:S 7*(Q6>:&J^RPJB5H&O-MDS*@<\YI=>2TA.$XKG*5GKYGF(Y M1!_G(I ?N2S'@Q<: !@Y\T<+%I\S]],A*YD6\,J;N:'(B#_.HJ?*H@GQ/W?VK)2BS=F3LR=+[*DF$NI.6CLO M@CT7^L(/Y(V.J ._W[Z;*VDTVR\F=_\\"R\(Q'G?F5V("^D^F#+^9(PV[&5#9^S?)MU7VZX M*;UG<,OWT@= 9[OMSQ!"<.?X$+3U\\\?\8.^1']F%5\ >;\%&)>Z "%ADF>F MI,\'W$G!,)PI&NX;]M38:"(>T%WT,0(JA"!/KFZ!F>Z2D'Q_ CV(D8587W2L M509E&=!%GH\^(/4_SH_AC@NR84N36;Y/ !FB^(]/RZN)MGF69H^7UFUUP6,' MBH'F MV5/5(6NX8?2\GK!O>O$*5/9\'?%AXX783/DX4A@IY(=/PB CC#@KJ+ M<6T2W)(<4_B;V!R#%<,&% IN/](3(XEZX1/;I0_WZFC]$,+G3K17_S M5B9"1O[QR[ZDF89O]J=$>N\7^L&C8XW>?1ET_^S<_@$&_>O.K_MVP?]N[[CQTT0T?T)^OW;N'(>C?@*O.\'=P M<]O_\^";?SL?GB-AP[)T-VA7XLP]W1YY*=EB]80A!Q,PH&4%A^2O[Y"P@-_C M4S!\OX;P?U[9I9]3DSXV.*V0VX(DWT6')CW8W>53/AC(^M,[K5EP#_'J\+S6 M8X>X6]X6=SQK64@-ECJP;>^_-DGL2D&M_T88A&V"",NOH4$:U !%$HI?SS62 M70HK+Z>]#8^2V2<];-)CEL[XSFW?.9GO7$5W3F)VYP['=M: /"\*.E@2.>2^ M^? ;7QJ^-$?Q>@ISWR%(NK_K?0V\#N>SF46L(+H%1J9G6(XWQ^TOG3&P'?N, M..''EO."%$-J8S4=.SO8.6)ICC_<F>9X[1DX@W#K(;&]$8BJ7!HU0P#.^E- MG!UD[^T!RX! LO#^YNW973_R7/R]F?MRU:6RZ,L$UQ_W,;E=46KK$&)[<.X# M4NO8HVY(:'/;((-.9]Q/LN3SU8; M&;?4IM9HY:04*]FD,A3+:SG)U,S82M;)W:;]C.[BN&^;A>UB-JY,96U/ M!,M^0YE&N2*FFTKBT,2M*-@+2;E@43Y9;;*535/W IFH>&F$\SOG]UW\+F7/ M[WDH%HTF9W?.[IS=CV5W.7MVST6W*)#[2?D#C/3LLO'SCN/T9='4?$>$MIO?;@-S? M"G(<:%(V]?[9,RVP,%0.":<."8D^"-E"0@9:" M2$L<"C@7UQX)$:X=LL: F M&E,57 X%J4=9IZ=N;Y61)4#E]8 ].[CD/J6 MFTM\D<,AP8:D6^(@M@BDE5Z:G,&PVHO#Z8;3#:>;,NBFVK%@N!(S"?'""C4Z MF@UG"H&OOQ;EMF+$YE0C>U(A$:C-1,.@'B&=!TPY]XB<"O(#27(VW3AYZ GG MGT+Y)^%SW9'Y?S#^><(_DDX*'?S3QX9#FHVC25X@-9:XCA.JG6A M 48]P9Q=VO=W:VD6@7:8E%MME>J5?0"&AT$E%N4$"TH*L_# MYCR=NSF(;09-R!C:OLS)PYHX3W*>S)4G&_OR) \OXN%%/!R"R7 (UI:1[Q/? MIRKO4]W#B] I[]B&:9E133X<5"30T"*X:"=+BO*Y4;-9^KWN 6_BO-BTQ]U* M7\A%-\BE4*4\?*!L2*QLRJ*57AH>9L+IAM,->X,X<;JID&)'O#;X[%X]T&ND MZ['E,BG T:$HFM906^U$$EDDG^%M[]CD3W>QYQW_2G==W.;[7[HUA^M<(=G5 MNV\)8JN00(A34L-.D-0;HM9J-[,G]2PKL JM=B$QA^XTJ*J4 MOTOER"7*RW>(AA4T6#Z%$)T29YL.XM2F(K?VA;@[QPZ:\^4JLS;%=@FNR*/X MIMCP ,[BG,5WLK@F:K*8+'9T#(MG**MKG,4YBW,6/Y+%T2:O*7%X#(MGIZ,T M2\F_*8+%JYT6^^#@$A97:]W+PCK_,L^691NERFM,B2%(UII*P@*.J6L%=1*H MM/Q![,J\[>'--J_ISEFM@JRF:8U6HF)AUJR6H8S?$M"0.:MQ5JLN(,O8.!,=5L Y ,!>- UQXBT\%J& MSUF^S;HO-]R4WC.XY7OI Z"SW?9G""&XXNYTZ!FZBSZV26[WDXL4MIGN^CB"UY] M;R7$=VS:NFV8Z*)%L._Y,=QQ039L:3++]PG@0!3_\6EY-=$VS]+L\=*ZK2YX M[(@P($Z#6MDC9;%K^+&4O&[^^6-+%J5/9\'?-AXX783/$S<<4W#&T/&+"+P, M"^HNQJQ)<$MR\.!O8G,,5@S;%JA!X4>:LY6T-(1?S/0G>/;H0OW[F3Y&,[C0 MK1?]S5N9"!GYQR_[DF8:OEE'B<%JQ/;QW1>"NZF?GPN+?Z:,&OS7=QW[ZX0L3B]>H7E']V/P5#P MX8YQX2_"1N9KQS8FCKO^D7>$[7P'7,5YZR;BK6'$6YN>N_KXE0=\.Q^>(Y'& MLG37HZ'ZSMS3[=&N^RT!V3Y[M4P#5#:XFT_1JAL;4A 3\3U]]TFWS;])5L)B M7= ;).K)NT?(A%HABU<[AR^6V!/ M)#(LRS1+[Y+OL9R#A0I@0,L*A)=?WXGOR'LLG83OUU#MSRMD^_-VV(H!1@S! ML#%N&37>+8^/B#[+_ULR*L8_'BT#<%-&CUT1OQ ]K,DOR9EM[_H/72!=G&TG MX+CTN656^MQWULTJMJC_F7N^.7Y+K.2"!I:F4^12_-:]ZPXZM]M7(D&DP<#7 M+E'CMMPBM>*@F)(8\8_6$&/N9)04Y,OCI;SG.H!_ MZM9W=!4ZO$S# [?^Z!R\QW*<+'X:#&[)*^D3=4[XSA,DD54OIC\!IN\!;_[H MF2-3=TU,;#@!+OCI%96I@Y]_ "^Z1\J NC/')8<[DMO0C? O+/W%"Z1K>M#C M-SW/U:$%'!O\[]R&0!8%]*\HT3A^9XK.. /=Q*'M0-#AB*_$-_#0$0JP^+!C M#SD*F"PW?>B.L9]KA MVP]+O'\!WIL?P J8"*!G&W$TZ45PL ,*KB%ZA;5PQ-4W\-&=Z^X;D#2, 9(L MH&^Q9OZ5]UF_016OS1J!&M^F35/(DA:(>>AIZ7,="JN1O*U.B M'ZY_$M(RXM/H&[[SB!XM2P3)U-A(L-A/1N+JS_-PU?H!\BD4^32*K@&L A>> M;7P8@4C2,&E$,)K<'NE62S- /QC"&5(6R)C0_3E>[C"T;00P-'I"C@*Z#ES,CK2)AQL?)N_HTMD*9M M.\](IGE&/ N-B8THZ\G$QA%\*V@36I\ZM.T9N<$+(G0;>L2LX<()[8A&2QG@ MKT$:(V\M#[;XZ MWG=H01^]IHOHK1^OAY:.#,[%J/>?.8+K]XC]+'0HH36SWI:DT.%5#]S3X7DA M2I/)>#!Z"H9,EQXB "Y&$:PX_I;N'AQM6$#=U6<6?#)U^HNY!^-0'2W7# &U MC;':-RU$CM#VT-VB+:9[B.6C]T3?/Q!(43C>^%$"W:,>VP/YT+'0O84036(J\A%0^8>= &)TM)#*]6&7ZPA6#6A"\2&5<\]AWX"QY&SG1F&QQ.5["?EAMQE"#Q8_U M.>%?_GW]^=]?C2\+_W)A@;KY]/$6J<&P\!.-)?6"V!K&('ML"V?6T8(!HI6. M](*K3N]1+_@7B@CY=/,!%!9I.7S/K?' 8,U,+R'#_[T D0*2*H3]. 5CMO(2 MP_4^D)1%YO#*-0"%?N='0(=W]+42I\:]XX\9L_'TR> +#A9T\;*_@U$^HDAL M*4Z\@9F1[(8'G^1;!ILP3?7)'GSA0435/LS'^0'.,VM MV'.["%W8%OG[;70O?#FP(Z7+;@B7/7;,%_@X>$+,H MZ0V;QX=+P!NW+! $\?GS9>$[3.NOR GP5QHM/5?^*9ENZ3 U8EO7 M,CA6"OH$<@>S$R(/.QXC\^_#(F% -] MXJ1.Z&+YPE@Y*B6F7S=CX=2W<=>2X9T:<2+(@&[5E)36FK'9V[R--C-M1A;1 MV F K?251H,B[GY)U\16V"3P'\$8>9PR#VVE#/NA4'"9:1/A!/X#[C]NF"2+ M"]BS$XPWH>6BU)BRAD"=E7N%:;U^*I. ].E0VR]3U#< S5I@^:&YZ0@-]W

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Ð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end XML 110 zk2431037_htm.xml IDEA: XBRL DOCUMENT 0001607962 2023-01-01 2023-12-31 0001607962 lfwd:AltergIncMember 2023-08-08 0001607962 lfwd:AltergIncMember 2023-08-01 2023-08-08 0001607962 2023-12-31 0001607962 us-gaap:TrademarksMember 2023-01-01 2023-12-31 0001607962 us-gaap:TrademarksMember 2023-12-31 0001607962 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0001607962 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-01-01 2023-12-31 0001607962 lfwd:CustomerRelationshipWarrantyMember 2023-12-31 0001607962 lfwd:CustomerRelationshipWarrantyMember 2023-01-01 2023-12-31 0001607962 lfwd:CustomerRelationshipRentalMember 2023-12-31 0001607962 lfwd:CustomerRelationshipRentalMember 2023-01-01 2023-12-31 0001607962 lfwd:CustomerRelationshipDistributionMember 2023-12-31 0001607962 lfwd:CustomerRelationshipDistributionMember 2023-01-01 2023-12-31 0001607962 us-gaap:OrderOrProductionBacklogMember 2023-12-31 0001607962 us-gaap:OrderOrProductionBacklogMember 2023-01-01 2023-12-31 0001607962 2022-01-01 2022-12-31 0001607962 2023-08-01 2023-08-08 0001607962 lfwd:AltergIncMember 2023-01-01 2023-12-31 0001607962 2021-01-01 2021-12-31 0001607962 2022-12-31 0001607962 lfwd:IsraelInnovationAuthorityMember 2023-01-01 2023-12-31 0001607962 us-gaap:ConvertiblePreferredStockMember lfwd:IsraelInnovationAuthorityMember 2023-01-01 2023-12-31 0001607962 us-gaap:ConvertiblePreferredStockMember lfwd:IsraelInnovationAuthorityMember 2023-12-31 0001607962 us-gaap:IPOMember 2023-01-01 2023-12-31 0001607962 lfwd:IsraelInnovationAuthorityMember 2023-12-31 0001607962 country:US 2023-01-01 2023-12-31 0001607962 country:US 2022-01-01 2022-12-31 0001607962 country:US 2021-01-01 2021-12-31 0001607962 srt:EuropeMember 2023-01-01 2023-12-31 0001607962 srt:EuropeMember 2022-01-01 2022-12-31 0001607962 srt:EuropeMember 2021-01-01 2021-12-31 0001607962 srt:AsiaPacificMember 2023-01-01 2023-12-31 0001607962 srt:AsiaPacificMember 2022-01-01 2022-12-31 0001607962 srt:AsiaPacificMember 2021-01-01 2021-12-31 0001607962 country:IL 2023-12-31 0001607962 country:IL 2022-12-31 0001607962 country:US 2023-12-31 0001607962 country:US 2022-12-31 0001607962 country:DE 2023-12-31 0001607962 country:DE 2022-12-31 0001607962 lfwd:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001607962 lfwd:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001607962 lfwd:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001607962 lfwd:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001607962 lfwd:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001607962 lfwd:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001607962 lfwd:RestOfWorldMember 2023-01-01 2023-12-31 0001607962 lfwd:RestOfWorldMember 2022-01-01 2022-12-31 0001607962 lfwd:RestOfWorldMember 2021-01-01 2021-12-31 0001607962 us-gaap:CustomerRelationshipsMember 2023-12-31 0001607962 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0001607962 lfwd:BacklogMember 2023-12-31 0001607962 lfwd:BacklogMember 2023-01-01 2023-12-31 0001607962 lfwd:AltergIncMember 2023-01-01 2023-09-30 0001607962 us-gaap:PrivatePlacementMember 2023-01-01 2023-12-31 0001607962 lfwd:RegisteredDirectMember 2023-01-01 2023-12-31 0001607962 2021-12-31 0001607962 2020-12-31 0001607962 lfwd:LicenseAgreementAndCollaborationAgreementMember 2023-01-01 2023-12-31 0001607962 lfwd:LicenseAgreementAndCollaborationAgreementMember 2022-01-01 2022-12-31 0001607962 lfwd:LicenseAgreementAndCollaborationAgreementMember 2021-01-01 2021-12-31 0001607962 2023-06-30 0001607962 2024-02-27 0001607962 lfwd:PurchaseAgreementWithCertainInstitutionalAccerditedInvestorsMember 2021-02-02 2021-02-19 0001607962 lfwd:PurchaseAgreementWithCertainInstitutionalAccerditedInvestorsMember 2021-02-19 0001607962 lfwd:AdditionallyWarrantsIssuedMember lfwd:PurchaseAgreementWithCertainInstitutionalAccerditedInvestorsMember 2021-02-19 0001607962 lfwd:PurchaseAgreementWithCertainInstitutionalInvestorsMember 2021-09-01 2021-09-27 0001607962 lfwd:PurchaseAgreementWithCertainInstitutionalInvestorsMember 2021-09-27 0001607962 lfwd:AdditionallyWarrantsIssuedMember lfwd:PurchaseAgreementWithCertainInstitutionalInvestorsMember 2021-09-01 2021-09-27 0001607962 lfwd:AdditionallyWarrantsIssuedMember lfwd:PurchaseAgreementWithCertainInstitutionalInvestorsMember 2021-09-27 0001607962 lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember 2022-12-31 0001607962 lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember 2023-01-01 2023-12-31 0001607962 lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeMember 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeOneMember 2023-01-01 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeOneMember 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeTwoMember 2023-01-01 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeTwoMember 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeThreeMember 2023-01-01 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeFourMember 2023-01-01 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeFourMember 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeFiveMember 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember lfwd:ExercisePriceRangeFiveMember 2023-01-01 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001607962 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001607962 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001607962 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001607962 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001607962 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001607962 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001607962 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-12-31 0001607962 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0001607962 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001607962 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001607962 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001607962 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberTwoThousandFifteenMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberTwoThousandSixteenMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnNovemberTwentyTwoThousandEighteenMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnNovemberTwentyTwoThousandEighteenMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnNovemberTwentyTwoThousandEighteenOneMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnNovemberTwentyTwoThousandEighteenOneMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentyFiveTwoThousandNineteenMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentyFiveTwoThousandNineteenMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenOneMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnAprilFiveTwoThousandNineteenOneMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneFiveAndSixTwoThousandNineteenMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneFiveAndSixTwoThousandNineteenMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneFiveTwoThousandNineteenMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneFiveTwoThousandNineteenMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTweleveTwoThousandNineteenMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTweleveTwoThousandNineteenMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTenTwoThousandNineteenMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTenTwoThousandNineteenMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyOneMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTenTwoThousandTwentyOneMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyOneMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJulySixTwoThousandTwentyOneMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyOneMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyOneMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneMember 2023-01-01 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneOneMember 2023-12-31 0001607962 lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneOneMember 2023-01-01 2023-12-31 0001607962 lfwd:KreosCapitalVMember 2015-01-01 2015-12-31 0001607962 lfwd:KreosCapitalMember 2016-12-28 0001607962 srt:MinimumMember 2023-12-31 0001607962 srt:MaximumMember 2023-12-31 0001607962 us-gaap:EmployeeStockOptionMember 2022-12-31 0001607962 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001607962 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001607962 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001607962 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001607962 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001607962 lfwd:KreosCapitalMember 2015-12-31 0001607962 lfwd:ShareRepurchaseProgramMember 2022-06-02 0001607962 lfwd:ShareRepurchaseProgramMember 2023-12-31 0001607962 lfwd:ShareRepurchaseProgramMember 2023-01-01 2023-12-31 0001607962 lfwd:PurchaseAgreementWithCertainInstitutionalAccerditedInvestorsMember 2021-02-01 2021-02-19 0001607962 lfwd:AdditionallyWarrantsIssuedMember lfwd:PurchaseAgreementWithCertainInstitutionalAccerditedInvestorsMember 2021-02-01 2021-02-19 0001607962 lfwd:OfferingOfOrdinarySharesInDecember2020Member lfwd:CertainInstitutionalPurchasersMember 2022-12-31 0001607962 lfwd:OfferingOfOrdinarySharesInDecember2020Member lfwd:CertainInstitutionalPurchasersMember 2022-01-01 2022-12-31 0001607962 lfwd:OfferingOfOrdinarySharesInJuly2020Member lfwd:CertainInstitutionalPurchasersMember 2022-12-31 0001607962 lfwd:OfferingOfOrdinarySharesInJuly2020Member lfwd:CertainInstitutionalPurchasersMember 2022-01-01 2022-12-31 0001607962 lfwd:OfferingOfOrdinarySharesInFebruary2020TwoMember lfwd:CertainInstitutionalPurchasersMember 2022-12-31 0001607962 lfwd:OfferingOfOrdinarySharesInFebruary2020TwoMember lfwd:CertainInstitutionalPurchasersMember 2022-01-01 2022-12-31 0001607962 lfwd:OfferingOfOrdinarySharesInFebruary2020Member lfwd:CertainInstitutionalPurchasersMember 2022-12-31 0001607962 lfwd:OfferingOfOrdinarySharesInFebruary2020Member lfwd:CertainInstitutionalPurchasersMember 2022-01-01 2022-12-31 0001607962 lfwd:December2020PrivatePlacementMember lfwd:CertainInstitutionalPurchasersMember 2022-12-31 0001607962 lfwd:December2020PrivatePlacementMember lfwd:CertainInstitutionalPurchasersMember 2022-01-01 2022-12-31 0001607962 lfwd:ShareRepurchaseProgramMember 2022-07-21 0001607962 lfwd:ShareRepurchaseProgramMember 2022-12-22 0001607962 us-gaap:CommonStockMember 2020-12-31 0001607962 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001607962 us-gaap:RetainedEarningsMember 2020-12-31 0001607962 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001607962 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001607962 lfwd:BestOfferingMember 2021-01-01 2021-12-31 0001607962 lfwd:RegisteredDirectOfferingMember 2021-01-01 2021-12-31 0001607962 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001607962 us-gaap:CommonStockMember 2021-12-31 0001607962 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001607962 us-gaap:RetainedEarningsMember 2021-12-31 0001607962 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001607962 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001607962 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001607962 us-gaap:CommonStockMember 2022-12-31 0001607962 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001607962 us-gaap:RetainedEarningsMember 2022-12-31 0001607962 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001607962 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001607962 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001607962 us-gaap:RetainedEarningsMember 2023-12-31 0001607962 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001607962 us-gaap:CommonStockMember 2023-12-31 0001607962 us-gaap:TreasuryStockPreferredMember 2023-01-01 2023-12-31 0001607962 us-gaap:TreasuryStockPreferredMember 2023-12-31 0001607962 us-gaap:TreasuryStockPreferredMember 2020-12-31 0001607962 us-gaap:TreasuryStockPreferredMember 2021-01-01 2021-12-31 0001607962 us-gaap:TreasuryStockPreferredMember 2021-12-31 0001607962 us-gaap:TreasuryStockPreferredMember 2022-01-01 2022-12-31 0001607962 us-gaap:TreasuryStockPreferredMember 2022-12-31 0001607962 lfwd:TwoZeroTwoThreeReorganizationPlanMember 2023-12-01 2023-12-12 0001607962 lfwd:TwoZeroTwoThreeReorganizationPlanMember 2023-01-01 2023-12-31 0001607962 srt:MinimumMember us-gaap:ComputerEquipmentMember 2023-12-31 0001607962 srt:MaximumMember us-gaap:ComputerEquipmentMember 2023-12-31 0001607962 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0001607962 lfwd:MachineryAndLaboratoryEquipmentMember 2023-12-31 0001607962 srt:MaximumMember lfwd:FieldServiceUnitsMember 2023-12-31 0001607962 lfwd:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001607962 lfwd:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001607962 lfwd:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001607962 lfwd:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001607962 lfwd:ReStoreProductMember 2023-12-31 0001607962 lfwd:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2022-01-01 2022-12-31 0001607962 lfwd:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2022-01-01 2022-12-31 0001607962 lfwd:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2022-01-01 2022-12-31 0001607962 lfwd:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2022-01-01 2022-12-31 0001607962 lfwd:SCIProductsMember 2023-12-31 0001607962 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-12-31 0001607962 us-gaap:ProductMember 2021-01-01 2021-12-31 0001607962 us-gaap:ProductMember 2022-01-01 2022-12-31 0001607962 us-gaap:ProductMember 2023-01-01 2023-12-31 0001607962 lfwd:RentalMember 2021-01-01 2021-12-31 0001607962 lfwd:RentalMember 2022-01-01 2022-12-31 0001607962 lfwd:RentalMember 2023-01-01 2023-12-31 0001607962 lfwd:ServiceAndWarrantyMember 2021-01-01 2021-12-31 0001607962 lfwd:ServiceAndWarrantyMember 2022-01-01 2022-12-31 0001607962 lfwd:ServiceAndWarrantyMember 2023-01-01 2023-12-31 0001607962 2023-01-01 2023-09-30 0001607962 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001607962 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001607962 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001607962 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001607962 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001607962 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001607962 us-gaap:FairValueInputsLevel3Member lfwd:EarnoutMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001607962 us-gaap:FairValueInputsLevel3Member lfwd:EarnoutMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001607962 lfwd:EarnoutMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001607962 lfwd:EarnoutMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001607962 lfwd:EarnoutMember 2023-08-11 0001607962 lfwd:EarnoutMember 2023-08-12 2023-09-30 0001607962 lfwd:EarnoutMember 2023-09-30 0001607962 srt:MinimumMember lfwd:FieldServiceUnitsMember 2023-12-31 0001607962 srt:MinimumMember 2023-01-01 2023-12-31 0001607962 srt:MaximumMember 2023-01-01 2023-12-31 0001607962 us-gaap:ComputerEquipmentMember 2023-12-31 0001607962 us-gaap:ComputerEquipmentMember 2022-12-31 0001607962 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001607962 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001607962 lfwd:MachineryAndLaboratoryEquipmentMember 2022-12-31 0001607962 lfwd:FieldServiceUnitsMember 2023-12-31 0001607962 lfwd:FieldServiceUnitsMember 2022-12-31 0001607962 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001607962 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001607962 us-gaap:IsraelTaxAuthorityMember 2020-01-01 2020-12-31 0001607962 us-gaap:IsraelTaxAuthorityMember 2021-01-01 2021-12-31 0001607962 us-gaap:IsraelTaxAuthorityMember 2022-01-01 2022-12-31 0001607962 lfwd:ReWalkRoboticsIncMember 2023-01-01 2023-12-31 0001607962 lfwd:ReWalkRoboticsIncMember 2022-01-01 2022-12-31 0001607962 lfwd:ReWalkRoboticsIncMember 2021-01-01 2021-12-31 0001607962 lfwd:RewalkRoboticsGmbhMember 2023-01-01 2023-12-31 0001607962 lfwd:RewalkRoboticsGmbhMember 2022-01-01 2022-12-31 0001607962 lfwd:RewalkRoboticsGmbhMember 2021-01-01 2021-12-31 0001607962 lfwd:ReWalkRoboticsIncMember 2023-12-31 0001607962 lfwd:AltergIncMember 2023-12-31 0001607962 us-gaap:StateAndLocalJurisdictionMember lfwd:AltergIncMember 2023-12-31 0001607962 lfwd:AltergIncMember 2023-01-01 2023-12-31 0001607962 us-gaap:ForeignCountryMember lfwd:AltergIncMember 2018-01-01 0001607962 lfwd:AltergIncMember 2018-01-01 iso4217:ILS shares iso4217:USD iso4217:USD shares pure lfwd:segment shares 0001607962 FY false 00-0000000 P5Y 10-K true 2023-12-31 --12-31 2023 false 001-36612 ReWalk Robotics Ltd. L3 3 Hatnufa Street Floor 6 Yokneam Illit IL 2069203 972 4.959.0123 Ordinary Shares, par value NIS 0.25 per share LFWD NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 35050478 59480132 1281 KOST FORER GABBAY & Tel-Aviv, Israel 28083000 67896000 328000 26000 3120000 1036000 2366000 649000 5653000 2929000 39222000 72510000 784000 694000 1861000 836000 1262000 196000 12525000 0 7538000 0 23970000 1726000 63192000 74236000 5069000 1950000 2034000 1282000 1504000 301000 1296000 564000 576000 0 1316000 685000 11795000 4782000 2716000 0 1506000 890000 607000 333000 58000 66000 4887000 1289000 16682000 6071000 0.25 0.25 120000000 120000000 64132706 63023506 60110099 60090298 4487000 4489000 281109000 279857000 4022607 2933208 3203000 2431000 -235883000 -213750000 46510000 68165000 63192000 74236000 13854000 5511000 5966000 9401000 3606000 3063000 4453000 1905000 2903000 4148000 4031000 2939000 13922000 9842000 6993000 9995000 7134000 5626000 28065000 21007000 15558000 -23612000 -19102000 -12655000 -1467000 -13000 -22145000 -19102000 -12642000 -12000 467000 94000 -22133000 -19569000 -12736000 -0.37 -0.37 -0.31 -0.31 -0.27 -0.27 59719064 59719064 62378797 62378797 47935652 47935652 25332225 1827000 201392000 0 -181445000 21774000 0 833000 0 0 833000 398164 31000 -31000 0 0 0 3679000 10921502 832000 35489000 0 0 36321000 10425258 772000 14288000 0 0 15060000 3215000 15403014 1199000 26932000 0 0 28131000 0 0 0 -12736000 -12736000 62480163000 4661000 278903000 -194181000 89383000 0 993000 0 0 993000 543343 39000 -39000 0 0 0 -2933208 -211000 0 -2431000 0 -2642000 0 0 0 -19569000 -19569000 60090298 4489000 279857000 2431000 -213750000 68165000 0 1328000 0 0 1328000 1109200 76000 -76000 0 0 0 -1089399 -78000 0 -772000 0 -850000 -0 0 -0 -22133000 -22133000 60110099 4487000 281109000 -3203000 -235883000 46510000 -22133000 -19569000 -12736000 239000 202000 266000 1608000 0 0 1328000 993000 833000 0 316000 -29000 -315000 0 0 11000 0 0 -45000 79000 0 311000 408000 -99000 531000 -94000 -592000 277000 117000 -432000 1037000 566000 -884000 -14000 140000 275000 -269000 -34000 74000 -973000 -153000 -391000 -20667000 -17891000 -11469000 18068000 0 0 81000 25000 47000 -18149000 -25000 -47000 3679000 0 0 36321000 3215000 0 0 28131000 0 0 15060000 992000 2500000 0 -992000 -2500000 79512000 45000 -79000 0 -39763000 -20495000 67996000 68555000 89050000 21054000 28792000 68555000 89050000 0 22000 34000 481000 67000 32000 0 142000 0 513000 0 0 126000 113000 40000 1341000 0 0 28083000 67896000 88337000 709000 659000 713000 28792000 68555000 89050000 <div> <div> <div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE 1:-</span></span></span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>GENERAL</span></span></span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date.</span></span></span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>b.</span></span></span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>RRL has three wholly-owned (directly and indirectly) subsidiaries: (i) ReWalk Robotics, Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012, (ii) ReWalk Robotics GMBH (“RRG”) incorporated under the laws of Germany on January 14, 2013, and (iii) AlterG, Inc. (“AlterG”) incorporated in Delaware on October 21, 2004 under the name of Gravus, Inc. On June 30, 2005, the Company re-incorporated in Delaware and changed its name to AlterG, Inc. in September 2005.</span></span></span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>c.</span></span></span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company is a medical device company that is designing, developing, and commercializing innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions. The Company’s initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury (collectively, the “SCI Products”). These devices are robotic exoskeletons that are designed for individuals with paraplegia that use the Company’s patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. These SCI Products allow individuals with spinal cord injury the ability to stand and walk again during everyday activities at home or in the community.</span></span></span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company has sought to expand the product offerings beyond the SCI Products through internal development and distribution agreements. The Company has developed its ReStore Exo-Suit device, which it began commercializing in June 2019. The ReStore is a powered, lightweight soft exo-suit intended for use during the rehabilitation of individuals with lower limb disability due to stroke. During the second quarter of 2020, the Company signed two separate agreements to distribute additional product lines in the United States. The Company is the exclusive distributor of the MYOLYN MyoCycle FES Pro cycles to United States (“U.S.”) rehabilitation clinics and for the MyoCycle Home cycles available to US veterans through VA hospitals. In the second quarter of 2020, the Company also became the exclusive distributor of the MediTouch Tutor movement biofeedback systems in the United States; however, due to unsatisfactory sales performance of the MediTouch product lines, the Company terminated this agreement as of January 31, 2023. We refer to the MediTouch and MyoCycle devices as the Company’s “Distributed Products.”</span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On August 11, 2023, pursuant to an Agreement and Plan of Merger among RRI, AlterG, Atlas Merger Sub, Inc., a wholly owned subsidiary of RRI (“Merger Sub”), and Shareholder Representative Services LLC, dated August 11, 2023, RRI acquired AlterG and AlterG became a wholly owned subsidiary of the Company.</span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For accounting purposes, RRI was considered the acquirer and AlterG was considered the acquiree. The acquisition was accounted for using the acquisition method of accounting. See Note 5 for additional information.</span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company made its first acquisition to supplement its internal growth when it acquired AlterG, a leading provider of AlterG Anti-Gravity systems for use in physical and neurological rehabilitation.  The Company paid a cash purchase price of $19.0 million at closing and additional cash earnouts may be paid based upon a percentage of AlterG’s year-over-year revenue growth over the two years following the closing. The AlterG Anti-Gravity systems use patented, NASA-derived Differential Air Pressure (“DAP”) technology to reduce the effects of gravity and allow people to rehabilitate with finely calibrated support and reduced pain.  The Company will continue to evaluate other products for distribution or acquisition that can broaden its product offerings further to help individuals with physical and neurological injury and disability.</span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company markets and sells its products directly to institutions and individuals and through third-party distributors. The Company sells its products directly primarily in the United States, through a combination of direct sales and distributors (depending on the product line) in Germany, Canada, and Australia, and primarily through distributors in other markets. In its direct markets, the Company has established relationships with clinics and rehabilitation centers, professional and college sports teams, and individuals and organizations in the spinal cord injury community, and in its indirect markets, the Company’s distributors maintain these relationships. RRI and AlterG market and sell products mainly in the United States. RRG markets and sells the Company’s products mainly in Germany and Europe.</span></span></span></span></div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"> </div> <div style="text-align:justify;line-height:1.25"> <div></div> </div> <div style="text-align:justify;line-height:1.25"> <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>d.</span></span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company depends on one contract manufacturer to manufacture the ReWalk and the ReStore products in its portfolio, Sanmina. Reliance on this vendor makes the Company vulnerable to possible capacity constraints and reduces control over component availability, delivery schedules, manufacturing yields and costs.</span></span></span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> <div style="text-align:justify;line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>e.</span></span></span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>For the full year ended December 31, 2023 the Company incurred a consolidated net loss of $22.1 million and has an accumulated deficit in the total amount of $235.9 million. The Company’s negative operating cash flow for the full year ended December 31, 2023 was $20.7 million. Our cash and cash equivalent on December 31, 2023 totalled $28.1 million. The Company has sufficient funds to support its operation for more than 12 months following the approval of its consolidated financial statements for the fiscal year ended December 31, 2023.</span></span></span></span></span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The Company expects to incur future net losses and the transition to profitability is dependent upon, among other things, the successful development and commercialization of the Company’s products and product candidates, the establishment of contracts for the distribution of new product lines, or the acquisition of additional product lines, any of which, or in combination, would contribute to the achievement of a level of revenue adequate to support the cost structure. Until the Company achieves profitability or generates positive cash flows, it will continue to need to raise additional cash. The Company intends to fund future operations through existing cash on hand, additional private and/or public offerings of debt or equity securities, cash exercises of outstanding warrants or a combination of the foregoing. In addition, the Company may seek additional capital through arrangements with strategic partners or from other sources and will continue to address its cost structure. Notwithstanding, there can be no assurance that the Company will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.</span></span></span></span></span></span></div> </div> </div> </div> </div> </div> -22100000 -235900000 -20700000 28100000 <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt;vertical-align:top;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 2:-</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SIGNIFICANT ACCOUNTING POLICIES</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), applied on a consistent basis, as follows:</span></span></div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt;vertical-align:top"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Use of Estimates</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to inventories, fair values of share-based awards, contingent liabilities, provision for warranty, allowance for credit losses and sales return reserve. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial Statements in U.S. Dollars:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The functional currency is the currency that best reflects the economic environment in which the Company and its subsidiaries operate and conduct their transactions. Most of the Company’s revenues and costs are incurred in U.S. dollar. In addition, the Company’s financing activities are incurred in U.S. dollars. The Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and each of its subsidiaries operate. Thus, the dollar is the Company’s and its subsidiary's functional and reporting currency.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are remeasured into U.S. dollars in accordance with ASC 830 “Foreign Currency Matters.” All transaction gains and losses of the remeasured monetary balance sheet items are reflected in the consolidated statements of operations as financing income or expenses as appropriate.</span></span></div> </div> <p style="margin:0pt"> </p> <div></div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Principles of Consolidation:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances have been eliminated upon consolidation.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash Equivalents:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less, at the date acquired.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inventories:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inventories are stated at the lower of cost or net realizable value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company periodically evaluates the quantities on hand relative to historical, current, and projected sales volume. Based on this evaluation, an impairment charge is recorded when required to write-down inventory to its net realized value.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost is determined as follows:</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Finished products - based on raw materials and manufacturing costs on an average basis.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Raw materials - The weighted average cost method.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors, including historical usage rates and forecasted sales according to outstanding backlogs. Purchasing requirements and alternative usage are explored within these processes to mitigate inventory exposure. When recorded, the reserves are intended to reduce the carrying value of inventory to its net realizable value. If actual demand for the Company’s products deteriorates, or market conditions are less favourable than those projected, additional inventory reserves may be required.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and Equipment:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:95%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="width:65.04%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td style="width:34.96%;vertical-align:bottom;border-bottom:#000000 2px solid"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computer equipment</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20-33 (mainly 33)</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office furniture and equipment</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6 - 10 (mainly 10)</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Machinery and laboratory equipment</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Field service units</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20-50</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:top;background-color:rgb(204, 238, 255)"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Over the shorter of the lease term </span></span></div> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>or estimated useful life</span></span></span></div> </td> </tr> </table> </div> </div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Business Combinations</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for business combinations in accordance with ASC 805, “Business Combinations” (“ASC 805”). For business combinations accounted for under the acquisition method, ASC 805 requires recognition of assets acquired, liabilities assumed, and any non-controlling interest at the acquisition date, measured at their fair values as of that date. The Company determines the recognition of intangible assets based on the following criteria: (i) the intangible asset arises from contractual or other rights; or (ii) the intangible asset is separable or divisible from the acquired entity and capable of being sold, transferred, licensed, returned or exchanged.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The excess of the fair value of the purchase price over the fair values of the identifiable assets and liabilities is recorded as goodwill. Determining the fair value of the identifiable assets and liabilities requires management to use significant judgment and estimates including the forecasted revenue and revenues growth rates, discount rates, customer contract renewal rates and customer attrition rates. The process of estimating the fair values requires significant estimates, especially with respect to intangible assets. Management’s determination of fair value of assets acquired and liabilities assumed at the acquisition date is based on the best information available in the circumstances and incorporates management’s own assumptions and involves a significant degree of judgment.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Acquisition related costs include legal fees, consulting and success fees, and other non-recurring integration related costs. Acquisition-related costs are expensed as incurred.</span></span></div> </div> <p style="margin:0pt"> </p> <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"> <div></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">h.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Goodwill and Other Intangibles</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For business combinations, the purchase prices are allocated to the tangible assets and intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition dates, with the remaining unallocated purchase prices recorded as goodwill.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has no indefinite-lived intangible assets other than goodwill. Acquired identifiable finite-lived intangible assets include identifiable acquired technology, customer relationships, trademarks and backlog and are amortized on a straight-line basis over the estimated useful lives of the assets. The Company routinely reviews the remaining estimated useful lives of finite-lived intangible assets.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Goodwill is not amortized and is tested for impairment at least annually.</span></span></div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company operates as one reporting unit and the fair value of the reporting unit is estimated using quoted market prices of the Company’s stock in active markets. The Company tests goodwill for impairment annually in the fourth quarter and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When testing goodwill for impairment, the Company may first perform a qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. The Company may elect to bypass the qualitative assessment and proceed directly to performing a quantitative analysis. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company recognizes an impairment of goodwill for the amount of this excess.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, no impairments of goodwill have been recognized.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Impairment of Long-Lived Assets</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company’s long-lived assets, including right-of-use (“ROU”) assets and identifiable intangible assets that are subject to amortization, are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2023, 2022 and 2021, no impairment losses have been recorded.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">j.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash and Other long-term assets:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other long-term assets include long-term prepaid expenses and restricted cash deposits for offices and cars leasing based upon the term of the remaining restrictions.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">k.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Treasury shares</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company repurchased its ordinary shares and holds them as treasury shares. The Company presents the cost to repurchase treasury shares as a reduction of shareholders' equity.</span></span></div> </div> <p style="margin:0pt"> </p> <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"> <div></div> </div> <div> <div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">l.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue Recognition:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to clinics and rehabilitation centres, professional and college sports teams, private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), and distributors.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes revenue in accordance with ASC 606, “Revenue Recognition” when, or as, control of the promised good or service is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company applies the following five steps:</span></span></div> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Identify the contract with a customer</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generally considers a purchase order or a signed quote to be a contract with a customer. In evaluating the contract with a customer, the Company analyzes the customer’s intent and ability to pay the amount of promised consideration (credit risk) and considers the probability of collecting substantially all of the consideration.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Identify the performance obligations in the contract</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At a contract’s inception, the Company assesses the goods or services promised in a contract with a customer and identifies the performance obligations.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Determine the transaction price</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring products or services to the customer.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company does not offer extended payment terms beyond one year to customers.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Allocate the transaction price to performance obligations in the contract</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recognize revenue when or as the Company satisfies a performance obligation</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue is recognized when or as performance obligations are satisfied by transferring control of a promised good or service to a customer. Control either transfers over time or at a point in time, which affects when revenue is recorded.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has elected to apply the practical expedient for financing component for transactions in which the difference between the payment date and the revenue recognition timing is up to 12 months.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Disaggregation of Revenue (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:95%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Product</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,681</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,175</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,916</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rental</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,033</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">859</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">533</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Service and warranty</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,140</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">477</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">517</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total Revenues</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,854</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,511</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,966</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-style:italic"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Product revenue</span></span></div> <div style="line-height:1.25"> </div> <div style="line-height:1.25"> <div style="text-align:justify;margin-left:33.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue from Products is comprised of sale of Anti-Gravity products, sale of systems products to rehabilitation facilities and sale of ReWalk Personal Exoskeleton systems to end users. Revenues generated from the sale of Products are recognized at a point in time, once the customer has obtained the legal title to the items purchased.</span></span></div> </div> <div style="line-height:1.25"> <div style="margin-left:33.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"> </div> </div> <div style="line-height:1.25"> <div style="text-align:justify;margin-left:33.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For systems sold to rehabilitation facilities, the Company includes insignificant training and considers the elements in the arrangement to be a single performance obligation. Therefore, the Company recognizes revenue for the system only when control is transferred after delivery and when the training has been completed, in accordance with the agreements terms with the customer.</span></span> <p style="margin:0pt"> </p> </div> <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"> <div></div> </div> </div> <div style="line-height:1.25"> <div style="text-align:justify;margin-left:33.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For sales of ReWalk Personal Exoskeleton systems to end users, and for sales of ReWalk Personal or ReWalk Rehabilitation Exoskeleton systems to third party distributors, the Company does not provide training to the end user as this training is completed by the rehabilitation center or by the distributor that have previously completed the ReWalk Training program. Therefore, the Company recognizes revenue in such sales upon delivery.</span></span></div> </div> <div style="line-height:1.25"> <div style="margin-left:33.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"> </div> </div> <div style="line-height:1.25"> <div style="text-align:justify;margin-left:33.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generally does not grant a right of return for its products. In rare circumstances when the Company provides a right of return for its products. the Company records reductions to revenue for expected future product returns based on the Company’s historical experience and estimates.</span></span></div> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2023, the Company offered six products: (1) ReWalk Personal Exoskeletons, (2) ReWalk Rehabilitation Exoskeleton, (3) ReStore, (4) AlterG Anti-Gravity systems, (5) MyoCycle and (6) MediTouch. Due to unsatisfactory sales performance of the MediTouch product lines, the Company terminated this agreement as of January 31, 2023.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rental revenue</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rental revenue for the AlterG Anti-Gravity systems is accounted for under ASC Topic 842, Leases. The Company rents its products to customers for a fixed monthly fee over the rental term, which typically ranges from 2 to 3 years. Rental revenues are recorded as earned on a monthly basis. See Note 2x for additional information.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the SCI Products, the Company also offers a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee for a limited period prior to selling its products.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Service and warranties</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company services its products after expiration of the initial warranty. Service revenue, consisting of time and materials to perform the repairs, is recorded as services are rendered.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Determining the transaction price requires of level judgment, which is discussed by revenue category in further detail below.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warranties are classified as either an assurance type or a service type warranty. A warranty is considered an assurance type warranty if it provides the customer with assurance that the product will function as intended for a limited period of time. An assurance type warranty is not accounted for as a separate performance obligation under the revenue model.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SCI Products include a <span style="-sec-ix-hidden:Fxbrl_20230214112251731"> five -year warranty</span>. The first two years are considered as an assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. A service type warranty is either sold with a unit or separately for a unit for which the warranty has expired. A service type warranty is accounted as a separate performance obligation and revenue is recognized ratably over the life of the warranty.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The ReStore device is sold with a two-year warranty which is considered as assurance type warranty.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Distributed Products are sold with assurance type warranty ranging between three years to ten years, depending on the specific product and part.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F</span></span><span style="font-family:Times New Roman, Times, serif;font-size:10pt">or AlterG Anti-Gravity Products, the Company offers customers extended warranty contracts that extend or enhance the technical support, parts, and labor coverage offered as part of the base warranty included with the Anti-Gravity system products. Extended warranty revenue is recognized ratably over the extended warranty coverage period. The Company offers a one-year assurance type warranty to customers in the U.S. and two years assurance type warranty for spare parts only to its international distributors. For these products, the Company determines standalone selling price based on the price at which the performance obligation is sold separately.</span> <p style="margin:0pt"> </p> </div> <div style="line-height:1.25"> <div></div> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Contract balances (in thousands):</span></span></div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"> </div> <div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:95%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade receivable, net of credit losses (1)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,120</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,036</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred revenues (1) (2)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,010</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,191</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance presented net of unrecognized revenue that was not yet collected.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$435 thousands of the December 31, 2022 deferred revenue balance was recognized as revenue during the year ended December 31, 2023.</span></span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred revenue which represent a contract liability, include unearned amounts related to service type warranty obligations as well as other advances and payments which the Company received from customers prior to satisfying the performance obligation, for which revenue has not yet been recognized. The Company's unearned performance obligations as of December 31, 2023 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $3.1 million, which will be fulfilled over one to five years.</span></span></div> </div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">m.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accounting for Share-Based Compensation:</span></span></div> </td> </tr> </table> <div style="line-height:1.25;margin-left:18pt"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for share-based compensation in accordance with ASC 718, “Compensation-Stock Compensation” (“ASC 718”). ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model (“OPM”). The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations.</span></span></div> <div style="line-height:1.25;margin-left:18pt"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. The Company account for forfeitures as they occur.</span></span></div> <div style="line-height:1.25;margin-left:18pt"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its share-option awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary share, expected share price volatility and the expected option term. Expected volatility is calculated based on actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options, or based on certain peer companies that the Company considered to be comparable, in case there is no sufficient trading volume to rely on market volatility. The expected option term is determined based on the simplified method, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></div> <div style="line-height:1.25;margin-left:18pt"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of Restricted Stock Units (“RSUs”) granted is determined based on the price of the Company’s ordinary shares on the date of grant.</span></span></div> <div style="line-height:1.25;margin-left:18pt"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for options granted to consultants and other service providers under ASC 718. The fair value of these options was estimated using a Black-Scholes-Merton option-pricing model.</span></span></div> </div> <div style="line-height:1.25;margin-left:18pt"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">n.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants to Acquire Ordinary Shares:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the twelve -month ended December 31, 2021, the Company issued warrants to acquire up to 15,083,611 ordinary shares. There were no issued warrants during the twelve months ended December 31, 2023 and 2022. The Company assessed the warrants pursuant to ASC 480 "Distinguishing Liabilities from Equity" and ASC 815 "Derivatives and Hedging" and determined that the warrants should be accounted for as equity and not as a derivative liability. Refer to Note 9f for additional information.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">o.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and Development Costs:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are charged to the consolidated statement of operations as incurred and are presented net of the amount of any grants the Company received for research and development in the period in which the grant was received.</span></span></div> </div> <p style="margin:0pt"> </p> <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif"> <div></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">p.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income Taxes</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”), using the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits in its taxes on income. As of December 31, 2023, and 2022, the Company did not identify any significant uncertain tax positions.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">q.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warranty provision:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For assurance-type warranty, the Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">US Dollars</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">92</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AlterG acquisition – see note 5</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">535</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Provision</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">200</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:88%;padding-bottom:2px;vertical-align:baseline"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Usage</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(479</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">348</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">r.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Concentrations of Credit Risks:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company’s cash and cash equivalents are deposited in major banks in Israel, the United States and Germany. Such deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. The Company maintains cash and cash equivalents with diverse financial institutions and monitors the amount of credit exposure to each financial institution. The bank deposits are held in financial institutions which management believes are institutions with high credit standing, and accordingly, minimal credit risk from geographic or credit concentration exists with respect to these deposits.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The below table reflects the concentration of credit risk for the Company’s current customers as of December 31, 2023, to which substantial sales were made.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales.</span></span></div> <div style="line-height:1.25"> </div> <div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer A</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:FFact_0000000000446">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer B</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:FFact_0000000000448">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer C</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer D</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:54pt;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*)</span></span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less than 10%</span></span></div> </td> </tr> </table> <p style="margin:0pt"> </p> </div> <div style="line-height:1.25"> <div></div> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The allowance for credit losses is based on the Company's assessments of factors that may affect a customer's ability to pay. The Company regularly reviews the adequacy of the allowance for credit losses based on a combination of factors, including an assessment of the current customer's aging balance, the nature and size of the customer, the financial condition of the customer, and the amount of any receivables in dispute. The Company does not have any off-balance sheet credit exposure related to its customers. As of December 31, 2023, and 2022 trade receivables are presented net of $328 thousand and $26 thousand allowance for credit losses, respectively.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">s.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued Severance Pay:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to Israel’s Severance Pay Law, Israeli employees are entitled to severance pay equal to one month’s salary for each year of employment, or a portion thereof. All of the employees of the RRL elected to be included under section 14 of the Severance Pay Law, 1963 (“section 14”). According to this section, these employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total Company’s expenses related to severance pay amounted to $114 thousand , $113 thousand and $104 thousand for the years ended December 31, 2023, 2022 and 2021, respectively.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">t.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair Value Measurements:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a three -tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The three -tiers are defined as follows:</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:36pt;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">▪</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Level 1. </span>Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities;</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:36pt;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">▪</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Level 2. </span>Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:36pt;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">▪</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Level 3. </span>Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying amounts of cash and cash equivalents, short term deposits, trade receivables and trade payables approximate their fair value due to the short-term maturity of such instruments.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following tables present information about the Company’s financial assets and liabilities that are measured in fair value on a recurring basis as of December 31, 2023 and December 31, 2022 (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:bottom;padding-bottom:2px;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:middle;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value measurements as of</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:25%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:bottom;width:25%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair Value Hierarchy</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Financial assets:</span></span></span></div> </td> <td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:middle;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:middle;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Money market funds included in cash and cash equivalent</span></span></div> </td> <td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:25%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,550</span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Treasury bills included in cash and cash equivalent</span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,525</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:middle;width:2%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total Assets Measured at Fair Value</span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,075</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:middle;width:2%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Financial Liabilities:</span></span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Earnout</span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,292</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total liabilities measured at fair value</span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,292</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> <p style="margin:0pt"> </p> </div> <div style="line-height:1.25"> <div></div> </div> <div style="text-align:justify;margin-left:38.25pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company classifies cash equivalents within Level 1, because the Company uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair values.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:38.25pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The earnout was valued using a Monte Carlo simulation analysis, which is considered to be a Level 3 fair value measurement.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:38.25pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table summarizes the earnout liability activity as of December 31, 2023 (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:93%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="width:85.4%;vertical-align:top"> </td> <td style="width:1.06%;vertical-align:bottom"> </td> <td colspan="2" style="width:11.39%;vertical-align:top;border-bottom:#000000 2px solid"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Earnout</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;white-space:nowrap"> </td> <td style="width:1.08%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:85.4%;vertical-align:top;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Initial Measurement (August 11, 2023)</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> </td> <td style="width:1.34%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td style="width:10.05%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,607</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap"> </td> <td style="width:1.08%;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap"> </td> </tr> <tr> <td style="width:85.4%;vertical-align:top"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in fair value</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom"> </td> <td style="width:1.34%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> </td> <td style="width:10.05%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(315)</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;white-space:nowrap"> </td> <td style="width:1.08%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:85.4%;vertical-align:top;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance December 31, 2023</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> </td> <td style="width:1.34%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td style="width:10.05%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,292</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap"> </td> <td style="width:1.08%;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap"> </td> </tr> </table> </div> </div> </div> <div> <div style="line-height:1.25"> </div> <div> <div style="text-align:justify;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">u.<span style="padding-left:7pt"> </span>Basic and Diluted Net Loss Per Share:</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding during the period.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Diluted loss per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus dilutive potential shares considered outstanding during the period.</span></span></div> </div> </div> <div style="line-height:1.25"> </div> <div> <div style="margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">v.<span style="padding-left:8pt"> </span>Contingent liabilities</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for its contingent liabilities in accordance with ASC 450, “Contingencies.” A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <div style="margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">w.<span style="padding-left:8pt"> </span>Government grants</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalty and non-royalty-bearing grants from the Israeli Innovation Authority (the “IIA”) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a reduction from research and development expenses (see Note 8c).</span></span></div> </div> <p style="margin:0pt"> </p> <div style="line-height:1.25"> <div></div> </div> <div> <div style="margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">x.<span style="padding-left:8pt"> </span>Leases</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded at commencement date based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. </span></span></div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lessor accounting - Operating leases</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A portion of the AlterG rental revenues for the AlterG Anti-Gravity systems are made through lease arrangements.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AlterG products are available for lease agreements ranging from 12 to 42 months. If the customer terminates the contract during the lease period, they are required to pay a cancellation fee. The lease period may be extended by an additional period as specified in the contract.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In determining the leases classification as a sales type or operating lease, the Company assesses, among other criteria: (i) the lease term to determine if it is for the major part of the economic life of the underlying equipment; and (ii) the present value of the lease payments to determine if they are equal to or greater than substantially all of the fair market value of the equipment at the inception of the lease AlterG Anti-Gravity systems. When these criteria are not met, the lease accounted for as operating leases and revenues are recognized over the term of the lease.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under these arrangements, when the Company acts as the lessor for its product line, the Company accounted for the lease arrangements as operating leases in accordance with ASC 842, “Lease” (“ASC 842”).</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The total rental revenue for the AlterG Anti-Gravity Products has amounted to $249 thousand from the time of acquisition through December 31, 2023.</span></span></div> </div> <div style="line-height:1.25"> </div> <div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">y. <span style="padding-left:20pt"> </span>New Accounting Pronouncements</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently Implemented Accounting Pronouncements</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td rowspan="1" style="width:13.57%;vertical-align:top;font-family:'Times New Roman',Times,serif"> <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.           Financial Instruments</span></span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. The Company adopted ASU 2016-13 as of January 1, 2023. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recent Accounting Pronouncements Not Yet Adopted</span></span></div> <div style="line-height:1.25"> </div> <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:10%;vertical-align:top"> <div style="line-height:1.25"> </div> </td> <td style="width:6%;vertical-align:top"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></div> </td> <td style="width:84%;vertical-align:top"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes - Improvements to Income Tax Disclosures” requiring enhancements and further transparency to certain income tax disclosures, most notably the tax rate reconciliation and income taxes paid. This ASU is effective for fiscal years beginning after December 15, 2024 on a prospective basis and retrospective application is permitted. The Company is currently evaluating the impact of the adoption of this standard.</span></span></div> <div style="text-align:justify;line-height:1.25"> </div> </td> </tr> <tr> <td style="width:10%;vertical-align:top"> </td> <td style="width:6%;vertical-align:top"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ii.</span></span></div> </td> <td style="width:84%;vertical-align:top"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, “Segment Reporting” on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></span></div> </td> </tr> </table> </div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt;vertical-align:top"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Use of Estimates</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to inventories, fair values of share-based awards, contingent liabilities, provision for warranty, allowance for credit losses and sales return reserve. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.</span></span></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial Statements in U.S. Dollars:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The functional currency is the currency that best reflects the economic environment in which the Company and its subsidiaries operate and conduct their transactions. Most of the Company’s revenues and costs are incurred in U.S. dollar. In addition, the Company’s financing activities are incurred in U.S. dollars. The Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and each of its subsidiaries operate. Thus, the dollar is the Company’s and its subsidiary's functional and reporting currency.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are remeasured into U.S. dollars in accordance with ASC 830 “Foreign Currency Matters.” All transaction gains and losses of the remeasured monetary balance sheet items are reflected in the consolidated statements of operations as financing income or expenses as appropriate.</span></span></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Principles of Consolidation:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances have been eliminated upon consolidation.</span></span></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash Equivalents:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less, at the date acquired.</span></span></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inventories:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inventories are stated at the lower of cost or net realizable value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company periodically evaluates the quantities on hand relative to historical, current, and projected sales volume. Based on this evaluation, an impairment charge is recorded when required to write-down inventory to its net realized value.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost is determined as follows:</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Finished products - based on raw materials and manufacturing costs on an average basis.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:18pt;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Raw materials - The weighted average cost method.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors, including historical usage rates and forecasted sales according to outstanding backlogs. Purchasing requirements and alternative usage are explored within these processes to mitigate inventory exposure. When recorded, the reserves are intended to reduce the carrying value of inventory to its net realizable value. If actual demand for the Company’s products deteriorates, or market conditions are less favourable than those projected, additional inventory reserves may be required.</span></span></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and Equipment:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:95%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="width:65.04%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td style="width:34.96%;vertical-align:bottom;border-bottom:#000000 2px solid"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computer equipment</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20-33 (mainly 33)</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office furniture and equipment</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6 - 10 (mainly 10)</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Machinery and laboratory equipment</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Field service units</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20-50</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:top;background-color:rgb(204, 238, 255)"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Over the shorter of the lease term </span></span></div> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>or estimated useful life</span></span></span></div> </td> </tr> </table> </div> </div> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:95%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="width:65.04%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td style="width:34.96%;vertical-align:bottom;border-bottom:#000000 2px solid"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computer equipment</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20-33 (mainly 33)</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office furniture and equipment</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6 - 10 (mainly 10)</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Machinery and laboratory equipment</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Field service units</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20-50</span></span></div> </td> </tr> <tr> <td style="width:65.04%;vertical-align:top;background-color:rgb(204, 238, 255)"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements</span></span></div> </td> <td style="width:34.96%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Over the shorter of the lease term </span></span></div> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>or estimated useful life</span></span></span></div> </td> </tr> </table> </div> P20Y P33Y P6Y P10Y P15Y P20Y P50Y Over the shorter of the lease term <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Business Combinations</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for business combinations in accordance with ASC 805, “Business Combinations” (“ASC 805”). For business combinations accounted for under the acquisition method, ASC 805 requires recognition of assets acquired, liabilities assumed, and any non-controlling interest at the acquisition date, measured at their fair values as of that date. The Company determines the recognition of intangible assets based on the following criteria: (i) the intangible asset arises from contractual or other rights; or (ii) the intangible asset is separable or divisible from the acquired entity and capable of being sold, transferred, licensed, returned or exchanged.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The excess of the fair value of the purchase price over the fair values of the identifiable assets and liabilities is recorded as goodwill. Determining the fair value of the identifiable assets and liabilities requires management to use significant judgment and estimates including the forecasted revenue and revenues growth rates, discount rates, customer contract renewal rates and customer attrition rates. The process of estimating the fair values requires significant estimates, especially with respect to intangible assets. Management’s determination of fair value of assets acquired and liabilities assumed at the acquisition date is based on the best information available in the circumstances and incorporates management’s own assumptions and involves a significant degree of judgment.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Acquisition related costs include legal fees, consulting and success fees, and other non-recurring integration related costs. Acquisition-related costs are expensed as incurred.</span></span></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">h.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Goodwill and Other Intangibles</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For business combinations, the purchase prices are allocated to the tangible assets and intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition dates, with the remaining unallocated purchase prices recorded as goodwill.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has no indefinite-lived intangible assets other than goodwill. Acquired identifiable finite-lived intangible assets include identifiable acquired technology, customer relationships, trademarks and backlog and are amortized on a straight-line basis over the estimated useful lives of the assets. The Company routinely reviews the remaining estimated useful lives of finite-lived intangible assets.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Goodwill is not amortized and is tested for impairment at least annually.</span></span></div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company operates as one reporting unit and the fair value of the reporting unit is estimated using quoted market prices of the Company’s stock in active markets. The Company tests goodwill for impairment annually in the fourth quarter and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When testing goodwill for impairment, the Company may first perform a qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. The Company may elect to bypass the qualitative assessment and proceed directly to performing a quantitative analysis. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company recognizes an impairment of goodwill for the amount of this excess.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0pt;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, no impairments of goodwill have been recognized.</span></span></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Impairment of Long-Lived Assets</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company’s long-lived assets, including right-of-use (“ROU”) assets and identifiable intangible assets that are subject to amortization, are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2023, 2022 and 2021, no impairment losses have been recorded.</span></span></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">j.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash and Other long-term assets:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other long-term assets include long-term prepaid expenses and restricted cash deposits for offices and cars leasing based upon the term of the remaining restrictions.</span></span></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">k.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Treasury shares</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company repurchased its ordinary shares and holds them as treasury shares. The Company presents the cost to repurchase treasury shares as a reduction of shareholders' equity.</span></span></div> </div> <div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">l.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue Recognition:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to clinics and rehabilitation centres, professional and college sports teams, private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), and distributors.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes revenue in accordance with ASC 606, “Revenue Recognition” when, or as, control of the promised good or service is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company applies the following five steps:</span></span></div> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Identify the contract with a customer</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generally considers a purchase order or a signed quote to be a contract with a customer. In evaluating the contract with a customer, the Company analyzes the customer’s intent and ability to pay the amount of promised consideration (credit risk) and considers the probability of collecting substantially all of the consideration.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Identify the performance obligations in the contract</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At a contract’s inception, the Company assesses the goods or services promised in a contract with a customer and identifies the performance obligations.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Determine the transaction price</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring products or services to the customer.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company does not offer extended payment terms beyond one year to customers.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Allocate the transaction price to performance obligations in the contract</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recognize revenue when or as the Company satisfies a performance obligation</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue is recognized when or as performance obligations are satisfied by transferring control of a promised good or service to a customer. Control either transfers over time or at a point in time, which affects when revenue is recorded.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has elected to apply the practical expedient for financing component for transactions in which the difference between the payment date and the revenue recognition timing is up to 12 months.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Disaggregation of Revenue (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:95%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Product</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,681</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,175</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,916</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rental</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,033</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">859</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">533</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Service and warranty</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,140</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">477</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">517</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total Revenues</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,854</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,511</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,966</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-style:italic"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Product revenue</span></span></div> <div style="line-height:1.25"> </div> <div style="line-height:1.25"> <div style="text-align:justify;margin-left:33.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue from Products is comprised of sale of Anti-Gravity products, sale of systems products to rehabilitation facilities and sale of ReWalk Personal Exoskeleton systems to end users. Revenues generated from the sale of Products are recognized at a point in time, once the customer has obtained the legal title to the items purchased.</span></span></div> </div> <div style="line-height:1.25"> <div style="margin-left:33.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"> </div> </div> <div style="line-height:1.25"> <div style="text-align:justify;margin-left:33.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For systems sold to rehabilitation facilities, the Company includes insignificant training and considers the elements in the arrangement to be a single performance obligation. Therefore, the Company recognizes revenue for the system only when control is transferred after delivery and when the training has been completed, in accordance with the agreements terms with the customer.</span></span> <p style="margin:0pt"> </p> </div> <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"> <div></div> </div> </div> <div style="line-height:1.25"> <div style="text-align:justify;margin-left:33.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For sales of ReWalk Personal Exoskeleton systems to end users, and for sales of ReWalk Personal or ReWalk Rehabilitation Exoskeleton systems to third party distributors, the Company does not provide training to the end user as this training is completed by the rehabilitation center or by the distributor that have previously completed the ReWalk Training program. Therefore, the Company recognizes revenue in such sales upon delivery.</span></span></div> </div> <div style="line-height:1.25"> <div style="margin-left:33.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"> </div> </div> <div style="line-height:1.25"> <div style="text-align:justify;margin-left:33.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generally does not grant a right of return for its products. In rare circumstances when the Company provides a right of return for its products. the Company records reductions to revenue for expected future product returns based on the Company’s historical experience and estimates.</span></span></div> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During 2023, the Company offered six products: (1) ReWalk Personal Exoskeletons, (2) ReWalk Rehabilitation Exoskeleton, (3) ReStore, (4) AlterG Anti-Gravity systems, (5) MyoCycle and (6) MediTouch. Due to unsatisfactory sales performance of the MediTouch product lines, the Company terminated this agreement as of January 31, 2023.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rental revenue</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rental revenue for the AlterG Anti-Gravity systems is accounted for under ASC Topic 842, Leases. The Company rents its products to customers for a fixed monthly fee over the rental term, which typically ranges from 2 to 3 years. Rental revenues are recorded as earned on a monthly basis. See Note 2x for additional information.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the SCI Products, the Company also offers a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee for a limited period prior to selling its products.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Service and warranties</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company services its products after expiration of the initial warranty. Service revenue, consisting of time and materials to perform the repairs, is recorded as services are rendered.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Determining the transaction price requires of level judgment, which is discussed by revenue category in further detail below.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warranties are classified as either an assurance type or a service type warranty. A warranty is considered an assurance type warranty if it provides the customer with assurance that the product will function as intended for a limited period of time. An assurance type warranty is not accounted for as a separate performance obligation under the revenue model.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SCI Products include a <span style="-sec-ix-hidden:Fxbrl_20230214112251731"> five -year warranty</span>. The first two years are considered as an assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. A service type warranty is either sold with a unit or separately for a unit for which the warranty has expired. A service type warranty is accounted as a separate performance obligation and revenue is recognized ratably over the life of the warranty.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The ReStore device is sold with a two-year warranty which is considered as assurance type warranty.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Distributed Products are sold with assurance type warranty ranging between three years to ten years, depending on the specific product and part.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F</span></span><span style="font-family:Times New Roman, Times, serif;font-size:10pt">or AlterG Anti-Gravity Products, the Company offers customers extended warranty contracts that extend or enhance the technical support, parts, and labor coverage offered as part of the base warranty included with the Anti-Gravity system products. Extended warranty revenue is recognized ratably over the extended warranty coverage period. The Company offers a one-year assurance type warranty to customers in the U.S. and two years assurance type warranty for spare parts only to its international distributors. For these products, the Company determines standalone selling price based on the price at which the performance obligation is sold separately.</span> <p style="margin:0pt"> </p> </div> <div style="line-height:1.25"> <div></div> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Contract balances (in thousands):</span></span></div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"> </div> <div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:95%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade receivable, net of credit losses (1)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,120</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,036</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred revenues (1) (2)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,010</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,191</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance presented net of unrecognized revenue that was not yet collected.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$435 thousands of the December 31, 2022 deferred revenue balance was recognized as revenue during the year ended December 31, 2023.</span></span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred revenue which represent a contract liability, include unearned amounts related to service type warranty obligations as well as other advances and payments which the Company received from customers prior to satisfying the performance obligation, for which revenue has not yet been recognized. The Company's unearned performance obligations as of December 31, 2023 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $3.1 million, which will be fulfilled over one to five years.</span></span></div> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:95%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Product</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,681</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,175</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,916</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rental</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,033</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">859</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">533</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Service and warranty</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,140</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">477</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">517</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total Revenues</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,854</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,511</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,966</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> 10681000 4175000 4916000 1033000 859000 533000 2140000 477000 517000 13854000 5511000 5966000 P2Y <div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:95%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade receivable, net of credit losses (1)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,120</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,036</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred revenues (1) (2)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,010</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,191</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance presented net of unrecognized revenue that was not yet collected.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$435 thousands of the December 31, 2022 deferred revenue balance was recognized as revenue during the year ended December 31, 2023.</span></span></div> </td> </tr> </table> </div> 3120000 1036000 3010000 1191000 435000 the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $3.1 million, which will be fulfilled over one to five years. <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">m.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accounting for Share-Based Compensation:</span></span></div> </td> </tr> </table> <div style="line-height:1.25;margin-left:18pt"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for share-based compensation in accordance with ASC 718, “Compensation-Stock Compensation” (“ASC 718”). ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model (“OPM”). The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations.</span></span></div> <div style="line-height:1.25;margin-left:18pt"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. The Company account for forfeitures as they occur.</span></span></div> <div style="line-height:1.25;margin-left:18pt"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its share-option awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary share, expected share price volatility and the expected option term. Expected volatility is calculated based on actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options, or based on certain peer companies that the Company considered to be comparable, in case there is no sufficient trading volume to rely on market volatility. The expected option term is determined based on the simplified method, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></div> <div style="line-height:1.25;margin-left:18pt"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of Restricted Stock Units (“RSUs”) granted is determined based on the price of the Company’s ordinary shares on the date of grant.</span></span></div> <div style="line-height:1.25;margin-left:18pt"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for options granted to consultants and other service providers under ASC 718. The fair value of these options was estimated using a Black-Scholes-Merton option-pricing model.</span></span></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">n.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants to Acquire Ordinary Shares:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the twelve -month ended December 31, 2021, the Company issued warrants to acquire up to 15,083,611 ordinary shares. There were no issued warrants during the twelve months ended December 31, 2023 and 2022. The Company assessed the warrants pursuant to ASC 480 "Distinguishing Liabilities from Equity" and ASC 815 "Derivatives and Hedging" and determined that the warrants should be accounted for as equity and not as a derivative liability. Refer to Note 9f for additional information.</span></span></div> </div> 15083611000 <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">o.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and Development Costs:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are charged to the consolidated statement of operations as incurred and are presented net of the amount of any grants the Company received for research and development in the period in which the grant was received.</span></span></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">p.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income Taxes</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”), using the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits in its taxes on income. As of December 31, 2023, and 2022, the Company did not identify any significant uncertain tax positions.</span></span></div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">q.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warranty provision:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For assurance-type warranty, the Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">US Dollars</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">92</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AlterG acquisition – see note 5</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">535</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Provision</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">200</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:88%;padding-bottom:2px;vertical-align:baseline"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Usage</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(479</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">348</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">US Dollars</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">in</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">92</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AlterG acquisition – see note 5</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">535</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Provision</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">200</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:88%;padding-bottom:2px;vertical-align:baseline"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Usage</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(479</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">348</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> 92000 535000 200000 -479000 348000 <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">r.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Concentrations of Credit Risks:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company’s cash and cash equivalents are deposited in major banks in Israel, the United States and Germany. Such deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. The Company maintains cash and cash equivalents with diverse financial institutions and monitors the amount of credit exposure to each financial institution. The bank deposits are held in financial institutions which management believes are institutions with high credit standing, and accordingly, minimal credit risk from geographic or credit concentration exists with respect to these deposits.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The below table reflects the concentration of credit risk for the Company’s current customers as of December 31, 2023, to which substantial sales were made.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales.</span></span></div> <div style="line-height:1.25"> </div> <div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer A</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:FFact_0000000000446">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer B</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:FFact_0000000000448">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer C</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer D</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:54pt;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*)</span></span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less than 10%</span></span></div> </td> </tr> </table> <p style="margin:0pt"> </p> </div> <div style="line-height:1.25"> <div></div> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The allowance for credit losses is based on the Company's assessments of factors that may affect a customer's ability to pay. The Company regularly reviews the adequacy of the allowance for credit losses based on a combination of factors, including an assessment of the current customer's aging balance, the nature and size of the customer, the financial condition of the customer, and the amount of any receivables in dispute. The Company does not have any off-balance sheet credit exposure related to its customers. As of December 31, 2023, and 2022 trade receivables are presented net of $328 thousand and $26 thousand allowance for credit losses, respectively.</span></span></div> </div> <div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer A</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:FFact_0000000000446">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">27</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer B</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:FFact_0000000000448">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer C</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer D</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:54pt;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*)</span></span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less than 10%</span></span></div> </td> </tr> </table> <p style="margin:0pt"> </p> </div> 0.27 0.13 0 0.13 0 0.11 328000 26000 <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">s.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued Severance Pay:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to Israel’s Severance Pay Law, Israeli employees are entitled to severance pay equal to one month’s salary for each year of employment, or a portion thereof. All of the employees of the RRL elected to be included under section 14 of the Severance Pay Law, 1963 (“section 14”). According to this section, these employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total Company’s expenses related to severance pay amounted to $114 thousand , $113 thousand and $104 thousand for the years ended December 31, 2023, 2022 and 2021, respectively.</span></span></div> </div> 0.0833 114000 113000 104000 <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">t.</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair Value Measurements:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a three -tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The three -tiers are defined as follows:</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:36pt;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">▪</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Level 1. </span>Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities;</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:36pt;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">▪</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Level 2. </span>Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:36pt;vertical-align:top;font-family:'Times New Roman',Times,serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">▪</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Level 3. </span>Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying amounts of cash and cash equivalents, short term deposits, trade receivables and trade payables approximate their fair value due to the short-term maturity of such instruments.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following tables present information about the Company’s financial assets and liabilities that are measured in fair value on a recurring basis as of December 31, 2023 and December 31, 2022 (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:bottom;padding-bottom:2px;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:middle;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value measurements as of</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:25%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:bottom;width:25%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair Value Hierarchy</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Financial assets:</span></span></span></div> </td> <td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:middle;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:middle;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Money market funds included in cash and cash equivalent</span></span></div> </td> <td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:25%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,550</span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Treasury bills included in cash and cash equivalent</span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,525</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:middle;width:2%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total Assets Measured at Fair Value</span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,075</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:middle;width:2%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Financial Liabilities:</span></span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Earnout</span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,292</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total liabilities measured at fair value</span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,292</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> <p style="margin:0pt"> </p> </div> <div style="line-height:1.25"> <div></div> </div> <div style="text-align:justify;margin-left:38.25pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company classifies cash equivalents within Level 1, because the Company uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair values.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:38.25pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The earnout was valued using a Monte Carlo simulation analysis, which is considered to be a Level 3 fair value measurement.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:38.25pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table summarizes the earnout liability activity as of December 31, 2023 (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:93%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="width:85.4%;vertical-align:top"> </td> <td style="width:1.06%;vertical-align:bottom"> </td> <td colspan="2" style="width:11.39%;vertical-align:top;border-bottom:#000000 2px solid"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Earnout</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;white-space:nowrap"> </td> <td style="width:1.08%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:85.4%;vertical-align:top;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Initial Measurement (August 11, 2023)</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> </td> <td style="width:1.34%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td style="width:10.05%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,607</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap"> </td> <td style="width:1.08%;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap"> </td> </tr> <tr> <td style="width:85.4%;vertical-align:top"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in fair value</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom"> </td> <td style="width:1.34%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> </td> <td style="width:10.05%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(315)</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;white-space:nowrap"> </td> <td style="width:1.08%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:85.4%;vertical-align:top;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance December 31, 2023</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> </td> <td style="width:1.34%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td style="width:10.05%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,292</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap"> </td> <td style="width:1.08%;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap"> </td> </tr> </table> </div> </div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:bottom;padding-bottom:2px;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:middle;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair value measurements as of</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:25%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:bottom;width:25%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fair Value Hierarchy</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Financial assets:</span></span></span></div> </td> <td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:middle;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:middle;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:middle;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Money market funds included in cash and cash equivalent</span></span></div> </td> <td colspan="1" style="vertical-align:middle;background-color:rgb(204, 238, 255);width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:25%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,550</span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Treasury bills included in cash and cash equivalent</span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,525</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:middle;width:2%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total Assets Measured at Fair Value</span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,075</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:middle;width:2%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Financial Liabilities:</span></span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Earnout</span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,292</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:middle;width:2%;vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total liabilities measured at fair value</span></span></div> </td> <td colspan="1" style="vertical-align:middle;width:2%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td style="vertical-align:middle;width:25%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,292</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> <p style="margin:0pt"> </p> </div> 2550000 0 2525000 0 5075000 0 3292000 0 3292000 0 <div> <table border="0" cellpadding="0" cellspacing="0" style="width:93%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="width:85.4%;vertical-align:top"> </td> <td style="width:1.06%;vertical-align:bottom"> </td> <td colspan="2" style="width:11.39%;vertical-align:top;border-bottom:#000000 2px solid"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Earnout</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;white-space:nowrap"> </td> <td style="width:1.08%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:85.4%;vertical-align:top;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Initial Measurement (August 11, 2023)</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> </td> <td style="width:1.34%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td style="width:10.05%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,607</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap"> </td> <td style="width:1.08%;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap"> </td> </tr> <tr> <td style="width:85.4%;vertical-align:top"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in fair value</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom"> </td> <td style="width:1.34%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> </td> <td style="width:10.05%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(315)</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;white-space:nowrap"> </td> <td style="width:1.08%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:85.4%;vertical-align:top;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance December 31, 2023</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> </td> <td style="width:1.34%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td style="width:10.05%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,292</span></span></div> </td> <td style="width:1.06%;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap"> </td> <td style="width:1.08%;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap"> </td> </tr> </table> </div> 3607000 315000 3292000 <div> <div style="text-align:justify;margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">u.<span style="padding-left:7pt"> </span>Basic and Diluted Net Loss Per Share:</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding during the period.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Diluted loss per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus dilutive potential shares considered outstanding during the period.</span></span></div> </div> <div> <div style="margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">v.<span style="padding-left:8pt"> </span>Contingent liabilities</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for its contingent liabilities in accordance with ASC 450, “Contingencies.” A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.</span></span></div> </div> <div> <div style="margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">w.<span style="padding-left:8pt"> </span>Government grants</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalty and non-royalty-bearing grants from the Israeli Innovation Authority (the “IIA”) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a reduction from research and development expenses (see Note 8c).</span></span></div> </div> <div> <div style="margin-left:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">x.<span style="padding-left:8pt"> </span>Leases</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded at commencement date based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. </span></span></div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lessor accounting - Operating leases</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A portion of the AlterG rental revenues for the AlterG Anti-Gravity systems are made through lease arrangements.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AlterG products are available for lease agreements ranging from 12 to 42 months. If the customer terminates the contract during the lease period, they are required to pay a cancellation fee. The lease period may be extended by an additional period as specified in the contract.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In determining the leases classification as a sales type or operating lease, the Company assesses, among other criteria: (i) the lease term to determine if it is for the major part of the economic life of the underlying equipment; and (ii) the present value of the lease payments to determine if they are equal to or greater than substantially all of the fair market value of the equipment at the inception of the lease AlterG Anti-Gravity systems. When these criteria are not met, the lease accounted for as operating leases and revenues are recognized over the term of the lease.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under these arrangements, when the Company acts as the lessor for its product line, the Company accounted for the lease arrangements as operating leases in accordance with ASC 842, “Lease” (“ASC 842”).</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The total rental revenue for the AlterG Anti-Gravity Products has amounted to $249 thousand from the time of acquisition through December 31, 2023.</span></span></div> </div> P12Y P42Y 249000 <div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">y. <span style="padding-left:20pt"> </span>New Accounting Pronouncements</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently Implemented Accounting Pronouncements</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td rowspan="1" style="width:13.57%;vertical-align:top;font-family:'Times New Roman',Times,serif"> <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.           Financial Instruments</span></span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. The Company adopted ASU 2016-13 as of January 1, 2023. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recent Accounting Pronouncements Not Yet Adopted</span></span></div> <div style="line-height:1.25"> </div> <table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:10%;vertical-align:top"> <div style="line-height:1.25"> </div> </td> <td style="width:6%;vertical-align:top"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span></div> </td> <td style="width:84%;vertical-align:top"> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2023, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes - Improvements to Income Tax Disclosures” requiring enhancements and further transparency to certain income tax disclosures, most notably the tax rate reconciliation and income taxes paid. This ASU is effective for fiscal years beginning after December 15, 2024 on a prospective basis and retrospective application is permitted. The Company is currently evaluating the impact of the adoption of this standard.</span></span></div> <div style="text-align:justify;line-height:1.25"> </div> </td> </tr> <tr> <td style="width:10%;vertical-align:top"> </td> <td style="width:6%;vertical-align:top"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ii.</span></span></div> </td> <td style="width:84%;vertical-align:top"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, “Segment Reporting” on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></span></div> </td> </tr> </table> </div> <div> <div> <div> <div style="line-height:1.25"> <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"> <tr> <td style="vertical-align:top;font-weight:bold;width:67pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 3:-</span></td> <td style="vertical-align:top;text-align:justify;width:auto"> <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The components of prepaid expenses and other current assets are as follows (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:93%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government institutions</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">253</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">81</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,227</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">242</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Advances to vendors</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">139</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">174</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other assets</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">747</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">152</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,366</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">649</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> </div> </div> <table border="0" cellpadding="0" cellspacing="0" style="width:93%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government institutions</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">253</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">81</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,227</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">242</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Advances to vendors</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">139</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">174</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other assets</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">747</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">152</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,366</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">649</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> 253000 81000 1227000 242000 139000 174000 747000 152000 2366000 649000 <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"> <tr> <td style="vertical-align:top;font-weight:bold;width:67pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 4:-</span></td> <td style="vertical-align:top;text-align:justify;width:auto"> <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">INVENTORIES</span></div> </td> </tr> </table> <div> <div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The components of inventories are as follows (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:93%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Finished products</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,157</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,421</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Raw materials</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,496</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">508</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,653</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,929</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the twelve months ended December 31, 2023, 2022, and 2021, the Company recognized, at cost of revenues, reserves for excess and obsolete in the amount of $398 thousand, $502 thousand, and $252 thousand, respectively.</span></span></div> </div> </div> <table border="0" cellpadding="0" cellspacing="0" style="width:93%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Finished products</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,157</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,421</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Raw materials</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,496</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">508</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,653</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,929</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> 3157000 2421000 2496000 508000 5653000 2929000 398000 502000 252000 <div> <div> <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>NOTE 5:-</span></span><span style="padding-left:20pt"> </span><span><span>BUSINESS COMBINATION</span></span></span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On August 11, 2023, pursuant to an Agreement and Plan of Merger among RRI, AlterG, Merger Sub, and Shareholder Representative Services LLC, RRI, August 8, 2023, the Company acquired AlterG and AlterG became a wholly owned subsidiary of the Company. AlterG develops, manufactures, and markets Anti-Gravity systems for use in physical and neurological rehabilitation and athletic training, both in the United States and internationally. The aggregate purchase price was a total of $19.0 million in cash, subject to working capital and other customary purchase price adjustments. Additional cash earnouts may be paid based upon a percentage of AlterG’s year-over-year future revenue growth over the next two years subject to working capital and other customary purchase price adjustments.</span></span></span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="line-height:1.25"> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The total consideration transferred is as follows (in thousands):</span></span></span></span></span></span></div> </div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Cash</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>18,493</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Earnout payments</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>3,607</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Total consideration</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>22,100</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> <div style="line-height:1.25"> </div> <div style="text-indent:-42.55pt;margin-left:81.8pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Earnout payments</span></span></span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0.05pt;margin-right:6.3pt;margin-left:38.45pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The Company will pay an amount of cash equal to 65% of the amount, if any, by which <span>AlterG revenue attributable to the first 12 months period exceeds revenue target ("first earnout payment"), and an amount in cash equal to 65% of the amount, if any, by which AlterG revenue attributable to the following 12 months period exceeds the revenue from the first 12 month period ("second earnout payment").</span> At the date of acquisition, management estimated fair value of the earnout payment based on the actual up to date performance of the acquired entity and the probability of the earn out payment occurrence to be at approximately $3.6 million. The Earn-out was accounted for as a liability and will be remeasured at each reporting period through the consolidated statement of operations.</span></span></span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-indent:0.05pt;margin-right:9.3pt;margin-left:38.65pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The Company has accounted for the AlterG acquisition as a business combination. The Company has preliminarily allocated the purchase price of approximately $22.1 million fair values, and the excess of the purchase price over the aggregate fair values is recorded as goodwill.</span></span></span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:38.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date (in thousands):</span></span></span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Cash and cash equivalent</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>478</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Restricted cash</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>51</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Accounts receivable</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1,773</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Inventory</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>3,330</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Prepaid expenses and other current assets</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>470</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Right of use asset</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1,151</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Property and equipment, net</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>827</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Other non-current assets</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>30</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Goodwill</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>7,538</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Intangible assets</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>14,133</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Accounts payable</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(2,082</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Accrued compensation</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(766</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Other accrued liabilities</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(1,059</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Deferred revenue</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(2,088</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Warranty Obligations</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(535</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> <tr> <td style="width:88%;padding-bottom:2px;vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Leases Liability</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(1,151</span></span></span></span></span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Total purchase consideration</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>22,100</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> <p style="margin:0pt"> </p> </div> </div> <div></div> <div> <div style="margin-left:36.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The following table presents the details of the intangible assets acquired at the date of AlterG acquisition (in thousands):</span></span></span></span></span></span></div> </div> <div> <div> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;vertical-align:bottom"> <div style="line-height:1.25"> </div> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Estimated</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Estimated Useful Life</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Fair Value</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(Years)</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Trademark</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>795</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>3</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Technology</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>6,161</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>4</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Customer relationship - Warranty</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>201</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Customer relationship - Rental</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2,102</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>4</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Customer relationship - Distribution</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>4,578</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>5</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Backlog</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>296</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0.05pt;margin-right:6.25pt;margin-left:38.65pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Under the preliminary purchase price allocation, the Company allocates the purchase price to tangible and identified intangible assets acquired and liabilities assumed based on the preliminary estimates of their fair values. The fair values for the intangible assets acquired were primarily based on significant inputs that are not observable in the market and thus represent a Level 3 measurement in the fair value hierarchy. Customer relationships, distributor relationships, backlog, trademark and developed technology were valued using the income approach, based on estimated projections of expected cash flows to be generated by the assets, discounted to the present value at discount rates commensurate with perceived risk. The discounted cash flow analyses factor in assumptions on revenue and expense growth rates including estimates of customer growth and attrition rates, distributor growth and attrition rates, technology obsolescence, and relief from royalty projections. Additionally, these discounted cash flow analyses factor in expected amounts of working capital, fixed assets, assembled workforce and cost of capital for each intangible asset. Such estimates are subject to change during the measurement period which is not expected to exceed one year. Any adjustments to the preliminary purchase price allocation identified during the measurement period will be recognized in the period in which the adjustments are determined.</span></span></span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:38pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The Company incurred acquisition-related costs of $2.5 million included in General and administrative costs.</span></span></span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:38.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The table below presents the pro forma revenue and earnings of the combined business as if the acquisition had occurred as of January 1, 2022 (in thousands):</span></span></span></span></span></span></div> <div style="text-align:justify;margin-left:38.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Twelve Months Ended</span></span></span></span></span></span></div> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>December 31,</span></span></span></span></span></span></div> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2023</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2022</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:#CCEEFF;width:76%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Revenues</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>24,923</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>25,307</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Net loss</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(21,761</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(28,369</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> </table> </div> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0.05pt;margin-right:6.4pt;margin-left:38.65pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The total revenues and net loss of AlterG, included in the consolidated income statement, since the acquisition date through December 31, 2023, amounted to 7,658 thousand and 249 thousand, respectively.</span></span></span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0.05pt;margin-right:6.3pt;margin-left:38.65pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The pro forma financial information for all periods presented above has been calculated after adjusting the results of AlterG to reflect the business combinations accounting effects resulting from these acquisitions.</span></span></span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;text-indent:0.05pt;margin-right:6.3pt;margin-left:38.65pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>These proforma results reflect additional depreciation and amortization that would have been charged assuming the fair value adjustments to property, plant, and equipment and intangible asset occurred at the beginning of the period, along with consequential tax effects. The unaudited pro forma results have been prepared for comparative purposes only and are not necessarily indicative of what would have occurred had the business combinations been completed on January 1, 2022, nor it is necessarily indicative of future results of operations of the combined company. Furthermore, the unaudited pro forma financial information does not reflect the impact of any synergies resulting from the acquisition.</span></span></span></span></span></span></div> </div> 19000000 <div> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Cash</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>18,493</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Earnout payments</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>3,607</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Total consideration</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>22,100</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> 18493000 3607000 22100000 The Company will pay an amount of cash equal to 65% of the amount, if any, by which 3600000 22100000 <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Cash and cash equivalent</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>478</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Restricted cash</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>51</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Accounts receivable</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1,773</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Inventory</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>3,330</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Prepaid expenses and other current assets</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>470</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Right of use asset</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1,151</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Property and equipment, net</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>827</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Other non-current assets</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>30</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Goodwill</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>7,538</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Intangible assets</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>14,133</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Accounts payable</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(2,082</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Accrued compensation</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(766</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Other accrued liabilities</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(1,059</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> <tr> <td style="vertical-align:top;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Deferred revenue</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(2,088</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Warranty Obligations</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(535</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> <tr> <td style="width:88%;padding-bottom:2px;vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Leases Liability</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(1,151</span></span></span></span></span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:88%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Total purchase consideration</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>22,100</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> 478000 51000 1773000 3330000 470000 1151000 827000 30000 7538000 14133000 2082000 766000 1059000 2088000 535000 1151000 22100000 <div> <div> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;vertical-align:bottom"> <div style="line-height:1.25"> </div> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Estimated</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Estimated Useful Life</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Fair Value</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(Years)</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Trademark</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>795</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>3</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Technology</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>6,161</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>4</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Customer relationship - Warranty</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>201</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Customer relationship - Rental</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2,102</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>4</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Customer relationship - Distribution</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>4,578</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>5</span></span></span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Backlog</span></span></span></span></span></span></div> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>296</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> 795000 P3Y 6161000 P4Y 201000 P2Y 2102000 P4Y 4578000 P5Y 296000 P1Y 2500000 <div> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Twelve Months Ended</span></span></span></span></span></span></div> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>December 31,</span></span></span></span></span></span></div> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2023</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2022</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:#CCEEFF;width:76%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Revenues</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>24,923</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>25,307</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Net loss</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(21,761</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(28,369</span></span></span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></div> </td> </tr> </table> </div> 24923000 25307000 -21761000 -28369000 7658000 249000 <div> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">NOTE 6:-</span></span></span><span style="padding-left:20pt"> </span><span><span><span style="font-weight:bold">GOODWILL AND OTHER INTANGIBLE ASSETS, NET</span></span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-indent:0.05pt;margin-left:38.65pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company has $7.5 million of goodwill related to its purchase of AlterG in the third quarter of fiscal year 2023, which has an indefinite life, and is not deductible for tax purposes.</span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:38pt;line-height:1.25;font-family:Times New Roman, Times, serif;margin-bottom:0pt;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">As of December 31, 2023, the components of, and changes in, the carrying amount of intangible assets, net, were as follows (in thousands):</span></span></span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;text-align:center;padding-bottom:2px"> </td> <td colspan="1" style="vertical-align:bottom;text-align:center;padding-bottom:2px"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)"> <div style="line-height:1.25"> </div> <div style="line-height:1.25"> </div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:14pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cost</span></span></span></span></div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;text-align:center;padding-bottom:2px"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)"> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31, 2023 Accumulated</span></span></span></span></div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Amortization</span></span></span></span></div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;text-align:center;padding-bottom:2px"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)"> <div style="line-height:1.25"> </div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:6pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Intangible Assets, Net</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Trademark</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>795</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(104</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>691</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Technology</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,161</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(604</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5,557</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Customer relationship - Warranty</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>201</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(40</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>161</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Customer relationship - Rental</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,102</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(206</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,896</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Customer relationship - Distribution</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,578</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(358</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,220</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:2px;vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Backlog</span></span></span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>296</span></span></span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(296</span></span></span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total Amortized Intangible Assets</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14,133</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,608</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>12,525</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> <p style="margin:0pt;font-size:10pt"> </p> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The estimated amortization expense is shown below (in thousands):</span></span></span></p> <p style="margin:0pt"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fiscal 2024</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,347</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fiscal 2025</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,307</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fiscal 2026</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,143</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fiscal 2027</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,172</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fiscal 2028</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>556</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>12,525</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> 7500 <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;text-align:center;padding-bottom:2px"> </td> <td colspan="1" style="vertical-align:bottom;text-align:center;padding-bottom:2px"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)"> <div style="line-height:1.25"> </div> <div style="line-height:1.25"> </div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:14pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cost</span></span></span></span></div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;text-align:center;padding-bottom:2px"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)"> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31, 2023 Accumulated</span></span></span></span></div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Amortization</span></span></span></span></div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;text-align:center;padding-bottom:2px"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)"> <div style="line-height:1.25"> </div> <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-indent:6pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Intangible Assets, Net</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Trademark</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>795</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(104</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>691</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Technology</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6,161</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(604</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5,557</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Customer relationship - Warranty</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>201</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(40</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>161</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Customer relationship - Rental</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,102</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(206</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,896</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Customer relationship - Distribution</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,578</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(358</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4,220</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:2px;vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Backlog</span></span></span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>296</span></span></span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(296</span></span></span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:#CCEEFF;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total Amortized Intangible Assets</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>14,133</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(1,608</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>12,525</span></span></span></span></div> </td> <td colspan="1" style="background-color:#CCEEFF;vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> 795000 104000 691000 6161000 604000 5557000 201000 40000 161000 2102000 206000 1896000 4578000 358000 4220000 296000 296000 0 14133000 1608000 12525000 <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fiscal 2024</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,347</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fiscal 2025</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,307</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fiscal 2026</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3,143</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fiscal 2027</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2,172</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Fiscal 2028</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>556</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>12,525</span></span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> 3347000 3307000 3143000 2172000 556000 12525000 <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"> <tr> <td style="vertical-align:top;font-weight:bold;width:67pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 7:-</span></td> <td style="vertical-align:top;text-align:justify;width:auto"> <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">PROPERTY AND EQUIPMENT, NET</span></div> </td> </tr> </table> <div> <div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The components of property and equipment, net are as follows (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost:</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computer equipment </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,690</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">743</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office furniture and equipment </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">468</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">308</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Machinery and laboratory equipment </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">621</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">621</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Field service units </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,166</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,816</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">658</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">333</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,603</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,821</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,341</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,625</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment, net </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,262</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">196</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation expenses amounted to $239 thousand, $202 thousand, and $266 thousand for the years ended December 31, 2023, 2022 and 2021, respectively.</span></span></div> </div> </div> <div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost:</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computer equipment </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,690</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">743</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Office furniture and equipment </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">468</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">308</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Machinery and laboratory equipment </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">621</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">621</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Field service units </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,166</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,816</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Leasehold improvements </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">658</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">333</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,603</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,821</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated depreciation </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,341</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,625</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment, net </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,262</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">196</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> 1690000 743000 468000 308000 621000 621000 4166000 1816000 658000 333000 7603000 3821000 6341000 3625000 1262000 196000 239000 202000 266000 <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"> <tr> <td style="vertical-align:top;font-weight:bold;width:67pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 8:-</span></td> <td style="vertical-align:top;text-align:justify;width:auto"> <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">COMMITMENTS AND CONTINGENT LIABILITIES</span></div> </td> </tr> </table> <div> <div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase commitment:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has contractual obligations to purchase goods from its contract manufacturer as well as raw materials from different vendors. Purchase obligations do not include contracts that may be cancelled without penalty. As of December 31, 2023, non-cancellable outstanding obligations amounted to approximately $8.6 million.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease commitment:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(i)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company operates from leased facilities in Israel, the United States and Germany. These leases expire between 2024 and 2025. A portion of the Company’s facilities leases is generally subject to annual changes in the Consumer Price Index (CPI). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(ii)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates in between 2024 and 2026 A subset of the Company’s cars leases is considered variable. The variable lease payments for such cars leases are based on actual mileage incurred at the stated contractual rate. RRL and RRG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $30 thousand as of December 31, 2023.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company’s future lease payments for its facilities and cars, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company’s consolidated balance sheets as of December 31, 2023 are as follows (in thousands): </span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,363</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">674</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total lease payments</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,050</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: imputed interest</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(147</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of future lease payments</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,903</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: current maturities of operating leases</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,296</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current operating leases</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">607</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average remaining lease term (in years) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.92</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average discount rate</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9.21</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total lease expenses for the years ended December 31, 2023, 2022 and 2021 were $976 thousand, $739 thousand, and $730 thousand, respectively.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalties:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company’s research and development efforts are financed, in part, through funding from the Israel Innovation Authority (“IIA”). Since the Company’s inception through December 31, 2023, the Company received funding from the IIA in the total amount of $2.6 million. Out of the $2.6 million in funding from the IIA, a total amount of $1.6 million were royalty-bearing grants, $400 thousand was received in consideration of 209 convertible preferred A shares, which converted after the Company’s initial public offering in September 2014 into ordinary shares in a conversion ratio of 1 to 1, while $<span id="xbrl_20240224212733893">570</span> thousand was received without future obligation. The Company is obligated to pay royalties to the IIA, amounting to 3% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, the Company paid royalties to the IIA in the total amount of $110 thousand.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Royalties expenses in cost of revenue were $17 thousand, $7 thousand and $14 thousand, for the years ended December 31, 2023, 2022 and 2021, respectively.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, the contingent liability to the IIA amounted to $1.6 million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A</span></span><span style="font-family:Times New Roman, Times, serif;font-size:10pt">dditionally, the License Agreement requires the Company to pay College (“Harvard”) royalties on net sales, see Note 10 below for more information about the Collaboration Agreement (as defined below) and the License Agreement (as defined below).</span> <p style="margin:0pt"> </p> </div> <div></div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liens</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As part of the Company’s restricted cash and other long-term assets, as of December 31, 2023, an amount of $709 thousand has been pledged as security in respect of a guarantee granted to a third party. Such deposit cannot be pledged to others or withdrawn without the consent of such third party.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Legal Claims:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Occasionally, the Company is involved in various claims such as product liability claims, lawsuits, regulatory examinations, investigations, and other legal matters arising, for the most part, in the ordinary course of business. While the outcome of any pending or threatened litigation and other legal matters is inherently uncertain, the Company does not believe the outcome of any of the matters will have a material adverse effect on the Company’s consolidated results of operation, liquidity or financial condition.</span></span></div> </div> </div> 8600000 These leases expire between 2024 and 2025. <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,363</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">674</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total lease payments</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,050</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: imputed interest</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(147</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of future lease payments</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,903</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: current maturities of operating leases</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,296</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-current operating leases</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">607</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average remaining lease term (in years) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.92</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-average discount rate</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9.21</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> </table> 1363000 674000 13000 2050000 -147000 1903000 1296000 607000 P1Y11M1D 0.0921 976000 739000 730000 2600000 2600000 1600000 400000 209 ordinary shares in a conversion ratio of 1 to 1 0.03 1 110000 17000 7000 14000 1600000 709000 <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"> <tr> <td style="vertical-align:top;font-weight:bold;width:67pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">NOTE 9:-</span></td> <td style="vertical-align:top;text-align:justify;width:auto"> <div style="font-weight:bold"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">SHAREHOLDERS’ EQUITY</span></div> </td> </tr> </table> <div> <div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Equity raise:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Follow-on offerings</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On February 19, 2021, the Company entered into a purchase agreement with certain institutional and other accredited investors for the issuance and sale of 10,921,502 ordinary shares, par value NIS 0.25 per share at $3.6625 per ordinary share and warrants to purchase up to an aggregate of 5,460,751 ordinary shares with an exercise price of $3.6 per share, exercisable from February 19, 2021, until August 26, 2026. Additionally, the Company issued warrants to purchase up to 655,290 ordinary shares, with an exercise price of $4.578125 per share, exercisable from February 19, 2021, until August 26, 2026, to the Company February 2021 private placement offering.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 27, 2021, the Company signed a purchase agreement with certain institutional investors for the issuance and sale of 15,403,014 ordinary shares, par value NIS 0.25 per share, pre-funded warrants to purchase up to an aggregate of 610,504 ordinary shares and ordinary warrants to purchase up to an aggregate of 8,006,759 ordinary shares at an exercise price of $2.00 per share. The Pre-Funded Warrants have an exercise price of $0.001 per Ordinary Share and are immediately exercisable and can be exercised at any time after their original issuance until such pre-funded warrants are exercised in full. Each ordinary shares was sold at an offering price of $2.035 and each pre-funded warrant was sold at an offering price of $2.034 (equal to the purchase price per ordinary share minus the exercise price of the pre-funded warrant). The ordinary warrants are exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending five and one-half years from the date of issuance. All of the pre-funded warrants were exercised in full on September 27, 2021, and the offering closed on September 29, 2021. Additionally, the Company issued warrants to purchase up to 960,811 ordinary shares, with an exercise price of $2.5438 per share, exercisable from September 27, 2021, until September 27, 2026, to the Company September 2021 registered direct offering.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, a total of 9,814,754 outstanding warrants with exercise prices ranging from $1.25 to $1.79 were exercised, for total gross proceeds of approximately $13.8 million. During the twelve months that ended December 31, 2023 no warrants were exercised.</span></span></div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share option plans:</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 30, 2012, the Company’s board of directors adopted the ReWalk Robotics Ltd. 2012 Equity Incentive Plan.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 19, 2014, the Company’s board of directors adopted the ReWalk Robotics Ltd. 2014 Incentive Compensation Plan or the “Plan”. The Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, RSUs, cash-based awards, other stock-based awards and dividend equivalents to the Company’s and its affiliates’ respective employees, non-employee directors and consultants.</span></span></div> <div style="text-align:justify;line-height:1.25"> <p style="margin:0pt"> </p> <div></div> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Starting in 2014, the Company grants to directors and employees also RSU under this Plan. An RSU award is an agreement to issue shares of the company’s ordinary shares at the time the award is vested.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023 and 2022, the Company had reserved 1,018,945 and 2,934,679 shares of ordinary shares, respectively, available for issuance to employees, directors, officers, and non-employees of the Company.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The options generally vest over four years, with certain options granted to non-employee directors vesting over one year.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Any option or RSUs that are forfeited or cancelled before expiration becomes available for future grants under the Plan.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A summary of employee and non-employee shares options activity during the fiscal year ended 2023 is as follows: </span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">price</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">contractual</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">life (years)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">intrinsic</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value (in</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at the beginning of the year</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">43,994</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">41.27</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.39</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:52%;padding-bottom:4px;vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(10,823</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">52.78</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at the end of the year</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,171</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">37.51</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.39</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options exercisable at the end of the year</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,171</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">37.51</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.39</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">There were no options granted during the fiscal year ended December 31, 2023, 2022 and 2021. The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders, which hold options with positive intrinsic value, exercised their options on the last date of the exercise period. During the years ended December 31, 2023, 2022 and 2021, no options were exercised.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A summary of employee and non-employee RSUs activity during the fiscal year ended 2023 is as follows: </span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">shares</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">underlying</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">outstanding</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">RSUs</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">grant date</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">fair value</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unvested RSUs at the beginning of the year </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,755,057</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.16</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,258,370</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.66</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Vested </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,109,200</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.14</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:76%;padding-bottom:4px;vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited </span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(131,813</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.13</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unvested RSUs at the end of the year </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,772,414</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.87</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The weighted average grant date fair values of RSUs granted during the fiscal year ended December 31, 2023, 2022 and 2021, were $0.66, $1.00 and $1.69, respectively.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total fair value of shares vested during the year ended December 31, 2023, 2022 and 2021 were $1,268 thousand, $860 thousand, and $802 thousand, respectively. As of December 31, 2023, there were $2.7 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2014 Plan. This cost is expected to be recognized over a period of approximately 2.9 years.</span></span></div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"> </div> <div></div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The number of options and RSUs outstanding as of December 31, 2023 is set forth below, with options separated by range of exercise price:</span></span></div> <div style="text-align:justify;line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="width:42%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Range of exercise price</span></span></div> </td> <td style="width:1.8%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options and</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">RSUs</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">as of</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">contractual</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">life</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(years) (1)</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">as of</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">contractual</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">life</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(years) (1)</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="width:42%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">RSUs only </span></span></div> </td> <td style="width:1.8%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,772,414</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$5.37 </span></span></div> </td> <td style="width:1.8%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,425</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.24</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,425</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.24</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="width:42%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$20.42- $33.75 </span></span></div> </td> <td style="width:1.8%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,943</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.35</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,943</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.35</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$50-$52.5 </span></span></div> </td> <td style="width:1.8%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,230</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.46</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,230</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.46</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="width:42%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$182.5-$524.25 </span></span></div> </td> <td style="width:1.8%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,573</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.65</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,573</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.65</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="width:42%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1.8%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,805,585</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.39</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,171</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.39</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="vertical-align:top;width:34pt"> </td> <td style="vertical-align:top;width:20pt"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1) </span></span></div> </td> <td style="vertical-align:top;width:auto"> <div style="line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. </span></span></div> </td> </tr> </table> <div style="line-height:1.25"> <p style="margin-top:0pt;margin-bottom:0pt"> </p> <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">c.</span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Equity compensation issued to consultants:</span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company granted 32,895 RSUs during the fiscal year ended December 31, 2023, to non-employee consultants. As of December 31, 2023, there are 21,929 outstanding RSUs held by non-employee consultants.</span></span></div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"> </div> <div style="line-height:1.25"> <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">d.</span></td> <td style="width:auto;vertical-align:top"> <div style="text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Share-based compensation expense for employees and non-employees:</span></div> </td> </tr> </table> </div> <div style="text-indent:18pt;line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company recognized share-based compensation expense in the consolidated statements of operations as follows (in thousands): </span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenue </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development, net </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">157</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">94</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">55</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales and marketing </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">381</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">250</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">171</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">781</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">633</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">597</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,328</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">993</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">833</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> <p style="margin-top:0pt;margin-bottom:0pt"> </p> <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">e.</span></td> <td style="width:auto;vertical-align:top"> <div style="text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Treasury shares:</span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 2, 2022, the Company’s Board of Directors approved a share repurchase program to repurchase up to $8.0 million of its Ordinary Shares, par value NIS 0.25 per share. On July 21, 2022, the Company received approval from an Israeli court for the share repurchase program. The program was scheduled to expire on the earlier of January 20, 2023, or reaching $8.0 million of repurchases. On December 22, 2022, the Company’s Board of Directors approved an extension of the repurchase program, with such extension to be in the aggregate amount of up to $5.8 million. The extension was approved by an Israeli court on February 9, 2023, and it expired on August 9, 2023.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, pursuant to the Company’s share repurchase program, the Company had repurchased a total of 4,022,607 of its outstanding ordinary shares at a total cost of $3.5 million.</span></span> <p style="margin:0pt"> </p> </div> <div style="text-align:justify;line-height:1.25"> <div></div> <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);border:0px"> <tr> <td style="width:18pt"> </td> <td style="width:18pt;vertical-align:top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">f.</span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Warrants to purchase ordinary shares:</span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table summarizes information about warrants outstanding and exercisable as of December 31, 2023:</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;width:42%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance date</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">outstanding</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">per warrant</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">outstanding</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">and</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercisable</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Contractual</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">term</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;width:42%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(number)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(number)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;padding-bottom:2px;width:10%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2015 (1) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,771</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.500</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,771</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">See footnote (1)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 28, 2016 (2) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,908</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.500</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,908</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">See footnote (1)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 25, 2019 (5) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">45,600</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.187</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">45,600</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 21, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">April 5, 2019 (6) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">408,457</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.140</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">408,457</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">October 7, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">April 5, 2019 (7) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">49,015</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.503</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">49,015</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">April 3, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 5, 2019, and June 6, 2019 (8) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,464,665</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.500</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,464,665</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 5, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 5, 2019 (9) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87,880</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9.375</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87,880</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 5, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 12, 2019 (10) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">416,667</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.000</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">416,667</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 12, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 10, 2019 (11) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">50,000</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.500</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">50,000</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 10, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 10, 2020 (12) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">28,400</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.250</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">28,400</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 10, 2025</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 10, 2020 (13) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">105,840</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.563</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">105,840</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 10, 2025</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">July 6, 2020 (14) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">448,698</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.760</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">448,698</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">January 2, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">July 6, 2020 (15) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">296,297</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.278</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">296,297</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">January 2, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 8, 2020 (16) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">586,760</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.340</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">586,760</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 8, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 8, 2020 (17) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">108,806</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.792</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">108,806</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 8, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 26, 2021 (18) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,460,751</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.600</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,460,751</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">August 26, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 26, 2021 (19) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">655,290</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.578</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">655,290</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">August 26, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September 29, 2021 (20) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,006,759</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.000</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,006,759</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March 29, 2027</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September 29, 2021 (21) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">960,811</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.544</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">960,811</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September 27, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">19,187,375</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">19,187,375</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants for ordinary shares issuable upon an exercise price of $7.500 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2023.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents common warrants that were issued as part of the Company’s follow-on public offering in November 2018.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on public offering in November 2018.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on public offering in February 2019.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(7)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering.</span></span> <p style="margin:0pt"> </p> </div> </td> </tr> </table> <div style="line-height:1.25"> <div></div> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(8)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(9)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(10)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of December 31, 2023, 3,740,100 warrants were exercised for total consideration of $4,675,125. During the twelve months that ended December 31, 2023, no warrants were exercised.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(13)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of December 31, 2023, 230,160 warrants were exercised for total consideration of $359,625. During the twelve months that ended December 31, 2023, no warrants were exercised.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(14)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in July 2020. As of December 31, 2023, 2,020,441 warrants were exercised for total consideration of $3,555,976. During the twelve months that ended December 31, 2023, no warrants were exercised.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(15)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(16)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s private placement offering of ordinary shares in December 2020. As of December 31, 2023, 3,598,072 warrants were exercised for total consideration of $4,821,416. During the twelve months that ended December 31, 2023, no warrants were exercised.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(17)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of December 31, 2023, 225,981 warrants were exercised for total consideration of $405,003. During the twelve months that ended December 31, 2023, no warrants were exercised.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(18)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s private placement offering of ordinary shares in February 2021.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(20)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in September 2021.</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:36pt"> </td> <td style="width:36pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(21)</span></span></td> <td style="width:auto;vertical-align:top;text-align:justify"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.</span></span></div> </td> </tr> </table> </div> </div> 10921502 0.25 3.6625 5460751 3.6 exercisable from February 19, 2021, until August 26, 2026 655290 4.578125 exercisable from February 19, 2021, until August 26, 2026 15403014 0.25 610504 8006759 2 The Pre-Funded Warrants have an exercise price of $0.001 per Ordinary Share and are immediately exercisable and can be exercised at any time after their original issuance until such pre-funded warrants are exercised in full. Each ordinary shares was sold at an offering price of $2.035 and each pre-funded warrant was sold at an offering price of $2.034 (equal to the purchase price per ordinary share minus the exercise price of the pre-funded warrant). 960811 2.5438 9814754 1.25 1.79 13800000 1018945 2934679 <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercise</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">price</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">contractual</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">life (years)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">intrinsic</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">value (in</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">thousands)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at the beginning of the year</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">43,994</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">41.27</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.39</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:52%;padding-bottom:4px;vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(10,823</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">52.78</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options outstanding at the end of the year</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,171</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">37.51</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.39</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:52%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options exercisable at the end of the year</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,171</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">37.51</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.39</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> 43994 41.27 P4Y4M20D 0 0 0 0 10823 52.78 33171 37.51 P4Y4M20D 33171 37.51 P4Y4M20D <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number of</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">shares</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">underlying</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">outstanding</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">RSUs</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted-</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">grant date</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">fair value</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unvested RSUs at the beginning of the year </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,755,057</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.16</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,258,370</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.66</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Vested </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,109,200</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.14</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:76%;padding-bottom:4px;vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited </span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(131,813</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.13</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unvested RSUs at the end of the year </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,772,414</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.87</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> 2755057 1.16 2258370 0.66 1109200 1.14 131813 1.13 3772414 0.87 0.66 1 1.69 1268000 860000 802000 2700000 P2Y10M24D <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="width:42%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Range of exercise price</span></span></div> </td> <td style="width:1.8%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options and</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">RSUs</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">as of</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">contractual</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">life</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(years) (1)</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercisable</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">as of</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">average</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">remaining</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">contractual</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">life</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(years) (1)</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="width:42%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">RSUs only </span></span></div> </td> <td style="width:1.8%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,772,414</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$5.37 </span></span></div> </td> <td style="width:1.8%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,425</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.24</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,425</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.24</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="width:42%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$20.42- $33.75 </span></span></div> </td> <td style="width:1.8%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,943</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.35</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,943</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.35</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$50-$52.5 </span></span></div> </td> <td style="width:1.8%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,230</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.46</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,230</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.46</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="width:42%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$182.5-$524.25 </span></span></div> </td> <td style="width:1.8%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,573</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.65</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,573</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.65</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="width:42%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1.8%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,805,585</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.39</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,171</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td style="width:1%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="line-height:1.25"> </div> </td> <td style="width:9%;vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0)"> <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.39</span></span></div> </td> <td style="width:0.68%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> </tr> </table> 3772414 5.37 12425 P5Y2M26D 12425 P5Y2M26D 20.42 33.75 12943 P4Y4M6D 12943 P4Y4M6D 50 52.5 6230 P3Y5M15D 6230 P3Y5M15D 182.5 524.25 1573 P1Y7M24D 1573 P1Y7M24D 3805585 P4Y4M20D 33171 P4Y4M20D 32895 <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenue </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development, net </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">157</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">94</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">55</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sales and marketing </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">381</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">250</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">171</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">781</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">633</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">597</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,328</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">993</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">833</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> 9000 16000 10000 157000 94000 55000 381000 250000 171000 781000 633000 597000 1328000 993000 833000 8000000 0.25 8000000 5800000 4022607 3500000 <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;width:42%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance date</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">outstanding</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">per warrant</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">outstanding</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">and</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">exercisable</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Contractual</span></span></div> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">term</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;width:42%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(number)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(number)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;padding-bottom:2px;width:10%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31, 2015 (1) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,771</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.500</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,771</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">See footnote (1)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 28, 2016 (2) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,908</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.500</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,908</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">See footnote (1)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 25, 2019 (5) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">45,600</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.187</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">45,600</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 21, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">April 5, 2019 (6) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">408,457</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.140</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">408,457</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">October 7, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">April 5, 2019 (7) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">49,015</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.503</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">49,015</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">April 3, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 5, 2019, and June 6, 2019 (8) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,464,665</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.500</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,464,665</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 5, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 5, 2019 (9) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87,880</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9.375</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87,880</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 5, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 12, 2019 (10) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">416,667</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6.000</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">416,667</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 12, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 10, 2019 (11) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">50,000</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7.500</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">50,000</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 10, 2024</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 10, 2020 (12) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">28,400</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.250</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">28,400</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 10, 2025</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 10, 2020 (13) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">105,840</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.563</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">105,840</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 10, 2025</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">July 6, 2020 (14) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">448,698</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.760</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">448,698</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">January 2, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">July 6, 2020 (15) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">296,297</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.278</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">296,297</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">January 2, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 8, 2020 (16) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">586,760</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.340</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">586,760</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 8, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 8, 2020 (17) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">108,806</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.792</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">108,806</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 8, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 26, 2021 (18) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,460,751</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.600</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,460,751</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">August 26, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 26, 2021 (19) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">655,290</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.578</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">655,290</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">August 26, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September 29, 2021 (20) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,006,759</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.000</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,006,759</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March 29, 2027</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September 29, 2021 (21) </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">960,811</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.544</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">960,811</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">September 27, 2026</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:42%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">19,187,375</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">19,187,375</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td style="vertical-align:bottom;width:10%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> </tr> </table> 4771 7.5 4771 1908 7.5 1908 45600 7.187 45600 2024-02-21 408457 5.14 408457 2024-10-07 49015 6.503 49015 2024-04-03 1464665 7.5 1464665 2024-06-05 87880 9.375 87880 2024-06-05 416667 6 416667 2024-12-12 50000 7.5 50000 2024-06-10 28400 1.25 28400 2025-02-10 105840 1.563 105840 2025-02-10 448698 1.76 448698 2026-01-02 296297 2.278 296297 2026-01-02 586760 1.34 586760 2026-06-08 108806 1.792 108806 2026-06-08 5460751 3.6 5460751 2026-08-26 655290 4.578 655290 2026-08-26 8006759 2 8006759 2027-03-29 960811 2.544 960811 2026-09-27 19187375 19187375 7.5 2015-12-31 currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2023. 8000000 3740100 4675125000 230160 359625000 2020441 3555976000 3598072 4821416000 225981 405003000 <div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="vertical-align:top;font-weight:bold;width:72pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>NOTE 10:-</strong></span></span></td> <td style="vertical-align:top;width:auto"> <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT</strong></span></span></div> </td> </tr> </table> <div style="text-align:justify;margin-left:36pt;line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 16, 2016, the Company entered into a Collaboration Agreement (as amended, the “Collaboration Agreement”) and an Exclusive License Agreement (as amended, the “License Agreement”) with Harvard. The Collaboration Agreement concluded on March 31, 2022.</span></span></div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration.</span></span> <p style="margin:0pt"> </p> </div> <div style="text-align:justify;line-height:1.25"> <div></div> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The License Agreement required the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The Harvard License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, the Company achieved three of the milestones which represent all development milestones under the License Agreement. The Company continues to evaluate the likelihood that the other milestones will be achieved on a quarterly basis.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has recorded expenses in the amount of $29 thousand, $74 thousand, and $293 thousand as research and development expenses related to the License Agreement and to the Collaboration Agreement for the years ended December 31, 2023, 2022 and 2021, respectively. No withholding tax was deducted from the Company’s payments to Harvard in respect of the Collaboration Agreement and the License Agreement since this is not taxable income in Israel in accordance with Section 170 of the Israel Income Tax Ordinance 1961-5721.</span></span></div> </div> </div> 29000 74000 293000 <div> <div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="vertical-align:top;font-weight:bold;width:72pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 11:-</span></span></td> <td style="vertical-align:top;width:auto"> <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">INCOME TAXES</span></span></div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company’s subsidiaries are separately taxed under the domestic tax laws of the jurisdiction of incorporation of each entity.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span><span style="padding-left:8.5pt"> </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Corporate tax rates in Israel:</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Presented hereunder are the tax rates relevant to the Company in the years 2021-2023:</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Israeli statutory corporate tax rate and real capital gains were 23% in the years 2021-2023.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.<span style="padding-left:8.5pt"> </span>Income (loss) before taxes on income is comprised as follows (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Domestic</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,638</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,110</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,780</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="width:64%;padding-bottom:2px;vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,507</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">138</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22,145</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,102</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,642</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span><span style="padding-left:8.5pt"> </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes on income (benefit) are comprised as follows (in thousands):</span></span></div> <div style="text-indent:18pt;line-height:1.25"> </div> <div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">151</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">123</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">316</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(29</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">467</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">94</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Domestic</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:2px;vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">467</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">94</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:4px;vertical-align:baseline"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">467</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">94</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> </tr> </table> </div> </div> <p style="margin:0pt"> </p> <div></div> <div style="text-indent:18pt;line-height:1.25;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span><span style="padding-left:8.5pt"> </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred income taxes (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets as of December 31, 2023 and 2022 are derived from temporary differences.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In assessing the realization of deferred tax assets, the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. Based on the Company’s history of losses, the Company established a full valuation allowance for RRL.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Undistributed earnings of certain subsidiaries as of December 31, 2023 were immaterial. The Company intends to reinvest these earnings indefinitely in the foreign subsidiaries. As a result, the Company has not provided for any deferred income taxes.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax assets:</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Carry forward tax losses</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">64,090</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">50,833</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development carry forward expenses-temporary differences</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,311</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">844</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrual and reserves</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">849</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">392</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share based compensation</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">394</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">456</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Credit tax carry forwards</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,714</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">480</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">214</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total deferred tax assets</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">68,838</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">52,739</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities:</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right-of-use asset</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(470</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(214</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Intangible Assets</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,015</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(144</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">65,209</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">52,525</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:76%;padding-bottom:2px;vertical-align:baseline"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(65,209</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(52,525</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The net changes in the total valuation allowance for each of the years ended December 31, 2023, 2022 and 2021, are comprised as follows (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at beginning of year</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(52,525</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(48,098</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(42,941</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes due to exchange rate differences</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,418</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,488</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustment previous year loss</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">)</td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(14</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Acquisition</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(7,269</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions during the year</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,410</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,831</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,669</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at end of year</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(65,209</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(52,525</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(48,098</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> </table> </div> </div> </div> <p style="margin:0pt"> </p> <div></div> <div style="text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span><span style="padding-left:8.5pt"> </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Reconciliation of the theoretical tax expenses:</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A reconciliation between the theoretical tax expense, assuming all income is taxed at the statutory tax rate applicable to income of the Company, and the actual tax expense (benefit) as reported in the consolidated statements of operations is as follows (in thousands):</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before taxes, as reported in the consolidated statements of operations</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22,145</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,102</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,642</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statutory tax rate</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23.0</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23.0</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical tax benefits on the above amount at the Israeli statutory tax rate</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,093</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4,393</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,908</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax at rate other than the Israeli statutory tax rate</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">56</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible expenses including equity-based compensation expenses and other </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">262</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">102</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating losses and other temporary differences for which valuation allowance was provided</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,410</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,375</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,669</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Permanent differences</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(342</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(775</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(784</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustment in respect of prior years</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(43</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Actual tax expense (benefit)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">467</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">94</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span><span style="padding-left:9.5pt"> </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign tax rates:</span></span></div> <div style="line-height:1.25"> </div> <div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxable income of RRI and AlterG was subject to tax at the rate of 21% in 2023, 2022 and 2021.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxable income of RRG was subject to tax at the rate of 30% in 2023, 2022, and 2021.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">g.</span></span><span style="padding-left:8.5pt"> </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Investment Law”):</span></span></div> <div style="line-height:1.25"> </div> <div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Conditions for entitlement to the benefits:</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the Investment Law, in 2012 the Company elected “Beneficiary Enterprise” status which provides certain benefits, including tax exemptions and reduced tax rates. Income not eligible for Beneficiary Enterprise benefits is taxed at a regular rate.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income derived from Beneficiary Enterprise from productive activity will be exempt from tax for ten years from the year in which the Company first has taxable income, providing that 12 years have not passed from the beginning of the year of election. In the event of a dividend distribution from income that is exempt from company tax, as aforementioned, the Company will be required to pay tax of 10%-25% on that income.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In the event of distribution of dividends from the said tax-exempt income, the amount distributed will be subject to corporate tax at the rate ordinarily applicable to the Beneficiary Enterprise’s income. Tax-exempt income generated under the Company’s “Beneficiary Enterprise” program will be subject to taxes upon dividend distribution or complete liquidation.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The entitlement to the above benefits is conditional upon the Company’s fulfilling the conditions stipulated by the Law and regulations published thereunder.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">h.</span></span><span style="padding-left:8.5pt"> </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax assessments:</span></span></div> <div style="line-height:1.25"> </div> <div style="text-indent:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">RRL, RRI and RRG has had final tax assessments up to and including the 2017 tax year.</span></span></div> <p style="margin:0pt"> </p> <div></div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AlterG files income tax returns in the United States and in various U.S. states.  AlterG returns for the years ended December 31, 2020 and later are generally subject to federal tax examination, while the AlterG returns for the years ended December 31, 2019 and later are generally subject to state tax examination.  However, the AlterG net operating losses and tax credits generally remain subject to tax examination and adjustment until they are utilized on a future tax return and the statute of limitations closes for that year.  Thus, the AlterG tax attributes generally remain open to federal and state tax examination and adjustment.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-indent:18pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i.</span></span><span style="padding-left:9.5pt"> </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating carry-forward losses for tax purposes:</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, RRL has carry-forward losses amounting to approximately $242.6 million, which can be carried forward for an indefinite period.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2023, AlterG had approximately $31.4 million of federal net operating loss (“NOL”) carry forwards, and $47.2 million of state NOL carry forwards, which will begin to expire in 2025 and 2028, respectively.  The federal net operating losses from years beginning after January 1, 2018, of approximately $14.7 million may be carried forward indefinitely and losses prior to January 1, 2018 of approximately $16.7 million expire beginning in 2028 under prior law.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Internal Revenue Code Section 382 places a limitation ("Section 382 Limitation") on the amount of taxable income which can be offset by NOL carry forwards after a change in control (generally greater than 50% change in the value of the stock owned by 5% shareholders during the testing period) of a loss corporation. California has similar rules. On August 11, 2023, AlterG was involved in an equity transaction that constitutes a Section 382 change in ownership. The change in ownership limits the ability to utilize net operating loss carry forwards in future years. The 382-limitation impact on NOLs has been included in the current period provision. The Company may have had earlier Section 382 changes in ownership. This will be assessed upon realization of tax attributes.</span></span></div> </div> 0.23 0.23 0.23 <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Domestic</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,638</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,110</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,780</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="width:64%;padding-bottom:2px;vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,507</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">138</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22,145</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,102</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,642</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> </table> </div> -19638000 -19110000 -12780000 -2507000 8000 138000 -22145000 -19102000 -12642000 <div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">151</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">123</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">316</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(29</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">467</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">94</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Domestic</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:2px;vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">467</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">94</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:4px;vertical-align:baseline"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">467</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">94</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;vertical-align:baseline;white-space:nowrap"> </td> </tr> </table> </div> </div> -12000 151000 123000 0 -316000 29000 -12000 467000 94000 0 0 0 -12000 467000 94000 -12000 467000 94000 <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax assets:</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Carry forward tax losses</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">64,090</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">50,833</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development carry forward expenses-temporary differences</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,311</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">844</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrual and reserves</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">849</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">392</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share based compensation</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">394</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">456</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Credit tax carry forwards</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,714</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">480</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">214</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total deferred tax assets</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">68,838</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">52,739</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax liabilities:</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right-of-use asset</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(470</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(214</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Intangible Assets</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,015</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(144</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">65,209</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">52,525</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:76%;padding-bottom:2px;vertical-align:baseline"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(65,209</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(52,525</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> 64090000 50833000 1311000 844000 849000 392000 394000 456000 1714000 0 480000 214000 68838000 52739000 470000 214000 -3015000 0 -144000 0 65209000 52525000 65209000 52525000 0 0 <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at beginning of year</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(52,525</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(48,098</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(42,941</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes due to exchange rate differences</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,418</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,488</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustment previous year loss</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">)</td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(14</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Acquisition</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(7,269</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additions during the year</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,410</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,831</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,669</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at end of year</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(65,209</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(52,525</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(48,098</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> </table> </div> 52525000 48098000 42941000 0 1418000 -1488000 5000 14000 0 -7269000 0 0 5410000 5831000 3669000 65209000 52525000 48098000 <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before taxes, as reported in the consolidated statements of operations</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22,145</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,102</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,642</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statutory tax rate</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23.0</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23.0</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical tax benefits on the above amount at the Israeli statutory tax rate</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,093</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4,393</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,908</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax at rate other than the Israeli statutory tax rate</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">56</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible expenses including equity-based compensation expenses and other </span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">262</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">102</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating losses and other temporary differences for which valuation allowance was provided</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,410</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,375</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,669</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Permanent differences</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(342</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(775</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(784</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustment in respect of prior years</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(43</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Actual tax expense (benefit)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">467</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">94</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> </td> </tr> </table> </div> -22145000 -19102000 -12642000 0.23 0.23 0.23 -5093000 -4393000 -2908000 56000 -2000 7000 0 262000 102000 5410000 5375000 3669000 -342000 -775000 -784000 -43000 0 0 0 0 8000 -12000 467000 94000 0.21 0.21 0.21 0.30 0.30 0.30 P10Y P12Y 0.10 0.25 242600000 31400000 47200000 2025 and 2028 14700000 16700000 <table cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;color:rgb(0, 0, 0)"> <tr> <td style="vertical-align:top;font-weight:bold;width:72pt"><span style="font-size:10pt"><span>NOTE 12:-</span></span></td> <td style="vertical-align:top;width:auto"> <div style="font-weight:bold"><span style="font-size:10pt"><span>FINANCIAL (EXPENSES) INCOME, NET</span></span></div> </td> </tr> </table> <div> <div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The components of financial (expenses) income, net were as follows (in thousands):</span></span></div> <div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency transactions and other</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">133</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">22</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">38</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest Income</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,354</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank commissions</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(20</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(25</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,467</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230213140028626">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">*) </span>Represent an amount lower than $1.</span></span></div> </div> </div> <div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency transactions and other</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">133</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">22</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">38</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest Income</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,354</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Bank commissions</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(20</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(25</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,467</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230213140028626">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> 133000 -22000 38000 1354000 0 0 20000 22000 25000 1467000 13000 <div> <table cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%;color:rgb(0, 0, 0)"> <tr> <td style="vertical-align:top;font-weight:bold;width:72pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE 13:-</span></span></td> <td style="vertical-align:top;width:auto"> <div style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA</span></span></div> </td> </tr> </table> </div> <div> <div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company manages its business on a basis of one reportable segment.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total revenues from external customers on the basis of the Company's geographical areas are as follows (in thousands):</span></span></div> <div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue based on customer’s location:</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">United States</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,636</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,303</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,519</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Europe</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,044</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,057</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,381</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Asia-Pacific</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">387</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">115</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">60</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rest of the world</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">787</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total revenues</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,854</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,511</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,966</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> <div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-lived assets by geographic region:</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-indent:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israel</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">529</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">757</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">United States</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,404</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">231</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="text-indent:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Germany</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">190</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">44</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,123</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,032</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:36pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(*)</span></span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.</span></span></div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Major customers data as a percentage of total revenue:</span></span></div> </div> </div> <div> <div> <div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer A</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12.2</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14.2</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:FFact_0000000001035">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer B</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230213145458513">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230213145510899">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11.0</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> </table> </div> <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"> </p> <table cellpadding="0" cellspacing="0" style="border:0px;width:100%"> <tr> <td style="width:18pt"> </td> <td style="width:36pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*)</span></span></td> <td style="width:auto"> <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less than 10%</span></span></p> </td> </tr> </table> </div> </div> </div> 1 <div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue based on customer’s location:</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">United States</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,636</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,303</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,519</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Europe</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,044</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,057</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,381</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Asia-Pacific</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">387</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">115</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">60</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rest of the world</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">787</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total revenues</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,854</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,511</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,966</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> </div> 7636000 2303000 2519000 5044000 3057000 3381000 387000 115000 60000 787000 36000 6000 13854000 5511000 5966000 <div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-lived assets by geographic region:</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> <div style="text-indent:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Israel</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">529</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">757</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">United States</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,404</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">231</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> <div style="text-indent:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Germany</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">190</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">44</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,123</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,032</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:18pt"> </td> <td style="width:36pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(*)</span></span></td> <td style="width:auto;vertical-align:top"> <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.</span></span></div> </td> </tr> </table> </div> 529000 757000 2404000 231000 190000 44000 3123000 1032000 <div> <div> <div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year Ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer A</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12.2</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14.2</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:FFact_0000000001035">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Customer B</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230213145458513">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230213145510899">*</span></span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11.0</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div> </td> </tr> </table> </div> <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"> </p> <table cellpadding="0" cellspacing="0" style="border:0px;width:100%"> <tr> <td style="width:18pt"> </td> <td style="width:36pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*)</span></span></td> <td style="width:auto"> <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less than 10%</span></span></p> </td> </tr> </table> </div> </div> </div> 0.122 0.142 0.11 <div> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 14:-</span><span style="padding-left:20pt"> </span><span style="font-weight:bold">BASIC AND DILUTED NET LOSS PER SHARE</span></span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share (in thousands, except share and per share data):</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt"> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22,133</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,569</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,736</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss attributable to ordinary shares</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22,133</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,569</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,736</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Shares used in computing net loss per ordinary shares, basic and diluted</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">59,719,064</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">62,378,797</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">47,935,652</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss per ordinary share, basic and diluted</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.37</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.31</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.27</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> </table> </div> </div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of ordinary shares and warrants outstanding would have been anti-dilutive.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the twelve months ended December 31, 2023, the total number of ordinary shares related to the outstanding warrants and share option plans aggregated to 19,220,546, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect.</span></span></div> <div style="line-height:1.25"> </div> <div style="margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the twelve months ended December 31, 2022, the total number of ordinary shares related to the outstanding warrants and share option plans aggregated to 19,464,888, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect.</span></span></div> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22,133</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,569</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline"> </td> <td colspan="1" style="width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:baseline"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,736</span></span></div> </td> <td colspan="1" style="width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:baseline;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss attributable to ordinary shares</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(22,133</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,569</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,736</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Shares used in computing net loss per ordinary shares, basic and diluted</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">59,719,064</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">62,378,797</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">47,935,652</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> <div style="text-indent:-8.65pt;margin-left:8.65pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss per ordinary share, basic and diluted</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.37</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.31</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.27</span></span></div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div> </td> </tr> </table> </div> -22133000 -19569000 -12736000 -22133000 -19569000 -12736000 59719064 59719064 62378797 62378797 47935652 47935652 -0.37 -0.37 -0.31 -0.31 -0.27 -0.27 19220546 19464888 <div> <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 15:-</span></span></span><span style="padding-left:20pt"> </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">RESTRUCTURING ACTIVITIES</span></span></span> <div style="line-height:1.25"> </div> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 12, 2023, the Board of Directors of the Company approved a re-organization plan (the “2023 Reorganization Plan”) that included, among other things, downsizing approximately 15% of the Company’s workforce and adapting the Company's organizational structure, roles, and responsibilities accordingly.</span></span></div> <div style="line-height:1.25"> </div> <div style="text-align:justify;margin-left:36pt;line-height:1.25"> <div style="line-height:1.25;font-family:'Times New Roman',serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0)">During the year ended December 31, 2023, in connection with the 2023 Reorganization Plan, the Company recorded expenses of $670 thousand, for one time employee termination benefits and legal expenses. $175 thousand attributable to research and development, net, $70 thousand to sales and marketing and $425 thousand to General and administrative expenses.</span> <span style="color:rgb(0, 0, 0)">However, none of these amounts were paid in 2023. The Company does not expect to incur additional costs related to the 2023 Reorganization Plan.</span></span></span></div> </div> </div> 0.15 670000 175000 70000 425000 Less than 10% Represents an amount lower than $1. See Note 9a. See Note 9f. Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.  Represents warrants for ordinary shares issuable upon an exercise price of $7.500 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited (“Kreos”) in connection with a loan made by Kreos to the Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly owned subsidiary of the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2022. Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms. Represents common warrants that were issued as part of the Company’s follow-on public offering in November 2018. Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on public offering in November 2018. Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on public offering in February 2019. Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering. Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants. Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants. Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. As of December 31, 2022, 3,740,100 warrants were exercised for total consideration of $4,675,125. During the twelve months that ended December 31, 2022, no warrants were exercised. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. As of December 31, 2022, 230,160 warrants were exercised for total consideration of $359,625. During the twelve months that ended December 31, 2022, no warrants were exercised. Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. As of December 31, 2022, 2,020,441 warrants were exercised for total consideration of $3,555,976. During the twelve months that ended December 31, 2022, no warrants were exercised. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering. Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. As of December 31, 2022, 3,598,072 warrants were exercised for total consideration of $4,821,416. During the twelve months that ended December 31, 2022, no warrants were exercised. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of December 31, 2022, 225,981 warrants were exercised for total consideration of $405,003. During the twelve months that ended December 31, 2022, no warrants were exercised. Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021. Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering. Balance presented net of unrecognized revenue that was not yet collected. $401 thousands of the December 31, 2022 deferred revenue balance was recognized as revenue during the year ended December 31, 2023.

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